FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Kudesia, V Strymish, J D'Avolio, L Gupta, K AF Kudesia, Valmeek Strymish, Judith D'Avolio, Leonard Gupta, Kalpana TI Natural Language Processing to Identify Foley Catheter-Days SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID URINARY-TRACT-INFECTION; AUTOMATED IDENTIFICATION; CARE C1 [Kudesia, Valmeek; Gupta, Kalpana] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Kudesia, Valmeek; D'Avolio, Leonard; Gupta, Kalpana] Massachusetts Vet Epidemiol Res Informat Ctr, Boston, MA USA. [Kudesia, Valmeek; Strymish, Judith; D'Avolio, Leonard] Harvard Univ, Sch Med, Boston, MA USA. [Strymish, Judith; Gupta, Kalpana] Vet Affairs Boston Healthcare Syst, Dept Med, Boston, MA USA. RP Gupta, K (reprint author), VA Boston HCS, 1400 VFW Pkwy,111 Med, W Roxbury, MA 02132 USA. EM kalpana.gupta@va.gov NR 10 TC 2 Z9 2 U1 1 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD DEC PY 2012 VL 33 IS 12 BP 1270 EP 1272 DI 10.1086/668424 PG 5 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 037BP UT WOS:000311076300016 PM 23143371 ER PT J AU Shenoy, ES Hsu, H Noubary, F Hooper, DC Walensky, RP AF Shenoy, Erica S. Hsu, Heather Noubary, Farzad Hooper, David C. Walensky, Rochelle P. TI National Survey of Infection Preventionists: Policies for Discontinuation of Contact Precautions for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID HEALTH-CARE SETTINGS; ENVIRONMENTAL CONTAMINATION; TRANSMISSION; ACQUISITION; COSTS C1 [Shenoy, Erica S.; Hooper, David C.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Dept Med, Boston, MA 02114 USA. [Shenoy, Erica S.; Hooper, David C.] Massachusetts Gen Hosp, Infect Control Unit, Boston, MA 02114 USA. [Shenoy, Erica S.; Hsu, Heather; Hooper, David C.; Walensky, Rochelle P.] Harvard Univ, Sch Med, Boston, MA USA. [Noubary, Farzad; Walensky, Rochelle P.] Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA USA. RP Shenoy, ES (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Dept Med, 55 Fruit St,Bulfinch 340, Boston, MA 02114 USA. EM eseiguershenoy@partners.org OI Walensky, Rochelle P./0000-0002-8795-379X FU MGH Clinical Innovation Award; NIH [NIH T32 A107061, P30 AI060354]; MGH institutional funds; Harvard Catalyst/Harvard Clinical and Translational Science Center (NIH) [UL1RR025758, 8UL1TR000170-05]; Harvard University; Harvard University Center for AIDS Research (CFAR) FX This work was conducted with the support of a 2010 MGH Clinical Innovation Award (E. S. S.); an NIH training grant (E. S. S.; NIH T32 A107061); MGH institutional funds; the Harvard Catalyst/Harvard Clinical and Translational Science Center (NIH award UL1RR025758 and 8UL1TR000170-05 and financial contributions from Harvard University and its affiliated academic healthcare centers); and the Harvard University Center for AIDS Research (CFAR), an NIH-funded program (P30 AI060354) supported by the following NIH cofunding and participating institutes and centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, NCCAM, FIC, and OAR. NR 9 TC 12 Z9 12 U1 3 U2 7 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD DEC PY 2012 VL 33 IS 12 BP 1272 EP 1275 DI 10.1086/668427 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 037BP UT WOS:000311076300017 PM 23143372 ER PT J AU Berger, CT Kim, AY AF Berger, Christoph T. Kim, Arthur Y. TI IL28B Polymorphisms as a Pretreatment Predictor of Response to HCV Treatment SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE IL28B; Pharmacogenomics; Antiviral; Type III interferon; Interferon-lambda ID HEPATITIS-C-VIRUS; INTERFERON PLUS RIBAVIRIN; GENOME-WIDE ASSOCIATION; GENOTYPE 1 INFECTION; PEGYLATED INTERFERON; GENETIC-VARIATION; INTERLEUKIN 28B; COINFECTED PATIENTS; PEGINTERFERON ALPHA-2B; SPONTANEOUS CLEARANCE AB Genome-wide association studies have identified polymorphisms located near the gene encoding IL28B, which turned out to be the best predictor of response to pegylated interferon plus ribavirin for chronic hepatitis C virus (HCV) genotype 1 infection. This association was extended to spontaneous clearance of HCV, suggesting shared mechanisms of treatment and natural control of this virus. In addition to the biologic implications for innate immunity and HCV, a variety of clinical studies have suggested possible translation to a useful genetic test for practitioners. This article reviews the discovery, biology, and potential clinical applications that have stemmed from the seminal observation that IL28B polymorphisms are a main predictor of HCV clearance. C1 [Kim, Arthur Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02114 USA. [Berger, Christoph T.] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA 02129 USA. [Berger, Christoph T.] Harvard Univ, Sch Med, Boston, MA 02129 USA. [Berger, Christoph T.] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland. [Berger, Christoph T.] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland. RP Kim, AY (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, 55 Fruit St,Cox 5, Boston, MA 02114 USA. EM akim1@partners.org FU NIAID NIH HHS [U19 AI066345]; NIDA NIH HHS [R01 DA033541] NR 106 TC 2 Z9 2 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD DEC PY 2012 VL 26 IS 4 BP 863 EP + DI 10.1016/j.idc.2012.08.010 PG 16 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 038SG UT WOS:000311193800004 PM 23083820 ER PT J AU Chen, JY Chung, RT AF Chen, Jennifer Y. Chung, Raymond T. TI Future Classes of Hepatitis C Virus Therapeutic Agents SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Hepatitis C virus; Antiviral therapeutics; Direct-acting antivirals; Host-targeted agents ID GENOTYPE 1 INFECTION; SUSTAINED VIROLOGICAL RESPONSE; INHIBITOR DEBIO 025; PROTEASE INHIBITOR; IN-VITRO; PEGINTERFERON ALPHA-2A; COMBINATION THERAPY; ANTIVIRAL ACTIVITY; INTERFERON-LAMBDA; RNA REPLICATION AB Recent advances in understanding of the molecular characteristics of the hepatitis C virus have led to the development of novel antiviral therapeutics. Direct-acting antivirals are designed to inhibit viral targets, whereas host-targeted antivirals block host factors that are used by the virus for its own life cycle. The rapid development of agents in multiple classes has led to the promise of shorter therapy duration, an improved side effect profile, and eventually interferon-sparing regimens. This article reviews novel hepatitis C virus therapeutics in development, including mechanism of action, efficacy, and adverse effects. C1 [Chen, Jennifer Y.; Chung, Raymond T.] Massachusetts Gen Hosp, GI Unit, Boston, MA 02114 USA. RP Chung, RT (reprint author), Massachusetts Gen Hosp, GI Unit, GRJ724,55 Fruit St, Boston, MA 02114 USA. EM rtchung@partners.org FU NIDDK NIH HHS [T32 DK007191] NR 86 TC 1 Z9 1 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD DEC PY 2012 VL 26 IS 4 BP 949 EP + DI 10.1016/j.idc.2012.08.003 PG 19 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 038SG UT WOS:000311193800010 PM 23083826 ER PT J AU Begun, J Ng, A Xavier, R AF Begun, Jakob Ng, Aylwin Xavier, Ramnik TI ATG16L1 T300A Dependent Differential Gene Expression Identifies Genes Required for Anti-Bacterial Autophagy SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT Crohn's-and-Colitis-Foundation's-National-Clinical-and-Research Conference on Advances in Inflammatory Bowel Diseases CY DEC 13-15, 2012 CL Hollywood, FL SP Crohns & Colitis Fdn, Natl Clin & Res C1 [Xavier, Ramnik] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Ng, Aylwin] Ctr Computat & Integrat Biol, Boston, MA USA. OI Begun, Jakob/0000-0001-5256-7672 NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD DEC PY 2012 VL 18 SU 1 BP S103 EP S103 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 038KC UT WOS:000311172600261 ER PT J AU Chandrasekharan, B Kokkotou, E Tansey, M Srinivasan, S AF Chandrasekharan, Bindu Kokkotou, Efi Tansey, Malu Srinivasan, Shanthi TI TNF-alpha Inhibitors Attenuate Neuropeptide Y (NPY) Expression in the Murine Enteric Nervous System: Implications in Inflammation and Colonic Motility SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT Crohn's-and-Colitis-Foundation's-National-Clinical-and-Research Conference on Advances in Inflammatory Bowel Diseases CY DEC 13-15, 2012 CL Hollywood, FL SP Crohns & Colitis Fdn, Natl Clin & Res C1 [Chandrasekharan, Bindu; Tansey, Malu; Srinivasan, Shanthi] Emory Univ, Atlanta, GA 30322 USA. [Kokkotou, Efi] Harvard Univ, Sch Med, Beth Israel Deacones Med Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD DEC PY 2012 VL 18 SU 1 BP S93 EP S93 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 038KC UT WOS:000311172600230 ER PT J AU Docktor, M Wang, YY Abramowicz, S Weber, S Boisvert, H Duncan, M Bousvaros, A Paster, B AF Docktor, Michael Wang, Yaoyu Abramowicz, Shelly Weber, Sarah Boisvert, Heike Duncan, Margaret Bousvaros, Athos Paster, Bruce TI Disease Activity Is Associated With Increased Bacterial Diversity in Inflammatory Bowel Disease SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT Crohn's-and-Colitis-Foundation's-National-Clinical-and-Research Conference on Advances in Inflammatory Bowel Diseases CY DEC 13-15, 2012 CL Hollywood, FL SP Crohns & Colitis Fdn, Natl Clin & Res C1 [Docktor, Michael; Bousvaros, Athos] Harvard Univ, Sch Med, Ctr Inflammatory Bowel Dis, Boston Childrens Hosp, Boston, MA USA. [Wang, Yaoyu] Ctr Canc Computat Biol, Boston, MA USA. [Abramowicz, Shelly] Harvard Univ, Sch Dent Med, Dept Oral & Maxillofacial Surg, Dept Plast & Oral Surg,Boston Childrens Hosp, Boston, MA 02115 USA. [Boisvert, Heike; Duncan, Margaret; Paster, Bruce] Forsyth Inst, Dept Microbiol, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD DEC PY 2012 VL 18 SU 1 BP S63 EP S63 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 038KC UT WOS:000311172600155 ER PT J AU Garber, J Mallick, E Leong, J Snapper, S AF Garber, John Mallick, Emily Leong, John Snapper, Scott TI Enteropathogenic E. coli Induces Intestinal Barrier Dysfunction by Exploiting Novel N-WASP-Mediated Cytoskeletal Junction Regulatory Activities SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT Crohn's-and-Colitis-Foundation's-National-Clinical-and-Research Conference on Advances in Inflammatory Bowel Diseases CY DEC 13-15, 2012 CL Hollywood, FL SP Crohns & Colitis Fdn, Natl Clin & Res C1 [Garber, John] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mallick, Emily] Univ Massachusetts, Sch Med, Worcester, MA USA. [Leong, John] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Snapper, Scott] Boston Childrens Hosp, Boston, MA USA. [Snapper, Scott] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD DEC PY 2012 VL 18 SU 1 BP S99 EP S99 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 038KC UT WOS:000311172600251 ER PT J AU Kellermayer, R Nagy-Szakal, D Harris, R Cox, S Dowd, S Winter, H Mir, S AF Kellermayer, Richard Nagy-Szakal, Dorottya Harris, Ronald Cox, Stephen Dowd, Scot Winter, Harland Mir, Sabina TI DNA Methylation and Microbiota Separation of Ulcerative Colitis in Treatment Naive Children SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT Crohn's-and-Colitis-Foundation's-National-Clinical-and-Research Conference on Advances in Inflammatory Bowel Diseases CY DEC 13-15, 2012 CL Hollywood, FL SP Crohns & Colitis Fdn, Natl Clin & Res C1 [Kellermayer, Richard; Nagy-Szakal, Dorottya; Harris, Ronald; Mir, Sabina] Baylor Coll Med, Houston, TX 77030 USA. [Cox, Stephen] Res & Testing Lab, Lubbock, TX USA. [Dowd, Scot] MR DNA Mol Res, Shallowater, TX USA. [Winter, Harland] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD DEC PY 2012 VL 18 SU 1 BP S60 EP S61 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 038KC UT WOS:000311172600149 ER PT J AU Mukhopadhyay, S Acharya, M Paidassi, H Kwon, M Feliu, M Lacy-Hulbert, A AF Mukhopadhyay, Subhankar Acharya, Mridu Paidassi, Helena Kwon, Manjae Feliu, Marianela Lacy-Hulbert, Adam TI Loss of Reciprocal Regulation of Innate and Adaptive Immunity Causes Colitis in Alpha(V) Integrin-Deficient Mice SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT Crohn's-and-Colitis-Foundation's-National-Clinical-and-Research Conference on Advances in Inflammatory Bowel Diseases CY DEC 13-15, 2012 CL Hollywood, FL SP Crohns & Colitis Fdn, Natl Clin & Res C1 [Mukhopadhyay, Subhankar] Univ Oxford, Oxford, England. [Lacy-Hulbert, Adam] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD DEC PY 2012 VL 18 SU 1 BP S110 EP S110 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 038KC UT WOS:000311172600283 ER PT J AU Mukhopadhyay, S Acharya, M Paidassi, H Kwon, M Feliu, M Lacy-Hulbert, A AF Mukhopadhyay, Subhankar Acharya, Mridu Paidassi, Helena Kwon, Manjae Feliu, Marianela Lacy-Hulbert, Adam TI Loss of Reciprocal Regulation of Innate and Adaptive Immunity Causes Colitis in Alpha(V) Integrin-Deficient Mice SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT Crohn's-and-Colitis-Foundation's-National-Clinical-and-Research Conference on Advances in Inflammatory Bowel Diseases CY DEC 13-15, 2012 CL Hollywood, FL SP Crohns & Colitis Fdn, Natl Clin & Res C1 [Mukhopadhyay, Subhankar] Univ Oxford, Oxford, Oxon, England. [Lacy-Hulbert, Adam] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD DEC PY 2012 VL 18 SU 1 BP S11 EP S11 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 038KC UT WOS:000311172600028 ER PT J AU Mavros, MN Tansarli, GS Vardakas, KZ Rafailidis, PI Karageorgopoulos, DE Falagas, ME AF Mavros, Michael N. Tansarli, Giannoula S. Vardakas, Konstantinos Z. Rafailidis, Petros I. Karageorgopoulos, Drosos E. Falagas, Matthew E. TI Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS LA English DT Review DE Staphylococcus aureus; MRSA; Bacteraemia; MIC; Mortality; Treatment response; CLSI; EUCAST ID RANDOMIZED CONTROLLED-TRIALS; BLOOD-STREAM INFECTIONS; AGR GROUP-II; RISK-FACTORS; TREATMENT FAILURE; MRSA BACTEREMIA; MIC CREEP; REDUCED SUSCEPTIBILITY; BACTERICIDAL ACTIVITY; SIMPSONS PARADOX AB Although the vancomycin minimum inhibitory concentration (VMIC) susceptibility breakpoint for Staphylococcus aureus was recently lowered to <= 2 mg/L, it is argued that isolates in the higher levels of the susceptible range may bear adverse clinical outcomes. Clinical outcomes (all-cause mortality and treatment failure) of patients with S. aureus infections by 'high-VMIC' (conventionally defined as VMIC > 1 mg/L but <= 2 mg/L) and 'low-VMIC' (VMIC <= 1 mg/L) isolates were compared by performing a systematic review and meta-analysis. The effect of potential confounders was assessed by univariate meta-regression analyses. In total, 33 studies (6210 patients) were included. Most studies were retrospective (28/33), used the Etest (22/33) and referred to meticillin-resistant S. aureus (MRSA) infections (26/33) and bacteraemia (23/33). Irrespective of VMIC testing method, meticillin resistance and site of infection, the high-VMIC group had higher mortality [relative risk (RR) = 1.21 (95% confidence interval 1.03-1.43); 4612 patients] and more treatment failures [RR = 1.67 (1.26-2.21); 2049 patients] than the low-VMIC group. The results were not affected by the potential confounders and were reproduced in the subset of patients with MRSA infections [mortality, RR = 1.19 (1.02-1.40), 2956 patients; treatment failure, RR = 1.69 (1.26-2.25), 1793 patients]. In conclusion, infection by vancomycin-susceptible S. aureus with VMIC > 1 mg/L appears to be associated with higher mortality than VMIC <= 1 mg/L. Further research is warranted to verify these results and to assess the impact of VMIC on meticillin-susceptible S. aureus infections. Evaluation of alternative antimicrobial agents also appears justified. (c) 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. C1 [Mavros, Michael N.; Tansarli, Giannoula S.; Vardakas, Konstantinos Z.; Rafailidis, Petros I.; Karageorgopoulos, Drosos E.; Falagas, Matthew E.] Alfa Inst Biomed Sci, Athens 15123, Greece. [Mavros, Michael N.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Mavros, Michael N.] Harvard Univ, Sch Med, Boston, MA USA. [Vardakas, Konstantinos Z.; Falagas, Matthew E.] Mitera Hosp, Dept Internal Med Infect Dis, Athens, Greece. [Rafailidis, Petros I.] Henry Dunant Hosp, Dept Med, Athens, Greece. [Karageorgopoulos, Drosos E.] Hellen Ctr Dis Control & Prevent, Athens, Greece. [Falagas, Matthew E.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. RP Falagas, ME (reprint author), Alfa Inst Biomed Sci, 9 Neapoleos St, Athens 15123, Greece. EM m.falagas@aibs.gr NR 95 TC 24 Z9 25 U1 0 U2 16 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0924-8579 J9 INT J ANTIMICROB AG JI Int. J. Antimicrob. Agents PD DEC PY 2012 VL 40 IS 6 BP 496 EP 509 DI 10.1016/j.ijantimicag.2012.07.023 PG 14 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA 040TN UT WOS:000311347000002 PM 23068600 ER PT J AU Ionov, M Gordiyenko, NV Zukowska, I Tokhtaeva, E Mareninova, OA Baram, N Ziyaev, K Rezhepov, K Zamaraeva, M AF Ionov, Maksim Gordiyenko, Nataliya V. Zukowska, Izabela Tokhtaeva, Elmira Mareninova, Olga A. Baram, Nina Ziyaev, Khairulla Rezhepov, Kuralbay Zamaraeva, Maria TI Stability and antioxidant activity of gossypol derivative immobilized on N-polyvinylpyrrolidone SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES LA English DT Article DE Gossypol derivative; N-polyvinylpyrrolidone antioxidant; CCl4 oxidative damage; Lipid peroxidation; Oxidative phosphorylation ID CARBON-TETRACHLORIDE; LIPID-PEROXIDATION; REACTIVE OXYGEN; IN-VITRO; PHOSPHOLIPIDS; MITOCHONDRIA; ACTIVATION; MECHANISM; FULLERENE; TISSUES AB The objective of this study is analysis of stability and antioxidant and antiradical activities of the gossypol derivative - megosin conjugated with N-polyvinylpyrrolidone (PVP). The results of study have shown the greater stability of megosin + PVP than megosin in aqueous solution of wide range of pH. Here we also demonstrated that megosin + PVP, named rometin, possess high antioxidant activity in the same range as well known antioxidant trolox as determined by its ability to scavenge free ABTS' and DPPH center dot radicals in vitro. In addition, megosin + PVP was able to prevent accumulation of products of lipid peroxidation (thiobarbituric acid reactive substances and diene conjugates) and lysophospholipids formation in mitochondria membranes caused by CCl4-induced oxidative stress in rat liver in vivo. Furthermore, megosin + PVP rescued mitochondrial functions, such as respiration and oxidative phosphorylation, which declined after CCl4 administration. Thus we present that the conjugation of megosin to PVP increase its stability and remain antioxidant activity in vivo and in vitro. (C) 2012 Elsevier B.V. All rights reserved. C1 [Zukowska, Izabela; Zamaraeva, Maria] Univ Bialystok, Dept Biophys, PL-15950 Bialystok, Poland. [Ionov, Maksim] Univ Lodz, Dept Gen Biophys, PL-90237 Lodz, Poland. [Gordiyenko, Nataliya V.; Tokhtaeva, Elmira; Mareninova, Olga A.; Baram, Nina; Ziyaev, Khairulla; Rezhepov, Kuralbay] Uzbek Acad Sci, Inst Bioorgan Chem, Tashkent 100125, Uzbekistan. [Tokhtaeva, Elmira] Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Tokhtaeva, Elmira] Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. [Mareninova, Olga A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90073 USA. [Mareninova, Olga A.] Greater Los Angeles Healthcare Syst, Vet Affairs, Los Angeles, CA 90073 USA. RP Zamaraeva, M (reprint author), Univ Bialystok, Dept Biophys, Swierkowa St 208, PL-15950 Bialystok, Poland. EM m.zamaraeva@uwb.edu.pl NR 52 TC 0 Z9 0 U1 0 U2 19 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0141-8130 J9 INT J BIOL MACROMOL JI Int. J. Biol. Macromol. PD DEC PY 2012 VL 51 IS 5 BP 908 EP 914 DI 10.1016/j.ijbiomac.2012.08.005 PG 7 WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science SC Biochemistry & Molecular Biology; Chemistry; Polymer Science GA 038TD UT WOS:000311196100032 PM 22910577 ER PT J AU Yan, DNS Xing, YZ Ouyang, XM Zhu, JH Chen, ZY Lang, HN Liu, XZ AF Yan, Denise Xing, Yazhi Ouyang, Xiaomei Zhu, Juhong Chen, Zheng-yi Lang, Hainan Liu, Xue Z. TI Analysis of miR-376 RNA cluster members in the mouse inner ear SO INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY LA English DT Article DE A ? I editing; expression analysis; hearing loss; inner ear; microRNA-376; PRPS1 ID PROGRESSIVE HEARING-LOSS; MICRORNA EXPRESSION; MUTATIONS; TARGETS; DICER; MICE; MORPHOGENESIS; DEAMINASES; BIOGENESIS; PRECURSOR AB Mutations in phosphoribosyl pyrophosphate synthetase 1 (PRPS1) are associated with a spectrum of non-syndromic to syndromic hearing loss. PRPS1 transcript levels have been shown to be regulated by the microRNA-376 genes. The long primary RNA transcript of the miR-376 RNA cluster members undergo extensive and simultaneous A ? I editing at one or both of two specific sites (+4 and +44) in particular human and mouse tissues. The PRPS1 gene, which contains target sites for the edited version of miR-376a-5p within its 3'UTR, has been shown to be repressed in a tissue-specific manner. To investigate whether the transcription of Prps1 is regulated by miR-376 cluster members in the mouse inner ear, we first quantified the expression of the mature miR-376 RNAs by quantitative real-time-PCR. The spatio-temporal patterns of miR-376 expression were assessed by in situ hybridization. Finally, we examined whether A ?I editing of pri-miR-376 RNAs occurs in mouse inner ear by direct sequencing. Our data showed that the miR-376a-3p, b-3p, c-3p are present in mouse embryonic inner ears and intensive expression of miR-376a-3p/b-3p was detected in the sensory epithelia and ganglia of both auditory and vestibular portions of the inner ear. In adult inner ear, the expression of miR-376a-3p/b-3p is restricted within ganglion neurons of auditory and vestibular systems as well as the cells in the stria vascularis. Only unedited pri-miR-376 RNAs were detected in the cochlea suggesting that the activity of PRPS1 in the inner ear may not be regulated through the editing of miR-376 cluster. C1 [Yan, Denise; Ouyang, Xiaomei; Liu, Xue Z.] Univ Miami, Dept Otolaryngol, Miami, FL USA. [Xing, Yazhi; Zhu, Juhong; Lang, Hainan] Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA. [Chen, Zheng-yi] Harvard Univ, Sch Med, Dept Otolaryngol, Eaton Peabody Lab,Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. RP Liu, XZ (reprint author), Univ Miami, Dept Otolaryngol D48, 1666 NW 12th Ave, Miami, FL 33136 USA. EM xliu@med.miami.edu OI Lang, Hainan/0000-0003-2210-7856 FU National Institutes of Health, Office of Research & Development, Medical Research Services [NIH DC012546, DC05575, DC00422, DC07506]; South Carolina Clinical and Translational Research Institute (SCTR) Clinical and Translational Science Award [NIH/NCRR UL1RR029882] FX This work was supported by National Institutes of Health (NIH DC012546); Grant number: DC05575 (L.X.); Grant number: DC00422 (H.L.); Grant number: DC07506 (H.L.); Office of Research & Development, Medical Research Services. This work also benefitted from the South Carolina Clinical and Translational Research Institute (SCTR) Clinical and Translational Science Award (NIH/NCRR UL1RR029882). The funders had no role in study design, data collection and analysis. NR 44 TC 4 Z9 4 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0959-9673 J9 INT J EXP PATHOL JI Int. J. Exp. Pathol. PD DEC PY 2012 VL 93 IS 6 BP 450 EP 457 DI 10.1111/j.1365-2613.2012.00840.x PG 8 WC Pathology SC Pathology GA 034LQ UT WOS:000310875300008 PM 23136997 ER PT J AU Liptak, C Manley, P Recklitis, CJ AF Liptak, Cori Manley, Peter Recklitis, Christopher J. TI The feasibility of psychosocial screening for adolescent and young adult brain tumor survivors: the value of self-report SO JOURNAL OF CANCER SURVIVORSHIP-RESEARCH AND PRACTICE LA English DT Article DE Pediatric neuro-oncology; Psychosocial screening; Survivorship; Adolescent and young adult ID CHILDHOOD-CANCER SURVIVOR; QUALITY-OF-LIFE; BRIEF SYMPTOM INVENTORY-18; LONG-TERM SURVIVORS; ADJUSTMENT; OUTCOMES; CHILDREN; HEALTH AB Purpose Psychosocial screening is increasingly applied to childhood cancer survivors generally, but less so with pediatric brain tumor survivors despite their psychosocial risks. This study examined the utility and acceptability of psychological screening in pediatric brain tumor survivors. Methods Eighty-four adolescents (age 12-18) completed the Beck Youth Inventory-II and 79 young adults (age 19-30) completed the Brief Symptom Inventory-18. Their scores were compared to clinician ratings on the global assessment of functioning following clinical interviews. Results Eighty-four percent of participants completed measures in < 30 min, 90 % reported no associated distress, and 98 % found measures easy to understand. Using established cut-off scores, 14 adolescents (17 %) and 21 young adults (27 %) were identified as clinical cases by self-report. Agreement with clinician report was generally low (kappa = .19, p = .077, adolescents; kappa = .34, p = .003, young adults), with clinicians tending to rate a higher proportion of both groups as having significant distress (24 % in adolescents; 32 % in young adults). Low self-concept scores in adolescents and deficits in social and vocational functioning in young adults contributed significantly to the discrepancies between self-report and clinician ratings. Conclusions Pediatric brain tumor survivors are capable of completing self-report psychological measures without distress or burden. Self-report can be a valuable tool in the assessment of pediatric brain tumor survivors, particularly in adolescents, who may provide information not revealed in a clinical interview. However, self-report, should not be used as a "stand-alone" assessment because important areas of functioning may be minimized in survivors' reports. Implications for cancer survivors Utilizing self-report for psychosocial screening of adolescent and young adult brain tumor survivors may enhance clinical care and allow for better identification of survivors in need of psychological services. C1 [Liptak, Cori] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02215 USA. [Manley, Peter] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA. [Recklitis, Christopher J.] Dana Farber Canc Inst, Perini Family Survivors Ctr, Boston, MA 02215 USA. RP Liptak, C (reprint author), Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, 450 Brookline Ave, Boston, MA 02215 USA. EM Cori_Liptak@dfci.harvard.edu FU Children's Brain Tumor Foundation; Brain Tumor Network FX This work was supported in part by the Children's Brain Tumor Foundation and the Brain Tumor Network. NR 31 TC 13 Z9 13 U1 0 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1932-2259 J9 J CANCER SURVIV JI J. Cancer Surviv.-Res. Pract. PD DEC PY 2012 VL 6 IS 4 BP 379 EP 387 DI 10.1007/s11764-012-0237-7 PG 9 WC Oncology; Social Sciences, Biomedical SC Oncology; Biomedical Social Sciences GA 043HX UT WOS:000311534600004 PM 22903638 ER PT J AU Yabroff, KR Dowling, E Rodriguez, J Ekwueme, DU Meissner, H Soni, A Lerro, C Willis, G Forsythe, LP Borowski, L Virgo, KS AF Yabroff, K. Robin Dowling, Emily Rodriguez, Juan Ekwueme, Donatus U. Meissner, Helen Soni, Anita Lerro, Catherine Willis, Gordon Forsythe, Laura P. Borowski, Laurel Virgo, Katherine S. TI The Medical Expenditure Panel Survey (MEPS) Experiences with Cancer Survivorship Supplement SO JOURNAL OF CANCER SURVIVORSHIP-RESEARCH AND PRACTICE LA English DT Article DE Cost of illness; Health care expenditures; Burden of illness; Neoplasms; SEER-Medicare; NHIS; MEPS ID HEALTH-CARE COSTS; UNITED-STATES; BREAST-CANCER; LESS-THAN-65 YEARS; ECONOMIC BURDEN; POPULATION; TIME; AGE AB Introduction The prevalence of cancer survivorship in the USA is expected to increase in the future because the US population is increasing in size and is aging and because survival following diagnosis is improving for many types of cancer. Medical care costs associated with cancer are also projected to increase dramatically. However, currently available data for estimating medical care costs and other important aspects of the burden of cancer, including time spent receiving medical care, productivity loss due to morbidity for patients and their families, and financial hardship, are limited, particularly in the population under the age of 65. Methods We describe selected publicly available data sources for estimating the burden of cancer in the USA and a new collaborative effort to improve the quality of these data: the nationally representative Medical Expenditure Panel Survey (MEPS) Experiences with Cancer Survivorship Supplement. Conclusions Data from this effort can be used to address key gaps in cancer survivorship research related to medical care costs, employment patterns, financial hardship, and other aspects of the burden of illness for cancer survivors and their families. Implications for cancer survivors Research using the MEPS Experiences with Cancer Survivorship Supplement can inform efforts by health care policy makers, healthcare systems, providers, and employers to improve the cancer survivorship experience in the USA. C1 [Yabroff, K. Robin] NCI, Hlth Serv & Econ Branch, Appl Res Program, Bethesda, MD 20892 USA. [Yabroff, K. Robin; Dowling, Emily; Willis, Gordon; Forsythe, Laura P.; Borowski, Laurel] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Dowling, Emily] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [Rodriguez, Juan; Ekwueme, Donatus U.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Soni, Anita] Agcy Healthcare Res & Qual, Ctr Financing Access & Cost Trends, Rockville, MD USA. [Lerro, Catherine; Virgo, Katherine S.] Amer Canc Soc, Hlth Serv, Res Program, Intramural Res Dept,Natl Home Off, Atlanta, GA 30329 USA. RP Yabroff, KR (reprint author), NCI, Hlth Serv & Econ Branch, Appl Res Program, Execut Plaza N,Room 4005,6130 Execut Blvd,MSC 734, Bethesda, MD 20892 USA. EM yabroffr@mail.nih.gov OI Yabroff, K. Robin/0000-0003-0644-5572 FU NCI; CDC; National Institutes of Health Office of Behavioral and Social Sciences Research; ACS; AHRQ; Westat FX The authors wish to thank Cathy Bradley, Pamela Farley Short, Patricia Ganz, and Michael Feuerstein for comments on an early version of the MEPS Experiences with Cancer questionnaire; Martha Stapleton and Stephanie Beauvais of Westat for their detailed cognitive testing report describing responses in cancer survivors to the MEPS Experiences with Cancer questionnaire; and Stephanie Nutt and Ruth Rechis of LIVESTRONG, Neetu Chawla of the NCI for comments on an earlier version of the manuscript, and Timothy McNeel of IMS, Inc for programming assistance with the 2009 MEPS. Funding for the MEPS Experiences with Cancer Supplement was provided by the NCI, the CDC, the National Institutes of Health Office of Behavioral and Social Sciences Research, and the ACS and supported by the AHRQ and Westat. NR 40 TC 15 Z9 16 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1932-2259 J9 J CANCER SURVIV JI J. Cancer Surviv.-Res. Pract. PD DEC PY 2012 VL 6 IS 4 BP 407 EP 419 DI 10.1007/s11764-012-0221-2 PG 13 WC Oncology; Social Sciences, Biomedical SC Oncology; Biomedical Social Sciences GA 043HX UT WOS:000311534600007 PM 23011572 ER PT J AU Sharff, KA Monecke, S Slaughter, S Forrest, G Pfeiffer, C Ehricht, R Oethinger, M AF Sharff, Katie A. Monecke, Stefan Slaughter, Sarah Forrest, Graeme Pfeiffer, Chris Ehricht, Ralf Oethinger, Margret TI Genotypic Resistance Testing Creates New Treatment Challenges: Two Cases of Oxacillin-Susceptible Methicillin-Resistant Staphylococcus aureus SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CASSETTE CHROMOSOME MEC; IN-VIVO; STRAINS; SCCMEC; GENES AB Oxacillin-susceptible, mecA-positive Staphylococcus aureus isolates create a treatment challenge for the clinician. In this article, we describe two cases of bacteremia from isolates that carried the mecA gene but were susceptible to oxacillin ( oxacillin-susceptible methicillin-resistant S. aureus [OS-MRSA]). DNA microarray analysis was used to characterize these isolates as a mecA-positive, clonal complex 5, pediatric strain and a mecA-positive, clonal complex 8, USA300 strain. C1 [Sharff, Katie A.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Monecke, Stefan] Tech Univ Dresden, Inst Med Microbiol & Hyg, D-01062 Dresden, Germany. [Slaughter, Sarah] Prov Portland Med Ctr, Div Infect Dis, Portland, OR USA. [Forrest, Graeme; Pfeiffer, Chris] Portland VA Med Ctr, Div Infect Dis, Portland, OR USA. [Ehricht, Ralf] Alere Technol GmbH, Jena, Germany. [Oethinger, Margret] Prov Hlth & Serv, Dept Lab Serv, Portland, OR USA. RP Sharff, KA (reprint author), Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. EM sharffk@ohsu.edu NR 16 TC 13 Z9 13 U1 3 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 2012 VL 50 IS 12 BP 4151 EP 4153 DI 10.1128/JCM.01564-12 PG 3 WC Microbiology SC Microbiology GA 038ZE UT WOS:000311211800062 PM 22993184 ER PT J AU Osman, A Wong, JL Bagge, CL Freedenthal, S Gutierrez, PM Lozano, G AF Osman, Augustine Wong, Jane L. Bagge, Courtney L. Freedenthal, Stacey Gutierrez, Peter M. Lozano, Gregorio TI The Depression Anxiety Stress Scalesu21 (DASS-21): Further Examination of Dimensions, Scale Reliability, and Correlates SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE depression anxiety stress; self1-report inventory; bifactor IRT models; nonclinical ID CONFIRMATORY FACTOR-ANALYSIS; ADOLESCENT PSYCHIATRIC-INPATIENTS; CLINICAL-ASSESSMENT INSTRUMENTS; LARGE NONCLINICAL SAMPLE; PSYCHOMETRIC PROPERTIES; MEASUREMENT INVARIANCE; TRIPARTITE MODEL; PSYCHOLOGICAL-ASSESSMENT; NORMATIVE DATA; VALIDITY AB Objectives We conducted two studies to examine the dimensions, internal consistency reliability estimates, and potential correlates of the Depression Anxiety Stress Scales21 (DASS-21; Lovibond & Lovibond, 1995). Method Participants in Study 1 included 887 undergraduate students (363 men and 524 women, aged 18 to 35 years; mean [M] age = 19.46, standard deviation [SD] = 2.17) recruited from two public universities to assess the specificity of the individual DASS-21 items and to evaluate estimates of internal consistency reliability. Participants in a follow-up study (Study 2) included 410 students (168 men and 242 women, aged 18 to 47 years; M age = 19.65, SD = 2.88) recruited from the same universities to further assess factorial validity and to evaluate potential correlates of the original DASS-21 total and scale scores. Results Item bifactor and confirmatory factor analyses revealed that a general factor accounted for the greatest proportion of common variance in the DASS-21 item scores (Study 1). In Study 2, the fit statistics showed good fit for the bifactor model. In addition, the DASS-21 total scale score correlated more highly with scores on a measure of mixed depression and anxiety than with scores on the proposed specific scales of depression or anxiety. Coefficient omega estimates for the DASS-21 scale scores were good. Conclusions Further investigations of the bifactor structure and psychometric properties of the DASS-21, specifically its incremental and discriminant validity, using known clinical groups are needed. C1 [Osman, Augustine] Univ Texas San Antonio, Dept Psychol, San Antonio, TX 78249 USA. [Wong, Jane L.] Armstrong Atlantic State Univ, Savannah, GA USA. [Bagge, Courtney L.] Univ Mississippi, Med Ctr, University, MS 38677 USA. [Freedenthal, Stacey] Univ Denver, Denver, CO 80208 USA. [Gutierrez, Peter M.] MIRECC, Denver VA Med Ctr, Denver, CO USA. RP Osman, A (reprint author), Univ Texas San Antonio, Dept Psychol, 1 UTSA Circle, San Antonio, TX 78249 USA. EM augustine.osman@utsa.edu NR 73 TC 66 Z9 67 U1 10 U2 78 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9762 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD DEC PY 2012 VL 68 IS 12 BP 1322 EP 1338 DI 10.1002/jclp.21908 PG 17 WC Psychology, Clinical SC Psychology GA 035UY UT WOS:000310977100009 PM 22930477 ER PT J AU Williams, BR Lewis, DR Burgio, KL Goode, PS AF Williams, Beverly Rosa Lewis, Donna R. Burgio, Kathryn L. Goode, Patricia S. TI "Wrapped in Their Arms'' Next-of-Kin's Perceptions of How Hospital Nursing Staff Support Family Presence Before, During, and After the Death of a Loved One SO JOURNAL OF HOSPICE & PALLIATIVE NURSING LA English DT Article DE end of life; family; nursing care; qualitative analysis ID LIFE CARE; PEOPLE AB Family presence is a vital component of quality end-of-life (EOL) care. We conducted face-to-face, in-depth interviews with next-of-kin of deceased veterans to explore perceptions of how hospital nursing staff supported and facilitated family presence during the actively dying phase, at the time of death, and immediately following the patient's death. We used content analysis to examine respondents' accounts of the role of nursing staff in fostering and sustaining family presence in the hospital setting. We provide exemplary quotes to contextualize nursing staff behaviors that encouraged, supported, and guided families, enabling them to be present and to function adaptively before, during, and after the loved one's death. In particular, we focus on nursing behaviors that were responsive to family members' needs for information, privacy, intimacy, physical comfort, and emotional reassurance. Nurses' effectiveness in optimizing family support required clinical competency in recognizing the actively dying phase of life and engaging in behaviors that facilitated the delivery EOL care, with thoughtful attention to family needs. C1 [Williams, Beverly Rosa; Burgio, Kathryn L.; Goode, Patricia S.] Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham VA Med Ctr, Birmingham, AL 35294 USA. [Williams, Beverly Rosa] Univ Alabama Birmingham, UAB Ctr Aging, Div Gerontol Geriatr & Palliat Care, Dept Med, Birmingham, AL USA. [Lewis, Donna R.] Emory Univ, Community Living Ctr, Atlanta VA Med Ctr, Atlanta, GA 30322 USA. [Lewis, Donna R.] Emory Univ, Adjunct Fac, Sch Nursing, Atlanta, GA 30322 USA. RP Williams, BR (reprint author), Birmingham Atlanta VA Geriatr Res Educ & Clin Ctr, Birmingham VA Med Ctr, CH 19 218K,1530 3rd Ave S, Birmingham, AL 35294 USA. EM beverly.williams3@va.gov FU Veterans Affairs Health Services Research and Development [IIR 03-126] FX This research was funded by a grant from Veterans Affairs Health Services Research and Development (no. IIR 03-126). NR 24 TC 8 Z9 8 U1 1 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1522-2179 J9 J HOSP PALLIAT NURS JI J. Hosp. Palliat. Nurs. PD DEC PY 2012 VL 14 IS 8 BP 541 EP 550 DI 10.1097/NJH.0b013e31825d2af1 PG 10 WC Nursing SC Nursing GA 035AJ UT WOS:000310913700007 ER PT J AU Byrd, JB Powers, JD Magid, DJ Tavel, HM Schmittdiel, JA O'Connor, PJ Beck, AL Butler, MG Ho, PJM AF Byrd, James B. Powers, J. David Magid, David J. Tavel, Heather M. Schmittdiel, Julie A. O'Connor, Patrick J. Beck, Arne L. Butler, Melissa G. Ho, Pei-Jai M. TI Detection and recognition of hypertension in anxious and depressed patients SO JOURNAL OF HYPERTENSION LA English DT Article DE anxiety; depression; diagnosis; early diagnosis; hypertension ID SYSTOLIC HYPERTENSION; RISK; SYMPTOMS; ANXIETY; ADHERENCE; DISEASE; TRENDS; IMPACT; CARE AB Objective: Hypertension management requires detection (i.e. confirmation of persistently high blood pressure (BP) after an initial elevated measurement) and recognition of the condition (evidenced by a formal diagnosis and/or initiation of treatment). Our objective was to determine whether disparities exist in detection of elevated BP and recognition (i.e. diagnosis or treatment) of hypertension in patients with depression and anxiety. Methods: Using data from the Cardiovascular Research Network Hypertension Registry, we assessed time-to-detection of elevated BP and recognition of hypertension in patients with comorbid anxiety and depression compared with patients with neither disorder. We performed multivariable survival analysis of time to detection and recognition in patients who entered the registry in 2002-2006. We adjusted for primary care visit rate and other relevant clinical factors. Results: In 168 630 incident hypertension patients, detection occurred earlier among patients with anxiety and depression compared with patients without these diagnoses [adjusted hazard ratio for anxiety and depression 1.30, 95% confidence interval (CI) 1.26-1.35]. Recognition of hypertension within 12 months of the second elevated BP was similar (adjusted hazard ratio for anxiety and depression 0.94, 95% CI 0.89-1.00) or delayed (adjusted hazard ratio for anxiety 0.93, 95% CI 0.88-0.99 and for depression 0.93, 95% CI 0.90-0.97). Conclusions: Detection of elevated BP occurred earlier in patients with anxiety and depression. Time from detection to diagnosis or treatment was similar or delayed in patients with and without these diagnoses. Our findings suggest that as-yet-unidentified factors contribute to disparities in hypertension detection and recognition. C1 [Byrd, James B.] Univ Michigan, Dept Med, Div Cardiol, NCRC,Med Sch, Ann Arbor, MI 48109 USA. [Powers, J. David; Magid, David J.; Tavel, Heather M.; Beck, Arne L.] Kaiser Inst Hlth Res, Denver, CO USA. [Schmittdiel, Julie A.] Kaiser Permanente Div Res, Oakland, CA USA. [O'Connor, Patrick J.] HealthPartners Res Fdn, Minneapolis, MN USA. [Butler, Melissa G.] Kaiser Permanente Georgia, Ctr Hlth Res SE, Atlanta, GA USA. [Ho, Pei-Jai M.] Denver VA Med Ctr, Dept Med, Denver, CO USA. RP Byrd, JB (reprint author), Univ Michigan, Dept Med, Div Cardiol, NCRC,Med Sch, Room 20-209W,2800 Plymouth Rd, Ann Arbor, MI 48109 USA. EM jbbyrd@umich.edu OI Byrd, J. Brian/0000-0002-0509-3520 FU NIH, Cardiovascular Research Network [U19HL091179, 3U19HL091179-04S1]; Department of Veterans Affairs GME Enhancement Grant FX This work was supported by NIH grants U19HL091179 and 3U19HL091179-04S1 as part of the Cardiovascular Research Network and J.B.B was supported by a Department of Veterans Affairs GME Enhancement Grant. NR 13 TC 3 Z9 4 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 J9 J HYPERTENS JI J. Hypertens. PD DEC PY 2012 VL 30 IS 12 BP 2293 EP 2298 DI 10.1097/HJH.0b013e328359b6e6 PG 6 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 039VA UT WOS:000311273700008 PM 23032145 ER PT J AU Yoo, JW Nakagawa, S Kim, S AF Yoo, Ji Won Nakagawa, Shunichi Kim, Sulgi TI The Effect Modification of Supplemental Insurance on the Relationship Between Race and Bone Mineral Density Screening in Female Medicare Beneficiaries SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH LA English DT Article DE Bone mineral density; Accessibility of health services; Health Insurance for aged and disabled; Women's health service ID AFRICAN-AMERICAN WOMEN; X-RAY ABSORPTIOMETRY; OSTEOPOROSIS; DISPARITIES; WHITE; RISK; CARE; GUIDELINES; FRACTURES; HEALTH AB To determine the effect modification of supplemental insurance on the relationship between race and bone mineral density (BMD) in female Medicare beneficiaries. Retrospectively analyzing hospital administrative claim and clinical data of female Medicare beneficiaries (n = 1,398), we performed multivariate logistic regressions of BMD testing including data from all study participants and the subsets of health insurance. Significantly fewer Black than White female Medicare beneficiaries received the BMD testing in the overall sample (odds ratio, OR = 0.63; p = 0.02) and those without supplementary health insurance (n = 709; OR = 0.38; p = 0.004). By contrast, the magnitude of this racial disparity in the BMD testing was diminished among those with supplementary private health insurance (n = 689). We found a significant racial disparity in BMD testing for Black and White female Medicare beneficiaries. This disparity became more pronounced among those without supplementary private health insurance. C1 [Yoo, Ji Won] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA. [Yoo, Ji Won] Vet Affairs Ann Arbor Healthcare Syst, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA. [Nakagawa, Shunichi] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA. [Nakagawa, Shunichi] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Kim, Sulgi] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. RP Yoo, JW (reprint author), Univ Michigan, Sch Med, Dept Internal Med, 300 N Ingalls Bldg,Room 932, Ann Arbor, MI 48109 USA. EM yoojiw@trinity-health.org; nakagas@gmail.com; sulgik@gmail.com NR 33 TC 0 Z9 0 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1557-1912 J9 J IMMIGR MINOR HEALT JI J. Immigr. Minor. Health PD DEC PY 2012 VL 14 IS 6 BP 912 EP 917 DI 10.1007/s10903-012-9629-z PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 036MM UT WOS:000311030400002 PM 22535021 ER PT J AU Chen, JY Ribaudo, HJ Souda, S Parekh, N Ogwu, A Lockman, S Powis, K Dryden-Peterson, S Creek, T Jimbo, W Madidimalo, T Makhema, J Essex, M Shapiro, RL AF Chen, Jennifer Y. Ribaudo, Heather J. Souda, Sajini Parekh, Natasha Ogwu, Anthony Lockman, Shahin Powis, Kathleen Dryden-Peterson, Scott Creek, Tracy Jimbo, William Madidimalo, Tebogo Makhema, Joseph Essex, Max Shapiro, Roger L. TI Highly Active Antiretroviral Therapy and Adverse Birth Outcomes Among HIV-Infected Women in Botswana SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID IMMUNODEFICIENCY-VIRUS-INFECTION; TO-CHILD TRANSMISSION; CD4 CELL COUNTS; PRETERM DELIVERY; INCREASED RISK; CHRONIC HYPERTENSION; PREGNANCY OUTCOMES; HIV-1-INFECTED WOMEN; PREMATURE DELIVERY; CUBIC MILLIMETER AB Background. It is unknown whether adverse birth outcomes are associated with maternal highly active antiretroviral therapy (HAART) in pregnancy, particularly in resource-limited settings. Methods. We abstracted obstetrical records at 6 sites in Botswana for 24 months. Outcomes included stillbirths (SBs), preterm delivery (PTD), small for gestational age (SGA), and neonatal death (NND). Among human immunodeficiency virus (HIV)-infected women, comparisons were limited to HAART exposure status at conception, and those with similar opportunities for outcomes. Comparisons were adjusted for CD4(+) lymphocyte cell count. Results. Of 33 148 women, 32 113 (97%) were tested for HIV, of whom 9504 (30%) were HIV infected. Maternal HIV was significantly associated with SB, PTD, SGA, and NND. Compared with all other HIV-infected women, those continuing HAART from before pregnancy had higher odds of PTD (adjusted odds ratio [AOR], 1.2; 95% confidence interval [CI], 1.1, 1.4), SGA (AOR, 1.8; 95% CI, 1.6, 2.1) and SB (AOR, 1.5; 95% CI, 1.2, 1.8). Among women initiating antiretroviral therapy in pregnancy, HAART use (vs zidovudine) was associated with higher odds of PTD (AOR, 1.4; 95% CI, 1.2, 1.8), SGA (AOR, 1.5; 95% CI, 1.2, 1.9), and SB (AOR, 2.5; 95% CI, 1.6, 3.9). Low CD4(+) was independently associated with SB and SGA, and maternal hypertension during pregnancy with PTD, SGA, and SB. Conclusions. HAART receipt during pregnancy was associated with increased PTD, SGA, and SB. C1 [Shapiro, Roger L.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA. [Madidimalo, Tebogo] Botswana Minist Hlth, Gaborone, Botswana. [Powis, Kathleen] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Powis, Kathleen] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA. [Lockman, Shahin; Powis, Kathleen; Essex, Max; Shapiro, Roger L.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Cambridge, MA 02138 USA. [Lockman, Shahin; Dryden-Peterson, Scott] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Parekh, Natasha] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA USA. [Souda, Sajini; Ogwu, Anthony; Makhema, Joseph] Botswana Harvard AIDS Inst, Gaborone, Botswana. [Ribaudo, Heather J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Chen, Jennifer Y.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. RP Shapiro, RL (reprint author), Beth Israel Deaconess Med Ctr, Div Infect Dis, 110 Francis St,Ste GB, Boston, MA 02215 USA. EM rshapiro@hsph.harvard.edu FU Centers for Disease Control and Prevention [U2GPS000941]; National Institutes of Health (Harvard University CFAR) [P30 AI060354]; Doris Duke Charitable Research Foundation FX This work was supported by a grant from the Centers for Disease Control and Prevention (U2GPS000941), a grant from the National Institutes of Health (P30 AI060354, Harvard University CFAR, H. J. R), and by research fellowships from the Doris Duke Charitable Research Foundation (J. Y. C., N. P.) NR 48 TC 89 Z9 90 U1 1 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD DEC 1 PY 2012 VL 206 IS 11 BP 1695 EP 1705 DI 10.1093/infdis/jis553 PG 11 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 035SK UT WOS:000310968700011 PM 23066160 ER PT J AU Lopez, MF Sarracino, DA Vogelsang, M Sutton, JN Athanas, M Krastins, B Garces, A Prakash, A Peterman, S Demirjian, Z Inglessis-Azuaje, I Feeney, K Elia, M McMullin, D Dec, GW Palacios, I Lo, EH Buonanno, F Ning, MM AF Lopez, Mary F. Sarracino, David A. Vogelsang, Maryann Sutton, Jennifer N. Athanas, Michael Krastins, Bryan Garces, Alejandra Prakash, Amol Peterman, Scott Demirjian, Zareh Inglessis-Azuaje, Ignacio Feeney, Kathleen Elia, Mikaela McMullin, David Dec, G. William Palacios, Igor Lo, Eng H. Buonanno, Ferdinand Ning, MingMing TI Heart-Brain Signaling in Patent Foramen Ovale-Related Stroke: Differential Plasma Proteomic Expression Patterns Revealed With a 2-Pass Liquid Chromatography-Tandem Mass Spectrometry Discovery Workflow SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Article DE patent foramen ovale; PFO; proteomics; biomarker; discovery; stroke; cerebrovascular disease; ischemic stroke; mass spectrometry ID ATRIAL SEPTAL ANEURYSM; ISCHEMIC-STROKE; CRYPTOGENIC STROKE; RISK-FACTORS; DATA-BANK; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; BIOACTIVE MATERIALS; RECURRENT STROKE; CLOSURE; MIGRAINE AB Patent foramen ovale (PFO) is highly prevalent and associated with more than 150,000 strokes per year. Traditionally, it is thought that PFOs facilitate strokes by allowing venous clots to travel directly to the brain. However, only a small portion of PFO stroke patients have a known tendency to form blood clots, and the optimal treatment for this multiorgan disease is unclear. Therefore, mapping the changes in systemic circulation of PFO-related stroke is crucial in understanding the pathophysiology to individualize the best clinical treatment for each patient. We initiated a study using a novel quantitative, 2-pass discovery workflow using high-resolution liquid chromatography-mass spectrometry/mass spectrometry coupled with label-free analysis to track protein expression in PFO patients before and after endovascular closure of the PFO. Using this approach, we were able to demonstrate quantitative differences in protein expression between both PFO-related and non-PFO-related ischemic stroke groups as well as before and after PFO closure. As an initial step in understanding the molecular landscape of PFO-related physiology, our methods have yielded biologically relevant information on the synergistic and functional redundancy of various cell-signaling molecules with respect to PFO circulatory physiology. The resulting protein expression patterns were related to canonical pathways including prothrombin activation, atherosclerosis signaling, acute-phase response, LXR/RXR activation, and coagulation system. In particular, after PFO closure, numerous proteins demonstrated reduced expression in stroke-related canonical pathways such as acute inflammatory response and coagulation signaling. These findings demonstrate the feasibility and robustness of using a proteomic approach for biomarker discovery to help gauge therapeutic efficacy in stroke. C1 [Lopez, Mary F.; Sarracino, David A.; Vogelsang, Maryann; Sutton, Jennifer N.; Athanas, Michael; Krastins, Bryan; Garces, Alejandra; Prakash, Amol; Peterman, Scott] Thermo Fisher Sci, BRIMS, Cambridge, MA 02139 USA. [Demirjian, Zareh; Inglessis-Azuaje, Ignacio; Feeney, Kathleen; Elia, Mikaela; McMullin, David; Dec, G. William; Palacios, Igor; Lo, Eng H.; Buonanno, Ferdinand; Ning, MingMing] Harvard Univ, Sch Med, Clin Prote Res Ctr, Boston, MA 02114 USA. [Demirjian, Zareh; Inglessis-Azuaje, Ignacio; Feeney, Kathleen; Elia, Mikaela; McMullin, David; Dec, G. William; Palacios, Igor; Lo, Eng H.; Buonanno, Ferdinand; Ning, MingMing] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardioneurol Clin,Dept Neurol, Boston, MA 02114 USA. RP Lopez, MF (reprint author), Thermo Fisher Sci, BRIMS, 790 Mem Dr, Cambridge, MA 02139 USA. EM mary.lopez@thermofisher.com; ning@hms.harvard.edu FU NIH/NINDS [R01 NS067139, P01-NS55104]; National Center for Research Resources [R13 RR023236] FX This work was supported by the NIH/NINDS: R01 NS067139 (M.M.N.) and P01-NS55104 (E.H.L.). The symposium was supported in part by a grant from the National Center for Research Resources (R13 RR023236). NR 52 TC 10 Z9 10 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD DEC PY 2012 VL 60 IS 8 BP 1122 EP 1130 PG 9 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 041VW UT WOS:000311430500014 PM 23147404 ER PT J AU Sun, HQ Guo, S Chen, DF Yang, FD Zou, YZ Di, XL Cao, YJ Kosten, T Lu, L Zhang, XY AF Sun, Hongqiang Guo, Song Chen, Dafang Yang, Fude Zou, Yizhuang Di, Xiaolan Cao, Yanjun Kosten, Thomas Lu, Lin Zhang, Xiang Yang TI Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy SO JOURNAL OF NEURAL TRANSMISSION LA English DT Article DE Pharmacogenetics; COMT; Nicotine dependence; Smoking; Dopamine ID CATECHOL-O-METHYLTRANSFERASE; GENETIC-VARIATION; CONTROLLED TRIAL; CHINESE SMOKERS; DOUBLE-BLIND; DEPENDENCE; GENOTYPE; PHARMACOGENETICS; INHIBITORS; INITIATION AB Nicotine replacement treatment (NRT) can be efficacious for smoking cessation, but used by only a minority of smokers in China. Pharmacogenetic matching may improve treatment outcomes for NRT in subgroups of smokers. We evaluated the efficacy and safety of sublingual nicotine tablets (SNT) for smoking cessation and the association of catechol-O-methyltransferase (COMT) genotype with efficacy in this smoking cessation trial among Chinese smokers. We conducted a double-blind, placebo-controlled, 8-week trial of SNT with a follow-up at week 12 among 250 Chinese smokers. Efficacy and safety were evaluated at day 4 and weeks 2, 4, 6, 8, and 12. Abstinence was biochemically verified by exhaled carbon monoxide (CO) and urine cotinine. The COMT Val108Met genotype was determined as a restriction fragment length polymorphism. Our results showed that the success rates for complete abstinence were greater for active versus placebo treatments at 8 weeks (48 vs. 17 %) and 12 weeks (52 vs. 19 %) (both p < 0.0001). Craving was significantly reduced from week 2 on active treatment compared to placebo. Adverse events were mild and tolerable. We found a genotype by treatment interaction at 12 weeks with greater abstinence rates in the COMT Val/Val (50 vs. 15 %) than the Met/Val + Met/Met genotypes (46 vs. 25 %). We found that SNT significantly increased smoking abstinence, reduced craving and was well tolerated, and the COMT Val/Val genotype was associated with a greater improvement in smoking cessation. C1 [Guo, Song] Capital Univ Med Sci, Beijing Anding Hosp, Natl Drug Abuse Treatment Ctr, Beijing 100009, Peoples R China. [Sun, Hongqiang; Yang, Fude; Zou, Yizhuang; Di, Xiaolan; Cao, Yanjun; Zhang, Xiang Yang] Beijing Hui Long Guan Hosp, Beijing, Peoples R China. [Sun, Hongqiang; Lu, Lin] Peking Univ, Natl Inst Drug Dependence, Beijing 100871, Peoples R China. [Guo, Song] Inst Mental Hlth, Addict Med Dept, Singapore, Singapore. [Chen, Dafang] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100871, Peoples R China. [Kosten, Thomas; Zhang, Xiang Yang] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhang, Xiang Yang] VA Med Ctr, Houston, TX 77030 USA. RP Guo, S (reprint author), Capital Univ Med Sci, Beijing Anding Hosp, Natl Drug Abuse Treatment Ctr, Beijing 100009, Peoples R China. EM guosong23@263.net; xyzhang@bcm.edu FU National Natural Science Foundation of China [81071080]; Training Program Foundation for Excellent Talents by the Beijing Municipal Government, China [2010D003034000026]; Stanley Medical research Institute [03T-459, 05T-726]; Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639] FX This projects was supported by grants from the National Natural Science Foundation of China (No. 81071080) and Training Program Foundation for Excellent Talents by the Beijing Municipal Government, China (No. 2010D003034000026), the Stanley Medical research Institute (03T-459 and 05T-726), and the Department of Veterans Affairs, VISN 16, Mental Illness Research, Education and Clinical Center (MIRECC), United States National Institute of Health K05-DA0454, P50-DA18827 and U01-MH79639. NR 33 TC 3 Z9 4 U1 0 U2 7 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0300-9564 J9 J NEURAL TRANSM JI J. Neural Transm. PD DEC PY 2012 VL 119 IS 12 BP 1491 EP 1498 DI 10.1007/s00702-012-0841-8 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 042YW UT WOS:000311509900005 PM 22695756 ER PT J AU Duhaime, AC AF Duhaime, Ann-Christine TI Sports and concussion Response SO JOURNAL OF NEUROSURGERY LA English DT Editorial Material C1 Harvard Univ, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA. RP Duhaime, AC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD DEC PY 2012 VL 117 IS 6 BP 1090 EP 1091 PG 2 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 042IC UT WOS:000311463900015 ER PT J AU Duhaime, AC Beckwith, JG Maerlender, AC McAllister, TW Crisco, JJ Duma, SM Brolinson, PG Rowson, S Flashman, LA Chu, JJ Greenwald, RM AF Duhaime, Ann-Christine Beckwith, Jonathan G. Maerlender, Arthur C. McAllister, Thomas W. Crisco, Joseph J. Duma, Stefan M. Brolinson, P. Gunnar Rowson, Steven Flashman, Laura A. Chu, Jeffrey J. Greenwald, Richard M. TI Spectrum of acute clinical characteristics of diagnosed concussions in college athletes wearing instrumented helmets Clinical article SO JOURNAL OF NEUROSURGERY LA English DT Article DE concussion; traumatic brain injury; biomechanics; athletes; football; hockey ID TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; HEAD IMPACT EXPOSURES; RECURRENT CONCUSSION; CEREBRAL CONCUSSION; MILD; RISK; ACCELERATION; KINEMATICS; DEPRESSION AB Object. Concussive head injuries have received much attention in the medical and public arenas, as concerns have been raised about the potential short- and long-term consequences of injuries sustained in sports and other activities. While many student athletes have required evaluation after concussion, the exact definition of concussion has varied among disciplines and over time. The authors used data gathered as part of a multiinstitutional longitudinal study of the biomechanics of head impacts in helmeted collegiate athletes to characterize what signs, symptoms, and clinical histories were used to designate players as having sustained concussions. Methods. Players on 3 college football teams and 4 ice hockey teams (male and female) wore helmets instrumented with Head Impact Telemetry (HIT) technology during practices and games over 2-4 seasons of play. Preseason clinical screening batteries assessed baseline cognition and reported symptoms. If a concussion was diagnosed by the team medical staff, basic descriptive information was collected at presentation, and concussed players were reevaluated serially. The specific symptoms or findings associated with the diagnosis of acute concussion, relation to specific impact events, timing of symptom onset and diagnosis, and recorded biomechanical parameters were analyzed. Results. Data were collected from 450 athletes with 486,594 recorded head impacts. Forty-eight separate concussions were diagnosed in 44 individual players. Mental clouding, headache, and dizziness were the most common presenting symptoms. Thirty-one diagnosed cases were associated with an identified impact event; in 17 cases no specific impact event was identified. Onset of symptoms was immediate in 24 players, delayed in 11, and unspecified in 13. In 8 cases the diagnosis was made immediately after a head impact, but in most cases the diagnosis was delayed (median 17 hours). One diagnosed concussion involved a 30-second loss of consciousness; all other players retained alertness. Most diagnoses were based on self-reported symptoms. The mean peak angular and rotational acceleration values for those cases associated with a specific identified impact were 86.1 +/- 42.6g (range 16.5-177.9g) and 3620 +/- 2166 rad/sec(2) (range 183-7589 rad/sec(2)), respectively. Conclusions. Approximately two-thirds of diagnosed concussions were associated with a specific contact event. Half of all players diagnosed with concussions had delayed or unclear timing of onset of symptoms. Most had no externally observed findings. Diagnosis was usually based on a range of self-reported symptoms after a variable delay. Accelerations clustered in the higher percentiles for all impact events, but encompassed a wide range. These data highlight the heterogeneity of criteria for concussion diagnosis, and in this sports context, its heavy reliance on self-reported symptoms. More specific and standardized definitions of clinical and objective correlates of a "concussion spectrum" may be needed in future research efforts, as well as in the clinical diagnostic arena. (http://thejns.org/doi/abs/10.3171/2012.8.JNS112298) C1 [Duhaime, Ann-Christine] Harvard Univ, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Beckwith, Jonathan G.; Chu, Jeffrey J.; Greenwald, Richard M.] Simbex, Lebanon, NH USA. [Maerlender, Arthur C.] Dartmouth Med Sch, Pediat Neuropsychol Serv, Lebanon, NH USA. [McAllister, Thomas W.; Flashman, Laura A.] Dartmouth Med Sch, Dept Psychiat, Lebanon, NH USA. [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA. [Crisco, Joseph J.] Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Providence, RI 02912 USA. [Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI USA. [Duma, Stefan M.; Rowson, Steven] Virginia Tech, Wake Forest Ctr Injury Biomech, Blacksburg, VA USA. [Brolinson, P. Gunnar] Edward Via Virginia Coll Osteopath Med, Blacksburg, VA USA. RP Duhaime, AC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Neurosurg, 15 Parkman St,Wang 331, Boston, MA 02114 USA. EM aduhaime@partners.org RI Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012 OI Rowson, Steven/0000-0002-3227-0596; FU National Institute for Child Health and Human Development at the National Institutes of Health [R01HD048638] FX The research for this study is supported by the National Institute for Child Health and Human Development at the National Institutes of Health (Grant R01HD048638). NR 43 TC 38 Z9 38 U1 3 U2 30 PU AMER ASSOC NEUROLOGICAL SURGEONS PI ROLLING MEADOWS PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD DEC PY 2012 VL 117 IS 6 BP 1092 EP 1099 DI 10.3171/2012.8.JNS112298 PG 8 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 042IC UT WOS:000311463900016 PM 23030057 ER PT J AU Kimball, AB Alavian, C Alora-Palli, M Bagel, J AF Kimball, A. B. Alavian, C. Alora-Palli, M. Bagel, J. TI Weight loss in obese patients with psoriasis can be successfully achieved during a course of phototherapy SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY LA English DT Letter ID HEPATITIS-C; POPULATION; DISEASES; VIRUS C1 [Kimball, A. B.; Alora-Palli, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Alavian, C.] Univ Massachusetts, Worcester, MA 01605 USA. [Bagel, J.] Psoriasis Treatment Ctr Cent New Jersey, E Windsor, NJ USA. RP Kimball, AB (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM akimball@partners.org NR 10 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0926-9959 J9 J EUR ACAD DERMATOL JI J. Eur. Acad. Dermatol. Venereol. PD DEC PY 2012 VL 26 IS 12 BP 1582 EP 1584 DI 10.1111/j.14682011.04361.x PG 3 WC Dermatology SC Dermatology GA 038IO UT WOS:000311168600020 PM 22126311 ER PT J AU Cardarella, S Ortiz, TM Joshi, VA Butaney, M Jackman, DM Kwiatkowski, DJ Yeap, BY Janne, PA Lindeman, NI Johnson, BE AF Cardarella, Stephanie Ortiz, Taylor M. Joshi, Victoria A. Butaney, Mohit Jackman, David M. Kwiatkowski, David J. Yeap, Beow Y. Jaenne, Pasi A. Lindeman, Neal I. Johnson, Bruce E. TI The Introduction of Systematic Genomic Testing for Patients with Non-Small-Cell Lung Cancer SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE Lung cancer; Cancer genomics; Molecular targeted therapy ID GROWTH-FACTOR RECEPTOR; BRAF GENE; PHASE-III; MUTATIONS; GEFITINIB; ADENOCARCINOMA; ERLOTINIB; ALK; RESISTANCE; SURVIVAL AB Background: Genomic testing to identify driver mutations that enable targeted therapy is emerging for patients with non-small-cell lung cancer (NSCLC). We report the implementation of systematic prospective genotyping for somatic alterations in BRAF, PIK3CA, HER2, and ALK, in addition to EGFR and KRAS, in NSCLC patients at the Dana-Farber Cancer Institute. Methods: Patients with NSCLC were prospectively referred by their providers for clinical genotyping. Formalin-fixed, paraffin embedded tumor samples were analyzed by Sanger sequencing for mutations in selected exons of EGFR, KRAS, BRAF, PIK3CA, and HER2. ALK rearrangements were detected by fluorescence in situ hybridization or immunohistochemistry. Results: Between July 1, 2009 and August 1, 2010, 427 specimens from 419 patients were referred for genomic characterization; 344 (81%) specimens were successfully genotyped with a median turnaround time of 31 days (range, 9-155). Of the 344 specimens, 185 (54%) had at least one identifiable somatic alteration (KRAS: 24%, EGFR: 17%, ALK: 5%, BRAF: 5%, HER2: 4%, PIK3CA: 2%). As of August 1, 2011, 63 of 288 advanced NSCLC patients (22%) had received molecularly targeted therapy based on their genotypic results, including 34 of 42 patients (81%) with EGFR mutations, 12 of 15 (80%) with ALK rearrangements, and 17 of 95 (18%) with KRAS, BRAF, or HER2 mutations. Conclusions: Large-scale testing for somatic alterations in EGFR, KRAS, BRAF, PIK3CA, HER2, and ALK is feasible and impacts therapeutic decisions. As the repertoire for personalized therapies expands in lung cancer and other malignancies, there is a need to develop new genomics technologies that can generate a comprehensive genetic profile of tumor specimens in a time-and cost-effective manner. C1 [Cardarella, Stephanie; Ortiz, Taylor M.; Butaney, Mohit; Jackman, David M.; Kwiatkowski, David J.; Jaenne, Pasi A.; Johnson, Bruce E.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Dept Med Oncol, Boston, MA 02215 USA. [Cardarella, Stephanie; Jackman, David M.; Kwiatkowski, David J.; Jaenne, Pasi A.; Johnson, Bruce E.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Cardarella, Stephanie; Jackman, David M.; Kwiatkowski, David J.; Yeap, Beow Y.; Jaenne, Pasi A.; Johnson, Bruce E.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Joshi, Victoria A.] Partners Healthcare Ctr Personalized Genet Med, Mol Med Lab, Cambridge, MA USA. [Joshi, Victoria A.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Yeap, Beow Y.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Jaenne, Pasi A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA. [Lindeman, Neal I.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Lindeman, Neal I.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Cardarella, S (reprint author), Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Dept Med Oncol, 450 Brookline Ave,Dana 1234C, Boston, MA 02215 USA. EM scardarella@partners.org FU American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Translational Research Professorship; National Institutes of Health [5R01-CA114465, 1RC2 CA148394-01]; Alice and Stephen D. Cutler Investigator Fund in Thoracic Oncology at the Dana-Farber Cancer Institute FX This work was funded in part by the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Translational Research Professorship (BEJ), National Institutes of Health grant 5R01-CA114465 (BEJ, PAJ, and BYY), National Institutes of Health grant 1RC2 CA148394-01 (DJK), and the Alice and Stephen D. Cutler Investigator Fund in Thoracic Oncology at the Dana-Farber Cancer Institute (DMJ and SH). NR 28 TC 49 Z9 50 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD DEC PY 2012 VL 7 IS 12 BP 1767 EP 1774 DI 10.1097/JTO.0b013e3182745bcb PG 8 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 041GM UT WOS:000311387700014 PM 23154547 ER PT J AU Heist, RS Mino-Kenudson, M Sequist, LV Tammireddy, S Morrissey, L Christiani, DC Engelman, JA Iafrate, AJ AF Heist, Rebecca S. Mino-Kenudson, Mari Sequist, Lecia V. Tammireddy, Swathi Morrissey, Laura Christiani, David C. Engelman, Jeffrey A. Iafrate, A. John TI FGFR1 Amplification in Squamous Cell Carcinoma of The Lung SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE Squamous cell lung cancer; FGFR1; Amplification ID FIBROBLAST GROWTH-FACTORS; FACTOR RECEPTORS; BREAST-CANCER; PHASE-III; GEFITINIB; MUTATIONS; TUMORS; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL AB Introduction: Amplification of fibroblast growth factor receptor 1 (FGFR1) has been reported in squamous cell lung carcinoma and may be a molecular target for therapy. Little is known, however, about the clinical and demographic correlates of FGFR1 amplification. Methods: The study is an Institutional Review Board approved retrospective analysis of 226 patients with squamous cell lung cancer seen at the Massachusetts General Hospital from 2005 to 2011. Clinical and demographic characteristics of all patients were obtained, as well as treatment details including surgery, radiation, and chemotherapy, and overall survival. fluorescence in situ hybridization was performed for FGFR1 on formalin-fixed paraffin-embedded tumor tissue. Clinical genotyping results were also reviewed where available. Results: Thirty-seven of 226 patients (16%) with squamous cell lung cancer were found positive for amplification using a definition of amplification of a gene to copy number control ratio of 2.2 or higher. FGFR1 amplification status was not associated with age, sex, stage, histologic subtype within squamous cell, smoking history, or pack-years of smoking. We found no significant difference in overall survival by FGFR1 amplification status as a whole; in the advanced stage subset, our findings are inconclusive because of the small sample size. Conclusion: FGFR1 amplification was found in 16% of a clinical cohort of squamous cell lung cancer patients. The lack of any specific clinicodemographic features that correlates with FGFR1 amplification suggests that all squamous cell patients should be tested for this genomic change. C1 [Heist, Rebecca S.; Sequist, Lecia V.; Tammireddy, Swathi; Morrissey, Laura; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Dept Thorac Oncol, Boston, MA 02114 USA. [Mino-Kenudson, Mari; Iafrate, A. John] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Christiani, David C.] Massachusetts Gen Hosp, Dept Pulm Med, Boston, MA 02114 USA. RP Heist, RS (reprint author), Massachusetts Gen Hosp, Ctr Canc, Dept Thorac Oncol, Yawkey 7B,55 Fruit St, Boston, MA 02114 USA. EM rheist@partners.org FU Specialized Program of Research Excellence (SPORE) Career Development Award FX This study was supported by Specialized Program of Research Excellence (SPORE) Career Development Award. NR 32 TC 60 Z9 71 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD DEC PY 2012 VL 7 IS 12 BP 1775 EP 1780 DI 10.1097/JTO.0b013e31826aed28 PG 6 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 041GM UT WOS:000311387700015 PM 23154548 ER PT J AU Kozak, KR Milne, GL Bentzen, SM Yock, TI AF Kozak, Kevin R. Milne, Ginger L. Bentzen, Soren M. Yock, Torunn I. TI Elevation of Prostaglandin E-2 in Lung Cancer Patients with Digital Clubbing SO JOURNAL OF THORACIC ONCOLOGY LA English DT Article DE Digital clubbing; Lung cancer; Prostaglandin ID HYPERTROPHIC OSTEOARTHROPATHY AB To test the hypothesis that digital clubbing in patients with lung cancer reflects elevated systemic levels of prostaglandin E-2 (PGE(2)), we quantified levels of the major urinary PGE(2) metabolite in 29 patients with lung cancer with or without clubbing. We found that digital clubbing was associated with markedly elevated urinary levels of PGE(2) metabolite. These findings highlight a potential role for PGE(2) in the pathogenesis of digital clubbing. Furthermore, this result identifies a lung cancer subpopulation that may uniquely benefit from cyclooxygenase inhibition. C1 [Kozak, Kevin R.; Bentzen, Soren M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Madison, WI 53792 USA. [Milne, Ginger L.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA. [Yock, Torunn I.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Kozak, KR (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Madison, WI 53792 USA. EM kozak@humonc.wisc.edu RI Bentzen, Soren/E-3997-2012; Milne, Ginger/D-7648-2014 OI Bentzen, Soren/0000-0002-7444-7564; Milne, Ginger/0000-0003-3890-151X FU NCATS NIH HHS [UL1 TR000427]; NCI NIH HHS [P30 CA014520]; NCRR NIH HHS [UL1 RR025011, UL1 RR025011-04, UL1 RR025011-05] NR 6 TC 5 Z9 5 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD DEC PY 2012 VL 7 IS 12 BP 1877 EP 1878 DI 10.1097/JTO.0b013e3181fc76a9 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA 041GM UT WOS:000311387700029 PM 22024643 ER PT J AU Patil, S Manola, J Elson, P Negrier, S Escudier, B Eisen, T Atkins, M Bukowski, R Motzer, RJ AF Patil, Sujata Manola, Judith Elson, Paul Negrier, Sylvie Escudier, Bernard Eisen, Tim Atkins, Michael Bukowski, Ronald Motzer, Robert J. TI Improvement in Overall Survival of Patients with Advanced Renal Cell Carcinoma: Prognostic Factor Trend Analysis from an International Data Set of Clinical Trials SO JOURNAL OF UROLOGY LA English DT Article DE kidney; carcinoma, renal cell; neoplasm metastasis; risk; SEER program ID CANCER WORKING GROUP; INTERFERON-ALPHA; TARGETED THERAPY; SUNITINIB; CYTOKINE; MODEL AB Purpose: We assessed temporal shifts in the frequency of risk factors for patients with metastatic renal cell carcinoma in a multicenter, international data set. Materials and Methods: An international database of 3,748 patients treated with systemic therapy for metastatic renal cell carcinoma from 1975 to 2002 was constructed by pooling clinical trial data. Proportions of previously identified risk factors were examined during 6 specified time cohorts. Overall survival for each cohort was examined using the Kaplan-Meier method. Trends in overall survival from 1973 to 2008 were also examined in 25,271 patients from the SEER (Surveillance, Epidemiology and End Results) database. Results: Median overall survival from start of treatment increased with each consecutive time cohort group. In the earliest cohort median overall survival was 0.5 years (95% CI 0.43-0.57), which increased to 1.63 years (95% CI 1.28-1.79) in 2001 to 2002. More patients had a history of nephrectomy in the most recent cohort (p = 0.001). The proportion of patients with low performance status, high lactate dehydrogenase and high adjusted calcium decreased by study entry year (each p <0.01). Analysis of overall survival from the SEER database showed similar improvement in the more contemporary diagnosis cohorts (p <0.001). Two-year overall survival in the earliest and latest diagnosis cohort was 14% (95% CI 13-14) and 22% (95% CI 21-24), respectively. Conclusions: Higher representation of favorable risk factors in recent years may have partly contributed to the improvement in overall survival observed in more recent metastatic renal cell carcinoma clinical trials. These shifts could affect the outcome interpretation. C1 [Patil, Sujata] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, New York, NY 10065 USA. [Manola, Judith] Dana Farber Canc Inst, Boston, MA 02115 USA. [Elson, Paul; Bukowski, Ronald] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA. [Negrier, Sylvie] Ctr Leon Berard, F-69373 Lyon, France. [Escudier, Bernard] Inst Gustave Roussy, Paris, France. [Eisen, Tim] Cambridge Biomed Res Ctr, Cambridge, England. [Atkins, Michael] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA. RP Patil, S (reprint author), Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, 307 E 63rd St, New York, NY 10065 USA. EM patils@mskcc.org FU Kidney Cancer Association FX Supported by the Kidney Cancer Association. NR 23 TC 18 Z9 19 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 EI 1527-3792 J9 J UROLOGY JI J. Urol. PD DEC PY 2012 VL 188 IS 6 BP 2095 EP 2100 DI 10.1016/j.juro.2012.08.026 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 043WM UT WOS:000311581400016 PM 23083849 ER PT J AU Olumi, AF AF Olumi, Aria F. TI Detecting DNA Methylation of the BCL2, CDKN2A and NID2 Genes in Urine Using a Nested Methylation Specific Polymerase Chain Reaction Assay to Predict Bladder Cancer EDITORIAL COMMENT SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA 02163 USA. RP Olumi, AF (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA 02163 USA. NR 3 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD DEC PY 2012 VL 188 IS 6 BP 2107 EP 2107 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 043WM UT WOS:000311581400018 PM 23083855 ER PT J AU Kilbridge, KL AF Kilbridge, Kerry L. TI Readability of Websites Containing Information About Prostate Cancer Treatment Options EDITORIAL COMMENT SO JOURNAL OF UROLOGY LA English DT Editorial Material C1 Massachusetts Gen Hosp, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Mongan Inst Hlth Policy, Boston, MA 02114 USA. RP Kilbridge, KL (reprint author), Massachusetts Gen Hosp, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Mongan Inst Hlth Policy, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5347 J9 J UROLOGY JI J. Urol. PD DEC PY 2012 VL 188 IS 6 BP 2176 EP 2176 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA 043WM UT WOS:000311581400041 ER PT J AU Carlson, JM Brumme, CJ Martin, E Listgarten, J Brockman, MA Le, AQ Chui, CKS Cotton, LA Knapp, DJHF Riddler, SA Haubrich, R Nelson, G Pfeifer, N DeZiel, CE Heckerman, D Apps, R Carrington, M Mallal, S Harrigan, PR John, M Brumme, ZL AF Carlson, Jonathan M. Brumme, Chanson J. Martin, Eric Listgarten, Jennifer Brockman, Mark A. Le, Anh Q. Chui, Celia K. S. Cotton, Laura A. Knapp, David J. H. F. Riddler, Sharon A. Haubrich, Richard Nelson, George Pfeifer, Nico DeZiel, Charles E. Heckerman, David Apps, Richard Carrington, Mary Mallal, Simon Harrigan, P. Richard John, Mina Brumme, Zabrina L. CA Int HIV Adaptation Collaborative TI Correlates of Protective Cellular Immunity Revealed by Analysis of Population-Level Immune Escape Pathways in HIV-1 SO JOURNAL OF VIROLOGY LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD8(+) T-CELLS; CLASS-I MOLECULES; VIRAL LOAD; SELECTION PRESSURE; LYMPHOCYTE RESPONSES; HLA ALLELES; DISEASE PROGRESSION; PRIMARY INFECTION; PEPTIDE BINDING AB HLA class I-associated polymorphisms identified at the population level mark viral sites under immune pressure by individual HLA alleles. As such, analysis of their distribution, frequency, location, statistical strength, sequence conservation, and other properties offers a unique perspective from which to identify correlates of protective cellular immunity. We analyzed HLA-associated HIV-1 subtype B polymorphisms in 1,888 treatment-naive, chronically infected individuals using phylogenetically informed methods and identified characteristics of HLA-associated immune pressures that differentiate protective and nonprotective alleles. Over 2,100 HLA-associated HIV-1 polymorphisms were identified, approximately one-third of which occurred inside or within 3 residues of an optimally defined cytotoxic T-lymphocyte (CTL) epitope. Differential CTL escape patterns between closely related HLA alleles were common and increased with greater evolutionary distance between allele group members. Among 9-mer epitopes, mutations at HLA-specific anchor residues represented the most frequently detected escape type: these occurred nearly 2-fold more frequently than expected by chance and were computationally predicted to reduce peptide-HLA binding nearly 10-fold on average. Characteristics associated with protective HLA alleles (defined using hazard ratios for progression to AIDS from natural history cohorts) included the potential to mount broad immune selection pressures across all HIV-1 proteins except Nef, the tendency to drive multisite and/or anchor residue escape mutations within known CTL epitopes, and the ability to strongly select mutations in conserved regions within HIV's structural and functional proteins. Thus, the factors defining protective cellular immune responses may be more complex than simply targeting conserved viral regions. The results provide new information to guide vaccine design and immunogenicity studies. C1 [Brumme, Chanson J.; Brockman, Mark A.; Chui, Celia K. S.; Knapp, David J. H. F.; Harrigan, P. Richard; Brumme, Zabrina L.] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Carlson, Jonathan M.; Listgarten, Jennifer; Pfeifer, Nico; DeZiel, Charles E.; Heckerman, David] Microsoft Res, Los Angeles, CA USA. [Martin, Eric; Brockman, Mark A.; Le, Anh Q.; Cotton, Laura A.; Brumme, Zabrina L.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada. [Riddler, Sharon A.] Univ Pittsburgh, Dept Infect Dis & Microbiol, Pittsburgh, PA USA. [Haubrich, Richard] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Nelson, George] SAIC Frederick Inc, Basic Res Program, Ctr Canc Res Genet Core, Frederick Natl Lab Canc Res, Frederick, MD USA. [Apps, Richard; Carrington, Mary] SAIC Frederick Inc, Canc & Inflammat Program, Expt Immunol Lab, Frederick Natl Lab Canc Res, Frederick, MD USA. [Apps, Richard; Carrington, Mary] Ragon Inst Massachusetts Gen Hosp MIT & Harvard, Charlestown, MA USA. [Mallal, Simon; John, Mina] Murdoch Univ, Ctr Clin Immunol & Biomed Stat, Inst Immunol & Infect Dis, Murdoch, WA 6150, Australia. [Mallal, Simon; John, Mina] Royal Perth Hosp, Dept Clin Immunol, Perth, WA 6001, Australia. RP Brumme, ZL (reprint author), British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada. EM carlson@microsoft.com; zbrumme@sfu.ca RI Pfeifer, Nico/G-1559-2016; OI Knapp, David/0000-0002-2161-9959; Pfeifer, Nico/0000-0002-4647-8566; Brumme, Chanson/0000-0003-2722-5288; Brockman, Mark/0000-0001-6432-1426 FU Canadian Institutes for Health Research (CIHR) [MOP-93536, HOP-115700]; NIAID [AI27670, AI36214, AI064086]; Frederick National Laboratory for Cancer Research [HHSN261200800001E]; Intramural Research Program of the NIH; Frederick National Lab; Center for Cancer Research; Vanier Canada Graduate Scholarship from the CIHR; Master's Scholarship from the Canadian Association of HIV Research and Abbott Virology; CIHR New Investigator Award; Michael Smith Foundation for Health Research; Northwestern University [AI 069471]; University of Minnesota [AI 27661]; Vanderbilt University [AI-069439]; Indiana University [AI25859, MO1RR000750]; University of Miami School of Medicine [AI069477]; University of Cincinnati [AI-069513]; University of Alabama [1 U01 AI069452-01, M01 RR-00032]; University of Southern California [AI27673]; Cornell CTU [AI069419-01, CTSC RR024996]; Ohio State University [AI069474]; University of Rochester [AI69411, 5-MO1 RR00044]; Univeristy of North Carolina-Chapel Hill [AI50410, AI69423-01, RR00046]; University of Pittsburgh [AI69494-01]; Duke University Medical Center [1U01-AI069484]; Harvard/BMC CTU [AI069472, AI060354, RR02635]; Durban International CTU [UOIA138858]; Case Western Reserve University [AI 069501]; University of Pennsylvania, Philadelphia [AI 69467-01, 5-P30-AI-045008-07]; Colorado ACTU [AI069450, RR00051]; University of Texas Medical Branch-Galveston [AI32782]; Johns Hopkins University [AI-69465, RR-00052]; University of California, Los Angeles [AI069424]; University of California, Davis Medical Center [AI38858-09S1]; University of Maryland, Institute of Human Virology [AI069447-01]; Washington University in St. Louis [AI069495]; University of California, San Francisco [AI069502-01]; Stanford University [AI069556]; University of California, San Diego [AI069432]; Beth Israel Medical Center [AI46370]; New York University/New York City Health and Hospitals Corp. at Bellevue Hospital Center [AI069532, M01-RR00096]; Miriam Hospital [AI69472]; University of Texas Southwestern Medical Center at Dallas [AI046376-05]; University of Hawaii at Manoa and Queen's Medical Center [AI34853]; University of Washington, Seattle [AI069434]; [AI068636]; [RR024975] FX This work was supported by operating grants from the Canadian Institutes for Health Research (CIHR) (MOP-93536 and HOP-115700) to Z.L.B./M.A.B. In addition this project has been funded in part by NIAID grants AI27670, AI36214, and AI064086 to University of California, San Diego (UCSD; R. Haubrich) and in whole or in part with federal funds from the Frederick National Laboratory for Cancer Research, under contract number HHSN261200800001E. This Research was supported in part by the Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer Research. C.J.B. is supported by a Vanier Canada Graduate Scholarship from the CIHR. E. M. is supported by a Master's Scholarship from the Canadian Association of HIV Research and Abbott Virology. M. A. B. holds a Canada Research Chair, Tier 2, in Viral Pathogenesis and Immunity. J.M.C., J.L., N.P., C. E. D., and D. H. are employees of Microsoft Corporation. Z.L.B. is the recipient of a CIHR New Investigator Award and a scholar award from the Michael Smith Foundation for Health Research. The ACTG Human DNA Repository is supported by grants AI068636 and RR024975. The following is a list of ACTG sites that participated in both A5142 and A5128 protocols, along with their grant numbers: Northwestern University (sites 2701, 2702, and 2705), Clinical Trials Unit (CTU) grant AI 069471; University of Minnesota (sites 1501, 1504, and 1505), CTU grant AI 27661; Vanderbilt University (site 3652), CTU grant AI-069439; Indiana University (sites 2601 and 2603), CTU grant AI25859 and GCRC grant MO1RR000750; University of Miami School of Medicine (site 901), CTU grant AI069477; University of Cincinnati (site 2401), CTU grant AI-069513; University of Alabama (sites 5801 and 5802), CTU grant 1 U01 AI069452-01 and GCRC grant M01 RR-00032; University of Southern California (site 1201), CTU grant AI27673; Cornell CTU (site 30329, 7803, and 7804), CTU grants AI069419-01 and CTSC RR024996; The Ohio State University (Site 2301), CTU grant AI069474; University of Rochester (sites 1101, 1102, 1107, and 1108), CTU grant AI69411 and GCRC grant 5-MO1 RR00044; Univeristy of North Carolina-Chapel Hill (site 3201), CFAR grant AI50410, CTU grant AI69423-01, and GCRC grant RR00046; University of Pittsburgh (site 1001 and 1008), CTU grant AI69494-01; Duke University Medical Center (site 1601), CTU grant 1U01-AI069484; Harvard/BMC CTU (sites 103, 104, and 107), CTU grant AI069472, CFAR grant AI060354, and GCRC grant RR02635; Durban International CTU (site 11201), grant UOIA138858; Case Western Reserve University (sites 2501, 2503, and 2508), CTU grant AI 069501; University of Pennsylvania, Philadelphia (sites 6201 and 6206), CTU grant AI 69467-01 and CFAR grant 5-P30-AI-045008-07; Colorado ACTU (site 6101), CTU grant AI069450 and GCRC grant RR00051; University of Texas Medical Branch-Galveston (site 6301), CTU grant AI32782; Johns Hopkins University (site 201), CTU grant AI-69465 and GCRC grant RR-00052; University of California, Los Angeles (sites 601 and 603), CTU grant AI069424; University of California, Davis Medical Center (site 3852), CTU grant AI38858-09S1; University of Maryland, Institute of Human Virology (site 4651), CTU grant AI069447-01; Washington University in St.; Louis (site 2101), CTU grant AI069495; University of California, San Francisco (site 801), CTU grant AI069502-01; Stanford University (sites 501, 505, and 506), CTU grant AI069556; University of California, San Diego (site 701), grant AI069432; Beth Israel Medical Center (site 2851), CTU grant AI46370; New York University/New York City Health and Hospitals Corp. at Bellevue Hospital Center (site 401), CTU grant AI069532 and GCRC grant M01-RR00096; The Miriam Hospital (site 2951), CTU grant AI69472; University of Texas Southwestern Medical Center at Dallas (site 3751), CTU grant AI046376-05; University of Hawaii at Manoa and Queen's Medical Center (site 5201), CTU grant AI34853; University of Washington, Seattle (site 1401), CTU grant AI069434. NR 124 TC 42 Z9 44 U1 2 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD DEC PY 2012 VL 86 IS 24 BP 13202 EP 13216 DI 10.1128/JVI.01998-12 PG 15 WC Virology SC Virology GA 040DC UT WOS:000311299600006 PM 23055555 ER PT J AU Chopera, DR Cotton, LA Zawaira, A Mann, JK Ngandu, NK Ntale, R Carlson, JM Mlisana, K Woodman, Z Rosa, DD Martin, E Miura, T Pereyra, F Walker, BD Gray, CM Martin, DP Ndung'u, T Brockman, MA Karim, SA Brumme, ZL Williamson, C AF Chopera, Denis R. Cotton, Laura A. Zawaira, Alexander Mann, Jaclyn K. Ngandu, Nobubelo K. Ntale, Roman Carlson, Jonathan M. Mlisana, Koleka Woodman, Zenda Rosa, Debra de Assis Martin, Eric Miura, Toshiyuki Pereyra, Florencia Walker, Bruce D. Gray, Clive M. Martin, Darren P. Ndung'u, Thumbi Brockman, Mark A. Karim, Salim Abdool Brumme, Zabrina L. Williamson, Carolyn CA CAPRISA 002 Acute Infection Study Team TI Intersubtype Differences in the Effect of a Rare p24 Gag Mutation on HIV-1 Replicative Fitness SO JOURNAL OF VIROLOGY LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; STRUCTURE PREDICTION SERVER; T-LYMPHOCYTE ESCAPE; ELITE CONTROLLERS; CHRONIC INFECTION; IMMUNE ESCAPE; SUBTYPE B; PEP-FOLD; HLA; CAPACITY AB Certain immune-driven mutations in HIV-1, such as those arising in p24(Gag), decrease viral replicative capacity. However, the intersubtype differences in the replicative consequences of such mutations have not been explored. In HIV-1 subtype B, the p24(Gag) M250I mutation is a rare variant (0.6%) that is enriched among elite controllers (7.2%) (P = 0.0005) and appears to be a rare escape variant selected by HLA-B58 supertype alleles (P < 0.01). In contrast, in subtype C, it is a relatively common minor polymorphic variant (10 to 15%) whose appearance is not associated with a particular HLA allele. Using site-directed mutant viruses, we demonstrate that M250I reduces in vitro viral replicative capacity in both subtype B and subtype C sequences. However, whereas in subtype C downstream compensatory mutations at p24(Gag) codons 252 and 260 reduce the adverse effects of M250I, fitness costs in subtype B appear difficult to restore. Indeed, patient-derived subtype B sequences harboring M250I exhibited in vitro replicative defects, while those from subtype C did not. The structural implications of M250I were predicted by protein modeling to be greater in subtype B versus C, providing a potential explanation for its lower frequency and enhanced replicative defects in subtype B. In addition to accounting for genetic differences between HIV-1 subtypes, the design of cytotoxic-T-lymphocyte-based vaccines may need to account for differential effects of host-driven viral evolution on viral fitness. C1 [Gray, Clive M.; Williamson, Carolyn] Univ Cape Town, Inst Infect Dis & Mol Med, Div Immunol, ZA-7925 Cape Town, South Africa. [Chopera, Denis R.; Ngandu, Nobubelo K.; Ntale, Roman; Martin, Darren P.; Williamson, Carolyn] Univ Cape Town, Div Med Virol, ZA-7925 Cape Town, South Africa. [Chopera, Denis R.; Ngandu, Nobubelo K.; Ntale, Roman; Martin, Darren P.; Williamson, Carolyn] Natl Hlth Lab Serv, Cape Town, South Africa. [Chopera, Denis R.; Cotton, Laura A.; Martin, Eric; Brockman, Mark A.; Brumme, Zabrina L.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada. [Chopera, Denis R.; Brockman, Mark A.; Brumme, Zabrina L.] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Zawaira, Alexander] CSIR, Gene Express & Biophys Grp, Pretoria, South Africa. [Mann, Jaclyn K.; Ndung'u, Thumbi] Univ KwaZulu Natal, HIV Pathogenesis Programme, Doris Duke Med Res Inst, Nelson R Mandela Sch Med, Durban, South Africa. [Carlson, Jonathan M.] Microsoft Res, Los Angeles, CA USA. [Mlisana, Koleka; Karim, Salim Abdool] Univ KwaZulu Natal, Ctr AIDS Programme Res S Africa, Durban, South Africa. [Woodman, Zenda] Univ Cape Town, Dept Mol & Cell Biol, ZA-7925 Cape Town, South Africa. [Rosa, Debra de Assis] Natl Inst Communicable Dis, Johannesburg, South Africa. [Miura, Toshiyuki] Univ Tokyo, Tokyo, Japan. [Pereyra, Florencia; Walker, Bruce D.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Boston, MA USA. RP Williamson, C (reprint author), Univ Cape Town, Inst Infect Dis & Mol Med, Div Immunol, ZA-7925 Cape Town, South Africa. EM zbrumme@sfu.ca; carolyn.williamson@uct.ac.za RI Abdool Karim, Salim Safurdeen/N-5947-2013; OI Abdool Karim, Salim Safurdeen/0000-0002-4986-2133; , Carolyn/0000-0003-0125-1226; Mlisana, Koleka/0000-0002-8436-3268; Ndung'u, Thumbi/0000-0003-2962-3992; Brockman, Mark/0000-0001-6432-1426 FU Canadian Institutes for Health Research (CIHR) [MOP-93536, HOP-115700]; Microsoft Research; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH); U.S. Department of Health and Human Services grant [U19 A151794]; NIAID International Research in Infectious Diseases (IRID) [1R01AI078936]; Technology Innovation Agency, South Africa (TIA); Centre for the AIDS Program of Research in South Africa (CAPRISA); Canada-HOPE fellowship from CIHR; Sanofi-Aventis; Clinical Infectious Diseases Research Initiative (CIDRI) fellowship; Sydney Brenner fellowship; National Research Foundation; Ragon Institute of Massachusetts General Hospital; Massachusetts Institute of Technology; Harvard University; Howard Hughes Medical Institute (HHMI); CIHR New Investigator Award; Michael Smith Foundation for Health Research (MSFHR) Scholar Award FX This study was supported by operating grants from the Canadian Institutes for Health Research (CIHR; MOP-93536 and HOP-115700 to Z.L.B./M.A.B.), a Jim Gray seed grant from Microsoft Research (to Z.L.B./M.A.B.), a National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), U.S. Department of Health and Human Services grant U19 A151794, and a NIAID International Research in Infectious Diseases (IRID) grant 1R01AI078936 (to C. W.). An India-South Africa collaborative grant was provided through the Technology Innovation Agency, South Africa (TIA), and the Centre for the AIDS Program of Research in South Africa (CAPRISA) (to C. W.). D. R. C. is a recipient of the Canada-HOPE fellowship from CIHR and Sanofi-Aventis and the Clinical Infectious Diseases Research Initiative (CIDRI) fellowship. A.Z. is funded by a Sydney Brenner fellowship. J.K.M. is funded by the National Research Foundation and the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University. T.N. holds the South African Department of Science and Technology/National Research Foundation Research Chair in Systems Biology of HIV/AIDS and an International Early Career Scientist Award from the Howard Hughes Medical Institute (HHMI). M. A. B. holds a Canada Research Chair, Tier 2, in Viral Pathogenesis and Immunity. Z.L.B. is the recipient of a CIHR New Investigator Award and a Michael Smith Foundation for Health Research (MSFHR) Scholar Award. NR 53 TC 5 Z9 5 U1 1 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD DEC PY 2012 VL 86 IS 24 BP 13423 EP 13433 DI 10.1128/JVI.02171-12 PG 11 WC Virology SC Virology GA 040DC UT WOS:000311299600025 PM 23015721 ER PT J AU Nguyen, PL AF Nguyen, Paul L. TI Harms versus benefits with duration of androgen suppression SO LANCET ONCOLOGY LA English DT Editorial Material ID ADVANCED PROSTATE-CANCER; RADIATION-THERAPY; RADIOTHERAPY; DEPRIVATION; TRIAL C1 Harvard Univ, Dept Radiat Oncol, Dana Farber & Brigham & Womens Canc Ctr, Sch Med, Boston, MA 02115 USA. RP Nguyen, PL (reprint author), Harvard Univ, Dept Radiat Oncol, Dana Farber & Brigham & Womens Canc Ctr, Sch Med, 75 Francis St, Boston, MA 02115 USA. EM pnguyen@LROC.harvard.edu NR 8 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1470-2045 J9 LANCET ONCOL JI Lancet Oncol. PD DEC PY 2012 VL 13 IS 12 BP 1182 EP 1183 DI 10.1016/S1470-2045(12)70480-1 PG 3 WC Oncology SC Oncology GA 042YR UT WOS:000311509400025 PM 23151430 ER PT J AU Cornelis, MC Glymour, MM Chang, SC Tchetgen, EJT Liang, L Koenen, KC Kang, JH Pasquale, LR Rimm, EB Kawachi, I Kubzansky, LD AF Cornelis, M. C. Glymour, M. M. Chang, S-C Tchetgen, E. J. T. Liang, L. Koenen, K. C. Kang, J. H. Pasquale, L. R. Rimm, E. B. Kawachi, I. Kubzansky, L. D. TI Oxytocin receptor (OXTR) is not associated with optimism in the Nurses' Health Study SO MOLECULAR PSYCHIATRY LA English DT Letter ID GENE OXTR C1 [Cornelis, M. C.; Rimm, E. B.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Glymour, M. M.; Chang, S-C; Koenen, K. C.; Rimm, E. B.; Kawachi, I.; Kubzansky, L. D.] Dept Soc Human Dev & Hlth, Boston, MA USA. [Tchetgen, E. J. T.; Liang, L.; Kang, J. H.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Koenen, K. C.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Kang, J. H.; Pasquale, L. R.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Pasquale, L. R.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Pasquale, L. R.; Rimm, E. B.] Harvard Univ, Sch Med, Boston, MA USA. RP Cornelis, MC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. EM mcorneli@hsph.harvard.edu FU NEI NIH HHS [R01 EY015473]; NIDDK NIH HHS [P01 DK070756, 5P01DK070756]; NIMH NIH HHS [RC4 MH092707, 1RC4 MH092707]; PHS HHS [UOHG004728] NR 10 TC 14 Z9 15 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD DEC PY 2012 VL 17 IS 12 BP 1157 EP 1159 DI 10.1038/mp.2011.178 PG 4 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA 041UB UT WOS:000311425600005 PM 22212599 ER PT J AU Lin, PY Mischoulon, D Freeman, MP Matsuoka, Y Hibbeln, J Belmaker, RH Su, KP AF Lin, P-Y Mischoulon, D. Freeman, M. P. Matsuoka, Y. Hibbeln, J. Belmaker, R. H. Su, K-P TI Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression SO MOLECULAR PSYCHIATRY LA English DT Letter ID EICOSAPENTAENOIC ACID; DOUBLE-BLIND; METAANALYSIS; TRIALS; EPA C1 [Lin, P-Y] Kaohsiung Chang Gung Mem Hosp, Dept Psychiat, Kaohsiung, Taiwan. [Lin, P-Y] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan. [Mischoulon, D.; Freeman, M. P.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Mischoulon, D.; Freeman, M. P.] Harvard Univ, Sch Med, Boston, MA USA. [Matsuoka, Y.] Natl Ctr Neurol & Psychiat, Dept Psychiat, Tokyo, Japan. [Hibbeln, J.] NIAAA, NIH, Sect Nutr Neurosci, Bethesda, MD USA. [Belmaker, R. H.] Ben Gurion Univ Negev, Dept Psychiat, IL-84105 Beer Sheva, Israel. [Su, K-P] China Med Univ, Grad Inst Neural & Cognit Sci, Taichung, Taiwan. [Su, K-P] China Med Univ Hosp, Dept Psychiat, Taichung, Taiwan. RP Lin, PY (reprint author), Kaohsiung Chang Gung Mem Hosp, Dept Psychiat, Kaohsiung, Taiwan. EM cobolsu@gmail.com FU Intramural NIH HHS [ZIA AA000115-12] NR 9 TC 41 Z9 41 U1 0 U2 25 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD DEC PY 2012 VL 17 IS 12 BP 1161 EP 1163 DI 10.1038/mp.2012.111 PG 3 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA 041UB UT WOS:000311425600007 PM 22824812 ER PT J AU Hollingworth, P Sweet, R Sims, R Harold, D Russo, G Abraham, R Stretton, A Jones, N Gerrish, A Chapman, J Ivanov, D Moskvina, V Lovestone, S Priotsi, P Lupton, M Brayne, C Gill, M Lawlor, B Lynch, A Craig, D McGuinness, B Johnston, J Holmes, C Livingston, G Bass, NJ Gurling, H McQuillin, A Holmans, P Jones, L Devlin, B Klei, L Barmada, MM Demirci, FY DeKosky, ST Lopez, OL Passmore, P Owen, MJ O'Donovan, MC Mayeux, R Kamboh, MI Williams, J AF Hollingworth, P. Sweet, R. Sims, R. Harold, D. Russo, G. Abraham, R. Stretton, A. Jones, N. Gerrish, A. Chapman, J. Ivanov, D. Moskvina, V. Lovestone, S. Priotsi, P. Lupton, M. Brayne, C. Gill, M. Lawlor, B. Lynch, A. Craig, D. McGuinness, B. Johnston, J. Holmes, C. Livingston, G. Bass, N. J. Gurling, H. McQuillin, A. Holmans, P. Jones, L. Devlin, B. Klei, L. Barmada, M. M. Demirci, F. Y. DeKosky, S. T. Lopez, O. L. Passmore, P. Owen, M. J. O'Donovan, M. C. Mayeux, R. Kamboh, M. I. Williams, J. CA GERAD Consortium Natl Inst Aging Late-Onset Alzheim TI Genome-wide association study of Alzheimer's disease with psychotic symptoms SO MOLECULAR PSYCHIATRY LA English DT Article DE Alzheimer's disease; psychosis; behavioural symptoms; genome-wide association study; genetic ID INCREASED FAMILIAL RISK; COMPLEMENT RECEPTOR 1; COMMON VARIANTS; BIPOLAR DISORDER; URIC-ACID; NEUROPSYCHIATRIC INVENTORY; COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; IDENTIFIES VARIANTS; NATIONAL INSTITUTE AB Psychotic symptoms occur in similar to 40% of subjects with Alzheimer's disease (AD) and are associated with more rapid cognitive decline and increased functional deficits. They show heritability up to 61% and have been proposed as a marker for a disease subtype suitable for gene mapping efforts. We undertook a combined analysis of three genome-wide association studies (GWASs) to identify loci that (1) increase susceptibility to an AD and subsequent psychotic symptoms; or (2) modify risk of psychotic symptoms in the presence of neurodegeneration caused by AD. In all, 1299 AD cases with psychosis (AD+P), 735 AD cases without psychosis (AD-P) and 5659 controls were drawn from Genetic and Environmental Risk in AD Consortium 1 (GERAD1), the National Institute on Aging Late-Onset Alzheimer's Disease (NIA-LOAD) family study and the University of Pittsburgh Alzheimer Disease Research Center (ADRC) GWASs. Unobserved genotypes were imputed to provide data on > 1.8 million single-nucleotide polymorphisms (SNPs). Analyses in each data set were completed comparing (1) AD+P to AD-P cases, and (2) AD+P cases with controls (GERAD1, ADRC only). Aside from the apolipoprotein E (APOE) locus, the strongest evidence for association was observed in an intergenic region on chromosome 4 (rs753129; 'AD+PvAD-P' P=2.85 x 10(-7); 'AD+PvControls' P=1.11 x 10(-4)). SNPs upstream of SLC2A9 (rs6834555, P=3.0 x 10(-7)) and within VSNL1 (rs4038131, P=5.9 x 10(-7)) showed strongest evidence for association with AD+P when compared with controls. These findings warrant further investigation in larger, appropriately powered samples in which the presence of psychotic symptoms in AD has been well characterized. Molecular Psychiatry (2012) 17, 1316-1327; doi: 10.1038/mp.2011.125; published online 18 October 2011 C1 [Sweet, R.; Devlin, B.; Klei, L.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. [Hollingworth, P.; Sims, R.; Harold, D.; Russo, G.; Abraham, R.; Stretton, A.; Jones, N.; Gerrish, A.; Chapman, J.; Ivanov, D.; Moskvina, V.; Holmans, P.; Owen, M. J.; O'Donovan, M. C.; Williams, J.] Cardiff Univ, Neurosci & Mental Hlth Res Inst, Ctr Neuropsychiat Genet & Genom, Dept Psychol Med & Neurol,Sch Med,MRC, Cardiff, S Glam, Wales. [Sweet, R.; DeKosky, S. T.; Lopez, O. L.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Sweet, R.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res 4, Educ & Clin Ctr MIRECC, Pittsburgh, PA USA. [Lovestone, S.; Priotsi, P.; Lupton, M.] Kings Coll London, Dept Neurosci, Inst Psychiat, London WC2R 2LS, England. [Brayne, C.] Univ Cambridge, Inst Publ Hlth, Cambridge, England. [Gill, M.; Lawlor, B.; Lynch, A.] St James Hosp, Mercers Inst Res Aging, Dublin 8, Ireland. [Gill, M.; Lawlor, B.; Lynch, A.] Trinity Coll Dublin, Dublin, Ireland. [Craig, D.; McGuinness, B.; Johnston, J.; Passmore, P.] Queens Univ Belfast, Ageing Grp, Ctr Publ Hlth, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland. [Holmes, C.] Univ Southampton, Div Clin Neurosci, Sch Med, Southampton, Hants, England. [Livingston, G.; Bass, N. J.; Gurling, H.; McQuillin, A.] UCL, Dept Mental Hlth Sci, London, England. [Barmada, M. M.; Mayeux, R.] Columbia Univ, Coll Phys & Surg, Taub Inst, New York, NY USA. [Barmada, M. M.; Mayeux, R.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA. [Demirci, F. Y.; Kamboh, M. I.] Univ Pittsburgh, Dept Human Genet, Grad Sch Publ Hlth, Pittsburgh, PA 15213 USA. [DeKosky, S. T.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA. RP Sweet, R (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA. EM SweetRA@upmc.edu; williamsj@cardiff.ac.uk RI Al-Chalabi, Ammar/E-5361-2010; Gurling, Hugh/A-5029-2010; Kowall, Neil/G-6364-2012; Kornhuber, Johannes/B-9613-2014; Singleton, Andrew/C-3010-2009; Holmans, Peter/F-4518-2015; Livingston, Gill/C-7081-2008; Guerreiro, Rita/A-1327-2011; McQuillin, Andrew/C-1623-2008; OI Kamboh, M. Ilyas/0000-0002-3453-1438; Barmada, M Michael/0000-0002-3604-6460; Al-Chalabi, Ammar/0000-0002-4924-7712; Kowall, Neil/0000-0002-6624-0213; Kornhuber, Johannes/0000-0002-8096-3987; Holmans, Peter/0000-0003-0870-9412; McQuillin, Andrew/0000-0003-1567-2240; O'Donovan, Michael/0000-0001-7073-2379; Demirci, F. Yesim/0000-0001-6907-9843; Gill, Michael/0000-0003-0206-5337; Escott-Price, Valentina/0000-0003-1784-5483; Harold, Denise/0000-0001-5195-0143; Ivanov, Dobril/0000-0001-6271-6301; Nothen, Markus/0000-0002-8770-2464; Livingston, Gill/0000-0001-6741-5516 FU MRC; Wellcome Trust; Alzheimer's Research Trust; Welsh Assembly Government; Alzheimer's Society; Ulster Garden Villages; N Ireland RD Office; Royal College of Physicians/Dunhill Medical Trust; Mercer's Institute for Research on Ageing; Lundbeck SA; MRC [G0800509]; National Institutes of Health [HHSN268200782096C]; NIA-LOAD Family Study [U24AG026395]; University of Pittsburgh [R01AG027224, R01AG030653, P50AG005133]; Rush University Medical Center [P30AG10161]; Boston Universit [P30AG013846]; Columbia University [P50AG08702]; Duke University [P30AG028377]; Indiana University [P30AG010133]; Massachusetts General Hospital [P50AG05134]; Mayo Clinic, Rochester [P50AG165574]; Mayo Clinic, Jacksonville [P50AG165574]; Mount Sinai School of Medicine [P01AG05138, P01AG02219, P50AG05138]; Northwestern University Medical School [P30AG13854]; Oregon Health and Science University [P30AG008017]; University of Alabama at Birmingham [P50AG016582]; David Geffen School of Medicine, University of California, Los Angeles [P50AG016579]; University of Kentucky, Lexington [P30AG028383]; University of Pennsylvania [P30AG10124]; University of Southern California [P50AG05142]; University of Texas Southwestern Medical Center [P30AG12300]; University of Washington [P50AG05136]; Washington University School of Medicine [P50AG05681, P01AG03991]; USPHS [AG027224]; [U24AG021886] FX Professor Williams and Dr Harold have a patent application with respect to genes identified in the GWAS of Harold et al.:2 this study provided data for this manuscript and was funded by the MRC and the Wellcome Trust.; GERAD1: We thank the patients and families who took part in this research. The Cardiff University group was supported by the Wellcome Trust, Medical Research Council, Alzheimer's Research Trust and the Welsh Assembly Government. The Alzheimer's Research Trust also supported and funded DNA sample collections at the Institute of Psychiatry, Cambridge University, University of Nottingham and University of Belfast. The University of Belfast group are supported by the Alzheimer's Society, Alzheimer's Research Trust, Ulster Garden Villages, N Ireland R&D Office and the Royal College of Physicians/Dunhill Medical Trust. The Trinity College Dublin sample was supported by the MRC and Mercer's Institute for Research on Ageing. The LASER-AD study was funded by Lundbeck SA. GR is supported by a program grant from the MRC (G0800509). We also thank Advanced Research Computing @ Cardiff (ARCCA) who facilitated data analysis. NIA-LOAD: Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. Samples used in this study were obtained from the National Cell Repository for Alzheimer's Disease (NCRAD). Jennifer Williamson, Susan LaRusse Eckert and Stephanie Doan (Columbia University), Michele Goodman (Indiana University) and Elise Weamer (University of Pittsburgh) helped coordinate the project across the United States. We especially acknowledge the support and guidance of Creighton H Phelps, PhD, at the National Institute on Aging. ADRC: The following investigators and Alzheimer's Disease Centers participated in the Study: Boston University Robert Green, Neil Kowall, Lindsay Farrer; Columbia University Jennifer Williamson, Vincent Santana; Duke University Donald Schmechel, Peter Gaskel; Indiana University, Bernardino Ghetti, Martin R Farlow, Kelly Horner; Massachusetts General Hospital John H Growdon, Deborah Blacker, Rudolph E Tanzi, Bradley T Hyman; Mayo Clinic-Rochester Bradley Boeve, Karen Kuntz, Lindsay Norgaard, Nathan Larson; Mayo Clinic-Jacksonville Dana Kistler, Fracine Parfitt, Jenny Haddow; Mount Sinai School of Medicine Jeremy Silverman, Michal Schnaider Beeri, Mary Sano, Joy Wang, Rachel Lally; Northwestern University Nancy Johnson, Marcel Mesulum, Sandra Weintraub, Eileen Bigio; Oregon Health and Science University Jeffery Kaye, Patricia Kramer, Jessica Payne-Murphy; Rush University David Bennett, Holli Jacobs, Jeen-Soo Chang, Danielle Arends; University of Alabama at Birmingham Lindy Harrell; University of California, Los Angeles George Bartzokis, Jeffery Cummings, Po H Lu, Usha Toland; University of Kentucky William Markesbery, Charles Smith, Alise Brickhouse; University of Pennsylvania John Trojanowski, Vivianna Van Deerlin, Elisabeth McCarty Wood; University of Pittsburgh Oscar L Lopez, Robert A Sweet; University of Southern California I Helena Chui, Arousiak Varpetian; University of Texas Southwestern Ramon Diaz-Arrastia, Roger Rosenberg, Barbara Davis; University of Washington Thomas Bird, Malia Rumbaugh, Gerard D Schellenberg, Murray Raskind; Washington University at St Louis Alison Goate, John Morris, Joanne Norton, Denise Levitch, Betsy Grant, Mary Coats.; This study was supported by the following federal grants: U24AG026395 (NIA-LOAD Family Study); U24AG021886 (National Cell Repository for Alzheimer's Disease); R01AG027224, R01AG030653 and P50AG005133 University of Pittsburgh; P30AG10161 Rush University Medical Center; P30AG013846 Boston University; P50AG08702 Columbia University; P30AG028377 Duke University; P30AG010133 Indiana University; P50AG05134 Massachusetts General Hospital; P50AG165574 Mayo Clinic, Rochester and Mayo Clinic, Jacksonville; P01AG05138, P01AG02219, and P50AG05138 Mount Sinai School of Medicine; P30AG13854 Northwestern University Medical School; P30AG008017 Oregon Health and Science University; P50AG016582 University of Alabama at Birmingham; P50AG016579 David Geffen School of Medicine, University of California, Los Angeles; P30AG028383 University of Kentucky, Lexington; P30AG10124 University of Pennsylvania; P50AG05142 University of Southern California; P30AG12300 The University of Texas Southwestern Medical Center; P50AG05136 University of Washington; and P50AG05681 and P01AG03991 Washington University School of Medicine. Collection and ascertainment of the ADRC subjects was supported by USPHS grants AG027224. We thank contributors who collected samples used in this study, and we particularly thank the patients and their families, whose help and participation made this work possible. NR 72 TC 33 Z9 33 U1 3 U2 24 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD DEC PY 2012 VL 17 IS 12 BP 1316 EP 1327 DI 10.1038/mp.2011.125 PG 12 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA 041UB UT WOS:000311425600023 PM 22005930 ER PT J AU Kobayashi, KS van den Elsen, PJ AF Kobayashi, Koichi S. van den Elsen, Peter J. TI NLRC5: a key regulator of MHC class I-dependent immune responses SO NATURE REVIEWS IMMUNOLOGY LA English DT Article ID BARE-LYMPHOCYTE-SYNDROME; COMPLEX CLASS-II; NUCLEOTIDE-BINDING DOMAIN; FAMILY-MEMBER NLRC5; NF-KAPPA-B; TRANSACTIVATOR CIITA; GENE-EXPRESSION; MICE LACKING; IFN-GAMMA; TRANSCRIPTIONAL COACTIVATOR AB The expression of MHC class I molecules is crucial for the initiation and regulation of adaptive immune responses against pathogens. NOD-, LRR- and CARD-containing 5 (NLRC5) was recently identified as a specific transactivator of MHC class I genes (CITA). NLRC5 and the master regulator for MHC class II genes, class II transactivator (CIITA), interact with similar MHC promoter-bound factors. Here, we provide a broad overview of the molecular mechanisms behind MHC class I transcription and the role of the class I transactivator NLRC5 in MHC class I-dependent immune responses. C1 [Kobayashi, Koichi S.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Microbial & Mol Pathogenesis, College Stn, TX 77843 USA. [van den Elsen, Peter J.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands. [Kobayashi, Koichi S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA. [van den Elsen, Peter J.] Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 NA Leiden, Netherlands. [Kobayashi, Koichi S.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02215 USA. RP Kobayashi, KS (reprint author), Texas A&M Hlth Sci Ctr, Coll Med, Dept Microbial & Mol Pathogenesis, 415A Reynolds Med Bldg, College Stn, TX 77843 USA. EM kobayashi@medicine.tamhsc.edu; P.J.van_den_Elsen@lumc.nl OI Van den Elsen, Peter/0000-0002-5196-0082 FU US National Institutes of Health; Broad Medical Research Program of the Eli and Edythe L. Broad Foundation; Investigator Award from the Cancer Research Institute; Claudia Adams Barr Award for Innovative Basic Cancer Research; Dutch Cancer Society; Dutch MS Research Foundation; Netherlands Organization for Research FX This work was supported by grants from the US National Institutes of Health and the Broad Medical Research Program of the Eli and Edythe L. Broad Foundation (to K.S.K.). K.S.K. is a recipient of the Investigator Award from the Cancer Research Institute and the Claudia Adams Barr Award for Innovative Basic Cancer Research. The work of P.v.d.E. was supported by grants from the Dutch Cancer Society, the Dutch MS Research Foundation and the Netherlands Organization for Research. The authors thank Y.-J. Liu for proofreading the manuscript. NR 53 TC 61 Z9 61 U1 1 U2 22 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1474-1733 J9 NAT REV IMMUNOL JI Nat. Rev. Immunol. PD DEC PY 2012 VL 12 IS 12 BP 813 EP 820 DI 10.1038/nri3339 PG 8 WC Immunology SC Immunology GA 042OC UT WOS:000311479500010 PM 23175229 ER PT J AU Meijer, DH Kane, MF Mehta, S Liu, HY Harrington, E Taylor, CM Stiles, CD Rowitch, DH AF Meijer, Dimphna H. Kane, Michael F. Mehta, Shwetal Liu, Hongye Harrington, Emily Taylor, Christopher M. Stiles, Charles D. Rowitch, David H. TI Separated at birth? The functional and molecular divergence of OLIG1 and OLIG2 SO NATURE REVIEWS NEUROSCIENCE LA English DT Review ID TRANSCRIPTION FACTOR OLIG2; CENTRAL-NERVOUS-SYSTEM; OLIGODENDROCYTE PROGENITOR CELLS; VENTRAL NEURAL-TUBE; DORSAL SPINAL-CORD; MULTIPLE-SCLEROSIS; STEM-CELLS; DOWN-SYNDROME; BRAIN-INJURY; RHEUMATOID-ARTHRITIS AB The basic helix-loop-helix transcription factors oligodendrocyte transcription factor 1 (OLIG1) and OLIG2 are structurally similar and, to a first approximation, coordinately expressed in the developing CNS and postnatal brain. Despite these similarities, it was apparent from early on after their discovery that OLIG1 and OLIG2 have non-overlapping developmental functions in patterning, neuron subtype specification and the formation of oligodendrocytes. Here, we summarize more recent insights into the separate roles of these transcription factors in the postnatal brain during repair processes and in neurological disease states, including multiple sclerosis and malignant glioma. We discuss how the unique functions of OLIG1 and OLIG2 may reflect their distinct genetic targets, co-regulator proteins and/or post-translational modifications. C1 [Meijer, Dimphna H.; Kane, Michael F.; Mehta, Shwetal; Taylor, Christopher M.; Stiles, Charles D.] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02215 USA. [Meijer, Dimphna H.; Kane, Michael F.; Mehta, Shwetal; Taylor, Christopher M.; Stiles, Charles D.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. [Liu, Hongye] Childrens Hosp, Informat Program, Boston, MA 02115 USA. [Harrington, Emily; Rowitch, David H.] Univ Calif San Francisco, Dept Pediat, Howard Hughes Med Inst, San Francisco, CA 94143 USA. [Harrington, Emily; Rowitch, David H.] Univ Calif San Francisco, Dept Neurol Surg, Howard Hughes Med Inst, San Francisco, CA 94143 USA. [Taylor, Christopher M.] EMD Serono Res Inst, Billerica, MA 01821 USA. RP Stiles, CD (reprint author), Harvard Univ, Sch Med, Dept Neurobiol, 450 Brookline Ave, Boston, MA 02215 USA. EM Charles_Stiles@dfci.harvard.edu; RowitchD@peds.ucsf.edu FU National Institutes of Health [NS047572, NS057727, NS040511]; Pediatric Low-Grade Astrocytoma Foundation; Howard Hughes Medical Institute FX The authors gratefully acknowledge helpful conversations with W. Richardson (University College London, UK), R. Miller (Case Western Reserve University, USA) and Y. Sun (Dana-Farber Cancer Institute, USA). Work from the authors' laboratories that is cited here was supported by grants from the National Institutes of Health (NS047572 and NS057727 to C. D. S. and NS040511 to D. H. R.) and from the Pediatric Low-Grade Astrocytoma Foundation (grant awarded to C. D. S.). D. H. R. is supported by the Howard Hughes Medical Institute. NR 127 TC 52 Z9 54 U1 5 U2 23 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1471-003X J9 NAT REV NEUROSCI JI Nat. Rev. Neurosci. PD DEC PY 2012 VL 13 IS 12 BP 819 EP 831 DI 10.1038/nrn3386 PG 13 WC Neurosciences SC Neurosciences & Neurology GA 041IA UT WOS:000311393000010 PM 23165259 ER PT J AU Lee, EQ Kuhn, J Lamborn, KR Abrey, L DeAngelis, LM Lieberman, F Robins, HI Chang, SM Yung, WKA Drappatz, J Mehta, MP Levin, VA Aldape, K Dancey, JE Wright, JJ Prados, MD Cloughesy, TF Gilbert, MR Wen, PY AF Lee, Eudocia Q. Kuhn, John Lamborn, Kathleen R. Abrey, Lauren DeAngelis, Lisa M. Lieberman, Frank Robins, H. Ian Chang, Susan M. Yung, W. K. Alfred Drappatz, Jan Mehta, Minesh P. Levin, Victor A. Aldape, Kenneth Dancey, Janet E. Wright, John J. Prados, Michael D. Cloughesy, Timothy F. Gilbert, Mark R. Wen, Patrick Y. TI Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02 SO NEURO-ONCOLOGY LA English DT Article DE anaplastic glioma; glioblastoma; malignant glioma; sorafenib; temsirolimus ID ANTITUMOR-ACTIVITY; MALIGNANT GLIOMA; CCI-779; MULTIFORME; RAPAMYCIN; TRIAL; RADIOTHERAPY; TEMOZOLOMIDE; CARCINOMA; AKT AB The activity of single-agent targeted molecular therapies in glioblastoma has been limited to date. The North American Brain Tumor Consortium examined the safety, pharmacokinetics, and efficacy of combination therapy with sorafenib, a small molecule inhibitor of Raf, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor, and temsirolimus (CCI-779), an inhibitor of mammalian target of rapamycin. This was a phase I/II study. The phase I component used a standard 3 3 dose escalation scheme to determine the safety and tolerability of this combination therapy. The phase II component used a 2-stage design; the primary endpoint was 6-month progression-free survival (PFS6) rate. Thirteen patients enrolled in the phase I component. The maximum tolerated dosage (MTD) for combination therapy was sorafenib 800 mg daily and temsirolimus 25 mg once weekly. At the MTD, grade 3 thrombocytopenia was the dose-limiting toxicity. Eighteen patients were treated in the phase II component. At interim analysis, the study was terminated and did not proceed to the second stage. No patients remained progression free at 6 months. Median PFS was 8 weeks. The toxicity of this combination therapy resulted in a maximum tolerated dose of temsirolimus that was only one-tenth of the single-agent dose. Minimal activity in recurrent glioblastoma multiforme was seen at the MTD of the 2 combined agents. C1 [Lee, Eudocia Q.; Kuhn, John; Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA 02215 USA. [Kuhn, John] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Lamborn, Kathleen R.; Chang, Susan M.; Prados, Michael D.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA. [Abrey, Lauren; DeAngelis, Lisa M.] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA. [Drappatz, Jan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA. [Robins, H. Ian] Univ Wisconsin, Madison, WI USA. Northwestern Univ, Chicago, IL 60611 USA. [Yung, W. K. Alfred; Levin, Victor A.; Aldape, Kenneth; Gilbert, Mark R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Dancey, Janet E.; Wright, John J.] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA. [Cloughesy, Timothy F.] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. RP Wen, PY (reprint author), Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, 450 Brookline Ave,SW 430, Boston, MA 02215 USA. EM pwen@partners.org RI Gilbert, Mark/J-7494-2016; OI Gilbert, Mark/0000-0003-2556-9722; mehta, minesh/0000-0002-4812-5713 FU NIH [U01 CA062399]; Astrazeneca; Pfizer; Amgen; Esai; Sanofi-Aventis; Genentech; Genzyme; Novartis; Medimmune; Vascular Biogenics FX This study was sponsored by NIH grant number U01 CA062399.; Kenneth Aldape-Speaker: Merck; Grant funding: Astrazeneca. Lauren Abrey-now employed by Roche. Janet Dancey-Research Support from Pfizer. Lisa DeAngelis-Consultant: Genentech, Pharmacokinesis. Eudocia Q. Lee-Consultant: Novartis, Genentech. Royalties: UpToDate, DEMOS Publishers. Minesh Mehta-Consultant: Abbott, Bayer, Bristol-Meyers-Squibb, Elekta, Merck, Novartis, Quark, Tomotherapy, US Oncology, Vertex; Stock Options: Accuray, Colby, Pharmacyclics, Procertus, Stemina; Data Safety Monitoring Boards: Apogenix Protocol Data Review: Adnexus; Board of Directors: Pharmacyclics; Medical Advisory Boards: Colby, Stemina, Procertus; Speaker: GRACE Foundation, MCM, Medscape, Merck, priME Oncology, Strategic Edge, WebMD; Patents: WARF/Procertus, Royalties: DEMOS Publishers. Patrick Wen-Consultant: Novartis, Merck. Paid Speaker: Merck. Research Support: Amgen, AstraZeneca, Esai, Sanofi-Aventis, Genentech, Genzyme, Novartis, Medimmune, Vascular Biogenics, Royalties: UpToDate, DEMOS Publishers. All remaining authors-no disclosures. NR 28 TC 42 Z9 43 U1 2 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD DEC PY 2012 VL 14 IS 12 BP 1511 EP 1518 DI 10.1093/neuonc/nos264 PG 8 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 040HP UT WOS:000311313600011 PM 23099651 ER PT J AU Hagel, C Stemmer-Rachamimov, AO Bornemann, A Schuhmann, M Nagel, C Huson, S Evans, DG Plotkin, S Matthies, C Kluwe, L Mautner, VF AF Hagel, Christian Stemmer-Rachamimov, Anat O. Bornemann, Antje Schuhmann, Martin Nagel, Christoph Huson, Susan Evans, D. Gareth Plotkin, Scott Matthies, Cordula Kluwe, Lan Mautner, Victor-Felix TI Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas SO NEUROPATHOLOGY LA English DT Article DE electron microscopy; ependymoma; glioma; immunohistochmistry; neurofibromatosis type 2 ID BILATERAL ACOUSTIC NEUROFIBROMATOSIS; NF2; TUMORS; GENE; INTRAMEDULLARY; TUMORIGENESIS AB Neurofibromatosis type 2 (NF2) is a hereditary tumor syndrome. The hallmark of NF2 is bilateral vestibular schwannoma. In addition, glioma is one of the diagnostic criteria of NF2. In this retrospective study the clinical presentation and histopathological features of 12 spinal gliomas from NF2 patients were assessed. Ten tumors were previously diagnosed as ependymomas and two as astrocytomas. However, upon re-evaluation both astrocytomas expressed epithelial membrane antigen in a dot-like fashion and in one case it was possible to perform electron microscopy revealing junctional complexes and cilia typical for ependymoma. The findings suggest that NF2-associated spinal gliomas are ependymomas. Based on the fact that NF2-associated gliomas are almost exclusively spinal and that no NF2 mutations have been found in sporadic cerebral gliomas, we suggest that glioma in the current diagnostic criteria for NF2 should be specified as spinal ependymoma. C1 [Hagel, Christian] Univ Med Ctr Hamburg Eppendorf, Inst Neuropathol, D-20246 Hamburg, Germany. [Kluwe, Lan; Mautner, Victor-Felix] Univ Med Ctr Hamburg Eppendorf, Dept Maxillofacial Surg, D-20246 Hamburg, Germany. [Bornemann, Antje] Inst Hirnforschung, Tubingen, Germany. [Schuhmann, Martin; Nagel, Christoph] Univ Klin Neurochirurg, Tubingen, Germany. [Matthies, Cordula] Klinikum Univ Wurzburg, Neurochirurg Klin & Poliklin, Wurzburg, Germany. [Stemmer-Rachamimov, Anat O.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Stemmer-Rachamimov, Anat O.] Harvard Univ, Sch Med, Boston, MA USA. [Plotkin, Scott] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Huson, Susan] Univ Manchester, St Marys Hosp, Med Genet Res Grp, Manchester M13 0JH, Lancs, England. [Huson, Susan] Univ Manchester, St Marys Hosp, Reg Genet Serv, Manchester M13 0JH, Lancs, England. [Evans, D. Gareth] Univ Manchester, St Marys Hosp, Dept Med Genet, Manchester Acad Hlth Sci Ctr, Manchester M13 0JH, Lancs, England. RP Hagel, C (reprint author), Univ Med Ctr Hamburg Eppendorf, Inst Neuropathol, Martinistr 52, D-20246 Hamburg, Germany. EM hagel@uke.de OI Evans, Gareth/0000-0002-8482-5784 NR 17 TC 10 Z9 10 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0919-6544 J9 NEUROPATHOLOGY JI Neuropathology PD DEC PY 2012 VL 32 IS 6 BP 611 EP 616 DI 10.1111/j.1440-1789.2012.01306.x PG 6 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA 041JN UT WOS:000311398200004 PM 22394059 ER PT J AU Kan, P Siddiqui, A Veznedaroglu, E Liebman, KM Binning, MJ Dumont, TM Ogilvy, CS Gaughen, JR Mocco, J Velat, GJ Ringer, AJ Welch, BG Horowitz, MB Snyder, KV Hopkins, LN Levy, EI AF Kan, Peter Siddiqui, AdnanH. Veznedaroglu, Erol Liebman, Kenneth M. Binning, Mandy J. Dumont, Travis M. Ogilvy, Christopher S. Gaughen, John R., Jr. Mocco, J. Velat, Gregory J. Ringer, Andrew J. Welch, Babu G. Horowitz, Michael B. Snyder, Kenneth V. Hopkins, L. Nelson Levy, Elad I. TI Early Postmarket Results After Treatment of Intracranial Aneurysms With the Pipeline Embolization Device: A US Multicenter Experience SO NEUROSURGERY LA English DT Article DE Endovascular treatment; Flow diversion; Intracranial aneurysm; Pipeline device ID PERCUTANEOUS CORONARY INTERVENTION; POLYUNSATURATED OMEGA-3-FATTY-ACIDS; PARENT ARTERY; RECONSTRUCTION; RESPONSIVENESS AB BACKGROUND: The Pipeline embolization device (PED) is the latest technology available for intracranial aneurysm treatment. OBJECTIVE: To report early postmarket results with the PED. METHODS: This study was a prospective registry of patients treated with PEDs at 7 American neurosurgical centers subsequent to Food and Drug Administration approval of this device. Data collected included clinical presentation, aneurysm characteristics, treatment details, and periprocedural events. Follow-up data included degree of aneurysm occlusion and delayed (>30 days after the procedure) complications. RESULTS: Sixty-two PED procedures were performed to treat 58 aneurysms in 56 patients. Thirty-seven of the aneurysms (64%) treated were located from the cavernous to the superior hypophyseal artery segment of the internal carotid artery; 22% were distal to that segment, and 14% were in the vertebrobasilar system. A total of 123 PEDs were deployed with an average of 2 implanted per aneurysm treated. Six devices were incompletely deployed; in these cases, rescue balloon angioplasty was required. Six periprocedural (during the procedure/within 30 days after the procedure) thromboembolic events occurred, of which 5 were in patients with vertebrobasilar aneurysms. There were 4 fatal postprocedural hemorrhages (from 2 giant basilar trunk and 2 large ophthalmic artery aneurysms). The major complication rate (permanent disability/death resulting from perioperative/delayed complication) was 8.5%. Among 19 patients with 3-month follow-up angiography, 68% (13 patients) had complete aneurysm occlusion. Two patients presented with delayed flow-limiting in-stent stenosis that was successfully treated with angioplasty. CONCLUSION: Unlike conventional coil embolization, aneurysm occlusion with PED is not immediate. Early complications include both thromboembolic and hemorrhagic events and appear to be significantly more frequent in association with treatment of vertebrobasilar aneurysms. C1 [Kan, Peter; Siddiqui, AdnanH.; Dumont, Travis M.; Ogilvy, Christopher S.; Snyder, Kenneth V.; Hopkins, L. Nelson; Levy, Elad I.] SUNY Buffalo, Dept Neurosurg, Buffalo, NY 14260 USA. [Kan, Peter; Siddiqui, AdnanH.; Dumont, Travis M.; Ogilvy, Christopher S.; Snyder, Kenneth V.; Hopkins, L. Nelson; Levy, Elad I.] SUNY Buffalo, Toshiba Stroke & Vasc Res Ctr, Buffalo, NY 14260 USA. [Siddiqui, AdnanH.; Snyder, Kenneth V.; Hopkins, L. Nelson; Levy, Elad I.] SUNY Buffalo, Dept Radiol, Sch Med & Biomed Sci, Buffalo, NY 14260 USA. [Kan, Peter; Siddiqui, AdnanH.; Dumont, Travis M.; Ogilvy, Christopher S.; Snyder, Kenneth V.; Hopkins, L. Nelson; Levy, Elad I.] Kaleida Hlth, Gates Vasc Inst, Dept Neurosurg, Buffalo, NY USA. [Veznedaroglu, Erol; Liebman, Kenneth M.; Binning, Mandy J.] Capital Hlth, Stroke & Cerebrovasc Ctr New Jersey, Dept Neurosci, Trenton, NJ USA. [Ogilvy, Christopher S.] Massachusetts Gen Hosp, Neurovasc Serv, Boston, MA 02114 USA. [Gaughen, John R., Jr.] Univ S Florida, Dept Neurosurg, Tampa, FL USA. [Mocco, J.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN USA. [Velat, Gregory J.] Univ Florida, Dept Neurosurg, Gainesville, FL USA. [Ringer, Andrew J.] Univ Cincinnati, Dept Neurosurg, Mayfield Clin, Cincinnati, OH USA. [Welch, Babu G.] Univ Texas SW Med Ctr Dallas, Dept Neurosurg, Dallas, TX 75390 USA. [Welch, Babu G.] Univ Texas SW Med Ctr Dallas, Dept Neuroradiol, Dallas, TX 75390 USA. [Horowitz, Michael B.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA. [Hopkins, L. Nelson] Jacobs Inst, Buffalo, NY USA. RP Levy, EI (reprint author), Univ Buffalo Neurosurg, 100 High St,Ste B4, Buffalo, NY 14203 USA. EM elevy@ubns.com FU St. Jude Medical; Toshiba; Boston Scientific; Codman Shurtleff, Inc; ev3/Covidien Vascular Therapies; Abbott Vascular; National Institutes of Health [NINDS 1R01NS064592-01A1] FX Dr Hopkins receives university grant/research support from St. Jude Medical and Toshiba; serves as a consultant to Abbott, Boston Scientific (Boston Scientific's neurovascular business has been acquired by Stryker), Cordis, Micrus, and W.L. Gore; holds a financial interest in AccessClosure, Augmenix, Boston Scientific, Claret Medical Inc, Micrus, and Valor Medical; has a board/trustee/officer position with AccessClosure and Claret Medical Inc; belongs to the Abbott Vascular speakers' bureau; and receives honoraria from Bard, Boston Scientific, Cordis, Memorial Healthcare System, Complete Conference Management, SCAI, and the Cleveland Clinic. Dr Horowitz has been a consultant (on an hourly basis) for ev3/Covidien. Dr Levy receives research grant support (principal investigator in the Stent-Assisted Recanalization in Acute Ischemic Stroke study), other research support (devices), and honoraria from Boston Scientific and research support from Codman & Shurtleff, Inc and ev3/Covidien Vascular Therapies; has ownership interests in Intratech Medical Ltd and Mynx/Access Closure; serves as a consultant on the Board of Scientific Advisors to Codman & Shurtleff, Inc; serves as a consultant per project and/or per hour for Codman & Shurtleff, Inc, ev3/Covidien Vascular Therapies, and TheraSyn Sensors, Inc; and receives fees for carotid stent training from Abbott Vascular and ev3/Covidien Vascular Therapies. Dr Levy receives no consulting salary arrangements; all consulting is per project and/or per hour. Dr Mocco has been a consultant for Lazarus Effect, Nfocus, and Edge Therapeutics and is an investor in Blockade. Dr Ringer has been a consultant and proctor for ev3/Covidien. Dr Siddiqui has received research grants from the National Institutes of Health (coinvestigator on NINDS 1R01NS064592-01A1, hemodynamic induction of pathologic remodeling leading to intracranial aneurysms [not related to the present article]) and the University at Buffalo (Research Development Award); holds financial interests in Hotspur, Intratech Medical, StimSox, and Valor Medical; serves as a consultant to Codman & Shurtleff, Inc, Concentric Medical, ev3/Covidien Vascular Therapies, GuidePoint Global Consulting, and Penumbra; belongs to the speakers' bureaus of Codman & Shurtleff, Inc and Genentech; serves on an advisory board for Codman & Shurtleff; and has received honoraria from Peripheral Angioplasty and All the Jazz and American Association of Neurological Surgeons' courses, an Emergency Medicine Conference, Genentech, and Neocure Group LLC, and from Abbott Vascular and Codman & Shurtleff, Inc for training other neurointerventionists in carotid stenting and training physicians in endovascular stenting for aneurysms. Dr Siddiqui receives no consulting salary arrangements; all consulting is per project and/or per hour. Dr Snyder serves as a consultant to and a member of the speakers' bureau for and has received honoraria from Toshiba. He serves as a member of the speakers' bureau for and has received honoraria from ev3 and The Stroke Group (consultants to the healthcare industry, Littleton, Colorado). The other authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article. NR 15 TC 73 Z9 74 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-396X J9 NEUROSURGERY JI Neurosurgery PD DEC PY 2012 VL 71 IS 6 BP 1080 EP 1087 DI 10.1227/NEU.0b013e31827060d9 PG 8 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 040RC UT WOS:000311339600021 PM 22948199 ER PT J AU Lubelski, D Abdullah, KG Mroz, TE Shin, JH Alvin, MD Benzel, EC Steinmetz, MP AF Lubelski, Daniel Abdullah, Kalil G. Mroz, Thomas E. Shin, John H. Alvin, Matthew D. Benzel, Edward C. Steinmetz, Michael P. TI Lateral Extracavitary vs Costotransversectomy Approaches to the Thoracic Spine: Reflections on Lessons Learned SO NEUROSURGERY LA English DT Article DE Complications; Costotransversectomy; Indications; Lateral extracavitary; Thoracic spine ID THORACOLUMBAR BURST FRACTURES; LUMBAR SPINE; TRAUMATIC FRACTURES; POSTERIOR; COMPLICATIONS; MANAGEMENT; ANTERIOR; LESIONS; FUSION; TUMORS AB BACKGROUND: The lateral extracavitary approach (LECA) and costotransversectomy (CTE) are 2 dorsolateral approaches that avoid entrance into the pleural cavity and facilitate ventral decompression. The indications and outcomes of each of these approaches have not been fully defined in the literature. OBJECTIVE: To assess the techniques, indications, and complications associated with the LECA and CTE approaches to the thoracic spine. METHODS: A retrospective analysis was performed on all patients who underwent LECA and CTE between 2000 and 2009 at our institution. RESULTS: A total of 54 patient charts were reviewed (19 LECA, 35 CTE). Indications for operation included disk herniation, trauma, tumor, osteomyelitis, and scoliosis/kyphosis. Osteomyelitis was treated significantly more often with LECA (47%) than with CTE (9%; P = .002). Mean blood loss was 2134 mL and 1556 mL (P = .3) in LECA and CTE, respectively, and hospital stay was 17.2 days for LECA and 9.8 days for CTE (P = .07). Thirteen LECA patients (68%) and 19 CTE patients (54%; P = 1.0) had preoperative or postoperative complications. CONCLUSION: LECA was used more often to treat complex pathologies such as osteomyelitis and trended toward significance for more frequent use in extensive procedures involving 1- or 2-level corpectomies. As can be expected, CTE was associated with slightly less blood loss and a shorter hospital stay compared with the more extensive LECA operation. Adverse outcomes occurred with similar frequency for CTE and LECA. C1 [Steinmetz, Michael P.] Metrohlth Med Ctr, Dept Neurosci, Cleveland, OH 44109 USA. [Lubelski, Daniel; Abdullah, Kalil G.; Mroz, Thomas E.; Alvin, Matthew D.; Benzel, Edward C.] Cleveland Clin, Ctr Spine Hlth, Cleveland, OH 44195 USA. [Lubelski, Daniel; Abdullah, Kalil G.; Mroz, Thomas E.; Benzel, Edward C.] Cleveland Clin, Dept Neurol Surg, Cleveland, OH 44195 USA. [Lubelski, Daniel; Abdullah, Kalil G.; Mroz, Thomas E.; Benzel, Edward C.] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44195 USA. [Shin, John H.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Alvin, Matthew D.; Steinmetz, Michael P.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. RP Steinmetz, MP (reprint author), Metrohlth Med Ctr, Dept Neurol Surg, 2500 MetroHlth Dr, Cleveland, OH 44109 USA. EM dlubelski@gmail.com; msteinmetz@metrohealth.org OI Alvin, Matthew/0000-0003-0362-1526; Lubelski, Daniel/0000-0002-9403-9509 NR 33 TC 6 Z9 6 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-396X J9 NEUROSURGERY JI Neurosurgery PD DEC PY 2012 VL 71 IS 6 BP 1096 EP 1102 DI 10.1227/NEU.0b013e3182706102 PG 7 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 040RC UT WOS:000311339600025 PM 22948200 ER PT J AU Halg, RA Besserer, J Boschung, M Mayer, S Clasie, B Kry, SF Schneider, U AF Haelg, Roger A. Besserer, Juergen Boschung, Markus Mayer, Sabine Clasie, Benjamin Kry, Stephen F. Schneider, Uwe TI Field calibration of PADC track etch detectors for local neutron dosimetry in man using different radiation qualities SO NUCLEAR INSTRUMENTS & METHODS IN PHYSICS RESEARCH SECTION A-ACCELERATORS SPECTROMETERS DETECTORS AND ASSOCIATED EQUIPMENT LA English DT Article DE Secondary neutron; Dose equivalent; Track etch; Field calibration ID PROTON THERAPY; DOSE-EQUIVALENT; PHOTON; RADIOTHERAPY; MV; ACCELERATOR; SPECTRA; MOTHER; CANCER; FETUS AB In order to quantify the dose from neutrons to a patient for contemporary radiation treatment techniques, measurements inside phantoms, representing the patient, are necessary. Published reports on neutron dose measurements cover measurements performed free in air or on the surface of phantoms and the doses are expressed in terms of personal dose equivalent or ambient dose equivalent. This study focuses on measurements of local neutron doses inside a radiotherapy phantom and presents a field calibration procedure for PADC track etch detectors. An initial absolute calibration factor in terms of H-p(10) for personal dosimetry is converted into neutron dose equivalent and additional calibration factors are derived to account for the spectral changes in the neutron fluence for different radiation therapy beam qualities and depths in the phantom. The neutron spectra used for the calculation of the calibration factors are determined in different depths by Monte Carlo simulations for the investigated radiation qualities. These spectra are used together with the energy dependent response function of the PADC detectors to account for the spectral changes in the neutron fluence. The resulting total calibration factors are 0.76 for a photon beam (in- and out-of-field), 1.00 (in-field) and 0.84 (out-of-field) for an active proton beam and 1.05 (in-field) and 0.91 (out-of-field) for a passive proton beam, respectively. The uncertainty for neutron dose measurements using this field calibration method is less than 40%. The extended calibration procedure presented in this work showed that it is possible to use PADC track etch detectors for measurements of local neutron dose equivalent inside anthropomorphic phantoms by accounting for spectral changes in the neutron fluence. (c) 2012 Elsevier B.V. All rights reserved. C1 [Haelg, Roger A.; Besserer, Juergen; Schneider, Uwe] Hirslanden Med Ctr, Radiotherapie Hirslanden AG, Inst Radiotherapy, CH-5000 Aarau, Switzerland. [Boschung, Markus; Mayer, Sabine] Paul Scherrer Inst, Div Radiat Safety & Secur, CH-5232 Villigen, Switzerland. [Clasie, Benjamin] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Kry, Stephen F.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA. [Schneider, Uwe] Univ Zurich, Vetsuisse Fac, CH-8057 Zurich, Switzerland. RP Halg, RA (reprint author), Hirslanden Med Ctr, Radiotherapie Hirslanden AG, Inst Radiotherapy, Rain 34, CH-5000 Aarau, Switzerland. EM rhaelg@phys.ethz.ch RI Schneider, Uwe/E-9594-2011; OI Schneider, Uwe/0000-0002-6403-204X; Kry, Stephen/0000-0001-6899-197X NR 37 TC 2 Z9 2 U1 0 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-9002 J9 NUCL INSTRUM METH A JI Nucl. Instrum. Methods Phys. Res. Sect. A-Accel. Spectrom. Dect. Assoc. Equip. PD DEC 1 PY 2012 VL 694 BP 205 EP 210 DI 10.1016/j.nima.2012.08.021 PG 6 WC Instruments & Instrumentation; Nuclear Science & Technology; Physics, Nuclear; Physics, Particles & Fields SC Instruments & Instrumentation; Nuclear Science & Technology; Physics GA 036IV UT WOS:000311020500030 ER PT J AU Hogan, MJ Marshalleck, FE Sidhu, MK Connolly, BL Towbin, RB Saad, WA Cahill, AM Crowley, J Heran, MKS Hohenwalter, EJ Roebuck, DJ Temple, MJ Walker, TG Cardella, JF AF Hogan, Mark J. Marshalleck, Francis E. Sidhu, Manrita K. Connolly, Bairbre L. Towbin, Richard B. Saad, Wael A. Cahill, Ann Marie Crowley, John Heran, Manraj K. S. Hohenwalter, Eric J. Roebuck, Derek J. Temple, Michael J. Walker, T. Gregory Cardella, John F. CA Soc Interventional Radiology Stand Soc Pediat Radiology Interventiona TI Quality improvement guidelines for pediatric abscess and fluid drainage SO PEDIATRIC RADIOLOGY LA English DT Article ID DEEP PELVIC ABSCESSES; ASSISTED THORACOSCOPIC SURGERY; GUIDED TRANSGLUTEAL DRAINAGE; INTERVENTIONAL RADIOLOGY; TRANSRECTAL DRAINAGE; COMPLICATED APPENDICITIS; INTRAABDOMINAL ABSCESSES; PERCUTANEOUS TREATMENT; LUNG ABSCESS; CHILDREN C1 [Hogan, Mark J.] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH USA. [Marshalleck, Francis E.] Indiana Univ Sch Med, Riley Hosp Children, Dept Radiol, Indianapolis, IN USA. [Sidhu, Manrita K.] Univ Washington, Seattle Childrens Hosp, Dept Radiol, Seattle, WA 98195 USA. [Connolly, Bairbre L.; Temple, Michael J.] Univ Toronto, Hosp Sick Children, Ctr Image Guided Therapy, Toronto, ON M5G 1X8, Canada. [Heran, Manraj K. S.] Vancouver Gen Hosp, British Columbia Childrens Hosp, Dept Radiol, Vancouver, BC, Canada. [Towbin, Richard B.] Phoenix Childrens Hosp, Dept Radiol, Phoenix, AZ USA. [Saad, Wael A.] Univ Virginia Hlth Syst, Dept Radiol, Charlottesville, VA USA. [Cahill, Ann Marie] Childrens Hosp Philadelphia, Dept Intervent Radiol, Philadelphia, PA 19104 USA. [Crowley, John] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Radiol, Pittsburgh, PA 15213 USA. [Cardella, John F.] Geisinger Hlth Syst, Dept Radiol, Danville, PA USA. [Hohenwalter, Eric J.] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Dept Radiol, Milwaukee, WI 53226 USA. [Roebuck, Derek J.] Great Ormond St Hosp Sick Children, Dept Radiol, London, England. [Walker, T. Gregory] Massachusetts Gen Hosp, Div Vasc Imaging & Intervent, Boston, MA 02114 USA. RP Hogan, MJ (reprint author), Care of Katsarelis D, 3975 Fair Ridge Dr,Suite 400N, Fairfax, VA 22033 USA. EM mark.hogan@nationwidechildrens.org RI Temple, Michael/E-4082-2013; OI Temple, Michael/0000-0002-5843-0519; Roebuck, Derek/0000-0003-1734-2536 FU Siemens (Forchheim, Germany) FX W.A.S. has research funded by Siemens (Forchheim, Germany) and is a paid consultant for Boston Scientific (Natick, MA). None of the other authors have identified a conflict of interest. NR 62 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0301-0449 EI 1432-1998 J9 PEDIATR RADIOL JI Pediatr. Radiol. PD DEC PY 2012 VL 42 IS 12 BP 1527 EP 1535 DI 10.1007/s00247-012-2499-7 PG 9 WC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging SC Pediatrics; Radiology, Nuclear Medicine & Medical Imaging GA 041LS UT WOS:000311403900018 PM 23114633 ER PT J AU Kivikko, M Nieminen, MS Pollesello, P Pohjanjousi, P Colucci, WS Teerlink, JR Mebazaa, A AF Kivikko, Matti Nieminen, Markku S. Pollesello, Piero Pohjanjousi, Pasi Colucci, Wilson S. Teerlink, John R. Mebazaa, Alexandre TI The clinical effects of levosimendan are not attenuated by sulfonylureas SO SCANDINAVIAN CARDIOVASCULAR JOURNAL LA English DT Article DE levosimendan; acute decompensated heart failure; inodilator; diabetes mellitus; ATP-dependent potassium channels; sulfonylureas ID DECOMPENSATED HEART-FAILURE; SENSITIVE POTASSIUM CHANNELS; INTRAVENOUS LEVOSIMENDAN; CONTINUOUS-INFUSION; DIABETES-MELLITUS; GUINEA-PIG; K-ATP; DOBUTAMINE; PHARMACOKINETICS; POPULATION AB Objectives. Levosimendan is an inodilator indicated for acute heart failure (AHF). Its vasodilatory and anti-ischemic effects are mediated by the opening of ATP-dependent potassium channels (K-ATP channels). Diabetes mellitus is common in AHF patients and sulfonylureas are often prescribed. Sulfonylureas act by blocking the K-ATP channels. An interaction between levosimendan and sulfonylureas has been shown in preclinical models and could be hypothesized in clinical practice. Design. We produced a pooled analysis of six randomized levosimendan trials (in total of 3004 patients of which 1700 were treated with levosimendan and 226 both with levosimendan and sulfonylureas) with the aim to study the influence of concurrent sulfonylurea treatment to the levosimendan effects. Invasive and non-invasive hemodynamics, biomarkers (BNP), adverse events related to myocardial ischemia, and survival were evaluated. Results. In our relatively small data set, we could not detect any clinically relevant interactions between the sulfonylureas and levosimendan. Similar decreases in systolic and diastolic blood pressure, pulmonary capillary wedge pressure and BNP, and similar survival and adverse event profiles were seen in sulfonylurea users and non-users exposed to levosimendan. Conclusions. Concomitant use of sulfonylureas with levosimendan does not attenuate the hemodynamic or other effects of levosimendan. C1 [Kivikko, Matti] Univ Helsinki, Cent Hosp, Div Cardiol, HUS, Helsinki 00029, Finland. [Colucci, Wilson S.] Boston Univ, Med Ctr, Boston, MA USA. [Kivikko, Matti; Pollesello, Piero; Pohjanjousi, Pasi] Orion Pharma, Espoo, Finland. [Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Teerlink, John R.] Univ Calif San Francisco, Cardiol Sect, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Mebazaa, Alexandre] Univ Paris 07, Hop Lariboisiere, Assistance Publ Hop Paris, Dept Anesthesiol & Crit Care Med, Paris, France. RP Kivikko, M (reprint author), Univ Helsinki, Cent Hosp, Div Cardiol, HUS, Haartmaninkatu 4,Box 340, Helsinki 00029, Finland. EM matti.kivikko@hus.fi OI pollesello, piero/0000-0001-6994-768X FU Orion Pharma, Finland FX This work was funded by Orion Pharma, Finland. NR 28 TC 2 Z9 2 U1 0 U2 6 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1401-7431 J9 SCAND CARDIOVASC J JI Scand. Cardiovasc. J. PD DEC PY 2012 VL 46 IS 6 BP 330 EP 338 DI 10.3109/14017431.2012.725206 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 043LF UT WOS:000311544400003 PM 22928945 ER PT J AU Dickey, CC Vu, MAT Voglmaier, MM Niznikiewicz, MA McCarley, RW Panych, LP AF Dickey, Chandlee C. Vu, Mai-Anh T. Voglmaier, Martina M. Niznikiewicz, Margaret A. McCarley, Robert W. Panych, Lawrence P. TI Prosodic abnormalities in schizotypal personality disorder SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizotypal personality disorder; Schizophrenia; Prosody; Vocal affect; Pars opercularis; Inferior frontal lobe; Alexithymia; Social cognition ID OBSESSIVE-COMPULSIVE DISORDER; FACIAL EMOTION RECOGNITION; SUPERIOR TEMPORAL GYRUS; BROCAS-AREA; STRUCTURAL MRI; PARS OPERCULARIS; RIGHT-HEMISPHERE; FMRI EXPERIMENT; GRAY-MATTER; SCHIZOPHRENIA AB Objective: Patients with schizophrenia speak with blunted vocal affect but little is known regarding the prosody of persons with schizotypal personality disorder (SPD). This work examined expressive prosody in SPD, its relationship to brain structure, and outlined a framework for measuring elements of prosody in clinical populations. Methods: Twenty-eight antipsychotic-naive SPD subjects were matched with 27 healthy comparison (HC) subjects. Subjects read aloud short sentences and responded to probes to record both predetermined and self-generated speech samples. Samples were analyzed acoustically (pause proportion, duration, attack, and pitch variability) and subjectively by raters (amount of pauses, degree of emotion portrayed, and how much they wanted to hear more from the subjects) on paragraph, sentence, word, word-fragment, and syllable levels. Alexithymia and ability to self-monitor behavior were compared between groups. The pars opercularis was manually traced on structural MRI data. Results: SPD subjects' speech had significantly more pauses, was slower, had less pitch variability, and expressed less emotion than HC subjects. Pitch variability correlated with socio-economic status achievement. There was no difference between groups in left or right pars opercularis volumes. A statistically significant correlation suggested that smaller left pars opercularis volumes in SPD subjects correlated with more pauses and less emotion. SPD subjects reported more alexithymia and difficulty self-monitoring their behavior compared with controls. In SPD subjects the high alexithymia correlated with raters not wanting to hear more from them and SPD subjects' inability to modulate their social behavior correlated with their having fewer friends. Thus, the SPD subjects exhibited insight. Conclusions: SPD subjects displayed significant prosodic deficits that were measurable in speech samples as brief as a word-fragment. The determinants of these deficits are not known although these may include a dysfunctional pars opercularis. These data add to the nascent literature describing social cognition deficits in SPD. Published by Elsevier B.V. C1 [Dickey, Chandlee C.; Voglmaier, Martina M.; Niznikiewicz, Margaret A.; McCarley, Robert W.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Neurosci Lab, Brockton, MA 02301 USA. [Vu, Mai-Anh T.; Niznikiewicz, Margaret A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Psychiat Neuroimaging Lab, Boston, MA 02215 USA. [Panych, Lawrence P.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02216 USA. RP Dickey, CC (reprint author), Harvard Univ, Sch Med, VA Boston Healthcare Syst, Neurosci Lab, 940 Belmont St, Brockton, MA 02301 USA. EM chandlee.dickey@va.gov RI McCarley, Robert/N-5562-2014 OI McCarley, Robert/0000-0001-5705-7495 FU VA Boston Healthcare System [R21MH077979]; VA Schizophrenia Center Award from the National Institute of Mental Health [RO1 MH52807] FX The project described was supported by the VA Boston Healthcare System and award number R21MH077979 (CCD) and VA Schizophrenia Center Award and award number RO1 MH52807 (RWM) from the National Institute of Mental Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, or the VA. NR 63 TC 7 Z9 7 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2012 VL 142 IS 1-3 BP 20 EP 30 DI 10.1016/j.schres.2012.09.006 PG 11 WC Psychiatry SC Psychiatry GA 039CR UT WOS:000311220900003 PM 23068317 ER PT J AU Addington, J Cadenhead, KS Cornblatt, BA Mathalon, DH McGlashan, TH Perkins, DO Seidman, LJ Tsuang, MT Walker, EF Woods, SW Addington, JA Cannon, TD AF Addington, Jean Cadenhead, Kristin S. Cornblatt, Barbara A. Mathalon, Daniel H. McGlashan, Thomas H. Perkins, Diana O. Seidman, Larry J. Tsuang, Ming T. Walker, Elaine F. Woods, Scott W. Addington, Jack A. Cannon, Tyrone D. TI North American Prodrome Longitudinal Study (NAPLS 2): Overview and recruitment SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Psychosis; High risk; Methods; Recruitment ID SCHIZOPHRENIA AB The North American Prodrome Longitudinal Study (NAPLS) is a consortium of eight programs focusing on the psychosis prodrome. Funded by the National Institute of Mental Health (NIMH), the sites are located at Emory University, Harvard University, University of Calgary, UCLA, UCSD, University of North Carolina Chapel Hill, Yale University, and Zucker Hillside Hospital. Although the programs initially developed independently, they previously collaborated to combine their historical datasets and to produce a series of analyses on predictors of psychosis in one of the largest samples of longitudinally followed prodromal subjects worldwide. This led to the development of a five year prospective study "Predictors and Mechanisms of Conversion to Psychosis", (also known as NAPLS-2) with three major aims: (1) to prospectively test the prediction algorithm developed in NAPLS-1, (2) to investigate the neuroanatomical, neurophysiological, neurocognitive, and neurohormonal factors that may contribute to the development of psychosis, and (3) to develop a repository of DNA, RNA, and plasma from participants meeting diagnostic criteria for a clinical high risk (CHR) state and from demographically similar healthy subjects. Funded by NIMH in 2008, NAPLS-2 will generate the largest CHR for psychosis sample with 720 CHR and 240 healthy comparison subjects, and thus will provide statistical power and scientific scope that cannot be duplicated by any single site study. This paper describes the overall methodology of the NAPLS-2 project and reports on the ascertainment and demographics at the midway point of the study with (360 CHR) and 180 controls. (C) 2012 Elsevier B.V. All rights reserved. C1 [Addington, Jean] Univ Calgary, Mathison Ctr Mental Hlth Res & Educ, Dept Psychiat, Calgary, AB T2N 4Z6, Canada. [Cadenhead, Kristin S.] Univ Calif San Diego, Dept Psychiat, San Diego, CA USA. [Cornblatt, Barbara A.; Tsuang, Ming T.] Zucker Hillside Hosp, Dept Psychiat, Long Isl City, NY USA. [Mathalon, Daniel H.; Woods, Scott W.] UCSF, Dept Psychiat, San Francisco, CA USA. [Mathalon, Daniel H.; Woods, Scott W.] SFVA Med Ctr, San Francisco, CA USA. [McGlashan, Thomas H.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Perkins, Diana O.] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. [Seidman, Larry J.] Harvard Univ, Sch Med, Dept Psychiat, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. [Seidman, Larry J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Walker, Elaine F.] Emory Univ, Dept Psychol, Atlanta, GA 30322 USA. [Walker, Elaine F.] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA. [Cannon, Tyrone D.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Cannon, Tyrone D.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Cannon, Tyrone D.] Univ Calif Los Angeles, Dept Biobehav Sci, Los Angeles, CA USA. RP Addington, J (reprint author), Univ Calgary, Mathison Ctr Mental Hlth Res & Educ, Dept Psychiat, 3280 Hosp Dr NW, Calgary, AB T2N 4Z6, Canada. EM jmadding@ucalgary.ca OI Mathalon, Daniel/0000-0001-6090-4974 FU NIMH NIH HHS [U01MH081984, K24 MH076191, K24 MH76191, MH081902, P50 MH080272, R01 MH060720, R01 MH60720, U01 MH081857, U01 MH081857-05, U01 MH081928, U01 MH081984, U01 MH081988, U01 MH082004, U01 MH082022, U01MH081988, U01MH082004-01A1, U01MH082022] NR 5 TC 65 Z9 65 U1 2 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2012 VL 142 IS 1-3 BP 77 EP 82 DI 10.1016/j.schres.2012.09.012 PG 6 WC Psychiatry SC Psychiatry GA 039CR UT WOS:000311220900011 PM 23043872 ER PT J AU Jalbrzikowski, M Carter, C Senturk, D Chow, C Hopkins, JM Green, MF Galvan, A Cannon, TD Bearden, CE AF Jalbrzikowski, Maria Carter, Chelsea Senturk, Damla Chow, Carolyn Hopkins, Jessica M. Green, Michael F. Galvan, Adriana Cannon, Tyrone D. Bearden, Carrie E. TI Social cognition in 22q11.2 microdeletion syndrome: Relevance to psychosis? SO SCHIZOPHRENIA RESEARCH LA English DT Article DE 22q11.2 microdeletion syndrome; Social cognition; Schizophrenia; Prodromal; Psychosis ID CARDIO-FACIAL SYNDROME; DELETION SYNDROME; VELOCARDIOFACIAL SYNDROME; 1ST-DEGREE RELATIVES; NEUROCOGNITIVE ENDOPHENOTYPES; SCHIZOPHRENIA; BRAIN; ADOLESCENTS; RECOGNITION; EMOTION AB 22q11.2 deletion syndrome (22qDS) represents one of the largest known genetic risk factors for schizophrenia. Approximately 30% of individuals with 22qDS develop psychotic illness in adolescence or young adulthood. Given that deficits in social cognition are increasingly viewed as a central aspect of idiopathic schizophrenia, we sought to investigate abilities in this domain as a predictor of psychotic symptoms in 22qDS participants. We assessed multiple domains of social and non-social cognition in 22qDS youth to: 1) characterize performance across these domains in 22qDS, and identify whether 22qDS participants fail to show expected patterns of age-related improvements on these tasks; and 2) determine whether social cognition better predicts positive and negative symptoms than does non-social cognition. Task domains assessed were: emotion recognition and differentiation, Theory of Mind (ToM), verbal knowledge, visuospatial skills, working memory, and processing speed. Positive and negative symptoms were measured using scores obtained from the Structured Interview for Prodromal Symptoms (SIPS). 22qDS participants (N = 31, mean age: 15.9) showed the largest impairment, relative to healthy controls (N = 31, mean age: 15.6), on measures of ToM and processing speed. In contrast to controls, 22qDS participants did not show age-related improvements on measures of working memory and verbal knowledge. Notably, ToM performance was the best predictor of positive symptoms in 22qDS, accounting for 39% of the variance in symptom severity. Processing speed emerged as the best predictor of negative symptoms, accounting for 37% of the variance in symptoms. Given that ToM was a robust predictor of positive symptoms in our sample, these findings suggest that social cognition may be a valuable intermediate trait for predicting the development of psychosis. (C) 2012 Elsevier B.V. All rights reserved. C1 [Jalbrzikowski, Maria; Carter, Chelsea; Hopkins, Jessica M.; Galvan, Adriana; Cannon, Tyrone D.; Bearden, Carrie E.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Senturk, Damla] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA. [Chow, Carolyn; Green, Michael F.; Cannon, Tyrone D.; Bearden, Carrie E.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Green, Michael F.] VISN22 Mental Illness Res Educ & Clin Ctr, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA. RP Bearden, CE (reprint author), UCLA Psychiat & Biobehav Sci, Box 956968,300 Med Pl,Rm 2267, Los Angeles, CA 90095 USA. EM cbearden@mednet.ucla.edu FU National Institute of Mental Health [RO1 MH085953]; NIH/NIMH [5T32MH073526-05]; Heyler Meyer Research Award FX Funding for this study was provided by the National Institute of Mental Health grant RO1 MH085953 (CEB). Funding was also provided by the NIH/NIMH 5T32MH073526-05 (Training Grant in Neurobehavioral Genetics) and Heyler Meyer Research Award given to Ms. Jalbrzikowski. These funding sources had no further role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. NR 78 TC 27 Z9 27 U1 4 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2012 VL 142 IS 1-3 BP 99 EP 107 DI 10.1016/j.schres.2012.10.007 PG 9 WC Psychiatry SC Psychiatry GA 039CR UT WOS:000311220900016 PM 23122739 ER PT J AU Tregellas, JR Smucny, J Eichman, L Rojas, DC AF Tregellas, Jason R. Smucny, Jason Eichman, Lindsay Rojas, Donald C. TI The effect of distracting noise on the neuronal mechanisms of attention in schizophrenia SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Distraction; Hippocampus; fMRI; Sensory processing ID AUDITORY ODDBALL TASK; HEMODYNAMIC-RESPONSE; PREFRONTAL CORTEX; NEGATIVE SYMPTOMS; SELECTION CONTROL; FMRI; HIPPOCAMPUS; DYSFUNCTION; STIMULUS; BRAIN AB Objective: The inability to ignore irrelevant environmental noise is a common problem for people with schizophrenia. The purpose of this study was to determine if the neuronal response to distracting noise is related to mechanisms of altered attention observed in the illness. Method: Twenty-two outpatients with schizophrenia and seventeen healthy comparison subjects performed a selective attention task in the presence or absence of distracting environmental noise while undergoing functional magnetic resonance imaging at 3 T. A separate condition examining passive response to the distracting noise also was included. Results: Group differences in neuronal response during the attention task were magnified by distracting noise, with the greatest difference being less response by patients, relative to comparison subjects, in the temporoparietal junction. Separate passive listening to distracting noise resulted in greater hippocampal response in patients, relative to comparison subjects. Across all subjects, hippocampal response to noise was inversely related to the degree to which the attention-task-related network was up-regulated to perform the task during distracting noise. Conclusions: Given the observed hippocampal hyperactivity in response to environmental noise in patients and the inverse relationship between hippocampal response to noise and the effects of noise on the task-related network, hippocampal hyperactivity may contribute to impaired recruitment of attention networks in schizophrenia. Published by Elsevier B.V. C1 [Tregellas, Jason R.; Smucny, Jason; Eichman, Lindsay; Rojas, Donald C.] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO 80045 USA. [Tregellas, Jason R.; Smucny, Jason; Rojas, Donald C.] Univ Colorado, Sch Med, Neurosci Program, Aurora, CO 80045 USA. [Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA. RP Tregellas, JR (reprint author), Univ Colorado, Sch Med, Dept Psychiat, 13001 E 17th Pl,MS F546, Aurora, CO 80045 USA. EM Jason.Tregellas@ucdenver.edu RI Tregellas, Jason/J-3637-2015; OI Rojas, Don/0000-0001-6560-9616; Smucny, Jason/0000-0001-5656-7987 FU Veterans Administration Biomedical Laboratory and Clinical Science Research and Development Service; National Institutes of Mental Health [MH-086383]; National Association for Research in Schizophrenia and Affective Disorders; Blowitz-Ridgeway Foundation FX This work was supported by the Veterans Administration Biomedical Laboratory and Clinical Science Research and Development Service, the National Institutes of Mental Health grant MH-086383, the National Association for Research in Schizophrenia and Affective Disorders, and the Blowitz-Ridgeway Foundation. NR 37 TC 13 Z9 13 U1 1 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2012 VL 142 IS 1-3 BP 230 EP 236 DI 10.1016/j.schres.2012.09.008 PG 7 WC Psychiatry SC Psychiatry GA 039CR UT WOS:000311220900035 PM 23062751 ER PT J AU Ougland, R Lando, D Jonson, I Dahl, JA Moen, MN Nordstrand, LM Rognes, T Lee, JT Klungland, A Kouzarides, T Larsen, E AF Ougland, Rune Lando, David Jonson, Ida Dahl, John A. Moen, Marivi Nabong Nordstrand, Line M. Rognes, Torbjorn Lee, Jeannie T. Klungland, Arne Kouzarides, Tony Larsen, Elisabeth TI ALKBH1 Is a Histone H2A Dioxygenase Involved in Neural Differentiation SO STEM CELLS LA English DT Article DE ALKBH1; Stem cells; Histone dioxygenase; Neural development; Epigenetics ID EMBRYONIC STEM-CELLS; ESCHERICHIA-COLI; OXIDATIVE DEMETHYLATION; TRANSCRIPTION FACTORS; ALKYLATION DAMAGE; TRANSFER-RNA; ES CELLS; DNA; REPAIR; EXPRESSION AB AlkB homolog 1 (ALKBH1) is one of nine members of the family of mammalian AlkB homologs. Most Alkbh1(-/-) mice die during embryonic development, and survivors are characterized by defects in tissues originating from the ectodermal lineage. In this study, we show that deletion of Alkbh1 prolonged the expression of pluripotency markers in embryonic stem cells and delayed the induction of genes involved in early differentiation. In vitro differentiation to neural progenitor cells (NPCs) displayed an increased rate of apoptosis in the Alkbh1(-/-) NPCs when compared with wild-type cells. Whole-genome expression analysis and chromatin immunoprecipitation revealed that ALKBH1 regulates both directly and indirectly, a subset of genes required for neural development. Furthermore, our in vitro enzyme activity assays demonstrate that ALKBH1 is a histone dioxygenase that acts specifically on histone H2A. Mass spectrometric analysis demonstrated that histone H2A from Alkbh1(-/-) mice are improperly methylated. Our results suggest that ALKBH1 is involved in neural development by modifying the methylation status of histone H2A. STEM CELLS 2012; 30: 2672-2682 C1 [Ougland, Rune; Jonson, Ida; Dahl, John A.; Moen, Marivi Nabong; Nordstrand, Line M.; Rognes, Torbjorn; Klungland, Arne; Larsen, Elisabeth] Natl Hosp Norway, Ctr Mol Biol & Neurosci, Inst Med Microbiol, Oslo Univ Hosp, NO-0027 Oslo, Norway. [Ougland, Rune; Jonson, Ida; Dahl, John A.; Moen, Marivi Nabong; Nordstrand, Line M.; Rognes, Torbjorn; Klungland, Arne; Larsen, Elisabeth] Univ Oslo, NO-0027 Oslo, Norway. [Lando, David; Kouzarides, Tony] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England. [Lando, David; Kouzarides, Tony] Univ Cambridge, Gurdon Inst, Cambridge, England. [Lee, Jeannie T.] Massachusetts Gen Hosp, Dept Mol Biol, Howard Hughes Med Inst, Boston, MA 02114 USA. [Lee, Jeannie T.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. RP Larsen, E (reprint author), Natl Hosp Norway, Ctr Mol Biol & Neurosci, Inst Med Microbiol, Oslo Univ Hosp, NO-0027 Oslo, Norway. EM elisabeth.larsen@rr-research.no OI Rognes, Torbjorn/0000-0002-9329-9974 FU University of Oslo; Norwegian Cancer Society FX We thank Kjersti Bolstad at Oslo University for help with bioinformatics, Jon LIrdal for modeling of protein structure, and Gaute Nesse, Linda Tveteras, and Marit Sletten at Oslo University Hospital, for technical assastance. This work was supported by University of Oslo and Norwegian Cancer Society. NR 54 TC 33 Z9 36 U1 2 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 J9 STEM CELLS JI Stem Cells PD DEC PY 2012 VL 30 IS 12 BP 2672 EP 2682 DI 10.1002/stem.1228 PG 11 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA 042TJ UT WOS:000311493600007 PM 22961808 ER PT J AU Falcone, GJ Brouwers, HB Rosand, J AF Falcone, Guido J. Brouwers, H. Bart Rosand, Jonathan TI Risk of Intracranial Hemorrhage With Protease-Activated Receptor-1 Antagonists SO STROKE LA English DT Editorial Material ID RANDOMIZED CLINICAL-TRIALS; ACUTE CORONARY SYNDROMES; ST-SEGMENT ELEVATION; SAFETY; METAANALYSIS; PREVENTION; VORAPAXAR; EFFICACY; DISEASE C1 [Rosand, Jonathan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. Massachusetts Gen Hosp, Hemorrhag Stroke Res Grp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care & Emergency Neurol, Boston, MA 02114 USA. Broad Inst, Program Med & Populat Genet, Cambridge, MA USA. RP Rosand, J (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, 185 Cambridge St,CPZN 6818, Boston, MA 02114 USA. EM jrosand@partners.org RI Falcone, Guido/L-2287-2016 OI Falcone, Guido/0000-0002-6407-0302 NR 22 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD DEC PY 2012 VL 43 IS 12 BP 3158 EP 3159 DI 10.1161/STROKEAHA.112.676932 PG 2 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 042UU UT WOS:000311497600011 PM 23160886 ER PT J AU Wimmer, NJ Yeh, RW Cutlip, DE Mauri, L AF Wimmer, Neil J. Yeh, Robert W. Cutlip, Donald E. Mauri, Laura TI Risk Prediction for Adverse Events After Carotid Artery Stenting in Higher Surgical Risk Patients SO STROKE LA English DT Article DE carotid arteries; risk factors; stenting; stents ID STROKE-ASSOCIATION; INDIVIDUAL PATIENTS; ISCHEMIC-STROKE; ENDARTERECTOMY; STENOSIS; PREVENTION; PROTECTION; OUTCOMES; COMPLICATIONS; GUIDELINES AB Background and Purpose-The goal of carotid artery stenting is to decrease the risk of stroke or other adverse events from carotid artery disease. Choosing a treatment strategy requires patient-specific information regarding periprocedural risk of adverse neurologic events. The aim of this study was to predict individual patient risk after carotid artery stenting in patients at higher risk for carotid endarterectomy. Methods-Subjects enrolled in the Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterectomy (SAPPHIRE) worldwide study underwent carotid artery stenting with distal protection. Only patients with at least 1 anatomic or comorbid factor associated with elevated surgical risk were included. Preprocedural factors were used to develop a model and integer-based risk score predicting stroke or death within 30 days. The model was calibrated and internally validated using bootstrap resampling. Results-Ten thousand one hundred eighty-six patients were included in the analysis. The overall rate of stroke or death was 3.6% at 30 days after carotid artery stenting. Independent predictors of adverse outcomes were increased age (P=0.006), history of stroke (P<0.001), history of transient ischemic attack presentation (P=0.001), recent (<4 weeks) myocardial infarction (P=0.006), dialysis treatment (P=0.007), need for cardiac surgery in addition to carotid revascularization (P=0.005), a right-sided carotid stenosis (P=0.006), a longer carotid plaque (P=0.012), the presence of a Type II or III aortic arch (P=0.035), and a tortuous carotid arterial system (P=0.004). The optimism-adjusted C-statistic was 0.691. Conclusions-Commonly collected clinical and anatomic variables can identify patients at high and low risk for stroke or death after carotid artery stenting. (Stroke. 2012; 43: 3218-3224.) C1 [Wimmer, Neil J.; Mauri, Laura] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02120 USA. [Yeh, Robert W.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [Cutlip, Donald E.] Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA. [Wimmer, Neil J.; Yeh, Robert W.; Cutlip, Donald E.; Mauri, Laura] Harvard Univ, Sch Med, Boston, MA USA. RP Mauri, L (reprint author), Brigham & Womens Hosp, Div Cardiovasc, 1620 Tremont St, Boston, MA 02120 USA. EM lmauri1@partners.org FU National Institutes of Health [T32-HL007604] FX Dr Wimmer is supported by National Institutes of Health T32-HL007604. NR 40 TC 16 Z9 17 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD DEC PY 2012 VL 43 IS 12 BP 3218 EP 3224 DI 10.1161/STROKEAHA.112.673194 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 042UU UT WOS:000311497600022 PM 23127975 ER PT J AU Brouwers, HB Goldstein, JN Romero, JM Rosand, J AF Brouwers, H. Bart Goldstein, Joshua N. Romero, Javier M. Rosand, Jonathan TI Clinical Applications of the Computed Tomography Angiography Spot Sign in Acute Intracerebral Hemorrhage A Review SO STROKE LA English DT Review DE computed tomography angiography; computed tomography angiography spot sign; functional outcome; hematoma expansion intracerebral hemorrhage ID PREDICTS HEMATOMA EXPANSION; ACUTE CEREBRAL-HEMORRHAGE; APOLIPOPROTEIN-E GENOTYPE; BLOOD-PRESSURE REDUCTION; CT ANGIOGRAPHY; CONTRAST EXTRAVASATION; MORTALITY; GROWTH; VOLUME; TRIAL C1 [Brouwers, H. Bart] Harvard Univ, Massachusetts Gen Hosp, Ctr Human Genet Res, Med Sch,Rosand Lab, Boston, MA 02114 USA. [Brouwers, H. Bart; Goldstein, Joshua N.; Rosand, Jonathan] Harvard Univ, Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care & Emergency Neurol,Med Sch, Boston, MA 02114 USA. [Brouwers, H. Bart; Goldstein, Joshua N.; Rosand, Jonathan] Harvard Univ, Massachusetts Gen Hosp, Hemorrhag Stroke Res Grp, Sch Med, Boston, MA 02114 USA. [Brouwers, H. Bart; Goldstein, Joshua N.; Rosand, Jonathan] Harvard Univ, Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, Sch Med, Boston, MA 02114 USA. [Goldstein, Joshua N.] Harvard Univ, Massachusetts Gen Hosp, Dept Emergency Med, Sch Med, Boston, MA 02114 USA. [Romero, Javier M.] Harvard Univ, Massachusetts Gen Hosp, Dept Radiol, Neuroradiol Serv,Med Sch, Boston, MA 02114 USA. RP Brouwers, HB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Human Genet Res, Med Sch,Rosand Lab, 185 Cambridge St,CPZN 6818, Boston, MA 02114 USA. EM brouwers@chgr.mgh.harvard.edu RI Goldstein, Joshua/H-8953-2016 FU NIH-NINDS [R01NS073344, R01NS059727, 5K23NS059774]; American Heart Association [0755984T]; NIH-NINDS SPOTRIAS [P50NS051343] FX All funding entities had no involvement in study design, data collection, analysis, and interpretation, writing of the article, and in the decision to submit for publication. The project described was supported by grants R01NS073344, R01NS059727, and 5K23NS059774 from the NIH-NINDS and American Heart Association grant 0755984T. Dr Brouwers was supported by the NIH-NINDS SPOTRIAS fellowship grant P50NS051343. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the NINDS. NR 35 TC 32 Z9 33 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD DEC PY 2012 VL 43 IS 12 BP 3427 EP 3432 DI 10.1161/STROKEAHA.112.664003 PG 6 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 042UU UT WOS:000311497600060 PM 23132779 ER PT J AU Weinsheimer, S Brettman, AD Pawlikowska, L Wu, DC Mancuso, MR Kuhnert, F Lawton, MT Sidney, S Zaroff, JG McCulloch, CE Young, WL Kuo, C Kim, H AF Weinsheimer, Shantel Brettman, Ari D. Pawlikowska, Ludmila Wu, D. Christine Mancuso, Michael R. Kuhnert, Frank Lawton, Michael T. Sidney, Stephen Zaroff, Jonathan G. McCulloch, Charles E. Young, William L. Kuo, Calvin Kim, Helen TI G Protein-Coupled Receptor 124 (GPR124) Gene Polymorphisms and Risk of Brain Arteriovenous Malformation SO TRANSLATIONAL STROKE RESEARCH LA English DT Review DE Angiogenesis; Genetics; Intracerebral hemorrhage; Risk factor; Vascular malformation ID INTRACRANIAL HEMORRHAGE; ANGIOGENESIS; ASSOCIATION; HUMANS; MICE AB Abnormal endothelial proliferation and angiogenesis may contribute to brain arteriovenous malformation (BAVM) formation. G protein-coupled receptor 124 (GPR124) mediates embryonic central nervous system angiogenesis; thus, we investigated the association of single nucleotide polymorphisms (SNPs) and haplotypes in GPR124 with risk of BAVM. Ten tagging SNPs spanning 39 kb of GPR124 were genotyped in 195 Caucasian BAVM patients and 243 Caucasian controls. SNP and haplotype association with risk of BAVM was screened using chi (2) analysis. Associated variants were further evaluated using multivariable logistic regression, adjusting for age and sex. The minor alleles of three GPR124 SNPs adjacent to exon 2 and localized to a 16-kb region of high linkage disequilibrium were associated with reduced risk of BAVM (rs7015566 A, P = 0.001; rs7823249 T, P = 0.014; rs12676965 C, P = 0.007). SNP rs7015566 (intron 1) remained associated after permutation testing (additive model P = 0.033). Haplotype analysis revealed a significant overall association (chi (2) = 12.55, 4 degrees of freedom, P = 0.014); two haplotypes (ATCC, P = 0.006 and GGCT, P = 0.008) were associated with risk of BAVM. We genotyped a known synonymous SNP (rs16887051) in exon 2; however, genotype frequency did not differ between cases and controls. Sequencing of conserved GPR124 regions revealed a novel insertion/deletion polymorphism in intron 2. Immunohistochemistry confirmed GPR124 expression in the endothelium with no qualitative difference in expression between BAVM cases and controls. SNP rs7015566 mapping to intron 1 of GPR124 was associated with BAVM susceptibility among Caucasians. Future work is focused on investigating this gene region. C1 [Weinsheimer, Shantel; Pawlikowska, Ludmila; Young, William L.; Kim, Helen] Univ Calif San Francisco, Ctr Cerebrovasc Res, Dept Anesthesia & Perioperat Care, San Francisco, CA 94110 USA. [Brettman, Ari D.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Brettman, Ari D.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Pawlikowska, Ludmila] Univ Calif San Francisco, Inst Human Genet, San Francisco, CA 94110 USA. [Wu, D. Christine; Mancuso, Michael R.; Kuhnert, Frank; Kuo, Calvin] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA. [Lawton, Michael T.; Young, William L.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA. [Sidney, Stephen; Zaroff, Jonathan G.] Kaiser Permanente Med Care Program No Calif KPNC, Div Res, Oakland, CA USA. [McCulloch, Charles E.; Kim, Helen] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94110 USA. [Young, William L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94110 USA. RP Kim, H (reprint author), Univ Calif San Francisco, Ctr Cerebrovasc Res, Dept Anesthesia & Perioperat Care, 1001 Potrero Ave,Box 1363, San Francisco, CA 94110 USA. EM kimhel@anesthesia.ucsf.edu FU National Institutes of Health [K23 NS058357, R01 NS034949, P01 NS044155, R01 NS064517, R01 NS052830, T32 GM008440]; American Heart Association Western States Affiliate [10POST3640020]; Sarnoff Foundation Research Fellowship; Medical Scientist Training Program at Stanford University FX The authors would like to thank the patients who participated in this study and members of the Brain AVM Project for the assistance with patient recruitment, technical support, and data management. This study was supported by National Institutes of Health grants: K23 NS058357 (HK), R01 NS034949 (WLY), P01 NS044155 (WLY), R01 NS064517 (CJK), R01 NS052830 (CJK), and T32 GM008440 (SW); American Heart Association Western States Affiliate Post-doctoral Fellowship 10POST3640020 (SW) and Pre-doctoral Fellowship (MRM); Sarnoff Foundation Research Fellowship (ADB); and Medical Scientist Training Program at Stanford University (MRM). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. NR 39 TC 5 Z9 5 U1 1 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-4483 EI 1868-601X J9 TRANSL STROKE RES JI Transl. Stroke Res. PD DEC PY 2012 VL 3 IS 4 BP 418 EP 427 DI 10.1007/s12975-012-0202-9 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 041MX UT WOS:000311407000002 PM 23329986 ER PT J AU Saidi, RF Markmann, JF Jabbour, N Li, YF Shah, SA Cosimi, AB Bozorgzadeh, A AF Saidi, Reza F. Markmann, James F. Jabbour, Nicolas Li, YouFu Shah, Shimul A. Cosimi, A. B. Bozorgzadeh, Adel TI The Faltering Solid Organ Donor Pool in the United States (2001-2010) SO WORLD JOURNAL OF SURGERY LA English DT Article ID CARDIAC DEATH; KIDNEY-TRANSPLANTATION; EXTRACORPOREAL SUPPORT; RISK INDEX; DONATION; AVAILABILITY AB Organ shortage is the greatest challenge facing the field of organ transplantation today. Use of more organs of marginal quality has been advocated to address the shortage. We examined the pattern of donation and organ use in the United States as shown in the Organ Procurement and Transplantation Network/United Network for Organ Sharing database of individuals who were consented for and progressed to organ donation between January 2001 and December 2010. There were 66,421 living donors and 73,359 deceased donors, including 67,583 (92.1 %) identified as donation after brain death and 5,776 (7.9 %) as donation after circulatory death (DCD). Comparing two periods, era 1 (01/2001-12/2005) and era 2 (01/2006-12/2010), the number of deceased donors increased by 20.3 % from 33,300 to 40,059 while there was a trend for decreasing living donation. The DCD subgroup increased from 4.9 to 11.7 % comparing the two eras. A significant increase in cardiovascular/cerebrovascular disease as a cause of death was also noted, from 38.1 % in era 1 to 56.1 % in era 2 (p < 0.001), as was a corresponding decrease in the number of deaths due to head trauma (48.8 vs. 34.9 %). The overall discard rate also increased from 13,411 (11.5 %) in era 1 to 19,516 (13.7 %) in era 2. This increase in discards was especially prominent in the DCD group [440 (20.9 %) in era 1 vs. 2,089 (24.9 %) in era 2]. We detect a significant change in pattern of organ donation and use in the last decade in the United States. The transplant community should consider every precaution to prevent the decay of organ quality and to improve the use of marginal organs. C1 [Saidi, Reza F.; Jabbour, Nicolas; Li, YouFu; Shah, Shimul A.; Bozorgzadeh, Adel] Univ Massachusetts, Sch Med, Dept Surg, Div Organ Transplantat, Worcester, MA 01655 USA. [Markmann, James F.; Cosimi, A. B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplant Ctr, Boston, MA 02114 USA. RP Saidi, RF (reprint author), Univ Massachusetts, Sch Med, Dept Surg, Div Organ Transplantat, 55 Lake Ave N,S6-426, Worcester, MA 01655 USA. EM Reza.Saidi@umassmemorial.org NR 20 TC 18 Z9 19 U1 2 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2313 J9 WORLD J SURG JI World J.Surg. PD DEC PY 2012 VL 36 IS 12 BP 2909 EP 2913 DI 10.1007/s00268-012-1748-0 PG 5 WC Surgery SC Surgery GA 040II UT WOS:000311315700023 PM 22933050 ER PT J AU Brunelli, SM Waikar, SS Bateman, BT Chang, TI Lii, J Garg, AX Winkelmayer, WC Choudhry, NK AF Brunelli, Steven M. Waikar, Sushrut S. Bateman, Brian T. Chang, Tara I. Lii, Joyce Garg, Amit X. Winkelmayer, Wolfgang C. Choudhry, Niteesh K. TI Preoperative Statin Use and Postoperative Acute Kidney Injury SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Acute kidney injury; Acute renal failure; 3-Hydroxy-3-glutaryl Co-A reductase inhibitors; Perioperative complications; Statins; Surgery ID ACUTE-RENAL-FAILURE; ISCHEMIA-REPERFUSION INJURY; RANDOMIZED CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION; CARDIAC-SURGERY; HOSPITALIZED-PATIENTS; SERUM CREATININE; RISK; THERAPY; MORTALITY AB BACKGROUND: Acute kidney injury is a frequent postoperative complication that confers increased mortality, morbidity, and costs. The purpose of this study was to evaluate whether preoperative statin use is associated with a decreased risk of postoperative acute kidney injury. METHODS: We assembled a retrospective cohort of 98,939 patients who underwent a major open abdominal, cardiac, thoracic, or vascular procedure between 2000 and 2010. Statin users were pair-matched to nonusers on the basis of surgery type, baseline kidney function, days from admission until surgery, and propensity score based on demographics, comorbid conditions, and concomitant medications. Acute kidney injury was defined based on changes in serum creatinine measurements applying Acute Kidney Injury Network and Risk-Injury-Failure staging systems, and on the need for renal replacement therapy. Associations between statin use and acute kidney injury were estimated by conditional logistic regression. RESULTS: Across various acute kidney injury definitions, statin use was consistently associated with a decreased risk: adjusted odds ratios (95% confidence intervals) varied from 0.74 (0.58-0.95) to 0.80 (0.71-0.90). Associations were similar among diabetics and nondiabetics, and across strata of baseline kidney function. The protective association of statins was most pronounced among patients undergoing vascular surgery and least among patients undergoing cardiac surgery. CONCLUSIONS: Preoperative statin use is associated with a decreased risk of postoperative acute kidney injury. Future randomized clinical trials are needed to determine causality. (C) 2012 Elsevier Inc. All rights reserved. circle The American Journal of Medicine (2012) 125, 1195-1204 C1 [Brunelli, Steven M.; Bateman, Brian T.; Lii, Joyce; Choudhry, Niteesh K.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA. [Brunelli, Steven M.; Waikar, Sushrut S.] Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02120 USA. [Brunelli, Steven M.; Waikar, Sushrut S.; Bateman, Brian T.; Choudhry, Niteesh K.] Harvard Univ, Sch Med, Boston, MA USA. [Bateman, Brian T.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Chang, Tara I.; Winkelmayer, Wolfgang C.] Stanford Univ, Sch Med, Dept Med, Div Nephrol, Palo Alto, CA 94304 USA. [Garg, Amit X.] Univ Western Ontario, Dept Med & Epidemiol, London, ON, Canada. [Garg, Amit X.] London Hlth Sci Ctr, Dept Med, Div Nephrol, London, ON, Canada. RP Brunelli, SM (reprint author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 30303, Boston, MA 02120 USA. EM sbrunelli@partners.org OI Chang, Tara/0000-0002-4691-1681 FU National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases [DK079056] FX This work was supported by a grant from the National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases: DK079056 (S.M.B.). The NIH had no role in the design or conduct of this study, or in the drafting of this manuscript or decision to publish. NR 43 TC 25 Z9 26 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD DEC PY 2012 VL 125 IS 12 BP 1195 EP + DI 10.1016/j.amjmed.2012.06.021 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 039BK UT WOS:000311217600020 PM 23062398 ER PT J AU Upadhyay, GA Gainor, JF Stamm, LM Weinberg, AN Dec, GW Ruskin, JN AF Upadhyay, Gaurav A. Gainor, Justin F. Stamm, Luisa M. Weinberg, Arnold N. Dec, G. William Ruskin, Jeremy N. TI Acute Nonrheumatic Streptococcal Myocarditis: STEMI Mimic in Young Adults SO AMERICAN JOURNAL OF MEDICINE LA English DT Article DE Myocarditis; Pharyngitis; Streptococcal infection; ST-segment elevation myocardial infarction ID COMPLICATING ACUTE TONSILLITIS; MYOPERICARDITIS AB BACKGROUND: Mimicking ST-segment elevation myocardial infarction upon presentation, acute nonrheumatic streptococcal myocarditis is a treatable etiology of myocarditis which has only been infrequently reported. METHODS: Patients were identified through a retrospective query of electronic medical records over a 17-year period (January 1994 to December 2010). We describe a case series of acute nonrheumatic streptococcal myocarditis complicating pharyngitis in young adults. RESULTS: Nine patients were identified; 89% were male, patients had an average age of 28.6 years, and 56% and 22% had confirmed group A and group G streptococcus, respectively. Latency from pharyngitis to chest pain averaged 3.1 +/- 1.1 days. No patients met the revised Jones criteria for acute rheumatic fever. All 9 patients (100%) presented with ST-segment elevations on electrocardiography and elevated cardiac biomarkers. Average peak creatine kinase was 934 U/L (normal < 400 U/L), creatine kinase-MB was 82 ng/mL (normal < 6.9 ng/mL), and troponin T was 2.30 ng/mL (normal < 0.03 ng/mL). Six patients underwent coronary angiography, which revealed no obstructive culprit lesions. Cardiac magnetic resonance imaging confirmed myocarditis in 3 patients and was used to document resolution in follow-up for 2 patients. All patients had a complete clinical recovery. CONCLUSIONS: Acute nonrheumatic streptococcal myocarditis is an under-recognized and treatable cause of ST-segment elevation and chest pain in young adults with a history of recent pharyngitis. Etiopathology extends beyond Lancefield group A streptococcus and includes group G streptococcal infection. Cardiac magnetic resonance may be useful in confirming the diagnosis and documenting the resolution. (C) 2012 Elsevier Inc. All rights reserved. circle The American Journal of Medicine (2012) 125, 1230-1233 C1 [Upadhyay, Gaurav A.; Gainor, Justin F.; Stamm, Luisa M.; Weinberg, Arnold N.; Dec, G. William; Ruskin, Jeremy N.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Upadhyay, Gaurav A.; Dec, G. William; Ruskin, Jeremy N.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Stamm, Luisa M.; Weinberg, Arnold N.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. RP Upadhyay, GA (reprint author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St,Gray Bigelow 109, Boston, MA 02114 USA. EM gaupadhyay@partners.org FU NIAID NIH HHS [T32 AI007061] NR 12 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9343 J9 AM J MED JI Am. J. Med. PD DEC PY 2012 VL 125 IS 12 BP 1230 EP 1233 DI 10.1016/j.amjmed.2012.06.016 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 039BK UT WOS:000311217600028 PM 23062402 ER PT J AU Lobo, AZC Tanabe, KK Luo, S Muzikansky, A Sober, AJ Tsao, H Cosimi, AB Duncan, LM AF Lobo, Alice Z. C. Tanabe, Kenneth K. Luo, Su Muzikansky, Alona Sober, Arthur J. Tsao, Hensin Cosimi, A. Benedict Duncan, Lyn M. TI The Distribution of Microscopic Melanoma Metastases in Sentinel Lymph Nodes Implications for Pathology Protocols SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY LA English DT Article DE melanoma; sentinel lymph node; micrometastasis; metastasis ID POLYMERASE-CHAIN-REACTION; PROGNOSTIC-SIGNIFICANCE; CUTANEOUS MELANOMA; MALIGNANT-MELANOMA; CLINICAL-RELEVANCE; NONSENTINEL NODES; POSITIVE MELANOMA; S-100 PROTEIN; BIOPSY; DISSECTION AB The utility of sectioning at multiple levels in the histopathologic analysis of sentinel lymph nodes (SLNs) for melanoma and the correlation of metastasis size with risk of subsequent metastasis were investigated. Metastatic melanoma was identified in SLNs from 91 of 475 (19%) melanoma patients with SLN sampling at the Massachusetts General Hospital between 2004 and 2008. All SLNs were evaluated by a 9-slide protocol: sets of MART-1, hematoxylin and eosin, and S100 stains at 3 distinct levels separated by 80 mm. The location and size of the tumor deposits were evaluated in the context of subsequent metastasis and overall survival. Of the 91 patients with positive sentinel nodes, all 9 protocol slides were available for review in 61 (67%). Eleven of 61 patients had no tumor present in the first set of levels; 2 of these patients died of metastatic melanoma. Patients in whom 11 or more tumor cells were detected in the sentinel node had a greater chance of developing subsequent metastases when compared with patients in whom 10 or fewer tumor cells were detected (P = 0.05). Of those with either metastases > 2mm in diameter or extracapsular extension, 50% developed metastases beyond the SLN basin. Eliminating 1 of the 3 levels in the SLN detection protocol would have led to a false-negative diagnosis in 18% of patients. C1 [Lobo, Alice Z. C.; Luo, Su; Duncan, Lyn M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pathol Serv, Boston, MA USA. [Lobo, Alice Z. C.; Luo, Su; Duncan, Lyn M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dermatopathol Unit, Boston, MA USA. [Tanabe, Kenneth K.; Cosimi, A. Benedict] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg Oncol, Boston, MA USA. [Muzikansky, Alona] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Biostat, Boston, MA USA. [Sober, Arthur J.; Tsao, Hensin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA USA. RP Duncan, LM (reprint author), Massachusetts Gen Hosp, Dermatopathol Unit WRN 825, 55 Fruit St, Boston, MA 02114 USA. EM duncan@helix.mgh.harvard.edu FU Dermatopathology Unit of the Pathology Service, Massachusetts General Hospital, Boston, MA FX Supported by departmental research funds from the Dermatopathology Unit of the Pathology Service, Massachusetts General Hospital, Boston, MA. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. NR 49 TC 8 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0147-5185 J9 AM J SURG PATHOL JI Am. J. Surg. Pathol. PD DEC PY 2012 VL 36 IS 12 BP 1841 EP 1848 DI 10.1097/PAS.0b013e31826d25f9 PG 8 WC Pathology; Surgery SC Pathology; Surgery GA 039GV UT WOS:000311233500012 PM 23154770 ER PT J AU Waern, I Karlsson, I Thorpe, M Schlenner, SM Feyerabend, TB Rodewald, HR Abrink, M Hellman, L Pejler, G Wernersson, S AF Waern, Ida Karlsson, Iulia Thorpe, Michael Schlenner, Susan M. Feyerabend, Thorsten B. Rodewald, Hans-Reimer Abrink, Magnus Hellman, Lars Pejler, Gunnar Wernersson, Sara TI Mast cells limit extracellular levels of IL-13 via a serglycin proteoglycan-serine protease axis SO BIOLOGICAL CHEMISTRY LA English DT Article DE allergy; cytokine; mast cell; proteoglycan; serine protease ID EXTENDED SUBSTRATE-SPECIFICITY; MICE LACKING HEPARIN; SECRETORY GRANULE; CYTOKINE PRODUCTION; CARBOXYPEPTIDASE-A; CHYMASE; ASTHMA; STORAGE; ACCUMULATION; DEGRADATION AB Mast cell (MC) granules contain large amounts of proteases of the chymase, tryptase and carboxypeptidase A (MC-CPA) type that are stored in complex with serglycin, a proteoglycan with heparin side chains. Hence, serglycin-protease complexes are released upon MC degranulation and may influence local inflammation. Here we explored the possibility that a serglycin-protease axis may regulate levels of IL-13, a cytokine involved in allergic asthma. Indeed, we found that wild-type MCs efficiently degraded exogenous or endogenously produced IL-13 upon degranulation, whereas serglycin(-/-) MCs completely lacked this ability. Moreover, MC-mediated IL-13 degradation was blocked both by a serine protease inhibitor and by a heparin antagonist, which suggests that IL-13 degradation is catalyzed by serglycin-dependent serine proteases and that optimal IL-13 degradation is dependent on both the serglycin and the protease component of the serglycin-protease complex. Moreover, IL-13 degradation was abrogated in MC-CPA(-/-) MC cultures, but was normal in cultures of MCs with an inactivating mutation of MC-CPA, which suggests that the IL-13-degrading serine proteases rely on MC-CPA protein. Together, our data implicate a serglycin-serine protease axis in the regulation of extracellular levels of IL-13. Reduction of IL-13 levels through this mechanism possibly can provide a protective function in the context of allergic inflammation. C1 [Waern, Ida; Karlsson, Iulia; Pejler, Gunnar; Wernersson, Sara] Swedish Univ Agr Sci, Biomed Ctr, Dept Anat Physiol & Biochem, SE-75123 Uppsala, Sweden. [Thorpe, Michael] Uppsala Univ, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden. [Schlenner, Susan M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA. [Feyerabend, Thorsten B.; Rodewald, Hans-Reimer] German Canc Res Ctr, Div Cellular Immunol, D-69120 Heidelberg, Germany. [Abrink, Magnus] Swedish Univ Agr Sci, Dept Biomed Sci & Vet Publ Hlth, SE-75123 Uppsala, Sweden. [Hellman, Lars] Uppsala Univ, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden. RP Wernersson, S (reprint author), Swedish Univ Agr Sci, Biomed Ctr, Dept Anat Physiol & Biochem, Box 575, SE-75123 Uppsala, Sweden. EM sara.wernersson@slu.se RI Wernersson, Sara/D-4580-2011; Thorpe, Michael/P-6838-2015 OI Wernersson, Sara/0000-0003-3067-7875; Thorpe, Michael/0000-0002-4771-0080 FU Vardal Foundation; Swedish Society of Medicine; Ake Wiberg Foundation; Konsul Th C Bergh Foundation; Swedish Research Council [K2012-57X-22048-01-6]; European Research Council under the European Community [233074] FX We thank D. M. Lee for providing mMCP-6 null mice and M. Daeron for providing stem cell factor-transfected Chinese hamster ovary cells. This work was supported by grants (to SW) from the Vardal Foundation, the Swedish Society of Medicine, the Ake Wiberg Foundation, the Konsul Th C Bergh Foundation and the Swedish Research Council [grant number K2012-57X-22048-01-6]. HRR was supported by the European Research Council under the European Community's Seventh Framework Program [grant agreement number 233074]. NR 44 TC 11 Z9 11 U1 0 U2 3 PU WALTER DE GRUYTER & CO PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 1431-6730 J9 BIOL CHEM JI Biol. Chem. PD DEC PY 2012 VL 393 IS 12 BP 1555 EP 1567 DI 10.1515/hsz-2012-0189 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 036SQ UT WOS:000311051400017 PM 23667909 ER PT J AU Mortensen, EM Nakashima, B Cornell, J Copeland, LA Pugh, MJ Anzueto, A Good, C Restrepo, MI Downs, JR Frei, CR Fine, MJ AF Mortensen, Eric M. Nakashima, Brandy Cornell, John Copeland, Laurel A. Pugh, Mary Jo Anzueto, Antonio Good, Chester Restrepo, Marcos I. Downs, John R. Frei, Christopher R. Fine, Michael J. TI Population-Based Study of Statins, Angiotensin II Receptor Blockers, and Angiotensin-Converting Enzyme Inhibitors on Pneumonia-Related Outcomes SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; CYTOKINE LEVELS; DISEASE; THERAPY; TRIAL AB Background. Studies suggest that statins and angiotensin-converting enzyme (ACE) inhibitors might be beneficial for the treatment of infections. Our purpose was to examine the association of statin, ACE inhibitor, and angiotensin II receptor blocker (ARB) use with pneumonia-related outcomes. Methods. We conducted a retrospective cohort study using Department of Veterans Affairs data of patients aged >= 65 years hospitalized with pneumonia. We performed propensity-score matching for 3 medication classes simultaneously. Results. Of 50 119 potentially eligible patients, we matched 11 498 cases with 11 498 controls. Mortality at 30 days was 13%; 34% used statins, 30% ACE inhibitors, and 4% ARBs. In adjusted models, prior statin use was associated with decreased mortality (odds ratio [OR], 0.74; 95% confidence interval [CI],.68-.82) and mechanical ventilation (OR, 0.81; 95% CI, .70-.94), and inpatient use with decreased mortality (OR, 0.68; 95% CI, .59-.78) and mechanical ventilation (OR, 0.68; 95% CI, .60-.90). Prior (OR, 0.88; 95% CI, .80-.97) and inpatient (OR, 0.58; 95% CI, .48-.69) ACE inhibitor use was associated with decreased mortality. Prior (OR, 0.73; 95% CI, .58-.92) and inpatient ARB use (OR, 0.47; 95% CI, .30-.72) was only associated with decreased mortality. Use of all 3 medications was associated with reduced length of stay. Conclusions. Statins, and to a lesser extent ACE inhibitors and ARBs, are associated with improved pneumonia-related outcomes. Prospective cohort and randomized controlled trials are needed to examine potential mechanisms of action and whether acute initiation at the time of presentation with these infections is beneficial. C1 [Mortensen, Eric M.; Nakashima, Brandy; Pugh, Mary Jo; Anzueto, Antonio; Restrepo, Marcos I.; Downs, John R.] VERDICT Res Program, San Antonio, TX USA. [Mortensen, Eric M.; Nakashima, Brandy; Pugh, Mary Jo; Anzueto, Antonio; Restrepo, Marcos I.; Downs, John R.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA. [Mortensen, Eric M.; Downs, John R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hosp Med, San Antonio, TX 78229 USA. [Anzueto, Antonio; Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, Div Pulm Crit Care Med, San Antonio, TX 78229 USA. [Cornell, John; Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol, San Antonio, TX 78229 USA. [Cornell, John; Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat, San Antonio, TX 78229 USA. [Copeland, Laurel A.] Scott & White Healthcare, Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Temple, TX USA. [Good, Chester; Fine, Michael J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Frei, Christopher R.] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA. [Frei, Christopher R.] Univ Texas Hlth Sci Ctr San Antonio, Pharmacotherapy Educ & Res Ctr, San Antonio, TX 78229 USA. RP Mortensen, EM (reprint author), Dallas VA Med Ctr, 4500 S Lancaster, Dallas, TX 75216 USA. EM eric.mortensen@utsouthwestern.edu RI Restrepo, Marcos/H-4442-2014; OI Mortensen, Eric/0000-0002-3880-5563; Copeland, Laurel/0000-0002-9478-0209 FU National Institute of Nursing Research [R01NR010828] FX This work was supported by the National Institute of Nursing Research (grant number R01NR010828). This material is the result of work supported with resources and the use of facilities at the South Texas Veterans Health Care System. NR 26 TC 43 Z9 43 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2012 VL 55 IS 11 BP 1466 EP 1473 DI 10.1093/cid/cis733 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 035RR UT WOS:000310966200010 PM 22918991 ER PT J AU Musher, DM AF Musher, Daniel M. TI Pneumococcal Polysaccharide Vaccine Efficacy and Routine Use of Conjugate Vaccines in Infants: There Is No Need for a Vaccine Program in Older Adults at Present Reply SO CLINICAL INFECTIOUS DISEASES LA English DT Letter C1 Baylor Coll Med, Infect Dis Sect, ME DeBakey VA Med Ctr, Houston, TX 77030 USA. RP Musher, DM (reprint author), Baylor Coll Med, Infect Dis Sect, ME DeBakey VA Med Ctr, 2002 Holcombe, Houston, TX 77030 USA. EM daniel.musher@va.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2012 VL 55 IS 11 BP 1579 EP 1579 DI 10.1093/cid/cis701 PG 1 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 035RR UT WOS:000310966200027 ER PT J AU Beheshti, M Graber, CJ Goetz, MB Bluestone, GL AF Beheshti, Manie Graber, Christopher J. Goetz, Matthew B. Bluestone, Gary L. TI Clarifying the Role of Adjunctive Metronidazole in the Treatment of Biliary Infections SO CLINICAL INFECTIOUS DISEASES LA English DT Letter ID TOKYO GUIDELINES; ANTIMICROBIAL STEWARDSHIP; ACUTE CHOLECYSTITIS; DISEASES SOCIETY; THERAPY; AMERICA C1 [Graber, Christopher J.; Goetz, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90073 USA. [Beheshti, Manie; Bluestone, Gary L.] Kaiser Permanente, Dept Internal Med, Div Infect Dis, Los Angeles, CA USA. RP Graber, CJ (reprint author), VA Greater Los Angeles Healthcare Syst, 111F,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM christopher.graber@va.gov OI Goetz, Matthew/0000-0003-4542-992X NR 9 TC 0 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2012 VL 55 IS 11 BP 1583 EP 1584 DI 10.1093/cid/cis718 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 035RR UT WOS:000310966200030 PM 22942200 ER PT J AU Anaya, JM Castiblanco, J Rojas-Villarraga, A Pineda-Tamayo, R Levy, RA Gomez-Puerta, J Dias, C Mantilla, RD Gallo, JE Cervera, R Shoenfeld, Y Arcos-Burgos, M AF Anaya, Juan-Manuel Castiblanco, John Rojas-Villarraga, Adriana Pineda-Tamayo, Ricardo Levy, Roger A. Gomez-Puerta, Jose Dias, Carlos Mantilla, Ruben D. Esteban Gallo, Juan Cervera, Ricard Shoenfeld, Yehuda Arcos-Burgos, Mauricio TI The Multiple Autoimmune Syndromes. A Clue for the Autoimmune Tautology SO CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY LA English DT Review DE Autoimmune diseases; Systemic lupus erythematosus; Sjogren's syndrome; Autoimmune thyroid diseases; Genetic association studies; Familial aggregation ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENOME-WIDE ASSOCIATION; PEDIGREE DISEQUILIBRIUM TEST; SUSCEPTIBILITY LOCI; COMPLEX DISEASES; CANDIDATE LOCI; LINKAGE; FAMILIES; POLYAUTOIMMUNITY; SCLEROSIS AB The multiple autoimmune syndromes (MAS) consist on the presence of three or more well-defined autoimmune diseases (ADs) in a single patient. The aim of this study was to analyze the clinical and genetic characteristics of a large series of patients with MAS. A cluster analysis and familial aggregation analysis of ADs was performed in 84 patients. A genome-wide microsatellite screen was performed in MAS families, and associated loci were investigated through the pedigree disequilibrium test. Systemic lupus erythematosus (SLE), autoimmune thyroid disease (AITD), and Sjogren's syndrome together were the most frequent ADs encountered. Three main clusters were established. Aggregation for type 1 diabetes, AITD, SLE, and all ADs as a trait was found. Eight loci associated with MAS were observed harboring autoimmunity genes. The MAS represent the best example of polyautoimmunity as well as the effect of a single genotype on diverse phenotypes. Its study provides important clues to elucidate the common mechanisms of ADs (i.e., autoimmune tautology). C1 [Anaya, Juan-Manuel; Rojas-Villarraga, Adriana; Pineda-Tamayo, Ricardo; Mantilla, Ruben D.] Univ Rosario, Sch Med & Hlth Sci, Ctr Autoimmune Dis Res CREA, Bogota, Colombia. [Castiblanco, John; Esteban Gallo, Juan] Univ Rosario, Doctoral Program Biomed Sci, Bogota, Colombia. [Castiblanco, John] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, S Texas Vet Hlth Care Syst, Vet Adm Ctr Personalized Med, San Antonio, TX 78229 USA. [Pineda-Tamayo, Ricardo] ART Med IPS, Medellin, Colombia. [Levy, Roger A.] Univ Estado Rio de Janeiro, Discipline Rheumatol, BR-20550011 Rio De Janeiro, Brazil. [Levy, Roger A.] Federico Fdn, Rio De Janeiro, Brazil. [Gomez-Puerta, Jose; Cervera, Ricard] Hosp Clin Barcelona, Dept Autoimmune Dis, Barcelona, Catalonia, Spain. [Dias, Carlos] Hosp Sao Joao, Internal Med Serv, Oporto, Portugal. [Mantilla, Ruben D.] Riesgo Fractura CAYRE IPS, Bogota, Colombia. [Shoenfeld, Yehuda] Chaim Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, Tel Aviv, Israel. [Arcos-Burgos, Mauricio] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia. RP Anaya, JM (reprint author), Univ Rosario, Sch Med & Hlth Sci, Ctr Autoimmune Dis Res CREA, Carrera 24,63C-69,Piso 3, Bogota, Colombia. EM anayajm@gmail.com RI CASTIBLANCO, JOHN/B-6599-2009; Gomez-Puerta, Jose /H-3550-2015; Anaya, Juan-Manuel/J-1960-2016; Rojas-Villarraga, Adriana/J-2404-2016; OI CASTIBLANCO, JOHN/0000-0002-7965-9822; Levy, Roger/0000-0001-6393-6031; Anaya, Juan-Manuel/0000-0002-6444-1249; Rojas-Villarraga, Adriana/0000-0003-3145-2440; Universidad del Rosario, Biblioteca/0000-0003-3491-9392; CASTIBLANCO, JOHN/0000-0003-2556-3697 FU Colciencias [122254531722]; School of Medicine and Health Sciences at the Universidad del Rosario, Bogota, Colombia; Marshfield Foundation, WI, USA FX We thank all patients and participants. This study was financed by Colciencias (122254531722), the School of Medicine and Health Sciences at the Universidad del Rosario, Bogota, Colombia, and Marshfield Foundation, WI, USA. NR 54 TC 18 Z9 19 U1 2 U2 16 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1080-0549 J9 CLIN REV ALLERG IMMU JI Clin. Rev. Allergy Immunol. PD DEC PY 2012 VL 43 IS 3 BP 256 EP 264 DI 10.1007/s12016-012-8317-z PG 9 WC Allergy; Immunology SC Allergy; Immunology GA 034QX UT WOS:000310889100007 PM 22648455 ER PT J AU Klupa, T Skupien, J Malecki, MT AF Klupa, Tomasz Skupien, Jan Malecki, Maciej T. TI Monogenic Models: What Have the Single Gene Disorders Taught Us? SO CURRENT DIABETES REPORTS LA English DT Article DE Monogenic diabetes; Gene; Mutation; Pharmacogenetics ID NEONATAL DIABETES-MELLITUS; SEVERE INSULIN-RESISTANCE; FANCONI-BICKEL-SYNDROME; PANCREATIC BETA-CELLS; ACTIVATING MUTATIONS; SULFONYLUREA THERAPY; GLUCOSE-TRANSPORTER; MOLECULAR-GENETICS; KIR6.2 MUTATIONS; RECEPTOR GENE AB Monogenic diabetes constitutes a heterogeneous group of single gene disorders. The molecular background and clinical picture of many of these diseases have been described. While each of these forms is much less prevalent than multifactorial type 1 and type 2 diabetes mellitus (T2DM), together they affect millions of patients worldwide. Genetic diagnosis, which has become widely available, is of great clinical importance for patients with single gene diabetes. It helps to fully understand the pathophysiology of the disease, tailor the optimal hypoglycemic treatment, and define the prognosis for the entire family. Monogenic diabetes forms can be divided into 2 large groups, resulting from impaired insulin secretion or from an abnormal response to insulin. There are several lessons we have been taught by single-gene diabetes. We learned that the gene responsible for the occurrence of diabetes can be identified if an appropriate search strategy is used. In addition, discoveries of genes responsible for monogenic disorders pointed to them as susceptibility candidates for T2DM. Moreover, establishing that some families of proteins or biological pathways, such as transcription factors or potassium channel subunits, are involved in monogenic diabetes sparked research on their involvement in multifactorial diabetes. Finally, the example of single gene diabetes, particularly HNF1A MODY and permanent neonatal diabetes associated with the KCNJ11 and ABCC8 genes, all efficiently controlled on sulfonylurea, inspires us to continue the efforts to tailor individual treatment for T2DM patients. In this review paper, we summarize the impact of single gene disease discoveries on diabetes research and clinical practice. C1 [Klupa, Tomasz; Malecki, Maciej T.] Jagiellonian Univ, Dept Metab Dis, Coll Med, PL-31501 Krakow, Poland. [Klupa, Tomasz; Malecki, Maciej T.] Univ Hosp, Krakow, Poland. [Skupien, Jan] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Genet & Epidemiol, Boston, MA 02115 USA. RP Malecki, MT (reprint author), Jagiellonian Univ, Dept Metab Dis, Coll Med, 15 Kopernika St, PL-31501 Krakow, Poland. EM malecki_malecki@yahoo.com FU EU [HEALTH-F2-2008-223211] FX The authors are grateful to Ms. Alekasandra Malecka for her editorial assistance. This work was supported by the EU Framework 7 CEED3 grant (HEALTH-F2-2008-223211). NR 75 TC 9 Z9 10 U1 1 U2 6 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD DEC PY 2012 VL 12 IS 6 BP 659 EP 666 DI 10.1007/s11892-012-0325-0 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 032HP UT WOS:000310706500004 PM 22996131 ER PT J AU Hirose, M Beverly, EA Weinger, K AF Hirose, Masakazu Beverly, Elizabeth A. Weinger, Katie TI Quality of Life and Technology: Impact on Children and Families With Diabetes SO CURRENT DIABETES REPORTS LA English DT Article DE Adolescents; Children; Quality of life; Type 1 diabetes; Continuous glucose monitoring; Continuous subcutaneous insulin infusion; Insulin pump; Technology ID SUBCUTANEOUS INSULIN INFUSION; MULTIPLE DAILY INJECTIONS; RANDOMIZED CONTROLLED-TRIAL; GLUCOSE MONITORING-SYSTEM; PATIENT-REPORTED OUTCOMES; PUMP THERAPY; METABOLIC-CONTROL; GLYCEMIC CONTROL; YOUNG-CHILDREN; SELF-MANAGEMENT AB Ensuring quality of life (QOL) while maintaining glycemic control within targets is an important challenge in type 1 and type 2 diabetes treatment. For children with diabetes, QOL includes enjoying meals, feeling safe in school, and perceiving positive, supportive relationships with parents, siblings, and friends. Yet many treatment-related and psychosocial barriers can interfere with a child's QOL and their ability to manage diabetes effectively. Diabetes management also imposes considerable lifestyle demands that are difficult and often frustrating for children to negotiate at a young age. Recent advances in diabetes medications and technologies have improved glycemic control in children with diabetes. Two widely used technologies are the insulin pump and continuous glucose monitoring (CGM) system. These technologies provide patients with more flexibility in their daily life and information about glucose fluctuations. Several studies report improvements in glycemic control in children with type 1 diabetes using the insulin pump or sensor-augmented pump therapy. Importantly, these technologies may impact QOL for children and families with diabetes, although they are rarely used or studied in the treatment of children with type 2 diabetes. Further, emerging closed loop and web- and phone-based technologies have great potential for supporting diabetes self-management and perhaps QOL. A deeper understanding and appreciation of the impact of diabetes technology on children's and parents' QOL is critical for both the medical and psychological care of diabetes. Thus, the purpose of this review is to discuss the impact of new diabetes technologies on QOL in children, adolescents and families with type 1 diabetes. C1 [Hirose, Masakazu; Beverly, Elizabeth A.; Weinger, Katie] Joslin Diabet Ctr, Boston, MA 02215 USA. [Hirose, Masakazu; Beverly, Elizabeth A.; Weinger, Katie] Harvard Univ, Sch Med, Boston, MA USA. RP Weinger, K (reprint author), Joslin Diabet Ctr, 1 Joslin Pl,Suite 350, Boston, MA 02215 USA. EM katie.weinger@joslin.harvard.edu FU National Institutes of Health (NIH) [R01 DK60115, T32 DK007260] FX This work was partially supported by National Institutes of Health (NIH) grant R01 DK60115 and the NIH Training Grant No. T32 DK007260. NR 113 TC 10 Z9 10 U1 7 U2 39 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD DEC PY 2012 VL 12 IS 6 BP 711 EP 720 DI 10.1007/s11892-012-0313-4 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 032HP UT WOS:000310706500010 PM 22903783 ER PT J AU DiNardo, MM Gibson, JM Siminerio, L Morell, AR Lee, ES AF DiNardo, Monica M. Gibson, Jolynn M. Siminerio, Lara Morell, Allison R. Lee, Edward S. TI Complementary and Alternative Medicine in Diabetes Care SO CURRENT DIABETES REPORTS LA English DT Article DE Complementary and alternative medicine; Herbal supplements; Nutritional supplements; Mind-body therapies; Diabetes mellitus; Type 2 diabetes; Prediabetes; Insulin resistance ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; IMPROVED GLYCEMIC CONTROL; BLIND CLINICAL-TRIAL; OXIDATIVE STRESS; MINDFULNESS MEDITATION; ALMOND CONSUMPTION; INSULIN-RESISTANCE; GYMNEMA-SYLVESTRE; MELLITUS PATIENTS AB Growing numbers of people with diabetes in the U.S. and worldwide use complementary and alternative medicine (CAM) while receiving conventional medical therapy as a means of managing disease and improving quality of life. Although herbal and natural products are the most commonly used forms of CAM, mind-body approaches are also gaining popularity and scientific interest. Current findings suggest that CAM may help to promote an integrative, participatory model of diabetes care that relies upon provider knowledge of evidence-based therapies and patient disclosure of CAM use. Emerging evidence of positive findings with some natural products and mind-body therapies have been reported in glycemic parameters, markers of cardiovascular risk, and quality of life in individuals with type 2 diabetes; however, further investigation in well-designed, adequately powered studies is needed before use of CAM modalities can be recommended as part of clinical care. C1 [DiNardo, Monica M.] Univ Pittsburgh, Sch Nursing, Pittsburgh, PA 15261 USA. [DiNardo, Monica M.] Vet Affairs Pittsburgh Hlth Care Syst, Pittsburgh, PA 15240 USA. [Gibson, Jolynn M.] UPMC St Margaret Hosp, Pittsburgh, PA 15215 USA. [Morell, Allison R.; Lee, Edward S.] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA 15240 USA. RP DiNardo, MM (reprint author), Univ Pittsburgh, Sch Nursing, 3500 Victoria St, Pittsburgh, PA 15261 USA. EM mmm52@pitt.edu; gibsonjm@upmc.edu; lara.siminerio@gmail.com; allison.morell@va.gov; edward.lee6@va.gov FU VA Integrated Service Network (VISN) 4 for a Competitive Pilot Project Fund FX Conflicts of interest: M. DiNardo, none; J. M. Gibson, none; L. Siminerio, none; A. R. Morell, none. E. S. Lee is a Medical Acupuncture Instructor at the Helms Medical Institute; is Director, Acupuncture Clinic, @ VA Pittsburgh Healthcare System; has received grant support from the VA Integrated Service Network (VISN) 4 for a Competitive Pilot Project Fund, Study on Acupuncture as an adjunctive treatment for poststroke depression (VA VISN 4 Competitive Pilot Fund, 2010); and is a member for the American Academy of Medical Acupuncture, Annual Symposium Planning Committee. NR 68 TC 8 Z9 8 U1 3 U2 61 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD DEC PY 2012 VL 12 IS 6 BP 749 EP 761 DI 10.1007/s11892-012-0315-2 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 032HP UT WOS:000310706500014 PM 22986889 ER PT J AU Betancourt, JR Duong, JV Bondaryk, MR AF Betancourt, Joseph R. Duong, Jason V. Bondaryk, Matthew R. TI Strategies to Reduce Diabetes Disparities: An Update SO CURRENT DIABETES REPORTS LA English DT Article DE Disparities; Diabetes; Community health workers; Health information technology; Promotora; Cultural competence; Diabetes management; Telemedicine; Multifactorial approaches; Treatment algorithms; Diabetes education; Nurse case management ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-CARE; GLYCEMIC CONTROL; UNITED-STATES; ETHNIC-DIFFERENCES; AFRICAN-AMERICAN; SELF-MANAGEMENT; LATINO ADULTS; HEALTH-CARE; POPULATION AB Racial and ethnic minorities in the US have a higher prevalence, as well as suffer from more complications, lower quality care, and poorer outcomes for diabetes than their counterparts. Given the US health care system is in the midst of drastic transformation, with the passage of health care reform, and efforts in payment reform, and value-based purchasing, there is now support to provide more intensive, team-based care for those conditions that are complex, costly, and highly prevalent. Addressing and improving diabetes disparities, given they are prevalent and costly, will be an important area of focus in the years to come. The latest research demonstrates that community-based efforts, multifactorial approaches, and the deployment of health information technology can be successful in addressing diabetes disparities, and require support, attention, resources, and continued evaluation. Ultimately, these efforts should improve the quality of care for all persons with diabetes, especially those who are most vulnerable. C1 [Betancourt, Joseph R.; Duong, Jason V.; Bondaryk, Matthew R.] Massachusetts Gen Hosp, Dispar Solut Ctr, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Betancourt, Joseph R.] Harvard Univ, Sch Med, Boston, MA USA. RP Betancourt, JR (reprint author), Massachusetts Gen Hosp, Dispar Solut Ctr, Mongan Inst Hlth Policy, 50 Staniford St,Suite 901, Boston, MA 02114 USA. EM jbetancourt@partners.org NR 52 TC 9 Z9 9 U1 2 U2 16 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD DEC PY 2012 VL 12 IS 6 BP 762 EP 768 DI 10.1007/s11892-012-0324-1 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 032HP UT WOS:000310706500015 PM 22976538 ER PT J AU Strom, JL Egede, LE AF Strom, Joni L. Egede, Leonard E. TI The Impact of Social Support on Outcomes in Adult Patients with Type 2 Diabetes: A Systematic Review SO CURRENT DIABETES REPORTS LA English DT Review DE Diabetes; Type 2 diabetes; Social support; Glycemic control; Psychosocial factors ID SELF-MANAGEMENT BEHAVIORS; AFRICAN-AMERICAN ADULTS; US-MEXICO BORDER; QUALITY-OF-LIFE; FAMILY SUPPORT; RANDOMIZED-TRIAL; GLYCEMIC CONTROL; GLUCOSE CONTROL; CARE BEHAVIORS; PEER SUPPORT AB Diabetes is one of the fastest growing chronic diseases globally and in the United States. Although preventable, type 2 diabetes accounts for 90 % of all cases of diabetes worldwide and continues to be a source of increased disability, lost productivity, mortality, and amplified health-care costs. Proper disease management is crucial for achieving better diabetes-related outcomes. Evidence suggests that higher levels of social support are associated with improved clinical outcomes, reduced psychosocial symptomatology, and the adaptation of beneficial lifestyle activities; however, the role of social support in diabetes management is not well understood. The purpose of this systematic review is to examine the impact of social support on outcomes in adults with type 2 diabetes. C1 [Strom, Joni L.; Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Strom, Joni L.; Egede, Leonard E.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston VA REAP, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G,POB 250593, Charleston, SC 29425 USA. EM stromjl@musc.edu; egedel@musc.edu FU NIDDK NIH HHS [K24 DK093699, R01 DK081121] NR 52 TC 33 Z9 33 U1 3 U2 51 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD DEC PY 2012 VL 12 IS 6 BP 769 EP 781 DI 10.1007/s11892-012-0317-0 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 032HP UT WOS:000310706500016 PM 22949135 ER PT J AU Lawasut, P Chauhan, D Laubach, J Hayes, C Fabre, C Maglio, M Mitsiades, C Hideshima, T Anderson, K Richardson, P AF Lawasut, Panisinee Chauhan, Dharminder Laubach, Jacob Hayes, Catriona Fabre, Claire Maglio, Michelle Mitsiades, Constantine Hideshima, Teru Anderson, Kenneth C. Richardson, Paul G. TI New Proteasome Inhibitors in Myeloma SO CURRENT HEMATOLOGIC MALIGNANCY REPORTS LA English DT Article DE Second generation proteasome inhibitors; Proteasome inhibitors; Myeloma; MLN9708; MLN2238; Ixazomib; CEP-18770; Delanzomib; Carfilzomib; PR-171; Oprozomib; ONX 0912; PR-047; NPI-0052; Marizomib; Salinosporamide ID VIVO SYNERGISTIC CYTOTOXICITY; REFRACTORY MULTIPLE-MYELOMA; IN-VIVO; ANTITUMOR-ACTIVITY; HEMATOLOGIC MALIGNANCIES; IRREVERSIBLE INHIBITOR; PRECLINICAL MODELS; B-CELL; BORTEZOMIB; CARFILZOMIB AB Proteasome inhibition has a validated role in cancer therapy since the successful introduction of bortezomib for the treatment of multiple myeloma (MM) and mantle cell lymphoma, leading to the development of second-generation proteasome inhibitors (PI) for MM patients in whom currently approved therapies have failed. Five PIs have reached clinical evaluation, with the goals of improving efficacy and limiting toxicity, including peripheral neuropathy (PN). Carfilzomib, an epoxyketone with specific chymothrypsin-like activity, acts as an irreversible inhibitor and was recently FDA approved for the response benefit seen in relapsed and refractory MM patients previously treated with bortezomib, thalidomide and lenalidomide. ONX-0912 is now under evaluation as an oral form with similar activity. The boronate peptides MLN9708 and CEP-18770 are orally bioactive bortezomib analogs with prolonged activity and greater tissue penetration. NPI-0052 (marizomib) is a unique, beta-lactone non-selective PI that has been shown to potently overcome bortezomib resistance in vitro. All of these second-generation PIs demonstrate encouraging anti-MM activity and appear to reduce the incidence of PN, with clinical trials ongoing. C1 [Lawasut, Panisinee; Chauhan, Dharminder; Laubach, Jacob; Hayes, Catriona; Fabre, Claire; Maglio, Michelle; Mitsiades, Constantine; Hideshima, Teru; Anderson, Kenneth C.; Richardson, Paul G.] Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst,Dept Med Oncol,Div Hematol, Boston, MA 02215 USA. [Lawasut, Panisinee] Chulalongkorn Univ, Fac Med, Dept Med, Div Hematol, Bangkok 10330, Thailand. [Lawasut, Panisinee] King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Bangkok, Thailand. [Fabre, Claire] Inst Curie, Dept Med Oncol, Paris, France. RP Richardson, P (reprint author), Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst,Dept Med Oncol,Div Hematol, 450 Brookline Ave,Mayer 228, Boston, MA 02215 USA. EM panisinee_lawasut@dfci.harvard.edu; dharminder_chauhan@dfci.harvard.edu; jacobp_laubach@dfci.harvard.edu; catrionaa_hayes@dfci.harvard.edu; claire.fabre@curie.net; michelle_maglio@dfci.harvard.edu; constantine_mitsiades@dfci.harvard.edu; teru_hideshima@dfci.harvard.edu; kenneth_anderson@dfci.harvard.edu; Paul_Richardson@dfci.harvard.edu FU Amgen; AVEO Pharma; OSI; EMD Serono; Sunesis; Genzyme; Johnson Johnson FX C. Mitsiades has been a consultant for Millennium, Celgene, Novartis, Bristol-Myers Squibb, Merck &Co., Centocor, and Arno Therapeutics, and has received research funding from Amgen, AVEO Pharma, OSI, EMD Serono, Sunesis, Genzyme, and Johnson & Johnson. NR 59 TC 43 Z9 44 U1 3 U2 33 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1558-8211 EI 1558-822X J9 CURR HEMATOL MALIG R JI Curr. Hematol. Malig. Rep. PD DEC PY 2012 VL 7 IS 4 BP 258 EP 266 DI 10.1007/s11899-012-0141-2 PG 9 WC Oncology; Hematology SC Oncology; Hematology GA 035MS UT WOS:000310951900002 PM 23065395 ER PT J AU Steensma, DP AF Steensma, David P. TI Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors SO CURRENT HEMATOLOGIC MALIGNANCY REPORTS LA English DT Article DE Myelodysplastic syndromes (MDS); Differential diagnosis; Pathology; Dysplasia; Aplastic anemia; Nutritional deficiency; Copper deficiency; Sideroblastic anemia; Leukemia; Molecular diagnostics ID ACUTE MYELOID-LEUKEMIA; WORLD-HEALTH-ORGANIZATION; MARROW FAILURE SYNDROMES; IDIOPATHIC SIDEROBLASTIC ANEMIA; THERAPY-RELATED MYELODYSPLASIA; UNDETERMINED SIGNIFICANCE ICUS; SEVERE CONGENITAL NEUTROPENIA; ACUTE ERYTHROID LEUKEMIA; BONE-MARROW; APLASTIC-ANEMIA AB Just as a pawnshop owner who is unable to distinguish a genuine Rolex (TM) watch from a cheap knockoff courts financial ruin, the physician who fails to discriminate between authentic myelodysplastic syndromes (MDS) and conditions resembling MDS risks misinforming or harming patients. This review summarizes minimal criteria for diagnosing MDS and discusses common diagnostic challenges. MDS needs to be separated from numerous neoplastic and non-clonal hematologic disorders that can mimic MDS, including other myeloid neoplasms, nutritional deficiencies, toxin exposures, aplastic anemia, and inherited disorders (e.g., congenital sideroblastic anemia). Some distinctions are more critical therapeutically than others; e.g., recognizing B12 deficiency is more important than parsing high-risk MDS from erythroleukemia. Diagnostically ambiguous cases may be assigned holding-pattern terms, "idiopathic cytopenia(s) of undetermined significance" (ICUS) or "idiopathic dysplasia of undetermined significance" (IDUS), while awaiting clarifying information or further clinical developments. In the future, advances in molecular pathology will improve diagnostic accuracy, especially in morphologically non-descript cases. C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. RP Steensma, DP (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Suite D1B30,Mayer 1B21, Boston, MA 02215 USA. EM david_steensma@dfci.harvard.edu OI Steensma, David/0000-0001-5130-9284 NR 85 TC 15 Z9 15 U1 1 U2 8 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1558-8211 J9 CURR HEMATOL MALIG R JI Curr. Hematol. Malig. Rep. PD DEC PY 2012 VL 7 IS 4 BP 310 EP 320 DI 10.1007/s11899-012-0140-3 PG 11 WC Oncology; Hematology SC Oncology; Hematology GA 035MS UT WOS:000310951900008 PM 23015360 ER PT J AU Kotton, CN AF Kotton, Camille N. TI Travel and transplantation: travel-related diseases in transplant recipients SO CURRENT OPINION IN ORGAN TRANSPLANTATION LA English DT Review DE solid organ transplant; travel medicine; vaccinations; vaccines ID SOLID-ORGAN TRANSPLANTATION; HEPATITIS-A VACCINE; RENAL-TRANSPLANTATION; KIDNEY-TRANSPLANTATION; UNITED-STATES; SINGLE-CENTER; TOURISM; PATIENT; LIVER; INFECTIONS AB Purpose of review Travel-related diseases may be seen in transplant recipients after travel, after transplant tourism, and via transmission from blood and organ donors, augmented by recent increases in travel, migration, and globalization. Such infections include tuberculosis, Plasmodium (malaria), Babesia, Trypanosoma cruzi (Chagas disease), Strongyloides, Coccidioides, Histoplasma, Leishmania, Brucella, HTLV, dengue, among numerous others. Recent findings Review of cohorts of transplant recipients show that they tend to have minimal or suboptimal preparation prior to travel, with limited pretravel vaccination, medications, and education, which poses a greatly increased risk of travel-related infections and complications. The epidemiology of such travel-related infections in transplant recipients, along with methods for prevention, including vaccines, chemoprophylaxis, and education may help SOT recipients avoid travel-related infections, and are discussed in this review. Summary Optimizing the understanding of the risk of tropical, geographically restricted, and other unusual or unexpected, travel-related infections will enhance the safety of vulnerable transplant recipients from potentially life-threatening infections. C1 [Kotton, Camille N.] Harvard Univ, Div Infect Dis, Massachusetts Gen Hosp, Sch Med,Travelers Advice & Immunizat Ctr, Boston, MA 02114 USA. [Kotton, Camille N.] Harvard Univ, Sch Med, Transplant Infect Dis & Compromised Host Program, Boston, MA 02114 USA. [Kotton, Camille N.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA. RP Kotton, CN (reprint author), Harvard Univ, Div Infect Dis, Massachusetts Gen Hosp, Sch Med,Travelers Advice & Immunizat Ctr, 55 Fruit St,Cox 5, Boston, MA 02114 USA. EM ckotton@partners.org NR 46 TC 5 Z9 5 U1 0 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1087-2418 J9 CURR OPIN ORGAN TRAN JI Curr. Opin. Organ Transpl. PD DEC PY 2012 VL 17 IS 6 BP 594 EP 600 DI 10.1097/MOT.0b013e328359266b PG 7 WC Transplantation SC Transplantation GA 037LT UT WOS:000311107100003 PM 23147910 ER PT J AU Mehta, DD Hillman, RE AF Mehta, Daryush D. Hillman, Robert E. TI Current role of stroboscopy in laryngeal imaging SO CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY LA English DT Review DE clinical voice assessment; imaging; larynx; stroboscopy; vocal folds ID VOCAL FOLD; VISUALIZATION TECHNIQUES; PHASE ASYMMETRIES; DISORDERS; VOICE; HOARSENESS; CANCER AB Purpose of review To summarize recent technological advancements and insight into the role of stroboscopy in laryngeal imaging. Recent findings Although stroboscopic technology has not undergone major technological improvements, recent clarifications have been made to the application of stroboscopic principles to video-based laryngeal imaging. Also recent advances in coupling stroboscopy with high-definition video cameras provide higher spatial resolution of vocal fold vibratory function during phonation. Studies indicate that the interrater reliability of visual stroboscopic assessment varies depending on the laryngeal feature being rated and that only a subset of features may be needed to be representative of an entire assessment. High-speed videoendoscopy (HSV) judgments have been shown to be more sensitive than stroboscopy for evaluating vocal fold phase asymmetry, pointing to the future potential of complementing stroboscopy with alternative imaging modalities in hybrid systems. Laryngeal videostroboscopy alone continues to play a central role in clinical voice assessment. Even though HSV may provide more detailed information about phonatory function, its eventual clinical adoption will depend on how remaining practical, technical, and methodological challenges will be met. Summary Laryngeal videostroboscopy continues to be the modality of choice for imaging vocal fold vibration, but technological advancements in HSV and associated research findings are driving increased interest in the clinical adoption of HSV to complement videostroboscopic assessment. C1 [Mehta, Daryush D.; Hillman, Robert E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Laryngeal Surg & Voice Rehabil,Dept Surg, Boston, MA 02114 USA. [Mehta, Daryush D.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA. [Hillman, Robert E.] Massachusetts Gen Hosp, Inst Hlth Profess, Boston, MA 02114 USA. RP Mehta, DD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Laryngeal Surg & Voice Rehabil,Dept Surg, 1 Bowdoin Sq,11th Floor, Boston, MA 02114 USA. EM daryush.mehta@alum.mit.edu FU Institute of Laryngology and Voice Restoration; National Institutes of Health [R01 DC007640, R33 DC011588] FX The authors report no conflicts of interest. Support provided by the Institute of Laryngology and Voice Restoration and the National Institutes of Health (grants R01 DC007640 and R33 DC011588). NR 30 TC 17 Z9 17 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1068-9508 J9 CURR OPIN OTOLARYNGO JI Curr. Opin. Otolaryngol. Head Neck Surg. PD DEC PY 2012 VL 20 IS 6 BP 429 EP 436 DI 10.1097/MOO.0b013e3283585f04 PG 8 WC Otorhinolaryngology SC Otorhinolaryngology GA 037LP UT WOS:000311106500002 PM 22931908 ER PT J AU Burns, JA AF Burns, James A. TI Optical coherence tomography: imaging the larynx SO CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY LA English DT Review DE larynx; optical coherence tomography; polarization-sensitive optical coherence tomography ID HUMAN VOCAL FOLD; IN-VIVO; BENIGN AB Purpose of review Using optical coherence tomography (OCT) to image the larynx during diagnosis and treatment of a vast array of laryngeal disorders continues to develop along with innovative surgical techniques. Precise delineation of vocal fold-layered microstructure allows for better understanding of the impact of benign and malignant lesions on laryngeal function, and optical coherence is uniquely suited to provide detail of the interface between these lesions and adjacent normal tissue. This review provides the reader with a timely update on current clinical and research applications of OCT. Recent findings Recent advances in OCT include adaptation of these modalities to obtain images of moving vocal folds and provide real-time information during procedures. Additionally, an augmented form of OCT called polarization-sensitive optical coherence tomography (PS-OCT) shows promise in further characterizing benign and malignant lesions and in delineating areas of normal pliability from scar. PS-OCT can quantify areas of increased collagen (scar) and three-dimensional PS-OCT imaging can visualize the extent and location of lesions within vocal folds. Summary Imaging the layered microstructure of vocal folds to precisely delineate boundaries between normal pliability and scar provides valuable information during diagnosis and treatment of benign and malignant disorders. Current OCT imaging techniques are guiding phonomicrosurgical interventions and improving patient care. C1 Harvard Univ, Sch Med, Ctr Laryngeal Surg & Voice Rehabil, Massachusetts Gen Hosp,Dep Surg, Boston, MA 02114 USA. RP Burns, JA (reprint author), Harvard Univ, Sch Med, Ctr Laryngeal Surg & Voice Rehabil, Massachusetts Gen Hosp,Dep Surg, 1 Bowdoin Sq,11th Floor, Boston, MA 02114 USA. EM burns.james@mgh.harvard.edu NR 11 TC 11 Z9 11 U1 1 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1068-9508 J9 CURR OPIN OTOLARYNGO JI Curr. Opin. Otolaryngol. Head Neck Surg. PD DEC PY 2012 VL 20 IS 6 BP 477 EP 481 DI 10.1097/MOO.0b013e3283582d7d PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA 037LP UT WOS:000311106500009 PM 22913932 ER PT J AU Setlur, J Hartnick, CJ AF Setlur, Jennifer Hartnick, Christopher J. TI Management of unilateral true vocal cord paralysis in children SO CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY LA English DT Review DE dysphagia; hoarseness; laryngology; pediatric; vocal cord paralysis; voice ID RECURRENT LARYNGEAL NERVE; PATENT DUCTUS-ARTERIOSUS; FOLD PARALYSIS; IMMOBILITY; ELECTROMYOGRAPHY; MEDIALIZATION; REINNERVATION; DIAGNOSIS; LIGATION AB Purpose of review Historically, information gained from the treatment of unilateral true vocal cord paralysis (UVCP) in adults was the same used to treat children. Today, there is a growing body of literature aimed specifically at the treatment of this condition in children. It is an area of growing interest as UVCP can significantly impact a child's quality of life. Recent findings Children with UVCP may present with stridor, dysphonia, aspiration, feeding difficulties, or a combination of these symptoms. Diagnosis relies on laryngoscopy, but other adjuncts such as ultrasound and laryngeal electromyography may also be helpful in making the diagnosis and forming a treatment plan. In many instances, there is effective compensation by the contralateral vocal fold, making surgical intervention unnecessary. Children who cannot compensate for a unilateral defect may suffer from significant dysphonia that can affect their quality of life because their ability to be understood may be diminished. In these patients, treatment in the form of medialization or reinnervation of the affected recurrent laryngeal nerve may be warranted. Summary UVCP is a well recognized problem in pediatric patients with disordered voice and feeding problems. Some patients will spontaneously recover their laryngeal function. For those who do not, a variety of reliable techniques are available for rehabilitative treatment. Improved diagnostics and a growing understanding of prognosis can help guide therapy decisions along with the goals and desires of the patient and his or her family. C1 [Hartnick, Christopher J.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Hartnick, CJ (reprint author), 243 Charles St, Boston, MA 02114 USA. EM christopher_hartnick@meei.harvard.edu NR 25 TC 7 Z9 8 U1 1 U2 11 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1068-9508 J9 CURR OPIN OTOLARYNGO JI Curr. Opin. Otolaryngol. Head Neck Surg. PD DEC PY 2012 VL 20 IS 6 BP 497 EP 501 DI 10.1097/MOO.0b013e3283590b56 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA 037LP UT WOS:000311106500012 PM 23150153 ER PT J AU Madan, JC Farzan, SF Hibberd, PL Karagas, MR AF Madan, Juliette C. Farzan, Shohreh F. Hibberd, Patricia L. Karagas, Margaret R. TI Normal neonatal microbiome variation in relation to environmental factors, infection and allergy SO CURRENT OPINION IN PEDIATRICS LA English DT Review DE allergy; infection; microbiome; neonate ID BIRTH-WEIGHT INFANTS; CHRONIC INFLAMMATORY DISORDERS; 99TH DAHLEM CONFERENCE; HUMAN GUT MICROBIOME; INTESTINAL MICROBIOTA; DELIVERY MODE; GASTROINTESTINAL MICROBIOTA; ANTIBIOTIC-TREATMENT; REDUCED DIVERSITY; FECAL MICROBIOTA AB Purpose of review Bacterial colonization of the infant intestinal tract begins at birth. We are at the forefront of understanding complex relationships between bacteria and multiple parameters of health of the developing infant. Moreover, the establishment of the microbiome in the critical neonatal period is potentially foundational for lifelong health and disease susceptibility. Recent studies utilizing state-of-the-art culture-independent technologies have begun to increase our knowledge about the gut microbiome in infancy, the impact of multiple exposures, and its effects on immune response and clinical outcomes such as allergy and infection. Recent findings Postnatal exposures play a central role in the complex interactions between the nearly blank canvas of the neonatal intestine, whereas genetic factors do not appear to be a major factor. Infant microbial colonization is affected by delivery mode, dietary exposures, antibiotic exposure, and environmental toxicants. Successive microbiome acquisition in infancy is likely a determinant of early immune programming, subsequent infection, and allergy risk. Summary The novel investigation of the neonatal microbiome is beginning to unearth substantial information, with a focus on immune programming that coevolves with the developing microbiome early in life. Several exposures common to neonatal and infant populations could exert pressure on the development of the microbiome and major diseases including allergy and infection in large populations. C1 [Madan, Juliette C.] Childrens Hosp Dartmouth, Div Neonatol, Dept Pediat, Dartmouth Hitchcock Med Ctr, Lebanon, NH 03753 USA. [Farzan, Shohreh F.; Karagas, Margaret R.] Geisel Sch Med Dartmouth, Epidemiol & Biostat Sect, Dept Community & Family Med, Hanover, NH USA. [Hibberd, Patricia L.] Massachusetts Gen Hosp, Dept Pediat, Div Global Hlth, Boston, MA 02114 USA. RP Madan, JC (reprint author), Childrens Hosp Dartmouth, Div Neonatol, Dept Pediat, Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03753 USA. EM Juliette.C.Madan@Hitchcock.Org FU Hearst Foundation; Synergy Grant (Dartmouth); Joshua Burnett Career Development Award through the Hitchcock Foundation (Dartmouth); Department of Pediatrics, Dartmouth; Cystic Fibrosis Foundation Research Development Program [STANTO07R0]; CF Foundation Harry Shwachman Clinical Investigator Award; NIH [2K24AT003683]; [R25CA134286] FX Special thanks to Claudia Cornejo for her research assistance. M. R. K. and J.C.M. are members of the formative Children's Environmental Health and Disease Prevention Research Center at Dartmouth (P20 ES018175 from NIEHS and RD-83459901 from the EPA). S. F. F. is funded by R25CA134286. J.C.M. also received funds from The Hearst Foundation, The Synergy Grant (Dartmouth), The Joshua Burnett Career Development Award through the Hitchcock Foundation (Dartmouth), the Department of Pediatrics, Dartmouth and a pilot grant to J.C.M. from the Cystic Fibrosis Foundation Research Development Program (STANTO07R0) and the CF Foundation Harry Shwachman Clinical Investigator Award. P. L. H. is funded by NIH grant 2K24AT003683. NR 78 TC 34 Z9 34 U1 4 U2 75 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8703 J9 CURR OPIN PEDIATR JI CURR. OPIN. PEDIATR. PD DEC PY 2012 VL 24 IS 6 BP 753 EP 759 DI 10.1097/MOP.0b013e32835a1ac8 PG 7 WC Pediatrics SC Pediatrics GA 037LR UT WOS:000311106800015 PM 23111681 ER PT J AU Waung, MW Abrams, GM AF Waung, Maggie W. Abrams, Gary M. TI Combat-Related Headache and Traumatic Brain Injury SO CURRENT PAIN AND HEADACHE REPORTS LA English DT Review DE Post-traumatic headache; Blast injury; Traumatic brain injury; Post-traumatic stress disorder; PTSD; Veterans; Migraine; Tension-type headache; Concussion; Combat; Alteration of consciousness; Loss of consciousness ID POSTTRAUMATIC-STRESS-DISORDER; US SOLDIERS; MILITARY PERSONNEL; CHRONIC PAIN; ENDURING FREEDOM; VETERANS; PREVALENCE; CONCUSSION; SEVERITY; IRAQ AB Post-traumatic headache is a commonly described complication of traumatic brain injury. Recent studies highlight differences between headache features of combat veterans who suffered traumatic brain injury compared to civilians. Not surprisingly, there is a higher rate of associated PTSD and sleep disturbances among veterans. Factors of lower socioeconomic status, rank, and multiple head injuries appear to have a similar effect on post-traumatic headache in combat-related traumatic brain injury. Areas of discordance in the literature include the effect of prolonged loss of consciousness and the prevalence of specific headache phenotypes following head trauma. To date, there have been no randomized trials of treatment for post-traumatic headache. This may be related to the variability of headache features and uncertainty of pathophysiologic mechanisms. Given this lack of data, many practitioners follow treatment guidelines for primary headaches. Additionally, because of mounting data linking PTSD to post-traumatic headache in combat veterans, it may be crucial to choose multimodal agents and take a multidisciplinary approach to combat-related headache. C1 [Waung, Maggie W.; Abrams, Gary M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Abrams, Gary M.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Abrams, GM (reprint author), San Francisco VA Med Ctr, 4150 Clement St,MS 117, San Francisco, CA 94121 USA. EM Maggie.Waung@ucsf.edu; Gary.Abrams@ucsf.edu NR 39 TC 5 Z9 5 U1 1 U2 15 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1531-3433 EI 1534-3081 J9 CURR PAIN HEADACHE R JI Curr. Pain Headache Rep. PD DEC PY 2012 VL 16 IS 6 BP 533 EP 538 DI 10.1007/s11916-012-0294-7 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 035MV UT WOS:000310952200007 PM 22956047 ER PT J AU Bowden, MG Embry, AE Perry, LA Duncan, PW AF Bowden, Mark G. Embry, Aaron E. Perry, Lindsay A. Duncan, Pamela W. TI Rehabilitation of Walking After Stroke SO CURRENT TREATMENT OPTIONS IN NEUROLOGY LA English DT Review DE Walking; Rehabilitation; Stroke; Physical therapy; Strength training; Treadmill training; Speed paradigm; Split-belt paradigm; Locomotor training; External devices ID RANDOMIZED CONTROLLED-TRIAL; NEUROMUSCULAR ELECTRICAL-STIMULATION; BODY-WEIGHT SUPPORT; SUBACUTE STROKE; IMPROVE GAIT; CASE SERIES; OVERGROUND WALKING; TREADMILL; EXERCISE; SPEED AB Rehabilitation of walking after stroke has been investigated with a variety of interventions, which will be outlined in this review. To date, the majority of interventions have demonstrated a positive, but similar effect in the primary clinical outcome of self-selected walking speed. Consistent among the most successful interventions is a focus on the intensity of the intervention and the ability to progress rehabilitation in a structured fashion. Successful progression of rehabilitation of walking likely lies in the ability to combine interventions based on an understanding of contributing underlying deficits (eg, motor control, strength, cardiovascular endurance, and dynamic balance). Rehabilitation programs must account for the need to train dynamic balance for falls prevention. Lastly, clinicians and researchers need to measure the effects of rehabilitation on participation and health related quality of life. C1 [Bowden, Mark G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Bowden, Mark G.; Embry, Aaron E.; Perry, Lindsay A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Bowden, Mark G.; Embry, Aaron E.; Perry, Lindsay A.] Med Univ S Carolina, Div Phys Therapy, Charleston, SC 29425 USA. [Duncan, Pamela W.] Wake Forest Baptist Med Ctr, Dept Neurol, Winston Salem, NC USA. RP Bowden, MG (reprint author), Ralph H Johnson VA Med Ctr, Charleston, SC USA. EM bowdenm@musc.edu FU VA Rehabilitation, Research, and Development FX This material is the result of work supported with resources and the use of facilities at the Ralph H. Johnson VA Medical Center and the Medical University of South Carolina in Charleston, SC. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. Dr. Bowden has received VA Rehabilitation, Research, and Development grant support. NR 50 TC 5 Z9 5 U1 2 U2 28 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1092-8480 J9 CURR TREAT OPTION NE JI Curr. Treat. Options Neurol. PD DEC PY 2012 VL 14 IS 6 BP 521 EP 530 DI 10.1007/s11940-012-0198-1 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 038UU UT WOS:000311200400002 PM 22991142 ER PT J AU Aguilar, LK Arvizu, M Aguilar-Cordova, E Chiocca, EA AF Aguilar, Laura K. Arvizu, Mariel Aguilar-Cordova, Estuardo Chiocca, E. Antonio TI The Spectrum of Vaccine Therapies for Patients With Glioblastoma Multiforme SO CURRENT TREATMENT OPTIONS IN ONCOLOGY LA English DT Article DE Glioblastoma; Glioblastoma multiforme; Malignant gliomas; Vaccine; Immunotherapy ID NEWLY-DIAGNOSED GLIOBLASTOMA; REGULATORY T-CELLS; MALIGNANT GLIOMA; ADJUVANT TEMOZOLOMIDE; NERVOUS-SYSTEM; PHASE-III; TRIAL; RADIOTHERAPY; IMMUNOTHERAPY; CONCOMITANT AB Glioblastoma multiforme (GBM) is the most common primary malignant tumor of the central nervous system (CNS) and one of the most lethal cancers in adults and children. Despite aggressive treatment with surgery, radiation, and chemotherapy, median survival is less than 15 months and overall survival is less than 10 % at 5 years. Development of therapeutics for malignant gliomas has been hampered by their natural complexity as well as protective mechanisms unique to the CNS. Better understanding of the pathogenesis of GBM is opening the path to novel, specific-targeted therapies. Recently, multiple immunotherapy approaches have been acquiring substantial indication of therapeutic efficacy with a very safe profile. Examples of the leading clinical approaches for GBM will be discussed in detail in this review. C1 [Aguilar, Laura K.; Arvizu, Mariel; Aguilar-Cordova, Estuardo] Advantagene Inc, Auburndale, MA 02466 USA. [Chiocca, E. Antonio] Brigham & Womens Faulkner Hosp, Inst Neurosci, Dept Neurosurg, Boston, MA 02116 USA. [Chiocca, E. Antonio] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02116 USA. RP Aguilar, LK (reprint author), Advantagene Inc, 440 Lexington St, Auburndale, MA 02466 USA. EM lkaguilar@advantagene.com; marvizu@advantagene.com; eaguilar@advantagene.com; EACHIOCCA@PARTNERS.ORG FU NCI NIH HHS [R44 CA107745] NR 43 TC 10 Z9 10 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1527-2729 J9 CURR TREAT OPTION ON JI Curr. Treat. Options Oncol. PD DEC PY 2012 VL 13 IS 4 BP 437 EP 450 DI 10.1007/s11864-012-0208-2 PG 14 WC Oncology SC Oncology GA 040AY UT WOS:000311292500002 PM 22903697 ER PT J AU Egede, LE Gebregziabher, M Dismuke, CE Lynch, CP Axon, RN Zhao, YM Mauldin, PD AF Egede, Leonard E. Gebregziabher, Mulugeta Dismuke, Clara E. Lynch, Cheryl P. Axon, R. Neal Zhao, Yumin Mauldin, Patrick D. TI Medication Nonadherence in Diabetes Longitudinal effects on costs and potential cost savings from improvement SO DIABETES CARE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; CLINICAL PHARMACIST INTERVENTION; HEALTH-CARE-SYSTEM; ELDERLY OUTPATIENTS; GLYCEMIC CONTROL; ADHERENCE; VETERANS; MANAGEMENT; ADULTS; MELLITUS AB OBJECTIVE-To examine the longitudinal effects of medication nonadherence (MNA) on key costs and estimate potential savings from increased adherence using a novel methodology that accounts for shared correlation among cost categories. RESEARCH DESIGN AND METHODS-Veterans with type 2 diabetes (740,195) were followed from January 2002 until death, loss to follow-up, or December 2006. A novel multivariate, generalized, linear, mixed modeling approach was used to assess the differential effect of MNA, defined as medication possession ratio (MPR) >= 0.8 on healthcare costs. A sensitivity analysis was performed to assess potential cost savings at different MNA levels using the Consumer Price Index to adjust estimates to 2012 dollar value. RESULTS-Mean MPR for the full sample over 5 years was 0.78, with a mean of 0.93 for the adherent group and 0.58 for the MNA group. In fully adjusted models, all annual cost categories increased similar to 3% per year (P = 0.001) during the 5-year study time period. MNA was associated with a 37% lower pharmacy cost, 7% lower outpatient cost, and 41% higher inpatient cost. Based on sensitivity analyses, improving adherence in the MNA group would result in annual estimated cost savings ranging from similar to$661 million (MPR <0.6 vs. >= 0.6) to similar to$1.16 billion (MPR <1 vs. 1). Maximal incremental annual savings would occur by raising MPR from <0.8 to >= 0.8 ($204,530,778) among MNA subjects. CONCLUSIONS-Aggressive strategies and policies are needed to achieve optimal medication adherence in diabetes. Such approaches may further the so-called "triple aim" of achieving better health, better quality care, and lower cost. C1 [Egede, Leonard E.; Gebregziabher, Mulugeta; Dismuke, Clara E.; Lynch, Cheryl P.; Axon, R. Neal; Mauldin, Patrick D.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Egede, Leonard E.; Dismuke, Clara E.; Lynch, Cheryl P.; Axon, R. Neal; Zhao, Yumin; Mauldin, Patrick D.] Med Univ S Carolina, Div Gen Internal Med, Ctr Hlth Disparities Res, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA. RP Egede, LE (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. EM egedel@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU VHA Health Services Research and Development (HSRD) program; [IIR-06-219] FX This study was supported by Grant IIR-06-219 funded by the VHA Health Services Research and Development (HSR&D) program. NR 37 TC 38 Z9 38 U1 2 U2 16 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD DEC PY 2012 VL 35 IS 12 BP 2533 EP 2539 DI 10.2337/dc12-0572 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 041UF UT WOS:000311426000037 PM 22912429 ER PT J AU Kirkman, MS Briscoe, VJ Clark, N Florez, H Haas, LB Halter, JB Huang, ES Korytkowski, MT Munshi, MN Odegard, PS Pratley, RE Swift, CS AF Kirkman, M. Sue Briscoe, Vanessa Jones Clark, Nathaniel Florez, Hermes Haas, Linda B. Halter, Jeffrey B. Huang, Elbert S. Korytkowski, Mary T. Munshi, Medha N. Odegard, Peggy Soule Pratley, Richard E. Swift, Carrie S. TI Diabetes in Older Adults SO DIABETES CARE LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; NUTRITION EXAMINATION SURVEY; INTENSIVE GLUCOSE CONTROL; LIFE-STYLE INTERVENTION; QUALITY-OF-LIFE; HOC EPIDEMIOLOGIC ANALYSIS; BASE-LINE CHARACTERISTICS; NURSING-HOME RESIDENTS; BLOOD-PRESSURE CONTROL; 10-YEAR FOLLOW-UP C1 [Kirkman, M. Sue] Amer Diabet Assoc, Alexandria, VA USA. [Briscoe, Vanessa Jones] Vanderbilt Univ, Dept Med, Nashville, TN USA. [Clark, Nathaniel] Emerald Phys, Diabet Ctr Cape Cod, Hyannis, MA USA. [Florez, Hermes] Miami Vet Affairs Healthcare Syst, Geriatr Res Educ & Clin Ctr, Miami, FL USA. [Florez, Hermes] Univ Miami, Miami, FL USA. [Haas, Linda B.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Halter, Jeffrey B.] Univ Michigan, Div Geriatr Med, Ann Arbor, MI 48109 USA. [Huang, Elbert S.] Univ Chicago, Sect Gen Internal Med, Chicago, IL 60637 USA. [Korytkowski, Mary T.] Univ Pittsburgh, Div Endocrinol, Pittsburgh, PA USA. [Munshi, Medha N.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Munshi, Medha N.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. [Odegard, Peggy Soule] Univ Washington, Dept Pharm, Seattle, WA 98195 USA. [Pratley, Richard E.] Florida Hosp Diabet Inst, Orlando, FL USA. [Swift, Carrie S.] Kadlec Med Ctr, Richland, WA USA. RP Kirkman, MS (reprint author), Amer Diabet Assoc, Alexandria, VA USA. EM skirkman@diabetes.org FU ASPE HHS [1R18AE000049-01]; NIA NIH HHS [P30 AG024824]; NIAID NIH HHS [R18 AE000049]; NIDDK NIH HHS [P30 DK092949, P30DK092949, P60 DK020595, P60 DK20595, R01 DK081796] NR 131 TC 204 Z9 209 U1 5 U2 28 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD DEC PY 2012 VL 35 IS 12 BP 2650 EP 2664 DI 10.2337/dc12-1801 PG 15 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 041UF UT WOS:000311426000058 PM 23100048 ER PT J AU Lochhead, P Imamura, Y Morikawa, T Kuchiba, A Yamauchi, M Liao, XY Qian, ZR Nishihara, R Wu, K Meyerhardt, JA Fuchs, CS Ogino, S AF Lochhead, Paul Imamura, Yu Morikawa, Teppei Kuchiba, Aya Yamauchi, Mai Liao, Xiaoyun Qian, Zhi Rong Nishihara, Reiko Wu, Kana Meyerhardt, Jeffrey A. Fuchs, Charles S. Ogino, Shuji TI Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer SO EUROPEAN JOURNAL OF CANCER LA English DT Article DE Adenocarcinoma; Rectal cancer; Cancer testis antigen; MAGE; Carcinogenesis; Diagnostic marker; Pathology; Therapeutic target; Personalised medicine ID ISLAND METHYLATOR PHENOTYPE; MOLECULAR PATHOLOGICAL EPIDEMIOLOGY; COLON-CANCER; MICROSATELLITE INSTABILITY; IMP3 EXPRESSION; BRAF MUTATION; CARCINOMA; SURVIVAL; ADENOCARCINOMA; PROGRESSION AB Background: Evidence suggests that insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3, also known as IMP3) represents a promising cancer biomarker. However, the clinical, pathological, molecular and prognostic features of IGF2BP3-positive colorectal cancers remain uncertain. Materials and methods: We evaluated IGF2BP3 expression by immunohistochemistry in 671 rectal and colon cancer cases that form part of a molecular pathological epidemiology database. Cox proportional hazards regression models were used to compute mortality hazard ratio (HR), adjusting for clinical, pathological and molecular features, including microsatellite instability, the CpG island methylator phenotype, LINE-1 methylation and KRAS, BRAF and PIK3CA mutations. Results: Among 671 colorectal cancers, 234 (35%) tumours were positive for IGF2BP3. In contrast, normal colorectal epithelium was negative for IGF2BP3 in all 403 specimens of normal mucosa adjacent to carcinoma. IGF2BP3 positivity was associated with poor differentiation (p = 0.0003), stage III-IV disease (p = 0.0081), BRAF mutation (p = 0.031), and LINE-1 hypomethylation (p = 0.020). IGF2BP3 positivity was significantly associated with shorter colorectal cancer-specific [log-rank p < 0.0001; multivariate HR, 1.37; 95% confidence interval (CI), 1.02-1.84] and overall survival (log-rank p = 0.0004; multivariate HR, 1.32; 95% CI, 1.05-1.66). Conclusions: IGF2BP3 expression in colorectal cancer is associated with adverse clinical outcome. Our findings support a role for IGF2BP3 as a diagnostic and/or prognostic biomarker in colorectal cancer. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Lochhead, Paul; Imamura, Yu; Morikawa, Teppei; Kuchiba, Aya; Yamauchi, Mai; Liao, Xiaoyun; Qian, Zhi Rong; Nishihara, Reiko; Meyerhardt, Jeffrey A.; Fuchs, Charles S.; Ogino, Shuji] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Dept Med Oncol, Boston, MA 02215 USA. [Lochhead, Paul; Imamura, Yu; Morikawa, Teppei; Kuchiba, Aya; Yamauchi, Mai; Liao, Xiaoyun; Qian, Zhi Rong; Nishihara, Reiko; Meyerhardt, Jeffrey A.; Fuchs, Charles S.; Ogino, Shuji] Harvard Univ, Sch Med, Boston, MA USA. [Kuchiba, Aya; Nishihara, Reiko; Wu, Kana] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA. [Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Ogino, Shuji] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Lochhead, P (reprint author), Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Dept Med Oncol, 450 Brookline Ave,Room JF 208E, Boston, MA 02215 USA. EM paul.lochhead@channing.harvard.edu; tmorikawa-tky@umin.ac.jp OI Qian, Zhi rong/0000-0003-1633-4120 FU U.S. National Institute of Health (NIH) [P01 CA87969, P01 CA55075, P50 CA127003, R01 CA151993]; Bennett Family Fund; Entertainment Industry Foundation through National Colorectal Cancer Research Alliance; Harvard University Frank Knox Memorial Fellowship; Japan Society for Promotion of Science FX Funding: This work was supported by U.S. National Institute of Health (NIH) grants P01 CA87969 (to S. Hankinson), P01 CA55075 (to W.C. Willett), P50 CA127003 (to C.S.F.), and R01 CA151993 (to S.O.) and by grants from the Bennett Family Fund and the Entertainment Industry Foundation through National Colorectal Cancer Research Alliance. P.L. is a Scottish Government Clinical Academic Fellow and was supported by a Harvard University Frank Knox Memorial Fellowship. T.M. was supported by a fellowship grant from the Japan Society for Promotion of Science. The content is solely the responsibility of the authors and does not necessarily represent the official views of NCI or NIH. NR 40 TC 29 Z9 32 U1 0 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0959-8049 J9 EUR J CANCER JI Eur. J. Cancer PD DEC PY 2012 VL 48 IS 18 BP 3405 EP 3413 DI 10.1016/j.ejca.2012.06.021 PG 9 WC Oncology SC Oncology GA 039BP UT WOS:000311218100009 PM 22840368 ER PT J AU Preusser, M Winkler, F Collette, L Haller, S Marreaud, S Soffietti, R Klein, M Reijneveld, JC Tonn, JC Baumert, BG Mulvenna, P Schadendorf, D Duchnowska, R Berghoff, AS Lin, N Cameron, DA Belkacemi, Y Jassem, J Weber, DC AF Preusser, Matthias Winkler, Frank Collette, Laurence Haller, Sven Marreaud, Sandrine Soffietti, Riccardo Klein, Martin Reijneveld, Jaap C. Tonn, Joerg-Christian Baumert, Brigitta G. Mulvenna, Paula Schadendorf, Dirk Duchnowska, Renata Berghoff, Anna Sophie Lin, Nancy Cameron, David A. Belkacemi, Yazid Jassem, Jacek Weber, Damien C. TI Trial design on prophylaxis and treatment of brain metastases: Lessons learned from the EORTC Brain Metastases Strategic Meeting 2012 SO EUROPEAN JOURNAL OF CANCER LA English DT Article DE Brain metastases; Clinical trail; Prophylaxis; EORTC ID QUALITY-OF-LIFE; CLINICAL-PRACTICE GUIDELINE; GRADED PROGNOSTIC ASSESSMENT; RANDOMIZED CONTROLLED-TRIAL; CELL LUNG-CANCER; CRANIAL IRRADIATION; SURGICAL RESECTION; RADIATION-THERAPY; CAREGIVER RATINGS; BREAST-CANCER AB Brain metastases (BM) occur in a significant proportion of cancer patients and are associated with considerable morbidity and poor prognosis. The trial design in BM patients is particularly challenging, as many disease and patient variables, statistical issues, and the selection of appropriate end-points have to be taken into account. During a meeting organised on behalf of the European Organisation for Research and Treatment of Cancer (EORTC), methodological aspects of trial design in BM were discussed. This paper summarises the issues and potential trial strategies discussed during this meeting and may provide some guidance for the design of trials in BM patients. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Preusser, Matthias; Berghoff, Anna Sophie] Med Univ Vienna, Dept Med 1, A-1090 Vienna, Austria. [Preusser, Matthias; Berghoff, Anna Sophie] Med Univ Vienna, Ctr Comprehens Canc, A-1090 Vienna, Austria. [Winkler, Frank] Heidelberg Univ, Neurol Clin, Heidelberg, Germany. [Winkler, Frank] Heidelberg Univ, Natl Ctr Tumor Dis, Heidelberg, Germany. [Collette, Laurence] EORTC, Ctr Data, Dept Stat, Brussels, Belgium. [Haller, Sven] Univ Hosp Geneva, DISIM, Dept Diagnost & Intervent Neuroradiol, Geneva, Switzerland. [Marreaud, Sandrine] European Org Res & Treatment Canc Headquarters, Brussels, Belgium. [Soffietti, Riccardo] Univ & San Giovanni Battista Hosp, Dept Neurosci, Div Neurooncol, Turin, Italy. [Klein, Martin] Vrije Univ Amsterdam, Med Ctr, Dept Med Psychol, Amsterdam, Netherlands. [Reijneveld, Jaap C.] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam, Netherlands. [Tonn, Joerg-Christian] Univ Munich, Dept Neurosurg, Munich, Germany. [Baumert, Brigitta G.] Maastricht Univ, Med Ctr, Sch Oncol & Dev Biol, GROW,Dept Radiat Oncol,MAASTRO, Maastricht, Netherlands. [Mulvenna, Paula] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England. [Schadendorf, Dirk] Univ Hosp Essen, Skin Canc Ctr, Dept Dermatol, Essen, Germany. [Duchnowska, Renata] Mil Inst Med, Dept Oncol, Warsaw, Poland. [Berghoff, Anna Sophie] Med Univ Vienna, Inst Neurol, Vienna, Austria. [Lin, Nancy] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Cameron, David A.] Western Gen Hosp, Edinburgh Canc Res Ctr, Edinburgh EH4 2XU, Midlothian, Scotland. [Jassem, Jacek] Hop Henri Mondor, AP HP, Serv Oncol Radiotherapie, Creteil, France. [Belkacemi, Yazid] Univ Paris Est Creteil, Paris, France. [Belkacemi, Yazid] AROME Assoc Radiotherapy & Oncol Mediterranean Ar, Paris, France. [Jassem, Jacek] Med Univ Gdansk, Gdansk, Poland. [Weber, Damien C.] Univ Hosp Geneva, Dept Radiat Oncol, Geneva, Switzerland. RP Preusser, M (reprint author), Med Univ Vienna, Dept Med 1, Waehringer Guertel 18-20, A-1090 Vienna, Austria. EM matthias.preusser@meduniwien.ac.at RI Klein, Martin/C-4192-2012; OI Klein, Martin/0000-0003-4160-5746; Preusser, Matthias/0000-0003-3541-2315; Haller, Sven/0000-0001-7433-0203 FU Roche; Novocure; Merck Serono; Comprehensive Cancer Center Vienna; Genentech; EU; Dutch Epilepsy Foundation (NEF); Dutch Cancer Society (KWF Kankerbestrijding); Foundation "NutsOhra"; Foundation "STOPhersentumoren. nl"; National Brain Tumor Foundation/Tug McGraw Foundation; UCB; Sanofi-Aventis; GSK FX The Meeting was kindly supported by Roche, Novocure, Merck Serono and the Comprehensive Cancer Center Vienna. The sponsors had no role or influence in the content of the meeting or this manuscript.; Matthias Preusser has received travel support (scientific meetings), research support (unrestricted grants) and lecture honoraria by Roche. Frank Winkler has received lecture honoraria by Roche, and research support restricted grants) by Roche and Genentech. Sven Haller has received travel support (scientific meetings) and research support (unrelated to the current manuscript). Riccardo Soffietti has received honoraria for Advisory Boards from Roche, Merck and MSD. Jaap Reijneveld received funding from EU Framework Program 7, the Dutch Epilepsy Foundation (NEF), the Dutch Cancer Society (KWF Kankerbestrijding), Foundation "NutsOhra", Foundation "STOPhersentumoren. nl", and the National Brain Tumor Foundation/Tug McGraw Foundation, and received unrestricted grants from UCB and Sanofi-Aventis. Brigitta G. Baumert has received travel support by Roche. Jacek Jassem has received travel support (scientific meetings) from Roche, Boehringer Ingelheim and Astra Zeneca, research support (unrestricted grants) from Roche and GSK and lecture or advisory board honoraria from Roche, GSK, Pfizer, Saladax and Amgen. Dirk Schadendorf has attended compensated advisory boards and received honoraria as part of its speaker's bureau from Roche, Genentech, Amgen, Novartis, BMS, GSK and Merck. None of the other authors have reported conflicts of interest. NR 55 TC 20 Z9 21 U1 0 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0959-8049 EI 1879-0852 J9 EUR J CANCER JI Eur. J. Cancer PD DEC PY 2012 VL 48 IS 18 BP 3439 EP 3447 DI 10.1016/j.ejca.2012.07.002 PG 9 WC Oncology SC Oncology GA 039BP UT WOS:000311218100013 PM 22883982 ER PT J AU Garrido, MM Deb, P Burgess, JF Penrod, JD AF Garrido, Melissa M. Deb, Partha Burgess, James F., Jr. Penrod, Joan D. TI Choosing Models for Health Care Cost Analyses: Issues of Nonlinearity and Endogeneity SO HEALTH SERVICES RESEARCH LA English DT Article DE Costs; endogeneity; nonlinear models; treatment effects; palliative care ID SIMULATED LIKELIHOOD ESTIMATION; GENERALIZED LINEAR-MODELS; SELECTION AB Objective To compare methods of analyzing endogenous treatment effect models for nonlinear outcomes and illustrate the impact of model specification on estimates of treatment effects such as health care costs. Data Sources Secondary data on cost and utilization for inpatients hospitalized in five Veterans Affairs acute care facilities in 20052006. Study Design We compare results from analyses with full information maximum simulated likelihood (FIMSL); control function (CF) approaches employing different types and functional forms for the residuals, including the special case of two-stage residual inclusion; and two-stage least squares (2SLS). As an example, we examine the effect of an inpatient palliative care (PC) consultation on direct costs of care per day. Data Collection/Extraction Methods We analyzed data for 3,389 inpatients with one or more life-limiting diseases. Principal Findings The distribution of average treatment effects on the treated and local average treatment effects of a PC consultation depended on model specification. CF and FIMSL estimates were more similar to each other than to 2SLS estimates. CF estimates were sensitive to choice and functional form of residual. Conclusions When modeling cost or other nonlinear data with endogeneity, one should be aware of the impact of model specification and treatment effect choice on results. C1 [Garrido, Melissa M.; Penrod, Joan D.] James J Peters VA Med Ctr, GRECC REAP, Bronx, NY USA. [Garrido, Melissa M.; Penrod, Joan D.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, Bronx, NY 10468 USA. [Deb, Partha] CUNY, Hunter Coll, Dept Econ, New York, NY 10021 USA. [Deb, Partha] CUNY, Grad Ctr, New York, NY USA. [Deb, Partha] Natl Bur Econ Res, Cambridge, MA 02138 USA. [Burgess, James F., Jr.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Burgess, James F., Jr.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA. RP Garrido, MM (reprint author), James J Peters VA Med Ctr, GRECC REAP, Bronx, NY USA. EM melissa.garri-do@mssm.edu OI Burgess, James/0000-0002-6646-7071; Garrido, Melissa/0000-0002-8986-3536 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service [IAD-06-060-2, REA 08-260]; NIH/NIA Claude D. Pepper Older Americans Independence Center [1P30AG28741-01] FX This material is based on work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service (IAD-06-060-2; REA 08-260). This work was also supported in part by a NIH/NIA Claude D. Pepper Older Americans Independence Center (1P30AG28741-01). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 33 TC 16 Z9 16 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD DEC PY 2012 VL 47 IS 6 BP 2377 EP 2397 DI 10.1111/j.1475-6773.2012.01414.x PG 21 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 035WL UT WOS:000310983100016 PM 22524165 ER PT J AU Sharma, A Tian, F Yin, MT Keller, MJ Cohen, M Tien, PC AF Sharma, Anjali Tian, Fang Yin, Michael T. Keller, Marla J. Cohen, Mardge Tien, Phyllis C. TI Association of Regional Body Composition With Bone Mineral Density in HIV-Infected and HIV-Uninfected Women: Women's Interagency HIV Study SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE body composition; fat redistribution; bone mineral density; HIV; women ID MODERATE ALCOHOL-CONSUMPTION; PROTON MR SPECTROSCOPY; X-RAY ABSORPTIOMETRY; BIOELECTRICAL-IMPEDANCE; ANTIRETROVIRAL THERAPY; ELDERLY-WOMEN; MARROW FAT; NAIVE PATIENTS; MASS; OSTEOPOROSIS AB Objective: To understand how regional body composition affects bone mineral density (BMD) in HIV-infected and HIV-uninfected women. Methods: Dual energy x-ray absorptiometry was used to measure regional lean and fat mass and BMD at lumbar spine (LS), total hip (TH), and femoral neck (FN) in 318 HIV-infected and 122 HIV-uninfected Women's Interagency HIV Study participants at baseline and 2 and 5 years later. Total lean and fat mass were measured using bioimpedance analysis. Multivariate marginal linear regression models assessed the association of HIV status and body composition on BMD change. Results: Compared with HIV-uninfected women, HIV-infected women were older (44 vs. 37 years), more likely to be Hepatitis C virus-infected (32% vs. 14%), and postmenopausal (26% vs. 3%) and had lower baseline total fat mass, trunk fat, and leg fat. In multivariate models, increased total lean mass was independently associated with increased BMD at LS, TH, and FN, and total fat mass was associated with increased BMD at TH and FN (all P < 0.05). When total fat was replaced in multivariate models with trunk fat and leg fat, increased trunk fat (and not leg fat) was associated with increased TH and FN BMD (P < 0.001). Conclusions: Total fat and lean mass are strong independent predictors of TH and FN BMD, and lean mass was associated with greater LS BMD. Regardless of HIV status, greater trunk fat (and not leg fat) was associated with increased TH and FN BMD, suggesting that weight-bearing fat may be a more important predictor of BMD in the hip. C1 [Sharma, Anjali] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11205 USA. [Tian, Fang] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Yin, Michael T.] Columbia Univ, Dept Med, New York, NY USA. [Keller, Marla J.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Cohen, Mardge] John H Stroger Jr Hosp Cook Cty, CORE Ctr, Dept Med, Chicago, IL USA. [Tien, Phyllis C.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Tien, Phyllis C.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Sharma, A (reprint author), Suny Downstate Med Ctr, Dept Med, 450 Clarkson Ave,Box 1240, Brooklyn, NY 11205 USA. EM anjali.sharma@downstate.edu FU National Institute of Allergy and Infectious Diseases [UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, UO1-AI-42590]; National Institute of Child Health and Human Development [UO1-HD-32632]; National Cancer Institute; National Institute on Drug Abuse; National Institute on Deafness and Other Communication Disorders; National Center for Research Resources UCSF-CTSI [UL1 RR024131]; NIH [AI-095089]; Robert Wood Johnson Foundation Physician Faculty Scholars Program FX Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (Kathryn Anastos); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases Grants UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590 and by the National Institute of Child Health and Human Development Gant UO1-HD-32632. The study is cofunded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is provided by the National Center for Research Resources UCSF-CTSI Grant UL1 RR024131. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. Dr Yin is supported by NIH Grant AI-095089. Dr Sharma is supported by the Robert Wood Johnson Foundation Physician Faculty Scholars Program. NR 51 TC 12 Z9 12 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 1 PY 2012 VL 61 IS 4 BP 469 EP 476 DI 10.1097/QAI.0b013e31826cba6c PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 037DU UT WOS:000311083200013 PM 22895436 ER PT J AU Hahn, JA Fatch, R Kabami, J Mayanja, B Emenyonu, NI Martin, J Bangsberg, DR AF Hahn, Judith A. Fatch, Robin Kabami, Jane Mayanja, Bernard Emenyonu, Nneka I. Martin, Jeffrey Bangsberg, David R. TI Self-Report of Alcohol Use Increases When Specimens for Alcohol Biomarkers Are Collected in Persons With HIV in Uganda SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Letter ID BOGUS-PIPELINE; DRUG-USE; CONSUMPTION; PHOSPHATIDYLETHANOL; VALIDITY C1 [Hahn, Judith A.; Fatch, Robin; Emenyonu, Nneka I.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Hahn, Judith A.; Martin, Jeffrey] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Bangsberg, David R.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA. Ragon Inst MGH MIT & Harvard, Charlestown, MA USA. Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA. Mbarara Univ Sci & Technol, Fac Med, Mbarara, Uganda. RP Hahn, JA (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. FU NIAAA NIH HHS [R01 AA018631]; NIAID NIH HHS [P30 AI027763, P30 AI060354]; NIDDK NIH HHS [P30 DK026743]; NIMH NIH HHS [K-24 MH87227, K24 MH087227, R01 MH054907, R01 MH54907] NR 14 TC 13 Z9 13 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 1 PY 2012 VL 61 IS 4 BP E63 EP E64 DI 10.1097/QAI.0b013e318267c0f1 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 037DU UT WOS:000311083200004 PM 23138732 ER PT J AU Biederman, J Fried, R Hammerness, P Surman, C Mehler, B Petty, CR Faraone, SV Miller, C Bourgeois, M Meller, B Godfrey, KM Baer, L Reimer, B AF Biederman, Joseph Fried, Ronna Hammerness, Paul Surman, Craig Mehler, Bruce Petty, Carter R. Faraone, Stephen V. Miller, Carolyn Bourgeois, Michelle Meller, Benjamin Godfrey, Kathryn M. Baer, Lee Reimer, Bryan TI The Effects of Lisdexamfetamine Dimesylate on Driving Behaviors in Young Adults With ADHD Assessed With the Manchester Driving Behavior Questionnaire SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE ADHD; Driving; Driving behavior questionnaire; Youth ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; SALTS EXTENDED-RELEASE; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; OROS METHYLPHENIDATE; PERFORMANCE; SIMULATION; OUTCOMES; DRIVERS AB Purpose: Young adults with ADHD have been shown to be at increased risk for impairment in driving behaviors. Although stimulant medications have proven efficacy in reducing ADHD symptomatology, there is limited knowledge as to their effects on driving behavior. The focus of this report is on assessing the impact of lisdexamfetamine dimesylate (LDX) on driving behaviors in young adults with ADHD using a validated driving behavior questionnaire. Methods: This assessment was carried out in the context of a randomized, double-blind, 6-week, placebo-controlled, parallel-design study of LDX versus placebo. Subjects were 61 outpatients of both sexes, 18-26 years of age, who met Diagnostic and Statistical Manual of Mental Disorders, fourth edition, criteria for ADHD. Subjects were randomized to receive LDX or placebo for 6 weeks. Driving behavior was assessed at baseline and at the end of treatment using a U.S. version of the Manchester Driving Behavior Questionnaire (DBQ). Results: Highly significant improvements were documented on LDX, over placebo, in driving behaviors assessed through the DBQ in measures of driving errors, driving lapses, and a trend toward fewer driving violations. There were no meaningful associations between these DBQ results and previously documented changes in a laboratory driving simulation paradigm or with improvement in symptoms of ADHD assessed through the ADHD rating scale. Conclusions: LDX treatment was associated with significant improvements in self-reported driving behaviors that were independent of improvement in symptoms of ADHD. These results suggest that LDX may reduce behaviors associated with driving risks in young adults with ADHD. (C) 2012 Society for Adolescent Health and Medicine. All rights reserved. C1 [Biederman, Joseph; Fried, Ronna; Hammerness, Paul; Surman, Craig; Petty, Carter R.; Miller, Carolyn; Bourgeois, Michelle; Meller, Benjamin; Baer, Lee] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol & Adult, Boston, MA 02114 USA. [Biederman, Joseph; Fried, Ronna; Hammerness, Paul; Surman, Craig; Baer, Lee] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA. [Mehler, Bruce; Godfrey, Kathryn M.; Reimer, Bryan] MIT, New England Univ Transportat Ctr, Cambridge, MA 02139 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY USA. RP Biederman, J (reprint author), Massachusetts Gen Hosp, Clin Program Pediat Psychopharmacol & Adult ADHD, 55 Fruit St,YAW 6A, Boston, MA 02114 USA. EM jbiederman@partners.org RI Mehler, Bruce/E-4538-2017; OI Mehler, Bruce/0000-0001-5929-4179; Faraone, Stephen/0000-0002-9217-3982 FU Shire Pharmaceuticals, Inc.; ElMindA; Janssen; McNeil; Next Wave Pharmaceuticals; Shire; Fundacion Dr. Manuel Camelo A.C.; Fundacion Areces; Medice Pharmaceuticals; Spanish Child Psychiatry Association; Abbott; Alza; AstraZeneca; Bristol-Myers Squibb; Celltech; Cephalon; Eli Lilly and Co.; Eisai; Forest; Glaxo; Gliatech; Merck; National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD); National Institute on Drug Abuse (NIDA); New River; National Institute of Child Health and Human Development (NICHD); National Institute of Mental Health (NIMH); Novartis; Noven; NeuroSearch; Organon; Otsuka; Pfizer; Pharmacia; Prechter Foundation; Stanley Foundation; UCB Pharma, Inc.; Wyeth; Ortho-McNeil Janssen and Shire and served on the advisory board for Shire; pharmaceutical companies/companies: Cephalon; Eli Lilly; ElMindA Ltd; GlaxoSmithKline; Johnson and Johnson; Ortho-McNeil Janssen; Takeda; Hilda and Preston Davis Foundation; National Institutes of Health (NIH); NIH FX This study was funded by Shire Pharmaceuticals, Inc. The study sponsor had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. The authors acknowledge Dr. Eric Mick for statistical analysis of data in this study.; J.B. is currently receiving research support from the following sources: ElMindA, Janssen, McNeil, Next Wave Pharmaceuticals, and Shire. In 2011, he gave a single unpaid talk for Juste Pharmaceuticals (Spain), received honoraria from the Massachusetts General Hospital (MGH) Psychiatry Academy for a tuition-funded continuing medical education (CME) course, and received an honorarium for presenting at an international scientific conference on ADHD. He also received an honorarium from Cambridge University Press for a chapter publication. He received departmental royalties for a copyrighted rating scale used for ADHD diagnoses, paid by Eli Lilly, Shire, and AstraZeneca; these royalties are paid to the Department of Psychiatry at MGH. In 2010, he received a speaker's fee from Fundacion Dr. Manuel Camelo A.C., provided single consultations for Shionogi Pharma, Inc. and Cipher Pharmaceuticals, Inc., and received honoraria from the MGH Psychiatry Academy for a tuition-funded CME course. In 2009, he received a speaker's fee from the following sources: Fundacion Areces, Medice Pharmaceuticals, and the Spanish Child Psychiatry Association. In previous years, he received research support, consultation fees, or speaker's fees from the following additional sources: Abbott, Alza, AstraZeneca, Bristol-Myers Squibb, Celltech, Cephalon, Eli Lilly and Co., Eisai, Forest, Glaxo, Gliatech, Janssen, McNeil, Merck, National Alliance for Research in Schizophrenia and Affective Disorders (NARSAD), National Institute on Drug Abuse (NIDA), New River, National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), Novartis, Noven, NeuroSearch, Organon, Otsuka, Pfizer, Pharmacia, The Prechter Foundation, Shire, The Stanley Foundation, UCB Pharma, Inc., and Wyeth.; In the past 2 years, Dr Hammerness has participated in CME activities/professional talks supported by Ortho-McNeil Janssen and Shire and served on the advisory board for Shire. In the past 2 years, P.H. has participated, as an investigator/principal investigator, in research studies funded by the following pharmaceutical companies/companies: Cephalon, Eli Lilly, ElMindA Ltd, GlaxoSmithKline, Johnson and Johnson, McNeil, Merck, New River, Novartis, Ortho-McNeil Janssen, Pfizer, Shire, and Takeda. He has also received honoraria from commercial entities supporting the MGH Psychiatry Academy, www.mghcme.org.; C.S. has received research support from Abbott, Alza, Cephalon, Eli Lilly, the Hilda and Preston Davis Foundation, McNeil, Merck, New River, National Institutes of Health (NIH), Organon, Pfizer, Shire, and Takeda; has received support from Janssen-Ortho, McNeil, Novartis, and Shire for speaking and other educational activities; and has been a consultant/adviser for McNeil, Shire, and Takeda. He has also received honoraria from Reed Medical Education (a logistics collaborator for the MGH Psychiatry Academy). Commercial entities supporting the MGH Psychiatry Academy are listed on the Academy's Web site, www.mghcme.org.; S.F. has received consulting fees and was on advisory boards for Shire Development and received research support from Shire and the NIH. In previous years, he received consulting fees or was on Advisory Boards or participated in CME programs sponsored by Shire, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly. In previous years, he received research support from Eli Lilly, Shire, Pfizer, and the NIH. S.V.F. receives royalties for a book published by Guilford Press: Straight Talk About Your Child's Mental Health. NR 39 TC 7 Z9 7 U1 2 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD DEC PY 2012 VL 51 IS 6 BP 601 EP 607 DI 10.1016/j.jadohealth.2012.03.005 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 040SE UT WOS:000311342500011 PM 23174471 ER PT J AU Ding, YP Fu, YM Lee, JC Hooper, DC AF Ding, Yanpeng Fu, Yingmei Lee, Jean C. Hooper, David C. TI Staphylococcus aureus NorD, a Putative Efflux Pump Coregulated with the Opp1 Oligopeptide Permease, Contributes Selectively to Fitness In Vivo SO JOURNAL OF BACTERIOLOGY LA English DT Article ID OVERLAP EXTENSION; MURINE MODEL; MGRA; EXPRESSION; REGULATOR; VIRULENCE; GROWTH; FUR; RESISTANCE; INFECTION AB Staphylococcus aureus readily infects humans, causing infections from mild superficial skin infections to lethal bacteremia and endocarditis. Transporters produced by S. aureus allow the pathogen to adapt to a variety of settings, including survival at sites of infection and in the presence of antibiotics. The native functions of many transporters are unknown, but their potential dual contribution to fitness and antimicrobial resistance highlights their importance in staphylococcal infections. Here, we show that S. aureus NorD, a newly recognized efflux pump of the major facilitator superfamily, contributes to fitness in a murine subcutaneous abscess model. In community-associated methicillin-resistant S. aureus (CA-MRSA) strain MW2, norD was selectively upregulated 36-fold at the infection site relative to growth in vitro, and the norD mutant demonstrated significant fitness impairment in abscesses, with fitness 20- to 40-fold lower than that of the parent MW2 strain. Plasmid-encoded NorD could complement the fitness defect of the MW2 norD mutant. Chromosomal norD expression is polycistronic with the upstream oligopeptide permease genes (opp1ABCDF), which encode an ABC oligopeptide transporter. Both norD and opp1 were upregulated in abscesses and iron-restricted culture medium and negatively regulated by Fur, but only NorD contributed to fitness in the murine abscess model. C1 [Ding, Yanpeng; Fu, Yingmei; Hooper, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA. [Lee, Jean C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Infect Dis,Dept Med, Boston, MA USA. [Fu, Yingmei] Harbin Med Univ, Dept Microbiol, Harbin, Heilongjiang, Peoples R China. RP Hooper, DC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Infect Dis, Boston, MA 02115 USA. EM dhooper@partners.org FU Public Health Service from the National Institutes of Health [R37-AI023988] FX This project was supported in part by Public Health Service grant R37-AI023988 from the National Institutes of Health (to D.C.H.). NR 38 TC 12 Z9 13 U1 0 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD DEC PY 2012 VL 194 IS 23 BP 6586 EP 6593 DI 10.1128/JB.01414-12 PG 8 WC Microbiology SC Microbiology GA 035DV UT WOS:000310924300023 PM 23042988 ER PT J AU Feres, M Soares, GMS Mendes, JAV Silva, MP Faveri, M Teles, R Socransky, SS Figueiredo, LC AF Feres, Magda Silva Soares, Geisla Mary Velloso Mendes, Juliana Alethusa Silva, Maike Paulino Faveri, Marcelo Teles, Ricardo Socransky, Sigmund S. Figueiredo, Luciene Cristina TI Metronidazole alone or with amoxicillin as adjuncts to non-surgical treatment of chronic periodontitis: a 1-year double-blinded, placebo-controlled, randomized clinical trial SO JOURNAL OF CLINICAL PERIODONTOLOGY LA English DT Article DE amoxicillin; chronic periodontitis; metronidazole; periodontal disease; periodontal treatment; scaling and root planing ID GENERALIZED AGGRESSIVE PERIODONTITIS; SYSTEMIC METRONIDAZOLE; MICROBIOLOGICAL BENEFITS; ANTIMICROBIAL THERAPY; TOOTH LOSS; PROGRESSION; EFFICACY AB Aim To evaluate the effects of the adjunctive use of metronidazole (MTZ) or MTZ + amoxicillin (AMX) in the treatment of generalized chronic periodontitis (ChP). A secondary aim was to examine a possible added effect of chlorhexidine to these therapies. Methods One hundred and eighteen subjects received scaling and root planing (SRP) only or with MTZ [400 mg/thrice a day (TID)] or MTZ+AMX (500 mg/TID) for 14 days. Half of the subjects in each group rinsed with 0.12% chlorhexidine twice a day (BID) for 2 months. Subjects were clinically monitored at baseline, 3, 6 and 12-months post-therapy. Results The two antibiotic groups showed lower mean number of sites with probing depth (PD) =5 mm and fewer subjects exhibiting =9 of these sites at 1-year post-treatment. Logistic regression analysis showed that antibiotics were the only significant predictors of subjects presenting =4 sites with PD =5 mm at 1 year (MTZ+AMX: OR, 13.33; 95%CI, 3.75-47.39/p = 0.0000; MTZ: OR, 7.26; 95%CI, 2.26-23.30/p = 0.0004). The frequency of adverse events did not differ between the two antibiotic treatments (p > 0.05). The chlorhexidine subgroups showed a trend (p > 0.05) to present fewer residual sites =5 mm compared with the placebo subgroups at 1 year. Conclusion Treatment of generalized ChP is significantly improved by the adjunctive use of MTZ+AMX and MTZ. C1 [Feres, Magda] Univ Guarulhos, Ctr Posgrad & Pesquisa CEPPE, Dent Res Div, Dept Periodontol, BR-07023070 Guarulhos, SP, Brazil. [Teles, Ricardo; Socransky, Sigmund S.] Forsyth Inst, Cambridge, MA USA. [Teles, Ricardo] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. RP Feres, M (reprint author), Univ Guarulhos, Ctr Posgrad & Pesquisa CEPPE, Dent Res Div, Dept Periodontol, Praca Tereza Cristina,229 Ctr, BR-07023070 Guarulhos, SP, Brazil. EM mferes@ung.br RI Soares, Geisla/D-9778-2014; Feres, Magda/H-7964-2012 FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Brazil) [07/55291-9] FX The authors declare that they have no conflict of interests. This study was supported by Research Grant #07/55291-9 from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Brazil). NR 31 TC 32 Z9 32 U1 1 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0303-6979 J9 J CLIN PERIODONTOL JI J. Clin. Periodontol. PD DEC PY 2012 VL 39 IS 12 BP 1149 EP 1158 DI 10.1111/jcpe.12004 PG 10 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 037FQ UT WOS:000311088000005 PM 23016867 ER PT J AU Ehrlich, S Leopold, K Merle, JV Theophil, I Haag, W Lautenschlager, M Schaefer, M AF Ehrlich, Stefan Leopold, Karolina Merle, Julia V. Theophil, Ines Haag, Wiebke Lautenschlager, Marion Schaefer, Martin TI Trajectories of Agouti-Related Protein and Leptin Levels During Antipsychotic-Associated Weight Gain in Patients With Schizophrenia SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE AGRP; leptin; weight gain; second-generation antipsychotics; olanzapine; ziprasidone; schizophrenia; appetite; fat mass ID ANOREXIA-NERVOSA; 2ND-GENERATION ANTIPSYCHOTICS; MELANOCORTIN RECEPTORS; ENERGY-EXPENDITURE; EATING-DISORDERS; FEMALE RATS; FOOD-INTAKE; OBESE MEN; IN-VIVO; OLANZAPINE AB Objective: Some but not all second-generation antipsychotics can induce considerable weight gain and metabolic syndrome. Although the exact biochemical mechanisms for these adverse effects are unclear, appetite-regulating neuropeptides of the central nervous system are thought to be implicated in this process. The hypothalamic mediator Agouti-related protein (AGRP) is inhibited by leptin and was shown to increase food intake. The aim of the present study was to investigate the trajectory of AGRP levels during antipsychotic-induced weight gain. Methods: As part of a controlled prospective clinical study, we determined indicators of body fat mass, plasma AGRP, and leptin levels in 16 patients with schizophrenia treated with ziprasidone and 21 patients with schizophrenia treated with olanzapine. Measurements by enzyme-linked immunosorbent assay were obtained before treatment (T0), after 4 weeks (T1), and after 3 months (T2) of treatment. Results: Whereas body mass index and leptin levels increased in patients treated with olanzapine compared to patients treated with ziprasidone, plasma AGRP levels did not differ among the treatment groups and did not change over time. Associations between AGRP and fat mass as well as appetite were disrupted in the olanzapine-treated patients but not in the ziprasidone group. Conclusion: Future studies are needed to test whether the lack of a decrease in AGRP levels during weight gain in patients treated with olanzapine could perpetuate adverse metabolic long-term effects. C1 [Ehrlich, Stefan; Merle, Julia V.] Tech Univ Dresden, Dept Child & Adolescent Psychiat, Translat Dev Neurosci Sect, D-01307 Dresden, Germany. [Ehrlich, Stefan] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat,Athinoula A Martinos Ctr Biomed Ima, Charlestown, MA USA. [Leopold, Karolina] Tech Univ Dresden, Dept Psychiat, D-01307 Dresden, Germany. [Merle, Julia V.] Charite, Dept Child & Adolescent Psychiat, Berlin, Germany. [Theophil, Ines; Haag, Wiebke; Lautenschlager, Marion; Schaefer, Martin] Charite Univ Med Berlin, Dept Psychiat & Psychotherapy, CCM, Berlin, Germany. [Schaefer, Martin] Kliniken Essen Mitte, Dept Psychiat Psychotherapy & Addict Med, Essen, Germany. RP Ehrlich, S (reprint author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dept Child & Adolescent Psychiat, Fetscherstr 74, D-01307 Dresden, Germany. EM stefan@nmr.mgh.harvard.edu OI Ehrlich, Stefan/0000-0003-2132-4445 FU AstraZeneca; Pfizer Germany; Charite Research Fund FX KL and MS received payment for lectures from AstraZeneca, Janssen-Cilag, Bristol-Meyers Squibb, Pfizer, Lilly, and Servier. KL's current institution also received a research grant from AstraZeneca. MS received payment for lectures and consulting honoraria from Shire, Roche Pharma (Germany/Switzerland), AstraZeneca, Janssen, and Bristol-Meyers Squibb. ML received payment for lectures from Pfizer. All other authors declare no biomedical financial interests or other potential conflicts of interest.; The main clinical study comparing 2 SGAs was supported in part by an unrestricted grant of Pfizer Germany. The assessment of the endocrine parameters was supported by the Charite Research Fund. NR 59 TC 7 Z9 7 U1 2 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD DEC PY 2012 VL 32 IS 6 BP 767 EP 772 DI 10.1097/JCP.0b013e318270e5c5 PG 6 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 035DN UT WOS:000310923500006 PM 23131879 ER PT J AU Witte, J Bentley, K Evins, AE Clain, AJ Baer, L Pedrelli, P Fava, M Mischoulon, D AF Witte, Janet Bentley, Kate Evins, Anne Eden Clain, Alisabet J. Baer, Lee Pedrelli, Paola Fava, Maurizio Mischoulon, David TI A Randomized, Controlled, Pilot Study of Acamprosate Added to Escitalopram in Adults With Major Depressive Disorder and Alcohol Use Disorder SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY LA English DT Article DE acamprosate; alcohol use disorder; AUD; depression; MDD; escitalopram ID PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; PHARMACOLOGICAL-TREATMENT; NEFAZODONE TREATMENT; ANXIETY DISORDERS; CLINICAL-TRIAL; RATING-SCALE; DEPENDENCE; CITALOPRAM; SERTRALINE AB We sought to examine the efficacy and safety of acamprosate augmentation of escitalopram in patients with concurrent major depressive disorder (MDD) and alcohol use disorders. Twenty-three adults (43% female; mean +/- SD age, 46 +/- 14 years) were enrolled and received 12 weeks of treatment with psychosocial support; escitalopram, 10 to 30 mg/d; and either acamprosate, 2000 mg/d (n = 12), or identical placebo (n = 11). Outcomes included change in clinician ratings of depressive symptoms, MDD response and remission rates, changes in frequency and intensity of alcohol use, retention rates, and adverse events. Twelve subjects (acamprosate, n = 7; placebo, n = 5) completed the study. There was significant mean reduction in ratings of depressive symptoms from baseline in both treatment arms (P < 0.05), with no significant difference between the groups. Those in the acamprosate group had a 50% MDD response rate and a 42% remission rate, whereas those in the placebo arm had a 36% response and remission rate (not significant). Those assigned to acamprosate had significant reduction in number of drinks per week and drinks per month during the trial, whereas those assigned to placebo demonstrated no significant change in any alcohol use parameter, but the between-group difference was not significant. There were no significant associations between change in depressive symptoms and change in alcohol use. Attrition rates did not differ significantly between the 2 arms. Acamprosate added to escitalopram in adults with MDD and alcohol use disorders was associated with reduction in the frequency of alcohol use. The present study was not powered to detect superiority versus placebo. Further study in a larger sample is warranted. C1 [Mischoulon, David] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Mischoulon, D (reprint author), Massachusetts Gen Hosp, Depress Clin & Res Program, 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA. EM dmischoulon@partners.org FU National Association for Research on Schizophrenia and Depression (NARSAD); Forest Laboratories; Bristol-Meyers Squibb; National Institutes of Health [K23DA00510, K24DA030443]; GlaxoSmithKline; Pfizer; Bowman Family Foundation; Abbott Laboratories; Alkermes; Aspect Medical Systems; AstraZeneca; BioResearch; BrainCells, Inc; Bristol-Myers Squibb Company; Cephalon; Clinical Trial Solutions; LLC; Eli Lilly Company; EnVivo Pharmaceuticals, Inc; Forest Pharmaceuticals, Inc; Ganeden; J & J Pharmaceuticals; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; NCCAM; NIDA; NIMH; Novartis; Organon, Inc; PamLab; Pfizer, Inc; Pharmavite; Roche; Sanofi-Aventis; Shire; Solvay Pharmaceuticals, Inc; Synthelabo; Wyeth-Ayerst Laboratories; Amarin (Laxdale); Bristol-Myers Squibb; Cederroth; Nordic Naturals; Swiss Medica; Fisher-Wallace FX Dr Janet Witte was supported by a Young Investigator Award from The National Association for Research on Schizophrenia and Depression (NARSAD). She has also received research support from Forest Laboratories and Bristol-Meyers Squibb and honoraria from Eli Lilly. Escitalopram, acamprosate, and matching placebo for this study were kindly donated by Forest Laboratories. Dr A. Eden Evins was supported by National Institutes of Health Grants K23DA00510 and K24DA030443. She has received research support from GlaxoSmithKline, Pfizer, and the Bowman Family Foundation; she has served in advisory/consultative relationships with Boehringer Ingelheim and Pfizer. Dr Maurizio Fava has received research support from Abbott Laboratories, Alkermes, Aspect Medical Systems, AstraZeneca, BioResearch, BrainCells, Inc, Bristol-Myers Squibb Company, Cephalon, Clinical Trial Solutions, LLC, Eli Lilly & Company, EnVivo Pharmaceuticals, Inc, Forest Pharmaceuticals, Inc, Ganeden, GlaxoSmithKline, J & J Pharmaceuticals, Lichtwer Pharma GmbH, Lorex Pharmaceuticals, NARSAD, NCCAM, NIDA, NIMH, Novartis, Organon, Inc, PamLab, LLC, Pfizer, Inc, Pharmavite, Roche, Sanofi-Aventis, Shire, Solvay Pharmaceuticals, Inc, Synthelabo, and Wyeth-Ayerst Laboratories. He has served as an advisor and consultant to Abbott Laboratories, Affectis Pharmaceuticals AG, Amarin, Aspect Medical Systems, AstraZeneca, Auspex Pharmaceuticals, Bayer AG, Best Practice Project Management, Inc, BioMarin Pharmaceuticals, Inc, Biovail Pharmaceuticals, Inc, BrainCells, Inc, Bristol-Myers Squibb Company, Cephalon, Clinical Trials Solutions, LLC, CNS Response, Compellis, Cypress Pharmaceuticals, Dov Pharmaceuticals, Eisai, Inc, Eli Lilly & Company, EPIX Pharmaceuticals, Euthymics Bioscience, Inc, Fabre-Kramer, Pharmaceuticals, Inc, Forest Pharmaceuticals, Inc, GlaxoSmithKline, Grunenthal GmBH, Janssen Pharmaceutica, Jazz Pharmaceuticals, J & J Pharmaceuticals, Knoll Pharmaceutical Company, Labopharm, Lorex Pharmaceuticals, Lundbeck, MedAvante, Inc, Merck, Methylation Sciences, Neuronetics, Novartis, Nutrition 21, Organon, Inc, PamLab, LLC, Pfizer, Inc, PharmaStar, Pharmavite, Precision Human Biolaboratory, Prexa Pharmaceuticals, Inc, PsychoGenics, Psylin Neurosciences, Inc, Ridge Diagnostics, Inc, Roche, Sanofi-Aventis, Sepracor, Schering-Plough, Solvay Pharmaceuticals, Inc, Somaxon, Somerset Pharmaceuticals, Synthelabo, Takeda, Tetragenex, TransForm Pharmaceuticals, Inc, Transcept Pharmaceuticals, Vanda Pharmaceuticals Inc, Wyeth-Ayerst Laboratories. He has received speaking and publishing honoraria from Adamed, Co, Advanced Meeting Partners, American Psychiatric Association, American Society of Clinical Psychopharmacology, AstraZeneca, Belvoir, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Cephalon, EliLilly&Company, ForestPharmaceuticals, Inc, GlaxoSmithKline, Imedex, Novartis, Organon Inc, Pfizer Inc, PharmaStar, MGH Psychiatry Academy/Primedia, MGH Psychiatry Academy/Reed-Elsevier, UBC, and Wyeth-Ayerst Laboratories. He holds equity in Compellis. He currently holds a patent for SPCD and a patent application for a combination of azapirones and bupropion in MDD and has received copyright royalties for the MGH CPFQ, SFI, ATRQ, DESS, and SAFER diagnostic instruments.; Dr David Mischoulon has received research support for other clinical trials from Amarin (Laxdale), Bowman Family Foundation, Bristol-Myers Squibb, Cederroth, Lichtwer Pharma GmbH, Nordic Naturals, Ganeden, Swiss Medica, and Fisher-Wallace; he has received consulting and writing honoraria from Pamlab; he has received speaking honoraria from Bristol-Myers Squibb, Nordic Naturals, Pfizer, Pamlab, and Virbac as well as from Reed Medical Education (a company working as a logistics collaborator for the Massachusetts General Hospital Psychiatry Academy); he has received royalty income from Back Bay Scientific for PMS Escape, and from Lippincott Williams & Wilkins for the book, Natural Medications for Psychiatric Disorders: Considering the Alternatives (Editors: David Mischoulon and Jerrold F. Rosenbaum). The remaining authors (Ms Kate Bentley, Dr Paola Pedrelli, Dr Lee Baer, and Ms Alisabet Clain) have no conflicts of interest to disclose. NR 45 TC 3 Z9 4 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0271-0749 J9 J CLIN PSYCHOPHARM JI J. Clin. Psychopharmacol. PD DEC PY 2012 VL 32 IS 6 BP 787 EP 796 DI 10.1097/JCP.0b013e3182726764 PG 10 WC Pharmacology & Pharmacy; Psychiatry SC Pharmacology & Pharmacy; Psychiatry GA 035DN UT WOS:000310923500009 PM 23131884 ER PT J AU Adams, JM AF Adams, Jeffrey M. TI Influencing the Language of Nursing An Interview With T. Heather Herdman and Sue Moorhead SO JOURNAL OF NURSING ADMINISTRATION LA English DT Editorial Material C1 Massachusetts Gen Hosp, Ctr Innovat Care Delivery, Boston, MA 02114 USA. RP Adams, JM (reprint author), Massachusetts Gen Hosp, Ctr Innovat Care Delivery, 275 Cambridge St,POB 4, Boston, MA 02114 USA. EM jadams9@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0002-0443 J9 J NURS ADMIN JI J. Nurs. Adm. PD DEC PY 2012 VL 42 IS 12 BP 545 EP 547 DI 10.1097/NNA.0b013e318274b4ff PG 3 WC Nursing SC Nursing GA 039AX UT WOS:000311216300002 ER PT J AU Boden, MT Bonn-Miller, MO Vujanovic, AA Drescher, KD AF Boden, Matthew Tyler Bonn-Miller, Marcel O. Vujanovic, Anka A. Drescher, Kent D. TI A Prospective Investigation of Changes in Avoidant and Active Coping and Posttraumatic Stress Disorder Symptoms among Military Veteran SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT LA English DT Article DE Posttraumatic Stress; PTSD; Coping; Avoidance; Treatment ID PSYCHOMETRIC PROPERTIES; PTSD CHECKLIST; SYMPTOMATOLOGY; PSYCHOTHERAPY; PREDICTORS; STRATEGIES; SEVERITY; THERAPY; ABUSE; LONG AB The present investigation utilized a prospective design to investigate associations between changes in self-reported avoidant and active coping occurring during residential treatment for posttraumatic stress disorder (PTSD) and PTSD symptom severity at treatment discharge. Participants were 636 military Veteran patients (91.4 % male; M-age = 51.7 years) admitted to a Veterans Affairs (VA) residential rehabilitation program for PTSD, between 2000 and 2008. Results indicated that increases in avoidant coping and decreases in active coping from treatment intake to discharge were simultaneously and incrementally predictive of total PTSD symptom severity at treatment discharge, after accounting for PTSD symptom severity at treatment intake. These findings hold particular relevance for treatment-seeking populations with severe PTSD and researchers and clinicians attempting to understand and treat these populations. C1 [Boden, Matthew Tyler] Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk Div 152, Menlo Pk, CA 94025 USA. [Bonn-Miller, Marcel O.] Hlth Care Syst, Vet Affairs Palo Alto, Natl Ctr PTSD, Menlo Pk, CA USA. [Bonn-Miller, Marcel O.] Hlth Care Syst, Vet Affairs Palo Alto, Ctr Hlth Care Evaluat, Menlo Pk, CA USA. [Vujanovic, Anka A.] Vet Affairs Boston Healthcare Syst, Behav Sci Div, Natl Ctr PTSD, Boston, MA USA. [Vujanovic, Anka A.] Boston Univ, Sch Med, Boston, MA 02118 USA. [Drescher, Kent D.] Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA 94025 USA. [Bonn-Miller, Marcel O.] Philadelphia Vet Affair Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, Philadelphia, PA USA. [Vujanovic, Anka A.] Univ Texas Hlth Sci Ctr, Houston, TX USA. RP Boden, MT (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk Div 152, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM matthew.t.boden@gmail.com NR 37 TC 10 Z9 10 U1 7 U2 27 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0882-2689 J9 J PSYCHOPATHOL BEHAV JI J. Psychopathol. Behav. Assess. PD DEC PY 2012 VL 34 IS 4 BP 433 EP 439 DI 10.1007/s10862-012-9293-6 PG 7 WC Psychology, Clinical SC Psychology GA 035OU UT WOS:000310957600001 ER PT J AU Gros, DF Gros, KS McCabe, RE Antony, MM AF Gros, Daniel F. Gros, Kirstin Stauffacher McCabe, Randi E. Antony, Martin M. TI Psychometric Evaluation of the Factor Structure of the Teasing Questionnaire - Revised (TQ-R) SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT LA English DT Article DE Teasing questionnaire-revised; TQ-R; Psychometrics; Factor analyses; Anxiety ID ANXIETY; ADULTS AB Recent literature has focused on the relation between childhood teasing and adulthood psychopathology, with the majority of this work dependent on a single measure, the Teasing Questionnaire-Revised (TQ-R; Storch et al. Journal of Anxiety Disorders 18:681-694, 2004). However, the factor structure and reliability of the TQ-R requires further examination. The present investigation reevaluated the factor structure of the TQ-R in two large samples. In Study 1, three previous factor models were investigated through confirmatory factor analyses (CFAs) in a large clinical sample. Due to their poor fit, exploratory factor analyses (EFAs) were used to investigate alternative factor models. In Study 2, the factor structure of the previous models and new models from Study 1 EFAs were investigated through CFAs and estimates of internal consistency in a large college sample. Together, these findings provided the most support for a new 21-item five factor model, identified in the Study 1 EFAs and supported by the Study 2 CFAs, with the content of the teasing subscales consistent with the constructs of anxiety, appearance, academics, weight, and height. C1 [Gros, Daniel F.] Ralph H Johnson VAMC, Mental Hlth Serv 116, Charleston, SC 29401 USA. [Gros, Daniel F.; Gros, Kirstin Stauffacher] Med Univ S Carolina, Charleston, SC 29425 USA. [McCabe, Randi E.] St Josephs Healthcare, Anxiety Treatment & Res Ctr, Hamilton, ON, Canada. [McCabe, Randi E.] McMaster Univ, Hamilton, ON, Canada. [Antony, Martin M.] Ryerson Univ, Toronto, ON, Canada. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu NR 20 TC 1 Z9 1 U1 1 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0882-2689 J9 J PSYCHOPATHOL BEHAV JI J. Psychopathol. Behav. Assess. PD DEC PY 2012 VL 34 IS 4 BP 542 EP 551 DI 10.1007/s10862-012-9301-x PG 10 WC Psychology, Clinical SC Psychology GA 035OU UT WOS:000310957600013 ER PT J AU Chong, W Li, YQ Liu, BL Zhao, T Fukudome, EY Liu, ZC Smith, WM Velmahos, GC deMoya, MA Alam, HB AF Chong, Wei Li, Yongqing Liu, Baoling Zhao, Ting Fukudome, Eugene Y. Liu, Zhengcai Smith, William M. Velmahos, George C. deMoya, Marc A. Alam, Hasan B. TI Histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates Toll-like receptor 4 signaling in lipopolysaccharide-stimulated mouse macrophages SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Suberoylanilide hydroxamic acid; Lipopolysaccharide; Toll-like receptor 4; HSP90; Macrophages; Inflammation; Immune response; Acetylation ID GLUCOCORTICOID-RECEPTOR; CHAPERONE MACHINERY; SEPTIC SHOCK; KINASE; HSP90; LPS; TLR4; MICE; ACTIVATION; ENDOTOXIN AB Objective: We have previously demonstrated that pretreatment and posttreatment of animals with suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, can improve survival in a mouse model of lipopolysaccharide (LPS)-induced severe shock. This study was designed to assess whether SAHA affects LPS/Toll-like receptor 4 signaling through acetylation of heat shock protein 90 (HSP90) and degradation of its client protein interleukin-1 receptor-associated kinase 1 (IRAK1). Methods: RAW264.7 cells were exposed to LPS (1 mu g/mL) for 2 h, followed by treatment with SAHA (10 mu M) or geldanamycin (3 mu M), an inhibitor of HSP90. Sham (no SAHA, no LPS) macrophages served as a control. The cells were harvested at different time points, and time zero served as the reference point. Results: LPS dramatically increased protein expression of myeloid differentiation factor 88 and IRAK1, and stimulated nuclear translocation of nuclear factor kappa B, leading to an increases of gene expression and protein production of tumor necrosis factor alpha and interleukin-6. Treatment with SAHA significantly attenuated these LPS-stimulated alterations. LPS or SAHA did not change the levels of HSP90 protein, but immunoprecipitation studies demonstrated that SAHA treatment enhanced acetylation of HSP90, and increased the dissociation of IRAK1, compared to the LPS control. Conclusions: SAHA suppresses LPS/Toll-like receptor 4 signaling in LPS-stimulated macrophages through multiple potential mechanisms. It inhibits the function of HSP90 through hyperacetylation of the chaperone protein, which results in dissociation and degradation of the client protein IRAK1 and, at least in part, leads to a decrease in nuclear translocation of nuclear factor kappa B and attenuation of key proinflammatory cytokine expression. (C) 2012 Elsevier Inc. All rights reserved. C1 [Chong, Wei; Li, Yongqing; Liu, Baoling; Zhao, Ting; Fukudome, Eugene Y.; Liu, Zhengcai; Smith, William M.; Velmahos, George C.; deMoya, Marc A.; Alam, Hasan B.] Harvard Univ, Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Sch Med,Dept Surg, Boston, MA 02114 USA. [Chong, Wei] China Med Univ, Hosp 1, Emergency Dept, Shenyang, Peoples R China. [Liu, Zhengcai] Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian 710032, Peoples R China. RP Li, YQ (reprint author), Harvard Univ, Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Sch Med,Dept Surg, 165 Cambridge St,Suite 810, Boston, MA 02114 USA. EM yli2@partners.org FU NIH [RO1 GM084127] FX This work was funded by a grant from NIH RO1 GM084127 to H. B. A. (senior author). NR 37 TC 17 Z9 18 U1 2 U2 12 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD DEC PY 2012 VL 178 IS 2 BP 851 EP 859 DI 10.1016/j.jss.2012.07.023 PG 9 WC Surgery SC Surgery GA 037GR UT WOS:000311090700052 PM 22868051 ER PT J AU Fallon, EM Nehra, D Carlson, SJ Potemkin, AK Mitchell, PD Nedder, AP Rueda, BR Puder, M AF Fallon, Erica M. Nehra, Deepika Carlson, Sarah J. Potemkin, Alexis K. Mitchell, Paul D. Nedder, Arthur P. Rueda, Bo R. Puder, Mark TI Sunitinib reduces recurrent pelvic adhesions in a rabbit model SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Adhesion; Recurrent; Uterine abrasions; Adhesiolysis; Postoperative; Sunitinib; Rabbit model ID CLINICAL-SIGNIFICANCE; SURGERY; READMISSIONS; LAPAROSCOPY; INFERTILITY; PREVENTION; LAPAROTOMY; ETIOLOGY AB Background: Adhesions represent a major problem after abdominal and pelvic procedures. The purpose of the present study was to determine the effect of sunitinib (Sutent, SU11248), a Food and Drug Administration-approved receptor tyrosine kinase inhibitor, on recurrent pelvic adhesion formation after pelvic adhesiolysis in a rabbit model. Materials and methods: A total of 20 New Zealand white rabbits underwent a uterine abrasion procedure, followed by an adhesiolysis procedure 4 weeks later. Before adhesiolysis, the rabbits were randomized to sunitinib at 10 mg/kg/d or placebo. These were administered as 1 dose preoperatively followed by 10 doses postoperatively. The rabbits were killed 30 d after the adhesiolysis procedure. At death, the adhesions were scored, and a total adhesion score (presented as the median and interquartile range [IQR]) was calculated according to the percentage of uterine involvement and the tenacity of the adhesions. Results: All the rabbits survived the operative procedures without complications. The sunitinib-treated rabbits (n = 10) had a significantly lower uterine involvement score (median 2.0, IQR 1.0-3.0) than the placebo-treated rabbits (median 4.0, IQR 3.0-4.0; P = 0.02). The sunitinib-treated rabbits also had median tenacity score of 3.0 (IQR 3.0-4.0) compared with a median of 4.0 (IQR 4.0-4.0; P = 0.04) in the placebo-treated rabbits (n 10). The median total score in the sunitinib-treated rabbits was 5.0 (IQR 4.0-6.25) compared with 8.0 (IQR 6.75, 8.0) in the placebo-treated rabbits (P = 0.01). Conclusions: Sunitinib treatment might be an efficacious strategy to reduce recurrent adhesion formation after pelvic procedures. (C) 2012 Elsevier Inc. All rights reserved. C1 [Fallon, Erica M.; Nehra, Deepika; Carlson, Sarah J.; Potemkin, Alexis K.; Puder, Mark] Boston Childrens Hosp, Dept Surg, Boston, MA 02115 USA. [Fallon, Erica M.; Nehra, Deepika; Carlson, Sarah J.; Potemkin, Alexis K.; Puder, Mark] Boston Childrens Hosp, Vasc Biol Program, Boston, MA 02115 USA. [Fallon, Erica M.; Nehra, Deepika; Carlson, Sarah J.; Potemkin, Alexis K.; Mitchell, Paul D.; Nedder, Arthur P.; Rueda, Bo R.; Puder, Mark] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Mitchell, Paul D.] Boston Childrens Hosp, Clin Res Ctr, Boston, MA 02115 USA. [Rueda, Bo R.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Vincent Ctr Reprod Biol, Boston, MA 02114 USA. RP Puder, M (reprint author), Boston Childrens Hosp, Dept Surg, 300 Longwood Ave,Fegan 3, Boston, MA 02115 USA. EM mark.puder@childrens.harvard.edu FU Children's Hospital Surgical Foundation; Vascular Biology Program within Boston Children's Hospital; Joshua Ryan Rappaport Fellowship; National Institutes of Health [T32DK007754-12]; Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital FX This work was funded by the Children's Hospital Surgical Foundation and the Vascular Biology Program within Boston Children's Hospital (E. M. F., D.N., S.J.C., A. K. P., M. P.), the Joshua Ryan Rappaport Fellowship (E. M. F.), the National Institutes of Health grant T32DK007754-12 (D.N.), and the Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital (B. R. R.). A patent application for the use of sunitinib in the prevention of adhesions has been submitted by Boston Children's Hospital on behalf of Dr Mark Puder. All the authors would like to thank the entire veterinary staff at the large animal facility and the chemotherapy pharmacy at Boston Children's Hospital for their invaluable assistance with the present study. NR 19 TC 2 Z9 2 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 J9 J SURG RES JI J. Surg. Res. PD DEC PY 2012 VL 178 IS 2 BP 860 EP 865 DI 10.1016/j.jss.2012.07.038 PG 6 WC Surgery SC Surgery GA 037GR UT WOS:000311090700053 PM 22884447 ER PT J AU Suri, RM Michelena, HI Burkhart, HM Greason, KL Daly, RC Dearani, JA Park, SJ Joyce, LD Stulak, JM Sundt, TM Li, Z Schaff, HV AF Suri, Rakesh M. Michelena, Hector I. Burkhart, Harold M. Greason, Kevin L. Daly, Richard C. Dearani, Joseph A. Park, Soon J. Joyce, Lyle D. Stulak, John M. Sundt, Thoralf M., III Li, Zhuo Schaff, Hartzell V. TI A prospective, randomized comparison of 3 contemporary bioprosthetic aortic valves: Should hemodynamic performance influence device selection? SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article ID PROSTHESIS-PATIENT MISMATCH; LONG-TERM SURVIVAL; LEFT-VENTRICULAR DYSFUNCTION; EJECTION FRACTION; DOPPLER-ECHOCARDIOGRAPHY; STANDARDS COMMITTEE; AMERICAN-SOCIETY; MASS REGRESSION; TASK-FORCE; HANCOCK II AB Objective: Latest generation biologic aortic valve prostheses were designed to improve hemodynamic performance. We sought to determine whether there are clinically important early differences among these devices. Methods: Three hundred adults with severe aortic valve stenosis undergoing aortic valve replacement were randomized to receive the Edwards Magna, Sorin Mitroflow, or St. Jude Epic bioprostheses (n = 100, n = 101, n = 99, respectively). Early hemodynamic performance was studied by echocardiography. Results: Mean patient age was 76 +/- 8 years and there were 203 men (68%). There were no significant differences in baseline characteristics among implant groups. Early mortality was 1.7%, and there were no differences in early adverse events. Postoperative echocardiography showed small but statistically significant differences overall between the Magna, Mitroflow, and Epic valves in mean gradient (14.2 mm Hg, 16.3 mm Hg, 16.5 mm Hg, respectively; P = .011), aortic valve area (2.05 cm(2), 1.88 cm(2), 1.86 cm(2), respectively; P = .012), and indexed aortic valve area (1.05 cm(2)/m(2), 0.97 cm(2)/m(2), 0.95 cm(2)/m(2), respectively; P = .012). Prosthetic performance was similar among all with a small (<= 21 mm) aortic annulus. Patients who received the Magna device with a 23-mm annulus had slightly greater indexed aortic valve area; those with >23 mm had a slightly lower transprosthetic gradient. Analogous trends were found when data were stratified by either commercial implant size or echocardiography-determined aortic annulus size. Severe patient-prosthesis mismatch was infrequent overall and was similarly low among devices (P value not significant). Conclusions: This prospective, randomized comparison reveals that there are small but consistent early postoperative hemodynamic differences among current third-generation porcine and pericardial aortic valve prostheses. The 3 valves studied performed equally well in patients with a small (<= 21 mm) aortic annulus. The Magna valve had a slightly lower mean gradient in those with larger annular size (>23 mm). Longitudinal follow-up of these randomized cohorts is essential to determine late clinical implications of these early postoperative findings. (J Thorac Cardiovasc Surg 2012; 144:1387-98) C1 [Suri, Rakesh M.; Burkhart, Harold M.; Greason, Kevin L.; Daly, Richard C.; Dearani, Joseph A.; Park, Soon J.; Joyce, Lyle D.; Stulak, John M.; Schaff, Hartzell V.] Mayo Clin, Div Cardiovasc Surg, Rochester, MN 55905 USA. [Michelena, Hector I.] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA. [Li, Zhuo] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA. [Sundt, Thoralf M., III] Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA. RP Suri, RM (reprint author), Mayo Clin, Div Cardiovasc Surg, 200 1st St SW, Rochester, MN 55905 USA. EM suri.rakesh@mayo.edu OI Schaff, Hartzell/0000-0003-0994-027X NR 45 TC 16 Z9 16 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD DEC PY 2012 VL 144 IS 6 BP 1387 EP 1398 DI 10.1016/j.jtcvs.2012.07.105 PG 12 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 037FC UT WOS:000311086600020 PM 23140964 ER PT J AU Al-Aly, Z Balasubramanian, S McDonald, JR Scherrer, JF O'Hare, AM AF Al-Aly, Ziyad Balasubramanian, Sumitra McDonald, Jay R. Scherrer, Jeffrey F. O'Hare, Ann M. TI Greater variability in kidney function is associated with an increased risk of death SO KIDNEY INTERNATIONAL LA English DT Article DE acute kidney injury; chronic kidney disease; eGFR slope; longitudinal data; mortality risk; variability ID GLOMERULAR-FILTRATION-RATE; HEMOGLOBIN VARIABILITY; FUNCTION DECLINE; MORTALITY RISK; ADMINISTRATIVE DATABASES; SERUM CREATININE; RENAL-DISEASE; OUTCOMES; CARE; CONSEQUENCES AB Intra-individual variability in kidney function is a common phenomenon; however, predictors of kidney function variability and its prognostic significance are not known. To examine this question, we assembled a cohort of 51,304 US veterans with an estimated glomerular filtration rate (eGFR) <60 ml/min at the end of the study period and who had at least two eGFR measurements during the previous 3 years. Variability in kidney function was defined for each patient as the coefficient of variation of the regression line fitted to all outpatient measures of eGFR during this time frame. In adjusted analyses, blacks, women, and those with Current Procedural Terminology and ICD-9-CM diagnostic codes for hypertension, diabetes, cardiovascular disease, peripheral artery disease, chronic lung disease, hepatitis C, dementia, acute kidney injury, and those with a greater number of hospitalizations had greater variability in eGFR. After a median follow-up of 4.9 years, there were 23.66%, 25.68%, and 31.23% deaths among patients in the lowest, intermediate, and highest tertiles of eGFR variability, respectively. Compared with the referent (those in the lowest tertile), patients in the highest tertile had a significantly increased risk of death with a hazard ratio of 1.34 (1.28-1.40), an association consistently present in all sensitivity analyses. Thus, our results demonstrate that greater variability in kidney function is independently associated with increased risk of death. Kidney International (2012) 82, 1208-1214; doi:10.1038/ki.2012.276; published online 1 August 2012 C1 [Al-Aly, Ziyad] St Louis Vet Affairs Med Ctr, Dept Med, Div Nephrol, St Louis, MO 63106 USA. [Al-Aly, Ziyad; Balasubramanian, Sumitra; McDonald, Jay R.; Scherrer, Jeffrey F.] St Louis Vet Affairs Clin Res & Epidemiol Ctr, St Louis, MO USA. [McDonald, Jay R.] Washington Univ, Sch Med, Dept Med, Div Infect Dis, St Louis, MO 63110 USA. [Scherrer, Jeffrey F.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. [O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Div Nephrol, Dept Med, Seattle, WA USA. [O'Hare, Ann M.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. RP Al-Aly, Z (reprint author), St Louis Vet Affairs Med Ctr, Dept Med, Div Nephrol, 915 N Grand Blvd,111B-JC, St Louis, MO 63106 USA. EM zalaly@gmail.com RI Al-Aly, Ziyad/S-4439-2016 OI Al-Aly, Ziyad/0000-0002-2600-0434 FU Department of Veterans Affairs VISN 15 Career Development Award FX This work was funded by a Department of Veterans Affairs VISN 15 Career Development Award to ZA-A. NR 54 TC 18 Z9 18 U1 1 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD DEC PY 2012 VL 82 IS 11 BP 1208 EP 1214 DI 10.1038/ki.2012.276 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 038DV UT WOS:000311156300010 PM 22854642 ER PT J AU Zarjou, A Guo, LL Sanders, PW Mannon, RB Agarwal, A George, JF AF Zarjou, Abolfazl Guo, Lingling Sanders, Paul W. Mannon, Roslyn B. Agarwal, Anupam George, James F. TI A reproducible mouse model of chronic allograft nephropathy with vasculopathy SO KIDNEY INTERNATIONAL LA English DT Article DE arteriosclerosis; renal transplantation; transplant pathology; vascular disease ID IMPROVED RENAL-FUNCTION; KIDNEY ALLOGRAFTS; INTIMAL ARTERITIS; TRANSPLANTATION; REJECTION; EXPRESSION AB Although short-term outcomes in kidney transplantation have improved dramatically, long-term survival remains a major challenge. A key component of long-term, chronic allograft injury in solid organ transplants is arteriosclerosis characterized by vascular neointimal hyperplasia and inflammation. Establishing a model of this disorder would provide a unique tool not only to identify mechanisms of disease but also to test potential therapeutics for late graft injury. To this end, we utilized a mouse orthotopic renal transplant model in which C57BL/6J (H-2b) recipients were given either a kidney allograft from a completely mismatched Balb/cJ mouse (H-2d) or an isograft from a littermate. A unilateral nephrectomy was performed at the time of transplant followed by a contralateral nephrectomy on post-transplant day 7. Recipients were treated with daily cyclosporine subcutaneously for 14 days and then studied 8 and 12 weeks post transplantation. Renal function was significantly worse in allograft compared with isograft recipients. Moreover, the allografts had significantly more advanced tubulointerstitial fibrosis and profound vascular disease characterized by perivascular leukocytic infiltration and neointimal hyperplasia affecting the intrarenal blood vessels. Thus, we describe a feasible and reproducible murine model of intrarenal transplant arteriosclerosis that is useful to study allograft vasculopathy. Kidney International (2012) 82, 1231-1235; doi:10.1038/ki.2012.277; published online 8 August 2012 C1 [Agarwal, Anupam] Univ Alabama Birmingham, Div Nephrol, Dept Med, Birmingham, AL 35294 USA. [Zarjou, Abolfazl; Guo, Lingling; Sanders, Paul W.; Mannon, Roslyn B.; Agarwal, Anupam; George, James F.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Sanders, Paul W.; Agarwal, Anupam] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Agarwal, A (reprint author), Univ Alabama Birmingham, Div Nephrol, Dept Med, THT 647,1530 3rd Ave S, Birmingham, AL 35294 USA. EM agarwal@uab.edu; jgeorge@uab.edu OI Sanders, Paul/0000-0002-2915-5714 FU NIH [R01 DK59600, R01 DK75532, R01 DK046199]; UAB-UCSD O'Brien Center [P30 DK079337]; AHA [0655318B] FX This work was supported by NIH grants R01 DK59600 (AA), R01 DK75532 (AA), R01 DK046199 (PWS), the core resource of the UAB-UCSD O'Brien Center (P30 DK079337) (AA), and AHA grant 0655318B (JFG). NR 21 TC 6 Z9 8 U1 0 U2 3 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 J9 KIDNEY INT JI Kidney Int. PD DEC PY 2012 VL 82 IS 11 BP 1231 EP 1235 DI 10.1038/ki.2012.277 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 038DV UT WOS:000311156300013 PM 22874842 ER PT J AU Davids, MS Brown, JR AF Davids, Matthew S. Brown, Jennifer R. TI Targeting the B cell receptor pathway in chronic lymphocytic leukemia SO LEUKEMIA & LYMPHOMA LA English DT Review DE Lymphoid leukemia; signaling therapies; prognostication ID TYROSINE KINASE INHIBITOR; X-LINKED AGAMMAGLOBULINEMIA; THERAPEUTIC TARGET; MAMMALIAN TARGET; CLL CELLS; SUSTAINED ACTIVATION; ZAP-70 EXPRESSION; SURVIVAL SIGNALS; GENE-EXPRESSION; SYK AB The B cell receptor (BCR) pathway plays a crucial role in the survival, proliferation and trafficking of chronic lymphocytic leukemia (CLL) cells. Inhibitors of the key kinases in this pathway, including spleen tyrosine kinase (SYK), mammalian target of rapamycin (mTOR), phosphoinositide 3'-kinase (PI3K) and Bruton's tyrosine kinase (BTK), have been found in preclinical models to decrease CLL cell viability both directly and indirectly through modulation of the microenvironment. Recently, oral agents targeting each of these kinases have been explored in early phase clinical trials in patients with CLL. BCR pathway antagonists appear to be highly active in relapsed/refractory CLL, independent of high-risk disease markers such as del (17p). These agents have shown a unique pattern of inducing early transient lymphocytosis, which typically is associated with nodal response. Here, we review the biology of the BCR, the kinases within this pathway and their interaction with the CLL microenvironment. We also discuss data from recent and ongoing clinical trials of BCR antagonists. We address the development of potential biomarkers for response to these agents such as ZAP-70, IGHV status and CCL3, and discuss where these exciting new drugs may fit in the evolving landscape of CLL therapy. C1 [Davids, Matthew S.; Brown, Jennifer R.] Harvard Univ, Sch Med, CLL Ctr, Dana Farber Canc Inst, Boston, MA 02215 USA. RP Brown, JR (reprint author), Harvard Univ, Sch Med, CLL Ctr, Dana Farber Canc Inst, 450 Brookline Ave,M232, Boston, MA 02215 USA. EM Jennifer_Brown@dfci.harvard.edu FU NCI NIH HHS [T32 CA009172] NR 69 TC 38 Z9 39 U1 0 U2 16 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1042-8194 EI 1029-2403 J9 LEUKEMIA LYMPHOMA JI Leuk. Lymphoma PD DEC PY 2012 VL 53 IS 12 BP 2362 EP 2370 DI 10.3109/10428194.2012.695781 PG 9 WC Oncology; Hematology SC Oncology; Hematology GA 032IJ UT WOS:000310709000008 PM 22616724 ER PT J AU Steensma, DP AF Steensma, David P. TI Historical perspectives on myelodysplastic syndromes SO LEUKEMIA RESEARCH LA English DT Review DE Medical history; Myelodysplastic syndromes (MDS); Refractory anemia; Preleukemia; French-American-British Co-operative; Group; Disease classification ID PROGNOSTIC SCORING SYSTEM; FRENCH-AMERICAN-BRITISH; ACUTE MYELOID-LEUKEMIA; HYPERGRANULAR PROMYELOCYTIC LEUKEMIA; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; BONE-MARROW TRANSPLANTATION; INTERNATIONAL WORKING GROUP; WORLD-HEALTH-ORGANIZATION; PREDICTING SURVIVAL AB Although Georg Hegel quipped, "We learn from history that we do not learn from history", Aldous Hux-ley expressed a more nuanced view: "The charm of history and its enigmatic lesson consist in the fact that, from age to age, nothing changes and yet everything is completely different." In order to understand present-day positions and peculiarities in any field of human endeavor, familiarity with the past is essential. Those of us who study myelodysplastic syndromes (MDS) or care for patients diagnosed with these troublesome conditions may wonder also how the current state of affairs evolved with respect to our narrow area of focus, and how we know what we think we know now about these still-enigmatic bone marrow diseases. Here, I review a number of developments that collectively represent a brief "history of MDS." I first highlight a few landmark observations that preceded any concept of MDS by hundreds of years. Twentieth-century case descriptions and series with hypotheses about the etiology and nature of disorders described as "refractory anemia", "preleukemia", and with other terminology culminated in the efforts of the French-American-British (FAB) Co-operative Group of morphologists, whose landmark 1976 and 1982 papers provided the first widely-used classification of MDS. More recent developments in the MDS field include new mechanistic biological insights, regulatory approval of several somewhat-effective treatments, and improved organizational support and advocacy. The history of a disease concept like MDS, as for history in general, provides both inspiration and cautionary tales that can inform present and future work. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Steensma, David P.] Dana Farber Canc Inst, Adult Leukemia Program, Dept Med Oncol, Boston, MA 02115 USA. RP Steensma, DP (reprint author), Harvard Univ, Sch Med, 450 Brookline Ave,Suite D1B30,Mayer Bldg 1B21, Boston, MA 02215 USA. EM david_steensma@dfci.harvard.edu OI Steensma, David/0000-0001-5130-9284 NR 144 TC 8 Z9 8 U1 0 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2126 J9 LEUKEMIA RES JI Leuk. Res. PD DEC PY 2012 VL 36 IS 12 BP 1441 EP 1452 DI 10.1016/j.leukres.2012.08.007 PG 12 WC Oncology; Hematology SC Oncology; Hematology GA 031LR UT WOS:000310642500005 PM 22921019 ER PT J AU Chen, YX Bodhankar, S Murphy, SJ Vandenbark, AA Alkayed, NJ Offner, H AF Chen, Yingxin Bodhankar, Sheetal Murphy, Stephanie J. Vandenbark, Arthur A. Alkayed, Nabil J. Offner, Halina TI Intrastriatal B-cell administration limits infarct size after stroke in B-cell deficient mice SO METABOLIC BRAIN DISEASE LA English DT Article DE Regulatory B-cells; Experimental stroke; Intrastriatal transfer; mu MT-/- mice ID REGULATORY T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATORY RESPONSES; ISCHEMIC-STROKE; BRAIN ISCHEMIA; B10 CELLS; NEUROPROTECTION; LYMPHOCYTES AB Recent evidence emphasizes B-cells as a major regulatory cell type that plays an important role in limiting the pathogenic effects of ischemic stroke. The aim of the current study was to extend this initial observation to specifically examine the infiltration of regulatory B-cells and to determine if the effect of B-cells to limit the inflammatory response to cerebral ischemia is mediated by their action centrally or peripherally. Our data demonstrate the increased presence of a regulatory B-cell subset in the affected hemisphere of wild-type mice after middle cerebral artery occlusion (MCAO). We further explored the use of a novel method of stereotaxic cell delivery to bypass the blood brain barrier (BBB) and introduce CD19(+) B-cells directly into the striatum as compared to peripheral administration of B-cells. Infarct volumes after 60 minutes of MCAO and 48 hours of reperfusion were determined in B-cell deficient mu MT (-/-) mice with and without replacement of either B-cells or medium. Infarct size was significantly decreased in cerebral cortex after intrastriatal transfer of 100,000 B-cells to mu MT-/- mice vs. controls, with a comparable effect on infarct size as obtained by 50 million B-cells transferred intraperitoneally. These findings support the hypothesis that B-cells play a protective role against ischemic brain injury, and suggest that B-cells may serve as a novel therapeutic agent for modulating the immune response in central nervous system inflammation after stroke. C1 [Chen, Yingxin; Murphy, Stephanie J.; Alkayed, Nabil J.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA. [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Portland VA Med Ctr, Neuroimmunol Res R&D 31, Portland, OR 97239 USA. [Bodhankar, Sheetal; Vandenbark, Arthur A.; Offner, Halina] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Vandenbark, Arthur A.] Dept Vet Affairs Med Ctr, Res Serv, Portland, OR 97239 USA. [Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. RP Offner, H (reprint author), Portland VA Med Ctr, Neuroimmunol Res R&D 31, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM offnerva@ohsu.edu FU NIH [NS075887]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development FX The authors wish to thank Drs. Xuefang Ren, Wenri Zhang and Kozaburo Akiyoshi for assistance in some experiments, Ms. Eva Niehaus for assistance with manuscript preparation and Ms. Zefora Alderman for graphics. This work was supported by NIH grant NS075887. This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. NR 20 TC 16 Z9 16 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-7490 J9 METAB BRAIN DIS JI Metab. Brain Dis. PD DEC PY 2012 VL 27 IS 4 BP 487 EP 493 DI 10.1007/s11011-012-9317-7 PG 7 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA 040CT UT WOS:000311298300010 PM 22618587 ER PT J AU Shen, RR Zhou, AY Kim, E Lim, E Habelhah, H Hahn, WC AF Shen, Rhine R. Zhou, Alicia Y. Kim, Eejung Lim, Elgene Habelhah, Hasem Hahn, William C. TI I kappa B Kinase epsilon Phosphorylates TRAF2 To Promote Mammary Epithelial Cell Transformation SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID BREAST-CANCER ONCOGENE; TUMOR-SUPPRESSOR CYLD; IKK-EPSILON; DEUBIQUITINATING ENZYME; MOUSE MODEL; ACTIVATION; INFLAMMATION; MUTATIONS; COMPLEX; PROTEIN AB NF-kappa B transcription factors are central regulators of inflammation and when dysregulated contribute to malignant transformation. I kappa B kinase epsilon (IKK epsilon; IKKi, encoded by IKBKE) is a breast oncogene that is amplified in 30% of breast cancers and drives transformation in an NF-kappa B-dependent manner. Here we demonstrate that IKK epsilon interacts with and phosphorylates tumor necrosis factor receptor-associated factor 2 (TRAF2) at Ser11 in vitro and in vivo. This activity promotes Lys63-linked TRAF2 ubiquitination and NF-kappa B activation and is essential for IKK epsilon transformation. Breast cancer cells that depend on IKK epsilon expression for survival are also dependent on TRAF2. This work defines TRAF2 phosphorylation to be one key effector of IKK epsilon-induced mammary epithelial cell transformation. C1 [Shen, Rhine R.; Zhou, Alicia Y.; Kim, Eejung; Lim, Elgene; Hahn, William C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Hahn, William C.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA. [Shen, Rhine R.; Zhou, Alicia Y.; Kim, Eejung; Hahn, William C.] Broad Inst Harvard & MIT, Cambridge, MA USA. [Habelhah, Hasem] Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA 52242 USA. RP Hahn, WC (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. EM William_Hahn@dfci.harvard.edu FU Ruth L. Kirschstein National Research Service Award [F32 CA128265]; Aid for Cancer Research; [R01 CA130988] FX This work was supported in part by R01 CA130988 (to W. C. H.), Ruth L. Kirschstein National Research Service Award F32 CA128265 (to R. R. S.), and a grant from Aid for Cancer Research (to R.R.S.). NR 35 TC 15 Z9 16 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD DEC PY 2012 VL 32 IS 23 BP 4756 EP 4768 DI 10.1128/MCB.00468-12 PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 036LU UT WOS:000311028500002 PM 23007157 ER PT J AU Subrahmanyam, R Du, HS Ivanova, I Chakraborty, T Ji, YH Zhang, Y Alt, FW Schatz, DG Sen, RJ AF Subrahmanyam, Ramesh Du, Hansen Ivanova, Irina Chakraborty, Tirtha Ji, Yanhong Zhang, Yu Alt, Frederick W. Schatz, David G. Sen, Ranjan TI Localized epigenetic changes induced by D-H recombination restricts recombinase to DJ(H) junctions SO NATURE IMMUNOLOGY LA English DT Article ID CHAIN GENE LOCUS; V(D)J RECOMBINATION; V-H; PLANT HOMEODOMAIN; REARRANGEMENT; ACTIVATION; LYSINE-4; SEGMENTS; MICE; PAX5 AB Genes encoding immunoglobulin heavy chains (Igh) are assembled by rearrangement of variable (V-H), diversity (D-H) and joining (J(H)) gene segments. Three critical constraints govern V-H recombination. These include timing (V-H recombination follows D-H recombination), precision (V-H gene segments recombine only to DJ(H) junctions) and allele specificity (V-H recombination is restricted to DJ(H)-recombined alleles). Here we provide a model for these universal features of V-H recombination. Analyses of DJ(H)-recombined alleles showed that DJ(H) junctions were selectively epigenetically marked, became nuclease sensitive and bound RAG recombinase proteins, which thereby permitted D-H-associated recombination signal sequences to initiate the second step of Igh gene assembly. We propose that V-H recombination is precise, because these changes did not extend to germline D-H segments located 5' of the DJ(H) junction. C1 [Subrahmanyam, Ramesh; Du, Hansen; Ivanova, Irina; Chakraborty, Tirtha; Sen, Ranjan] NIA, US NIH, Lab Mol Biol & Immunol, Baltimore, MD 21224 USA. [Ji, Yanhong; Schatz, David G.] Yale Med Sch, Dept Immunobiol, Howard Hughes Med Inst, New Haven, CT USA. [Zhang, Yu; Alt, Frederick W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Zhang, Yu; Alt, Frederick W.] Harvard Univ, Sch Med, Howard Hughes Med Inst,Childrens Hosp, Immune Dis Inst, Boston, MA 02115 USA. RP Sen, RJ (reprint author), NIA, US NIH, Lab Mol Biol & Immunol, Baltimore, MD 21224 USA. EM senranja@grc.nia.nih.gov RI Subrahmanyam, Ramesh/K-5503-2012; Schatz, David/A-6748-2013 OI Schatz, David/0000-0002-5669-1176 FU Intramural Research Program of the National Institute on Aging (US National Institutes of Health) [AI20047, AI32524]; Howard Hughes Medical Institute FX Supported by the Intramural Research Program of the National Institute on Aging (US National Institutes of Health; AI20047 to F.W.A., and AI32524 to D.G.S.) and the Howard Hughes Medical Institute (F.W.A. and D.G.S.). NR 39 TC 17 Z9 17 U1 1 U2 11 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1529-2908 J9 NAT IMMUNOL JI Nat. Immunol. PD DEC PY 2012 VL 13 IS 12 BP 1205 EP + DI 10.1038/ni.2447 PG 9 WC Immunology SC Immunology GA 039BN UT WOS:000311217900014 PM 23104096 ER PT J AU Wang, SK Yuan, JL Guo, XJ Peng, P Gu, H Niu, SQ Fregni, F Chen, ACN Hu, WL AF Wang, Shuangkun Yuan, Junliang Guo, Xiaojuan Peng, Peng Gu, Hua Niu, Shiqin Fregni, Felipe Chen, Andrew C. N. Hu, Wenli TI Neurochemical correlates of cognitive dysfunction in patients with leukoaraiosis: a proton magnetic resonance spectroscopy study SO NEUROLOGICAL RESEARCH LA English DT Article DE Leukoaraiosis; Small vessel disease; Proton magnetic resonance spectroscopy; Cognitive function ID SMALL-VESSEL DISEASE; WHITE-MATTER HYPERINTENSITIES; ALZHEIMERS-DISEASE; NEUROPSYCHOLOGICAL BATTERY; MULTIPLE-SCLEROSIS; VASCULAR DEMENTIA; METABOLIC-CHANGES; MR SPECTROSCOPY; IMPAIRMENT; BRAIN AB Objectives: Leukoaraiosis (LA) is a common radiological finding in the elderly and may reflect cerebral small vessel disease (SVD). Although SVD has been identified as a major cause of vascular cognitive impairment or vascular dementia, the mechanisms for this association remain unclear. We therefore aimed to measure brain metabolites in LA using proton magnetic resonance spectroscopy (H-1-MRS) as to determine the relationship between cognitive function and neurochemical white matter profile. Methods: We recruited 23 patients with LA and 23 age-and sex-matched healthy controls consecutively. Multi-voxel H-1-MRS was performed with a volume of interest located in centrum semiovale that contained mainly white matter voxels. Three main ratios of N-acetyl aspartate (NAA)/Cr, choline (Cho)/Cr and NAA/Cho were obtained. Spearman rank correlation coefficients were calculated between the cognitive function and the measured metabolite ratios. Results: We found significantly lower levels of NAA/Cho and NAA/Cr ratios in lesioned white matter in patients with LA than healthy controls (P<0.05). The ratios of NAA/Cho and NAA/Cr in normal appearing white matter (NAWM) were higher than lesioned white matter and lower than controls, but this difference was not significant (P>0.05). There was a positive relationship between Mini-Mental State Examination (MMSE) and NAA/Cho in NAWM (r=0.417, P=0.048), and also a positive relationship between MMSE and NAA/Cr in lesioned white matter (r=0.551, P=0.006) in patients with LA. A positive relationship between the Z scores of the executive function and NAA/Cho in lesioned white matter (r=0.557, P=0.006) was also found. Conclusion: The main finding of this study was a significant reduction in the ratios of NAA/Cr and NAA/Cho in lesioned white matter, which indicates a marker of neuronal loss or dysfunction in patients with LA, which was correlated with cognitive function. This relationship between cognitive function and metabolic changes suggests that H-1-MRS can be explored as a marker for cognitive dysfunction in patients with LA. C1 [Yuan, Junliang; Niu, Shiqin; Hu, Wenli] Capital Med Univ, Beijing Chaoyang Hosp, Dept Neurol, Beijing 100020, Peoples R China. [Wang, Shuangkun; Guo, Xiaojuan; Peng, Peng; Gu, Hua] Capital Med Univ, Beijing Chaoyang Hosp, Dept Radiol, Beijing 100020, Peoples R China. [Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Lab Neuromodulat,Dept Phys Med & Rehabil, Boston, MA USA. [Fregni, Felipe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Chen, Andrew C. N.] Capital Med Univ, Ctr Higher Brain Funct, Beijing 100020, Peoples R China. RP Hu, WL (reprint author), Capital Med Univ, Beijing Chaoyang Hosp, Dept Neurol, Beijing 100020, Peoples R China. EM huwenli@sina.com NR 60 TC 3 Z9 3 U1 2 U2 7 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 0161-6412 J9 NEUROL RES JI Neurol. Res. PD DEC PY 2012 VL 34 IS 10 BP 989 EP 997 DI 10.1179/1743132812Y.0000000104 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 036ME UT WOS:000311029600013 PM 23146302 ER PT J AU Gamache, K Pitman, RK Nader, K AF Gamache, Karine Pitman, Roger K. Nader, Karim TI Preclinical Evaluation of Reconsolidation Blockade by Clonidine as a Potential Novel Treatment for Posttraumatic Stress Disorder SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE clonidine; memory; reconsolidation; fear conditioning; alpha 2-adrenoreceptor agonist; posttraumatic stress disorder ID FEAR MEMORY RECONSOLIDATION; ALPHA(2A)-ADRENERGIC RECEPTOR; GLUCOCORTICOID-RECEPTORS; CAMBODIAN PATIENTS; AMYGDALA; INHIBITION; SUBTYPE; PERFORMANCE; DISRUPTION; GUANFACINE AB Exposure to traumatic events can lead to posttraumatic stress disorder (PTSD). Current PTSD treatments typically only produce partial improvement. Hence, there is a need for preclinical research to identify new candidate drugs and to develop novel therapeutic approaches. Animal studies have indicated that fear memories can be weakened by blocking restabilization after retrieval, a process known as reconsolidation. Furthermore, evidence suggests that there are important alterations of the noradrenergic system in PTSD, and hence it may be of interest to study drugs that target this pathway. Here, we investigated the efficacy of clonidine, an alpha 2-adrenoreceptor agonist, to block reconsolidation in an animal model of persistent traumatic memories. Using an auditory fear conditioning paradigm in rats, we tested the efficacy of clonidine to weaken fear memory retention when administered systemically after retrieval. We evaluated dosage, number of treatments, and specificity in reconsolidation blockade. We found that postretrieval administration of clonidine disrupts fear-related memories in a dose-dependent manner and that two treatments are sufficient for maximal memory impairment. Furthermore, we determined that this effect is long lasting and specific to reconsolidation processes as shown by the selectivity to affect reactivated memories and the absence of spontaneous recovery and of postreactivation short-term memory impairment. Our results demonstrate the efficacy of systemic administration of clonidine following retrieval to persistently disrupt fear memory retention through reconsolidation blockade. This study provides important preclinical parameters for future therapeutic strategies involving clonidine to block reconsolidation as a novel treatment for PTSD symptoms. Neuropsychopharmacology (2012) 37, 2789-2796; doi:10.1038/npp.2012.145; published online 8 August 2012 C1 [Gamache, Karine; Nader, Karim] McGill Univ, Dept Psychol, Montreal, PQ H3A 1B1, Canada. [Pitman, Roger K.] Harvard Univ, Sch Med, Boston, MA USA. [Pitman, Roger K.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Gamache, K (reprint author), McGill Univ, Dept Psychol, 1205 Docteur Penfield Ave, Montreal, PQ H3A 1B1, Canada. EM karine.gamache@mcgill.ca FU USARAA [W81XWH-08-2-0126 (PT075809)] FX This work was supported by USARAA grant W81XWH-08-2-0126 (PT075809). NR 48 TC 22 Z9 23 U1 2 U2 13 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2012 VL 37 IS 13 BP 2789 EP 2796 DI 10.1038/npp.2012.145 PG 8 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 037GT UT WOS:000311090900006 PM 22871915 ER PT J AU Nierenberg, AA AF Nierenberg, Andrew A. TI Andrew C Leon Obituary SO NEUROPSYCHOPHARMACOLOGY LA English DT Biographical-Item C1 [Nierenberg, Andrew A.] Massachusetts Gen Hosp, Bipolar Clin, Boston, MA 02114 USA. [Nierenberg, Andrew A.] Massachusetts Gen Hosp, Res Program, Boston, MA 02114 USA. RP Nierenberg, AA (reprint author), Massachusetts Gen Hosp, Bipolar Clin, Boston, MA 02114 USA. EM anierenberg@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2012 VL 37 IS 13 BP 2890 EP 2890 DI 10.1038/npp.2012.201 PG 1 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 037GT UT WOS:000311090900023 ER PT J AU Haigentz, M Kim, M Sarta, C Lin, J Keresztes, RS Culliney, B Gaba, AG Smith, RV Shapiro, GI Chirieac, LR Mariadason, JM Belbin, TJ Greally, JM Wright, JJ Haddad, RI AF Haigentz, Missak, Jr. Kim, Mimi Sarta, Catherine Lin, Juan Keresztes, Roger S. Culliney, Bruce Gaba, Anu G. Smith, Richard V. Shapiro, Geoffrey I. Chirieac, Lucian R. Mariadason, John M. Belbin, Thomas J. Greally, John M. Wright, John J. Haddad, Robert I. TI Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer SO ORAL ONCOLOGY LA English DT Article DE Romidepsin; Head and neck cancer; Squamous cell carcinoma; Histone deacetylase (HDAC) inhibitors; Phase II trial ID SQUAMOUS-CELL CARCINOMA; SUBEROYLANILIDE HYDROXAMIC ACID; SOUTHWEST-ONCOLOGY-GROUP; DEPSIPEPTIDE FK228; PROSTATE-CANCER; METASTATIC HEAD; BREAST-CANCER; COLON-CANCER; OPEN-LABEL; RECURRENT AB Objectives: Patients with advanced squamous cell carcinoma of the head and neck (SCCHN) have limited treatment options. Inhibition of histone deacetylases (HDACs) represents a novel therapeutic approach warranting additional investigation in solid tumors. Methods: A phase II trial of single agent romidepsin, an HDAC inhibitor, was performed in 14 patients with SCCHN who provided consent for pre- and post-therapy samples of accessible tumor, blood and uninvolved oral mucosa. Romidepsin was administered at 13 mg/m(2) as a 4-h intravenous infusion on days 1, 8 and 15 of 28 day cycles, with response assessment by RECIST every 8 weeks. Results: Objective responses were not observed, although 2 heavily pretreated patients had brief clinical disease stabilization. Observed toxicities were expected, including frequent severe fatigue. Immunohistochemical analysis of 7 pre- and post-treatment tumor pairs demonstrated induction of p21(Waf1/Cip1) characteristic of HDAC inhibition, as well as decreased Ki67 staining. Exploratory microarray analyses of mucosal and tumor samples detected changes in gene expression following romidepsin treatment that were most commonly associated with regulation of transcription, cell cycle control, signal transduction, and electron transport. Treatment with romidepsin did not alter the extent of DNA methylation of candidate gene loci (including CDH1 and hMLH1) in SCCHN tumors. Conclusions: Single agent romidepsin has limited activity for the treatment of SCCHN but can effectively achieve tumor-associated HDAC inhibition. Although tolerability of romidepsin in this setting may be limiting, further evaluation of other HDAC inhibitors in combination with active therapies may be justified. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Haigentz, Missak, Jr.; Gaba, Anu G.; Mariadason, John M.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Oncol, Bronx, NY 10467 USA. [Haigentz, Missak, Jr.; Sarta, Catherine; Smith, Richard V.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Bronx, NY 10467 USA. [Kim, Mimi; Lin, Juan] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Div Biostat, Bronx, NY 10467 USA. [Keresztes, Roger S.] Weill Cornell Med Coll, Dept Med, Div Hematol & Med Oncol, New York, NY USA. [Culliney, Bruce] Beth Israel Deaconess Med Ctr, Dept Med, Div Oncol, New York, NY 10003 USA. [Shapiro, Geoffrey I.; Haddad, Robert I.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Shapiro, Geoffrey I.; Chirieac, Lucian R.; Haddad, Robert I.] Harvard Univ, Sch Med, Boston, MA USA. [Shapiro, Geoffrey I.; Haddad, Robert I.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Chirieac, Lucian R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Belbin, Thomas J.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA. [Greally, John M.] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10467 USA. [Wright, John J.] NCI, Invest Drug Branch, Canc Therapy Evaluat Program, Rockville, MD USA. RP Haigentz, M (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Oncol, 111 E 210th St,Hofheimer Room 100, Bronx, NY 10467 USA. EM mhaigent@montefiore.org RI Mariadason, John/N-2003-2013 FU American Society of Clinical Oncology Career Development Award; NIH [R21-CA110342, U01-CA062490, N01-CM-62204] FX This study was supported by the American Society of Clinical Oncology Career Development Award and NIH Grant R21-CA110342 (M. H.), U01-CA062490, and N01-CM-62204. NR 44 TC 19 Z9 19 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1368-8375 J9 ORAL ONCOL JI Oral Oncol. PD DEC PY 2012 VL 48 IS 12 BP 1281 EP 1288 DI 10.1016/j.oraloncology.2012.05.024 PG 8 WC Oncology; Dentistry, Oral Surgery & Medicine SC Oncology; Dentistry, Oral Surgery & Medicine GA 038BW UT WOS:000311151200014 PM 22748449 ER PT J AU Santos, F McCall, AA Chien, WD Merchant, S AF Santos, Felipe McCall, Andrew A. Chien, Wade Merchant, Saumil TI Otopathology in Osteogenesis Imperfecta SO OTOLOGY & NEUROTOLOGY LA English DT Article DE Hearing loss; Histopathology; Osteogenesis imperfect; Otosclerosis ID TEMPORAL BONE; HEARING-LOSS; OTOSCLEROSIS; HISTOPATHOLOGY; CONGENITA; COL1A2; TARDA AB Background: Osteogenesis Imperfecta (OI) is a genetic disorder of connective tissue matrix. OI is caused by mutations that affect type I collagen. The hearing loss in OI is characterized by onset in early adulthood and can be conductive, sensorineural, or mixed. Objectives: To describe the temporal bone histopathology in 9 individuals with OI. Materials and Methods: Four adult, 1 pediatric, and 4 infant specimens were identified. Temporal bones were removed at autopsy and studied using light microscopy. Results: All adults and 1 pediatric specimen showed otosclerotic lesions. The findings included examples of clinical, histologic, and cochlear otosclerosis. The temporal bones of infants showed delayed ossification of the endochondral layer of bone and of the ossicles. There were no infant specimens with otosclerotic lesions. Conclusion: Hearing loss in OI may be the result of clinical or cochlear otosclerosis. Fracture or atrophy of the ossicles may also be present in OI. A third unidentified mechanism of hearing loss may lead to cochlear degeneration. The described findings of otosclerotic lesions have implications for the observed heterogeneity of hearing loss patterns and for the surgical management of hearing loss in OI. C1 [Santos, Felipe; Merchant, Saumil] Harvard Univ, Sch Med, Dept Otol & Laryngol, Dept Otolaryngol,Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. [McCall, Andrew A.] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA USA. [Chien, Wade] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA. RP Santos, F (reprint author), Harvard Univ, Sch Med, Dept Otol & Laryngol, Dept Otolaryngol,Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. EM felipe_santos@meei.harvard.edu OI Santos, Felipe/0000-0002-3523-665X FU [NIDCD: IU24DC011943-01] FX This study was supported by NIDCD: IU24DC011943-01. NR 13 TC 6 Z9 6 U1 2 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1531-7129 J9 OTOL NEUROTOL JI Otol. Neurotol. PD DEC PY 2012 VL 33 IS 9 BP 1562 EP 1566 DI 10.1097/MAO.0b013e31826bf19b PG 5 WC Clinical Neurology; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 039AF UT WOS:000311214500023 PM 22996160 ER PT J AU Holzinger, ER Grady, B Ritchie, MD Ribaudo, HJ Acosta, EP Morse, GD Gulick, RM Robbins, GK Clifford, DB Daar, ES McLaren, P Haas, DW AF Holzinger, Emily R. Grady, Benjamin Ritchie, Marylyn D. Ribaudo, Heather J. Acosta, Edward P. Morse, Gene D. Gulick, Roy M. Robbins, Gregory K. Clifford, David B. Daar, Eric S. McLaren, Paul Haas, David W. TI Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants SO PHARMACOGENETICS AND GENOMICS LA English DT Article DE CYP2B6; efavirenz; HIV; pharmacogenomics; pharmacokinetics ID SEQUENTIAL 3-DRUG REGIMENS; HIV-INFECTED INDIVIDUALS; ANTIRETROVIRAL REGIMENS; INITIAL TREATMENT; POLYMORPHISMS; THERAPY; PHARMACOGENETICS; METABOLISM; CYP2B6-ASTERISK-6; EXPRESSION AB Objectives Prior candidate gene studies have associated CYP2B6 516G -> T [rs3745274] and 983T -> C [rs28399499] with increased plasma efavirenz exposure. We sought to identify novel variants associated with efavirenz pharmacokinetics. Materials and methods Antiretroviral therapy-naive AIDS Clinical Trials Group studies A5202, A5095, and ACTG 384 included plasma sampling for efavirenz pharmacokinetics. Log-transformed trough efavirenz concentrations (C-min) were previously estimated by population pharmacokinetic modeling. Stored DNA was genotyped with Illumina HumanHap 650Y or 1MDuo platforms, complemented by additional targeted genotyping of CYP2B6 and CYP2A6 with MassARRAY iPLEX Gold. Associations were identified by linear regression, which included principal component vectors to adjust for genetic ancestry. Results Among 856 individuals, CYP2B6 516G -> T was associated with efavirenz estimated C-min (P = 8.5 x 10(-41)). After adjusting for CYP2B6 516G -> T, CYP2B6 983T -> C was associated (P = 9.9 x 10(-11)). After adjusting for both CYP2B6 516G -> T and 983T -> C, a CYP2B6 variant (rs4803419) in intron 3 was associated (P = 4.4 x 10(-15)). After adjusting for all the three variants, non-CYP2B6 polymorphisms were associated at P-value less than 5 x 10(-8). In a separate cohort of 240 individuals, only the three CYP2B6 polymorphisms replicated. These three polymorphisms explained 34% of interindividual variability in efavirenz estimated C-min. The extensive metabolizer phenotype was best defined by the absence of all three polymorphisms. Conclusion Three CYP2B6 polymorphisms were independently associated with efavirenz estimated C-min at genome-wide significance, and explained one-third of interindividual variability. These data will inform continued efforts to translate pharmacogenomic knowledge into optimal efavirenz utilization. Pharmacogenetics and Genomics 22:858-867 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Holzinger, Emily R.; Grady, Benjamin; Haas, David W.] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37204 USA. [Haas, David W.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37204 USA. [Haas, David W.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37204 USA. [Haas, David W.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37204 USA. [Haas, David W.] Vanderbilt Univ, Sch Med, Dept Microbiol, Nashville, TN 37204 USA. [Haas, David W.] Vanderbilt Univ, Sch Med, Dept Immunol, Nashville, TN 37204 USA. [Ritchie, Marylyn D.] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA. [Ribaudo, Heather J.] Harvard Univ, Sch Publ Hlth, Stat Data Anal Ctr, Boston, MA 02138 USA. [Robbins, Gregory K.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Robbins, Gregory K.] Harvard Univ, Sch Med, Boston, MA USA. [McLaren, Paul] Harvard Univ, Broad Inst MIT & Harvard, Cambridge, MA 02138 USA. [Acosta, Edward P.] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL USA. [Morse, Gene D.] SUNY Buffalo, Sch Pharm & Pharmacal Sci, Buffalo, NY 14260 USA. [Gulick, Roy M.] Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA. [Clifford, David B.] Washington Univ, Dept Neurol, St Louis, MO USA. [Daar, Eric S.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Dept Med, Torrance, CA 90509 USA. RP Haas, DW (reprint author), Vanderbilt Univ, Sch Med, Ctr Human Genet Res, 1 Hundred Oaks,719 Thompson Lane,Ste 47183, Nashville, TN 37204 USA. EM david.haas@vanderbilt.edu RI Ritchie, Marylyn/C-1114-2012 FU AIDS Clinical Trials Group; National Institute of Allergy and Infectious Diseases [AI-068634, AI-038855, AI-54999, BRS-ACURE-06-00140-T001, AI-051966, AI-069419, UL1 RR-024996, AI-069472, AI-062435, AI-069439, TR-000011, AI-068636, AI-038858]; NIH National Institute of Allergy and Infectious Diseases (NIAID) [AI-069419, AI-069472, AI-069439, AI-069532, AI-069484, AI-069432, AI-069450, AI-069495, AI-069434, AI-069424, AI-069467, AI-069423, AI-069513, AI-069477, AI-069465, AI-069502, AI-069474, AI-069501, AI-069418, AI-069494, AI-069471, AI-069511, AI-069452]; NIH National Center for Research Resources (NCRR) [RR-000046, RR-000425, RR-025747, RR-025777, RR-025780, RR-024996, RR-024160, RR-023561, RR-024156]; Bristol-Myers Squibb; Abbott; Merck; Pfizer; ViiV; Gilead; Janssen; Gilead Sciences; Schering-Plough; The NIH National Institute of Allergy and Infectious Diseases (NIAID) [AI-038858, AI-069428, AI-069556, AI-069415, AI-032782, AI-046376, AI-046370, AI-034853, AI-027661, AI-025859, AI-069470, AI-027675, AI-073961, AI-050410, AI-045008, AI-050409, AI-072626, AI-069447, AI-027658, AI-027666, AI-058740, AI-025868] FX This work was supported in part by the AIDS Clinical Trials Group funded by the National Institute of Allergy and Infectious Diseases (AI-068636, AI-038858, AI-068634, and AI-038855). Grant support included AI-069439, TR-000011, and AI-54999 (D. W. H.), BRS-ACURE-06-00140-T001 (G. D. M.), AI-051966, AI-069419, and UL1 RR-024996 (R. M. G.), AI-069472 and AI-062435 (G. K. R.). Study drugs were provided by Bristol-Myers Squibb Company (Princeton, New Jersey, USA), Gilead Sciences (Gilead Sciences Inc., Foster City, California, USA), and GlaxoSmithKline Inc. (Research Triangle Park, North Carolina, USA).; Clinical Research Sites that participated in ACTG protocols ACTG 384, A5095, or A5202, and collected DNA under protocol A5128, were supported by the following grants from NIH National Institute of Allergy and Infectious Diseases (NIAID): AI-069532, AI-069484, AI-069432, AI-069450, AI-069495, AI-069434, AI-069424, AI-069439, AI-069467, AI-069423, AI-069513, AI-069477, AI-069465, AI-069419, AI-069502, AI-069474, AI-069472, AI-069501, AI-069418, AI-069494, AI-069471, AI-069511, AI-069452, AI-069428, AI-069556, AI-069415, AI-032782, AI-046376, AI-046370, AI-038858, AI-034853, AI-027661, AI-025859, AI-069470, AI-027675, AI-073961, AI-050410, AI-045008, AI-050409, AI-072626, AI-069447, AI-027658, AI-027666, AI-058740, and AI-025868, and by the following grants from NIH National Center for Research Resources (NCRR): RR-000046, RR-000425, RR-025747, RR-025777, RR-025780, RR-024996, RR-024160, RR-023561, RR-024156, RR-024160, and RR-024160.; Eric S. Daar: Research grants from Bristol-Myers Squibb, Abbott, Merck, Pfizer, ViiV, and Gilead and a consultant/advisor to Bristol-Myers Squibb, Merck, ViiV, and Gilead. Roy M. Gulick: Research Grants from Gilead, Janssen, Pfizer, and ViiV, ad-hoc consultant to Gilead, GlaxoSmithKline, Janssen, and Koronis. Gregory K. Robbins: Research support from Gilead Sciences and Schering-Plough. Received royalties from Wolters Kluwer. David B. Clifford: Serves on Data Safety Boards for Biogen, Millennium, Genzyme, Genentech, and Pfizer. He has been a consultant to Genentech, Genzyme, Bristol-Myers Squibb, Millennium, Biogen Idec, Janssen, and Pfizer. He has received research support from Biogen Idec, NeurogesX, Tibotec, and Pfizer. David W. Haas: Research grants from Bristol-Myers Squibb, Boehringer Ingelheim, Merck, and Gilead Sciences. For the remaining authors there are no conflicts of interest. NR 38 TC 47 Z9 48 U1 0 U2 12 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1744-6872 J9 PHARMACOGENET GENOM JI Pharmacogenet. Genomics PD DEC PY 2012 VL 22 IS 12 BP 858 EP 867 DI 10.1097/FPC.0b013e32835a450b PG 10 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy SC Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy GA 036NA UT WOS:000311031800004 PM 23080225 ER PT J AU Shields, RK Nguyen, MH Shullo, MA Silveira, FP Kwak, EJ Massih, RCA Toyoda, Y Bermudez, CA Bhama, JK Kormos, RL Clancy, CJ AF Shields, Ryan K. Nguyen, M. Hong Shullo, Michael A. Silveira, Fernanda P. Kwak, Eun J. Massih, Rima C. Abdel Toyoda, Yoshiya Bermudez, Christian A. Bhama, Jay K. Kormos, Robert L. Clancy, Cornelius J. TI Invasive aspergillosis among heart transplant recipients is rare but causes rapid death due to septic shock and multiple organ dysfunction syndrome SO SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Aspergillosis; septic shock; heart transplant ID PULMONARY ASPERGILLOSIS; CARDIAC TRANSPLANTATION; FUNGAL-INFECTIONS; EARLY-DIAGNOSIS; SEVERE SEPSIS; GALACTOMANNAN; PROPHYLAXIS; THERAPIES; RISK AB Between 2000 and 2011, proven or probable invasive aspergillosis (IA) was diagnosed in 1.7% (8/455) of heart transplant (HTx) recipients at our center, in the absence of antifungal prophylaxis. All patients had invasive pulmonary infections and 75% (6/8) were diagnosed during 2 separate 3-month periods. Cases were notable for their association with septic shock and multiple organ dysfunction syndrome (MODS) (75%, 6/8 each), non-specific clinical and radiographic findings, and rapid mortality despite mould-active antifungal therapy (88%, 7/8; occuring at a median 11 days after diagnosis). All patients had predisposing conditions known to be risk factors for IA. For patients with early IA (within 90 days of HTx), conditions included hemodialysis, thoracic re-operation, and the presence of another case in the institution within the preceding 3 months. For late-onset IA, conditions included hemodialysis and receipt of augmented immunosuppression. Clinicians should suspect IA in HTx recipients with risk factors who present with non-specific and unexplained respiratory syndromes, including those in septic shock and MODS, and institute prompt antifungal therapy without waiting for the results of cultures or other diagnostic tests. C1 [Shields, Ryan K.; Nguyen, M. Hong; Silveira, Fernanda P.; Kwak, Eun J.; Massih, Rima C. Abdel; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15261 USA. [Shullo, Michael A.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Toyoda, Yoshiya; Bermudez, Christian A.; Bhama, Jay K.; Kormos, Robert L.] Univ Pittsburgh, Dept Cardiothorac Surg, Pittsburgh, PA 15261 USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Nguyen, MH (reprint author), Univ Pittsburgh, Dept Med, 3550 Terrace St,Scaife Hall,Suite 871, Pittsburgh, PA 15261 USA. EM mhn5@pitt.edu FU NCATS NIH HHS [KL2 TR000146, KL2TR000146]; NCRR NIH HHS [KL2 RR024154, KL2RR024154] NR 21 TC 4 Z9 4 U1 0 U2 1 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0036-5548 J9 SCAND J INFECT DIS JI Scand. J. Infect. Dis. PD DEC PY 2012 VL 44 IS 12 BP 982 EP 986 DI 10.3109/00365548.2012.705018 PG 5 WC Infectious Diseases SC Infectious Diseases GA 037SW UT WOS:000311127800015 PM 22830948 ER PT J AU Jung, M AF Jung, Minsoo TI Sexual, Behavioral, and Social Characteristics of Female Sex Workers and Their Risk of Sexually Transmitted Infections: In South Korea SO SEXUALITY AND DISABILITY LA English DT Article DE Female sex workers; Sexual risk behavior; Sexual transmitted infection; Social support; South Korea ID HIV TRANSMISSION; DISEASES; CHINA; POPULATIONS; PREVENTION; PREVALENCE; BANGLADESH; SYPHILIS; HEALTH AB This study calculated the sexually transmitted infection (STI) prevalence rates among female sex workers (FSWs) in South Korea and elucidated the social and behavioral risk factors that affect FSW's infection with STIs. FSWs were recruited using a multistage cluster probability sampling method (N = 1,073). STI prevalence rates were 9.8 % for Treponema pallidum, 2.6 % for gonorrhea, and 12.5 % for Chlamydia. The risk probability of STI infection was higher for participants with fewer social relationships (OR = 0.99), more suicide attempt experiences (OR = 1.36), lower frequency of condom use (OR = 0.81), lower self-efficacy (OR = 0.78), and more irregular STI examination experiences (OR = 0.69). The STI prevalence rates of FSWs in South Korea were lower than those of FSWs in other Southeast Asian nations. While the direct factors for STI prevalence among this population were related to safe sex, indirect factors such as social support were also significant. Because this affects the self-efficacy of isolated individuals among sex workers, preventive interventions in STIs among FSWs must be expanded to the promotion of social support and mental health programs. C1 [Jung, Minsoo] Harvard Univ, Ctr Community Based Res, Dept Med Oncol, Dana Farber Canc Inst,Sch Publ Hlth, Boston, MA 02215 USA. [Jung, Minsoo] Korea Univ, Hlth Sci Res Inst, Seoul, South Korea. RP Jung, M (reprint author), Harvard Univ, Ctr Community Based Res, Dept Med Oncol, Dana Farber Canc Inst,Sch Publ Hlth, 450 Brookline Ave, Boston, MA 02215 USA. EM minsoo_jung@dfci.harvard.edu OI Jung, Minsoo/0000-0003-3317-6507 NR 30 TC 5 Z9 5 U1 0 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0146-1044 EI 1573-6717 J9 SEX DISABIL JI Sex. Disabil. PD DEC PY 2012 VL 30 IS 4 BP 421 EP 431 DI 10.1007/s11195-012-9261-9 PG 11 WC Rehabilitation SC Rehabilitation GA 035TL UT WOS:000310971900005 ER PT J AU Chang, BH Stein, NR Trevino, K Stewart, M Hendricks, A Skarf, LM AF Chang, Bei-Hung Stein, Nathan R. Trevino, Kelly Stewart, Max Hendricks, Ann Skarf, Lara M. TI Spiritual Needs and Spiritual Care for Veterans at End of Life and Their Families SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE spirituality; spiritual needs; spiritual care; care satisfaction; Veterans; palliative care; family caregivers ID QUALITY-OF-LIFE; PALLIATIVE CARE; CANCER-PATIENTS; ASSOCIATIONS; PERCEPTIONS; PROVIDERS; FAILURE AB Spiritual care is an important domain of palliative care programs across the country and in the Veterans Affairs (VA) Healthcare System specifically. This qualitative study assessed the spiritual needs, spiritual care received, and satisfaction with spiritual care of both Veterans at the end of life and their families. Seventeen Veterans and 9 family members participated. They expressed a wide range of spiritual needs, including a wish of Veterans to have a better understanding of traumatic events that occurred during their combat experience. Some Veterans reported military experience enhanced their spirituality. Generally, respondents reported satisfaction with VA spiritual care, but indicated that Veterans may benefit from greater access to VA chaplains and explicit discussion of the impact of their military experience on their spirituality. C1 [Chang, Bei-Hung; Stein, Nathan R.; Stewart, Max; Hendricks, Ann; Skarf, Lara M.] VA Boston Healthcare Syst, Boston, MA USA. [Chang, Bei-Hung] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Trevino, Kelly] Dana Farber Canc Inst, Boston, MA 02115 USA. [Trevino, Kelly] Harvard Univ, Sch Med, Boston, MA USA. RP Chang, BH (reprint author), 150 S Huntington Ave,152H, Boston, MA 02130 USA. EM bhchang@bu.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Services [PPO-10107] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Services: PPO-10107. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 23 TC 9 Z9 9 U1 1 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD DEC PY 2012 VL 29 IS 8 BP 610 EP 617 DI 10.1177/1049909111434139 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 033LM UT WOS:000310797900006 PM 22363038 ER PT J AU Shin, JT Ward, JE Collins, PA Dai, M Semigran, HL Semigran, MJ Seldin, DC AF Shin, Jordan T. Ward, Jennifer E. Collins, Patricia A. Dai, Matthew Semigran, Hannah L. Semigran, Marc J. Seldin, David C. TI Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report SO AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS LA English DT Article DE Amyloidosis; animal models; heart failure; zebrafish ID PRIMARY SYSTEMIC AMYLOIDOSIS; AL AMYLOIDOSIS; IN-VIVO; CARDIOMYOPATHY; DYSFUNCTION; MELPHALAN; FEATURES AB AL cardiomyopathy leading to heart failure (HF) represents a significant cause of morbidity and mortality in systemic amyloidosis. However, the paucity of robust in vivo models of AL-induced cardiac dysfunction has limited our ability to probe the mechanisms of AL heart disease. To address this problem, we have developed a model of AL HF in zebrafish embryos by injection of in vitro transcribed mRNA encoding amyloidogenic light chain (aLC) into fertilized oocytes. We demonstrate that expression of aLC causes cardiomyopathy in developing zebrafish without significantly impairing extracardiac development. The cardiac ventricle of embryos expressing aLC exhibit impaired contractility, smaller size, and increased myocardial thickness which result in congestion and edema, features paralleling the clinical manifestations of amyloid cardiomyopathy. Phosphorylated p38, a marker of oxidative stress, was increased in response to aLC expression. No evidence of amyloid fibril deposition was identified. Thus, expression of aLC mRNA in zebrafish results in cardio toxic effects without fibril deposition. This is consistent with prior evidence indicating that aLC oligomers mediate cardiac dysfunction in vitro. This model will allow exploration of amyloid pathophysiology and testing of interventions to reduce and reverse the deleterious effects of amyloidosis on myocardial function. C1 [Shin, Jordan T.; Collins, Patricia A.; Dai, Matthew; Semigran, Hannah L.; Semigran, Marc J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA. [Shin, Jordan T.; Collins, Patricia A.; Dai, Matthew; Semigran, Hannah L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr, Boston, MA USA. [Ward, Jennifer E.; Seldin, David C.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Ward, Jennifer E.; Seldin, David C.] Boston Univ, Sch Med, Amyloid Treatment & Res Program, Boston, MA 02118 USA. [Ward, Jennifer E.; Seldin, David C.] Boston Med Ctr, Boston, MA USA. RP Shin, JT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA. EM jshin1@partners.org OI Ward, Jennifer/0000-0003-0158-9091 FU National Institutes of Health [HL085280, 1RC1DK090696]; Wildflower Foundation FX This work is supported by grants from the National Institutes of Health [HL085280 to JTS and 1RC1DK090696 to DCS and JEW] and a grant from the Wildflower Foundation (DCS and JEW). The authors have no conflicts of interest. NR 23 TC 9 Z9 9 U1 0 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1350-6129 J9 AMYLOID JI Amyloid-J. Protein Fold. Disord. PD DEC PY 2012 VL 19 IS 4 BP 191 EP 196 DI 10.3109/13506129.2012.733741 PG 6 WC Biochemistry & Molecular Biology; Medicine, General & Internal; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; General & Internal Medicine; Research & Experimental Medicine GA 032GY UT WOS:000310704000006 PM 23126591 ER PT J AU Black, ME Hedgire, SS Camposano, S Paul, E Harisinghani, M Thiele, EA AF Black, M. E. Hedgire, S. S. Camposano, S. Paul, E. Harisinghani, M. Thiele, E. A. TI Hepatic manifestations of tuberous sclerosis complex: a genotypic and phenotypic analysis SO CLINICAL GENETICS LA English DT Article DE angiomyolipoma; cysts; hepatic masses; mTORC1; sirolimus; tuberous sclerosis ID MUTATIONAL ANALYSIS; ANGIOMYOLIPOMA; LYMPHANGIOLEIOMYOMATOSIS; HAMARTOMAS; TSC2 AB A retrospective review of the clinical records and radiological images of 205 patients with tuberous sclerosis complex (TSC) was performed to evaluate the prevalence and progression of hepatic lesions; examine the association of hepatic phenotype with genotype, age, and gender; and investigate the relationships between hepatic, renal, and pulmonary involvement. Hepatic angiomyolipomas (AML), cysts, and other benign lesions were identified in 30% of the cohort, and some lesions grew significantly over time. However, no patient had clinical symptoms or complications from hepatic lesions. TSC2 patients exhibited a higher frequency of AML compared to TSC1 patients (p = 0.037), and patients with no mutation identified exhibited a higher frequency of cysts compared to TSC2 patients (p = 0.023). Age was positively correlated with frequency of hepatic involvement (p < 0.001), whereas hepatic phenotype was independent of gender. Presence of hepatic AML was associated with presence of renal AML (p = 0.001). These findings confirm a high rate of asymptomatic hepatic lesions in TSC and further characterize the TSC phenotype. C1 [Black, M. E.; Camposano, S.; Thiele, E. A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Hedgire, S. S.; Harisinghani, M.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Paul, E.] Massachusetts Gen Hosp, Dept Pediat Nephrol, Boston, MA 02114 USA. RP Thiele, EA (reprint author), Herscot Ctr Tuberous Sclerosis Complex, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM ethiele@partners.org FU Herscot Center for Tuberous Sclerosis Complex; NIH/NINDS [P01 NS024279] FX This study was supported by the Herscot Center for Tuberous Sclerosis Complex and NIH/NINDS P01 NS024279. We thank Kevin Rader for assisting with the statistical analysis. NR 23 TC 4 Z9 5 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9163 EI 1399-0004 J9 CLIN GENET JI Clin. Genet. PD DEC PY 2012 VL 82 IS 6 BP 552 EP 557 DI 10.1111/j.1399-0004.2012.01845.x PG 6 WC Genetics & Heredity SC Genetics & Heredity GA 032ON UT WOS:000310728700010 PM 22251200 ER PT J AU Larson, AM Hedgire, SS Deshpande, V Stemmer-Rachamimov, AO Harisinghani, MG Ferrone, CR Shah, U Thiele, EA AF Larson, A. M. Hedgire, S. S. Deshpande, V. Stemmer-Rachamimov, A. O. Harisinghani, M. G. Ferrone, C. R. Shah, U. Thiele, E. A. TI Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex SO CLINICAL GENETICS LA English DT Article DE mTOR pathway; pancreatic endocrine neoplasm; pancreatic neuroendocrine tumor; TSC2 gene; tuberous sclerosis complex ID ENDOCRINE TUMORS; MTOR PATHWAY; SUGAR TUMOR; INSULINOMA; ASSOCIATION; NEOPLASMS; SURVIVAL; CELLS AB We explored pancreatic neuroendocrine tumors (PanNETs) associated with tuberous sclerosis complex (TSC) to determine their incidence in the TSC population; define their clinical, radiological, and pathological characteristics; and investigate their association with underlying genotypes. Retrospectively reviewed abdominal imaging of 219 patients with TSC, evaluating the incidence, size, and architecture of pancreatic lesions. Pathology records at Massachusetts General Hospital (MGH) were reviewed for all PanNET diagnoses in patients with TSC. Literature was reviewed for TSC-related PanNET cases. Nine patients with TSC were found to have a pancreatic lesion(s) on abdominal imaging and six patients have been diagnosed with a PanNET by pathology at MGH. Twelve cases of TSC-associated PanNETs have been reported in the literature. Of these 18 PanNET cases, one third were cystic, and the average age at resection was 26 years. Germline TSC2 mutations were found in all patients for whom genetic data were available (n = 3). We did not identify pancreatic angiomyolipomas in this series. Our results suggest that PanNETs are the most common pancreatic lesion in patients with TSC. Focal pancreatic mass lesions, solid or cystic, in patients with TSC should be considered possible PanNETs, and resection of the lesion may be clinically indicated. C1 [Thiele, E. A.] Massachusetts Gen Hosp, Herscot Ctr Tuberous Sclerosis Complex, Dept Neurol, Boston, MA 02114 USA. [Hedgire, S. S.; Harisinghani, M. G.] Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol, Boston, MA 02114 USA. [Deshpande, V.; Stemmer-Rachamimov, A. O.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Ferrone, C. R.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Shah, U.] MassGen Hosp Children, Hepatobiliary & Pancreat Program, Boston, MA USA. RP Thiele, EA (reprint author), Massachusetts Gen Hosp, Herscot Ctr Tuberous Sclerosis Complex, Dept Neurol, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM ethiele@partners.org FU Herscot Center for Tuberous Sclerosis Complex; NIH/NINDS [P01 NS024279] FX This study was approved and supported by the Herscot Center for Tuberous Sclerosis Complex, and NIH/NINDS P01 NS024279. Special thanks to Agnies van Eeghen, MD, and Susana Camposano, MD, for their help with language translations. NR 33 TC 12 Z9 12 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9163 J9 CLIN GENET JI Clin. Genet. PD DEC PY 2012 VL 82 IS 6 BP 558 EP 563 DI 10.1111/j.1399-0004.2011.01805.x PG 6 WC Genetics & Heredity SC Genetics & Heredity GA 032ON UT WOS:000310728700011 PM 22035404 ER PT J AU Yovel, I Gershuny, BS Steketee, G Buhlmann, U Fama, JM Mitchell, J Wilhelm, S AF Yovel, Iftah Gershuny, Beth S. Steketee, Gail Buhlmann, Ulrike Fama, Jeanne M. Mitchell, Janice Wilhelm, Sabine TI Idiosyncratic Severity Profiles of Obsessive Compulsive Dysfunction: A Detailed Self Report Assessment of a Multifaceted Syndrome SO COGNITIVE THERAPY AND RESEARCH LA English DT Article DE Obsessive-compulsive disorder; Severity profile; Assessment; Obsessions; Compulsions ID SYMPTOM DIMENSIONS; DISORDER; SCALE; INVENTORY; VALIDATION; RELIABILITY; INTERVIEW; VALIDITY; VERSION; OCD AB In this paper we present an assessment method designed to detect specific individual severity profiles of obsessive-compulsive areas of dysfunction. This method is based on the Obsessive Compulsive Symptoms Rating Scale (OCSRS; Wilhelm and Steketee 2006), a comprehensive self-report instrument that measures the severity of a wide variety of symptom categories associated with obsessive compulsive disorder (OCD). A total of 127 patients diagnosed with OCD completed the OCSRS and other measures of OCD, anxiety, and depression. Statistical analyses confirmed the convergent and discriminant validity of the OCSRS symptom categories, and indicated that each of these symptom clusters contains internally-consistent symptoms that can be meaningfully measured by a single severity score. Additional analyses demonstrated the clinical utility of this fine-grained severity assessment of OCD. The findings indicate that the severity profile of the OCSRS provides unique information that may be useful for a variety of research and clinical purposes. C1 [Yovel, Iftah] Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel. [Gershuny, Beth S.] Bard Coll, Annandale on Hudson, NY 12504 USA. [Steketee, Gail] Boston Univ, Boston, MA 02215 USA. [Buhlmann, Ulrike; Fama, Jeanne M.; Wilhelm, Sabine] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Buhlmann, Ulrike; Fama, Jeanne M.; Wilhelm, Sabine] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Mitchell, Janice] Wing Mem Hosp, Palmer, MA 01069 USA. RP Yovel, I (reprint author), Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel. EM yoveli@mscc.huji.ac.il; gershuny@bard.edu; steketee@bu.edu; ulrike.buhlmann@hu-berlin.de; jfama@partners.org; janice.mitchell@umassmemorial.org; wilhelm@psych.mgh.harvard.edu NR 47 TC 4 Z9 4 U1 1 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0147-5916 J9 COGNITIVE THER RES JI Cogn. Ther. Res. PD DEC PY 2012 VL 36 IS 6 BP 694 EP 713 DI 10.1007/s10608-011-9427-2 PG 20 WC Psychology, Clinical SC Psychology GA 032TJ UT WOS:000310741700011 ER PT J AU Gallagher, MW Resick, PA AF Gallagher, Matthew W. Resick, Patricia A. TI Mechanisms of Change in Cognitive Processing Therapy and Prolonged Exposure Therapy for PTSD: Preliminary Evidence for the Differential Effects of Hopelessness and Habituation SO COGNITIVE THERAPY AND RESEARCH LA English DT Article DE PTSD; Trauma; Mechanism; Mediation; Hopelessness; Habituation ID POSTTRAUMATIC-STRESS-DISORDER; SOCIAL SUPPORT; HOPE; STRATEGIES; VETERANS; MODELS; SCALE AB The present study examined two potential mechanisms of change, hopelessness cognitions and habituation, in a randomized controlled trial of cognitive processing therapy (CPT) and prolonged exposure therapy (PE) for posttraumatic stress disorder (PTSD). Participants were 171 adult women with a current primary diagnosis of sexual assault related PTSD. The potential mechanisms were examined by evaluating the intraindividual change in hopelessness within the course of both treatments and subjective units distress (SUDS) ratings (a proxy for habituation) within the course of PE. The effects of intraindividual change in the proposed mechanisms were then examined on within-treatment changes in PTSD symptoms. Findings indicated that the participants assigned to the CPT treatment had significantly greater pre-post reductions in hopelessness than those assigned to PE and that the changes in hopelessness predicted changes in PTSD symptoms (R-2 = .24). Intraindividual changes in SUDS ratings for participants in the PE treatment condition also predicted changes in PTSD symptoms and did so independently of the effect of changes in hopelessness. Future research should examine these mechanisms using more intensive methods of data collection that would permit the demonstration of temporality of change. C1 [Gallagher, Matthew W.; Resick, Patricia A.] Boston Univ, Natl Ctr PTSD, VA Boston Healthcare Syst, Boston, MA 02215 USA. RP Gallagher, MW (reprint author), Boston Univ, Ctr Anxiety & Related Disorders, 648 Beacon St,6th Floor, Boston, MA 02215 USA. EM mwg@bu.edu NR 26 TC 9 Z9 10 U1 4 U2 31 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0147-5916 J9 COGNITIVE THER RES JI Cogn. Ther. Res. PD DEC PY 2012 VL 36 IS 6 BP 750 EP 755 DI 10.1007/s10608-011-9423-6 PG 6 WC Psychology, Clinical SC Psychology GA 032TJ UT WOS:000310741700016 ER PT J AU Chou, J Ohsumi, TK Geha, RS AF Chou, Janet Ohsumi, Toshiro K. Geha, Raif S. TI Use of whole exome and genome sequencing in the identification of genetic causes of primary immunodeficiencies SO CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Review DE next-generation DNA sequencing; primary immunodeficiencies; whole exome sequencing; whole genome sequencing ID STRUCTURAL VARIATION; AUTOIMMUNITY; MUTATIONS; P85-ALPHA; TECHNOLOGIES; DEFICIENCY; DISCOVERY; SUBUNIT; CAPTURE; QUALITY AB Purpose of review This review discusses the strengths and challenges of using whole genome sequencing (WGS)/whole exome sequencing (WES) for identifying novel genetic causes of primary immunodeficiencies. Recent findings WGS permits comprehensive sequencing of introns and exons, whereas WES allows deeper sequencing of exonic regions at a lower cost. Due to the large number of genetic variants found in each genome, it is necessary to use filtering approaches to distinguish deleterious from benign variants. WES has been used successfully to identify novel genetic causes of primary immunodeficiency. Complex structural variations and non-Mendelian disorders remain challenges for WGS/WES. Summary WGS/WES is a powerful screening tool with great potential to identify genetic causes of primary immunodeficiencies for research and clinical applications. To use WGS/WES effectively, it is necessary to understand how to filter the sequencing data and to realize its limitations as well as its strengths. C1 [Chou, Janet; Geha, Raif S.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA. [Chou, Janet; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Ohsumi, Toshiro K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Ohsumi, Toshiro K.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. RP Geha, RS (reprint author), Boston Childrens Hosp, Div Immunol, Karp Bldg,10th Floor,1 Blackfan Circle, Boston, MA 02115 USA. EM raif.geha@childrens.harvard.edu FU NIH [AI-076210, AI-094017]; Perkin-Elmer Foundation; Dubai-Harvard Foundation for Medical Research; Jeffrey Modell Foundation FX This work was funded in part by NIH Grants AI-076210 (RSG) and AI-094017 (RSG), the Perkin-Elmer Foundation (RSG), the Dubai-Harvard Foundation for Medical Research (RSG), and the Jeffrey Modell Foundation (RSG). NR 48 TC 25 Z9 25 U1 1 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1528-4050 J9 CURR OPIN ALLERGY CL JI Curr. Opin. Allergy Clin. Immunol. PD DEC PY 2012 VL 12 IS 6 BP 623 EP 628 DI 10.1097/ACI.0b013e3283588ca6 PG 6 WC Allergy; Immunology SC Allergy; Immunology GA 029TY UT WOS:000310520100008 PM 23095910 ER PT J AU Kilbourne, AM Goodrich, DE O'Donnell, AN Miller, CJ AF Kilbourne, Amy M. Goodrich, David E. O'Donnell, Allison N. Miller, Christopher J. TI Integrating Bipolar Disorder Management in Primary Care SO CURRENT PSYCHIATRY REPORTS LA English DT Article DE Bipolar disorder; Mood disorder; Co-occurring conditions; Primary care; Integrated care; Collaborative care; Chronic Care Model; CCM; Screening; Diagnosis; Treatment; Access; Mental health services; Psychiatry ID TASK-FORCE RECOMMENDATIONS; ANXIETY TREATMENTS CANMAT; COMORBIDITY SURVEY REPLICATION; RANDOMIZED CONTROLLED-TRIAL; MAJOR DEPRESSIVE DISORDER; CANADIAN NETWORK; MOOD DISORDERS; SPECTRUM DISORDER; UNITED-STATES; INTERNATIONAL SOCIETY AB There is growing realization that persons with bipolar disorder may exclusively be seen in primary (general medical) care settings, notably because of limited access to mental health care and stigma in seeking mental health treatment. At least two clinical practice guidelines for bipolar disorder recommend collaborative chronic care models (CCMs) to help integrate mental health care to better manage this illness. CCMs, which include provider guideline support, self-management support, care management, and measurement-based care, are well-established in primary care settings, and may help primary care practitioners manage bipolar disorder. However, further research is required to adapt CCMs to support complexities in diagnosing persons with bipolar disorder, and integrate decision-making processes regarding medication safety and tolerability in primary care. Additional implementation studies are also needed to adapt CCMs for persons with bipolar disorder in primary care, especially those seen in smaller practices with limited infrastructure and access to mental health care. C1 [Kilbourne, Amy M.; Goodrich, David E.; O'Donnell, Allison N.] VA Ann Arbor Ctr Clin Management Res, Ann Arbor, MI 48105 USA. [Kilbourne, Amy M.; Goodrich, David E.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA. [Miller, Christopher J.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA. RP Kilbourne, AM (reprint author), VA Ann Arbor Ctr Clin Management Res, 2215 Fuller Rd,Mail Stop 152, Ann Arbor, MI 48105 USA. EM amykilbo@umich.edu OI Goodrich, David/0000-0003-3232-2189 FU Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development [CSRD S06]; VA Health Services Research and Development Center for Organization, Leadership, and Management Research (COLMR); National Institute of Mental Health [RO1 MH 79994, R01 74509]; University of Michigan Comprehensive Depression Center FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Clinical Sciences Research and Development [CSRD S06], the VA Health Services Research and Development Center for Organization, Leadership, and Management Research (COLMR), the National Institute of Mental Health [RO1 MH 79994 and R01 74509] and the University of Michigan Comprehensive Depression Center (Director's Innovation Fund). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 84 TC 8 Z9 9 U1 3 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD DEC PY 2012 VL 14 IS 6 BP 687 EP 695 DI 10.1007/s11920-012-0325-4 PG 9 WC Psychiatry SC Psychiatry GA 033WB UT WOS:000310831000012 PM 23001382 ER PT J AU Khalili, H Huang, ES Ananthakrishnan, AN Higuchi, L Richter, JM Fuchs, CS Chan, AT AF Khalili, Hamed Huang, Edward S. Ananthakrishnan, Ashwin N. Higuchi, Leslie Richter, James M. Fuchs, Charles S. Chan, Andrew T. TI Geographical variation and incidence of inflammatory bowel disease among US women SO GUT LA English DT Article ID AMBIENT AIR-POLLUTION; VITAMIN-D-RECEPTOR; CROHNS-DISEASE; ULCERATIVE-COLITIS; NURSES HEALTH; ASSOCIATION; PREVALENCE; SMOKING; NUMBER; RISK AB Objective Geographical variation in the incidence of Crohn's disease (CD) and ulcerative colitis (UC) according to the latitude of residence has been reported in Europe. However, there are no comparable data in the USA. The incidence of CD and UC in relation to latitude was assessed in a geographically diverse population of women enrolled in two large prospective studies in the USA. Design A prospective study was undertaken of women enrolled in the Nurses' Health Study I (NHS) in 1976 and in the NHS II in 1989. Information on state of residence at the time of birth, at age 15 years and age 30 years was collected in 1992 in NHS I and in 1993 in NHS II. Reported diagnoses of incident CD or UC to the end of 2003 were confirmed by medical record review. Cox proportional hazards models were used to calculate HRs and 95% CIs for risk of CD and UC. Results In both cohorts, among 175 912 women reporting their residence in 1992, 257 cases of CD and 313 cases of UC were documented over 3 428 376 person-years of follow-up. The incidence of CD and UC increased significantly with increasing latitude (p(trend)<0.01), with residence at age 30 years more strongly associated with risk. Compared with women residing in northern latitudes at age 30, the multivariate-adjusted HR for women residing in southern latitudes was 0.48 (95% CI 0.30 to 0.77) for CD and 0.62 (95% CI 0.42 to 0.90) for UC. The effect of latitude of residence on risk of CD and UC did not vary according to smoking history (p(interaction)=0.26 for CD and 0.99 for UC). Conclusion In a population of US women, increasing latitude of residence was associated with a higher incidence of CD and UC. C1 [Khalili, Hamed; Huang, Edward S.; Ananthakrishnan, Ashwin N.; Richter, James M.; Chan, Andrew T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gastroenterol,Gastrointestinal Unit, Boston, MA 02114 USA. [Higuchi, Leslie] Childrens Hosp, Div Gastroenterol, Boston, MA 02115 USA. [Fuchs, Charles S.] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA. [Fuchs, Charles S.; Chan, Andrew T.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA. RP Chan, AT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gastroenterol,Gastrointestinal Unit, 55 Fruit St,GRJ-728A, Boston, MA 02114 USA. EM achan@partners.org FU National Institute of Health [R01 CA137178, P01 CA55075, P01 CA87969, DK043351]; Broad Medical Research Program of The Broad Foundation; IBD Working Group; Crohn's and Colitis Foundation of America; American Gastroenterological Association FX Funded by National Institute of Health R01 CA137178, P01 CA55075, P01 CA87969, DK043351, and the Broad Medical Research Program of The Broad Foundation. ATC is a Damon Runyon Cancer Research Foundation Clinical Investigator. HK is supported by a career development award from the IBD Working Group and the Crohn's and Colitis Foundation of America. ANA is supported by a career development award from the American Gastroenterological Association. NR 26 TC 69 Z9 71 U1 1 U2 11 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 J9 GUT JI Gut PD DEC PY 2012 VL 61 IS 12 BP 1686 EP 1692 DI 10.1136/gutjnl-2011-301574 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 035DB UT WOS:000310922000007 PM 22241842 ER PT J AU Ramos, EM Latourelle, JC Lee, JH Gillis, T Mysore, JS Squitieri, F Di Pardo, A Di Donato, S Hayden, MR Morrison, PJ Nance, M Ross, CA Margolis, RL Gomez-Tortosa, E Ayuso, C Suchowersky, O Trent, RJ McCusker, E Novelletto, A Frontali, M Jones, R Ashizawa, T Frank, S Saint-Hilaire, MH Hersch, SM Rosas, HD Lucente, D Harrison, MB Zanko, A Marder, K Gusella, JF Lee, JM Alonso, I Sequeiros, J Myers, RH MacDonald, ME AF Ramos, Eliana Marisa Latourelle, Jeanne C. Lee, Ji-Hyun Gillis, Tammy Mysore, Jayalakshmi S. Squitieri, Ferdinando Di Pardo, Alba Di Donato, Stefano Hayden, Michael R. Morrison, Patrick J. Nance, Martha Ross, Christopher A. Margolis, Russell L. Gomez-Tortosa, Estrella Ayuso, Carmen Suchowersky, Oksana Trent, Ronald J. McCusker, Elizabeth Novelletto, Andrea Frontali, Marina Jones, Randi Ashizawa, Tetsuo Frank, Samuel Saint-Hilaire, Marie-Helene Hersch, Steven M. Rosas, Herminia D. Lucente, Diane Harrison, Madaline B. Zanko, Andrea Marder, Karen Gusella, James F. Lee, Jong-Min Alonso, Isabel Sequeiros, Jorge Myers, Richard H. MacDonald, Marcy E. TI Population stratification may bias analysis of PGC-1 alpha as a modifier of age at Huntington disease motor onset SO HUMAN GENETICS LA English DT Article ID TRINUCLEOTIDE REPEAT; MEDITERRANEAN DIET; OF-ONSET; AT-ONSET; ASSOCIATION; NEURODEGENERATION; COACTIVATOR; GENOTYPES; DEFECTS; EUROPE AB Huntington's disease (HD) is an inherited neurodegenerative disorder characterized by motor, cognitive and behavioral disturbances, caused by the expansion of a CAG trinucleotide repeat in the HD gene. The CAG allele size is the major determinant of age at onset (AO) of motor symptoms, although the remaining variance in AO is highly heritable. The rs7665116 SNP in PPARGC1A, encoding the mitochondrial regulator PGC-1 alpha, has been reported to be a significant modifier of AO in three European HD cohorts, perhaps due to affected cases from Italy. We attempted to replicate these findings in a large collection of (1,727) HD patient DNA samples of European origin. In the entire cohort, rs7665116 showed a significant effect in the dominant model (p value = 0.008) and the additive model (p value = 0.009). However, when examined by origin, cases of Southern European origin had an increased rs7665116 minor allele frequency (MAF), consistent with this being an ancestry-tagging SNP. The Southern European cases, despite similar mean CAG allele size, had a significantly older mean AO (p < 0.001), suggesting population-dependent phenotype stratification. When the generalized estimating equations models were adjusted for ancestry, the effect of the rs7665116 genotype on AO decreased dramatically. Our results do not support rs7665116 as a modifier of AO of motor symptoms, as we found evidence for a dramatic effect of phenotypic (AO) and genotypic (MAF) stratification among European cohorts that was not considered in previously reported association studies. A significantly older AO in Southern Europe may reflect population differences in genetic or environmental factors that warrant further investigation. C1 [Ramos, Eliana Marisa; Lee, Ji-Hyun; Gillis, Tammy; Mysore, Jayalakshmi S.; Lucente, Diane; Gusella, James F.; Lee, Jong-Min; MacDonald, Marcy E.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Ramos, Eliana Marisa; Alonso, Isabel; Sequeiros, Jorge] Univ Porto, Inst Mol & Cell Biol, IBMC, UnIGENe, P-4100 Oporto, Portugal. [Latourelle, Jeanne C.; Frank, Samuel; Saint-Hilaire, Marie-Helene; Myers, Richard H.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Squitieri, Ferdinando; Di Pardo, Alba] IRCCS Neuromed, Ctr Neurogenet & Rare Dis, I-86077 Pozzilli, IS, Italy. [Di Donato, Stefano] Fdn IRCCS Ist Neurol Carlo Besta, I-20133 Milan, Italy. [Hayden, Michael R.] Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada. [Morrison, Patrick J.] Belfast HSC Trust, Reg Med Genet Ctr, Belfast BT9 7AB, Antrim, North Ireland. [Morrison, Patrick J.] Univ Ulster, Coleraine BT52 15A, Londonderry, North Ireland. [Nance, Martha] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Ross, Christopher A.; Margolis, Russell L.] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA. [Gomez-Tortosa, Estrella] Fdn Jimenez Diaz, Dept Neurol, E-28040 Madrid, Spain. [Ayuso, Carmen] Fdn Jimenez Diaz, CIBERER, IIS, Dept Genet, E-28040 Madrid, Spain. [Suchowersky, Oksana] Univ Alberta, Dept Med, Edmonton, AB T6G 2B7, Canada. [Suchowersky, Oksana] Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2B7, Canada. [Trent, Ronald J.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia. [McCusker, Elizabeth] Westmead Hosp, Dept Neurol, Westmead Sydney, NSW 2145, Australia. [Novelletto, Andrea] Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy. [Frontali, Marina] CNR, Inst Translat Pharmacol, I-00133 Rome, Italy. [Jones, Randi] Emory Univ, Dept Neurol, Atlanta, GA 30329 USA. [Ashizawa, Tetsuo] Univ Florida, Dept Neurol, Gainesville, FL 32610 USA. [Hersch, Steven M.; Rosas, Herminia D.] Massachusetts Gen Hosp, MIND, Charlestown, MA 02129 USA. [Harrison, Madaline B.] Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA. [Zanko, Andrea] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Marder, Karen] Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA. [Gusella, James F.; Lee, Jong-Min; MacDonald, Marcy E.] Broad Inst Harvard & Massachusetts Inst Technol, Program Med & Populat Genet, Cambridge, MA 02142 USA. [Gusella, James F.; Lee, Jong-Min; MacDonald, Marcy E.] Harvard Univ, Sch Med, Cambridge, MA 02142 USA. [Alonso, Isabel; Sequeiros, Jorge] Univ Porto, Inst Mol & Cell Biol, IBMC, CGPP, P-4100 Oporto, Portugal. [Alonso, Isabel; Sequeiros, Jorge] Univ Porto, ICBAS, Inst Ciencias Biomed Abel Salazar, P-4100 Oporto, Portugal. RP MacDonald, ME (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Simches Res Bldg,Room 5414,185 Cambridge St, Boston, MA 02114 USA. EM macdonam@helix.mgh.harvard.edu RI Di Donato, Stefano/B-9717-2012; Alonso, Isabel/I-4307-2013; Ross, Christopher/H-8395-2013; Hayden, Michael/D-8581-2011 OI Alonso, Isabel/0000-0001-8549-6903; Hayden, Michael/0000-0001-5159-1419 FU Fundacao para a Ciencia e a Tecnologia of Portugal [SFRH/BD/44335/2008]; NIH from NINDS [NS16367, NS32765]; CHDI Foundation, Inc. FX We thank the HD families, whose participation in genetic studies made this work possible, the COHORT co-investigators and contributors (see "Appendix"), contributors to the HD-MAPS study, Ruth Abramson, Alexandra Durr, Adam Rosenblatt, Luigi Frati, Susan Perlman, P. Michael Conneally, Mary Lou Klimek, Melissa Diggin, Tiffany Hadzi and Ayana Duckett, as well as the Harvard Brain Tissue Resource Center at McLean Hospital and the National Neurological Research Specimen Bank at the VA West Los Angeles Healthcare Center. EMR is the recipient of a scholarship from the Fundacao para a Ciencia e a Tecnologia of Portugal (SFRH/BD/44335/2008). Study funding supported by NIH grants from the NINDS NS16367 (The Massachusetts HD Center Without Walls) and NS32765, and the CHDI Foundation, Inc. NR 28 TC 15 Z9 15 U1 0 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-6717 J9 HUM GENET JI Hum. Genet. PD DEC PY 2012 VL 131 IS 12 BP 1833 EP 1840 DI 10.1007/s00439-012-1205-z PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 034JU UT WOS:000310869700003 PM 22825315 ER PT J AU Rajaraman, P Melin, BS Wang, ZM McKean-Cowdin, R Michaud, DS Wang, SS Bondy, M Houlston, R Jenkins, RB Wrensch, M Yeager, M Ahlbom, A Albanes, D Andersson, U Freeman, LEB Buring, JE Butler, MA Braganza, M Carreon, T Feychting, M Fleming, SJ Gapstur, SM Gaziano, JM Giles, GG Hallmans, G Henriksson, R Hoffman-Bolton, J Inskip, PD Johansen, C Kitahara, CM Lathrop, M Liu, CW Le Marchand, L Linet, MS Lonn, S Peters, U Purdue, MP Rothman, N Ruder, AM Sanson, M Sesso, HD Severi, G Shu, XO Simon, M Stampfer, M Stevens, VL Visvanathan, K White, E Wolk, A Zeleniuch-Jacquotte, A Zheng, W Decker, P Enciso-Mora, V Fridley, B Gao, YT Kosel, M Lachance, DH Lau, C Rice, T Swerdlow, A Wiemels, JL Wiencke, JK Shete, S Xiang, YB Xiao, YY Hoover, RN Fraumeni, JF Chatterjee, N Hartge, P Chanock, SJ AF Rajaraman, Preetha Melin, Beatrice S. Wang, Zhaoming McKean-Cowdin, Roberta Michaud, Dominique S. Wang, Sophia S. Bondy, Melissa Houlston, Richard Jenkins, Robert B. Wrensch, Margaret Yeager, Meredith Ahlbom, Anders Albanes, Demetrius Andersson, Ulrika Freeman, Laura E. Beane Buring, Julie E. Butler, Mary Ann Braganza, Melissa Carreon, Tania Feychting, Maria Fleming, Sarah J. Gapstur, Susan M. Gaziano, J. Michael Giles, Graham G. Hallmans, Goran Henriksson, Roger Hoffman-Bolton, Judith Inskip, Peter D. Johansen, Christoffer Kitahara, Cari M. Lathrop, Mark Liu, Chenwei Le Marchand, Loic Linet, Martha S. Lonn, Stefan Peters, Ulrike Purdue, Mark P. Rothman, Nathaniel Ruder, Avima M. Sanson, Marc Sesso, Howard D. Severi, Gianluca Shu, Xiao-Ou Simon, Matthias Stampfer, Meir Stevens, Victoria L. Visvanathan, Kala White, Emily Wolk, Alicja Zeleniuch-Jacquotte, Anne Zheng, Wei Decker, Paul Enciso-Mora, Victor Fridley, Brooke Gao, Yu-Tang Kosel, Matthew Lachance, Daniel H. Lau, Ching Rice, Terri Swerdlow, Anthony Wiemels, Joseph L. Wiencke, John K. Shete, Sanjay Xiang, Yong-Bing Xiao, Yuanyuan Hoover, Robert N. Fraumeni, Joseph F., Jr. Chatterjee, Nilanjan Hartge, Patricia Chanock, Stephen J. TI Genome-wide association study of glioma and meta-analysis SO HUMAN GENETICS LA English DT Article ID HIGH-GRADE GLIOMA; NERVOUS-SYSTEM; 1ST-DEGREE RELATIVES; BRAIN-TUMORS; CANCER; RISK; SUSCEPTIBILITY; ALLELES; VARIANTS; ALLERGY AB Gliomas account for approximately 80 % of all primary malignant brain tumors and, despite improvements in clinical care over the last 20 years, remain among the most lethal tumors, underscoring the need for gaining new insights that could translate into clinical advances. Recent genome-wide association studies (GWAS) have identified seven new susceptibility regions. We conducted a new independent GWAS of glioma using 1,856 cases and 4,955 controls (from 14 cohort studies, 3 case-control studies, and 1 population-based case-only study) and found evidence of strong replication for three of the seven previously reported associations at 20q13.33 (RTEL), 5p15.33 (TERT), and 9p21.3 (CDKN2BAS), and consistent association signals for the remaining four at 7p11.2 (EGFR both loci), 8q24.21 (CCDC26) and 11q23.3 (PHLDB1). The direction and magnitude of the signal were consistent for samples from cohort and case-control studies, but the strength of the association was more pronounced for loci rs6010620 (20q,13.33; RTEL) and rs2736100 (5p15.33, TERT) in cohort studies despite the smaller number of cases in this group, likely due to relatively more higher grade tumors being captured in the cohort studies. We further examined the 85 most promising single nucleotide polymorphism (SNP) markers identified in our study in three replication sets (5,015 cases and 11,601 controls), but no new markers reached genome-wide significance. Our findings suggest that larger studies focusing on novel approaches as well as specific tumor subtypes or subgroups will be required to identify additional common susceptibility loci for glioma risk. C1 [Rajaraman, Preetha] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, Bethesda, MD 20892 USA. [Rajaraman, Preetha; Wang, Zhaoming; Yeager, Meredith; Albanes, Demetrius; Freeman, Laura E. Beane; Braganza, Melissa; Inskip, Peter D.; Kitahara, Cari M.; Linet, Martha S.; Purdue, Mark P.; Rothman, Nathaniel; Hartge, Patricia; Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. [Melin, Beatrice S.; Andersson, Ulrika; Henriksson, Roger] Umea Univ, Dept Radiat Sci, Umea, Sweden. [Wang, Zhaoming; Yeager, Meredith; Liu, Chenwei; Chanock, Stephen J.] NCI, Core Genotyping Facil, SAIC Frederick Inc, Gaithersburg, MD USA. [McKean-Cowdin, Roberta] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Michaud, Dominique S.] Brown Univ, Div Biol & Med, Dept Epidemiol, Providence, RI 02912 USA. [Michaud, Dominique S.] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, London, England. [Wang, Sophia S.] City Hope Natl Med Ctr, Div Canc Etiol, Dept Populat Sci, Duarte, CA USA. [Wang, Sophia S.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA. [Bondy, Melissa; Lau, Ching] Baylor Coll Med, Houston, TX 77030 USA. [Houlston, Richard; Enciso-Mora, Victor; Swerdlow, Anthony] Inst Canc Res, Div Genet & Epidemiol, Sutton, Surrey, England. [Jenkins, Robert B.; Decker, Paul; Fridley, Brooke; Kosel, Matthew; Lachance, Daniel H.] Mayo Clin, Rochester, MN USA. [Wrensch, Margaret; Rice, Terri; Wiemels, Joseph L.; Wiencke, John K.; Xiao, Yuanyuan] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Ahlbom, Anders; Feychting, Maria; Lonn, Stefan] Karolinska Inst, Inst Environm Med, Div Epidemiol, S-10401 Stockholm, Sweden. [Buring, Julie E.; Gaziano, J. Michael; Sesso, Howard D.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA. [Buring, Julie E.; Gaziano, J. Michael; Sesso, Howard D.] Harvard Univ, Sch Med, Boston, MA USA. [Butler, Mary Ann; Carreon, Tania; Ruder, Avima M.] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Cincinnati, OH USA. [Fleming, Sarah J.] Univ Leeds, Div Biostat, Leeds, W Yorkshire, England. [Gapstur, Susan M.; Stevens, Victoria L.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA. [Gaziano, J. Michael] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol, Res & Informat Ctr, Geriatr Res Educ & Clin Ctr, Boston, MA USA. [Giles, Graham G.; Severi, Gianluca] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia. [Giles, Graham G.; Severi, Gianluca] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia. [Hallmans, Goran] Umea Univ, Dept Publ Hlth & Clin Med Nutr Res, Umea, Sweden. [Hoffman-Bolton, Judith; Visvanathan, Kala] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Johansen, Christoffer] Danish Canc Soc, Res Ctr, Unit Survivorship, Copenhagen, Denmark. [Lathrop, Mark] IG CEA, Ctr Natl Genotypage, Evry, France. [Lathrop, Mark] Fdn Jean Dauset CEPH, Paris, France. [Le Marchand, Loic] Univ Hawaii, Canc Res Ctr, Honolulu, HI 96822 USA. [Lonn, Stefan] AstraZeneca Nord, Dept Med, Sodertalje, Sweden. [Peters, Ulrike; White, Emily] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Peters, Ulrike; White, Emily] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Sanson, Marc] APHP, GH Pitie Salpetriere, Serv Neurol Mazarin, Paris, France. [Sanson, Marc] CRICM, UMR INSERM UPMC 975, Paris, France. [Shu, Xiao-Ou; Zheng, Wei] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Simon, Matthias] Neurochirurg Univklin, Bonn, Germany. [Stampfer, Meir] Harvard Univ, Sch Med, Channing Lab, Brigham & Womens Hosp, Boston, MA 02115 USA. [Stampfer, Meir] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Stampfer, Meir] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Visvanathan, Kala] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Wolk, Alicja] Karolinska Inst, Inst Environm Med, Div Nutr Epidemiol, S-10401 Stockholm, Sweden. [Zeleniuch-Jacquotte, Anne] NYU, Sch Med, Div Epidemiol, Dept Environm Med, New York, NY USA. [Gao, Yu-Tang; Xiang, Yong-Bing] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, Dept Epidemiol,Renji Hosp, Shanghai 200030, Peoples R China. [Swerdlow, Anthony] Inst Canc Res, Div Breast Canc Res, London SW3 6JB, England. [Shete, Sanjay] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Orlando, TX USA. RP Rajaraman, P (reprint author), NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, 6120 Execut Blvd, Bethesda, MD 20892 USA. EM rajarama@mail.nih.gov RI Simon, Matthias/F-3046-2014; Michaud, Dominique/I-5231-2014; Rice, Terri/J-6071-2014; Albanes, Demetrius/B-9749-2015; Fridley, Brooke/D-8315-2015; Purdue, Mark/C-9228-2016; Kitahara, Cari/R-8267-2016 OI Giles, Graham/0000-0003-4946-9099; Fleming, Sarah/0000-0002-7655-4806; Fridley, Brooke/0000-0001-7739-7956; Zeleniuch-Jacquotte, Anne/0000-0001-9350-1303; Houlston, Richard/0000-0002-5268-0242; Purdue, Mark/0000-0003-1177-3108; FU NCI, NIH, Department of Health and Human Services; NCI, NIH [1-CO-12400] FX This research was supported by intramural funds from the NCI, NIH, Department of Health and Human Services, and has been funded in whole or in part with federal funds from the NCI, NIH, under contract N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government. We are indebted to the scientific and field efforts of Michelle Brotzman (Westat), Laurie Burdette, Peter Hui (IMS), Annelie Landgren, Leah Mechanic, Lisa Newman (RTI), Aurelie Vogt, Tim Sheehy, Mitchel Berger, Susan Chang, Mike Prados, Tarik Tihan, Ivan Smirnov, and Lucie McCoy. NR 30 TC 88 Z9 89 U1 3 U2 42 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-6717 J9 HUM GENET JI Hum. Genet. PD DEC PY 2012 VL 131 IS 12 BP 1877 EP 1888 DI 10.1007/s00439-012-1212-0 PG 12 WC Genetics & Heredity SC Genetics & Heredity GA 034JU UT WOS:000310869700008 PM 22886559 ER PT J AU Hinton, L Apesoa-Varano, EC Gonzalez, HM Aguilar-Gaxiola, S Dwight-Johnson, M Barker, JC Tran, C Zuniga, R Unutzer, J AF Hinton, Ladson Apesoa-Varano, Ester Carolina Gonzalez, Hector M. Aguilar-Gaxiola, Sergio Dwight-Johnson, Megan Barker, Judith C. Tran, Cindy Zuniga, Ramiro Unuetzer, Juergen TI Falling through the cracks: gaps in depression treatment among older Mexican-origin and white men SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE depression; access and quality of care; elderly; men; minorities; primary care ID LATE-LIFE DEPRESSION; PRIMARY-CARE; UNITED-STATES; COLLABORATIVE CARE; DISPARITIES; ADULTS; HEALTH; TRIAL; POPULATIONS; IMPAIRMENT AB Objectives This study aims (i) to compare depression frequency and self-reported depression treatment in Mexican-origin and white men; (ii) to examine ethnic differences in self-reported prior depression diagnosis and types of treatment; and (iii) to determine whether Mexican-origin men (both English and Spanish language preferring) are less likely than white men to report receiving depression treatment after controlling for potential confounders. Methods This is a cross-sectional, observational study of Mexican-origin and white men (60?years old and over) presenting for primary care visits at six outpatient clinics in California's Central Valley. Clinical depression was assessed with the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), module for past-year major depression and questions for chronic depression. Past year, self-reported prior depression diagnosis and treatment (i.e., medication, psychotherapy, mental health referral) were assessed through a structured questionnaire. Results The frequency of past-year clinical depression was similar for both ethnic groups, yet Mexican-origin men were significantly less likely than whites to report receiving a prior diagnosis of depression or prior depression treatment. Compared with whites, the odds of untreated depression in Mexican-origin men was 4.35 (95% CI 1.3514.08) for those interviewed in English and 10.40 (95% CI 2.1151.25) for those interviewed in Spanish. For both ethnic groups, the majority (i.e., approximately two-thirds) of men receiving depression treatment also met criteria for past-year clinical depression. Conclusions Mexican-origin older men in primary care suffer from significant gaps in depression care (i.e., diagnosis and treatment) compared with whites. Delivering effective depression treatment (i.e., so that depression remits) remains elusive for both ethnic groups. Copyright (c) 2012 John Wiley & Sons, Ltd. C1 [Hinton, Ladson; Apesoa-Varano, Ester Carolina] Univ Calif Davis, Betty Irene Sch Nursing, Sacramento, CA 95817 USA. [Gonzalez, Hector M.] Wayne State Univ, Detroit, MI USA. [Dwight-Johnson, Megan] RAND Corp, Los Angeles, CA USA. [Dwight-Johnson, Megan] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. [Barker, Judith C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Zuniga, Ramiro] San Joaquin Gen Hosp, French Camp, CA USA. [Unuetzer, Juergen] Univ Washington, Seattle, WA 98195 USA. RP Hinton, L (reprint author), Univ Calif Davis, Betty Irene Sch Nursing, Sacramento, CA 95817 USA. EM ladson.hinton@ucdmc.ucdavis.edu FU National Institute of Mental Health (NIMH) [R01MH080067, R01MH84994]; NHLBI [HC65233] FX The authors are grateful to Eduardo Alvarado and Mauricio Rodriguez who assisted in data collection. This study was supported by Award Number R01MH080067 from the National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. Dr Gonzalez is supported by the NIMH (R01MH84994) and NHLBI (HC65233). Results of this study were presented at the American Association of Geriatric Psychiatry meeting in San Antonio in March of 2011. NR 33 TC 4 Z9 4 U1 3 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD DEC PY 2012 VL 27 IS 12 BP 1283 EP 1290 DI 10.1002/gps.3779 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 033LP UT WOS:000310798300008 PM 22383214 ER PT J AU Childs, SK Chen, YH Duggan, MM Golshan, M Pochebit, S Wong, JS Bellon, JR AF Childs, Stephanie K. Chen, Yu-Hui Duggan, Margaret M. Golshan, Mehra Pochebit, Stephen Wong, Julia S. Bellon, Jennifer R. TI Surgical Margins and the Risk of Local-Regional Recurrence After Mastectomy Without Radiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID EARLY BREAST-CANCER; POSITIVE MARGIN; AXILLARY NODES; COMPETING RISK; RADIOTHERAPY; RATES; CARCINOMA; SURVIVAL; FAILURE; RELAPSE AB Purpose: Although positive surgical margins are generally associated with a higher risk of local-regional recurrence (LRR) for most solid tumors, their significance after mastectomy remains unclear. We sought to clarify the influence of the mastectomy margin on the risk of LRR. Methods and Materials: The retrospective cohort consisted of 397 women who underwent mastectomy and no radiation for newly diagnosed invasive breast cancer from 1998-2005. Time to isolated LRR and time to distant metastasis (DM) were evaluated by use of cumulative-incidence analysis and competing-risks regression analysis. DM was considered a competing event for analysis of isolated LRR. Results: The median follow-up was 6.7 years (range, 0.5-12.8 years). The superficial margin was positive in 41 patients (10%) and close (<= 2 mm) in 56 (14%). The deep margin was positive in 23 patients (6%) and close in 34 (9%). The 5-year LRR and DM rates for all patients were 2.4% (95% confidence interval, 0.9-4.0) and 3.5% (95% confidence interval, 1.6-5.3) respectively. Fourteen patients had an LRR. Margin status was significantly associated with time to isolated LRR (PZ=.04); patients with positive margins had a 5-year LRR of 6.2%, whereas patients with close margins and negative margins had 5-year LRRs of 1.5% and 1.9%, respectively. On univariate analysis, positive margins, positive nodes, lymphovascular invasion, grade 3 histology, and triple-negative subtype were associated with significantly higher rates of LRR. When these factors were included in a multivariate analysis, only positive margins and triple-negative subtype were associated with the risk of LRR. Conclusions: Patients with positive mastectomy margins had a significantly higher rate of LRR than those with a close or negative margin. However, the absolute risk of LRR in patients with a positive surgical margin in this series was low, and therefore the benefit of postmastectomy radiation in this population with otherwise favorable features is likely to be small. (C) 2012 Elsevier Inc. C1 [Wong, Julia S.; Bellon, Jennifer R.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Chen, Yu-Hui] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Childs, Stephanie K.] Harvard Radiat Oncol Program, Boston, MA USA. [Duggan, Margaret M.] Faulkner Hosp, Dept Surg, Boston, MA USA. [Pochebit, Stephen] Faulkner Hosp, Dept Pathol, Boston, MA USA. [Duggan, Margaret M.; Golshan, Mehra] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. RP Bellon, JR (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. EM jbellon@lroc.harvard.edu NR 19 TC 7 Z9 7 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD DEC 1 PY 2012 VL 84 IS 5 BP 1133 EP 1138 DI 10.1016/j.ijrobp.2012.02.048 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 037GH UT WOS:000311089700027 PM 22543200 ER PT J AU Lee, LJ Viswanathan, AN AF Lee, Larissa J. Viswanathan, Akila N. TI Predictors of Toxicity After Image-guided High-dose-rate Interstitial Brachytherapy for Gynecologic Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article; Proceedings Paper CT Annual Meeting of the American-Brachytherapy-Society CY APR 14-16, 2011 CL San Diego, CA SP Amer Brachytherapy Soc DE Gynecologic brachytherapy; High-dose-rate brachytherapy; Interstitial brachytherapy; Rectal toxicity ID MAGNETIC-RESONANCE; VOLUME PARAMETERS; CERVICAL-CANCER; MALIGNANCIES; RECOMMENDATIONS; LAPAROSCOPY; LAPAROTOMY; IMPLANTS; GUIDANCE; TERMS AB Purpose: To identify predictors of grade 3-4 complications and grade 2-4 rectal toxicity after three-dimensional image-guided high-dose-rate (HDR) interstitial brachytherapy for gynecologic cancer. Methods and Materials: Records were reviewed for 51 women (22 with primary disease and 29 with recurrence) treated with HDR interstitial brachytherapy. A single interstitial insertion was performed with image guidance by computed tomography (n = 43) or magnetic resonance imaging (n = 8). The median delivered dose in equivalent 2-Gy fractions was 72.0 Gy (45 Gy for external-beam radiation therapy and 24 Gy for brachytherapy). Toxicity was reported according to the Common Toxicity Criteria for Adverse Events. Actuarial toxicity estimates were calculated by the Kaplan-Meier method. Results: At diagnosis, the median patient age was 62 years and the median tumor size was 3.8 cm. The median D90 and V100 were 71.4 Gy and 89.5%; the median D2cc for the bladder, rectum, and sigmoid were 64.6 Gy, 61.0 Gy, and 52.7 Gy, respectively. The actuarial rates of all grade 3-4 complications at 2 years were 20% gastrointestinal, 9% vaginal, 6% skin, 3% musculoskeletal, and 2% lymphatic. There were no grade 3-4 genitourinary complications and no grade 5 toxicities. Grade 2-4 rectal toxicity was observed in 10 patients, and grade 3-4 complications in 4; all cases were proctitis with the exception of 1 rectal fistula. D2cc for rectum was higher for patients with grade 2-4 (68 Gy vs 57 Gy for grade 0-1, P=.03) and grade 3-4 (73 Gy vs 58 Gy for grade 0-2, P=.02) rectal toxicity. The estimated dose that resulted in a 10% risk of grade 2-4 rectal toxicity was 61.8 Gy (95% confidence interval, 51.5-72.2 Gy). Discussion: Image-guided HDR interstitial brachytherapy results in acceptable toxicity for women with primary or recurrent gynecologic cancer. D2cc for the rectum is a reliable predictor of late rectal complications. Three-dimensional-based treatment planning should be performed to ensure adequate tumor coverage while minimizing the D2cc to the rectum. (C) 2012 Elsevier Inc. C1 [Lee, Larissa J.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol,Sch Med, Boston, MA 02115 USA. RP Viswanathan, AN (reprint author), Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol,Sch Med, 75 Francis St,ASBI L2, Boston, MA 02115 USA. EM aviswanathan@lroc.harvard.edu OI Viswanathan, Akila/0000-0002-2003-0392 NR 17 TC 24 Z9 24 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD DEC 1 PY 2012 VL 84 IS 5 BP 1192 EP 1197 DI 10.1016/j.ijrobp.2012.01.085 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 037GH UT WOS:000311089700036 PM 22592049 ER PT J AU Gierga, DP Turcotte, JC Sharp, GC Sedlacek, DE Cotter, CR Taghian, AG AF Gierga, David P. Turcotte, Julie C. Sharp, Gregory C. Sedlacek, Daniel E. Cotter, Christopher R. Taghian, Alphonse G. TI A Voluntary Breath-Hold Treatment Technique for the Left Breast With Unfavorable Cardiac Anatomy Using Surface Imaging SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article ID MODULATED RADIATION-THERAPY; ADAPTED RADIOTHERAPY; CANCER RADIOTHERAPY; PATIENT SETUP; HEART; IRRADIATION; REPRODUCIBILITY; REDUCTION; SYSTEM; MOTION AB Purpose: Breath-hold (BH) treatments can be used to reduce cardiac dose for patients with left-sided breast cancer and unfavorable cardiac anatomy. A surface imaging technique was developed for accurate patient setup and reproducible real-time BH positioning. Methods and Materials: Three-dimensional surface images were obtained for 20 patients. Surface imaging was used to correct the daily setup for each patient. Initial setup data were recorded for 443 fractions and were analyzed to assess random and systematic errors. Real time monitoring was used to verify surface placement during BH. The radiation beam was not turned on if the BH position difference was greater than 5 mm. Real-time surface data were analyzed for 2398 BHs and 363 treatment fractions. The mean and maximum differences were calculated. The percentage of BHs greater than tolerance was calculated. Results: The mean shifts for initial patient setup were 2.0 mm, 1.2 mm, and 0.3 mm in the vertical, longitudinal, and lateral directions, respectively. The mean 3-dimensional vector shift was 7.8 mm. Random and systematic errors were less than 4 mm. Real-time surface monitoring data indicated that 22% of the BHs were outside the 5-mm tolerance (range, 7%-41%), and there was a correlation with breast volume. The mean difference between the treated and reference BH positions was 2 mm in each direction. For out-of-tolerance BHs, the average difference in the BH position was 6.3 mm, and the average maximum difference was 8.8 mm. Conclusions: Daily real-time surface imaging ensures accurate and reproducible positioning for BH treatment of left-sided breast cancer patients with unfavorable cardiac anatomy. (C) 2012 Elsevier Inc. C1 [Gierga, David P.; Turcotte, Julie C.; Sharp, Gregory C.; Sedlacek, Daniel E.; Cotter, Christopher R.; Taghian, Alphonse G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Gierga, David P.; Sharp, Gregory C.; Taghian, Alphonse G.] Harvard Univ, Sch Med, Boston, MA USA. RP Gierga, DP (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02114 USA. EM dgierga@partners.org NR 22 TC 13 Z9 13 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD DEC 1 PY 2012 VL 84 IS 5 BP E663 EP E668 DI 10.1016/j.ijrobp.2012.07.2379 PG 6 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 037GH UT WOS:000311089700014 PM 22975605 ER PT J AU Wong, HJ Abrams, H AF Wong, H. J. Abrams, H. TI 'Actors' and 'clients': why systems dynamics needs help from soft systems methodology and unbounded systems thinking Reply SO JOURNAL OF THE OPERATIONAL RESEARCH SOCIETY LA English DT Editorial Material C1 [Wong, H. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. Harvard Univ, Sch Med, Cambridge, MA 02138 USA. Univ Toronto, Univ Hlth Network, Toronto, ON M5S 1A1, Canada. RP Wong, HJ (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 6 PU PALGRAVE MACMILLAN LTD PI BASINGSTOKE PA BRUNEL RD BLDG, HOUNDMILLS, BASINGSTOKE RG21 6XS, HANTS, ENGLAND SN 0160-5682 J9 J OPER RES SOC JI J. Oper. Res. Soc. PD DEC PY 2012 VL 63 IS 12 BP 1789 EP 1789 DI 10.1057/jors.2012.100 PG 1 WC Management; Operations Research & Management Science SC Business & Economics; Operations Research & Management Science GA 033JP UT WOS:000310791800013 ER PT J AU Matthews, PC Koyanagi, M Kloverpris, HN Harndahl, M Stryhn, A Akahoshi, T Gatanaga, H Oka, S Molina, CJ Ponce, HV Rios, SA Cole, D Carlson, J Payne, RP Ogwu, A Bere, A Ndung'u, T Gounder, K Chen, FB Riddell, L Luzzi, G Shapiro, R Brander, C Walker, B Sewell, AK Teran, GR Heckerman, D Hunter, E Buus, S Takiguchi, M Goulder, PJR AF Matthews, Philippa C. Koyanagi, Madoka Kloverpris, Henrik N. Harndahl, Mikkel Stryhn, Anette Akahoshi, Tomohiro Gatanaga, Hiroyuki Oka, Shinichi Molina, Claudia Juarez Ponce, Humberto Valenzuela Rios, Santiago Avila Cole, David Carlson, Jonathan Payne, Rebecca P. Ogwu, Anthony Bere, Alfred Ndung'u, Thumbi Gounder, Kamini Chen, Fabian Riddell, Lynn Luzzi, Graz Shapiro, Roger Brander, Christian Walker, Bruce Sewell, Andrew K. Teran, Gustavo Reyes Heckerman, David Hunter, Eric Buus, Soren Takiguchi, Masafumi Goulder, Philip J. R. TI Differential Clade-Specific HLA-B*3501 Association with HIV-1 Disease Outcome Is Linked to Immunogenicity of a Single Gag Epitope SO JOURNAL OF VIROLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; CLASS-I ALLELES; HLA-B; SELECTION PRESSURE; IMMUNE CONTROL; VIRAL LOAD; LYMPHOCYTE RESPONSE; RHESUS MACAQUES; P24 GAG AB The strongest genetic influence on immune control in HIV-1 infection is the HLA class I genotype. Rapid disease progression in B-clade infection has been linked to HLA-B*35 expression, in particular to the less common HLA-B*3502 and HLA-B*3503 subtypes but also to the most prevalent subtype, HLA-B*3501. In these studies we first demonstrated that whereas HLA-B*3501 is associated with a high viral set point in two further B-clade-infected cohorts, in Japan and Mexico, this association does not hold in two large C-clade-infected African cohorts. We tested the hypothesis that clade-specific differences in HLA associations with disease outcomes may be related to distinct targeting of critical CD8(+) T-cell epitopes. We observed that only one epitope was significantly targeted differentially, namely, the Gag-specific epitope NPPIPVGDIY (NY10, Gag positions 253 to 262) (P = 2 x 10(-5)). In common with two other HLA-B*3501-restricted epitopes, in Gag and Nef, that were not targeted differentially, a response toward NY10 was associated with a significantly lower viral set point. Nonimmunogenicity of NY10 in B-clade-infected subjects derives from the Gag-D260E polymorphism present in similar to 90% of B-clade sequences, which critically reduces recognition of the Gag NY10 epitope. These data suggest that in spite of any inherent HLA-linked T-cell receptor repertoire differences that may exist, maximizing the breadth of the Gag-specific CD8(+) T-cell response, by the addition of even a single epitope, may be of overriding importance in achieving immune control of HIV infection. This distinction is of direct relevance to development of vaccines designed to optimize the anti-HIV CD8(+) T-cell response in all individuals, irrespective of HLA type. C1 [Matthews, Philippa C.; Kloverpris, Henrik N.; Molina, Claudia Juarez; Payne, Rebecca P.; Goulder, Philip J. R.] Univ Oxford, Dept Paediat, Oxford, England. [Koyanagi, Madoka; Akahoshi, Tomohiro; Gatanaga, Hiroyuki; Oka, Shinichi; Takiguchi, Masafumi] Kumamoto Univ, Ctr AIDS Res, Kumamoto, Japan. [Gatanaga, Hiroyuki; Oka, Shinichi] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan. [Harndahl, Mikkel; Stryhn, Anette; Buus, Soren] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Copenhagen, Denmark. [Ponce, Humberto Valenzuela; Rios, Santiago Avila; Teran, Gustavo Reyes] Natl Inst Resp Dis, Ctr Res Infect Dis, Mexico City, DF, Mexico. [Cole, David; Sewell, Andrew K.] Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff, S Glam, Wales. [Carlson, Jonathan; Heckerman, David] ESci Grp, Microsoft Res, Los Angeles, CA USA. [Ogwu, Anthony] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana. [Ndung'u, Thumbi; Gounder, Kamini] Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, Durban, South Africa. [Chen, Fabian] Royal Berkshire Hosp, Dept Sexual Hlth, Reading RG1 5AN, Berks, England. [Riddell, Lynn] Northamptonshire Healthcare NHS Trust, Northampton Gen Hosp, Dept Genitourinary Med, Northampton, England. [Luzzi, Graz] Wycombe Hosp, Dept Sexual Hlth, High Wycombe, Bucks, England. [Shapiro, Roger] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. [Brander, Christian] Autonomous Univ Barcelona, Hosp Univ Germans Trias & Pujol, Fundacio IrsiCaixa HIVACAT, Barcelona, Spain. [Brander, Christian] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain. [Walker, Bruce] Massachusetts Gen Hosp, Ragon Inst, Boston, MA 02114 USA. [Walker, Bruce] Harvard Univ, Sch Med, Boston, MA USA. [Bere, Alfred; Hunter, Eric] Emory Vaccine Ctr, Atlanta, GA USA. RP Kloverpris, HN (reprint author), Univ Oxford, Dept Paediat, Oxford, England. EM henrik.kloverpris@paediatrics.ox.ac.uk RI Takiguchi, Masafumi/E-7468-2013; Kumamoto University, CAIDS/G-8446-2013; Publications, Remarkable/I-1756-2013; Buus, Soren/F-5446-2010; OI Matthews, Philippa/0000-0002-4036-4269; Sewell, Andrew/0000-0003-3194-3135; Brander, Christian/0000-0002-0548-5778; Cole, David/0000-0003-0028-9396; Buus, Soren/0000-0001-8363-1999; Ndung'u, Thumbi/0000-0003-2962-3992 FU Welcome Trust; National Institutes of Health grant [R01 AI46995]; Global COE program "Global Education and Research Center Aiming at the Control of AIDS" FX This work was supported by the Welcome Trust (P.J.R.G.), National Institutes of Health grant R01 AI46995, and the Global COE program "Global Education and Research Center Aiming at the Control of AIDS," launched as a project commissioned by the Ministry of Education, Science, Sports, and Culture, Japan. NR 70 TC 20 Z9 21 U1 1 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD DEC PY 2012 VL 86 IS 23 BP 12643 EP 12654 DI 10.1128/JVI.01381-12 PG 12 WC Virology SC Virology GA 030QN UT WOS:000310585300017 PM 22973023 ER PT J AU Maloney, NS Thackray, LB Goel, G Hwang, S Duan, E Vachharajani, P Xavier, R Virgin, HW AF Maloney, Nicole S. Thackray, Larissa B. Goel, Gautam Hwang, Seungmin Duan, Erning Vachharajani, Punit Xavier, Ramnik Virgin, Herbert W. TI Essential Cell-Autonomous Role for Interferon (IFN) Regulatory Factor 1 in IFN-gamma-Mediated Inhibition of Norovirus Replication in Macrophages SO JOURNAL OF VIROLOGY LA English DT Article ID SWITCH GENE 50; MURINE NOROVIRUS; FACTOR-I; TARGETED DISRUPTION; VIRUS-REPLICATION; IMMUNE-RESPONSE; EXPRESSION; IRF-1; MICE; INFECTION AB Noroviruses (NVs) cause the majority of cases of epidemic nonbacterial gastroenteritis worldwide and contribute to endemic enteric disease. However, the molecular mechanisms responsible for immune control of their replication are not completely understood. Here we report that the transcription factor interferon regulatory factor 1 (IRF-1) is required for control of murine NV (MNV) replication and pathogenesis in vivo. This led us to studies documenting a cell-autonomous role for IRF-1 in gamma interferon (IFN-gamma)-mediated inhibition of MNV replication in primary macrophages. This role of IRF-1 in the inhibition of MNV replication by IFN-gamma is independent of IFN-alpha beta signaling. While the signal transducer and activator of transcription STAT-1 was also required for IFN-gamma-mediated inhibition of MNV replication in vitro, class II transactivator (CIITA), interferon regulatory factor 3 (IRF-3), and interferon regulatory factor 7 (IRF-7) were not required. We therefore hypothesized that there must be a subset of IFN-stimulated genes (ISGs) regulated by IFN-gamma in a manner dependent only on STAT-1 and IRF-1. Analysis of transcriptional profiles of macrophages lacking various transcription factors confirmed this hypothesis. These studies identify a key role for IRF-1 in IFN-gamma-dependent control of norovirus infection in mice and macrophages. C1 [Maloney, Nicole S.; Thackray, Larissa B.; Hwang, Seungmin; Duan, Erning; Vachharajani, Punit; Virgin, Herbert W.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63130 USA. [Maloney, Nicole S.; Thackray, Larissa B.; Hwang, Seungmin; Duan, Erning; Vachharajani, Punit; Virgin, Herbert W.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA. [Goel, Gautam; Xavier, Ramnik] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA USA. [Goel, Gautam; Xavier, Ramnik] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Study Inflammatory Bowel Dis, Boston, MA USA. RP Virgin, HW (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63130 USA. EM virgin@wustl.edu RI zhou, zhenqing/H-4580-2014; Duan, Erning /H-4608-2014 FU National Institutes of Health [ROI AI054483, U54 AI057160]; institutional training grant [T32-AI007172]; NCI Cancer Center support grant [P30 CA91842]; ICTS/CTSA grant from the National Center for Research Resources (NCRR) [UL1RR024992] FX This work was supported by National Institutes of Health grants ROI AI054483 and U54 AI057160, project 3, to H.W.V.N.S.M. was supported by institutional training grant T32-AI007172. Washington University and H.W.V. receive income based on licenses for MNV technology. The Genome Technology Access Center is partially supported by NCI Cancer Center support grant P30 CA91842 to the Siteman Cancer Center and by ICTS/CTSA grant UL1RR024992 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. NR 44 TC 14 Z9 14 U1 1 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD DEC PY 2012 VL 86 IS 23 BP 12655 EP 12664 DI 10.1128/JVI.01564-12 PG 10 WC Virology SC Virology GA 030QN UT WOS:000310585300018 PM 22973039 ER PT J AU Liu, SW Chang, YC Camargo, CA Weissman, JS Walsh, K Schuur, JD Deal, J Singer, SJ AF Liu, Shan W. Chang, Yuchiao Camargo, Carlos A., Jr. Weissman, Joel S. Walsh, Kathleen Schuur, Jeremiah D. Deal, Jeffrey Singer, Sara J. TI A Mixed-Methods Study of the Quality of Care Provided to Patients Boarding in the Emergency Department: Comparing Emergency Department and Inpatient Responsibility Models SO MEDICAL CARE RESEARCH AND REVIEW LA English DT Article DE emergency department; hospital quality; patient safety ID HEALTH-SERVICES RESEARCH; COMMUNITY-ACQUIRED PNEUMONIA; ICD-9-CM ADMINISTRATIVE DATA; CLINICAL COMORBIDITY INDEX; HIGH-RELIABILITY; CHEST-PAIN; ADMITTED PATIENTS; SEVERITY INDEX; MEDICINE; SAFETY AB Concern exists regarding care patients receive while boarding (staying in the emergency department [ED] after a decision to admit has been made). This exploratory study compares care for such ED patients under "Inpatient Responsibility" (IPR) and "ED Responsibility" (EDR) models using mixed methods. The authors abstracted quantitative data from 1,431 patient charts for ED patients admitted to two academic hospitals in 2004-2005 and interviewed 10 providers for qualitative data. The authors compared delays using logistic regression and used provider interviews to explore reasons for quantitative findings. EDR patients had more delays to receiving home medications over the first 26 hours of admission but fewer while boarding; EDR patients had fewer delayed cardiac enzymes checks. Interviews revealed that culture, resource prioritization, and systems issues made care for boarded patients challenging. A theoretically better responsibility model may not deliver better care to boarded patients because of cultural, resource prioritization, and systems issues. C1 [Liu, Shan W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA 02114 USA. [Camargo, Carlos A., Jr.; Singer, Sara J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02114 USA. [Weissman, Joel S.; Schuur, Jeremiah D.; Singer, Sara J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02114 USA. [Deal, Jeffrey] Univ S Carolina, Charleston, SC USA. RP Liu, SW (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, 55 Fruit St,Room 3rd Floor, Boston, MA 02114 USA. EM sliu1@partners.org FU Eleanor and Miles Shore Foundation; Risk Management Foundation FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors received funding from the Eleanor and Miles Shore Foundation and Risk Management Foundation. NR 67 TC 6 Z9 6 U1 1 U2 9 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1077-5587 J9 MED CARE RES REV JI Med. Care Res. Rev. PD DEC PY 2012 VL 69 IS 6 BP 679 EP 698 DI 10.1177/1077558712457426 PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 032QI UT WOS:000310733600004 PM 22922635 ER PT J AU Oaklander, AL AF Oaklander, Anne Louise TI Development of CRPS after shingles: It's all about location SO PAIN LA English DT Editorial Material ID REGIONAL PAIN SYNDROME; REFLEX SYMPATHETIC DYSTROPHY; SYNDROME TYPE-I; NEUROPATHY; RSD C1 [Oaklander, Anne Louise] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA. [Oaklander, Anne Louise] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol Neuropathol, Boston, MA USA. RP Oaklander, AL (reprint author), Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, 275 Charles St,Warren Bldg 310, Boston, MA 02115 USA. EM aoaklander@partners.org FU NINDS NIH HHS [K24NS59892] NR 16 TC 2 Z9 2 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD DEC PY 2012 VL 153 IS 12 BP 2309 EP 2310 DI 10.1016/j.pain.2012.09.003 PG 2 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 033DB UT WOS:000310772600004 PM 23059053 ER PT J AU Inquimbert, P Bartels, K Babaniyi, OB Barrett, LB Tegeder, I Scholz, J AF Inquimbert, Perrine Bartels, Karsten Babaniyi, Olusegun B. Barrett, Lee B. Tegeder, Irmgard Scholz, Joachim TI Peripheral nerve injury produces a sustained shift in the balance between glutamate release and uptake in the dorsal horn of the spinal cord SO PAIN LA English DT Article DE Glutamate release; mGluR5 Glutamate uptake; Spinal dorsal horn; Neuropathic pain ID SUBSTANCE-P RELEASE; NEUROPATHIC PAIN; ROOT GANGLION; GROUP-I; METABOTROPIC GLUTAMATE-RECEPTOR-5; UP-REGULATION; SENSORY TRANSMISSION; THERMAL HYPERALGESIA; KAINATE RECEPTORS; PATHOLOGICAL PAIN AB Peripheral nerve injury provokes heightened excitability of primary sensory afferents including nociceptors, and elicits ectopic activity in lesioned and neighboring intact nerve fibers. The major transmitter released by sensory afferents in the superficial dorsal horn of the spinal cord is glutamate. Glutamate is critically involved in nociceptive signaling and the development of neuropathic pain. We recorded miniature excitatory postsynaptic currents (mEPSCs) from neurons in lamina II of the rat dorsal horn to assess spontaneous synaptic activity after spared nerve injury (SNI), a model of chronic neuropathic pain. Following SNI, the frequency of mEPSCs doubled, indicating heightened glutamate release from primary afferents or spinal interneurons. Consistent with this finding, glutamate concentrations in the cerebrospinal fluid were elevated at 1 and 4 weeks after SNI. Transmitter uptake was insufficient to prevent the rise in extracellular glutamate as the expression of glutamate transporters remained unchanged or decreased. 2-Methyl-6-(phenylethynyl) pyridine hydrochloride, an antagonist of metabotropic glutamate receptor 5 (mGluR5), reduced the frequency of mEPSCs to its preinjury level, suggesting a positive feedback mechanism that involves facilitation of transmitter release by mGluR5 activation in the presence of high extracellular glutamate. Treatment with the beta-lactam antibiotic ceftriaxone increased the expression of glutamate transporter 1 (Glt1) in the dorsal horn after SNI, raised transmitter uptake, and lowered extracellular glutamate. Improving glutamate clearance prevented the facilitation of transmitter release by mGluR5 and attenuated neuropathic pain-like behavior. Balancing glutamate release and uptake after nerve injury should be an important target in the management of chronic neuropathic pain. (c) 2012 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 [Scholz, Joachim] Columbia Univ Coll Phys & Surg, Dept Anesthesiol, New York, NY 10032 USA. [Scholz, Joachim] Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA. [Inquimbert, Perrine; Babaniyi, Olusegun B.; Barrett, Lee B.] Harvard Univ, Sch Med, Boston, MA USA. [Inquimbert, Perrine; Babaniyi, Olusegun B.; Barrett, Lee B.] Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA. [Inquimbert, Perrine] CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, F-06560 Valbonne, France. [Inquimbert, Perrine] Univ Nice Sophia Antipolos, UMR 6097, Valbonne, France. [Bartels, Karsten; Scholz, Joachim] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Charlestown, MA USA. [Bartels, Karsten; Scholz, Joachim] Harvard Univ, Sch Med, Charlestown, MA USA. [Bartels, Karsten] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA. [Tegeder, Irmgard] Goethe Univ Frankfurt, Inst Clin Pharmacol, Pharmazentrum Frankfurt, Frankfurt, Germany. RP Scholz, J (reprint author), Columbia Univ Coll Phys & Surg, Dept Anesthesiol, 630 W 168th St,P&S Box 46, New York, NY 10032 USA. EM js3932@mail.cumc.columbia.edu OI Tegeder, Irmgard/0000-0001-7524-8025 FU Pfizer; GlaxoSmithKline; National Institute of Neurological Disorders and Stroke [R01 NS050408]; Deutsche Forschungsgemeinschaft [SFB 815, A12] FX Joachim Scholz has served as consultant for Convergence Pharmaceuticals, GlaxoSmithKline, Pfizer, Saint-Jude Medical, and Sanofi-Aventis, and has received grant support from Pfizer and GlaxoSmithKline for unrelated research projects.; We thank Geraldine Gomez, PhD, and Paul A. Rosenberg, PhD, for their advice and for generously providing us with the antibody against Glt1b. We also thank Wei Chao, MD, PhD, for his support and Annett H ussler for technical assistance. This work was supported by grant R01 NS050408 (to Joachim Scholz) from the National Institute of Neurological Disorders and Stroke, and grant SFB 815, A12 (to Irmgard Tegeder) from the Deutsche Forschungsgemeinschaft. NR 66 TC 27 Z9 27 U1 0 U2 19 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD DEC PY 2012 VL 153 IS 12 BP 2422 EP 2431 DI 10.1016/j.pain.2012.08.011 PG 10 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 033DB UT WOS:000310772600018 PM 23021150 ER PT J AU Wang, SX Tian, YH Song, L Lim, G Tan, YH You, ZR Chen, L Mao, JR AF Wang, Shuxing Tian, Yinghong Song, Li Lim, Grewo Tan, Yonghui You, Zerong Chen, Lucy Mao, Jianren TI Exacerbated mechanical hyperalgesia in rats with genetically predisposed depressive behavior: Role of melatonin and NMDA receptors SO PAIN LA English DT Article DE Depression; Hyperalgesia; Inflammation; Melatonin; Temporomandibular joint; Trigeminal pain; WKY rat ID SUBSTANTIA GELATINOSA NEURONS; CHRONIC MUSCULOSKELETAL PAIN; RANDOMIZED CONTROLLED-TRIAL; PERIPHERAL-NERVE INJURY; PRIMARY-CARE; DORSAL HORN; SPINAL-CORD; TEMPOROMANDIBULAR DISORDERS; ANTIDEPRESSANT TREATMENTS; MORPHINE-TOLERANCE AB A connection between pain and depression has long been recognized in the clinical setting; however, its mechanism remains unclear. This study showed that mechanical hyperalgesia induced by unilateral temporomandibular joint (TMJ) inflammation was exacerbated in Wistar-Kyoto (WKY) rats with genetically predisposed depressive behavior. Reciprocally, TMJ inflammation enhanced depressive behavior such that a lower nociceptive threshold correlated with a higher score of depressive behavior in the same WKY rats. As compared with Wistar rats, WKY rats showed a lower plasma melatonin level, downregulation of the melatonin MT1 receptor, but upregulation of the NR1 subunit of the NMDA receptor in the ipsilateral trigeminal subnucleus caudalis (Sp5C). Intracisternal administration of 6-chloromelatonin (250 mu g, twice daily for 7 days) concurrently attenuated mechanical hyperalgesia and depressive behavior in WKY rats as well as downregulated the NR1 expression in the ipsilateral Sp5C. In patch-clamp recordings, melatonin dose-dependently decreased NMDA-induced currents in spinal cord dorsal horn substantia gelatinosa neurons. These results demonstrate a reciprocal relationship between TMJ inflammation-induced mechanical hyperalgesia and depressive behavior and suggest that the central melatoninergic system, through modulation of the NMDA receptor expression and activity, may play a role in the mechanisms of the comorbidity between pain and depression. (c) 2012 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved. C1 [Wang, Shuxing; Tian, Yinghong; Song, Li; Lim, Grewo; Tan, Yonghui; You, Zerong; Chen, Lucy; Mao, Jianren] Harvard Univ, Sch Med, Massachusetts Gen Hosp, MGH Ctr Translat Pain Res,Dept Anesthesia Crit Ca, Boston, MA 02114 USA. [Tian, Yinghong] So Med Univ, Dept Physiol, Guangzhou, Guangdong, Peoples R China. [Song, Li] Sichuan Univ, W China Hosp, Dept Anesthesia, Chengdu 610064, Sichuan, Peoples R China. [Tan, Yonghui] Peking Univ, Sch & Hosp Stomatol, Ctr TMD & Orofacial Pain, Beijing 100871, Peoples R China. RP Mao, JR (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, MGH Ctr Translat Pain Res,Dept Anesthesia Crit Ca, WACC 324,15 Parkman St, Boston, MA 02114 USA. EM jmao@partners.org FU US Public Health Service [RO1 DE18538, RO1 DE18214] FX This work was supported by US Public Health Service RO1 Grants DE18538 and DE18214. NR 98 TC 18 Z9 19 U1 0 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-3959 J9 PAIN JI Pain PD DEC PY 2012 VL 153 IS 12 BP 2448 EP 2457 DI 10.1016/j.pain.2012.08.016 PG 10 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA 033DB UT WOS:000310772600021 PM 23046768 ER PT J AU Fuzaylov, G Cauley, BD AF Fuzaylov, Gennadiy Cauley, Brian D. TI Spontaneous ventilation via facemask and laryngeal mask airway as bridge to extracorporeal membrane oxygenation during long-segment tracheal stenosis repair SO PEDIATRIC ANESTHESIA LA English DT Letter C1 [Fuzaylov, Gennadiy; Cauley, Brian D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med,Div Pediat A, Boston, MA 02115 USA. RP Fuzaylov, G (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med,Div Pediat A, Boston, MA 02115 USA. EM gfuzaylov@partners.org NR 6 TC 1 Z9 2 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1155-5645 J9 PEDIATR ANESTH JI Pediatr. Anesth. PD DEC PY 2012 VL 22 IS 12 BP 1226 EP 1228 DI 10.1111/pan.12044 PG 3 WC Anesthesiology; Pediatrics SC Anesthesiology; Pediatrics GA 033NB UT WOS:000310803000017 PM 23134166 ER PT J AU Molitch, ME Cowen, L Stadiem, R Uihlein, A Naidich, M Russell, E AF Molitch, Mark E. Cowen, Laura Stadiem, Raymond Uihlein, Alexander Naidich, Michelle Russell, Eric TI Tumors invading the cavernous sinus that cause internal carotid artery compression are rarely pituitary adenomas SO PITUITARY LA English DT Article DE Cavernous sinus; Carotid artery; Pituitary; Adenoma ID PARASELLAR MASSES; SURGICAL FINDINGS; INVASION; MENINGIOMAS; SELLAR; MR; LESIONS AB There is a clinical impression that when tumors invade the cavernous sinus, compression of the internal carotid artery is rare with pituitary adenomas and more common with other types of lesions but there are no actual data to support this impression. To confirm the impression that the finding of internal carotid artery compression by tumors invading the cavernous sinus is inconsistent with a diagnosis of a pituitary adenoma, we performed a retrospective analysis of MRI scans performed between 2000 and July 2009. An initial search of the radiology database was performed using the terms "invasive mass cavernous MRI" and subsequent refinement narrowed the evaluation to 141 patients with cavernous sinus invasion by sellar/parasellar tumors for whom there were clinical/pathological data to determine tumor type. 83 of the 141 patients with cavernous sinus invasion had carotid artery encasement; 58 were pituitary adenomas and 25 were other types of lesions. Eight of these 83 scans revealed compression of the internal carotid lumen, with only one being a pituitary adenoma and seven being other types of lesions. Therefore, only 1/58 (1.7%) of pituitary adenomas and 7/25 (28%) of non-pituitary adenoma lesions that encased the internal carotid artery caused compression of the artery (P = 0.0007). A mass lesion that invades the cavernous sinus and encases the internal carotid artery is very unlikely, therefore, to be a pituitary adenoma if it compresses the lumen of the internal carotid artery. C1 [Molitch, Mark E.] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Endocrinol Metab & Mol Med, Chicago, IL 60611 USA. [Cowen, Laura] Georgetown Univ, Sch Med, Div Endocrinol, Washington, DC USA. [Uihlein, Alexander] Massachusetts Gen Hosp, Div Endocrinol, Boston, MA 02114 USA. [Naidich, Michelle; Russell, Eric] Northwestern Univ, Feinberg Sch Med, Dept Radiol, Div Neuroradiol, Chicago, IL 60611 USA. RP Molitch, ME (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Med, Div Endocrinol Metab & Mol Med, 645 N Michigan Ave,Suite 530, Chicago, IL 60611 USA. EM molitch@northwestern.edu NR 16 TC 6 Z9 6 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1386-341X J9 PITUITARY JI Pituitary PD DEC PY 2012 VL 15 IS 4 BP 598 EP 600 DI 10.1007/s11102-012-0375-y PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 034UM UT WOS:000310898400019 PM 22307822 ER PT J AU Sacks, DB Arnold, M Bakris, GL Bruns, DE Horvath, AR Kirkman, MS Lernmark, A Metzger, BE Nathan, DM AF Sacks, David B. Arnold, Mark Bakris, George L. Bruns, David E. Horvath, Andrea Rita Kirkman, M. Sue Lernmark, Ake Metzger, Boyd E. Nathan, David M. TI Clinical Laboratory Practice Guides Instructions and recommendations for the diagnosis and management of diabetes mellitus Chapters 7 to 13 SO ACTA BIOQUIMICA CLINICA LATINOAMERICANA LA Spanish DT Article C1 [Sacks, David B.] NIH, Dept Lab Med, Bethesda, MD 20892 USA. [Arnold, Mark] Univ Iowa, Dept Chem, Iowa City, IA 52242 USA. [Bakris, George L.] Univ Chicago, Dept Med, Hypertens Dis Unit, Sect Endocrinol Diabet & Metab, Chicago, IL 60637 USA. [Bruns, David E.] Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA. [Horvath, Andrea Rita] Univ Sydney, Screening & Test Evaluat Program, Sch Publ Hlth, SEALS Dept Clin Chem,Prince Wales Hosp, Sydney, NSW 2006, Australia. [Kirkman, M. Sue] Amer Diabet Assoc, Alexandria, VA USA. [Lernmark, Ake] Lund Univ, Dept Clin Sci, CRC, Skane Univ Hosp Malmo, Malmo, Sweden. [Metzger, Boyd E.] Northwestern Univ, Feinberg Sch Med, Div Endocrinol, Chicago, IL 60611 USA. [Nathan, David M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nathan, David M.] Harvard Univ, Sch Med, Ctr Diabet, Boston, MA USA. [Nathan, David M.] Univ Toronto, Toronto, ON M5S 1A1, Canada. RP Sacks, DB (reprint author), NIH, Dept Lab Med, Bldg 10, Bethesda, MD 20892 USA. OI Sacks, David/0000-0003-3100-0735 NR 380 TC 0 Z9 0 U1 0 U2 1 PU FEDERACION BIOQUIMICA PROVINCIA BUENOS AIRES PI LA PLATA, BUENOS AIRES PA CALLE 6, NO. 1344, 1900 LA PLATA, BUENOS AIRES, ARGENTINA SN 0325-2957 EI 1851-6114 J9 ACTA BIOQUIM CLIN L JI Acta Bioquim. Clin. Latinoam. PD DEC PY 2012 VL 46 IS 4 BP 701 EP 741 PG 41 WC Medical Laboratory Technology SC Medical Laboratory Technology GA V33PY UT WOS:000209031900019 ER PT J AU Gordon, EA Pullatt, RC AF Gordon, Elizabeth A. Pullatt, Rana C. TI Treatment of Biliary Stricture: Stents versus Surgery SO AMERICAN SURGEON LA English DT Article C1 [Gordon, Elizabeth A.] Med Univ S Carolina, Dept Gen Surg, Div Gastrointestinal & Laparoscop Surg, Charleston, SC 29401 USA. [Pullatt, Rana C.] Ralph Johnson VA Med Ctr, Charleston, SC USA. RP Gordon, EA (reprint author), Med Univ S Carolina, Dept Surg, Div Gastrointestinal & Laparoscop Surg, 25 Courtenay Dr, Charleston, SC 29401 USA. EM eag2@musc.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU SOUTHEASTERN SURGICAL CONGRESS PI CUMMING PA 115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA SN 0003-1348 EI 1555-9823 J9 AM SURGEON JI Am. Surg. PD DEC PY 2012 VL 78 IS 12 BP E510 EP E512 PG 3 WC Surgery SC Surgery GA V32MD UT WOS:000208954400006 PM 23265103 ER PT J AU Sinclair, AH Schymura, MJ Boscoe, FP Yung, RL Chen, K Roohan, P Tai, E Schrag, D AF Sinclair, Amber H. Schymura, Maria J. Boscoe, Francis P. Yung, Rachel L. Chen, Kun Roohan, Patrick Tai, Eric Schrag, Deborah TI Measuring colorectal cancer care quality for the publicly insured in New York State SO CANCER MEDICINE LA English DT Article DE Colorectal cancer; guideline adherence; Medicaid; Medicare; quality of care AB The extent to which concordance with colorectal cancer treatment quality metrics varies by patient characteristics in the publicly insured is not well understood. Our objective was to evaluate the quality of colorectal cancer care for publicly insured residents of New York State (NYS). NYS cancer registry data were linked to Medicaid and Medicare claims and hospital discharge data. We identified colorectal cancer cases diagnosed from 2004 through 2006 and evaluated three treatment quality measures: adjuvant chemotherapy within 4 months of diagnosis for American Joint Cancer Committee (AJCC) stage III colon cancer, adjuvant radiation within 6 months of diagnosis for AJCC stage IIB or III rectal cancer, and adjuvant chemotherapy within 9 months of diagnosis for AJCC stage II-III rectal cancer. Concordance with guidelines was evaluated separately for Medicaid-enrollees under age 65 years and Medicare-enrollees aged 65-79 years. For adjuvant chemotherapy for colon cancer, 79.4% (274/345) of the Medicaid cohort and 71.8% (585/815) of the Medicare cohort were guideline concordant. For adjuvant radiation for rectal cancer, 72.3% (125/173) of the Medicaid cohort and 66.9% (206/308) of the Medicare cohort were concordant. For adjuvant chemotherapy for rectal cancer, 89.5% (238/266) of the Medicaid cohort and 76.0% (392/516) of the Medicare cohort were concordant. Younger age was associated with higher adjusted odds of concordance for all three measures in the Medicare cohort. Racial differences were not evident in either cohort. There is room for improvement in concordance with accepted metrics of cancer care quality. Feedback about performance may assist in targeting efforts to improve care. C1 [Sinclair, Amber H.; Schymura, Maria J.; Boscoe, Francis P.] New York State Dept Hlth, Canc Registry, Albany, NY USA. [Yung, Rachel L.; Chen, Kun; Schrag, Deborah] Ctr Outcomes & Policy Res, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Roohan, Patrick] New York State Dept Hlth, Off Hlth Insurance Programs, Albany, NY USA. [Tai, Eric] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Boscoe, FP (reprint author), New York State Dept Hlth, New York State Canc Registry, Bur Canc Epidemiol, 150 Broadway Suite 361, Albany, NY 12204 USA. EM fpb01@health.state.ny.us FU Association of Schools of Public Health/Centers for Disease Control Cooperative Agreement [S3888] FX This work was funded, in part, by the Association of Schools of Public Health/Centers for Disease Control Cooperative Agreement S3888, Augmenting New York Cancer Registry Data to Assess Breast and Colorectal Cancer Care. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 25 TC 5 Z9 5 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2045-7634 J9 CANCER MED-US JI Cancer Med. PD DEC PY 2012 VL 1 IS 3 BP 363 EP 371 DI 10.1002/cam4.30 PG 9 WC Oncology SC Oncology GA V36KG UT WOS:000209210400009 PM 23342286 ER PT J AU Boutrus, R Taghian, AG AF Boutrus, Rimoun Taghian, Alphonse G. CA AROME TI Post mastectomy radiation for large node negative breast cancer: Time for a second look SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY LA English DT Article DE Post mastectomy radiation; Breast cancer; Node negative breast cancer; Loco-regional failure AB Patients with node negative and large primary tumors >= 5 cm comprise a rare entity of breast cancer patients for which clear management guidelines are not available. Data about the rates of loco-regional failures (LRF) in this patient population are scarce and reporting widely varying observations. Post Mastectomy Radiation Therapy (PMRT) for this group of patients is controversial. In this review we examined the available literature discussing the LRF rates in this clinical setting and the value of adding PMRT in their management. (C) 2010 Elsevier Ireland Ltd. All rights reserved. C1 [Boutrus, Rimoun; Taghian, Alphonse G.; AROME] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA. RP Taghian, AG (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St Cox Bldg 302, Boston, MA 02114 USA. EM ataghian@partners.org NR 17 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1040-8428 EI 1879-0461 J9 CRIT REV ONCOL HEMAT JI Crit. Rev. Oncol./Hematol. PD DEC 1 PY 2012 VL 84 SU 1 BP E75 EP E78 DI 10.1016/j.critrevonc.2010.10.001 PG 4 WC Oncology; Hematology SC Oncology; Hematology GA V40VS UT WOS:000209506700011 PM 21115360 ER PT J AU Kamal, AH Swetz, KM Dy, S Tien, AY Temel, JS Abernethy, AP AF Kamal, Arif H. Swetz, Keith M. Dy, Sydney Tien, Allen Y. Temel, Jennifer S. Abernethy, Amy P. TI Integrating technology into palliative care research SO CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE LA English DT Review DE palliative care; research; technology AB Purpose of review As palliative care research evolves and grows within resource-strained environments, further integration of novel methods to assist in completing protocols is needed. Technology-assisted techniques, including the use of software and hardware, to aid in data collection, analysis and reporting are increasingly being incorporated into research investigations in palliative care. Reviewing reported successes of technology use in palliative care research is important to communicate lessons learned and principles to guide further implementation. Recent findings There is a growing body of evidence that technology can be effectively integrated into palliative care research. We review four diverse examples of the use of software and hardware technology for data collection from patients and other research participants. Early successes and challenges with technology are also discussed. In addition, seven guiding principles for technology design, implementation and upgrading are appraised to advise readers of the important pitfalls that can plague any well intentioned technology-based research programme. Summary Technology has been successfully integrated into some aspects of palliative care research. The growth of both palliative care research and use of electronic methods for data collection predict increased incorporation between the two fields. C1 [Kamal, Arif H.; Abernethy, Amy P.] Duke Univ, Med Ctr, Duke Canc Inst, Div Med Oncol, Durham, NC 27710 USA. [Swetz, Keith M.] Mayo Clin, Dept Med, Rochester, MN USA. [Dy, Sydney] Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA. [Tien, Allen Y.] Med Decis Log Inc, Baltimore, MD USA. [Temel, Jennifer S.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. RP Kamal, AH (reprint author), Duke Univ, Med Ctr, DUMC Box 3841,10 Bryan Searle Dr,Room 449B, Durham, NC 27710 USA. EM arif.kamal@duke.edu OI Abernethy, Amy/0000-0001-6930-8722 FU US National Institutes of Health; US Agency for Healthcare Research and Quality; Robert Wood Johnson Foundation; Pfizer; Helsinn Therapeutics; Amgen; Kanglaite; Alexion; Biovex; DARA Therapeutics; Mi-Co; Novartis; Bristol Meyers Squibb FX A.P.A has research funding from the US National Institutes of Health, US Agency for Healthcare Research and Quality, Robert Wood Johnson Foundation, Pfizer, Helsinn Therapeutics, Amgen, Kanglaite, Alexion, Biovex, DARA Therapeutics and Mi-Co; these funds are all distributed to Duke University Medical Center to support research. In the last 2 years, she has had nominal consulting agreements with or received honoraria from (<$5000 annually) Helsinn Therapeutics, Amgen and Novartis; similar nominal consulting income is anticipated with Bristol Meyers Squibb and Pfizer in 2012. NR 28 TC 3 Z9 3 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1751-4258 EI 1751-4266 J9 CURR OPIN SUPPORT PA JI Curr. Opin Support Palliat. Car. PD DEC PY 2012 VL 6 IS 4 BP 525 EP 532 DI 10.1097/SPC.0b013e32835998c6 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA V32OT UT WOS:000208961200017 PM 23080307 ER PT J AU Battaglino, RA Lazzari, AA Garshick, E Morse, LR AF Battaglino, Ricardo A. Lazzari, Antonio A. Garshick, Eric Morse, Leslie R. TI Spinal Cord Injury-Induced Osteoporosis: Pathogenesis and Emerging Therapies SO CURRENT OSTEOPOROSIS REPORTS LA English DT Article DE Osteoporosis; Sclerostin; Bone mineral density; Spinal cord injury; Mechanical unloading AB Spinal cord injury causes rapid, severe osteoporosis with increased fracture risk. Mechanical unloading after paralysis results in increased osteocyte expression of sclerostin, suppressed bone formation, and indirect stimulation of bone resorption. At this time, there are no clinical guidelines to prevent bone loss after SCI, and fractures are common. More research is required to define the pathophysiology and epidemiology of SCI-induced osteoporosis. This review summarizes emerging therapeutics including anti-sclerostin antibodies, mechanical loading of the lower extremity with electrical stimulation, and mechanical stimulation via vibration therapy. C1 [Battaglino, Ricardo A.; Morse, Leslie R.] Forsyth Inst, Cambridge, MA 02142 USA. [Battaglino, Ricardo A.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. [Lazzari, Antonio A.] VA Boston Healthcare Syst, Primary Care Sect, Boston, MA 02130 USA. [Lazzari, Antonio A.] VA Boston Healthcare Syst, Rheumatol Sect, Boston, MA 02130 USA. [Lazzari, Antonio A.] Boston Univ, Sch Med, Boston, MA 02130 USA. [Garshick, Eric] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Med Serv, West Roxbury, MA 02132 USA. [Garshick, Eric] Harvard Univ, Sch Med, Dept Med, Channing Lab,Brigham & Womens Hosp, Boston, MA USA. [Morse, Leslie R.] Spaulding Harvard SCI Model Syst, Spaulding Rehabil Hosp, Boston, MA 02114 USA. [Morse, Leslie R.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. RP Morse, LR (reprint author), Spaulding Harvard SCI Model Syst, Spaulding Rehabil Hosp, 125 Nashua St, Boston, MA 02114 USA. EM rbattaglino@forsyth.org; Antonio.Lazzari@va.gov; Eric.Garshick@va.gov; lmorse4@partners.org RI battaglino, ricardo/D-2892-2015; Morse, Leslie/C-9442-2015 OI Morse, Leslie/0000-0002-7426-6341 FU NIAMS NIH HHS [R01 AR059270]; NICHD NIH HHS [L30 HD056721] NR 85 TC 24 Z9 26 U1 0 U2 13 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA EI 1544-2241 J9 CURR OSTEOPOROS REP JI Curr. Osteoporos. Rep. PD DEC PY 2012 VL 10 IS 4 BP 278 EP 285 DI 10.1007/s11914-012-0117-0 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA V35YU UT WOS:000209181800006 PM 22983921 ER PT J AU Tabatabaei, S Talab, SS Zangi, M Woo, HH AF Tabatabaei, Shahin Talab, Saman Shafaat Zangi, Mahdi Woo, Henry H. TI Office Evaluation of Male Patients with Lower Urinary Tract Symptoms SO CURRENT UROLOGY REPORTS LA English DT Article DE Biological markers/blood/urine; Lower urinary tract symptoms/diagnosis/etiology; Male; Middle aged; Prostatic hyperplasia/diagnosis; Risk factors; Spectroscopy, Near-infrared; Ultrasonography/standards; Urodynamics AB Lower urinary tract symptoms due to benign prostatic hyperplasia (LUTS/BPH) are one of the most common urologic disorders in men. Accurate history-taking and focused physical examination allows us to diagnose the majority of cases. A better understanding of risk factors helps us tailor our treatment and predict outcomes more accurately. Population studies are crucial in our understanding of LUTS/BPH natural history. Temporary prostatic urethral stents that are used for the management of urinary retention may also be used for evaluation of patients with detrusor hypo-contractility. The use of ultrasound to measure intravesical prostatic protrusion (IPP) and the Doppler study for prostate capsular artery resistive index are promising. Near-infrared spectroscopy (NIRS) examines the tissue oxygenation that may be affected by bladder outlet obstruction. The mathematical algorithm needs some fine-tuning, and its reproducibility is debatable. Serum and urinary biomarkers may help us to diagnose the disorder, and more effectively monitor patients' response to therapy. Among all, IPP is clinically more applicable at this time. C1 [Tabatabaei, Shahin; Talab, Saman Shafaat] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA. [Zangi, Mahdi] Shahid Beheshti Univ Med Sci, Tehran, Iran. [Woo, Henry H.] Univ Sydney, Sydney Adventist Hosp, Sch Clin, Wahroonga, NSW 2076, Australia. RP Tabatabaei, S (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Urol, 55 Fruit St, Boston, MA 02114 USA. EM stabatabaei@partners.org; sshafaattalab@partners.org; mahdizangi@gmail.com; hwoo@urologist.net.au FU Ethicon FX S. Tabatabaei would like to disclose he has received compensation as a consultant for device development from Smith & Nephew and a research grant for treatment of BPH from Ethicon; S. Talab reported no potential conflicts of interest relevant to this article; M. Zangi reported no potential conflicts of interest relevant to this article; H. Woo would like to disclose he has received compensation as a consultant for American Medical Systems. NR 53 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1527-2737 J9 CURR UROL REP JI Curr. Urol. Rep. PD DEC PY 2012 VL 13 IS 6 BP 474 EP 481 DI 10.1007/s11934-012-0283-8 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA V32IB UT WOS:000208943800011 PM 23015073 ER PT J AU Sugawara, M Ly, T Hershman, JM AF Sugawara, Masahiro Ly, Tran Hershman, Jerome M. TI Medullary Thyroid Cancer-Current Treatment Strategy, Novel Therapies and Perspectives for the Future SO HORMONES & CANCER LA English DT Review AB Medullary thyroid cancer (MTC), an uncommon and slow-growing tumor, is difficult to eradicate when metastasis or recurrence develops. This review describes therapeutic approaches to patients with recurrent sporadic MTC, management of advanced cases of MTC, and future treatment options. A literature review of treatment of MTC in humans was conducted. Surgery is currently the only potentially curative treatment for MTC; complete tumor resection and removal of suspicious nodes is the most important initial treatment to prevent recurrence and metastasis. When recurrence or metastatic MTC develops, the decision for continued observation or initiation of systemic therapy is based on the degree of tumor aggressiveness. Lymph node involvement, calcitonin doubling time, types of RET mutation, and tumor stage are factors that help determine the need for further treatment. Therapeutic options for aggressive and inoperable MTC primarily include tyrosine kinase inhibitors, external beam radiation therapy, or other medications. Among tyrosine kinase inhibitors, vandetanib is the first drug that is FDA approved for treatment of MTC. Focused external beam radiation therapy can be reconsidered for patients with cervical node involvement. Although other targeted drug therapies have been tried, definitive clinical studies are lacking. In recurrent or advanced MTC, when systemic therapy is warranted, vandetanib is available for use in treatment; however, side effects of this drug can be problematic, and impact on overall survival is presently unknown. Newer therapeutics are being studied with the goal of balancing control of tumor growth with maintaining the patient's quality of life. RP Hershman, JM (reprint author), Greater Los Angeles VA Med Ctr, 11307 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jhershmn@ucla.edu NR 55 TC 1 Z9 2 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1868-8497 EI 1868-8500 J9 HORM CANCER-US JI Horm. Cancer PD DEC PY 2012 VL 3 IS 5-6 BP 218 EP 226 DI 10.1007/s12672-012-0119-5 PG 9 WC Oncology; Endocrinology & Metabolism SC Oncology; Endocrinology & Metabolism GA 034JO UT WOS:000310869100002 PM 23011723 ER PT J AU Billett, A Gaur, AH Werner, EJ Winkle, C Hord, JD Brown, R Bundy, D Miller, MR AF Billett, Amy Gaur, Aditya H. Werner, Eric J. Winkle, Cindi Hord, Jeffery D. Brown, Richard Bundy, David Miller, Marlene R. CA Children's Hosp Assoc Quality Tran TI Moving prevention of central line associated bloodstream infection efforts beyond the hospital walls: A multicenter pediatric hematology/oncology collaborative SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Boston Childrens Hosp, Boston, MA USA. St Jude Childrens Res Hosp, Memphis, TN 38105 USA. Eastern Virginia Med Sch, Norfolk, VA 23501 USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Akron Childrens Hosp, Akron, OH USA. Univ Alabama Birmingham, Div Pediat Hematol Oncol, Birmingham, AL USA. Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 86 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900086 ER PT J AU Bohlen, N Lyons, HF Cashavelly, BJ Lennes, IT AF Bohlen, Nie Lyons, Hannah Felton Cashavelly, Barbara J. Lennes, Inga Tolin TI Implementing independent double checks for patient-controlled analgesia (PCA) pump programming SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 153 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900153 ER PT J AU Bunnell, CA Gross, A Kalfin, M Partridge, AH Lane, S Burstein, HJ Fine, B Hilton, N Sullivan, C Colicchio, L Hagemeister, E Kelly, A Szabatura, A Winer, EP Mann, S Weingart, S AF Bunnell, Craig A. Gross, Anne Kalfin, Michael Partridge, Ann H. Lane, Sharon Burstein, Harold J. Fine, Barbara Hilton, Nancy Sullivan, Clare Colicchio, Lynn Hagemeister, Erin Kelly, Anne Szabatura, Audrea Winer, Eric P. Mann, Susan Weingart, Saul TI Implementation of team training in outpatient breast oncology SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 83 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900083 ER PT J AU Dalby, C Campos, SM Doverspike, L Spinks, M Jacobson, JO AF Dalby, Carole Campos, Susana M. Doverspike, Lisa Spinks, Melissa Jacobson, Joseph O. TI Securing discharge follow-up appointments in a women's cancer program SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 81 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900081 ER PT J AU Efstathiou, JA Nassif, D Chen, RC Hoffman, KE Kuban, DA Lawton, CA Michalski, JM Potters, L Rose, CM Sandler, HM Suh, W Wall, T Zietman, AL Bekelman, JE AF Efstathiou, Jason Alexander Nassif, Deborah Chen, Ronald C. Hoffman, Karen Elizabeth Kuban, Deborah A. Lawton, Colleen Anne Michalski, Jeff M. Potters, Louis Rose, Christopher M. Sandler, Howard Mark Suh, Warren Wall, Terry Zietman, Anthony L. Bekelman, Justin E. TI National Radiation Oncology Registry: The pilot prostate cancer registry SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. Univ N Carolina, Chapel Hill, NC USA. Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. Washington Univ, Sch Med, St Louis, MO USA. North Shore LIJ Hlth Syst, Manhasset, NY USA. Valley Radiotherapy Associates Med Grp, Manhattan Beach, CA USA. Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA. Canc Ctr Santa Barbara, Santa Barbara, CA USA. St Lukes Hosp, Kansas City, MO USA. Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 267 PG 2 WC Oncology SC Oncology GA V32IC UT WOS:000208943900265 ER PT J AU Fisch, M Zhao, FM Manola, J Miller, AH Pirl, WF Wagner, LI AF Fisch, Michael Zhao, Fengmin Manola, Judith Miller, Andrew H. Pirl, William F. Wagner, Lynne I. CA ECOG-ACRIN TI Patterns of antidepressant use in patients with cancer: An analysis from SOAPP (E2Z02: Symptom Outcomes and Practice Patterns) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Emory Univ, Sch Med, Atlanta, GA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 59 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900059 ER PT J AU Glotzbecker, B Yolin-Raley, D Close, S Soiffer, R Antin, JH Jacobson, JO Alyea, E AF Glotzbecker, Brett Yolin-Raley, Deborah Close, Sara Soiffer, Robert Antin, Joseph H. Jacobson, Joseph O. Alyea, Edwin TI Reducing unnecessary testing on admission in autologous stem cell transplant (SCT) patients SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Glotzbecker, Brett; Yolin-Raley, Deborah; Close, Sara; Soiffer, Robert; Antin, Joseph H.; Jacobson, Joseph O.; Alyea, Edwin] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 185 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900185 ER PT J AU Gross, A Mann, S Kalfin, M Lane, S Weingart, S Bunnell, CA AF Gross, Anne Mann, Susan Kalfin, Michael Lane, Sharon Weingart, Saul Bunnell, Craig A. TI Team training in adult oncology SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 27 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900028 ER PT J AU Howe, R Hassett, MJ Wheelock, A Thorsen, CM Kaplan, C Ozanne, E AF Howe, Rebecca Hassett, Michael J. Wheelock, Alyse Thorsen, Cristina M. Kaplan, Celia Ozanne, Elissa TI Cost of cancer care: The impact of disclosure on willingness to pay and treatment preferences SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Illinois, San Francisco, CA USA. Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 15 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900016 ER PT J AU Jacobson, JO Kadlubek, P Malin, JL Solem, CT Neuss, MN AF Jacobson, Joseph O. Kadlubek, Pamela Malin, Jennifer L. Solem, Caitlyn T. Neuss, Michael N. TI Concordance and disease type variables between adjuvant chemotherapy (AC) recommended and received as assessed by the Quality Oncology Practice Initiative (QOPI) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Amer Soc Clin Oncol, Alexandria, VA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Pharmerit, Bethesda, MD USA. Vanderbilt Ingram Canc Ctr, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 214 PG 2 WC Oncology SC Oncology GA V32IC UT WOS:000208943900213 ER PT J AU Kangovi, S Evans, TL Mitra, N AF Kangovi, Shreya Evans, Tracey L. Mitra, Nandita TI Patient-reported oncology readmission factors SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 48 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900048 ER PT J AU Klink, JC Michalski, JM Sanda, MG Litwin, MS Ferrer, M Hamstra, DA Regan, MM Saigal, C Kwan, L Gao, TM Klein, EA Kattan, MW Stephenson, AJ AF Klink, Joseph C. Michalski, Jeff M. Sanda, Martin G. Litwin, Mark S. Ferrer, Montserrat Hamstra, Daniel A. Regan, Meredith M. Saigal, Christopher Kwan, Lorna Gao, Tianming Klein, Eric A. Kattan, Michael W. Stephenson, Andrew J. TI Nomogram predicting treatment- related bowel dysfunction for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), and brachytherapy (PI) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Glickman Urol & Kidney Inst, Cleveland, OH USA. Cleveland Clin, Cleveland, OH 44106 USA. Washington Univ, Sch Med, St Louis, MO USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. Inst Hosp del Mar Invest Med, Barcelona, Spain. Univ Michigan, Med Ctr, Ann Arbor, MI USA. Dana Farber Canc Inst, Boston, MA 02115 USA. UCLAs Jonsson Comprehens Canc Ctr, Los Angeles, CA USA. Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA. Glickman Urol & Kidney Inst, Ctr Urol Oncol, Cleveland, OH USA. RI Sanda, Martin/B-2023-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 55 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900055 ER PT J AU Klink, JC Sanda, MG Litwin, MS Ferrer, M Regan, MM Saigal, C Kwan, L Gao, TM Klein, EA Kattan, MW Stephenson, AJ AF Klink, Joseph C. Sanda, Martin G. Litwin, Mark S. Ferrer, Montserrat Regan, Meredith M. Saigal, Christopher Kwan, Lorna Gao, Tianming Klein, Eric A. Kattan, Michael W. Stephenson, Andrew J. TI Nomogram predicting treatment-related sexual dysfunction for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), and brachytherapy (PI) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Glickman Urol & Kidney Inst, Cleveland, OH USA. Cleveland Clin, Cleveland, OH 44106 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. Inst Hosp Mar Invest Med, Barcelona, Spain. Dana Farber Canc Inst, Boston, MA 02115 USA. UCLAs Jonsson Comprehens Canc Ctr, Los Angeles, CA USA. Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA. Glickman Urol & Kidney Inst, Ctr Urol Oncol, Cleveland, OH USA. RI Sanda, Martin/B-2023-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 51 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900051 ER PT J AU Klink, JC Sanda, MG Litwin, MS Ferrer, M Regan, MM Saigal, C Kwan, L Gao, TM Klein, EA Kattan, MW Stephenson, AJ AF Klink, Joseph C. Sanda, Martin G. Litwin, Mark S. Ferrer, Montserrat Regan, Meredith M. Saigal, Christopher Kwan, Lorna Gao, Tianming Klein, Eric A. Kattan, Michael W. Stephenson, Andrew J. TI Nomogram predicting treatment-related urinary incontinence for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), or brachytherapy (PI) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Glickman Urol & Kidney Inst, Cleveland, OH USA. Cleveland Clin, Cleveland, OH 44106 USA. Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. Inst Hosp del Mar Invest Med, Barcelona, Spain. Dana Farber Canc Inst, Boston, MA 02115 USA. UCLAs Jonsson Comprehens Canc Ctr, Los Angeles, CA USA. Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA. Glickman Urol & Kidney Inst, Ctr Urol Oncol, Cleveland, OH USA. RI Sanda, Martin/B-2023-2015 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 49 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900049 ER PT J AU Mamon, HJ Steingisser, L Fallon, J Walsh, G Jacobson, JO AF Mamon, Harvey J. Steingisser, Lee Fallon, John Walsh, Gerard Jacobson, Joseph O. TI Rational use of intensity-modulated radiation therapy (IMRT) as determined by radiation oncologists in cooperation with Blue Cross Blue Shield of Massachusetts (BCBSMA) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA. Blue Cross & Blue Shield Massachusetts, North Quincy, MA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 73 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900073 ER PT J AU Miksad, RA Goyal, R Gazelle, GS Swan, JS AF Miksad, Rebecca A. Goyal, Rohit Gazelle, G. Scott Swan, J. Shannon TI Expanding patient-reported outcomes to oral health complications from systemic cancer therapy SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 60 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900060 ER PT J AU Neuss, MN Malin, J Chan, S Kadlubek, P Adams, JL Joseph, J Blayney, D Simone, JV AF Neuss, Michael N. Malin, Jennifer Chan, Stephanie Kadlubek, Pamela Adams, John L. Joseph, Jacobson Blayney, Douglas Simone, Joseph V. TI Measuring the improving quality of outpatient care in medical oncology practices in the United States SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA. WellPoint Inc, Indianapolis, IN USA. RAND Corp, Santa Monica, CA USA. Amer Soc Clin Oncol, Alexandria, VA USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Stanford Univ, Palo Alto, CA 94304 USA. Simone Consulting, Dunwoody, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 66 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900066 ER PT J AU Norden, AD Buswell, LA Amorati, M Arthur, L Bernard, A Constantine, M Dalby, C Farrar, W Fuller, F Kerivan, D Lacourse, K McNulty, BD Racicot, A Spinks, M Jacobson, JO Ponte, PR Shulman, LN AF Norden, Andrew David Buswell, Lori A. Amorati, Meg Arthur, Lois Bernard, Antoinette Constantine, Michael Dalby, Carole Farrar, Wendy Fuller, Frances Kerivan, Dawn Lacourse, Kristin McNulty, Brendan D. Racicot, Adonica Spinks, Melissa Jacobson, Joseph O. Ponte, Patricia Reid Shulman, Lawrence N. TI Wait time reduction for patients awaiting chemotherapy infusion using a formal process improvement approach and sequential SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Dana Farber Canc Inst, Boston, MA 02115 USA. Milford Reg Med Ctr, Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Milford, MA USA. Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 92 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900092 ER PT J AU Shelton, JB Skolarus, TA Malin, J Antonio, ALM He, R Saigal, C AF Shelton, Jeremy Bradford Skolarus, Ted A. Malin, Jennifer Antonio, Anna Liza M. He, Ren Saigal, Christopher TI Validation of electronic prostate cancer quality-of-care measures in the Veterans Health Administration (VHA) SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 213 PG 2 WC Oncology SC Oncology GA V32IC UT WOS:000208943900212 ER PT J AU Walling, AM Tisnado, DM Malin, J Asch, SM Pantoja, P Ettner, S Dy, SM Lorenz, KA AF Walling, Anne M. Tisnado, Diana M. Malin, Jennifer Asch, Steven M. Pantoja, Philip Ettner, Susan Dy, Sydney Morss Lorenz, Karl A. TI National evaluation of the VA's quality of supportive care. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 218 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900217 ER PT J AU Walling, AM Dy, SM Malin, J Mack, JW Kim, B Lorenz, K Tisnado, DM AF Walling, Anne M. Dy, Sydney Morss Malin, Jennifer Mack, Jennifer W. Kim, Benjamin Lorenz, Karl Tisnado, Diana M. TI Evaluating the quality of supportive oncology using patientreported survey data SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Univ Calif San Francisco, Sch Med, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 42 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900042 ER PT J AU Wolfgang, JA Hong, TS AF Wolfgang, John A. Hong, Theodore S. TI Radiation oncology whiteboard: Data and workflow manager for enhanced communication and task management SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 [Wolfgang, John A.; Hong, Theodore S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 304 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900301 ER PT J AU Zullig, LL Peppercorn, JM Schrag, D Taylor, DH Zhong, XY Samsa, G Abernethy, AP Zafar, Y AF Zullig, Leah L. Peppercorn, Jeffrey M. Schrag, Deborah Taylor, Donald H. Zhong, Xiaoyin Samsa, Gregory Abernethy, Amy Pickar Zafar, Yousuf TI Copayment assistance and adherence to prescription medication among patients with cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract C1 Univ N Carolina, Dept Hlth Policy & Management, Chapel Hill, NC USA. Duke Univ, Med Ctr, Durham, NC USA. Dana Farber Canc Inst, Boston, MA 02115 USA. Duke Canc Care Res Program, Durham, NC USA. Duke Univ, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD DEC 1 PY 2012 VL 30 IS 34 SU S MA 57 PG 1 WC Oncology SC Oncology GA V32IC UT WOS:000208943900057 ER PT J AU Jupiter, JB AF Jupiter, Jesse B. TI First Hand: Sports Journal Club Levels the Field of Education SO JOURNAL OF HAND SURGERY-AMERICAN VOLUME LA English DT Editorial Material C1 [Jupiter, Jesse B.] Massachusetts Gen Hosp, Handand Upper Extrem Serv, Boston, MA 02114 USA. RP Jupiter, JB (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Handand Upper Extrem Serv, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM jjupiter1@partners.org NR 1 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0363-5023 EI 1531-6564 J9 J HAND SURG-AM JI J. Hand Surg.-Am. Vol. PD DEC PY 2012 VL 37A IS 12 BP 2595 EP 2596 DI 10.1016/j.jhsa.2012.10.003 PG 2 WC Orthopedics; Surgery SC Orthopedics; Surgery GA V34LX UT WOS:000209089000024 ER PT J AU Guanci, MM AF Guanci, Mary McKenna TI Clinical Q & A: Translating Therapeutic Temperature Management from Theory to Practice SO THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT LA English DT Letter C1 Massachusetts Gen Hosp, Neurosci ICU, Boston, MA 02114 USA. RP Guanci, MM (reprint author), Massachusetts Gen Hosp, Neurosci ICU, Boston, MA 02114 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2153-7658 EI 2153-7933 J9 THER HYPOTHERMIA TEM JI Ther. Hypothermia Temp. Manag. PD DEC 1 PY 2012 VL 2 IS 4 BP 194 EP 195 PG 2 WC Critical Care Medicine SC General & Internal Medicine GA V38PM UT WOS:000209355300011 ER PT J AU Vlisides, P Xie, ZC AF Vlisides, Phillip Xie, Zhongcong TI Neurotoxicity of General Anesthetics: An Update SO CURRENT PHARMACEUTICAL DESIGN LA English DT Review DE Anesthesia; neurotoxicity; beta-amyloid protein; cognitive function ID POSTOPERATIVE COGNITIVE DYSFUNCTION; HYPOTHERMIC CIRCULATORY ARREST; ISOFLURANE INDUCES APOPTOSIS; FLOW CARDIOPULMONARY BYPASS; INDUCED CASPASE-3 ACTIVATION; RANDOMIZED CONTROLLED-TRIAL; MAJOR NONCARDIAC SURGERY; FOCAL CEREBRAL-ISCHEMIA; AMYLOID PROTEIN-LEVELS; INFANT MOUSE-BRAIN AB Though general anesthetics have now been used clinically for well over a century, both their mechanisms of action as well as the nature of any potentially neurotoxic side effects remain elusive. With roughly 234 million people undergoing surgery each year worldwide, it remains imperative that any potentially deleterious effects of anesthetics be investigated and addressed. The issue of anesthetic-induced neurotoxicity in certain subsets of patients has continued to garner attention over the past decade, as more pre-clinical and clinical studies released are suggesting that inhalational and intravenous anesthetics may both cause and mitigate existing significant neuropathology. Pre-clinically, both cell-culture and animal studies suggest that anesthetics may cause neuroapoptosis, caspase activation, neurodegeneration, beta-amyloid protein (A beta) accumulation and oligomerization, and ultimately, deficits in neurocognition. Interestingly, however, newer data suggest that certain volatile anesthetics, such as desflurane, may have a less harmful neurotoxic profile compared to others in the pre-clinical and clinical settings. Continued pre-clinical investigation may have significant impact on clinical practice in the near future. Clinically, recent studies have raised awareness that exposure to general anesthetics during childhood may be associated with an increased risk for subsequent deficits in learning, memory, and cognition. Furthermore, retrospective studies continue to allude to the potential effects of surgery and anesthesia on cognitive trajectory, and more specifically, post-operative cognitive dysfunction (POCD) in the elderly. Studies to date regarding both of these clinical topics, however, are fraught with confounders, and many are underpowered statistically. The aim of this review is to examine the current data (both pre-clinical and clinical) on anesthetic-induced neurotoxicity and argue that further data are needed to either support or refute the potential connection between anesthetics and neurotoxicity. C1 [Vlisides, Phillip; Xie, Zhongcong] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. RP Xie, ZC (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 149 13th St,Room 4310, Charlestown, MA 02129 USA. EM zxie@partners.org FU (National Institutes of Health), Cure Alzheimer's Fund, USA [R21AG029856, R21AG038994, R01 GM088801] FX This research was supported by R21AG029856, R21AG038994 and R01 GM088801 (National Institutes of Health), Cure Alzheimer's Fund, USA (to Zhongcong Xie). NR 120 TC 18 Z9 20 U1 3 U2 42 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1381-6128 J9 CURR PHARM DESIGN JI Curr. Pharm. Design PD DEC PY 2012 VL 18 IS 38 BP 6232 EP 6240 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 030OK UT WOS:000310579800007 PM 22762477 ER PT J AU Morshed, SA Latif, R Davies, TF AF Morshed, Syed A. Latif, Rauf Davies, Terry F. TI Delineating the autoimmune mechanisms in Graves' disease SO IMMUNOLOGIC RESEARCH LA English DT Article DE AITD; GD; HT; Autoimmunity; TSHR; Autoantibody ID REGULATORY T-CELLS; STIMULATING HORMONE-RECEPTOR; HUMAN THYROTROPIN RECEPTOR; OPPOSITE PHENOTYPIC MANIFESTATIONS; FAS-MEDIATED APOPTOSIS; THYROID-DISEASE; TSH-RECEPTOR; MONOCLONAL-ANTIBODIES; GENETIC SUSCEPTIBILITY; DENDRITIC CELLS AB The immunologic processes involved in autoimmune thyroid disease (AITD), particularly Graves' disease (GD), are similar to other autoimmune diseases with the emphasis on the antibodies as the most unique aspect. These characteristics include a lymphocytic infiltrate at the target organs, the presence of antigen-reactive T and B cells and antibodies, and the establishment of animal models of GD by antibody transfer or immunization with antigen. Similar to other autoimmune diseases, risk factors for GD include the presence of multiple susceptibility genes, including certain HLA alleles, and the TSHR gene itself. In addition, a variety of known risk factors and precipitators have been characterized including the influence of sex and sex hormones, pregnancy, stress, infection, iodine and other potential environmental factors. The pathogenesis of GD is likely the result of a breakdown in the tolerance mechanisms, both at central and peripheral levels. Different subsets of T and B cells together with their regulatory populations play important roles in the propagation and maintenance of the disease process. Understanding different mechanistic in the complex system biology interplay will help to identify unique factors contributing to the AITD pathogenesis. C1 [Morshed, Syed A.; Latif, Rauf; Davies, Terry F.] Mt Sinai Sch Med, Thyroid Res Unit, James J Peters VA Med Ctr, New York, NY 10468 USA. RP Morshed, SA (reprint author), Mt Sinai Sch Med, Thyroid Res Unit, James J Peters VA Med Ctr, Room 2F-26,130 W Kingsbridge Rd, New York, NY 10468 USA. EM syed.morshed@mssm.edu OI latif, rauf/0000-0002-4226-3728 FU NIH [DK069713, DK052464]; VA Merit Award Program FX Supported in part by NIH grants DK069713, DK052464 and the VA Merit Award Program. We thank Dr. Xiaoming Yin for help with the manuscript. NR 127 TC 28 Z9 32 U1 0 U2 23 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0257-277X J9 IMMUNOL RES JI Immunol. Res. PD DEC PY 2012 VL 54 IS 1-3 SI SI BP 191 EP 203 DI 10.1007/s12026-012-8312-8 PG 13 WC Immunology SC Immunology GA 025EK UT WOS:000310168100019 PM 22434518 ER PT J AU Hasham, A Tomer, Y AF Hasham, Alia Tomer, Yaron TI Genetic and epigenetic mechanisms in thyroid autoimmunity SO IMMUNOLOGIC RESEARCH LA English DT Article DE Thyroid genetics; Autoimmune thyroid disorders; Epigenetics ID SINGLE-NUCLEOTIDE POLYMORPHISM; GRAVES-DISEASE; SUSCEPTIBILITY LOCI; DIABETES-MELLITUS; CD40 GENE; THYROGLOBULIN; EXPRESSION; ACID; GENOME; REGION AB Autoimmune thyroid diseases (AITD), including Graves' disease and Hashimoto's thyroiditis, are among the commonest autoimmune disorders, affecting approximately 5 % of the population. Epidemiological data support strong genetic influences on the development of AITD. Since the identification of HLA-DR3 as a major AITD susceptibility gene, there have been significant advances made in our understanding of the genetic mechanisms leading to AITD. We have shown that an amino acid substitution of alanine or glutamine with arginine at position 74 in the HLA-DR peptide binding pocket is a critical factor in the development of AITD, and we are continuing to dissect these mechanisms at the molecular level. In addition to the MHC class II genes, there are now several other confirmed gene loci associated with AITD, including immune-regulatory (CD40, CTLA-4, PTPN22, FOXP3, and CD25) and thyroid-specific genes (thyroglobulin and TSHR). Mechanistically, it is postulated that susceptibility genes interact with certain environmental triggers to induce AITD through epigenetic effects. In this review, we summarize some of the recent advances made in our laboratory dissecting the genetic-epigenetic interactions underlying AITD. As shown in our recent studies, epigenetic modifications offer an attractive mechanistic possibility that can provide further insight into the etiology of AITD. C1 [Hasham, Alia; Tomer, Yaron] Mt Sinai Med Ctr, Div Endocrinol, Dept Med, New York, NY 10029 USA. [Hasham, Alia; Tomer, Yaron] James J Peters VA Med Ctr, Bronx, NY 10468 USA. RP Tomer, Y (reprint author), Mt Sinai Med Ctr, Div Endocrinol, Dept Med, 1 Gustave L Levy Pl,Box 1055, New York, NY 10029 USA. EM Yaron.Tomer@mssm.edu FU National Institutes of Health [DK61659, DK067555, DK073681]; Veterans Affairs merit award FX This work was supported in part by National Institutes of Health Grants DK61659, DK067555, and DK073681. This work was also supported by a Veterans Affairs merit award (to Y.T.). NR 35 TC 25 Z9 25 U1 1 U2 43 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 0257-277X EI 1559-0755 J9 IMMUNOL RES JI Immunol. Res. PD DEC PY 2012 VL 54 IS 1-3 SI SI BP 204 EP 213 DI 10.1007/s12026-012-8302-x PG 10 WC Immunology SC Immunology GA 025EK UT WOS:000310168100020 PM 22457094 ER PT J AU Hou, JB Jia, HB Liu, HX Han, ZG Yang, S Xu, CY Schmitt, J Zhang, SS Yu, B Jang, IK AF Hou, Jingbo Jia, Haibo Liu, Haixia Han, Zhigang Yang, Shuang Xu, Chenyang Schmitt, Joseph Zhang, Shaosong Yu, Bo Jang, Ik-Kyung TI Neointimal tissue characteristics following sirolimus-eluting stent implantation: OCT quantitative tissue property analysis SO INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING LA English DT Article DE Neointima coverage; Neointima heterogeneity; Optical coherence tomography; Sirolimus-eluting stent ID OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; INTRAVASCULAR ULTRASOUND; HUMAN ATHEROSCLEROSIS; ARTERY-DISEASE; THROMBOSIS; COVERAGE; RESTENOSIS; PATTERNS; REGISTRY AB The neointimal tissue characteristics inside sirolimus-eluting stent (SES) were evaluated by optical coherence tomography (OCT) according to follow-up duration. One hundred and thirty-three Optical coherence tomography was performed in 96 patients with 143 SES which were retrospectively included and divided into 2 groups according to follow-up duration: Group 1, < 24 months (98 stents in 71 patients); Group 2, > 24 months (35 stents in 25 patients). The neointimal tissue coverage pattern and characteristics were studied using a new OCT analysis system which can quantitatively analyze tissue property by measuring attenuation, backscatter and signal intensity in the region of interest. Using these parameters, a multivariable logistic regression model was constructed to divide neointima into homogenous or heterogeneous type. We defined homogeneous nointima as neointimal tissue having uniform optical properties and does not showing focal variations in backscattering pattern and heterogeneous neointima as neointimal tissue with focally changing optical properties and showing various backscattering patterns. The average time between stent implantation and follow-up OCT imaging was 1.2 years in Group 1 and 3.2 years in Group 2. The number of neointima covered cross-sections, neointimal thickness, and neointimal area increased significantly with the length of follow-up duration after SES implantation (P < 0.01). The incidence of heterogeneous neointima was higher in Group 2 than in Group 1 (P < 0.01). Heterogeneous neointima was associated with higher incidence of microvessels (P = 0.0023) and lipid rich plaque (P = 0.0015) compared with homogeneous neointima. The neointimal tissue characteristics may change over time after SES implantation. The incidence of heterogeneous pattern was higher in the SES group with longer follow-up duration. Microvessels and lipid rich plaques were more frequently observed in neointima with heterogeneous pattern. Neointimal heterogeneity could be an important factor for the late stability of SES. C1 [Hou, Jingbo; Jia, Haibo; Liu, Haixia; Han, Zhigang; Yang, Shuang; Yu, Bo] Harbin Med Univ, Dept Cardiol, Educ Minist Myocardial Ischemia Mech & Treatment, Key Labs,Affiliated Hosp 2, Harbin 150086, Peoples R China. [Xu, Chenyang; Schmitt, Joseph; Zhang, Shaosong] LightLab Imaging Inc, Westford, MA USA. [Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA. RP Yu, B (reprint author), Harbin Med Univ, Dept Cardiol, Educ Minist Myocardial Ischemia Mech & Treatment, Key Labs,Affiliated Hosp 2, Harbin 150086, Peoples R China. EM yubodr@163.com FU National Natural Science Foundation of China [30871064/C140401]; Open Foundation of Key Laboratory of Myocardial Ischemia Mechanism and Treatment (Harbin Medical University), Ministry of Education [KF201007]; LightLab Imaging; Science and Technology Key Project of Heilongjiang Province, China [GC10C305-3] FX Contract grant sponsor: Science and Technology Key Project of Heilongjiang Province, China; contract grant number: GC10C305-3. Contract grant sponsor: National Natural Science Foundation of China; contract grant number: 30871064/C140401. Contract grant sponsor: Open Foundation of Key Laboratory of Myocardial Ischemia Mechanism and Treatment (Harbin Medical University), Ministry of Education; contract grant number: KF201007.; S Zhang, Chenyang Xu, and Joseph Schmitt are employees of LightLab Imaging. IK Jang received research grant and honorarium from LightLab Imaging. The other authors have no potential conflict of interest with industry. NR 29 TC 10 Z9 12 U1 1 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1569-5794 J9 INT J CARDIOVAS IMAG JI Int. J. Cardiovasc. Imaging PD DEC PY 2012 VL 28 IS 8 BP 1879 EP 1886 DI 10.1007/s10554-012-0031-7 PG 8 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 030AJ UT WOS:000310539700005 PM 22422037 ER PT J AU Yeddula, K Ahmad, I Mohammed, SHS Hedgire, S Venkatesh, V Abbara, S Kalva, SP AF Yeddula, Kalpana Ahmad, Iftikhar Mohammed, Shafaath Husain Syed Hedgire, Sandeep Venkatesh, Vikram Abbara, Suhny Kalva, Sanjeeva P. TI Paradoxical air embolism following contrast material injection through power injectors in patients with a patent foramen ovale SO INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING LA English DT Article DE Patent foramen ovale; Paradoxical air embolism; Vascular air embolus; Contrast material injection ID IMAGING FINDINGS; STROKE; ECHOCARDIOGRAPHY; EVENTS; SIZE; CT AB In patients with a patent foramen ovale, use of air filters during intravenous infusions is common, but they are not compatible with power injection. Therefore we aimed to assess the incidence of paradoxical air embolism on CT of the chest and brain following contrast material injection through a power injector in patients with a patent foramen ovale, without the use of a filter. In this IRB approved, HIPAA compliant retrospective study, two independent radiologists reviewed 289 CT scans of the chest (n = 233) and brain (n = 56) for vascular air embolism following contrast material injection through a power injector in 93 subjects (43 men, mean age 66 y) with a known patent foramen ovale. The location and amount of the air were assessed. The medical records were reviewed for embolic symptoms. The prevalence and location of right sided and systemic luminal air were determined and inter-observer agreement for detection of intraluminal vascular air was calculated. Vascular air embolism was observed in 19.3% (56/289) of the studies; small in 52 and moderate in 4. In 42 studies, intravascular air was seen in a single territory and 14 studies had intravascular air in multiple territories. None had air in the left side of the heart or brain to suggest paradoxical air embolism. The inter-observer agreement for detection of vascular air was moderate (k = 0.6). Paradoxical air embolism in patients with a patent foramen ovale following contrast material injection with a power injector is rare. C1 [Yeddula, Kalpana; Ahmad, Iftikhar; Mohammed, Shafaath Husain Syed; Hedgire, Sandeep; Venkatesh, Vikram; Abbara, Suhny; Kalva, Sanjeeva P.] Massachusetts Gen Hosp, Dept Imaging, Boston, MA 02114 USA. [Yeddula, Kalpana; Ahmad, Iftikhar; Mohammed, Shafaath Husain Syed; Hedgire, Sandeep; Venkatesh, Vikram; Abbara, Suhny; Kalva, Sanjeeva P.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. RP Kalva, SP (reprint author), Massachusetts Gen Hosp, Dept Imaging, GRB 297,55 Fruit St, Boston, MA 02114 USA. EM skalva@partners.org NR 20 TC 1 Z9 1 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1569-5794 J9 INT J CARDIOVAS IMAG JI Int. J. Cardiovasc. Imaging PD DEC PY 2012 VL 28 IS 8 BP 2085 EP 2090 DI 10.1007/s10554-012-0017-5 PG 6 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA 030AJ UT WOS:000310539700025 PM 22302647 ER PT J AU Reme, SE Dennerlein, JT Hashimoto, D Sorensen, G AF Reme, Silje Endresen Dennerlein, Jack T. Hashimoto, Dean Sorensen, Glorian TI Musculoskeletal Pain and Psychological Distress in Hospital Patient Care Workers SO JOURNAL OF OCCUPATIONAL REHABILITATION LA English DT Article DE Healthcare workers; Nursing personnel; Musculoskeletal disorders (MSDs); Musculoskeletal pain; Psychological distress; Pain interference with work ID LOW-BACK-PAIN; NECK-PAIN; BEHAVIORAL TREATMENT; SCREENING SCALES; RISK-FACTORS; HEALTH; INTERVENTIONS; METAANALYSIS; POPULATION; PREDICTORS AB Purpose The aim of the study was to assess the association of psychological distress and musculoskeletal pain, how it is related to pain interference with work and multiple pain areas, and potential differences between the different pain areas in hospital patient care workers. Methods Data were collected from a cross-sectional survey of patient care workers (n = 1,572) from two large hospitals. Results Patient care workers with musculoskeletal pain reported significantly more psychological distress than those without pain. Psychological distress was significantly related to pain interference with work, even after adjusting for pain and demographics (OR = 1.05; CI = 1.01-1.09). The association was strongest for those with both upper- and lower body pain (OR = 1.12; CI = 1.06-1.18). Psychological distress was also independently associated with multiple pain areas. Conclusions Psychological distress was found to be higher in workers with musculoskeletal pain, and highest among workers with both upper and lower body pain. Distress was further significantly associated with pain interference with work as well as number of pain areas. The findings may be followed up with a longitudinal design to better determine the direction of the associations, and to investigate if psychological distress increases the risk of work disability and injuries. C1 [Reme, Silje Endresen; Dennerlein, Jack T.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02215 USA. [Reme, Silje Endresen] Liberty Mutual Res Inst Safety, Hopkinton, MA USA. [Dennerlein, Jack T.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Hashimoto, Dean] Partners HealthCare Inc, Dept Occupat Hlth, Boston, MA USA. [Sorensen, Glorian] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA. [Sorensen, Glorian] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA. RP Reme, SE (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 450 Brookline Ave, Boston, MA 02215 USA. EM sreme@hsph.harvard.edu OI Dennerlein, Jack/0000-0001-7703-643X FU NCI NIH HHS [K05 CA108663]; NIOSH CDC HHS [U19 OH008861] NR 38 TC 5 Z9 7 U1 1 U2 11 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1053-0487 J9 J OCCUP REHABIL JI J. Occup. Rehabil. PD DEC PY 2012 VL 22 IS 4 BP 503 EP 510 DI 10.1007/s10926-012-9361-5 PG 8 WC Rehabilitation; Social Issues SC Rehabilitation; Social Issues GA 029CM UT WOS:000310472400007 PM 22466375 ER PT J AU Lee, KB Taghavi, CE Murray, SS Song, KJ Keorochana, G Wang, JC AF Lee, Kwang-Bok Taghavi, Cyrus E. Murray, Samuel S. Song, Kyung-Jin Keorochana, Gun Wang, Jeffrey C. TI BMP induced inflammation: A comparison of rhBMP-7 and rhBMP-2 SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE soft tissue edema; inflammation; rhBMP-7; rhBMP-2; MIPAV ID BONE MORPHOGENETIC PROTEIN; ANTERIOR CERVICAL-SPINE; OSTEOGENIC PROTEIN-1; SAFETY PROFILE; FUSION; SURGERY; RATS AB Concern has been raised because of reports of inflammatory swelling following the use of recombinant human bone morphogenetic protein-2 (rhBMP-2) and recombinant human bone morphogenetic protein-7 (rhBMP-7). The purpose of this study is to compare the inflammatory action of rhBMP-7 with those of rhBMP-2. ELISA assays (IL-6, TNF-a) were used to measure the cytokine response to different concentrations of rhBMP-7 and -2. Recombinant human BMP-7 was absorbed into absorbable collagen sponges and different amounts were implanted either subcutaneously (SC) or intramuscularly (IM) into the backs of rats. Using MRI and MIPAV software, we measured the degree of soft tissue edema at 3?h and at 2, 4, and 7 days postoperatively. After sacrificing rats on day 7 the inflammatory zone and mass were measured and the tissue examined histologically. Soft tissue edema after rhBMP-7 and rhBMP-2 implantation was dose-dependent and peaked at 3?h for the subcutaneous implants and at 2 days for the intramuscular implants. RhBMP-7 was associated with a significantly smaller soft tissue edema volume than was rhBMP-2 only at the highest dose (20?mu g/ml). Both rhBMP-2 and rhBMP-7 triggered dose-dependent inflammatory reactions. Compared to rhBMP-2, rhBMP-7 is associated with somewhat smaller soft tissue edema volumes. Although rhBMP-7 is associated with an inflammatory reaction leading to soft tissue edema, at high doses this response is significantly less than that seen with rhBMP-2. Our animal model can be used to test materials that could ameliorate this reaction. (c) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:19851994, 2012 C1 [Lee, Kwang-Bok; Taghavi, Cyrus E.; Keorochana, Gun; Wang, Jeffrey C.] Univ Calif Los Angeles, UCLA Comprehens Spine Ctr, Dept Orthopaed Surg, Los Angeles, CA 90404 USA. [Lee, Kwang-Bok; Song, Kyung-Jin] Chonbuk Natl Univ, Sch Med, Chonbuk Natl Univ Hosp, Dept Orthopaed Surg,Res Inst Clin Med, Jeonju, South Korea. [Murray, Samuel S.] VA Greater Los Angeles Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Sepulveda, CA USA. [Murray, Samuel S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90404 USA. [Murray, Samuel S.; Wang, Jeffrey C.] Univ Calif Los Angeles, Biomed Engn Interdept Program, Los Angeles, CA 90404 USA. RP Wang, JC (reprint author), Univ Calif Los Angeles, UCLA Comprehens Spine Ctr, Dept Orthopaed Surg, 1250 16th St,7th Floor,Tower 745, Los Angeles, CA 90404 USA. EM jwang@mednet.ucla.edu NR 22 TC 30 Z9 31 U1 0 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 J9 J ORTHOP RES JI J. Orthop. Res. PD DEC PY 2012 VL 30 IS 12 BP 1985 EP 1994 DI 10.1002/jor.22160 PG 10 WC Orthopedics SC Orthopedics GA 027XO UT WOS:000310387600017 PM 22674456 ER PT J AU Murray, PS Kirkwood, CM Gray, MC Ikonomovic, MD Paljug, WR Abrahamson, EE Henteleff, RA Hamilton, RL Kofler, JK Klunk, WE Lopez, OL Penzes, P Sweet, RA AF Murray, Patrick S. Kirkwood, Caitlin M. Gray, Megan C. Ikonomovic, Milos D. Paljug, William R. Abrahamson, Eric E. Henteleff, Ruth A. Hamilton, Ronald L. Kofler, Julia K. Klunk, William E. Lopez, Oscar L. Penzes, Peter Sweet, Robert A. TI beta-Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis SO NEUROBIOLOGY OF AGING LA English DT Article DE beta-amyloid; Kalirin; Psychosis; Alzheimer disease ID GDP/GTP EXCHANGE FACTOR; LONG-TERM POTENTIATION; SYNAPSE LOSS; IN-VIVO; COGNITIVE IMPAIRMENT; SPINE MORPHOGENESIS; DENDRITIC SPINES; RISK-FACTORS; DBL FAMILY; A-BETA AB Psychosis in Alzheimer disease differentiates a subgroup with more rapid decline, is heritable, and aggregates within families, suggesting a distinct neurobiology. Evidence indicates that greater impairments of cerebral cortical synapses, particularly in dorsolateral prefrontal cortex, may contribute to the pathogenesis of psychosis in Alzheimer disease (AD) phenotype. Soluble beta-amyloid induces loss of dendritic spine synapses through impairment of long-term potentiation. In contrast, the Rho guanine nucleotide exchange factor (GEF) kalirin is an essential mediator of spine maintenance and growth in cerebral cortex. We therefore hypothesized that psychosis in AD would be associated with increased soluble beta-amyloid and reduced expression of kalirin in the cortex. We tested this hypothesis in postmortem cortical gray matter extracts from 52 AD subjects with and without psychosis. In subjects with psychosis, the beta-amyloid(1-42)/beta-amyloid(1-40) ratio was increased, due primarily to reduced soluble beta-amyloid(1-40), and kalirin-7, -9, and -12 were reduced. These findings suggest that increased cortical beta-amyloid(1-42)/beta-amyloid(1-40) ratio and decreased kalirin expression may both contribute to the pathogenesis of psychosis in AD. Published by Elsevier Inc. C1 [Murray, Patrick S.; Kirkwood, Caitlin M.; Gray, Megan C.; Ikonomovic, Milos D.; Henteleff, Ruth A.; Klunk, William E.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Murray, Patrick S.; Sweet, Robert A.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. [Ikonomovic, Milos D.; Paljug, William R.; Abrahamson, Eric E.; Klunk, William E.; Lopez, Oscar L.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Hamilton, Ronald L.; Kofler, Julia K.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA. [Penzes, Peter] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. RP Sweet, RA (reprint author), Biomed Sci Tower,W1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu RI Penzes, Peter/L-3987-2016; OI Penzes, Peter/0000-0001-5449-1640; Murray, Patrick/0000-0002-6525-2888; Klunk, William/0000-0001-5512-0251 FU Veterans Health Administration [5I01BX000452]; National Institute on Aging [5P01AG014449, 5P50AG005133, 5R01AG027224]; National Institute of Mental Health [5T32MH019986] FX This work was supported by the Veterans Health Administration (5I01BX000452 to RAS); and the National Institute on Aging (5P01AG014449 to MDI, 5P50AG005133 to OLL, and 5R01AG027224 to RAS). P. S. M. is supported by the National Institute of Mental Health (5T32MH019986). NR 67 TC 18 Z9 18 U1 3 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 J9 NEUROBIOL AGING JI Neurobiol. Aging PD DEC PY 2012 VL 33 IS 12 BP 2807 EP 2816 DI 10.1016/j.neurobiolaging.2012.02.015 PG 10 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA 025OJ UT WOS:000310200000009 PM 22429885 ER PT J AU Reiss, PT Schwartzman, A Lu, FH Huang, L Proal, E AF Reiss, Philip T. Schwartzman, Armin Lu, Feihan Huang, Lei Proal, Erika TI Paradoxical results of adaptive false discovery rate procedures in neuroimaging studies SO NEUROIMAGE LA English DT Article DE Adjusted p-values; Attention deficit/hyperactivity disorder; Cortical thickness; False discovery rate; Multiple testing; q-values ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; TENSOR-BASED MORPHOMETRY; VOXEL-BASED MORPHOMETRY; ADJUSTED P-VALUES; EMPIRICAL BAYES; STATISTICS; TESTS; NULL AB Adaptive false discovery rate (FDR) procedures, which offer greater power than the original FDR procedure of Benjamini and Hochberg, are often applied to statistical maps of the brain. When a large proportion of the null hypotheses are false, as in the case of widespread effects such as cortical thinning throughout much of the brain, adaptive FOR methods can surprisingly reject more null hypotheses than not accounting for multiple testing at all-i.e., using uncorrected p-values. A straightforward mathematical argument is presented to explain why this can occur with the q-value method of Storey and colleagues, and a simulation study shows that it can also occur, to a lesser extent, with a two-stage FOR procedure due to Benjamini and colleagues. We demonstrate the phenomenon with reference to a published data set documenting cortical thinning in attention deficit/hyperactivity disorder. The paper concludes with recommendations for how to proceed when adaptive FDR results of this kind are encountered in practice. (C) 2012 Elsevier Inc. All rights reserved. C1 [Reiss, Philip T.; Lu, Feihan; Proal, Erika] NYU, Sch Med, Dept Child & Adolescent Psychiat, New York, NY 10016 USA. [Reiss, Philip T.] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA. [Schwartzman, Armin] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Schwartzman, Armin] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Huang, Lei] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA. [Proal, Erika] NEUROingenia Clin & Res Ctr, Mexico City, DF, Mexico. RP Reiss, PT (reprint author), NYU, Sch Med, Dept Child & Adolescent Psychiat, 215 Lexington Ave,16th Floor, New York, NY 10016 USA. EM phil.reiss@nyumc.org OI Schwartzman, Armin/0000-0001-5335-1611; Reiss, Philip/0000-0002-8491-7080 FU National Science Foundation [DMS-0907017]; National Institutes of Health (NIH) [R01 EB009744-01A]; NIH [1R21 EB012177-01A1, 1P01 CA134294-01, R01 DA016979] FX We thank Xavier Castellanos, Eva Petkova, Catherine Sugar, Martin Lindquist and Jason Lerch for very helpful discussions; Yin-Hsiu Chen, for bringing a number of key references to our attention; and two anonymous referees, for suggesting a number of improvements in the manuscript. Philip Reiss's research was supported in part by National Science Foundation grant DMS-0907017 and National Institutes of Health (NIH) grant R01 EB009744-01A, Armin Schwartzman's research was partially supported by NIH grants 1R21 EB012177-01A1 and 1P01 CA134294-01. The cortical thickness study was funded by NIH grant R01 DA016979. NR 31 TC 7 Z9 7 U1 0 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1053-8119 J9 NEUROIMAGE JI Neuroimage PD DEC PY 2012 VL 63 IS 4 BP 1833 EP 1840 DI 10.1016/j.neuroimage.2012.07.040 PG 8 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 028BH UT WOS:000310397300008 PM 22842214 ER PT J AU Kuhlthau, K Bhat, S Yeap, BY Delahaye, J Hill, KS Pulsifer, M Delaney, TF Macdonald, SM Ebb, D Tarbell, NJ Fisher, PG Yock, TI AF Kuhlthau, Karen Bhat, Sundeep Yeap, Beow Y. Delahaye, Jennifer Hill, Kristen S. Pulsifer, Margaret Delaney, Thomas F. Macdonald, Shannon M. Ebb, David Tarbell, Nancy J. Fisher, Paul Graham Yock, Torunn I. TI HEALTH RELATED QUALITY OF LIFE IN PEDIATRIC BRAIN TUMOR PATIENTS: A COMPARISON OF PROTON AND PHOTON TREATED COHORTS SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Yeap, Beow Y.] Massachusetts Gen Hosp, Dept Med, Biostat Unit, Boston, MA 02114 USA. [Kuhlthau, Karen] Harvard Univ, Sch Med, Boston, MA USA. [Bhat, Sundeep] Stanford Kaiser Emergency Med Residency, Palo Alto, CA USA. [Pulsifer, Margaret] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Delaney, Thomas F.; Macdonald, Shannon M.; Tarbell, Nancy J.; Yock, Torunn I.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Ebb, David] Massachusetts Gen Hosp, Dept Pediat Oncol, Boston, MA 02114 USA. [Fisher, Paul Graham] Stanford Univ, Lucile Packard Childrens Hosp, Palo Alto, CA 94304 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 979 EP 979 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300056 ER PT J AU Geoerger, B Aerts, I Casanova, M Chisholm, J Hargrave, D Leary, SES Ashley, D Bouffet, E MacDonald, T Di Giannatale, A Hurh, E Dey, J Kalambakas, S Teasdale, T Kieran, M AF Geoerger, Birgit Aerts, Isabelle Casanova, Michela Chisholm, Julia Hargrave, Darren Leary, Sarah E. S. Ashley, David Bouffet, Eric MacDonald, Tobey Di Giannatale, Angela Hurh, Eunju Dey, Jyotirmoy Kalambakas, Stacey Teasdale, Terri Kieran, Mark TI UPDATED RESULTS FROM A PHASE I STUDY OF LDE225, A SMOOTHENED ANTAGONIST, IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA OR OTHER SOLID TUMORS SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Geoerger, Birgit; Di Giannatale, Angela] Univ Paris Sud, Inst Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France. [Aerts, Isabelle] Inst Curie, Dept Pediat Oncol, Paris, France. [Casanova, Michela] Fdn IRCCS Ist Nazl Tumori, Pediat Oncol Unit, Milan, Italy. [Chisholm, Julia; Hargrave, Darren] Royal Marsden Hosp, Sutton, Surrey, England. [Leary, Sarah E. S.] Seattle Childrens Hosp, Dept Hematol Oncol, Seattle, WA USA. [Ashley, David] Royal Childrens Hosp, Melbourne, Vic, Australia. [Bouffet, Eric] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada. [MacDonald, Tobey] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Hurh, Eunju; Dey, Jyotirmoy; Kalambakas, Stacey; Teasdale, Terri] Novartis Pharmaceut, E Hanover, NJ USA. [Kieran, Mark] Dana Farber Canc Inst, Boston, MA 02115 USA. RI MacDonald, Tobey/D-4554-2013; OI Hargrave, Darren/0000-0001-8219-9807 NR 0 TC 1 Z9 1 U1 0 U2 2 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 980 EP 980 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300059 ER PT J AU Jones, DTW Jager, N Kool, M Zichner, T Hutter, B Sultan, M Cho, YJ Pugh, TJ Hovestadt, V Rausch, T Stuetz, A Warnatz, HJ Reifenberger, G Scheurlen, W Northcott, PA Taylor, MD Meyerson, M Pomeroy, SL Yaspo, ML Korbel, JO Korshunov, A Eils, R Pfister, SM Lichter, P AF Jones, David T. W. Jaeger, Natalie Kool, Marcel Zichner, Thomas Hutter, Barbara Sultan, Marc Cho, Yoon-Jae Pugh, Trevor J. Hovestadt, Volker Rausch, Tobias Stuetz, Adrian Warnatz, Hans-Joerg Reifenberger, Guido Scheurlen, Wolfram Northcott, Paul A. Taylor, Michael D. Meyerson, Matthew Pomeroy, Scott L. Yaspo, Marie-Laure Korbel, Jan O. Korshunov, Andrey Eils, Roland Pfister, Stefan M. Lichter, Peter CA ICGC PedBrain Tumor Project TI ICGC PEDBRAIN TUMOR - DISSECTING THE GENOMIC COMPLEXITY UNDERLYING MEDULLOBLASTOMA SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Jones, David T. W.; Jaeger, Natalie; Kool, Marcel; Hutter, Barbara; Hovestadt, Volker; Northcott, Paul A.; Eils, Roland; Pfister, Stefan M.; Lichter, Peter] German Canc Res Ctr, Heidelberg, Germany. [Zichner, Thomas; Rausch, Tobias; Stuetz, Adrian; Korbel, Jan O.] European Mol Biol Lab EMBL, Heidelberg, Germany. [Sultan, Marc; Warnatz, Hans-Joerg; Yaspo, Marie-Laure] Max Planck Inst Mol Genet, D-14195 Berlin, Germany. [Cho, Yoon-Jae] Stanford Univ, Palo Alto, CA 94304 USA. [Pugh, Trevor J.] Broad Inst MIT & Harvard, Cambridge, MA USA. [Reifenberger, Guido] Univ Dusseldorf, D-40225 Dusseldorf, Germany. [Scheurlen, Wolfram] Cnopfsche Kinderklin, Nurnberg, Germany. [Taylor, Michael D.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Meyerson, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA. [Pomeroy, Scott L.] Childrens Hosp Boston, Boston, MA USA. [Korshunov, Andrey] Univ Heidelberg Hosp, Heidelberg, Germany. RI Kool, Marcel/H-2541-2013; Pfister, Stefan/F-6860-2013 OI Pfister, Stefan/0000-0002-5447-5322 NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 980 EP 980 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300058 ER PT J AU Strother, DR London, WB Tagge, E Shimada, H Cohn, SL AF Strother, Douglas R. London, Wendy B. Tagge, Edward Shimada, Hiroyuki Cohn, Susan L. CA Childrens Oncology Grp TI FACTORS THAT CONTRIBUTE TO INFERIOR SURVIVAL OF LOW-RISK STAGE 2B NEUROBLASTOMA PATIENTS: A CHILDREN'S ONCOLOGY GROUP STUDY SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Strother, Douglas R.] Univ Calgary, Calgary, AB, Canada. [London, Wendy B.] Harvard Univ, CHB, DFCI, Boston, MA 02115 USA. [London, Wendy B.] Childrens Oncol Grp, Arcadia, CA USA. [Tagge, Edward] Med Univ S Carolina, Charleston, SC 29425 USA. [Shimada, Hiroyuki] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Cohn, Susan L.] Univ Chicago, Sch Med, Chicago, IL 60637 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 995 EP 995 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300116 ER PT J AU Mason, C Recklitis, C AF Mason, Claire Recklitis, Christopher TI UTILITY OF PARENTAL INTAKE FORMS TO IDENTIFY CHILDHOOD CANCER SURVIVORS WITH BEHAVIORAL ADJUSTMENT PROBLEMS SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Mason, Claire; Recklitis, Christopher] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1001 EP 1001 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300140 ER PT J AU Schmiegelow, K Levinsen, M Biondi, A Attarbaschi, A Baruchel, A Devidas, M Escherich, G Gibson, B Heydrich, C Horibe, K Ishida, Y Liang, DC Pieters, R Piette, C Pui, CH Raimondi, S Silverman, L Stanulla, M Stark, B Winick, N Valsecchi, MG AF Schmiegelow, Kjeld Levinsen, Mette Biondi, Andrea Attarbaschi, Andishe Baruchel, Andre Devidas, Mini Escherich, Gabriele Gibson, Brenda Heydrich, Christiane Horibe, Keizo Ishida, Yasushi Liang, Der-Cherng Pieters, Rob Piette, Caroline Pui, Ching-Hon Raimondi, Susana Silverman, Lewis Stanulla, Martin Stark, Batia Winick, Naomi Valsecchi, Maria Grazia CA AEIOP BFM-Austria COALL DCOG DFCI EORTC FRALLE INS NOPHO St Jude Childrens Res Hosp TPOG TI SECOND NEOPLASMS AFTER TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Schmiegelow, Kjeld; Levinsen, Mette] Rigshosp, DK-2100 Copenhagen, Denmark. [Biondi, Andrea; Valsecchi, Maria Grazia] Univ Milan, Milan, Italy. [Attarbaschi, Andishe] St Anna Childrens Hosp, A-1090 Vienna, Austria. [Baruchel, Andre] Hop Robert Debre, F-75019 Paris, France. [Devidas, Mini] Childrens Oncol Grp, Dept Biostat, Gainesville, FL USA. [Escherich, Gabriele] Univ Med Ctr, Hamburg, Germany. [Gibson, Brenda] Royal Hosp Sick Children, Glasgow G3 8SJ, Lanark, Scotland. [Heydrich, Christiane] UNI Klinikum Campus Kiel, Kiel, Germany. [Horibe, Keizo] Natl Hosp Org, Nagoya, Aichi, Japan. [Ishida, Yasushi] Lukes Int Hosp, Tokyo, Japan. [Liang, Der-Cherng] Mackay Mem Hosp, Taipei, Taiwan. [Pieters, Rob] Erasmus MC Sophia Childrens Hosp, Rotterdam, Netherlands. [Piette, Caroline] Univ Dept Oncol, Liege, Belgium. [Pui, Ching-Hon; Raimondi, Susana] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Silverman, Lewis] Dana Farber Canc Inst, Boston, MA 02115 USA. [Stanulla, Martin] Univ Hosp Schleswig Holstein, Kiel, Germany. [Stark, Batia] Schneider Childrens Med Ctr, Petah Tiqwa, Israel. [Winick, Naomi] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. NR 2 TC 0 Z9 0 U1 0 U2 1 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1004 EP 1004 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300152 ER PT J AU Bona, K Dussel, V Kang, T Geyer, R Feudtner, C Wolfe, J AF Bona, Kira Dussel, Veronica Kang, Tammy Geyer, Russ Feudtner, Chris Wolfe, Joanne TI ECONOMIC IMPACT OF ADVANCED PEDIATRIC CANCER ON FAMILIES ENROLLED IN THE PEDIQUEST STUDY SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Dussel, Veronica] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA. [Bona, Kira; Wolfe, Joanne] Childrens Hosp Boston, Boston, MA USA. [Dussel, Veronica] Inst Clin Effectiveness & Hlth Policy, Buenos Aires, DF, Argentina. [Kang, Tammy; Feudtner, Chris] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Geyer, Russ] Seattle Childrens Hosp, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1007 EP 1007 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300162 ER PT J AU Lane, K Taylor, SD Reilly, C AF Lane, Kelly Taylor, Sara Dickison Reilly, Christine TI DANA FARBER/CHILDRENCS HOSPITAL CANCER CARE PEDIATRIC PATIENT AND FAMILY ADVISORY COUNCIL "WEEKEND INITIATIVE'': HOW WE HEAR THE VOICE OF PEDIATRIC PATIENTS AND FAMILIES WHO ARE CURRENTLY RECEIVING CANCER TREATMENT SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Taylor, Sara Dickison; Reilly, Christine] Dana Farber Childrens Hosp Canc Ctr, Boston, MA USA. [Lane, Kelly] Dana Farber Childrens Hosp Canc Care, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1025 EP 1025 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300236 ER PT J AU Quintero, MLP Marin, JEL Mattos, AS Rengifo, LA Mesa, M Cardenas, M Morrissey, L Veintemilla, G Vizcaino, MP Gutierrez, A AF Pina Quintero, Martha Ligia Lopera Marin, John Edgar Suarez Mattos, Amaranto Amparo Rengifo, Lyda Mesa, Mauricio Cardenas, Marcela Morrissey, Lisa Veintemilla, Galo Patricia Vizcaino, Martha Gutierrez, Alejandro CA Inst Nacl Cancerologia Danna Farber Inst TI A COMPREHENSIVE STRATEGY REDUCES TREATMENT MORTALITY AND ABANDONMENT RATES IN POOR CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED AT INSTITUTO NACIONAL DE CANCEROLOGIA, BOGOTA, COLOMBIA SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Pina Quintero, Martha Ligia; Lopera Marin, John Edgar; Suarez Mattos, Amaranto; Amparo Rengifo, Lyda; Mesa, Mauricio; Cardenas, Marcela; Veintemilla, Galo; Patricia Vizcaino, Martha] Inst Nacl Cancerol ESE, Bogota, Colombia. [Morrissey, Lisa; Gutierrez, Alejandro] Harvard Univ, Dana Farber Canc Inst, Childrens Hosp Boston, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1030 EP 1030 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300257 ER PT J AU Gutierrez, A Pan, L Kentsis, A Marineau, J Grebliunaite, R Kozakewich, E Reed, C Bradner, J Aster, J Look, AT AF Gutierrez, Alejandro Pan, Li Kentsis, Alex Marineau, Jason Grebliunaite, Ruta Kozakewich, Elena Reed, Casie Bradner, James Aster, Jon Look, A. Thomas TI PHENOTHIAZINE ANTIPSYCHOTICS ACTIVATE THE PP2A TUMOR SUPPRESSOR FOR THERAPEUTIC ACTIVITY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Gutierrez, Alejandro; Kentsis, Alex; Grebliunaite, Ruta; Kozakewich, Elena; Reed, Casie; Look, A. Thomas] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Marineau, Jason; Bradner, James] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Pan, Li; Aster, Jon] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1035 EP 1035 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300280 ER PT J AU Nuchtern, JG London, WB Barnewolt, CE Naranjo, A Geiger, JD Cohn, SL Shamberger, RC AF Nuchtern, Jed G. London, Wendy B. Barnewolt, Carol E. Naranjo, Arlene Geiger, James D. Cohn, Susan L. Shamberger, Robert C. TI A PROSPECTIVE STUDY OF EXPECTANT OBSERVATION AS PRIMARY THERAPY FOR NEUROBLASTOMA IN YOUNG INFANTS, A CHILDREN'S ONCOLOGY GROUP STUDY SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Nuchtern, Jed G.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Nuchtern, Jed G.] Texas Childrens Hosp, Dept Surg, Houston, TX 77030 USA. [London, Wendy B.] Harvard Univ, Sch Med, Dept Pediat, DFCI,CHB, Boston, MA 02115 USA. [Barnewolt, Carol E.] Harvard Univ, Sch Med, Dept Radiol, Childrens Hosp Boston, Boston, MA 02115 USA. [Naranjo, Arlene] Univ Florida, Dept Biostat, Gainesville, FL USA. [Geiger, James D.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA. [Cohn, Susan L.] Univ Chicago, Sch Med, Dept Pediat, Chicago, IL 60637 USA. [Shamberger, Robert C.] Harvard Univ, Sch Med, Dept Surg, Childrens Hosp Boston, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1059 EP 1059 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300378 ER PT J AU Abrantes, F Vergamini, L Ribeiro, K Rodriguez-Galindo, C Frazier, AL AF Abrantes, Fernanda Vergamini, Lucas Ribeiro, Karina Rodriguez-Galindo, Carlos Frazier, A. Lindsay TI POOR RISK SURVIVAL SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Ribeiro, Karina] Fac Ciencias Med Santa Casa, Dept Social Med, Sao Paulo, Brazil. [Rodriguez-Galindo, Carlos; Frazier, A. Lindsay] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1088 EP 1088 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300498 ER PT J AU Frazier, A Chang, J Egler, R Rodriguez-Galindo, C Abrantes, F Teot, L AF Frazier, A. Chang, Jenny Egler, Rachel Rodriguez-Galindo, Carlos Abrantes, Fernanda Teot, Lisa TI COMPLETELY RESECTED SACROCOCCYGEAL GERM CELL TUMORS WITH FOCI OF YOLK SAC TUMOR ARE CURED WITH SURGERY ALONE SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Frazier, A.; Rodriguez-Galindo, Carlos] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chang, Jenny] Wellesley Coll, Boston, MA USA. [Egler, Rachel] UH Rainbow Babies & Childrens Hosp, Cleveland, OH USA. [Abrantes, Fernanda] Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, Brazil. [Teot, Lisa] Childrens Hosp Boston, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1088 EP 1088 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300500 ER PT J AU Shaikh, F Nathan, PC Hale, J Frazier, AL AF Shaikh, Furqan Nathan, Paul C. Hale, Juliet Frazier, A. Lindsay TI IS THERE A ROLE FOR CARBOPLATIN IN THE TREATMENT OF MALIGNANT GERM CELL TUMORS? A SYSTEMATIC REVIEW OF ADULT AND PEDIATRIC TRIALS SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Shaikh, Furqan; Nathan, Paul C.] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada. [Hale, Juliet] Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England. [Frazier, A. Lindsay] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1090 EP 1090 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300507 ER PT J AU Senerchia, A Ribeiro, K Rodriguez-Galindo, C AF Senerchia, Andreza Ribeiro, Karina Rodriguez-Galindo, Carlos TI TRENDS IN INCIDENCE OF PRIMARY CUTANEOUS MALIGNANCIES IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS: A POPULATION-BASED STUDY SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Ribeiro, Karina] Fac Ciencias Med Santa Casa, Dept Social Med, Sao Paulo, Brazil. [Rodriguez-Galindo, Carlos] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1098 EP 1098 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300542 ER PT J AU Hinds, PS Baker, JN Freyer, D Hooke, C Joffe, S Mowbray, C Wang, J Withycombe, J Reeve, B AF Hinds, Pamela S. Baker, Justin N. Freyer, David Hooke, Casey Joffe, Steven Mowbray, Catriona Wang, Jichuan Withycombe, Janice Reeve, Bryce TI CREATING A CHILD SELF-REPORT MEASURE OF ADVERSE EVENTS RELATED TO CANCER TREATMENT SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Hinds, Pamela S.; Mowbray, Catriona; Wang, Jichuan] George Washington Univ, Childrens Natl Med Ctr, Washington, DC USA. [Baker, Justin N.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Freyer, David] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Hooke, Casey] Univ Minnesota, Minneapolis, MN USA. [Joffe, Steven] Dana Farber Canc Inst, Boston, MA 02115 USA. [Withycombe, Janice] Palmetto Hlth Ctr, Charleston, SC USA. [Reeve, Bryce] Univ N Carolina Chapel Hill, Washington, DC USA. NR 2 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1119 EP 1120 PG 2 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300633 ER PT J AU Brinkman, TM Zhang, N Recklitis, CJ Kimberg, C Zeltzer, LK Muriel, AC Stovall, M Srivastava, DK Robison, LL Krull, KR AF Brinkman, Tara M. Zhang, Nan Recklitis, Christopher J. Kimberg, Cara Zeltzer, Lonnie K. Muriel, Anna C. Stovall, Marilyn Srivastava, Deo Kumar Robison, Leslie L. Krull, Kevin R. TI VERY LATE ONSET AND RECURRENT SUICIDE IDEATION IN ADULT SURVIVORS OF CHILDHOOD CANCER: A REPORT FROM THE CHILDHOOD CANCER SURVIVOR STUDY SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [Brinkman, Tara M.; Zhang, Nan; Kimberg, Cara; Srivastava, Deo Kumar; Robison, Leslie L.; Krull, Kevin R.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Recklitis, Christopher J.; Muriel, Anna C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Zeltzer, Lonnie K.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Stovall, Marilyn] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1123 EP 1123 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300649 ER PT J AU El Malla, H Kreicbergs, U Steineck, G Wilderang, U Elborai, YES Ylitalo, N AF El Malla, Hanan Kreicbergs, Ulrika Steineck, Gunnar Wilderang, Ulrica Elborai, Yasser El Sayed Ylitalo, Nathalie TI THE VALUE OF INFORMATION IN GAINING TRUST - EXPERIENCES FROM CHILDREN'S CANCER HOSPITAL IN EGYPT SO PEDIATRIC BLOOD & CANCER LA English DT Meeting Abstract C1 [El Malla, Hanan; Steineck, Gunnar; Wilderang, Ulrica; Ylitalo, Nathalie] Gothenburgs Univ, Sahlgrenska Acad, Gothenburg, Sweden. [Kreicbergs, Ulrika; Steineck, Gunnar; Ylitalo, Nathalie] Karolinska Inst, Stockholm, Sweden. [Kreicbergs, Ulrika] Sophiahemmet Univ Coll, Stockholm, Sweden. [Elborai, Yasser El Sayed] Cairo Univ Hosp, Cairo, Egypt. [Elborai, Yasser El Sayed] Childrens Canc Hosp, Cairo, Egypt. [Elborai, Yasser El Sayed] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 6 SI SI BP 1127 EP 1127 PG 1 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019QL UT WOS:000309754300664 ER PT J AU Bierry, G Huang, AJ Chang, CY Torriani, M Bredella, MA AF Bierry, Guillaume Huang, Ambrose J. Chang, Connie Y. Torriani, Martin Bredella, Miriam A. TI MRI findings of treated bacterial septic arthritis SO SKELETAL RADIOLOGY LA English DT Article DE Septic arthritis; Infection; MRI ID RHEUMATOID-ARTHRITIS; GADOLINIUM-DTPA; FOLLOW-UP; KNEE; OSTEOMYELITIS; BONE; INFECTIONS; FEATURES; ADULTS; SPINE AB The purpose of this study was to report the MRI findings that can be encountered in successfully treated bacterial septic arthritis. The study included 12 patients (8 male and 4 female; mean age 38 years, range 9-85) with 13 proven cases of bacterial septic arthritis. The joints involved were hip (n = 3), knee (n = 3), shoulder (n = 2), sacroiliac (n = 2), ankle (n = 1), wrist (n = 1), and elbow (n = 1). MRI examinations following surgical debridement and at initiation of antibiotic therapy and after successful treatment were compared for changes in effusion, synovium, bone, and periarticular soft tissues. Imaging findings were correlated with microbiological and clinical findings. Joint effusions were present in all joints at baseline and regressed significantly at follow-up MRI (p = 0.001). Abscesses were present in 5 cases (38 %), and their sizes decreased significantly at follow-up (p = 0.001). Synovial enhancement and thickening were observed in all joints at both baseline and follow-up MRI. Myositis/cellulitis was present in 10 cases (77 %) at baseline and in 8 cases (62 %) at follow-up MRI. Bone marrow edema was present in 10 joints (77 %) at baseline and persisted in 8 joints (62 %). Bone erosions were found in 8 joints (62 %) and persisted at follow-up MRI in all cases. The sizes of joint effusions and abscesses appear to be the factors with the most potential for monitoring therapy for septic arthritis, since both decreased significantly following successful treatment. Synovial thickening and enhancement, periarticular myositis/cellulitis, and bone marrow edema can persist even after resolution of the infection. C1 [Bierry, Guillaume; Huang, Ambrose J.; Chang, Connie Y.; Torriani, Martin; Bredella, Miriam A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Bierry, Guillaume; Huang, Ambrose J.; Chang, Connie Y.; Torriani, Martin; Bredella, Miriam A.] Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Bredella, MA (reprint author), Massachusetts Gen Hosp, Dept Radiol, Yawkey 6E,55 Fruit St, Boston, MA 02114 USA. EM mbredella@partners.org NR 23 TC 5 Z9 7 U1 1 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0364-2348 J9 SKELETAL RADIOL JI Skeletal Radiol. PD DEC PY 2012 VL 41 IS 12 BP 1509 EP 1516 DI 10.1007/s00256-012-1397-2 PG 8 WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging GA 025WD UT WOS:000310226300003 PM 22430565 ER PT J AU Nedjat-Haiem, FR Carrion, IV Ell, K Palinkas, L AF Nedjat-Haiem, Frances R. Carrion, Iraida V. Ell, Kathleen Palinkas, Lawrence TI Navigating the advanced cancer experience of underserved Latinas SO SUPPORTIVE CARE IN CANCER LA English DT Article DE Advanced cancer; Cancer burden; Coping; Underserved Latinos; Sociocultural ID AMERICAN WOMEN; CARE; HEALTH; LIFE; END; DISPARITIES; SURVIVORS; FAMILIES AB Previous cancer research does not adequately inform us about the experiences of managing a more serious, life-threatening cancer condition, especially for underserved Latinas. This study was designed to explore the ways in which Latinas navigate through and deal with advanced cancers. A purposive sample of 24 underserved Latina women was selected from a randomized controlled trial. Data were analyzed using a phenomenological approach to explore navigation of the advanced cancer experience. This study outlines a conceptual framework which denotes the interconnectedness of multiple factors that influence the cancer experience for Latina women. Experiences with advanced cancer were embedded within a social, cultural, and systemic framework described as 1) intrapersonal experiences; 2) interpersonal experiences; 3) provider interactions; and 4) medical system factors. This study indicates that underserved Latinas face complex circumstances that interfere with the diagnosis and treatment of cancer. However, women expressed positive attitudes and held beliefs about survival which helped them through their experience with cancer. The implication of these findings is that Latinas have protective attitudes and beliefs that help them to overcome "tragic" circumstances. Providers need to become aware of the complexity of these issues in order to achieve competent, effective, and efficient practice in medical settings with Latinas. C1 [Nedjat-Haiem, Frances R.] Vet Affairs Greater Los Angeles Healthcare Syst, VA Associated Hlth Postdoctoral Fellowship Progra, Off Acad Affiliat, HSR&D Ctr Excellence, Los Angeles, CA 90073 USA. [Carrion, Iraida V.] Univ S Florida, Sch Social Work, Tampa, FL 33612 USA. [Ell, Kathleen; Palinkas, Lawrence] Univ So Calif, Sch Social Work, Los Angeles, CA 90089 USA. RP Nedjat-Haiem, FR (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, VA Associated Hlth Postdoctoral Fellowship Progra, Off Acad Affiliat, HSR&D Ctr Excellence, 11301 Wilshire Blvd,Code 111-G, Los Angeles, CA 90073 USA. EM nedjatha@gmail.com OI Carrion, Iraida/0000-0003-4076-6644 FU VA Associated Health Postdoctoral Fellowship Program, HSR&D Center of Excellence; American Cancer Society Doctoral Training Grant in Oncology Social Work [DSW-06-220-01-SW]; National Cancer Institute [R01CA105269] FX This research was supported by the VA Associated Health Postdoctoral Fellowship Program, HSR&D Center of Excellence, the American Cancer Society Doctoral Training Grant in Oncology Social Work DSW-06-220-01-SW (F. R. Nedjat-Haiem, PI), and the National Cancer Institute R01CA105269 (K. Ell, PI). NR 38 TC 11 Z9 11 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 EI 1433-7339 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD DEC PY 2012 VL 20 IS 12 BP 3095 EP 3104 DI 10.1007/s00520-012-1437-4 PG 10 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 025YD UT WOS:000310232500011 PM 22418600 ER PT J AU Chan, AW Bernstein, KD Adams, JA Parambi, RJ Loeffler, JS AF Chan, A. W. Bernstein, K. D. Adams, J. A. Parambi, R. J. Loeffler, J. S. TI Dose Escalation with Proton Radiation Therapy for High-Grade Meningiomas SO TECHNOLOGY IN CANCER RESEARCH & TREATMENT LA English DT Article DE High-grade meningiomas; Atypical meningioma; Malignant meningioma; Proton beam; Dose escalation; Radiation ID ANAPLASTIC MENINGIOMAS; III MENINGIOMAS; RADIOTHERAPY; RECURRENCE; SURGERY AB Purpose of this study was to determine the toxicity and treatment outcome after dose escalation with proton radiation therapy for patients with World Health Organization (WHO) grade II and grade III meningiomas. Between 1997 and 1999, 6 patients with newly diagnosed or recurrent grade II or III meningioma were treated on a Phase I/II dose escalation trial with combined proton-photon radiotherapy at the Harvard Cyclotron Laboratory/Massachusetts General Hospital. The median age was 46. The sites were sphenoid wing in 2 patients, parasagittal/falcine in 2, parasellar in 1, and olfactory groove in 1. The median gross total volume (GTV) at the time of radiation was 13.3 cc (range: 4.0-129.5). The total dose to the GTV for the grade II and III meningiomas was 68.4 and 72.0 Gy (RBE) in 1.8 Gy (RBE), respectively. The median percentage of proton was 80%. All patients tolerated radiation treatment without any treatment break. None of the patients required steroids or hospitalization during radiation. There was no acute grade 3 to 5 toxicity. With a median follow-up period of 145 months for all surviving patients, one patient developed local recurrence. For the 5 patients with tumor controlled at the primary sites, 3 patients developed new meningioma(s) distantly from the primary sites at a median time of 25 months (range, 9-79). The median survival for grade II and grade III tumors was 145 months and 28 months, respectively. One patient developed late grade 1 dry eye. Two patients developed late grade 2 hypothyroidism and two developed grade 2 hypogonadism. There was no late grade 3-5 toxicity. Dose escalation with proton radiation therapy resulted in low toxicity and high local control rate in patients with high-grade meningiomas. Development of distant meningioma(s) intracranially was the main pattern of failure. Larger prospective studies are necessary to confirm our results. C1 [Chan, A. W.; Bernstein, K. D.; Adams, J. A.; Parambi, R. J.; Loeffler, J. S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA. RP Chan, AW (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA. EM awchan@patners.org FU National Institute of Health [NCI-PO1CA21239] FX This study was supported in part by the National Institute of Health NCI-PO1CA21239. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institute of Health. NR 21 TC 8 Z9 8 U1 0 U2 6 PU ADENINE PRESS PI SCHENECTADY PA 2066 CENTRAL AVE, SCHENECTADY, NY 12304 USA SN 1533-0346 J9 TECHNOL CANCER RES T JI Technol. Cancer Res. Treat. PD DEC PY 2012 VL 11 IS 6 BP 607 EP 614 DI 10.7785/tcrt.2012.500267 PG 8 WC Oncology SC Oncology GA 031PV UT WOS:000310655300009 PM 22712601 ER PT J AU Resick, PA AF Resick, Patricia A. TI Getting Out of Our Own Way SO BEHAVIOR THERAPY LA English DT Article DE women's issues; gender differences; women in academia AB This paper, a follow-up from a 2009 panel discussion at ABCT's Annual Convention, focuses on the choices that women make (or don't make) that can affect their careers. Women are particularly prone to feeling guilty about their choices, and while a few decades ago there was a great deal of sexism in the workplace, at this point in time, I believe that we are more likely to make assumptions that impede our careers rather than face external barriers. The paper covers some "stuck points" that stop women from advocating for themselves or results in guilt regardless of their choice. C1 [Resick, Patricia A.] VA Boston Healthcare Syst, WHSD, NCPTSD 116B3, Boston, MA 02130 USA. [Resick, Patricia A.] Boston Univ, Boston, MA 02215 USA. RP Resick, PA (reprint author), VA Boston Healthcare Syst, WHSD, NCPTSD 116B3, 150 S Huntington Ave, Boston, MA 02130 USA. EM Patricia.Resick@va.gov NR 1 TC 2 Z9 2 U1 1 U2 8 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 J9 BEHAV THER JI Behav. Therapy PD DEC PY 2012 VL 43 IS 4 BP 708 EP 711 PG 4 WC Psychology, Clinical SC Psychology GA 024HW UT WOS:000310101300005 PM 23046773 ER PT J AU Zeiss, A AF Zeiss, Antonette TI Never Turn Your Back on a Wave SO BEHAVIOR THERAPY LA English DT Article DE women's issues; gender differences; women in VA health care AB This article reviews the intersections of personal and professional life development for the author. She offers perspective on three important life lessons that have guided her in this rewarding life path. First, be responsible in fulfilling and seeking professional opportunities. Second, be nice-respectful, warm, collegial, collaborative; treat others with the respect you want to receive yourself. Finally, "Never turn your back on a wave"-face the challenges that life presents, forthrightly, with energy and enthusiasm, and enjoy a full and fulfilling career and personal life. C1 US Dept Vet Affairs, Washington, DC 20420 USA. RP Zeiss, A (reprint author), US Dept Vet Affairs, 810 Vermont Ave NW, Washington, DC 20420 USA. EM Antonette.Zeiss@va.gov NR 0 TC 2 Z9 2 U1 0 U2 0 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 J9 BEHAV THER JI Behav. Therapy PD DEC PY 2012 VL 43 IS 4 BP 712 EP 714 PG 3 WC Psychology, Clinical SC Psychology GA 024HW UT WOS:000310101300006 PM 23213675 ER PT J AU Gonzalez, A Zvolensky, MJ Grover, KW Parent, J AF Gonzalez, Adam Zvolensky, Michael J. Grover, Kristin W. Parent, Justin TI The Role of Anxiety Sensitivity and Mindful Attention in Anxiety and Worry About Bodily Sensations Among Adults Living With HIV/AIDS SO BEHAVIOR THERAPY LA English DT Article DE bodily sensations; anxiety sensitivity; anxiety; mindful attention; HIV/AIDS ID POSTTRAUMATIC-STRESS-DISORDER; ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; BODY VIGILANCE; PANIC DISORDER; PSYCHIATRIC-DISORDERS; PHOBIA QUESTIONNAIRE; MEDICATION ADHERENCE; AWARENESS SCALE; SOCIAL ANXIETY AB The current study examined cognitive factors that may be relevant to understanding anxiety and worry about bodily sensations among an HIV/AIDS population. Specifically, this investigation tested the main and interactive effects of anxiety sensitivity and mindful attention on anxious arousal, bodily vigilance, interoceptive fear, and HIV symptom distress among 164 adults with HIV/AIDS. Results indicated that anxiety sensitivity was positively related to anxious arousal, bodily vigilance, and interoceptive fear, but not HIV symptom distress. Mindful attention was negatively related to anxious arousal, interoceptive fear, and HIV symptom distress, but not bodily vigilance. These main effects for anxiety sensitivity and mindful attention were evident after controlling for disease stage, years with HIV, and demographic variables. There were no interactive effects between anxiety sensitivity and mindful attention. Results are discussed in terms of the clinical implications for identifying and treating anxiety and worry about bodily sensations among adults with HIV/AIDS. Limitations of this study include the use of cross-sectional data and self-report assessments. C1 [Gonzalez, Adam] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Gonzalez, Adam] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Gonzalez, Adam; Grover, Kristin W.; Parent, Justin] Univ Vermont, Burlington, VT 05405 USA. [Zvolensky, Michael J.] Univ Houston, Houston, TX 77004 USA. RP Gonzalez, A (reprint author), 1 Bowdoin Sq,7th Floor, Boston, MA 02114 USA. EM agonzalez14@partners.org NR 49 TC 6 Z9 6 U1 5 U2 10 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 J9 BEHAV THER JI Behav. Therapy PD DEC PY 2012 VL 43 IS 4 BP 768 EP 778 PG 11 WC Psychology, Clinical SC Psychology GA 024HW UT WOS:000310101300013 PM 23046779 ER PT J AU Stein, NR Dickstein, BD Schuster, J Litz, BT Resick, PA AF Stein, Nathan R. Dickstein, Benjamin D. Schuster, Jennifer Litz, Brett T. Resick, Patricia A. TI Trajectories of Response to Treatment for Posttraumatic Stress Disorder SO BEHAVIOR THERAPY LA English DT Article DE posttraumatic stress disorder; treatment outcomes; cognitive behavior therapy; trajectories ID COGNITIVE-PROCESSING THERAPY; ADMINISTERED PTSD SCALE; SEXUAL ASSAULT VICTIMS; PROLONGED EXPOSURE; RANDOMIZED-TRIAL; RAPE VICTIMS; SELF-REPORT; METAANALYSIS; VALIDATION; PATTERNS AB Research on the predictors of response to cognitive-behavioral treatments for PTSD has often produced inconsistent or ambiguous results. We argue this is in part due to the use of statistical techniques that explore relationships among the entire sample of participants rather than homogeneous sub-groups. Using 2 large randomized controlled trials of Cognitive Processing Therapy (CPT), CPT components, and Prolonged Exposure, we employed growth mixture modeling to identify distinct trajectories of treatment response and to determine the predictors of those trajectories. We determined that the participants' trajectories could be best represented by 2 latent classes, which we subsequently labeled responders (87% of the sample) and nonresponders (13% of the sample). Notably, there was not a separate class for partial responders. Assignment to the nonresponder class was associated with receiving the written accounts (WA) component of CPT, a pretreatment diagnosis of major depression (MDD), and more pretreatment hyperarousal symptoms. Thus, it appears that some individuals do not benefit from merely writing about their trauma and processing it with the therapist; they may also need to engage in cognitive restructuring to successfully ameliorate their symptoms. Additionally, those who meet criteria for MDD or have high levels of hyperarousal at the onset of treatment might require additional treatment or support. C1 [Stein, Nathan R.; Dickstein, Benjamin D.; Litz, Brett T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA 02130 USA. [Resick, Patricia A.] Boston Univ, Sch Med, Womens Hlth Sci Div, Natl Ctr PTSD,VA Boston Healthcare Syst, Boston, MA 02215 USA. RP Stein, NR (reprint author), VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, 150 S Huntington Ave 116B-4, Boston, MA 02130 USA. EM nathan.stein@va.gov FU NIMH NIH HHS [1-R01-MH51509, 2-R01-MH51509, R01 MH051509] NR 48 TC 15 Z9 15 U1 2 U2 23 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 J9 BEHAV THER JI Behav. Therapy PD DEC PY 2012 VL 43 IS 4 BP 790 EP 800 PG 11 WC Psychology, Clinical SC Psychology GA 024HW UT WOS:000310101300015 PM 23046781 ER PT J AU Sun, D Jakobs, TC AF Sun, Daniel Jakobs, Tatjana C. TI Structural Remodeling of Astrocytes in the Injured CNS SO NEUROSCIENTIST LA English DT Review DE protoplasmic; fibrous; reactive astrocytes; review; GFAP; glial scar ID FIBRILLARY ACIDIC PROTEIN; IDENTIFIED GLIAL-CELLS; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; MOUSE OPTIC-NERVE; REACTIVE ASTROCYTES; TRANSGENIC MICE; IN-SITU; GLUTAMATE TRANSPORTERS; HIPPOCAMPAL ASTROCYTES AB Astrocytes respond to all forms of CNS insult and disease by becoming reactive, a nonspecific but highly characteristic response that involves various morphological and molecular changes. Probably the most recognized aspect of reactive astrocytes is the formation of a glial scar that impedes axon regeneration. Although the reactive phenotype was first suggested more than 100 years ago based on morphological changes, the remodeling process is not well understood. We know little about the actual structure of a reactive astrocyte, how an astrocyte remodels during the progression of an insult, and how populations of these cells reorganize to form the glial scar. New methods of labeling astrocytes, along with transgenic mice, allow the complete morphology of reactive astrocytes to be visualized. Recent studies show that reactivity can induce a remarkable change in the shape of a single astrocyte, that not all astrocytes react in the same way, and that there is plasticity in the reactive response. C1 [Sun, Daniel] Harvard Univ, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Sch Med, Boston, MA 02114 USA. RP Sun, D (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Sch Med, 243 Charles St, Boston, MA 02114 USA. EM daniel_sun@meei.harvard.edu OI Jakobs, Tatjana/0000-0002-8104-9206 FU National Institutes of Health (NIH) [RO1 017169, RO1 EY019703]; Glaucoma Foundation; American Health Assistance Foundation (AHAF); Research to Prevent Blindness (RPB) FX The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This work was supported by National Institutes of Health (NIH) grants RO1 017169 and RO1 EY019703 and grants from The Glaucoma Foundation, The American Health Assistance Foundation (AHAF), and Research to Prevent Blindness (RPB). NR 125 TC 38 Z9 41 U1 2 U2 26 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1073-8584 J9 NEUROSCIENTIST JI Neuroscientist PD DEC PY 2012 VL 18 IS 6 BP 567 EP 588 DI 10.1177/1073858411423441 PG 22 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 025BL UT WOS:000310158600007 PM 21982954 ER PT J AU Dimant, H Ebrahimi-Fakhari, D McLean, PJ AF Dimant, Hemi Ebrahimi-Fakhari, Darius McLean, Pamela J. TI Molecular Chaperones and Co-Chaperones in Parkinson Disease SO NEUROSCIENTIST LA English DT Review DE neurodegeneration; Parkinson disease; alpha-synuclein; molecular chaperone; heat shock protein (Hsp); co-chaperone ID ALPHA-SYNUCLEIN AGGREGATION; HEAT-SHOCK PROTEINS; LEWY BODIES; IN-VIVO; MOUSE MODEL; NEURON DEGENERATION; SUBSTANTIA-NIGRA; OXIDATIVE STRESS; DROSOPHILA MODEL; FIBRIL FORMATION AB Parkinson disease, a progressive neurodegenerative disorder, is caused by the pathological accumulation of proteins, including the ubiquitous presynaptic protein alpha-synuclein. Alterations in the metabolism of alpha-synuclein have clearly been linked to neurodegeneration, and early steps in the pathological sequence of this protein include the formation of oligomers, fibrils, and small aggregates. Targeting these early steps of oligomerization is one of the main therapeutic approaches in the quest to develop disease-modifying agents. Molecular chaperones, molecules that can mediate the proper folding and refolding of client proteins, are vital to cell function and survival and thus have been explored as potential therapeutic agents. Important to Parkinson disease, chaperones are capable of preventing alpha-synuclein misfolding, oligomerization, and aggregate formation as shown in vitro and in Parkinson disease animal models. Furthermore, chaperones and associated co-chaperones are closely linked to pathways of protein degradation, like the ubiquitin-proteasome system and autophagy, and are thus able to remove irreversibly misfolded proteins. In this review, we summarize the role of molecular chaperones in Parkinson disease models and discuss the importance of preserving protein homeostasis to prevent neurodegeneration. We also review the growing number of exciting studies that have targeted molecular chaperone function as a novel therapeutic approach. C1 [McLean, Pamela J.] Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02219 USA. RP McLean, PJ (reprint author), Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis, 114 16th St, Charlestown, MA 02219 USA. EM pmclean@partners.org OI Ebrahimi-Fakhari, Darius/0000-0002-0026-4714 FU National Institutes of Health [NS063963]; German National Academic Foundation; Hamburg Foundation for International Research and Studies; Parkinson's Disease Foundation; Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Institutes of Health (grant NS063963) (P.J.M.), the German National Academic Foundation (D.E.-F.), the Hamburg Foundation for International Research and Studies (D.E.-F.), the Parkinson's Disease Foundation (D.E.-F.), and the Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) (H.D.). NR 92 TC 17 Z9 17 U1 1 U2 28 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1073-8584 J9 NEUROSCIENTIST JI Neuroscientist PD DEC PY 2012 VL 18 IS 6 BP 589 EP 601 DI 10.1177/1073858412441372 PG 13 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 025BL UT WOS:000310158600008 PM 22829394 ER PT J AU Kieran, MW Roberts, CWM Chi, SN Ligon, KL Rich, BE MacConaill, LE Garraway, LA Biegel, JA AF Kieran, Mark W. Roberts, Charles W. M. Chi, Susan N. Ligon, Keith L. Rich, Benjamin E. MacConaill, Laura E. Garraway, Levi A. Biegel, Jaclyn A. TI Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors SO PEDIATRIC BLOOD & CANCER LA English DT Article DE AT; RT; OncoMap; rhabdoid; targeted therapy ID CANCER; BRAF; SMARCB1/INI1; INHIBITION; EXPRESSION; CARCINOMA; SURVIVAL; IMATINIB AB Background Rhabdoid tumors (also called atypical teratoid/rhabdoid tumor (AT/RT) in the brain), are highly malignant, poor prognosis lesions arising in the kidneys, soft tissues, and central nervous system. Targeted therapy in this disease would benefit from advanced technologies detecting relevant actionable mutations. Procedure Here we report on the evaluation of 25 tumors, all with known SMARCB1/INI1 alterations, for the presence of 983 different mutations in 115 oncogenes and tumor-suppressor genes using OncoMap, a mass spectrometric method of allele detection. Results Other than mutations in SMARCB1, our results identified a single activating mutation in NRAS and complete absence of oncogenic mutations in all other genes tested. Conclusion The absence of mutations in canonical pathways critical for development and progression of adult cancers suggests that distinct mechanisms drive these highly malignant pediatric tumors. This may limit the therapeutic utility of available targeted therapies and require a refocusing toward developmental and epigenetic pathways. Pediatr Blood Cancer 2012; 59: 11551157. (C) 2012 Wiley Periodicals, Inc. C1 [Kieran, Mark W.; Ligon, Keith L.; Rich, Benjamin E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Kieran, Mark W.; Roberts, Charles W. M.; Chi, Susan N.; Ligon, Keith L.; Rich, Benjamin E.] Boston Childrens Hosp, Boston, MA USA. [Ligon, Keith L.; Rich, Benjamin E.] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02215 USA. [Ligon, Keith L.; Rich, Benjamin E.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [MacConaill, Laura E.; Garraway, Levi A.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02215 USA. [Biegel, Jaclyn A.] Univ Penn, Dept Pediat, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Biegel, Jaclyn A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Kieran, MW (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Rm SW331, Boston, MA 02215 USA. EM mark_kieran@dfci.harvard.edu OI Kieran, Mark/0000-0003-2184-7692 FU National Brain Tumor Society (NBTS) Innovative Grant; Stop&Shop Pediatric Brain Tumor Program; Cure ATRT Foundation; NIH [CA46274]; National Brain Tumor Society FX Support for this project was provided by the National Brain Tumor Society (NBTS) Innovative Grant, the Stop&Shop Pediatric Brain Tumor Program, Cure ATRT Foundation and the NIH (CA46274 to J.A.B). We wish to thank Katherine Eaton for technical assistance.; Grant sponsor: National Brain Tumor Society; Grant sponsor: Cure ATRT Foundation; Grant sponsor: NIH; Grant number: CA46274. NR 25 TC 28 Z9 29 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 7 BP 1155 EP 1157 DI 10.1002/pbc.24315 PG 3 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019PS UT WOS:000309752400002 PM 22997201 ER PT J AU Williams, DA Mack, J AF Williams, David A. Mack, Jennifer TI Enough is indeed enough: ACGME required changes in pediatric training SO PEDIATRIC BLOOD & CANCER LA English DT Editorial Material ID DUTY HOURS C1 [Williams, David A.] Harvard Univ, Boston Childrens Hosp, Sch Med, Div Hematol Oncol, Boston, MA 02115 USA. Harvard Univ, Dept Pediat Oncol, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Williams, DA (reprint author), Harvard Univ, Boston Childrens Hosp, Sch Med, Div Hematol Oncol, 300 Longwood Ave,Karp 08125-3, Boston, MA 02115 USA. EM david.williams2@childrens.harvard.edu NR 8 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 7 BP 1158 EP 1159 DI 10.1002/pbc.24323 PG 2 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019PS UT WOS:000309752400003 PM 22996805 ER PT J AU Termuhlen, AM Smith, LM Perkins, SL Lones, M Finlay, JL Weinstein, H Gross, TG Abromowitch, M AF Termuhlen, Amanda M. Smith, Lynette M. Perkins, Sherrie L. Lones, Mark Finlay, Jonathan L. Weinstein, Howard Gross, Thomas G. Abromowitch, Minnie TI Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: A report from the Children's Oncology Group SO PEDIATRIC BLOOD & CANCER LA English DT Article DE lymphoblastic lymphoma; localized; pediatric ID NON-HODGKINS-LYMPHOMA; MINIMAL RESIDUAL DISEASE; CANCER GROUP; CLINICAL-FEATURES; CHILDHOOD; LEUKEMIA; PROTOCOL; THERAPY; STAGE; METHOTREXATE AB Background Localized lymphoblastic lymphoma (LL) is rare in pediatric patients. We report the 5-year event-free survival (EFS) and overall survival (OS) for children and adolescents with localized LL treated on a uniform regimen based on Children's Cancer Group (CCG) leukemia therapy (COG A5971). Procedure From June 2000 to October 2005, the study enrolled 60 patients >12 months old with Murphy stages I or II LL. Central review confirmed 56 eligible patients. Treatment consisted of 24 months of CCG BFM without day 28 intrathecal methotrexate in maintenance therapy or prophylactic cranial radiation. Results Most patients had pre-B immunophenotype (75%). At a median follow-up of 5.9 years (range 1.49.3 years), the 5-year EFS was 90% [95% confidence interval (CI), 78-96%] and the 5-year OS was 96% (95% CI, 8499%). Stage (I vs. II), immunophenotype, elevated LDH?>?institutional normal, or primary site did not impact outcome. Five relapses occurrednone in the CNS and none in patients with pre-T lymphoblastic disease. Patients tolerated treatment well with no toxic deaths. Conclusion Outcomes of pediatric patients with localized LL treated with 2 years of intensive acute lymphoblastic leukemia (ALL)-type therapy was excellent and is similar to the outcome for standard risk ALL treated less intensively. CNS prophylaxis was adequate with limited intrathecal methotrexate and no radiation. Future studies should identify biologic prognostic factors or biomarkers for pediatric patients with LL, explore less intensive treatment for patients with localized disease, and explore novel immunophenotype directed therapies. Pediatr Blood Cancer 2012; 59: 12291233. (C) 2012 Wiley Periodicals, Inc. C1 [Termuhlen, Amanda M.] Univ So Calif, Jonathan Jaques Childrens Canc Ctr, Miller Childrens Hosp, Dept Pediat,Keck Sch Med, Long Beach, CA 90806 USA. [Smith, Lynette M.] Univ Nebraska, Med Ctr, Dept Biostat, Omaha, NE USA. [Perkins, Sherrie L.] Univ Utah Hlth Sci, Dept Pathol, Salt Lake City, UT USA. [Perkins, Sherrie L.] Univ Utah Hlth Sci, ARUP Labs, Salt Lake City, UT USA. [Lones, Mark] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA. [Finlay, Jonathan L.] Univ So Calif, Dept Pediat, Childrens Hosp Los Angeles, Keck Sch Med, Long Beach, CA 90806 USA. [Weinstein, Howard] Harvard Univ, Sch Med, Dept Pediat, MassGen Hosp Children, Boston, MA 02115 USA. [Gross, Thomas G.] Ohio State Univ, Coll Med, Dept Pediat, Nationwide Childrens Hosp, Columbus, OH 43210 USA. [Abromowitch, Minnie] Univ Nebraska, Dept Pediat, Childrens Hosp, Omaha, NE USA. [Abromowitch, Minnie] Univ Nebraska, Med Ctr Omaha, Omaha, NE USA. RP Termuhlen, AM (reprint author), Univ So Calif, Jonathan Jaques Childrens Canc Ctr, Miller Childrens Hosp, Dept Pediat,Keck Sch Med, 701 E 28th St,Suite 202, Long Beach, CA 90806 USA. EM atermuhlen@chla.usc.edu FU Chair's Grant [U10 CA98543]; Statistics and Data Center Grant [U10 CA98413]; CCG; POG FX Grant sponsor: Chair's Grant; Grant number: U10 CA98543; Grant sponsor: Statistics and Data Center Grant; Grant number: U10 CA98413.; A complete listing of grant support for research conducted by CCG and POG before initiation of the COG grant in 2003 is available online at: http://applications.childrensoncologygroup.org/admin/grantinfo.htm. NR 32 TC 12 Z9 13 U1 1 U2 5 PU WILEY PERIODICALS, INC PI SAN FRANCISCO PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA SN 1545-5009 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 7 BP 1229 EP 1233 DI 10.1002/pbc.24149 PG 5 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019PS UT WOS:000309752400015 PM 22488718 ER PT J AU Tebbi, CK Mendenhall, NP London, WB Williams, JL Hutchison, RE FitzGerald, TJ de Alarcon, PA Schwartz, C Chauvenet, A AF Tebbi, Cameron K. Mendenhall, Nancy P. London, Wendy B. Williams, Jonathan L. Hutchison, Robert E. FitzGerald, Thomas J. de Alarcon, Pedro A. Schwartz, Cindy Chauvenet, Allen TI Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group SO PEDIATRIC BLOOD & CANCER LA English DT Article DE children and adolescents; Hodgkin lymphoma; response-dependent ID PROSPECTIVE CLINICAL-TRIAL; INVOLVED-FIELD RADIATION; PEDIATRIC-PATIENTS; STAGE-I; DISEASE; CHEMOTHERAPY; DEXRAZOXANE; RADIOTHERAPY; GPOH-HD-95; CANCER AB Background Hodgkin lymphoma is highly curable but associated with significant late effects. Reduction of total treatment would be anticipated to reduce late effects. This aim of this study was to demonstrate that a reduction in treatment was possible without compromising survival outcomes. Methods Protocol P9426, a response-dependent and reduced treatment for low risk Hodgkin lymphoma (stages I, IIA, and IIIA1) was designed in 1994 based on a previous pilot project. Patients were enrolled from October 15, 1996 to September 19, 2000. Patients were randomized to receive or not receive dexrazoxane and received two cycles of chemotherapy consisting of doxorubicin, bleomycin, vincristine, and etoposide. After two cycles, patients were evaluated for response. Those in complete response (CR) received 2,550?cGy of involved field radiation therapy (IFRT). Patient with partial response or stable disease, received two more cycles of chemotherapy and IFRT at 2,550?cGy. Results There were 294 patients enrolled, with 255 eligible for analysis. The 8-year event free survival (EFS) between the dexrazoxane randomized groups did not differ (EFS 86.8 +/- 3.1% with DRZ, and 85.7 +/- 3.3% without DRZ (P?=?0.70). Forty-five percent of patients demonstrated CR after two cycles of chemotherapy. There was no difference in EFS by histology, rapidity of response, or number of cycles of chemotherapy. Six of the eight secondary malignancies in this study have been previously reported. Conclusions Despite reduced therapy and exclusion of most patients with lymphocyte predominant histology, EFS and overall survival are similar to other reported studies. The protocol documents that it is safe and effective to reduce therapy in low-risk Hodgkin lymphoma based on early response to chemotherapy with rapid responding patients having the same outcome as slower-responding patients when given 50% of the chemotherapy. Pediatr Blood Cancer 2012; 59: 12591265. (C) 2012 Wiley Periodicals, Inc. C1 [Chauvenet, Allen] W Virginia Univ, Charleston, WV 25302 USA. [Tebbi, Cameron K.] Univ S Florida, Sch Med, Tampa Gen Hosp, Childrens Med Ctr,Div Pediat Hematol Oncol, Tampa, FL 33620 USA. [Mendenhall, Nancy P.] Univ Florida, Proton Therapy Inst, Jacksonville, FL USA. [London, Wendy B.] Harvard Univ, Sch Med, Childrens Oncol Grp Stat, Boston, MA USA. [London, Wendy B.] Harvard Univ, Sch Med, Ctr Data, Boston, MA USA. [London, Wendy B.] Harvard Univ, Sch Med, Dana Farber Harvard Canc Ctr, Boston, MA USA. [Williams, Jonathan L.] Univ Florida, Shands Hosp, Dept Radiol, Gainesville, FL USA. [Hutchison, Robert E.] Upstate Med Univ, Syracuse, NY USA. [FitzGerald, Thomas J.] UMass Mem Med Ctr, Worcester, MA USA. [de Alarcon, Pedro A.] Univ Illinois, Coll Med Peoria, Peoria, IL USA. [Schwartz, Cindy] Brown Univ, Providence, RI 02912 USA. [Schwartz, Cindy] Hasbro Childrens Hosp, Providence, RI USA. RP Chauvenet, A (reprint author), W Virginia Univ, 830 Penn Ave, Charleston, WV 25302 USA. EM achauvenet@hsc.wvu.edu OI Mendenhall, Nancy/0000-0003-2893-7703 FU QARC [NIH/NCI CA29511]; Chair's [U10 CA98543-08]; Statistics and Data Center; Statistics and Data Center Grant of the Children's Oncology Group from the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA [U10 CA98413-08] FX Grant sponsor: QARC; Grant number: NIH/NCI CA29511; Grant sponsor: Chair's; Grant number: U10 CA98543-08; Grant sponsor: Statistics and Data Center; Grant number: U10 CA98413-08.; QARC GRANT NIH/NCI CA29511, the Chair's Grant U10 CA98543-08 and Statistics and Data Center Grant U10 CA98413-08 of the Children's Oncology Group from the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or the NIH. A complete listing of grant support for research conducted by CCG and POG before initiation of the COG grant in 2003 is available online at: http://www.childrensoncologygroup.org/admin/grantinfo.htm. NR 25 TC 27 Z9 28 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD DEC PY 2012 VL 59 IS 7 BP 1259 EP 1265 DI 10.1002/pbc.24279 PG 7 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA 019PS UT WOS:000309752400020 PM 22911615 ER PT J AU Chabrol, H Valls, M van Leeuwen, N Bui, E AF Chabrol, Henri Valls, Marjorie van Leeuwen, Nikki Bui, Eric TI Callous-unemotional and borderline traits in nonclinical adolescents: Personality profiles and relations to antisocial behaviors SO PERSONALITY AND INDIVIDUAL DIFFERENCES LA English DT Article DE Callous-unemotional traits; Borderline traits; Personality profiles; Antisocial behavior; Adolescents ID PSYCHOPATHIC TRAITS; DEFENSE-MECHANISMS; VIOLENT OFFENDERS; CLUSTER-ANALYSIS; DISORDER; IMPULSIVITY; POPULATION; CHILDREN; VALIDITY; SAMPLE AB Callous-unemotional and borderline traits, antisocial behaviors, depressive symptoms and social anxiety were assessed in 972 high-school students. Cluster analysis yielded four groups: a low traits group, a second group that was above the mean in callous-unemotional traits and below the mean in borderline traits (moderate callous-unemotional traits cluster), a third group that was well above the mean in borderline traits but low on callous-unemotional traits (borderline traits cluster), and a fourth group that was high on both traits (high traits cluster). The high traits cluster was characterized by the highest level of antisocial behaviors and shared with the borderline traits cluster a high level of depressive symptoms and social anxiety. The moderate callous-unemotional traits cluster and the borderline traits cluster had similar levels of antisocial behaviors that were higher than those of the low traits cluster. This study suggests that there is a significant minority of non-clinical adolescents characterized by the presence of both callous-unemotional and borderline traits, and higher levels of antisocial behaviors and emotional distress. (C) 2012 Elsevier Ltd. All rights reserved. C1 [Chabrol, Henri; Valls, Marjorie; van Leeuwen, Nikki] Univ Toulouse, Dept Psychol, Toulouse, France. [Bui, Eric] Ctr Hosp Univ Toulouse, Lab Stress Traumat EA4580, Toulouse, France. [Bui, Eric] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bui, Eric] Harvard Univ, Sch Med, Boston, MA USA. RP Chabrol, H (reprint author), Univ Toulouse Le Mirail, Lab CERPP OCTOGONE, Pavilion Rech,5 Allees Antonio Machado, F-31058 Toulouse 9, France. EM chabrol@univ-tlse2.fr RI Bui, Eric/J-8347-2015 OI Bui, Eric/0000-0002-1413-6473 NR 38 TC 6 Z9 6 U1 1 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0191-8869 J9 PERS INDIV DIFFER JI Pers. Individ. Differ. PD DEC PY 2012 VL 53 IS 8 BP 969 EP 973 DI 10.1016/j.paid.2012.07.017 PG 5 WC Psychology, Social SC Psychology GA 023OL UT WOS:000310044200005 ER PT J AU Goncalves, LFH Fermiano, D Feres, M Figueiredo, LC Teles, FRP Mayer, MPA Faveri, M AF Goncalves, L. F. H. Fermiano, D. Feres, M. Figueiredo, L. C. Teles, F. R. P. Mayer, M. P. A. Faveri, M. TI Levels of Selenomonas species in generalized aggressive periodontitis SO JOURNAL OF PERIODONTAL RESEARCH LA English DT Article DE 16S ribosomal RNA; generalized aggressive periodontitis; molecular biology; not-yet-cultured species; Selenomonas sputigena ID EARLY-ONSET PERIODONTITIS; POLYMERASE-CHAIN-REACTION; SUBGINGIVAL PLAQUE; CLONAL ANALYSIS; YOUNG-ADULTS; MICROBIOTA; LESIONS; PATHOGENS; DISEASE; HEALTH AB Goncalves LFH, Fermiano D, Feres M, Figueiredo LC, Teles FRP, Mayer MPA, Faveri M. Levels of Selenomonas species in generalized aggressive periodontitis. J Periodont Res 2012; 47: 711718. (c) 2012 John Wiley & Sons A/S Background and Objective: To compare the levels of Selenomonas sputigena and uncultivated/unrecognized Selenomonas species in subgingival biofilms from periodontally healthy subjects and from subjects with generalized aggressive periodontitis. Material and Methods: Fifteen periodontally healthy subjects and 15 subjects with generalized aggressive periodontitis were recruited and their clinical periodontal parameters were evaluated. Nine subgingival plaque samples were collected from each subject and all were individually analyzed for the levels of 10 bacterial taxa, including cultured and uncultivated/unrecognized microorganisms, using the RNA-oligonucleotide quantification technique. Between-group differences in the levels of the test taxa were determined using the MannWhitney U-test. Results: Subjects with generalized aggressive periodontitis showed significantly higher mean counts of Porphyromonas gingivalis, S. sputigena and the Mitsuokella sp. Human Oral Taxon (HOT) 131 (previously described as Selenomonas sp. oral clone CS002), while higher mean counts of Actinomyces gerencseriae and Streptococcus sanguinis were found in periodontally healthy subjects (p < 0.01). Selenomonas sp. HOT 146 was only detected in the generalized aggressive periodontitis group. In the generalized aggressive periodontitis group, the levels of P.gingivalis and S.sputigena were higher in deep sites (probing depth = 5 mm) than in shallow sites (probing depth = 3 mm) (p < 0.01). Furthermore, in subjects with generalized aggressive periodontitis, sites with probing depth of = 3 mm harbored higher levels of these two species than sites with the same probing depth in periodontally healthy subjects. There were positive correlations between probing depth and the levels of P.gingivalis (r = 0.77; p < 0.01), S.sputigena (r = 0.60; p < 0.01) and Selenomonas dianae (previously described as Selenomonas sp. oral clone EW076) (r = 0.42, p < 0.05). Conclusion: S. sputigena and Mitsuokella sp. HOT 131 may be associated with the pathogenesis of generalized aggressive periodontitis, and their role in the onset and progression of this infection should be investigated further. C1 [Faveri, M.] Univ Guarulhos, Ctr Posgrad & Pesquisa CEPPE, Dept Periodontol, Dent Res Div, BR-07023070 Guarulhos, SP, Brazil. [Mayer, M. P. A.; Faveri, M.] Univ Sao Paulo, Dept Microbiol, Inst Biomed Sci, Sao Paulo, Brazil. [Teles, F. R. P.] Forsyth Inst, Dept Periodontol, Cambridge, MA USA. RP Faveri, M (reprint author), Univ Guarulhos, Ctr Posgrad & Pesquisa CEPPE, Dept Periodontol, Dent Res Div, Praca Tereza Cristina,229 Ctr, BR-07023070 Guarulhos, SP, Brazil. EM mfaveri@prof.ung.br RI Feres, Magda/H-7964-2012; Mayer, Marcia/D-4645-2012 OI Mayer, Marcia/0000-0002-5910-8433 FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Brazil) [2005/59443-2, 2009/12358-1]; NIH/NIDCR [R03-DE-021742]; Eleanor and Miles Shore Fellowship Program for Scholars in Medicine (The Forsyth Institute/Harvard Medical School) FX This study was supported by Research Grants 2005/59443-2 and 2009/12358-1 from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP, Brazil) and in part by NIH/NIDCR grant R03-DE-021742 (F.T.) and the Eleanor and Miles Shore Fellowship Program for Scholars in Medicine (The Forsyth Institute/Harvard Medical School) (F.T.). We want to thank Dr. Bruce Paster (The Forsyth Institute/Harvard Medical School) for his assistance with the oligonucleotide sequences employed in the present study. NR 43 TC 12 Z9 13 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3484 J9 J PERIODONTAL RES JI J. Periodont. Res. PD DEC PY 2012 VL 47 IS 6 BP 711 EP 718 DI 10.1111/j.1600-0765.2012.01485.x PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 017OT UT WOS:000309600600005 PM 22612405 ER PT J AU Zhu, B Dong, YL Xu, ZP Gompf, HS Ward, SAP Xue, ZG Miao, CH Zhang, YY Chamberlin, NL Xie, ZC AF Zhu, Biao Dong, Yuanlin Xu, Zhipeng Gompf, Heinrich S. Ward, Sarah A. P. Xue, Zhanggang Miao, Changhong Zhang, Yiying Chamberlin, Nancy L. Xie, Zhongcong TI Sleep disturbance induces neuroinflammation and impairment of learning and memory SO NEUROBIOLOGY OF DISEASE LA English DT Article DE Sleep disturbance; Hippocampus; Neuroinflammation; Learning and memory ID INTERLEUKIN-1-BETA MESSENGER-RNA; INTENSIVE-CARE-UNIT; EYE-MOVEMENT SLEEP; COGNITIVE DECLINE; SPATIAL MEMORY; RETROGRADE-AMNESIA; SYSTEMIC INFECTION; CONTEXTUAL FEAR; CARDIAC-SURGERY; TNF-ALPHA AB Hospitalized patients can develop cognitive function decline, the mechanisms of which remain largely to be determined. Sleep disturbance often occurs in hospitalized patients, and neuroinflammation can induce learning and memory impairment. We therefore set out to determine whether sleep disturbance can induce neuroinflammation and impairment of learning and memory in rodents. Five to 6-month-old wild-type C57BL/6J male mice were used in the studies. The mice were placed in rocking cages for 24 h, and two rolling balls were present in each cage. The mice were tested for learning and memory function using the Fear Conditioning Test one and 7 days post-sleep disturbance. Neuroinflammation in the mouse brain tissues was also determined. Of the Fear Conditioning studies at one day and 7 days after sleep disturbance, twenty-four hour sleep disturbance decreased freezing time in the context test, which assesses hippocampus-dependent learning and memory; but not the tone test, which assesses hippocampus-independent learning and memory. Sleep disturbance increased pro-inflammatory cytokine IL-6 levels and induced microglia activation in the mouse hippocampus, but not the cortex. These results suggest that sleep disturbance induces neuroinflammation in the mouse hippocampus, and impairs hippocampus-dependent learning and memory in mice. Pending further studies, these findings suggest that sleep disturbance-induced neuroinflammation and impairment of learning and memory may contribute to the development of cognitive function decline in hospitalized patients. (c) 2012 Elsevier Inc. All rights reserved. C1 [Zhu, Biao; Dong, Yuanlin; Xu, Zhipeng; Ward, Sarah A. P.; Zhang, Yiying; Xie, Zhongcong] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Geriatr Anesthesia Res Unit, Charlestown, MA 02129 USA. [Zhu, Biao; Dong, Yuanlin; Xu, Zhipeng; Ward, Sarah A. P.; Zhang, Yiying; Xie, Zhongcong] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Zhu, Biao; Xue, Zhanggang; Miao, Changhong] Fudan Univ, Affiliated Zhongshan Hosp, Dept Anesthesiol Crit Care & Pain Med, Shanghai 200032, Peoples R China. [Gompf, Heinrich S.; Chamberlin, Nancy L.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA. RP Xie, ZC (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Geriatr Anesthesia Res Unit, 149 13th St,Room 4310, Charlestown, MA 02129 USA. EM zxie@partners.org FU (National Institutes of Health), Cure Alzheimer's Fund, USA [R21AG029856, R21AG038994, R01 GM088801] FX This research was supported by R21AG029856, R21AG038994 and R01 GM088801 (National Institutes of Health), Cure Alzheimer's Fund, USA (to Z.X.). NR 58 TC 26 Z9 29 U1 1 U2 24 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0969-9961 J9 NEUROBIOL DIS JI Neurobiol. Dis. PD DEC PY 2012 VL 48 IS 3 BP 348 EP 355 DI 10.1016/j.nbd.2012.06.022 PG 8 WC Neurosciences SC Neurosciences & Neurology GA 018VG UT WOS:000309694000009 PM 22776332 ER PT J AU Cheung, WY Zhai, RH Bradbury, P Hopkins, J Kulke, MH Heist, RS Asomaning, K Ma, C Xu, W Wang, ZX Hooshmand, S Su, L Christiani, DC Liu, G AF Cheung, Winson Y. Zhai, Rihong Bradbury, Penny Hopkins, Jessica Kulke, Matthew H. Heist, Rebecca S. Asomaning, Kofi Ma, Clement Xu, Wei Wang, Zhaoxi Hooshmand, Suzanne Su, Li Christiani, David C. Liu, Geoffrey TI Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE matrix metalloproteinase; gene polymorphism; gastroesophageal reflux disease; esophageal cancer ID CIGARETTE-SMOKING EXPOSURE; LUNG-CANCER; LARYNGEAL FIBROBLASTS; HISTOLOGY DIFFERENCES; GASTRIC CANCERS; UNITED-STATES; EXPRESSION; PROGNOSIS; MATRIX-METALLOPROTEINASE-9; CARCINOMA AB The matrix metalloproteinase (MMP) family of proteins mediates various cellular pathways, including apoptosis and angiogenesis. Polymorphisms of MMP genes are associated with increased esophageal adenocarcinoma (EAC) risk. Gastroesophageal reflux disease (GERD) is an established EAC risk factor. We examined whether MMP polymorphism-EAC risk is modified by GERD. In total, 309 EAC patients and 279 frequency-matched healthy controls underwent MMP1 1G/2G, MMP3 6A/5A, MMP12 -82A/G and MMP12 1082A/G genotyping. Questionnaires collected GERD history. EAC risk was analyzed using logistic regression, adjusted for key covariates and stratified by GERD. Joint effects models explored GERD severity and duration, whereas additional models explored genotypeGERD interactions in EAC risk. We determined that each MMP1 and MMP3 minor (variant) allele was independently associated with increased EAC risk (adjusted odds ratio (AOR) 3.2, 95% confidence interval (CI) 2.05.1, p < 0.001 and AOR 1.8, 95% CI 1.12.7, p = 0.01, respectively) only among those with GERD but not in GERD-free individuals (all p = nonsignificant). There were significant interactions between the MMP1 variants and the presence of GERD (p = 0.002) and between MMP3 variants and GERD (p = 0.04). There was an equally strong interaction between cumulative GERD severity and MMP1 (p = 0.002). The AOR of each variant allele was 14.9 (95% CI 1.6136) for individuals with severe GERD, 1.7 (95% CI 1.02.7) for mild-moderate GERD and 0.98 (95% CI 0.71.4) for those without GERD. This was further reflected in separate analyses of frequency and duration of GERD. In conclusion, MMP1 1G/2G (and possibly MMP3 6A/5A) polymorphisms alter EAC risk differentially for GERD and GERD-free individuals. C1 [Zhai, Rihong; Asomaning, Kofi; Wang, Zhaoxi; Su, Li; Christiani, David C.; Liu, Geoffrey] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Cheung, Winson Y.] British Columbia Canc Agcy, Div Med Oncol, Vancouver, BC V5Z 4E6, Canada. [Bradbury, Penny; Hopkins, Jessica; Ma, Clement; Xu, Wei; Liu, Geoffrey] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada. [Kulke, Matthew H.; Hooshmand, Suzanne] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Heist, Rebecca S.; Christiani, David C.] Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA 02114 USA. [Liu, Geoffrey] Univ Toronto, Dept Med, Toronto, ON M5G 2M9, Canada. RP Christiani, DC (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 665 Huntington Ave,Bldg 1,Room 1407, Boston, MA 02115 USA. EM dchristi@hsph.harvard.edu; geoffrey.liu@uhn.on.ca RI Liu, Geoffrey/N-4421-2016 FU Flight Attendant Medical Research Institute (FAMRI) Award [062459_YCSA]; CIHR Operating Grant; Kevin Jackson Memorial Fund; CCO Chair in Experimental Therapeutics and Population Studies; Alan B. Brown Chair in Molecular Genomics; NCIC Dorothy Lamont Award; Posluns Family Fund PMH Foundation; National Cancer Institute [R01CA109193, R03CA110822, R01CA074386] FX Grant sponsor: Flight Attendant Medical Research Institute (FAMRI) Award; Grant number: 062459_YCSA; Grant sponsor: CIHR Operating Grant, Kevin Jackson Memorial Fund, CCO Chair in Experimental Therapeutics and Population Studies, Alan B. Brown Chair in Molecular Genomics, NCIC Dorothy Lamont Award, Posluns Family Fund PMH Foundation, National Cancer Institute; Grant numbers: R01CA109193, R03CA110822, R01CA074386 NR 31 TC 8 Z9 8 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 J9 INT J CANCER JI Int. J. Cancer PD DEC 1 PY 2012 VL 131 IS 11 BP 2478 EP 2486 DI 10.1002/ijc.27541 PG 9 WC Oncology SC Oncology GA 011SN UT WOS:000309185400002 PM 22422400 ER PT J AU Higashi, RT Tillack, AA Steinman, M Harper, M Johnston, CB AF Higashi, Robin T. Tillack, Allison A. Steinman, Michael Harper, Michael Johnston, C. Bree TI Elder care as "frustrating" and "boring": Understanding the persistence of negative attitudes toward older patients among physicians-in-training SO JOURNAL OF AGING STUDIES LA English DT Article DE Ageism; Medical education; Ethnograpy ID MEDICAL-STUDENTS; HIDDEN CURRICULUM; GERIATRIC-MEDICINE; KNOWLEDGE; EDUCATION; BIOMEDICALIZATION; SCIENCE; LEARN; SEE; AGE AB Objectives: This study explores the attitudes of physicians-in-training toward older patients. Specifically, we examine why, despite increasing exposure to geriatrics in medical school curricula, medical students and residents continue to have negative attitudes toward caring for older patients. Methods: This study used ethnography, a technique used by anthropologists that includes participant-observation, semi-structured interviews, and facilitated group discussions. Research was conducted at two tertiary-care academic hospitals in urban Northern California, and focused on eliciting the opinions, beliefs, and practices of physicians-in-training toward geriatrics. Results: We found that the majority of physicians-in-training in this study expressed a mix of positive and negative views about caring for older patients. We argue that physicians-in-trainings' attitudes toward older patients are shaped by a number of heterogeneous and frequently conflicting factors, including both the formal and so-called "hidden" curricula in medical education, institutional demands on physicians to encourage speed and efficiency of care, and portrayals of the process of aging as simultaneously as a "problem" of inevitable biological decay and an opportunity for medical intervention. Discussion: Efforts to educate medical students and residents about appropriate geriatric care tend to reproduce the paradoxes and uncertainties surrounding aging in biomedicine. These ambiguities contribute to the tendency of physicians-in-training to develop moralizing attitudes about older patients and other patient groups labeled "frustrating" or "boring". (C) 2012 Elsevier Inc. All rights reserved. C1 [Higashi, Robin T.; Tillack, Allison A.] Univ Calif San Francisco, Dept Anthropol Hist & Social Med, San Francisco, CA 94143 USA. [Steinman, Michael; Harper, Michael; Johnston, C. Bree] San Francisco VA Med Ctr, Dept Geriatr, San Francisco, CA USA. RP Higashi, RT (reprint author), Univ Calif San Francisco, Dept Anthropol Hist & Social Med, San Francisco, CA 94143 USA. EM robin.higashi@gmail.com NR 26 TC 13 Z9 13 U1 3 U2 27 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0890-4065 J9 J AGING STUD JI J. Aging Stud. PD DEC PY 2012 VL 26 IS 4 BP 476 EP 483 DI 10.1016/j.jaging.2012.06.007 PG 8 WC Gerontology SC Geriatrics & Gerontology GA 013NN UT WOS:000309312200012 PM 22939544 ER PT J AU Ellison, ML Mueller, L Smelson, D Corrigan, PW Stone, RAT Bokhour, BG Najavits, LM Vessella, JM Drebing, C AF Ellison, Marsha Langer Mueller, Lisa Smelson, David Corrigan, Patrick W. Stone, Rosalie A. Torres Bokhour, Barbara G. Najavits, Lisa M. Vessella, Jennifer M. Drebing, Charles TI Supporting the Education Goals of Post-9/11 Veterans with Self-Reported PTSD Symptoms: A Needs Assessment SO PSYCHIATRIC REHABILITATION JOURNAL LA English DT Article DE supported education; young adults; veterans; needs assessment ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; IRAQ; AFGHANISTAN; EMPLOYMENT; WAR; INDIVIDUALS; ADULTHOOD; AFFAIRS; COMBAT AB Purpose: The influx of young adult veterans with mental health challenges from recent wars combined with newly expanded veteran education benefits has highlighted the need for a supported education service within the Veterans Administration. However, it is unknown how such a service should be designed to best respond to these needs. This study undertook a qualitative needs assessment for education supports among veterans with post-9/11 service with self-reported PTSD symptoms. Methods: Focus groups were held with 31 veterans, 54% of whom were under age 30. Transcripts were analyzed and interpreted using a thematic approach and a Participatory Action Research team. Results: Findings indicate a need for age relevant services that assist with: education planning and access, counseling for the G.I. Bill, accommodations for PTSD symptoms, community and family re-integration, and outreach and support. Conclusions and Implications for Practice: The veterans recommended that supported education be integrated with the delivery of mental health services, that services have varied intensity, and there be linkages between colleges and the Veterans Health Administration. C1 [Ellison, Marsha Langer; Bokhour, Barbara G.; Vessella, Jennifer M.] ENRM Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Ellison, Marsha Langer] Univ Massachusetts, Sch Med, Worcester, MA USA. [Mueller, Lisa; Drebing, Charles] ENRM Vet Hosp, VISNi Mental Illness Res Educ & Clin Ctr, Bedford, MA USA. [Smelson, David] Univ Massachusetts, Sch Med, ENRM Vet Hosp, Natl Ctr Homeless Vet Bedford Node, Worcester, MA USA. [Corrigan, Patrick W.] IIT, Chicago, IL 60616 USA. [Stone, Rosalie A. Torres] Univ Massachusetts, Sch Med, Dept Psychiat, Ctr Mental Hlth Serv Res, Worcester, MA 01655 USA. [Bokhour, Barbara G.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Najavits, Lisa M.] Boston Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02118 USA. RP Ellison, ML (reprint author), ENRM Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. EM Marsha.Ellison@umassmed.edu RI Schueter, nicos/A-3625-2014; OI Bokhour, Barbara/0000-0001-8238-0745 NR 37 TC 8 Z9 8 U1 2 U2 18 PU CENTER PSYCHIATRIC REHABILITATION PI BOSTON PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA SN 1095-158X J9 PSYCHIATR REHABIL J JI Psychiatr. Rehabil. J. PD WIN PY 2012 VL 35 IS 3 SI SI BP 209 EP 217 DI 10.2975/35.3.2012.209.217 PG 9 WC Psychiatry; Rehabilitation SC Psychiatry; Rehabilitation GA 884PX UT WOS:000299721100006 PM 22246119 ER PT J AU Seeger, JD Quinn, S Earnest, DL Lembo, A Kuo, B Rivero, E Walker, AM AF Seeger, John D. Quinn, Sherry Earnest, David L. Lembo, Anthony Kuo, Braden Rivero, Elena Walker, Alexander M. TI The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment SO BMC GASTROENTEROLOGY LA English DT Article DE Abdominal surgery; Tegaserod; Cohort study ID IRRITABLE-BOWEL-SYNDROME; PROPENSITY SCORE; CLAIMS DATA; CHOLECYSTECTOMY; CONSTIPATION; POPULATION AB Background: Pre-marketing clinical studies of tegaserod suggested an increased risk of abdominal surgery, particularly cholecystectomy. We sought to quantify the association between tegaserod use and the occurrence of abdominal or pelvic surgery, including cholecystectomy. Methods: This cohort study was conducted within an insured population. Tegaserod initiators and similar persons who did not initiate tegaserod were followed for up to six months for the occurrence of abdominal or pelvic surgery. Surgical procedures were identified from health insurance claims validated by review of medical records. The incidence of confirmed outcomes was compared using both as-matched and as-treated analyses. Results: Among 2,762 tegaserod initiators, there were 94 abdominal or pelvic surgeries (36 gallbladder): among 2,762 comparators there were 134 abdominal or pelvic surgeries (37 gallbladder) (hazard ratio HR] = 0.70, 95% confidence interval [C. I.] = 0.54-0.91 overall, HR = 0.98, 95% C. I. = 0.62-1.55 for gallbladder). Current tegaserod exposure compared to nonexposure was associated with a rate ratio [RR] of 0.68 (95% C. I. = 0.48-0.95) overall, while the RR was 0.99 (95% C. I. = 0.56-1.77) for gallbladder surgery. Conclusions: In this study, tegaserod use was not found to increase the risk of abdominal or pelvic surgery nor the specific subset of gallbladder surgery. C1 [Seeger, John D.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Seeger, John D.] Harvard Univ, Sch Med, Boston, MA USA. [Seeger, John D.; Walker, Alexander M.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Seeger, John D.; Quinn, Sherry] OptumInsight, Waltham, MA USA. [Earnest, David L.] Novartis Pharmaceut, E Hanover, NJ USA. [Lembo, Anthony] Beth Israel Deaconess Med Ctr, Boston, MA USA. [Kuo, Braden] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Rivero, Elena] Novartis Farmaceut, Barcelona, Spain. [Seeger, John D.; Walker, Alexander M.] World Hlth Informat Sci Consultants WHISCON, Newton, MA USA. RP Seeger, JD (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM jdseeger@partners.org NR 21 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-230X J9 BMC GASTROENTEROL JI BMC Gastroenterol. PD NOV 30 PY 2012 VL 12 AR 171 DI 10.1186/1471-230X-12-171 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 063SH UT WOS:000313020100001 PM 23198861 ER PT J AU Glatman-Freedman, A Portelli, I Jacobs, SK Mathew, JI Slutzman, JE Goldfrank, LR Smith, SW AF Glatman-Freedman, Aharona Portelli, Ian Jacobs, Susan K. Mathew, Justin I. Slutzman, Jonathan E. Goldfrank, Lewis R. Smith, Silas W. TI Attack Rates Assessment of the 2009 Pandemic H1N1 Influenza A in Children and Their Contacts: A Systematic Review and Meta-Analysis SO PLOS ONE LA English DT Article ID APRIL-MAY 2009; NEW-YORK-CITY; CONFIRMED HOUSEHOLD TRANSMISSION; JUNE-JULY 2009; VIRUS-INFECTION; OUTBREAK; SCHOOL; INTERVENTIONS; CLOSURE; CANADA AB Background: The recent H1N1 influenza A pandemic was marked by multiple reports of illness and hospitalization in children, suggesting that children may have played a major role in the propagation of the virus. A comprehensive detailed analysis of the attack rates among children as compared with their contacts in various settings is of great importance for understanding their unique role in influenza pandemics. Methodology/Principal Findings: We searched MEDLINE (PubMed) and Embase for published studies reporting outbreak investigations with direct measurements of attack rates of the 2009 pandemic H1N1 influenza A among children, and quantified how these compare with those of their contacts. We identified 50 articles suitable for review, which reported school, household, travel and social events. The selected reports and our meta-analysis indicated that children had significantly higher attack rates as compared to adults, and that this phenomenon was observed for both virologically confirmed and clinical cases, in various settings and locations around the world. The review also provided insight into some characteristics of transmission between children and their contacts in the various settings. Conclusion/Significance: The consistently higher attack rates of the 2009 pandemic H1N1 influenza A among children, as compared to adults, as well as the magnitude of the difference is important for understanding the contribution of children to disease burden, for implementation of mitigation strategies directed towards children, as well as more precise mathematical modeling and simulation of future influenza pandemics. C1 [Glatman-Freedman, Aharona] New York Med Coll, Dept Family & Community Med, Valhalla, NY 10595 USA. [Glatman-Freedman, Aharona] NYU, Global Publ Hlth Masters Program, New York, NY USA. [Portelli, Ian; Goldfrank, Lewis R.; Smith, Silas W.] NYU, Sch Med, Dept Emergency Med, New York, NY USA. [Portelli, Ian; Goldfrank, Lewis R.; Smith, Silas W.] NYU, Ctr Catastrophe Preparedness & Response, New York, NY USA. [Jacobs, Susan K.] NYU, Elmer Holmes Bobst Lib, New York, NY USA. [Mathew, Justin I.] CUNY Hunter Coll, New York, NY 10021 USA. [Slutzman, Jonathan E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Emergency Med,Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Glatman-Freedman, A (reprint author), New York Med Coll, Dept Family & Community Med, Valhalla, NY 10595 USA. EM af1200@nyu.edu OI Jacobs, Susan Kaplan/0000-0002-9959-5627 FU United States Department of Defense [W81XW4-07-1-0517, DOD 2007-NYU-001]; New York University/Polytechnic Seed Funding; Nan A. Lightstone Foundation FX L.R.G. is a recipient of the United States Department of Defense contract numbers W81XW4-07-1-0517 (Agents of Opportunity) and DOD 2007-NYU-001 (LaSER PLAN C: Pandemic Influenza) as well as New York University/Polytechnic Seed Funding (Pandemic Influenza complex modeling). A.G.-F. is a recipient of the Nan A. Lightstone Foundation grant for innovation in infectious disease research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 67 TC 11 Z9 11 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 30 PY 2012 VL 7 IS 11 AR e50228 DI 10.1371/journal.pone.0050228 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 054WM UT WOS:000312376100058 PM 23284603 ER PT J AU Hirata, H Ueno, K Shahryari, V Tanaka, Y Tabatabai, ZL Hinoda, Y Dahiya, R AF Hirata, Hiroshi Ueno, Koji Shahryari, Varahram Tanaka, Yuichiro Tabatabai, Z. Laura Hinoda, Yuji Dahiya, Rajvir TI Oncogenic miRNA-182-5p Targets Smad4 and RECK in Human Bladder Cancer SO PLOS ONE LA English DT Article ID BETA-CATENIN ACTIVATION; TUMOR-SUPPRESSOR; SIGNALING ACTIVITY; CARCINOMA CELLS; EXPRESSION; METASTASIS; MICRORNAS; MIR-182; TUMORIGENESIS; RESTORATION AB Onco-miR-182-5p has been reported to be over-expressed in bladder cancer (BC) tissues however a detailed functional analysis of miR-182-5p has not been carried out in BC. Therefore the purpose of this study was to: 1. conduct a functional analysis of miR-182-5p in bladder cancer, 2. assess its usefulness as a tumor marker, 3. identify miR-182-5p target genes in BC. Initially we found that miR-182-5p expression was significantly higher in bladder cancer compared to normal tissues and high miR-182-5p expression was associated with shorter overall survival in BC patients. To study the functional significance of miR-182-5p, we over-expressed miR-182-5p with miR-182-5p precursor and observed that cell proliferation, migration and invasion abilities were increased in BC cells. However cell apoptosis was inhibited by miR-182-5p. We also identified Smad4 and RECK as potential target genes of miR-182-5p using several algorithms. 3'UTR luciferase activity of these target genes was significantly decreased and protein expression of these target genes was significantly up-regulated in miR-182-5p inhibitor transfected bladder cancer cells. MiR-182-5p also increased nuclear beta-catenin expression and while Smad4 repressed nuclear beta-catenin expression. In conclusion, our data suggests that miR-182-5p plays an important role as an oncogene by knocking down RECK and Smad4, resulting in activation of the Wnt-beta-catenin signaling pathway in bladder cancer. C1 [Hirata, Hiroshi; Ueno, Koji; Shahryari, Varahram; Tanaka, Yuichiro; Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. [Hirata, Hiroshi; Ueno, Koji; Shahryari, Varahram; Tanaka, Yuichiro; Tabatabai, Z. Laura; Dahiya, Rajvir] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Tabatabai, Z. Laura] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA USA. [Hinoda, Yuji] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Yamaguchi, Japan. RP Dahiya, R (reprint author), San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. EM rdahiya@urology.ucsf.edu FU National Center for Research Resources of the United States National Institutes of Health [RO1CA138642, RO1CA130860, RO1CA160079]; VA Merit Review grants; VA Program Project FX This study was supported by National Center for Research Resources of the United States National Institutes of Health through Grant Number RO1CA138642, RO1CA130860, RO1CA160079, VA Merit Review grants, and VA Program Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 50 Z9 53 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 30 PY 2012 VL 7 IS 11 AR e51056 DI 10.1371/journal.pone.0051056 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 054WM UT WOS:000312376100266 PM 23226455 ER PT J AU Maru, DSR Andrews, J Schwarz, D Schwarz, R Acharya, B Ramaiya, A Karelas, G Rajbhandari, R Mate, K Shilpakar, S AF Maru, Duncan Smith-Rohrberg Andrews, Jason Schwarz, Dan Schwarz, Ryan Acharya, Bibhav Ramaiya, Astha Karelas, Gregory Rajbhandari, Ruma Mate, Kedar Shilpakar, Sona TI Crossing the quality chasm in resource-limited settings SO GLOBALIZATION AND HEALTH LA English DT Review DE Resource-limited; Health system; Global health; Quality improvement ID SURGICAL SAFETY CHECKLIST; DEVELOPING-COUNTRIES; HEALTH-SYSTEMS; GLOBAL HEALTH; IMPLEMENTATION; DELIVERY; CARE; POPULATION; MANAGEMENT; MORBIDITY AB Over the last decade, extensive scientific and policy innovations have begun to reduce the "quality chasm" - the gulf between best practices and actual implementation that exists in resource-rich medical settings. While limited data exist, this chasm is likely to be equally acute and deadly in resource-limited areas. While health systems have begun to be scaled up in impoverished areas, scale-up is just the foundation necessary to deliver effective healthcare to the poor. This perspective piece describes a vision for a global quality improvement movement in resource-limited areas. The following action items are a first step toward achieving this vision: 1) revise global health investment mechanisms to value quality; 2) enhance human resources for improving health systems quality; 3) scale up data capacity; 4) deepen community accountability and engagement initiatives; 5) implement evidence-based quality improvement programs; 6) develop an implementation science research agenda. C1 [Maru, Duncan Smith-Rohrberg; Andrews, Jason; Schwarz, Dan; Schwarz, Ryan; Acharya, Bibhav; Ramaiya, Astha; Karelas, Gregory; Rajbhandari, Ruma; Shilpakar, Sona] Bayalpata Hosp, Ridikot VDC, Nyaya Hlth, Achham, Nepal. [Maru, Duncan Smith-Rohrberg; Schwarz, Dan; Schwarz, Ryan; Rajbhandari, Ruma; Mate, Kedar] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Maru, Duncan Smith-Rohrberg; Schwarz, Dan; Schwarz, Ryan] Childrens Hosp, Dept Med, Boston, MA 02115 USA. [Acharya, Bibhav] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. [Mate, Kedar] Inst Healthcare Improvement, Cambridge, MA USA. [Mate, Kedar] Weill Cornell Med Coll, Dept Med, New York, NY USA. [Andrews, Jason] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Maru, Duncan Smith-Rohrberg] Brigham & Womens Hosp, Global Hlth Equ Program, Boston, MA 02115 USA. RP Maru, DSR (reprint author), Bayalpata Hosp, Ridikot VDC, Nyaya Hlth, Achham, Nepal. EM duncansr@post.harvard.edu OI Rajbhandari, Ruma/0000-0001-8281-550X; Mate, Kedar/0000-0001-7579-6697 NR 32 TC 5 Z9 5 U1 0 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1744-8603 J9 GLOBALIZATION HEALTH JI Global. Health PD NOV 30 PY 2012 VL 8 AR 41 DI 10.1186/1744-8603-8-41 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 057YM UT WOS:000312600500001 PM 23193968 ER PT J AU Krishnan, L Engelman, A AF Krishnan, Lavanya Engelman, Alan TI Retroviral Integrase Proteins and HIV-1 DNA Integration SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Review ID HUMAN-IMMUNODEFICIENCY-VIRUS; SMALL-MOLECULE INHIBITORS; STRAND-TRANSFER; IN-VITRO; VIRAL-DNA; CONCERTED INTEGRATION; TYPE-1 INTEGRASE; PREINTEGRATION COMPLEXES; HUMAN GENOME; ACTIVE-SITE AB Retroviral integrases catalyze two reactions, 3'-processing of viral DNA ends, followed by integration of the processed ends into chromosomal DNA. X-ray crystal structures of integrase-DNA complexes from prototype foamy virus, a member of the Spumavirus genus of Retroviridae, have revealed the structural basis of integration and how clinically relevant integrase strand transfer inhibitors work. Underscoring the translational potential of targeting virus-host interactions, small molecules that bind at the host factor lens epithelium-derived growth factor/p75-binding site on HIV-1 integrase promote dimerization and inhibit integrase-viral DNA assembly and catalysis. Here, we review recent advances in our knowledge of HIV-1 DNA integration, as well as future research directions. C1 [Engelman, Alan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA. Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA. RP Engelman, A (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA. EM alan_engelman@dfci.harvard.edu FU National Institutes of Health [AI039394, AI070042] FX This work was supported, in whole or in part, by National Institutes of Health Grants AI039394 and AI070042. This is the third article in the Thematic Minireview Series on Understanding Human Immunodeficiency Virus-Host Interactions at the Biochemical Level. NR 100 TC 50 Z9 50 U1 3 U2 25 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 30 PY 2012 VL 287 IS 49 BP 40858 EP 40866 DI 10.1074/jbc.R112.397760 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 048CK UT WOS:000311887600004 PM 23043109 ER PT J AU Bauer, I Grozio, A Lasiglie, D Basile, G Sturla, L Magnone, M Sociali, G Soncini, D Caffa, I Poggi, A Zoppoli, G Cea, M Feldmann, G Mostoslavsky, R Ballestrero, A Patrone, F Bruzzone, S Nencioni, A AF Bauer, Inga Grozio, Alessia Lasiglie, Denise Basile, Giovanna Sturla, Laura Magnone, Mirko Sociali, Giovanna Soncini, Debora Caffa, Irene Poggi, Alessandro Zoppoli, Gabriele Cea, Michele Feldmann, Georg Mostoslavsky, Raul Ballestrero, Alberto Patrone, Franco Bruzzone, Santina Nencioni, Alessio TI The NAD(+)-dependent Histone Deacetylase SIRT6 Promotes Cytokine Production and Migration in Pancreatic Cancer Cells by Regulating Ca2+ Responses SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID CYCLIC ADP-RIBOSE; TRPM2 ION-CHANNEL; GENE-EXPRESSION; TRANSCRIPTION FACTOR; PROTEIN-SYNTHESIS; MAMMALIAN-CELLS; T-LYMPHOCYTES; CALCIUM; INFLAMMATION; CARCINOMA AB Cytokine secretion by cancer cells contributes to cancer-induced symptoms and angiogenesis. Studies show that the sirtuin SIRT6 promotes inflammation by enhancing TNF expression. Here, we aimed to determine whether SIRT6 is involved in conferring an inflammatory phenotype to cancer cells and to define the mechanisms linking SIRT6 to inflammation. We show that SIRT6 enhances the expression of pro-inflammatory cyto-/chemokines, such as IL8 and TNF, and promotes cell migration in pancreatic cancer cells by enhancing Ca2+ responses. Via its enzymatic activity, SIRT6 increases the intracellular levels of ADP-ribose, an activator of the Ca2+ channel TRPM2. In turn, TRPM2 and Ca2+ are shown to be involved in SIRT6-induced TNF and IL8 expression. SIRT6 increases the nuclear levels of the Ca2+-dependent transcription factor, nuclear factor of activated T cells (NFAT), and cyclosporin A, a calcineurin inhibitor that reduces NFAT activity, reduces TNF and IL8 expression in SIRT6-overexpressing cells. These results implicate a role for SIRT6 in the synthesis of Ca2+-mobilizing second messengers, in the regulation of Ca2+-dependent transcription factors, and in the expression of pro-inflammatory, pro-angiogenic, and chemotactic cytokines. SIRT6 inhibition may help combat cancer-induced inflammation, angiogenesis, and metastasis. C1 [Grozio, Alessia; Basile, Giovanna; Sturla, Laura; Magnone, Mirko; Sociali, Giovanna; Bruzzone, Santina] Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy. [Bauer, Inga; Lasiglie, Denise; Soncini, Debora; Caffa, Irene; Zoppoli, Gabriele; Cea, Michele; Ballestrero, Alberto; Patrone, Franco; Nencioni, Alessio] Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy. [Grozio, Alessia; Basile, Giovanna; Sturla, Laura; Magnone, Mirko; Sociali, Giovanna; Bruzzone, Santina] Univ Genoa, CEBR, I-16132 Genoa, Italy. [Poggi, Alessandro] IRCCS Azienda Osped Univ San Martino IST Natl Ins, Unit Mol Oncol & Angiogenesis, I-16132 Genoa, Italy. [Cea, Michele] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Dana Farber Canc Inst 02215, Boston, MA USA. [Cea, Michele] Harvard Univ, Sch Med, Jerome Lipper Ctr Multiple Myeloma Res, Dana Farber Canc Inst 02215, Boston, MA USA. [Feldmann, Georg] Univ Bonn, Dept Internal Med 3, Ctr Integrated Oncol Cologne Bonn, D-53127 Bonn, Germany. [Mostoslavsky, Raul] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02114 USA. RP Bruzzone, S (reprint author), Univ Genoa, Dept Expt Med, Biochem Sect, Viale Benedetto 15,1, I-16132 Genoa, Italy. EM santina.bruzzone@unige.it RI Bruzzone, Santina/A-4264-2015; Zoppoli, Gabriele/B-6935-2016; Caffa, Irene/J-9835-2016; Poggi, Alessandro/K-6664-2016 OI Bruzzone, Santina/0000-0003-2034-3716; Zoppoli, Gabriele/0000-0003-3890-5588; Caffa, Irene/0000-0003-1111-9915; Poggi, Alessandro/0000-0002-1860-430X FU Associazione Italiana per la Ricerca sul Cancro (AIRC) [6108]; European Seventh Framework Program [256986]; Ministero della Salute [GR-2008-1135635]; Fondazione CARIGE; Compagnia di San Paolo; University of Genoa FX This work was supported in part by the Associazione Italiana per la Ricerca sul Cancro (AIRC, Code 6108) (to A. N.), by the European Seventh Framework Program (Project 256986, PANACREAS) (to A. N.), by Ministero della Salute Grant GR-2008-1135635 (to A. N.), by the Fondazione CARIGE, by the Compagnia di San Paolo, and by the University of Genoa. NR 62 TC 51 Z9 55 U1 0 U2 16 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 30 PY 2012 VL 287 IS 49 BP 40924 EP 40937 DI 10.1074/jbc.M112.405837 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 048CK UT WOS:000311887600012 PM 23086953 ER PT J AU Ahn, BJ Le, H Shin, MW Bae, SJ Lee, EJ Wee, HJ Cha, JH Park, JH Lee, HS Lee, HJ Jung, H Park, ZY Park, SH Han, BW Seo, JH Lo, EH Kim, KW AF Ahn, Bum Ju Le, Hoang Shin, Min Wook Bae, Sung-Jin Lee, Eun Ji Wee, Hee-Jun Cha, Jong Ho Park, Ji-Hyeon Lee, Hye Shin Lee, Hyo-Jong Jung, Hyunsook Park, Zee-Yong Park, Sang Ho Han, Byung Woo Seo, Ji Hae Lo, Eng H. Kim, Kyu-Won TI The N-terminal ectodomain of Ninjurin1 liberated by MMP9 has chemotactic activity SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS LA English DT Article DE Ninjurin1; Posttranslational modification; MMP9; Proteolytic cleavage; Chemotaxis ID CENTRAL-NERVOUS-SYSTEM; ADHESION MOLECULE; MYELOID CELLS; CHEMOKINE; FRACTALKINE; MIGRATION; PROTEINS; CX(3)CR1; BINDING AB Ninjurin1 is known as an adhesion molecule promoting leukocyte trafficking under inflammatory conditions. However, the posttranslational modifications of Ninjurin1 are poorly understood. Herein, we defined the proteolytic cleavage of Ninjurin1 and its functions. HEK293T cells overexpressing the C- or N-terminus tagging mouse Ninjurin1 plasmid produced additional cleaved forms of Ninjurin1 in the lysates or conditioned media (CM). Two custom-made anti-Ninjurin1 antibodies, Ab(1-15) or Ab(139-152), specific to the N- or C-terminal regions of Ninjurin1 revealed the presence of its shedding fragments in the mouse liver and kidney lysates. Furthermore, Matrix Metalloproteinase (MMP) 9 was responsible for Ninjurin1 cleavage between Leu(56) and Leu(57). Interestingly, the soluble N-terminal Ninjurin1 fragment has structural similarity with well-known chemokines. Indeed, the CM from HEK293T cells overexpressing the GFP-mNinj1 plasmid was able to attract Raw264.7 cells in trans-well assay. Collectively, we suggest that the N-terminal ectodomain of mouse Ninjurin1, which may act as a chemoattractant, is cleaved by MMP9. (C) 2012 Elsevier Inc. All rights reserved. C1 [Ahn, Bum Ju; Le, Hoang; Shin, Min Wook; Bae, Sung-Jin; Lee, Eun Ji; Wee, Hee-Jun; Cha, Jong Ho; Park, Ji-Hyeon; Seo, Ji Hae; Kim, Kyu-Won] Seoul Natl Univ, Coll Pharm, NeuroVasc Coordinat Res Ctr, Seoul 151742, South Korea. [Park, Sang Ho; Han, Byung Woo] Seoul Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, Seoul 151742, South Korea. [Kim, Kyu-Won] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul 151742, South Korea. [Lee, Hye Shin] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA. [Lee, Hyo-Jong] Inje Univ, Coll Pharm, Gimhae 621749, South Korea. [Jung, Hyunsook; Park, Zee-Yong] Gwangju Inst Sci & Technol, Sch Life Sci, Kwangju 500712, South Korea. [Seo, Ji Hae; Lo, Eng H.] Massachusettes Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Boston, MA USA. [Seo, Ji Hae; Lo, Eng H.] Massachusettes Gen Hosp, Dept Neurol, Neuroprotect Res Lab, Boston, MA USA. [Seo, Ji Hae; Lo, Eng H.] Harvard Univ, Sch Med, Boston, MA USA. RP Kim, KW (reprint author), Seoul Natl Univ, Coll Pharm, NeuroVasc Coordinat Res Ctr, Seoul 151742, South Korea. EM qwonkim@snu.ac.kr FU National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology (MEST) through the Creative Research Initiative Program [R16-2004-001-01001-0]; World Class University Program [R31-2008-000-10103-0]; Global Research Laboratory Program [2011-0021874]; Global Core Research Center (GCRC) Program [2012-0001187]; GIST Basic Research Projects in High-tech Industrial Technology; National Institutes of Health [R37-NS37074, R01-76694, P01-NS55104] FX This work was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (MEST) through the Creative Research Initiative Program (R16-2004-001-01001-0), the World Class University Program (R31-2008-000-10103-0), the Global Research Laboratory Program (2011-0021874), and the Global Core Research Center (GCRC) Program (2012-0001187). Z.-Y Park was supported by the "2012 GIST Basic Research Projects in High-tech Industrial Technology". E.H. Lo was supported by grants from National Institutes of Health (R37-NS37074, R01-76694 and P01-NS55104). NR 21 TC 6 Z9 6 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0006-291X J9 BIOCHEM BIOPH RES CO JI Biochem. Biophys. Res. Commun. PD NOV 30 PY 2012 VL 428 IS 4 BP 438 EP 444 DI 10.1016/j.bbrc.2012.10.099 PG 7 WC Biochemistry & Molecular Biology; Biophysics SC Biochemistry & Molecular Biology; Biophysics GA 052YV UT WOS:000312237500003 PM 23142597 ER PT J AU Hu, XZ Tomlinson, S Barnum, SR AF Hu, Xianzhen Tomlinson, Stephen Barnum, Scott R. TI Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE SO NEUROSCIENCE LETTERS LA English DT Article DE Experimental autoimmune; encephalomyelitis; Neuroimmunology complement; Immunology; Autoimmune disease ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; COBRA VENOM FACTOR; MULTIPLE-SCLEROSIS; ALTERNATIVE PATHWAY; DISEASE; INJURY; NATALIZUMAB AB Multiple sclerosis (MS) is the most common autoimmune demyelinating disease, affecting millions of individuals worldwide. In the last two decades, many therapeutic options for the treatment of MS have become available, however they are limited in terms of effectiveness and some remain plagued by safety issues. The currently available treatment options target relapsing remitting forms of MS and are not effective against the more progressive forms of the disease. These limitations highlight a significant unmet treatment need for MS. In experimental autoimmune encephalomyelitis (EAE) studies from our laboratory, we have previously shown, using a number of complement mutant and transgenic mice, that inhibition of the alternative complement pathway and the C3 convertase confers significant protection from disease. We report here that targeted inhibition of complement activation using complement receptor 2 (CR2)-conjugated inhibitors significantly attenuates EAE. Administration of CR2-Crry (blocks all complement pathways at C3 activation) and CR2-fH (specifically blocks the alternative pathway) just prior to and during the onset of EAE blocks progression of both acute and chronic disease. These data indicate that inhibition of complement may offer an effective therapeutic approach to treating both acute and chronic forms of demyelinating disease through blocking the alternative pathway or complement convertases. (C) 2012 Elsevier Ireland Ltd. All rights reserved. C1 [Hu, Xianzhen; Barnum, Scott R.] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Tomlinson, Stephen] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA. [Barnum, Scott R.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. RP Barnum, SR (reprint author), Univ Alabama Birmingham, Dept Microbiol, 845 19th St S,BBRB-842, Birmingham, AL 35294 USA. EM tomlinss@musc.edu; sbarnum@uab.edu FU NIH [NS069365, HL082485]; VA Merit Award [IO1BX001201] FX This work was supported by NIH grants NS069365 to SRB and HL082485 to ST and VA Merit Award IO1BX001201 to ST. NR 50 TC 4 Z9 4 U1 1 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3940 J9 NEUROSCI LETT JI Neurosci. Lett. PD NOV 30 PY 2012 VL 531 IS 1 BP 35 EP 39 DI 10.1016/j.neulet.2012.10.012 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 052ZN UT WOS:000312239300008 PM 23079547 ER PT J AU Black, JC Van Rechem, C Whetstine, JR AF Black, Joshua C. Van Rechem, Capucine Whetstine, Johnathan R. TI Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological Impact SO MOLECULAR CELL LA English DT Review ID CELL-CYCLE PROGRESSION; EMBRYONIC STEM-CELLS; LONG NONCODING RNA; GENE-EXPRESSION; MAMMALIAN-CELLS; CHROMATIN MODIFICATIONS; EPIGENETIC REGULATION; H3K4 METHYLATION; DNA-REPLICATION; X-CHROMOSOME AB Histone lysine methylation has emerged as a critical player in the regulation of gene expression, cell cycle, genome stability, and nuclear architecture. Over the past decade, a tremendous amount of progress has led to the characterization of methyl modifications and the lysine methyltransferases (KMTs) and lysine demethylases (KDMs) that regulate them. Here, we review the discovery and characterization of the KMTs and KDMs and the methyl modifications they regulate. We discuss the localization of the KMTs and KDMs as well as the distribution of lysine methylation throughout the genome. We highlight how these data have shaped our view of lysine methylation as a key determinant of complex chromatin states. Finally, we discuss the regulation of KMTs and KDMs by proteasomal degradation, posttranscriptional mechanisms, and metabolic status. We propose key questions for the field and highlight areas that we predict will yield exciting discoveries in the years to come. C1 [Black, Joshua C.; Van Rechem, Capucine; Whetstine, Johnathan R.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA. [Black, Joshua C.; Van Rechem, Capucine; Whetstine, Johnathan R.] Harvard Univ, Sch Med, Dept Med, Charlestown, MA 02129 USA. RP Whetstine, JR (reprint author), Massachusetts Gen Hosp, Ctr Canc, 13th St, Charlestown, MA 02129 USA. EM jwhetstine@hms.harvard.edu RI Black, Joshua/Q-2484-2015 FU Ellison Medical Foundation [CA059267, R01GM097360]; Jane Coffin Childs Memorial Fund for Medical Research FX We would like to thank Nick Dyson and Brendon Ladd for helpful comments and suggestions on the manuscript. J.R.W. is supported by the Ellison Medical Foundation, CA059267 and R01GM097360. J.C.B. is a fellow of The Jane Coffin Childs Memorial Fund for Medical Research. This investigation has been aided by a grant from The Jane Coffin Childs Memorial Fund for Medical Research. NR 139 TC 258 Z9 264 U1 10 U2 162 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 1097-2765 J9 MOL CELL JI Mol. Cell PD NOV 30 PY 2012 VL 48 IS 4 BP 491 EP 507 DI 10.1016/j.molcel.2012.11.006 PG 17 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 048NP UT WOS:000311919500004 PM 23200123 ER PT J AU Ke, YG Ong, LL Shih, WM Yin, P AF Ke, Yonggang Ong, Luvena L. Shih, William M. Yin, Peng TI Three-Dimensional Structures Self-Assembled from DNA Bricks SO SCIENCE LA English DT Article ID NANOSCALE SHAPES; FOLDING DNA; ORIGAMI; RNA; LATTICES; NANOTECHNOLOGY; CRYSTAL; DESIGN; MOTOR AB We describe a simple and robust method to construct complex three-dimensional (3D) structures by using short synthetic DNA strands that we call "DNA bricks." In one-step annealing reactions, bricks with hundreds of distinct sequences self-assemble into prescribed 3D shapes. Each 32-nucleotide brick is a modular component; it binds to four local neighbors and can be removed or added independently. Each 8-base pair interaction between bricks defines a voxel with dimensions of 2.5 by 2.5 by 2.7 nanometers, and a master brick collection defines a "molecular canvas" with dimensions of 10 by 10 by 10 voxels. By selecting subsets of bricks from this canvas, we constructed a panel of 102 distinct shapes exhibiting sophisticated surface features, as well as intricate interior cavities and tunnels. C1 [Ke, Yonggang; Ong, Luvena L.; Shih, William M.; Yin, Peng] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA. [Ke, Yonggang; Shih, William M.] Harvard Univ, Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Ke, Yonggang; Shih, William M.] Harvard Univ, Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Ong, Luvena L.] MIT, Harvard Massachusetts Inst Technol MIT Div Hlth S, Cambridge, MA 02139 USA. [Yin, Peng] Harvard Univ, Harvard Med Sch, Dept Syst Biol, Boston, MA 02115 USA. RP Yin, P (reprint author), Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA. EM py@hms.harvard.edu OI /0000-0001-5317-3018 FU Office of Naval Research (ONR) Young Investigator Program award [N000141110914]; ONR grant [N000141010827, N000014091118, N000141010241]; Army Research Office [W911NF1210238]; NSF [CCF1054898]; NIH [1DP2OD007292, 1DP2OD004641]; Wyss Institute Faculty Startup Fund; Wyss Institute Faculty Grant FX The authors thank M. Dai for technical assistance; E. Winfree, B. Wei, and S. Woo for discussions; and D. Pastuszak for assistance in draft preparation. This work is supported by an Office of Naval Research (ONR) Young Investigator Program award N000141110914, an ONR grant N000141010827, an Army Research Office grant W911NF1210238, an NSF CAREER award CCF1054898, an NIH Director's New Innovator award 1DP2OD007292, and a Wyss Institute Faculty Startup Fund to P.Y., and by a Wyss Institute Faculty Grant, ONR grants N000014091118 and N000141010241, and an NIH Director's New Innovator award 1DP2OD004641 to W.M.S.. L.L.O. is supported by an NSF graduate research fellowship. Y.K. conceived the project, designed and performed the experiments, analyzed the data, and wrote the paper; L.L.O. designed and performed the experiments, analyzed the data, and wrote the paper; W.M.S. conceived the project, discussed the results, and wrote the paper; P.Y. conceived, designed, and supervised the study, interpreted the data, and wrote the paper. The DNA sequences for the nanostructures can be found in the supplementary materials. A provisional patent has been filed based on this work. NR 43 TC 332 Z9 340 U1 43 U2 351 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD NOV 30 PY 2012 VL 338 IS 6111 BP 1177 EP 1183 DI 10.1126/science.1227268 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 045AL UT WOS:000311666200038 PM 23197527 ER PT J AU Paley, MA Kroy, DC Odorizzi, PM Johnnidis, JB Dolfi, DV Barnett, BE Bikoff, EK Robertson, EJ Lauer, GM Reiner, SL Wherry, EJ AF Paley, Michael A. Kroy, Daniela C. Odorizzi, Pamela M. Johnnidis, Jonathan B. Dolfi, Douglas V. Barnett, Burton E. Bikoff, Elizabeth K. Robertson, Elizabeth J. Lauer, Georg M. Reiner, Steven L. Wherry, E. John TI Progenitor and Terminal Subsets of CD8(+) T Cells Cooperate to Contain Chronic Viral Infection SO SCIENCE LA English DT Article ID TRANSCRIPTION FACTOR; PD-1 EXPRESSION; HIV-1 INFECTION; CUTTING EDGE; EXHAUSTION; BET; RESPONSES; ANTIGEN; CD4(+); DIFFERENTIATION AB Chronic infections strain the regenerative capacity of antiviral T lymphocyte populations, leading to failure in long-term immunity. The cellular and molecular events controlling this regenerative capacity, however, are unknown. We found that two distinct states of virus-specific CD8(+) T cells exist in chronically infected mice and humans. Differential expression of the T-box transcription factors T-bet and Eomesodermin (Eomes) facilitated the cooperative maintenance of the pool of antiviral CD8(+) T cells during chronic viral infection. T-bet(hi) cells displayed low intrinsic turnover but proliferated in response to persisting antigen, giving rise to Eomes(hi) terminal progeny. Genetic elimination of either subset resulted in failure to control chronic infection, which suggests that an imbalance in differentiation and renewal could underlie the collapse of immunity in humans with chronic infections. C1 [Paley, Michael A.; Odorizzi, Pamela M.; Johnnidis, Jonathan B.; Dolfi, Douglas V.; Barnett, Burton E.; Wherry, E. John] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA. [Paley, Michael A.; Odorizzi, Pamela M.; Johnnidis, Jonathan B.; Dolfi, Douglas V.; Barnett, Burton E.; Wherry, E. John] Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA. [Kroy, Daniela C.; Lauer, Georg M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02115 USA. [Bikoff, Elizabeth K.; Robertson, Elizabeth J.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England. [Reiner, Steven L.] Univ Penn, Abramson Family Canc Res Inst, Dept Med, Philadelphia, PA 19104 USA. [Reiner, Steven L.] Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA. RP Wherry, EJ (reprint author), Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA. EM wherry@mail.med.upenn.edu FU Deutsche Forschungsgemeinschaft [r3839/1-1]; NIH [T32-AI-07324, AI0663445, AI061699, AI076458, AI083022, AI078897, HHSN266200500030C, AI082630]; Dana Foundation FX We thank the Wherry, Reiner, and Artis labs for helpful comments and the UPenn Flow Cytometry Core for cell sorting. We thank E. Crosby for isolation of skin lymphocytes. Supported by Deutsche Forschungsgemeinschaft grant r3839/1-1 (D.C.K.); NIH grants T32-AI-07324 (M.A.P.), AI0663445 (G.M.L.), AI061699 and AI076458 (S.L.R.), AI083022, AI078897, and HHSN266200500030C (E.J.W.), and AI082630 (E.J.W. and G.M.L.); and the Dana Foundation (E.J.W. and G.M.L.). E.J.W. has a patent licensing agreement on therapeutic targeting of the PD-1 pathway (U.S. patent application no. 20070122378). NR 31 TC 143 Z9 145 U1 0 U2 16 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 J9 SCIENCE JI Science PD NOV 30 PY 2012 VL 338 IS 6111 BP 1220 EP 1225 DI 10.1126/science.1229620 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 045AL UT WOS:000311666200049 PM 23197535 ER PT J AU Bin Riaz, I Riaz, H Riaz, T Rahman, S Amir, M Badshah, MB Kazi, AN AF Bin Riaz, Irbaz Riaz, Haris Riaz, Talha Rahman, Sophia Amir, Muhammad Badshah, Maaz B. Kazi, Abdul Nafey TI Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment: A meta-analysis of randomized controlled trials SO BMC GASTROENTEROLOGY LA English DT Article ID HEPATITIS-C VIRUS; INTERFERON THERAPY; LIVER-CANCER; INHIBITION; ABLATION; GROWTH; ANGIOGENESIS; RESECTION; TUMOR; MENATETRENONE AB Background: Hepatocellular cancer is notorious for recurrence even after curative therapy. High recurrence determines the long term prognosis of the patients. Vitamin K2 has been tested in trials for its effect on prevention of recurrence and improving survival. The results are inconclusive from individual trials and in our knowledge no systematic review which entirely focuses on Vitamin K2 as a chemo preventive agent is available to date. This review is an attempt to pool all the existing trials together and update the existing knowledge on the topic. Methods: Medline, Embase and Cochrane Register of Controlled trials were searched for randomized controlled trials where vitamin K2 or its analogues, in any dosage were compared to placebo or No vitamin K2, for participants of any age or sex. Reference lists and abstracts of conference proceedings were searched by hand. Additional papers were identified by a manual search of the references from the key articles. Attempt was made to contact the authors of primary studies for missing data and with the experts in the field. Trials were assessed for inclusion by two independent reviewers. Primary outcomes were recurrence rates and survival rates. There were no secondary outcomes. Data was synthesized using a random effects model and results presented as relative risk with 95% Confidence Intervals. Result: For recurrence of hepatocellular cancer after hepatic resection or local ablative therapy, compared with controls, participants receiving Vitamin K2, pooled relative risks for hepatocellular cancer were 0.60; 95% CI: 0.28-1.28, p = 0.64) at 1 yr 0.66; 95% CI: 0.47-0.91), p = 0.01) at 2 yr; 0.71; 95% CI: 0.58-0.85, p = 0.004) at 3 yr respectively. The results were combined using the random analysis model. Conclusion: Five RCTs evaluated the preventive efficacy of menatetrenone on HCC recurrence after hepatic resection or local ablative therapy. The meta-analysis of all five studies, failed to confirm significantly better tumor recurrence-free survival at 1 year. Improved tumor recurrence at 2nd and 3rd year may be just due to insufficient data. There was no beneficial effect on the overall survival. However, to confirm the beneficial effect or lack of it, large, higher quality randomized controlled trials are still required. C1 [Bin Riaz, Irbaz] Univ Arizona, Dept Internal Med, Tucson, AZ USA. [Riaz, Haris; Riaz, Talha; Kazi, Abdul Nafey] Dow Univ Hlth Sci, Civil Hosp Karachi, Karachi, Pakistan. [Rahman, Sophia] New York Methodist Hosp, New York, NY USA. [Amir, Muhammad] Albert Einstein Coll Med, New York, NY USA. [Badshah, Maaz B.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA. RP Riaz, H (reprint author), Dow Univ Hlth Sci, Civil Hosp Karachi, Karachi, Pakistan. EM harisriaz73@yahoo.com OI Riaz, Irbaz bin/0000-0003-4249-0311 NR 20 TC 0 Z9 0 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-230X J9 BMC GASTROENTEROL JI BMC Gastroenterol. PD NOV 29 PY 2012 VL 12 AR 170 DI 10.1186/1471-230X-12-170 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 096GR UT WOS:000315392700001 ER PT J AU Lichter, DI Danaee, H Pickard, MD Tayber, O Sintchak, M Shi, HL Richardson, PG Cavenagh, J Blade, J Facon, T Niesvizky, R Alsina, M Dalton, W Sonneveld, P Lonial, S van de Velde, H Ricci, D Esseltine, DL Trepicchio, WL Mulligan, G Anderson, KC AF Lichter, David I. Danaee, Hadi Pickard, Michael D. Tayber, Olga Sintchak, Michael Shi, Hongliang Richardson, Paul G. Cavenagh, Jamie Blade, Joan Facon, Thierry Niesvizky, Ruben Alsina, Melissa Dalton, William Sonneveld, Pieter Lonial, Sagar van de Velde, Helgi Ricci, Deborah Esseltine, Dixie-Lee Trepicchio, William L. Mulligan, George Anderson, Kenneth C. TI Sequence analysis of beta-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone SO BLOOD LA English DT Article ID INHIBITOR BORTEZOMIB; PROTEIN-DEGRADATION; RESISTANCE; PSMB5; CELLS; MUTATION; LINE AB Variations within proteasome beta (PSMB) genes, which encode the beta subunits of the 20S proteasome, may affect proteasome function, assembly, and/or binding of proteasome inhibitors. To investigate the potential association between PSMB gene variants and treatment-emergent resistance to bortezomib and/or long-term outcomes, in the present study, PSMB gene sequence variation was characterized in tumor DNA samples from patients who participated in the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib versus high-dose dexamethasone for treatment of relapsed multiple myeloma. Twelve new PSMB variants were identified. No associations were found between PSMB single nucleotide polymorphism genotype frequency and clinical response to bortezomib or dexamethasone treatment or between PSMB single nucleotide polymorphism allelic frequency and pooled overall survival or time to progression. Although specific PSMB5 variants have been identified previously in preclinical models of bortezomib resistance, these variants were not detected in patient tumor samples collected after clinical relapse from bortezomib, which suggests that alternative mechanisms underlie bortezomib insensitivity. This study is registered at www.clinicaltrials.gov as NCT00048230. (Blood. 2012;120(23):4513-4516) C1 [Lichter, David I.; Danaee, Hadi; Pickard, Michael D.; Tayber, Olga; Sintchak, Michael; Shi, Hongliang; Esseltine, Dixie-Lee; Trepicchio, William L.; Mulligan, George] Millennium Pharmaceut Inc, Cambridge, MA 02139 USA. [Richardson, Paul G.; Anderson, Kenneth C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Cavenagh, Jamie] St Bartholomews Hosp, Dept Haematol, London, England. [Blade, Joan] Univ Barcelona, Dept Hematol, Hosp Clin, Barcelona, Spain. [Facon, Thierry] Claude Huriez Hosp, Lille, France. [Niesvizky, Ruben] Cornell Univ, Ctr Excellence Lymphoma & Myeloma, Weill Med Coll, New York Presbyterian Hosp, New York, NY 10021 USA. [Alsina, Melissa; Dalton, William] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Sonneveld, Pieter] Univ Rotterdam Hosp, Rotterdam, Netherlands. [Lonial, Sagar] Emory Univ, Atlanta, GA 30322 USA. [van de Velde, Helgi] Janssen Res & Dev, Beerse, Belgium. [Ricci, Deborah] Janssen Res & Dev, Raritan, NJ USA. RP Lichter, DI (reprint author), Millennium Pharmaceut Inc, 35 Landsdowne St, Cambridge, MA 02139 USA. EM david.lichter@MPI.com RI FACON, THIERRY/M-9736-2014 OI FACON, THIERRY/0000-0001-7705-8460 FU Millennium Pharmaceuticals; Janssen Global Services; Celgene; Onyx; Janssen; Bristol-Myers Squibb; Merck; Novartis FX This work was supported by research funding from Millennium Pharmaceuticals and Janssen Global Services.; D.I.L., H.D., M.D.P., O.T., M.S., H.S., D.-L.E., W.L.T, and G.M. are employees of Millennium Pharmaceuticals. D.-L.E. has ownership interests in Millennium/Takeda and Johnson & Johnson. P. G. R. has served on advisory boards for Millennium Pharmaceuticals, Celgene, Novartis, Bristol-Myers Squibb, and Janssen. J. C. and J. B. have received honoraria from Janssen and Celgene. J. B. has served on advisory boards for Janssen and Celgene and has received research funding from Celgene. T. F. has served on advisory boards/speakers' bureaus for Janssen. R. N. has served as a consultant and on advisory boards/speakers' bureaus for and received research funding from Millennium Pharmaceuticals, Celgene, and Onyx. M. A. has served on advisory boards/speakers' bureaus and as a consultant for Celgene, Millennium Pharmaceuticals, and Ortho Biotech Products and has received research support from Celgene and Millennium Pharmaceuticals. P. S. has served on advisory boards for Millennium Pharmaceuticals, Janssen, Celgene, Novartis, and Onyx and has received research support from Janssen and Celgene. S. L. has served as a consultant for Bristol-Myers Squibb, Celgene, Merck, Millennium Pharmaceuticals, Novartis, and Onyx. H. v. d. V. and D. R. are employees of and have ownership interest in Janssen Research & Development. K. C. A. has served on advisory boards for and received research funding from Bristol-Myers Squibb, Celgene, Merck, Millennium Pharmaceuticals, Novartis, and Onyx and has ownership interest in Acetylon. W. D. declares no competing financial interests. NR 25 TC 27 Z9 27 U1 1 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 29 PY 2012 VL 120 IS 23 BP 4513 EP 4516 DI 10.1182/blood-2012-05-426924 PG 4 WC Hematology SC Hematology GA 064YY UT WOS:000313113300014 PM 23018640 ER PT J AU Fathi, AT Sadrzadeh, H Borger, DR Ballen, KK Amrein, PC Attar, EC Foster, J Burke, M Lopez, HU Matulis, CR Edmonds, KM Iafrate, AJ Straley, KS Yen, KE Agresta, S Schenkein, DP Hill, C Emadi, A Neuberg, DS Stone, RM Chen, YB AF Fathi, Amir T. Sadrzadeh, Hossein Borger, Darrell R. Ballen, Karen K. Amrein, Philip C. Attar, Eyal C. Foster, Julia Burke, Meghan Lopez, Hector U. Matulis, Christina R. Edmonds, Katherine M. Iafrate, A. John Straley, Kimberly S. Yen, Katharine E. Agresta, Samuel Schenkein, David P. Hill, Cedric Emadi, Ashkan Neuberg, Donna S. Stone, Richard M. Chen, Yi-Bin TI Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response SO BLOOD LA English DT Article ID ISOCITRATE DEHYDROGENASE 1; IDH2 MUTATIONS; CONVERSION; GLIOMAS AB Mutations of genes encoding isocitrate dehydrogenase (IDH1 and IDH2) have been recently described in acute myeloid leukemia (AML). Serum and myeloblast samples from patients with IDH-mutant AML contain high levels of the metabolite 2-hydroxyglutarate (2-HG), a product of the altered IDH protein. In this prospective study, we sought to determine whether 2-HG can potentially serve as a noninvasive biomarker of disease burden through serial measurements in patients receiving conventional therapy for newly diagnosed AML. Our data demonstrate that serum, urine, marrow aspirate, and myeloblast 2-HG levels are significantly higher in IDH-mutant patients, with a correlation between baseline serum and urine 2-HG levels. Serum and urine 2-HG, along with IDH1/2-mutant allele burden in mar-row, decreased with response to treatment. 2-HG decrease was more rapid with induction chemotherapy compared with DNA-methyltransferase inhibitor therapy. Our data suggest that serum or urine 2-HG may serve as noninvasive biomarkers of disease activity for IDH-mutant AML. (Blood. 2012; 120(23):4649-4652) C1 [Fathi, Amir T.; Sadrzadeh, Hossein; Borger, Darrell R.; Ballen, Karen K.; Amrein, Philip C.; Attar, Eyal C.; Foster, Julia; Burke, Meghan; Lopez, Hector U.; Matulis, Christina R.; Edmonds, Katherine M.; Iafrate, A. John; Hill, Cedric; Chen, Yi-Bin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02114 USA. [Straley, Kimberly S.; Yen, Katharine E.; Agresta, Samuel; Schenkein, David P.] Agios Pharmaceut, Cambridge, MA USA. [Emadi, Ashkan] Univ Maryland, Med Ctr, Greenebaum Canc Ctr, Baltimore, MD 21201 USA. [Neuberg, Donna S.; Stone, Richard M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02114 USA. RP Fathi, AT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Zero Emerson Pl,Suite 118, Boston, MA 02114 USA. EM afathi@partners.org FU Rogers Family Foundation in Boston, MA; Massachusetts General Hospital Cancer Center FX This work was supported in part by the Rogers Family Foundation in Boston, MA (philanthropic grant) and the Massachusetts General Hospital Cancer Center (Thematic Priority #3 Grant). NR 25 TC 42 Z9 44 U1 0 U2 7 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 29 PY 2012 VL 120 IS 23 BP 4649 EP 4652 DI 10.1182/blood-2012-06-438267 PG 4 WC Hematology SC Hematology GA 064YY UT WOS:000313113300030 PM 23074281 ER PT J AU Christopher-Stine, L Robinson, DR Wu, CC Mark, EJ AF Christopher-Stine, Lisa Robinson, Dwight R. Wu, Carol C. Mark, Eugene J. TI Case 37-2012: A 21-Year-Old Man with Fevers, Arthralgias, and Pulmonary Infiltrates SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID INTERSTITIAL LUNG-DISEASE; TRANSFER-RNA-SYNTHETASE; ADULT STILLS-DISEASE; IDIOPATHIC INFLAMMATORY MYOPATHIES; RHEUMATOID-ARTHRITIS; ANTISYNTHETASE SYNDROME; CLINICAL-COURSE; DERMATOMYOSITIS; AUTOANTIBODIES; ANTIBODIES C1 [Christopher-Stine, Lisa] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Christopher-Stine, Lisa] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. [Robinson, Dwight R.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA. [Wu, Carol C.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Mark, Eugene J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Robinson, Dwight R.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Wu, Carol C.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Mark, Eugene J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA. RP Christopher-Stine, L (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. FU Biogen Idec; Medimmune; Novartis; Questcor; URL FX Dr. Christopher-Stine reports receiving consulting fees from Biogen Idec, Medimmune, Novartis, Questcor, and URL; providing expert testimony on behalf of patients and providers in cases of myositis; submitting a patent application together with her institution for anti-HMG-CoA reductase autoantibody enzymelinked immunosorbent assay and immunoprecipitation; receiving travel expenses from Crescent Health Care; and receiving payment for manuscript preparation from Year Book of Medicine. Dr. Mark reports providing expert testimony on behalf of patients who believe they have been harmed by exposure to asbestos. No other potential conflict of interest relevant to this article was reported. NR 38 TC 2 Z9 2 U1 0 U2 4 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 29 PY 2012 VL 367 IS 22 BP 2134 EP 2146 DI 10.1056/NEJMcpc1208147 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 044MS UT WOS:000311624400013 PM 23190225 ER PT J AU Qu, J Matsouaka, R Betensky, RA Hyman, BT Grosskreutz, CL AF Qu, Juan Matsouaka, Roland Betensky, Rebecca A. Hyman, Bradley T. Grosskreutz, Cynthia L. TI Calcineurin activation causes retinal ganglion cell degeneration SO MOLECULAR VISION LA English DT Article ID OPTIC-NERVE CRUSH; EXPERIMENTAL GLAUCOMA; INTRAOCULAR-PRESSURE; DEATH; CALCIUM; LOCALIZATION; PROTEOLYSIS; APOPTOSIS; ISCHEMIA; CLEAVAGE AB Purpose: We previously reported that calcineurin, a Ca2+/calmodulin-dependent serine/threonine phosphatase, is activated and proposed that it participates in retinal ganglion cell (RGC) apoptosis in two rodent ocular hypertension models. In this study, we tested whether calcineurin activation by itself, even in the absence of ocular hypertension, is sufficient to cause RGC degeneration. Methods: We compared RGC and optic nerve morphology after adeno-associated virus serotype 2 (AAV2)-mediated transduction of RGCs with constitutively active calcineurin (CaNCA) or unactivated, wild-type calcineurin (CaNwt). Retinas and optic nerves were harvested 7-16 weeks after injection of the AAV into mouse vitreous. In flatmounted retinas, the transduced RGCs were identified with immunohistochemistry. The morphology of the RGCs was revealed by immunostaining for neurofilament SMI32 or by using GFP-M transgenic mice. A modified Sholl analysis was applied to analyze the RGC dendritic morphology. Optic nerve damage was assessed with optic nerve grading according to the Morrison standard. Results: CaNwt and CaNCA were highly expressed in the injected eyes. Compared to the CaNwt-expressing RGCs, the CaNCA-expressing RGCs had smaller somas, smaller dendritic field areas, shorter total dendrite lengths, and simpler dendritic branching patterns. At 16 weeks, the CaNCA-expressing eyes had greater optic nerve damage than the CaNwt-expressing eyes. Conclusions: Calcineurin activation is sufficient to cause RGC dendritic degeneration and optic nerve damage. These data support the hypothesis that calcineurin activation is an important mediator of RGC degeneration, and are consistent with the hypothesis that calcineurin activation may contribute to RGC neurodegeneration in glaucoma. C1 [Qu, Juan; Grosskreutz, Cynthia L.] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Matsouaka, Roland; Betensky, Rebecca A.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Hyman, Bradley T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Grosskreutz, CL (reprint author), Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM cynthia_grosskreutz@meei.harvard.edu FU NIH Grant [R01EY13399, 1R01AG041507]; Core Grant [P30EY014104]; Massachusetts Lions Eye Research; Research to Prevent Blindness Fund; Harvard NeuroDiscovery Center and Harvard Catalyst; Harvard Clinical and Translational Science Center (NIH) [UL1 RR 025758]; Harvard University; [256.05] FX This study is supported by NIH Grant R01EY13399, Core Grant P30EY014104, NIH Grant 1R01AG041507, Massachusetts Lions Eye Research, Research to Prevent Blindness Fund, Harvard NeuroDiscovery Center and Harvard Catalyst vertical bar The Harvard Clinical and Translational Science Center (NIH Award #UL1 RR 025758 and financial contributions from Harvard University and its affiliated academic health care centers). We thank Dr. Lai Ding at Harvard NeuroDiscovery Center Optical Imaging Core for help in writing a custom ImageJ macro for Sholl analysis. We also thank Dr. Haiyan Wu and Zhanyun Fan (Massachusetts General Hospital) for the gift of the AAV virus. Some of the data described in this manuscript were previously presented at the 2011 Society for Neuroscience Annual Meeting (Qu J, Hyman BT and Grosskreutz CL. Calcineurin activation causes retinal ganglion cell degeneration. Program No. 256.05). The authors wish it to be known that Dr. Cynthia Grosskreutz is currently a full-time employee of the Novartis Institutes for BioMedical Research, Cambridge, MA. NR 35 TC 4 Z9 4 U1 0 U2 2 PU MOLECULAR VISION PI ATLANTA PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E, ATLANTA, GA 30322 USA SN 1090-0535 J9 MOL VIS JI Mol. Vis. PD NOV 29 PY 2012 VL 18 IS 287-90 BP 2828 EP 2838 PG 11 WC Biochemistry & Molecular Biology; Ophthalmology SC Biochemistry & Molecular Biology; Ophthalmology GA 053AT UT WOS:000312242500003 PM 23233785 ER PT J AU Lafaille, FG Pessach, IM Zhang, SY Ciancanelli, MJ Herman, M Abhyankar, A Ying, SW Keros, S Goldstein, PA Mostoslavsky, G Ordovas-Montanes, J Jouanguy, E Plancoulaine, S Tu, E Elkabetz, Y Al-Muhsen, S Tardieu, M Schlaeger, TM Daley, GQ Abel, L Casanova, JL Studer, L Notarangelo, LD AF Lafaille, Fabien G. Pessach, Itai M. Zhang, Shen-Ying Ciancanelli, Michael J. Herman, Melina Abhyankar, Avinash Ying, Shui-Wang Keros, Sotirios Goldstein, Peter A. Mostoslavsky, Gustavo Ordovas-Montanes, Jose Jouanguy, Emmanuelle Plancoulaine, Sabine Tu, Edmund Elkabetz, Yechiel Al-Muhsen, Saleh Tardieu, Marc Schlaeger, Thorsten M. Daley, George Q. Abel, Laurent Casanova, Jean-Laurent Studer, Lorenz Notarangelo, Luigi D. TI Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells SO NATURE LA English DT Article ID HERPES-SIMPLEX ENCEPHALITIS; EMBRYONIC STEM-CELLS; TOLL-LIKE RECEPTOR-3; RETICULAR THALAMIC NEURONS; CENTRAL-NERVOUS-SYSTEM; DOUBLE-STRANDED-RNA; TLR3 DEFICIENCY; HUMAN ES; PROTECTIVE IMMUNITY; VIRUS ENCEPHALITIS AB In the course of primary infection with herpes simplex virus 1 (HSV-1), children with inborn errors of toll-like receptor 3 (TLR3) immunity are prone to HSV-1 encephalitis (HSE)(1-3). We tested the hypothesis that the pathogenesis of HSE involves non-haematopoietic CNS-resident cells. We derived induced pluripotent stem cells (iPSCs) from the dermal fibroblasts of TLR3- and UNC-93B-deficient patients and from controls. These iPSCs were differentiated into highly purified populations of neural stem cells (NSCs), neurons, astrocytes and oligodendrocytes. The induction of interferon-beta (IFN-beta) and/or IFN-lambda 1 in response to stimulation by the dsRNA analogue polyinosinic: polycytidylic acid (poly(I:C)) was dependent on TLR3 and UNC-93B in all cells tested. However, the induction of IFN-beta and IFN-lambda 1 in response to HSV-1 infection was impaired selectively in UNC-93B-deficient neurons and oligodendrocytes. These cells were also much more susceptible to HSV-1 infection than control cells, whereas UNC-93B-deficient NSCs and astrocytes were not. TLR3-deficient neurons were also found to be susceptible to HSV-1 infection. The rescue of UNC-93B- and TLR3-deficient cells with the corresponding wild-type allele showed that the genetic defect was the cause of the poly(I:C) and HSV-1 phenotypes. The viral infection phenotype was rescued further by treatment with exogenous IFN-alpha or IFN-beta (IFN-alpha/beta) but not IFN-lambda 1. Thus, impaired TLR3- and UNC-93B-dependent IFN-alpha/beta intrinsic immunity to HSV-1 in the CNS, in neurons and oligodendrocytes in particular, may underlie the pathogenesis of HSE in children with TLR3-pathway deficiencies. C1 [Zhang, Shen-Ying; Ciancanelli, Michael J.; Herman, Melina; Abhyankar, Avinash; Abel, Laurent; Casanova, Jean-Laurent] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, New York, NY 10065 USA. [Lafaille, Fabien G.; Studer, Lorenz] Sloan Kettering Inst Canc Res, Ctr Stem Cell Biol, New York, NY 10065 USA. [Lafaille, Fabien G.; Studer, Lorenz] Sloan Kettering Inst Canc Res, Dev Biol Program, New York, NY 10065 USA. [Pessach, Itai M.; Ordovas-Montanes, Jose; Notarangelo, Luigi D.] Harvard Univ, Childrens Hosp, Div Immunol, Sch Med, Boston, MA 02115 USA. [Pessach, Itai M.] Chaim Sheba Med Ctr, Talpiot Med Leadership Program, Edmond & Lily Safra Childrens Hosp, IL-52621 Tel Hashomer, Israel. [Pessach, Itai M.] Tel Aviv Univ, Sackler Fac Med, IL-52621 Tel Aviv, Israel. [Zhang, Shen-Ying; Herman, Melina; Jouanguy, Emmanuelle; Abel, Laurent; Casanova, Jean-Laurent] Univ Paris 05, Lab Human Genet Infect Dis, Inst Natl Sante & Rech Med, Necker Med Sch,U980, F-75015 Paris, France. [Ying, Shui-Wang; Goldstein, Peter A.] Weill Cornell Med Coll, CV Starr Lab Mol Neuropharmacol, Dept Anesthesiol, New York, NY 10065 USA. [Keros, Sotirios] Weill Cornell Med Coll, Div Pediat Neurol, Dept Pediat, New York, NY 10065 USA. [Mostoslavsky, Gustavo] Boston Univ, Sch Med, Sect Gastroenterol, Dept Med, Boston, MA 02118 USA. [Elkabetz, Yechiel] Tel Aviv Univ, Lab Pluripotent & Neural Stem Cell Biol, Dept Cell & Dev Biol, Sackler Sch Med, IL-69978 Tel Aviv, Israel. [Al-Muhsen, Saleh] King Saud Univ, Prince Naif Ctr Immunol Res, Dept Pediat, Coll Med, Riyadh 11451, Saudi Arabia. [Tardieu, Marc] Hop Bicetre, Assistance Publ Hop Paris, Dept Pediat Neurol, F-94275 Le Kremlin Bicetre, France. [Schlaeger, Thorsten M.; Daley, George Q.] Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA. [Schlaeger, Thorsten M.; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Casanova, Jean-Laurent] Hop Necker Enfants Malad, Pediat Hematol Immunol Unit, F-75015 Paris, France. [Notarangelo, Luigi D.] Childrens Hosp, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA. RP Zhang, SY (reprint author), Rockefeller Univ, St Giles Lab Human Genet Infect Dis, New York, NY 10065 USA. EM shzh289@rockefeller.edu; jean-laurent.casanova@rockefeller.edu RI Notarangelo, Luigi/F-9718-2016; Gouel-Plancoulaine, Sabine/E-2824-2017; OI Notarangelo, Luigi/0000-0002-8335-0262; Ordovas-Montanes, Jose/0000-0001-5444-5601; Ciancanelli, Michael/0000-0002-4623-852X; Casadio, Melina/0000-0003-2389-2243; Goldstein, Peter/0000-0002-5973-9104; Plancoulaine, Sabine/0000-0003-0725-8306 FU National Center for Translational Sciences (NCATS) [8UL1TR000043]; National Institutes of Health (NIH); Rockefeller University; St. Giles Foundation; ANR; INSERM; Paris Descartes University; March of Dimes; NIH [5R01NS072381-02, 1R03AI0883502-01, 1R01NS066390]; Manton Foundation; Israeli Centers of Research Excellence (I-CORE); Gene Regulation in Complex Human Disease [41/11]; New York Stem Cell Foundation FX We thank our patients, their families and physicians; and the members of the three laboratories for helpful discussions and critical reading of this manuscript. The work was funded by grant number 8UL1TR000043 from the National Center for Translational Sciences (NCATS), the National Institutes of Health (NIH), the Rockefeller University, the St. Giles Foundation, the ANR, INSERM, Paris Descartes University, the March of Dimes, NIH grant 5R01NS072381-02 (to J.-L.C., L.S. and L.D.N.), NIH grant 1R03AI0883502-01 (to L.D.N.), NIH grant 1R01NS066390 and the Manton Foundation, the Israeli Centers of Research Excellence (I-CORE), and Gene Regulation in Complex Human Disease, Center No 41/11 (to I.M.P.). F.G.L. is supported by the New York Stem Cell Foundation. NR 42 TC 105 Z9 107 U1 5 U2 55 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 EI 1476-4687 J9 NATURE JI Nature PD NOV 29 PY 2012 VL 491 IS 7426 BP 769 EP + DI 10.1038/nature11583 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 044FY UT WOS:000311606000048 PM 23103873 ER PT J AU Cote, GM Sawyer, DB Chabner, BA AF Cote, Gregory M. Sawyer, Douglas B. Chabner, Bruce A. TI BASIC IMPLICATIONS OF CLINICAL OBSERVATIONS ERBB2 Inhibition and Heart Failure SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID METASTATIC BREAST-CANCER; DILATED CARDIOMYOPATHY; NEUREGULIN RECEPTOR; CARDIAC DEVELOPMENT; TRASTUZUMAB; SURVIVAL; REVEALS; SYSTEMS; PLUS; GENE C1 [Cote, Gregory M.; Chabner, Bruce A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Sawyer, Douglas B.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. RP Cote, GM (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. FU NHLBI NIH HHS [P20 HL101425, R01 HL068144] NR 20 TC 23 Z9 23 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 29 PY 2012 VL 367 IS 22 BP 2150 EP 2153 DI 10.1056/NEJMcibr1203156 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 044MS UT WOS:000311624400015 PM 23190227 ER PT J AU van Holst, RJ van der Meer, JN McLaren, DG van den Brink, W Veltman, DJ Goudriaan, AE AF van Holst, Ruth J. van der Meer, Johan N. McLaren, Donald G. van den Brink, Wim Veltman, Dick J. Goudriaan, Anna E. TI Interactions between Affective and Cognitive Processing Systems in Problematic Gamblers: A Functional Connectivity Study SO PLOS ONE LA English DT Article ID STOP-SIGNAL TASK; PATHOLOGICAL GAMBLERS; RESPONSE-INHIBITION; PSYCHOPHYSIOLOGICAL INTERACTIONS; PREFRONTAL CORTEX; BRAIN ACTIVATION; DECISION-MAKING; NEURAL BASIS; INCENTIVE-SENSITIZATION; ADDICTIVE BEHAVIORS AB Background: Motivational and cognitive abnormalities are frequently reported in pathological gambling. However, studies simultaneously investigating motivational and cognitive processing in problematic gamblers are lacking, limiting our understanding of the interplay between these systems in problematic gambling. Studies in non-clinical samples indicate that interactions between dorsal "executive'' and ventral "affective'' processing systems are necessary for adequate responses in various emotive situations. Methods: We conducted a generalized Psycho-Physiological Interaction (gPPI) analysis to assess the influence of affective stimuli on changes in functional connectivity associated with response inhibition in 16 treatment seeking problematic gamblers (PRGs) and 15 healthy controls (HCs) using an affective Go-NoGo fMRI paradigm including neutral, gambling-related, positive and negative pictures as neutral and affective conditions. Results: Across groups, task performance accuracy during neutral inhibition trials was positively correlated with functional connectivity between the left caudate and the right middle frontal cortex. During inhibition in the gambling condition, only in PRGs accuracy of task performance was positively correlated with functional connectivity within sub-regions of the dorsal executive system. Group interactions showed that during neutral inhibition, HCs exhibited greater functional connectivity between the left caudate and occipital cortex than PRGs. In contrast, during inhibition in the positive condition, PRGs compared to HCs showed greater functional connectivity between the left caudate and occipital cortex. During inhibition trials in the negative condition, a stronger functional connectivity between the left caudate and the right anterior cingulate cortex in PRGs compared to HCs was present. There were no group interactions during inhibition in the gambling condition. Conclusions: During gamble inhibition PRGs seem to benefit more from functional connectivity within the dorsal executive system than HCs, because task accuracy in this condition in PRGs is positively correlated with functional connectivity, although the groups show similar connectivity patterns during gamble inhibition. Greater functional connectivity between the ventral affective system and the dorsal executive system in PRGs in the affective conditions compared to HCs, suggests facilitation of the dorsal executive system when affective stimuli are present specifically in PRGs. C1 [van Holst, Ruth J.; van der Meer, Johan N.; van den Brink, Wim; Veltman, Dick J.; Goudriaan, Anna E.] Univ Amsterdam, Acad Med Ctr, Dept Psychiat, NL-1105 AZ Amsterdam, Netherlands. [van Holst, Ruth J.; van den Brink, Wim; Veltman, Dick J.; Goudriaan, Anna E.] Amsterdam Inst Addict Res, Amsterdam, Netherlands. [McLaren, Donald G.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [McLaren, Donald G.] Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Boston, MA USA. [Veltman, Dick J.] Vrije Univ Amsterdam, Dept Psychiat, Med Ctr, Amsterdam, Netherlands. [Goudriaan, Anna E.] Arkin Mental Hlth Care, Amsterdam, Netherlands. [McLaren, Donald G.] Geriatr Res Educ & Clin Ctr, Edith Nourse Rogers Mem Vet Affairs Med Ctr, Bedford, MA USA. [McLaren, Donald G.] Harvard Univ, Sch Med, Boston, MA USA. RP van Holst, RJ (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Psychiat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. EM ruthvan.holst@gmail.com RI van Holst, Ruth/J-1655-2012; OI van Holst, Ruth/0000-0002-1184-9355; McLaren, Donald/0000-0002-0566-4610 FU Dutch Scientific Organization (NWO ZonMw) [91676084]; Amsterdam Brain Imaging Platform FX This study was funded by a New Investigator grant to AEG from the Dutch Scientific Organization (NWO ZonMw, #91676084, 2007-10). Scanning costs were partly funded by a grant of the Amsterdam Brain Imaging Platform to RJH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 69 TC 9 Z9 9 U1 1 U2 22 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 28 PY 2012 VL 7 IS 11 AR e49923 DI 10.1371/journal.pone.0049923 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 057YW UT WOS:000312601700026 PM 23209619 ER PT J AU Pasternak, O Westin, CF Bouix, S Seidman, LJ Goldstein, JM Woo, TUW Petryshen, TL Mesholam-Gately, RI McCarley, RW Kikinis, R Shenton, ME Kubicki, M AF Pasternak, Ofer Westin, Carl-Fredrik Bouix, Sylvain Seidman, Larry J. Goldstein, Jill M. Woo, Tsung-Ung W. Petryshen, Tracey L. Mesholam-Gately, Raquelle I. McCarley, Robert W. Kikinis, Ron Shenton, Martha E. Kubicki, Marek TI Excessive Extracellular Volume Reveals a Neurodegenerative Pattern in Schizophrenia Onset SO JOURNAL OF NEUROSCIENCE LA English DT Article ID DIFFUSION MRI; MATTER VOLUME; BRAIN; ABNORMALITIES; DEGENERATION; INFLAMMATION; INTEGRITY; PSYCHOSIS; PATHOLOGY; DENSITY AB Diffusion MRI has been successful in identifying the existence of white matter abnormalities in schizophrenia in vivo. However, the role of these abnormalities in the etiology of schizophrenia is not well understood. Accumulating evidence from imaging, histological, genetic, and immunochemical studies support the involvement of axonal degeneration and neuroinflammation-ubiquitous components of neurodegenerative disorders-as the underlying pathologies of these abnormalities. Nevertheless, the current imaging modalities cannot distinguish neuroinflammation from axonal degeneration, and therefore provide little specificity with respect to the pathophysiology progression and whether it is related to a neurodegenerative process. Free-water imaging is a new methodology that is sensitive to water molecules diffusing in the extracellular space. Excessive extracellular volume is a surrogate biomarker for neuroinflammation and can be separated out to reveal abnormalities such as axonal degeneration that affect diffusion characteristics in the tissue. We applied free-water imaging on diffusion MRI data acquired from schizophrenia-diagnosed human subjects with a first psychotic episode. We found a significant increase in the extracellular volume in both white and gray matter. In contrast, significant signs of axonal degeneration were limited to focal areas in the frontal lobe white matter. Our findings demonstrate that neuroinflammation is more prominent than axonal degeneration in the early stage of schizophrenia, revealing a pattern shared by many neurodegenerative disorders, in which prolonged inflammation leads to axonal degeneration. These findings promote anti-inflammatory treatment for early diagnosed schizophrenia patients. C1 [Pasternak, Ofer; Bouix, Sylvain; Goldstein, Jill M.; Shenton, Martha E.; Kubicki, Marek] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. [Westin, Carl-Fredrik; Kikinis, Ron] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. [Goldstein, Jill M.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. Harvard Univ, Sch Med, Boston, MA 02115 USA. [Seidman, Larry J.; Goldstein, Jill M.; Mesholam-Gately, Raquelle I.; McCarley, Robert W.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr,Publ Psychiat Div, Boston, MA 02215 USA. [Woo, Tsung-Ung W.] Harvard Univ, Sch Med, McLean Hosp, Dept Psychiat, Belmont, MA 02478 USA. [Seidman, Larry J.; Petryshen, Tracey L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Petryshen, Tracey L.] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Boston, MA 02142 USA. [Petryshen, Tracey L.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Ctr Human Genet Res, Boston, MA 02144 USA. [McCarley, Robert W.; Shenton, Martha E.] Vet Affairs Boston Healthcare Syst, Brockton Div, Dept Psychiat, Brockton, MA 02301 USA. RP Pasternak, O (reprint author), Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA. EM ofer@bwh.harvard.edu RI McCarley, Robert/N-5562-2014; OI McCarley, Robert/0000-0001-5705-7495; Bouix, Sylvain/0000-0003-1326-6054 FU National Institutes of Health [P50-MH080272, R01-MH074794, R01-MH050740, R01-MH082918, P41-RR013218, M01-RR01032]; Veterans Affairs (VA) merit award; VA Center grant; National Alliance for Research on Schizophrenia and Depression (NARSAD) distinguished investigator grant; Fulbright Fellowship (Fulbright Commission for Israel); Fulbright Fellowship (United States-Israel Educational Foundation); Brain and Behavior Research Foundation FX This work was supported by National Institutes of Health Grants P50-MH080272, R01-MH074794, R01-MH050740, R01-MH082918, P41-RR013218, and M01-RR01032; a Veterans Affairs (VA) merit award, a VA Center grant, and a National Alliance for Research on Schizophrenia and Depression (NARSAD) distinguished investigator grant (M.E.S). O.P. was partly supported by a Fulbright Fellowship (Fulbright Commission for Israel, the United States-Israel Educational Foundation) and by a NARSAD Young Investigator Grant from the Brain and Behavior Research Foundation. NR 57 TC 70 Z9 70 U1 2 U2 21 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 28 PY 2012 VL 32 IS 48 BP 17365 EP U792 DI 10.1523/JNEUROSCI.2904-12.2012 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 046WI UT WOS:000311794700031 PM 23197727 ER PT J AU Leary, RJ Sausen, M Kinde, I Papadopoulos, N Carpten, JD Craig, D O'Shaughnessy, J Kinzler, KW Parmigiani, G Vogelstein, B Diaz, LA Velculescu, VE AF Leary, Rebecca J. Sausen, Mark Kinde, Isaac Papadopoulos, Nickolas Carpten, John D. Craig, David O'Shaughnessy, Joyce Kinzler, Kenneth W. Parmigiani, Giovanni Vogelstein, Bert Diaz, Luis A., Jr. Velculescu, Victor E. TI Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; DETECTABLE CLONAL MOSAICISM; COPY-NUMBER; MUTATIONS; PLASMA; REARRANGEMENTS; BREAST; DNA; IDENTIFICATION AB Clinical management of cancer patients could be improved through the development of noninvasive approaches for the detection of incipient, residual, and recurrent tumors. We describe an approach to directly identify tumor-derived chromosomal alterations through analysis of circulating cell-free DNA from cancer patients. Whole-genome analyses of DNA from the plasma of 10 colorectal and breast cancer patients and 10 healthy individuals with massively parallel sequencing identified, in all patients, structural alterations that were not present in plasma DNA from healthy subjects. Detected alterations comprised chromosomal copy number changes and rearrangements, including amplification of cancer driver genes such as ERBB2 and CDK6. The level of circulating tumor DNA in the cancer patients ranged from 1.4 to 47.9%. The sensitivity and specificity of this approach are dependent on the amount of sequence data obtained and are derived from the fact that most cancers harbor multiple chromosomal alterations, each of which is unlikely to be present in normal cells. Given that chromosomal abnormalities are present in nearly all human cancers, this approach represents a useful method for the noninvasive detection of human tumors that is not dependent on the availability of tumor biopsies. C1 [Leary, Rebecca J.; Sausen, Mark; Kinde, Isaac; Papadopoulos, Nickolas; Kinzler, Kenneth W.; Vogelstein, Bert; Diaz, Luis A., Jr.; Velculescu, Victor E.] Johns Hopkins Kimmel Canc Ctr, Ludwig Ctr Canc Genet, Baltimore, MD 21287 USA. [Leary, Rebecca J.; Sausen, Mark; Kinde, Isaac; Papadopoulos, Nickolas; Kinzler, Kenneth W.; Vogelstein, Bert; Diaz, Luis A., Jr.; Velculescu, Victor E.] Johns Hopkins Kimmel Canc Ctr, Howard Hughes Med Inst, Baltimore, MD 21287 USA. [Carpten, John D.; Craig, David] Translat Genom Res Inst, Phoenix, AZ 85044 USA. [O'Shaughnessy, Joyce] US Oncol, Texas Oncol, Baylor Sammons Canc Ctr, Dallas, TX 75246 USA. [Parmigiani, Giovanni] Dana Farber Canc Inst, Dept Biostat & Comp Biol, Boston, MA 02215 USA. [Parmigiani, Giovanni] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Velculescu, VE (reprint author), Johns Hopkins Kimmel Canc Ctr, Ludwig Ctr Canc Genet, Baltimore, MD 21287 USA. EM ldiaz1@jhmi.edu; velculescu@jhmi.edu FU NIH [CA121113, CA057345, CA043460]; European Community; Virginia & D. K. Ludwig Fund for Cancer Research; American Association for Cancer Research Stand Up To Cancer-Dream Team Translational Cancer Research Grant; National Colorectal Cancer Research Alliance; United Negro College Fund-Merck Fellowship; Swim Across America FX Funding: The project was supported by NIH grants CA121113, CA057345, CA043460; The European Community's Seventh Framework Programme; the Virginia & D. K. Ludwig Fund for Cancer Research; the American Association for Cancer Research Stand Up To Cancer-Dream Team Translational Cancer Research Grant; National Colorectal Cancer Research Alliance; United Negro College Fund-Merck Fellowship; and Swim Across America. NR 41 TC 139 Z9 147 U1 2 U2 44 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 J9 SCI TRANSL MED JI Sci. Transl. Med. PD NOV 28 PY 2012 VL 4 IS 162 AR 162ra154 DI 10.1126/scitranslmed.3004742 PG 12 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 047FK UT WOS:000311823300003 PM 23197571 ER PT J AU Guo, YY Yuan, HS Rice, WL Kumar, ATN Goergen, CJ Jokivarsi, K Josephson, L AF Guo, Yanyan Yuan, Hushan Rice, William L. Kumar, Anand T. N. Goergen, Craig J. Jokivarsi, Kimmo Josephson, Lee TI The PEG-Fluorochrome Shielding Approach for Targeted Probe Design SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY LA English DT Article ID NANOPARTICLE; CANCER; DYES AB We provide a new approach for fluorescent probe design termed "PEG-fluorochrome where PEGylation enhances quantum yields while blocking troublesome interactions between fluorochromes and biomolecules. To demonstrate PEG-fluorochrome shielding, fluorochrome-bearing peptide probes were synthesized, three without PEG and three with a 5 kDa PEG functional group. In vitro, PEG blocked the interactions of fluorochrome-labeled peptide probes with each other (absorption spectra, self quenching) and reduced non-specific interactions with cells (by FACS). In vivo, PEG blocked interactions with biomolecules that lead to probe retention (by surface fluorescence). Integrin targeting in vivo was obtained as the differential uptake of an In-111-labeled fluorochrome-shielded, integrin-binding RGD probe and a control RAD. Using PEG to block fluorochrome-mediated interactions rather than synthesizing de nova fluorochromes, can yield new approaches for the design of actively or passively targeted near-infrared fluorescent probes. C1 [Guo, Yanyan; Yuan, Hushan; Josephson, Lee] Massachusetts Gen Hosp, Ctr Translat Nucl Med & Mol Imaging, Charlestown, MA 02129 USA. [Rice, William L.; Kumar, Anand T. N.; Goergen, Craig J.; Jokivarsi, Kimmo; Josephson, Lee] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Josephson, L (reprint author), Massachusetts Gen Hosp, Ctr Translat Nucl Med & Mol Imaging, 149 13th St, Charlestown, MA 02129 USA. EM ljosephson@mgh.harvard.edu OI Goergen, Craig/0000-0001-8883-7953 FU [NIH: EB 011996]; [EB 009691] FX This work was supported by R01's from the NIH: EB 011996 and EB 009691. NR 17 TC 14 Z9 14 U1 2 U2 56 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0002-7863 J9 J AM CHEM SOC JI J. Am. Chem. Soc. PD NOV 28 PY 2012 VL 134 IS 47 BP 19338 EP 19341 DI 10.1021/ja309085b PG 4 WC Chemistry, Multidisciplinary SC Chemistry GA 043CW UT WOS:000311521500008 PM 23137147 ER PT J AU Pereyra, F Lo, J Triant, VA Wei, J Buzon, MJ Fitch, KV Hwang, J Campbell, JH Burdo, TH Williams, KC Abbara, S Grinspoon, SK AF Pereyra, Florencia Lo, Janet Triant, Virginia A. Wei, Jeffrey Buzon, Maria J. Fitch, Kathleen V. Hwang, Janice Campbell, Jennifer H. Burdo, Tricia H. Williams, Kenneth C. Abbara, Suhny Grinspoon, Steven K. TI Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers SO AIDS LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL-ACTIVATION; LOW-LEVEL VIREMIA; ANTIRETROVIRAL THERAPY; VIRAL REPLICATION; ABSENCE; INDIVIDUALS; SUPPRESSORS; DISEASE AB HIV-1 elite controllers spontaneously maintain suppressed levels of viremia, but exhibit significant immune activation. We investigated coronary atherosclerosis by coronary computed tomography angiography (CTA) in elite controllers, nonelite controller, chronically HIV-1 infected, antiretroviral therapy (ART)-treated patients with undetectable viral load ('chronic HIV'), and HIV-negative controls. Prevalence of atherosclerosis (78 vs. 42%, P < 0.05) and markers of immune activation were increased in elite controllers compared with HIV-negative controls. sCD163, a monocyte activation marker, was increased in elite controllers compared with chronic HIV-1 (P< 0.05) and compared with HIV-negative controls (P< 0.05). These data suggest a significant degree of coronary atherosclerosis and monocyte activation among elite controllers. C1 [Lo, Janet; Wei, Jeffrey; Fitch, Kathleen V.; Hwang, Janice; Grinspoon, Steven K.] Massachusetts Gen Hosp, Program Nutr Metab, Boston, MA 02114 USA. [Pereyra, Florencia; Triant, Virginia A.; Buzon, Maria J.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Abbara, Suhny] Massachusetts Gen Hosp, Cardiovasc Imaging Sect, Dept Radiol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. [Pereyra, Florencia; Buzon, Maria J.] Ragon Inst MGH MIT & Harvard, Boston, MA USA. [Campbell, Jennifer H.; Burdo, Tricia H.; Williams, Kenneth C.] Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA. RP Grinspoon, SK (reprint author), Massachusetts Gen Hosp, Program Nutr Metab, 55 Fruit St,LON207, Boston, MA 02114 USA. EM sgrinspoon@partners.org RI Buzon, Maria J/G-8286-2015 OI Buzon, Maria J/0000-0003-4427-9413 FU Bristol Myers Squibb, Inc.; NIH [R01 095123, K24 DK064545, K23 HL092792, F32 HL088991, NS040237, M01 RR01066-25S1]; Bill and Melinda Gates Foundation FX Funding was received from Bristol Myers Squibb, Inc., NIH R01 095123 (S. K. G.), NIH K24 DK064545 (S. K. G.), NIH K23 HL092792 (J.L.), F32 HL088991 (J.L.), NIH NS040237 (K. C. W.) and M01 RR01066-25S1, the Bill and Melinda Gates Foundation (F. P.). Funding sources had no role in the design of the study, data analysis or the writing of the article. NR 22 TC 70 Z9 72 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD NOV 28 PY 2012 VL 26 IS 18 BP 2409 EP 2412 DI 10.1097/QAD.0b013e32835a9950 PG 4 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 039GP UT WOS:000311232900017 PM 23032411 ER PT J AU Fjell, AM Walhovd, KB Brown, TT Kuperman, JM Chung, Y Hagler, DJ Venkatraman, V Roddey, JC Erhart, M McCabe, C Akshoomoff, N Amaral, DG Bloss, CS Libiger, O Darst, BF Schork, NJ Casey, BJ Chang, L Ernst, TM Gruen, JR Kaufmann, WE Kenet, T Frazier, J Murray, SS Sowell, ER van Zijl, P Mostofsky, S Jernigan, TL Dale, AM AF Fjell, Anders M. Walhovd, Kristine Beate Brown, Timothy T. Kuperman, Joshua M. Chung, Yoonho Hagler, Donald J., Jr. Venkatraman, Vijay Roddey, J. Cooper Erhart, Matthew McCabe, Connor Akshoomoff, Natacha Amaral, David G. Bloss, Cinnamon S. Libiger, Ondrej Darst, Burcu F. Schork, Nicholas J. Casey, B. J. Chang, Linda Ernst, Thomas M. Gruen, Jeffrey R. Kaufmann, Walter E. Kenet, Tal Frazier, Jean Murray, Sarah S. Sowell, Elizabeth R. van Zijl, Peter Mostofsky, Stewart Jernigan, Terry L. Dale, Anders M. CA Pediat Imaging Neurocognition Gene TI Multimodal imaging of the self-regulating developing brain SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE executive function; cognitive conflict; inhibition; morphometry ID WHITE-MATTER INTEGRITY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; MAGNETIC-RESONANCE IMAGES; SURFACE-BASED ANALYSIS; ADULT AGE-DIFFERENCES; HUMAN CEREBRAL-CORTEX; DIFFUSION-TENSOR MRI; EXECUTIVE FUNCTIONS; CORTICAL THICKNESS; ANTERIOR CINGULATE AB Self-regulation refers to the ability to control behavior, cognition, and emotions, and self-regulation failure is related to a range of neuropsychiatric problems. It is poorly understood how structural maturation of the brain brings about the gradual improvement in self-regulation during childhood. In a large-scale multicenter effort, 735 children (4-21 y) underwent structural MRI for quantification of cortical thickness and surface area and diffusion tensor imaging for quantification of the quality of major fiber connections. Brain development was related to a standardized measure of cognitive control (the flanker task from the National Institutes of Health Toolbox), a critical component of self-regulation. Ability to inhibit responses and impose cognitive control increased rapidly during preteen years. Surface area of the anterior cingulate cortex accounted for a significant proportion of the variance in cognitive performance. This finding is intriguing, because characteristics of the anterior cingulum are shown to be related to impulse, attention, and executive problems in neurodevelopmental disorders, indicating a neural foundation for self-regulation abilities along a continuum from normality to pathology. The relationship was strongest in the younger children. Properties of large-fiber connections added to the picture by explaining additional variance in cognitive control. Although cognitive control was related to surface area of the anterior cingulate independently of basic processes of mental speed, the relationship between white matter quality and cognitive control could be fully accounted for by speed. The results underscore the need for integration of different aspects of brain maturation to understand the foundations of cognitive development. C1 [Fjell, Anders M.; Walhovd, Kristine Beate] Univ Oslo, Dept Psychol, N-0373 Oslo, Norway. [Brown, Timothy T.; Kuperman, Joshua M.; Chung, Yoonho; Hagler, Donald J., Jr.; Venkatraman, Vijay; Roddey, J. Cooper; Erhart, Matthew; Dale, Anders M.] Univ Calif San Diego, Multimodal Imaging Lab, La Jolla, CA 92037 USA. [Brown, Timothy T.; Dale, Anders M.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92037 USA. [Kuperman, Joshua M.; Hagler, Donald J., Jr.; Erhart, Matthew; Jernigan, Terry L.; Dale, Anders M.] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92037 USA. [Akshoomoff, Natacha; Jernigan, Terry L.; Dale, Anders M.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92037 USA. [Jernigan, Terry L.; Dale, Anders M.] Univ Calif San Diego, Dept Cognit Sci, La Jolla, CA 92037 USA. [Chung, Yoonho; McCabe, Connor; Akshoomoff, Natacha; Jernigan, Terry L.] Univ Calif San Diego, Ctr Human Dev, La Jolla, CA 92037 USA. [Amaral, David G.] Univ Calif Davis, Dept Psychiat & Behav Sci, Davis, CA 95817 USA. [Bloss, Cinnamon S.; Libiger, Ondrej; Darst, Burcu F.; Schork, Nicholas J.; Murray, Sarah S.] Scripps Translat Sci Inst, La Jolla, CA 92037 USA. [Bloss, Cinnamon S.; Libiger, Ondrej; Darst, Burcu F.; Schork, Nicholas J.; Murray, Sarah S.] Scripps Hlth, La Jolla, CA 92037 USA. [Casey, B. J.] Weill Cornell Med Coll, Sackler Inst Dev Psychobiol, New York, NY 10065 USA. [Chang, Linda; Ernst, Thomas M.] Univ Hawaii, Dept Med, Honolulu, HI 96813 USA. [Chang, Linda; Ernst, Thomas M.] Queens Med Ctr, Honolulu, HI 96813 USA. [Gruen, Jeffrey R.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA. [Gruen, Jeffrey R.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA. [van Zijl, Peter] Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, FM Kirby Res Ctr, Baltimore, MD 21205 USA. [van Zijl, Peter] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA. [Kaufmann, Walter E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA. [Kenet, Tal] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA. [Kenet, Tal] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Frazier, Jean] Univ Massachusetts, Sch Med, Dept Psychiat, Boston, MA 01655 USA. [Sowell, Elizabeth R.] Univ So Calif, Dept Pediat, Los Angeles, CA 90027 USA. [Sowell, Elizabeth R.] Childrens Hosp, Dev Cognit Neuroimaging Lab, Los Angeles, CA 90027 USA. RP Fjell, AM (reprint author), Univ Oslo, Dept Psychol, N-0373 Oslo, Norway. EM andersmf@psykologi.uio.no FU PING Study (National Institutes of Health) [RC2DA029475]; National Institute on Drug Abuse; Eunice Kennedy Shriver National Institute of Child Health & Human Development; Norwegian Research Council; European Research Council; National Institutes of Health FX The authors gratefully thank the children, adolescents, adults, and parents who participated in the research. Data collection and sharing for this project were funded by the PING Study (National Institutes of Health Grant RC2DA029475). PING is funded by the National Institute on Drug Abuse and the Eunice Kennedy Shriver National Institute of Child Health & Human Development. PING data are disseminated by the PING Coordinating Center at the Center for Human Development, University of California at San Diego. Additional support was received from the Norwegian Research Council (A.M.F. and K.B.W.), the European Research Council (A.M.F.), and National Institutes of Health Grant P41 EB015909. NR 82 TC 84 Z9 85 U1 4 U2 56 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 27 PY 2012 VL 109 IS 48 BP 19620 EP 19625 DI 10.1073/pnas.1208243109 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 053ZN UT WOS:000312313900031 PM 23150548 ER PT J AU Zhao, WA Cui, CH Bose, S Guo, DG Shen, C Wong, WP Halvorsen, K Farokhzad, OC Teo, GSL Phillips, JA Dorfman, DM Karnik, R Karp, JM AF Zhao, Weian Cui, Cheryl H. Bose, Suman Guo, Dagang Shen, Chong Wong, Wesley P. Halvorsen, Ken Farokhzad, Omid C. Teo, Grace Sock Leng Phillips, Joseph A. Dorfman, David M. Karnik, Rohit Karp, Jeffrey M. TI Bioinspired multivalent DNA network for capture and release of cells SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE circulating tumor cells; multivalency; point-of-care; cell sorting; microfluidics ID CIRCULATING TUMOR-CELLS; MINIMAL RESIDUAL DISEASE; ROLLING CIRCLE AMPLIFICATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CANCER-CELLS; EFFICIENT CAPTURE; APTAMERS; ENRICHMENT; RECEPTOR AB Capture and isolation of flowing cells and particulates from body fluids has enormous implications in diagnosis, monitoring, and drug testing, yet monovalent adhesion molecules used for this purpose result in inefficient cell capture and difficulty in retrieving the captured cells. Inspired by marine creatures that present long tentacles containing multiple adhesive domains to effectively capture flowing food particulates, we developed a platform approach to capture and isolate cells using a 3D DNA network comprising repeating adhesive aptamer domains that extend over tens of micrometers into the solution. The DNA network was synthesized from a microfluidic surface by rolling circle amplification where critical parameters, including DNA graft density, length, and sequence, could readily be tailored. Using an aptamer that binds to protein tyrosine kinase-7 (PTK7) that is overexpressed on many human cancer cells, we demonstrate that the 3D DNA network significantly enhances the capture efficiency of lymphoblast CCRF-CEM cells over monovalent aptamers and antibodies, yet maintains a high purity of the captured cells. When incorporated in a herringbone microfluidic device, the 3D DNA network not only possessed significantly higher capture efficiency than monovalent aptamers and antibodies, but also outperformed previously reported cell-capture microfluidic devices at high flow rates. This work suggests that 3D DNA networks may have broad implications for detection and isolation of cells and other bioparticles. C1 [Bose, Suman; Shen, Chong; Karnik, Rohit] MIT, Dept Mech Engn, Cambridge, MA 02139 USA. [Zhao, Weian; Cui, Cheryl H.; Guo, Dagang; Farokhzad, Omid C.; Teo, Grace Sock Leng; Phillips, Joseph A.; Karp, Jeffrey M.] Brigham & Womens Hosp, Ctr Regenerat Therapeut, Cambridge, MA 02139 USA. [Zhao, Weian; Cui, Cheryl H.; Guo, Dagang; Farokhzad, Omid C.; Teo, Grace Sock Leng; Phillips, Joseph A.; Karp, Jeffrey M.] Brigham & Womens Hosp, Dept Med, Cambridge, MA 02139 USA. [Zhao, Weian; Cui, Cheryl H.; Guo, Dagang; Wong, Wesley P.; Halvorsen, Ken; Teo, Grace Sock Leng; Phillips, Joseph A.; Karp, Jeffrey M.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. [Zhao, Weian; Cui, Cheryl H.; Guo, Dagang; Teo, Grace Sock Leng; Phillips, Joseph A.; Karp, Jeffrey M.] Harvard Stem Cell Inst, Cambridge, MA 02139 USA. [Zhao, Weian; Cui, Cheryl H.; Guo, Dagang; Farokhzad, Omid C.; Teo, Grace Sock Leng; Phillips, Joseph A.; Karp, Jeffrey M.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Guo, Dagang] Xi An Jiao Tong Univ, Sch Mat Sci & Engn, State Key Lab Mech Behav Mat, Xian 710049, Peoples R China. [Halvorsen, Ken] Harvard Univ, Rowland Inst Harvard, Cambridge, MA 02139 USA. [Wong, Wesley P.; Halvorsen, Ken] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. [Farokhzad, Omid C.] Brigham & Womens Hosp, Lab Nanomed & Biomat, Boston, MA 02115 USA. [Dorfman, David M.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. RP Karnik, R (reprint author), MIT, Dept Mech Engn, Cambridge, MA 02139 USA. EM karnik@mit.edu; jkarp@rics.bwh.harvard.edu FU International Human Frontier Science Program Organization; China Scholarship Council and National Natural Science Foundation of China [51273159, 51072159]; Program for New Century Excellent Talents in Universities (Chinese Ministry of Education) [NCET-08-0444 (2301G107aaa)]; National Institutes of Health [HL097172, HL095722] FX This work was supported by an International Human Frontier Science Program Organization postdoctoral fellowship (to W.Z.); the China Scholarship Council and National Natural Science Foundation of China Grants 51273159 and 51072159 (to D. G.); Program for New Century Excellent Talents in Universities (Chinese Ministry of Education) Grant NCET-08-0444 (2301G107aaa) (to D. G.); and National Institutes of Health Grants HL097172 and HL095722 (to J.M.K.). NR 43 TC 93 Z9 94 U1 20 U2 229 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 27 PY 2012 VL 109 IS 48 BP 19626 EP 19631 DI 10.1073/pnas.1211234109 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 053ZN UT WOS:000312313900032 PM 23150586 ER PT J AU Lee, J Li, M Milwid, J Dunham, J Vinegoni, C Gorbatov, R Iwamoto, Y Wang, FJ Shen, KY Hatfield, K Enger, M Shafiee, S McCormack, E Ebert, BL Weissleder, R Yarmush, ML Parekkadan, B AF Lee, Jungwoo Li, Matthew Milwid, Jack Dunham, Joshua Vinegoni, Claudio Gorbatov, Rostic Iwamoto, Yoshiko Wang, Fangjing Shen, Keyue Hatfield, Kimberley Enger, Marianne Shafiee, Sahba McCormack, Emmet Ebert, Benjamin L. Weissleder, Ralph Yarmush, Martin L. Parekkadan, Biju TI Implantable microenvironments to attract hematopoietic stem/cancer cells SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE hydrogel scaffolds; leukemia; mesenchymal stem cells; stem cell niche; tissue engineered bone marrow ID INVERTED COLLOIDAL CRYSTALS; MESENCHYMAL STEM-CELLS; BONE-MARROW; EXTRAMEDULLARY HEMATOPOIESIS; STEM/PROGENITOR CELLS; PROGENITOR CELLS; NICHE; TISSUES; REGENERATION; ENGRAFTMENT AB The environments that harbor hematopoietic stem and progenitor cells are critical to explore for a better understanding of hematopoiesis during health and disease. These compartments often are inaccessible for controlled and rapid experimentation, thus limiting studies to the evaluation of conventional cell culture and transgenic animal models. Here we describe the manufacture and image-guided monitoring of an engineered microenvironment with user-defined properties that recruits hematopoietic progenitors into the implant. Using intravital imaging and fluorescence molecular tomography, we show in real time that the cell homing and retention process is efficient and durable for short-and long-term engraftment studies. Our results indicate that bone marrow stromal cells, precoated on the implant, accelerate the formation of new sinusoidal blood vessels with vascular integrity at the micro-capillary level that enhances the recruitment hematopoietic progenitor cells to the site. This implantable construct can serve as a tool enabling the study of hematopoiesis. C1 [Lee, Jungwoo; Li, Matthew; Milwid, Jack; Wang, Fangjing; Shen, Keyue; Yarmush, Martin L.; Parekkadan, Biju] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA. [Lee, Jungwoo; Li, Matthew; Milwid, Jack; Wang, Fangjing; Shen, Keyue; Yarmush, Martin L.; Parekkadan, Biju] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Surg Serv, Boston, MA 02114 USA. [Lee, Jungwoo; Li, Matthew; Milwid, Jack; Wang, Fangjing; Shen, Keyue; Parekkadan, Biju] Shriners Hosp Children, Boston, MA 02114 USA. [Li, Matthew; Milwid, Jack] Harvard MIT Hlth Sci & Technol, Cambridge, MA 02139 USA. [Dunham, Joshua; Vinegoni, Claudio; Gorbatov, Rostic; Iwamoto, Yoshiko; Weissleder, Ralph] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Hatfield, Kimberley] Haukeland Hosp, Dept Med, Sect Hematol, N-5021 Bergen, Norway. [Enger, Marianne] Univ Bergen, Gade Inst, N-5020 Bergen, Norway. [Shafiee, Sahba; McCormack, Emmet] Univ Bergen, Haukeland Univ Hosp, Inst Internal Med, Dept Hematol, N-5020 Bergen, Norway. [Ebert, Benjamin L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Hematol, Boston, MA 02114 USA. [Ebert, Benjamin L.; Parekkadan, Biju] Harvard Stem Cell Inst, Boston, MA 02115 USA. [Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA. RP Parekkadan, B (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA. EM biju_parekkadan@hms.harvard.edu RI Mc Cormack, Emmet/D-2922-2012; Lee, Jungwoo/I-4219-2013 OI Mc Cormack, Emmet/0000-0002-7621-4625; FU National Institutes of Health [R01EB012521, K01DK087770]; Bergen Research Foundation; Norwegian Cancer Society; Shriners Hospitals for Children; National Cancer Institute [1K99CA163671-01A1] FX We thank Drs. Peter Miller and Ann Mullally for assistance with flow cytometry; Mihaela Popa and Lene M. Vikebo for technical assistance in animal work; and Peter Waterman for assistance in fluorescent molecular tomography analysis. This work was supported by National Institutes of Health Grants R01EB012521 and K01DK087770, by the Bergen Research Foundation and the Norwegian Cancer Society, by post-doctoral fellowships from the Shriners Hospitals for Children, and by National Cancer Institute Grant 1K99CA163671-01A1. NR 46 TC 30 Z9 30 U1 4 U2 41 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 27 PY 2012 VL 109 IS 48 BP 19638 EP 19643 DI 10.1073/pnas.1208384109 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 053ZN UT WOS:000312313900034 PM 23150542 ER PT J AU Read, EL Tovo-Dwyer, AA Chakraborty, AK AF Read, Elizabeth L. Tovo-Dwyer, Allison A. Chakraborty, Arup K. TI Stochastic effects are important in intrahost HIV evolution even when viral loads are high SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE rare events; viral dynamics ID IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL RESPONSES; LYMPHOCYTE RESPONSE; PRIMARY INFECTION; IDENTICAL-TWINS; ESCAPE MUTATION; SELECTION; GAG; THERAPY; PROGRESSION AB Blood plasma viral loads and the time to progress to AIDS differ widely among untreated HIV-infected humans. Although people with certain HLA (HLA-I) alleles are more likely to control HIV infections without therapy, the majority of such untreated individuals exhibit high viral loads and progress to AIDS. Stochastic effects are considered unimportant for evolutionary dynamics in HIV-infected people when viral load is high or when selective forces strongly drive mutation. We describe a computational study of host-pathogen interaction demonstrating that stochastic effects can have a profound influence on disease dynamics, even in cases of high viral load and strong selective pressure. These stochastic effects are pronounced when the virus must traverse a fitness "barrier" in sequence space to escape the host's cytotoxic T-lymphocyte (CTL) response, as often occurs when a fitness defect imposed by a CTL-driven mutation must be compensated for by other mutations. These "barrier-crossing" events are infrequent and stochastic, resulting in divergent disease outcomes in genetically identical individuals infected by the same viral strain. Our results reveal how genetic determinants of the CTL response control the probability with which an individual is able to control HIV infection indefinitely, and thus provide clues for vaccine design. C1 [Read, Elizabeth L.; Chakraborty, Arup K.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA. [Tovo-Dwyer, Allison A.; Chakraborty, Arup K.] MIT, Dept Chem, Cambridge, MA 02139 USA. [Chakraborty, Arup K.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA. [Chakraborty, Arup K.] MIT, Dept Phys, Cambridge, MA 02139 USA. [Read, Elizabeth L.; Tovo-Dwyer, Allison A.; Chakraborty, Arup K.] Massachusetts Inst Technol & Harvard, Massachusetts Gen Hosp, Ragon Inst, Boston, MA 02114 USA. RP Chakraborty, AK (reprint author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA. EM arupc@mit.edu FU Jane Coffins Childs Foundation; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard; National Institutes of Health FX We thank Dr. Bruce D. Walker for fruitful discussions. This study was supported by the Jane Coffins Childs Foundation (E. L. R.), Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard (A. K. C.), and a National Institutes of Health Director's Pioneer award (to A.K.C.). NR 52 TC 5 Z9 5 U1 1 U2 13 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 27 PY 2012 VL 109 IS 48 BP 19727 EP 19732 DI 10.1073/pnas.1206940109 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 053ZN UT WOS:000312313900049 PM 23112156 ER PT J AU Hoge, EA Ivkovic, A Fricchione, GL AF Hoge, Elizabeth A. Ivkovic, Ana Fricchione, Gregory L. TI Generalized anxiety disorder: diagnosis and treatment SO BRITISH MEDICAL JOURNAL LA English DT Review ID NATIONAL-COMORBIDITY-SURVEY; COGNITIVE-BEHAVIORAL THERAPY; MENTAL-DISORDERS; PRIMARY-CARE; APPLIED RELAXATION; MAJOR DEPRESSION; HEALTH-CARE; METAANALYSIS; PREVALENCE; RECOGNITION C1 [Hoge, Elizabeth A.; Ivkovic, Ana; Fricchione, Gregory L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Hoge, Elizabeth A.; Fricchione, Gregory L.] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA. [Hoge, Elizabeth A.] Massachusetts Gen Hosp, Ctr Anxiety & Traumat Stress Disorders, Boston, MA 02114 USA. RP Fricchione, GL (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. EM gfricchione@partners.org RI Hoge, Elizabeth/H-5879-2012 OI Hoge, Elizabeth/0000-0002-5513-2292 NR 35 TC 15 Z9 16 U1 2 U2 40 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BRIT MED J JI Br. Med. J. PD NOV 27 PY 2012 VL 345 AR e7500 DI 10.1136/bmj.e7500 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 048FM UT WOS:000311895700001 PM 23187094 ER PT J AU Schuetz, C Wamala, I Kim, K Varma, M Veilleitte, GR Smith, RN Elias, N Cosimi, AB Sachs, DH Hertl, M AF Schuetz, C. Wamala, I Kim, K. Varma, M. Veilleitte, G. R. Smith, R. N. Elias, N. Cosimi, A. B. Sachs, D. H. Hertl, M. TI Primate Recipients of Porcine Livers Develop Fatal Coagulopathy Despite Prevention of Thrombocytopenia SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Schuetz, C.; Wamala, I; Varma, M.; Elias, N.; Cosimi, A. B.; Hertl, M.] Massachusetts Gen Hosp, Surg Transplant Div, Boston, MA 02114 USA. [Schuetz, C.; Wamala, I; Kim, K.; Varma, M.; Veilleitte, G. R.; Sachs, D. H.] Harvard Univ, Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Charlestown, MA USA. [Kim, K.; Veilleitte, G. R.] Massachusetts Gen Hosp, Surg, Boston, MA 02114 USA. [Varma, M.] Apollo Hosp, Ctr Liver Dis & Transplantat, Surg Gastroenterol, Madras, Tamil Nadu, India. [Veilleitte, G. R.] Univ Calif San Francisco, Surg Transplant Div, San Francisco, CA 94143 USA. [Smith, R. N.] Massachusetts Gen Hosp, Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1676 BP 67 EP 67 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846400124 ER PT J AU Dick, AAS Mercer, LD Smith, JM McDonald, RA Young, B Healey, PJ AF Dick, A. A. S. Mercer, L. D. Smith, J. M. McDonald, R. A. Young, B. Healey, P. J. TI Donor and Recipient Size Mismatch in Pediatric Living Donor Renal Transplantation Affects Long-Term Graft Survival SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Dick, A. A. S.; Healey, P. J.] Seattle Childrens Hosp, Div Transplant, Surg, Seattle, WA USA. [Mercer, L. D.] Seattle Childrens Res Inst, Core Biomed Stat, Seattle, WA USA. [Smith, J. M.; McDonald, R. A.] Seattle Childrens Hosp, Div Nephrol, Pediat, Seattle, WA USA. [Young, B.] VA Puget Sound Hlth Care Syst, Div Nephrol, Med, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1735 BP 75 EP 75 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846400139 ER PT J AU Tena, A Germana, S Turcotte, N Barone, AAL Arn, S Terlouw, SL Dobrinsky, JR Mtango, N Verstegen, J Sachs, DH Hawley, RJ AF Tena, A. Germana, S. Turcotte, N. Barone, Leto A. A. Arn, S. Terlouw, S. L. Dobrinsky, J. R. Mtango, N. Verstegen, J. Sachs, D. H. Hawley, R. J. TI Miniature Swine Expressing Human CD47 to Enhance Bone Marrow Engraftment in Non-Human Primates SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Tena, A.; Germana, S.; Turcotte, N.; Barone, Leto A. A.; Arn, S.; Sachs, D. H.; Hawley, R. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Tena, A.] Harvard Med Sch, Surg, Boston, MA USA. [Germana, S.; Turcotte, N.; Barone, Leto A. A.; Arn, S.; Sachs, D. H.; Hawley, R. J.] Harvard Med Sch, Boston, MA USA. [Terlouw, S. L.; Dobrinsky, J. R.; Mtango, N.; Verstegen, J.] Minitube Amer, Verona, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1651 BP 97 EP 97 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846400179 ER PT J AU Tasaki, M Shimizu, A Hanekamp, I Torabi, R Villani, V Moran, S Cormack, T Gillon, B Yamada, R Fishman, J Robson, S Sachs, D Yamada, K AF Tasaki, M. Shimizu, A. Hanekamp, I Torabi, R. Villani, V. Moran, S. Cormack, T. Gillon, B. Yamada, R. Fishman, J. Robson, S. Sachs, D. Yamada, K. TI Prevention of Early Development of Proteinuria by Rituximab in a Pig to Baboon Thymokidney Model Likely Associated with Modulating Podocyte Function in An SMPDL-3b-Dependent Manner SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Tasaki, M.; Shimizu, A.; Hanekamp, I; Torabi, R.; Villani, V.; Moran, S.; Cormack, T.; Gillon, B.; Yamada, R.; Fishman, J.; Robson, S.; Sachs, D.; Yamada, K.] Harvard Med Sch, Mass Gen Hosp, Transplantat Biol Res Ctr, Surg, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1259 BP 98 EP 98 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846400181 ER PT J AU Tsoulfas, G Agorastou, P Ko, DS Hertl, M Elias, N Cosimi, AB Kawai, T AF Tsoulfas, G. Agorastou, P. Ko, D. S. Hertl, M. Elias, N. Cosimi, A. B. Kawai, T. TI Laparoscopic Living Donor Nephrectomy: Is it OK to Be Right? SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Tsoulfas, G.; Agorastou, P.] Aristoteleion Univ Thessaloniki, Thessaloniki, Greece. [Ko, D. S.; Hertl, M.; Elias, N.; Cosimi, A. B.; Kawai, T.] Harvard Med Sch, Mass Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 977 BP 152 EP 152 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846401079 ER PT J AU Lee, S Aoyama, A Tonsho, M Boskovic, S Yamada, Y Smith, RN Colvin, RB Cosimi, AB Benichou, G Madsen, JC Kawai, T Allan, JS AF Lee, S. Aoyama, A. Tonsho, M. Boskovic, S. Yamada, Y. Smith, R. -N. Colvin, R. B. Cosimi, A. B. Benichou, G. Madsen, J. C. Kawai, T. Allan, J. S. TI Anti-IL-6R Antibodies Prevent Acute Rejection of Allogeneic Lung Transplants in Monkeys SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Lee, S.; Aoyama, A.; Tonsho, M.; Boskovic, S.; Yamada, Y.; Cosimi, A. B.; Benichou, G.; Madsen, J. C.; Kawai, T.; Allan, J. S.] Massachusetts Gen Hosp, Transplant Surg, Boston, MA 02114 USA. [Smith, R. -N.; Colvin, R. B.] Massachusetts Gen Hosp, Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1637 BP 189 EP 189 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846401151 ER PT J AU Liu, W Xiao, X Demirci, G Madsen, J Li, XC AF Liu, W. Xiao, X. Demirci, G. Madsen, J. Li, X. C. TI Macrophages Licensed by CD4+T Cells Can Recognize and Reject Allogeneic Cells SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Liu, W.] Harvard Med Sch, Brigham & Womens Hosp, Renal, Boston, MA USA. [Xiao, X.; Demirci, G.; Li, X. C.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA. [Madsen, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Madsen, J.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 629 BP 230 EP 230 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846401225 ER PT J AU Tonsho, M Kawai, T Boskovic, S Cappetta, K Nadazdin, O Smith, NR Colvin, RB Benichou, G Cosimi, AB Madsen, JC AF Tonsho, M. Kawai, T. Boskovic, S. Cappetta, K. Nadazdin, O. Smith, N. R. Colvin, R. B. Benichou, G. Cosimi, A. B. Madsen, J. C. TI Effect of Kidney Cotransplantation on Induction of Heart Graft Tolerance in Nonhuman Primates (NHPs) SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Tonsho, M.; Kawai, T.; Boskovic, S.; Cappetta, K.; Nadazdin, O.; Benichou, G.; Cosimi, A. B.; Madsen, J. C.] Massachusetts Gen Hosp, Transplant Surg, Boston, MA 02114 USA. [Smith, N. R.; Colvin, R. B.] Massachusetts Gen Hosp, Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 764 BP 307 EP 307 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846401368 ER PT J AU Pathiraja, VA Tasaki, M Scalea, J Matar, A Duran-Struuck, R Gillon, B Sachs, DH Huang, CA Yamada, K AF Pathiraja, V. A. Tasaki, M. Scalea, J. Matar, A. Duran-Struuck, R. Gillon, B. Sachs, D. H. Huang, C. A. Yamada, K. TI Successful Induction of Tolerance of Both Islets and Kidneys and Cure of Diabetes Following Vascularized Islet-Kidney Transplantation in Non-human Primates SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Pathiraja, V. A.; Tasaki, M.; Scalea, J.; Matar, A.; Duran-Struuck, R.; Gillon, B.; Sachs, D. H.; Huang, C. A.; Yamada, K.] Harvard Med Sch, Mass Gen Hosp, Transplantat Biol Res Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 589 BP 347 EP 347 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846401441 ER PT J AU Liu, Q Rehman, H Krishnasamy, Y Haque, K Schnellmann, RG Lemasters, JJ Zhong, Z AF Liu, Q. Rehman, H. Krishnasamy, Y. Haque, K. Schnellmann, R. G. Lemasters, J. J. Zhong, Z. TI Role of Amphiregulin in Suppressed Liver Regeneration after Small-For-Size Liver Transplantation in Mice SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Liu, Q.; Rehman, H.; Krishnasamy, Y.; Haque, K.; Schnellmann, R. G.; Lemasters, J. J.; Zhong, Z.] Med Univ South Carolina, Pharmaceut & Biomed Sci, Charleston, SC USA. [Schnellmann, R. G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 631 BP 376 EP 376 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846401492 ER PT J AU Martins, PN Yeh, H Mcdaid, J Farrell, ML Hertl, M Cosimi, AB Markmann, JF AF Martins, P. N. Yeh, H. Mcdaid, J. Farrell, M. -L Hertl, M. Cosimi, A. B. Markmann, J. F. TI Biliary Complications and Outcomes of Liver Transplantation from Donors after Cardiac Death (DCD) SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Martins, P. N.; Yeh, H.; Mcdaid, J.; Farrell, M. -L; Hertl, M.; Cosimi, A. B.; Markmann, J. F.] Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Div Transplantat, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 635 BP 398 EP 398 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402029 ER PT J AU Martins, PN Mcdaid, J Hertl, M Kawai, T Chung, R Markmann, JF AF Martins, P. N. Mcdaid, J. Hertl, M. Kawai, T. Chung, R. Markmann, J. F. TI Heat-Stroke as a Cause of Liver Failure and Evaluation for Liver Transplant SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Martins, P. N.; Mcdaid, J.; Hertl, M.; Kawai, T.; Markmann, J. F.] Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Div Transplantat, Boston, MA 02115 USA. [Chung, R.] Harvard Univ, Massachusetts Gen Hosp, Dept Med, Hepatol Div, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1385 BP 413 EP 413 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402063 ER PT J AU Martins, PN Yeh, H Bruinsma, B Izamis, ML Abdelwahed, SA Mcdaid, J Uygun, K Yamursh, M Markmann, JF AF Martins, P. N. Yeh, H. Bruinsma, B. Izamis, M. -L Abdelwahed, S. A. Mcdaid, J. Uygun, K. Yamursh, M. Markmann, J. F. TI Modulation of Ischemia/Reperfusion Injury of Liver Grafts with An Oxygen Carrier (Perfluorocarbon)-Based Preservation Solution SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Martins, P. N.; Yeh, H.; Bruinsma, B.; Izamis, M. -L; Abdelwahed, S. A.; Mcdaid, J.; Uygun, K.; Yamursh, M.; Markmann, J. F.] Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Div Transplantat, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1850 BP 453 EP 453 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402149 ER PT J AU Janec, KJ DeFazio, M Williams, TD Kurtz, JM AF Janec, K. J. DeFazio, M. Williams, T. D. Kurtz, J. M. TI Contribution of Hematopoietically-Derived Progenitors to the Central Nervous System in Mixed Chimeric Mice SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Janec, K. J.; DeFazio, M.; Williams, T. D.; Kurtz, J. M.] Emmanuel Coll, Dept Biol, Boston, MA USA. [Kurtz, J. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kurtz, J. M.] Harvard Med Sch, Transplantat Biol Res Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 2016 BP 456 EP 456 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402157 ER PT J AU Liu, W Xiao, X Demirci, G Madsen, J Li, XC AF Liu, W. Xiao, X. Demirci, G. Madsen, J. Li, X. C. TI Macrophages Licensed by CD4+T Cells Can Recognize and Reject Allogeneic Cells SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Liu, W.] Harvard Med Sch, Brigham & Womens Hosp, Renal, Boston, MA USA. [Xiao, X.; Demirci, G.; Li, X. C.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA. [Madsen, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Madsen, J.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 629 BP 464 EP 464 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402172 ER PT J AU Tonsho, M Kawai, T Boskovic, S Cappetta, K Nadazdin, O Smith, NR Colvin, RB Benichou, G Cosimi, AB Madsen, JC AF Tonsho, M. Kawai, T. Boskovic, S. Cappetta, K. Nadazdin, O. Smith, N. R. Colvin, R. B. Benichou, G. Cosimi, A. B. Madsen, J. C. TI Effect of Kidney Cotransplantation on Induction of Heart Graft Tolerance in Nonhuman Primates (NHPs) SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Tonsho, M.; Kawai, T.; Boskovic, S.; Cappetta, K.; Nadazdin, O.; Benichou, G.; Cosimi, A. B.; Madsen, J. C.] Massachusetts Gen Hosp, Transplant Surg, Boston, MA 02114 USA. [Smith, N. R.; Colvin, R. B.] Massachusetts Gen Hosp, Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 764 BP 466 EP 466 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402177 ER PT J AU Peraino, JCS Zhang, H Hermanrud, C Li, G Schenk, M Duran-Struuk, R Sachs, DH Huang, CA Wang, Z AF Peraino, Stromp J. C. Zhang, H. Hermanrud, C. Li, G. Schenk, M. Duran-Struuk, R. Sachs, D. H. Huang, C. A. Wang, Z. TI Development of a Novel Fusion Toxin Reagent for Targeting Antigen Presenting Cells In Vivo: DT390-CTLA-4 SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Peraino, Stromp J. C.; Zhang, H.; Hermanrud, C.; Li, G.; Schenk, M.; Duran-Struuk, R.; Sachs, D. H.; Huang, C. A.; Wang, Z.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 615 BP 471 EP 471 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402188 ER PT J AU Yamada, Y Boskovic, S Lee, S Tonsho, M Nadazdin, O Smith, NR Colvin, RB Tocco, G Alessandrini, A Madsen, JC Sachs, D Benichou, G Cosimi, BA Kawai, T AF Yamada, Y. Boskovic, S. Lee, S. Tonsho, M. Nadazdin, O. Smith, N. R. Colvin, R. B. Tocco, G. Alessandrini, A. Madsen, J. C. Sachs, D. Benichou, G. Cosimi, B. A. Kawai, T. TI In Vivo IL-2 administration can abolish tolerance to kidney allografts induced via mixed chimerism in non-human primates SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Yamada, Y.; Boskovic, S.; Lee, S.; Tonsho, M.; Nadazdin, O.; Smith, N. R.; Colvin, R. B.; Tocco, G.; Alessandrini, A.; Madsen, J. C.; Sachs, D.; Benichou, G.; Cosimi, B. A.; Kawai, T.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 600 BP 471 EP 471 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402187 ER PT J AU Villani, V Gillon, BC Tasaki, M Hanekamp, I Cormack, TA Moran, S Sachs, DH Yamada, K AF Villani, V. Gillon, B. C. Tasaki, M. Hanekamp, I Cormack, T. A. Moran, S. Sachs, D. H. Yamada, K. TI The Thymus Is Required to Break Tolerance of Renal Allografts in a Miniature Swine Model SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Villani, V.; Gillon, B. C.; Tasaki, M.; Hanekamp, I; Cormack, T. A.; Moran, S.; Sachs, D. H.; Yamada, K.] Harvard Med Sch, Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 770 BP 472 EP 472 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402189 ER PT J AU Gillon, B Scalea, J Cormack, T Villani, V Tasaki, M Moran, S Torabi, R Pathiraja, V Sachs, DH Yamada, K AF Gillon, B. Scalea, J. Cormack, T. Villani, V. Tasaki, M. Moran, S. Torabi, R. Pathiraja, V Sachs, D. H. Yamada, K. TI The Successful Induction of Systemic Tolerance to a Class-I MHC Disparity through Adoptive Transfer in a Large Animal Model SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Gillon, B.; Scalea, J.; Cormack, T.; Villani, V.; Tasaki, M.; Moran, S.; Torabi, R.; Pathiraja, V; Sachs, D. H.; Yamada, K.] Harvard Med Sch, Transplantat Biol Res Ctr, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1302 BP 474 EP 474 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402194 ER PT J AU Le Page, AK Jager, MM Kotton, CN Simoons, AM Rawlinson, WD AF Le Page, A. K. Jager, M. M. Kotton, C. N. Simoons, A. M. Rawlinson, W. D. TI International Survey of Cytomegalovirus (CMV) Management in Solid Organ Transplantation (SOT) Following Publication of Consensus Guidelines SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Le Page, A. K.; Rawlinson, W. D.] Univ New South Wales, Virol Res Lab, Prince Wales Hosp, Randwick, NSW, Australia. [Le Page, A. K.; Rawlinson, W. D.] Univ New South Wales, Sch Med Sci, Fac Med, Kensington, NSW, Australia. [Jager, M. M.; Simoons, A. M.] Vrije Univ Amsterdam, Med Ctr, Dept Med Microbiol & Infect Control, Amsterdam, Netherlands. [Jager, M. M.; Rawlinson, W. D.] Prince Wales Hosp, Div Virol, SEALS Microbiol, Randwick, NSW, Australia. [Kotton, C. N.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1518 BP 542 EP 543 PG 2 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402335 ER PT J AU Duran-Struuck, R Matar, A Crepeau, R Gusha, A Schenk, M Pathiraja, V Hanekamp, I Spitzer, TR Sachs, DH Huang, CA AF Duran-Struuck, R. Matar, A. Crepeau, R. Gusha, A. Schenk, M. Pathiraja, V Hanekamp, I Spitzer, T. R. Sachs, D. H. Huang, C. A. TI Immune Responses Associated with Graft Loss Following Reduced Intensity Haploidentical Hematopoietic Cell Transplantation in a Pre-Clinical Large Animal Model: Lack of Anti-Donor Allo Antibody Response Does not Indicate Lack of Immune Sensitization SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Duran-Struuck, R.; Matar, A.; Crepeau, R.; Gusha, A.; Schenk, M.; Pathiraja, V; Hanekamp, I; Sachs, D. H.; Huang, C. A.] Harvard Med Sch, Massachusetts Gen Hosp, Surg, Boston, MA USA. [Spitzer, T. R.] Harvard Med Sch, Massachusetts Gen Hosp, Internal Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1267 BP 556 EP 556 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402361 ER PT J AU Matar, A Crepeau, R Pathiraja, V Robson, S Fishman, J Spitzer, TR Sachs, DH Huang, C Duran-Struuck, R AF Matar, A. Crepeau, R. Pathiraja, V Robson, S. Fishman, J. Spitzer, T. R. Sachs, D. H. Huang, C. Duran-Struuck, R. TI Impact of Donor Stem Cell Mobilization Reactions on Reduced Intensity Haploidentical HCT Outcomes in Miniature Swine SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Matar, A.; Crepeau, R.; Pathiraja, V; Sachs, D. H.; Huang, C.; Duran-Struuck, R.] Harvard Med Sch, Surg, Transplantat Biol Res Ctr, Massachusetts Gen Hosp, Boston, MA USA. [Robson, S.] Beth Israel Deaconess Med Ctr, Internal Med, Boston, MA USA. [Fishman, J.] Massachusetts Gen Hosp, Infect Dis, Boston, MA 02114 USA. [Spitzer, T. R.] Harvard Med Sch, Massachusetts Gen Hosp, Internal Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1285 BP 556 EP 556 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402362 ER PT J AU Mommeja-Marin, H Marty, F Boeckh, M Winston, D Rowley, SD Godkin, S Margolskee, D AF Mommeja-Marin, H. Marty, F. Boeckh, M. Winston, D. Rowley, S. D. Godkin, S. Margolskee, D. TI CMX001, a Novel Broad Spectrum Antiviral, May Mitigate Signs of BK Virus (BKV) Associated Bladder and Kidney End-Organ Damage SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Mommeja-Marin, H.; Godkin, S.; Margolskee, D.] Chimerix Inc, Durham, NC USA. [Marty, F.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Marty, F.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Boeckh, M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Winston, D.] Univ Calif Los Angeles, Ctr Hlth Sci, Los Angeles, CA 90024 USA. [Rowley, S. D.] Hackensack Univ Med, Hackensack, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 2576 BP 576 EP 576 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402401 ER PT J AU Surman, OS AF Surman, O. S. TI Informed Consent: What the Patient Heard SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Surman, O. S.] Harvard Med Sch, Psychiat, Mass Gen Hosp, Boston, MA USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 2565 BP 615 EP 615 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402479 ER PT J AU Liu, Q Rehman, H Krishnasamy, Y Haque, K Schnellmann, RG Lemasters, JJ Zhong, Z AF Liu, Q. Rehman, H. Krishnasamy, Y. Haque, K. Schnellmann, R. G. Lemasters, J. J. Zhong, Z. TI Role of Amphiregulin in Suppressed Liver Regeneration after Small-For-Size Liver Transplantation in Mice SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Liu, Q.; Rehman, H.; Krishnasamy, Y.; Haque, K.; Schnellmann, R. G.; Lemasters, J. J.; Zhong, Z.] Med Univ South Carolina, Pharmaceut & Biomed Sci, Charleston, SC USA. [Schnellmann, R. G.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 631 BP 649 EP 649 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846402556 ER PT J AU Walters, SN James, C Jung, MH Weinberg, A Cowley, MJ Kaplan, W Hawthorne, WJ O'Connell, PJ Weir, G Grey, ST AF Walters, S. N. James, C. Jung, M. -H. Weinberg, A. Cowley, M. J. Kaplan, W. Hawthorne, W. J. O'Connell, P. J. Weir, G. Grey, S. T. TI A Pre-Existent Hypoxic Gene Signature Predicts Impaired Islet Graft Function and Glucose Homeostasis SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Walters, S. N.; James, C.; Weinberg, A.; Cowley, M. J.; Kaplan, W.; Grey, S. T.] Garvan Inst Med Res, Darlinghurst, NSW, Australia. [Jung, M. -H.; Weir, G.] Joslin Diabet Ctr, Boston, MA 02215 USA. [Hawthorne, W. J.; O'Connell, P. J.] Westmead Hosp, Westmead, NSW, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1411 BP 710 EP 710 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846403089 ER PT J AU Tena, A Germana, S Turcotte, N Barone, AAL Arn, S Terlouw, SL Dobrinsky, JR Mtango, N Verstegen, J Sachs, DH Hawley, RJ AF Tena, A. Germana, S. Turcotte, N. Barone, Leto A. A. Arn, S. Terlouw, S. L. Dobrinsky, J. R. Mtango, N. Verstegen, J. Sachs, D. H. Hawley, R. J. TI Miniature Swine Expressing Human CD47 to Enhance Bone Marrow Engraftment in Non-Human Primates SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Tena, A.] Massachusetts Gen Hosp, Surg, Boston, MA 02114 USA. [Tena, A.] Harvard Med Sch, Surg, Boston, MA USA. [Germana, S.; Turcotte, N.; Barone, Leto A. A.; Arn, S.; Sachs, D. H.; Hawley, R. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Germana, S.; Turcotte, N.; Barone, Leto A. A.; Arn, S.; Sachs, D. H.; Hawley, R. J.] Harvard Med Sch, Boston, MA USA. [Terlouw, S. L.; Dobrinsky, J. R.; Mtango, N.; Verstegen, J.] Minitube Amer, Verona, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1651 BP 776 EP 776 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846403215 ER PT J AU Tasaki, M Shimizu, A Hanekamp, I Torabi, R Villani, V Moran, S Cormack, T Gillon, B Yamada, R Fishman, J Robson, S Sachs, D Yamada, K AF Tasaki, M. Shimizu, A. Hanekamp, I Torabi, R. Villani, V. Moran, S. Cormack, T. Gillon, B. Yamada, R. Fishman, J. Robson, S. Sachs, D. Yamada, K. TI Prevention of Early Development of Proteinuria by Rituximab in a Pig to Baboon Thymokidney Model Likely Associated with Modulating Podocyte Function in An SMPDL-3b-Dependent Manner SO TRANSPLANTATION LA English DT Meeting Abstract C1 [Tasaki, M.; Shimizu, A.; Hanekamp, I; Torabi, R.; Villani, V.; Moran, S.; Cormack, T.; Gillon, B.; Yamada, R.; Fishman, J.; Robson, S.; Sachs, D.; Yamada, K.] Harvard Med Sch, Mass Gen Hosp, Transplantat Biol Res Ctr, Surg, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD NOV 27 PY 2012 VL 94 IS 10 SU S MA 1259 BP 777 EP 777 PG 1 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA V45WJ UT WOS:000209846403217 ER PT J AU Zaman, MS Thamminana, S Shahryari, V Chiyomaru, T Deng, GR Saini, S Majid, S Fukuhara, S Chang, I Arora, S Hirata, H Ueno, K Singh, K Tanaka, Y Dahiya, R AF Zaman, Mohd Saif Thamminana, Sobha Shahryari, Varahram Chiyomaru, Takeshi Deng, Guoren Saini, Sharanjot Majid, Shahana Fukuhara, Shinichiro Chang, Inik Arora, Sumit Hirata, Hiroshi Ueno, Koji Singh, Kamaldeep Tanaka, Yuichiro Dahiya, Rajvir TI Inhibition of PTEN Gene Expression by Oncogenic miR-23b-3p in Renal Cancer SO PLOS ONE LA English DT Article ID CARCINOMA; PROTEIN; MYOFIBROBLASTS; PROGRESSION; MICRORNAS; GENISTEIN; PATHWAY; KINASE; BREAST; CELLS AB Background: miR-23b is located on chromosome number 9 and plays different roles in different organs especially with regards to cancer development. However, the functional significance of miR-23b-3p in renal cell carcinoma (RCC) has not been reported. Methods and Results: We measured miR-23b-3p levels in 29 pairs of renal cell carcinoma and their normal matched tissues using real-time PCR. The expression level of miR-23b-3p was correlated with the 5 year survival rate of renal cancer patients. In 15 cases (52%), miR-23b-3p expression was found to be high. All patients with moderate to low miR-23b-3p expression survived 5 years, while those with high miR-23b-3p expression, only 50% survived. After knocking down miRNA-23b-3p expression in RCC cell lines, there was an induction of apoptosis and reduced invasive capabilities. MiR-23b-3p was shown to directly target PTEN gene through 3'UTR reporter assays. Inhibition of miR-23b-3p induces PTEN gene expression with a concomitant reduction in PI3-kinase, total Akt and IL-32. Immunohistochemistry showed the lack of PTEN protein expression in cancerous regions of tissue samples where the expression of miR-23b-3p was high. We studied the in vitro effects of the dietary chemo preventive agent genistein on miR-23b-3p expression and found that it inhibited expression of miR-23b-3p in RCC cell lines. Conclusions: The current study shows that miR-23b-3p is an oncogenic miRNA and inhibits PTEN tumor suppressor gene in RCC. Therefore, inhibition of miR-23b-3p may be a useful therapeutic target for the treatment of renal cell carcinoma. C1 [Dahiya, Rajvir] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Dahiya, R (reprint author), San Francisco VA Med Ctr, Dept Urol, San Francisco, CA USA. EM rdahiya@urology.ucsf.edu FU VA Merit Review; VA Program Project; NIH [RO1CA130860] FX This study was supported by the VA Merit Review, VA Program Project and NIH Grant RO1CA130860 (PI: R. Dahiya). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 29 TC 35 Z9 36 U1 1 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 26 PY 2012 VL 7 IS 11 AR e50203 DI 10.1371/journal.pone.0050203 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 048RI UT WOS:000311929800064 PM 23189187 ER PT J AU Johansen, KL AF Johansen, Kirsten L. TI The Skinny on Obesity and End-Stage Renal Disease SO ARCHIVES OF INTERNAL MEDICINE LA English DT Editorial Material ID BODY-MASS INDEX; ADOLESCENTS; CHILDREN; RISK C1 San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 4150 Clement St,Box 111J, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu FU NIDDK NIH HHS [HHSN267200700005C]; None [HHSN267200700005C] NR 9 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 26 PY 2012 VL 172 IS 21 BP 1651 EP 1652 DI 10.1001/2013.jamainternmed.917 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 042ZY UT WOS:000311513000009 PM 23108610 ER PT J AU Regan, S Viana, JC Reyen, M Rigotti, NA AF Regan, Susan Viana, Joseph C. Reyen, Michele Rigotti, Nancy A. TI Prevalence and Predictors of Smoking by Inpatients During a Hospital Stay SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID NICOTINE-REPLACEMENT THERAPY; POLICY; ABSTINENCE; SMOKERS AB Background: Accredited US hospitals prohibit smoking inside hospital buildings. Patients are expected to abstain from smoking throughout their hospitalization, but how many do so is unclear. Smoking by inpatients may compromise patient safety, clinical outcomes, and hospital efficiency. Methods: We conducted an observational study of adult cigarette smokers visited by a tobacco counselor while hospitalized and reached for telephone follow-up in the 2 weeks after discharge. We assessed smoking during the hospital stay at the time of counseling for all patients and at follow-up for those reached. We used generalized linear models to estimate adjusted relative risk (ARR) for smoking while hospitalized, adjusted by patient and admission characteristics. Results: From May 1, 2007, through April 31, 2010, counselors visited 5399 smokers, of whom 14.9% had smoked between admission and the visit. Of 3555 eligible smokers who consented to follow-up, 2185 were reached. Smoking at any time during the hospitalization was reported by 18.4%, less often during winter months than the rest of the year (14.4% vs 19.7%, P=.007). Smoking at any time while hospitalized was less common among those 50 years or older (ARR, 0.74; 95% CI, 0.62-0.88), those admitted to a cardiac unit (0.64; 0.51-0.81), and those intending to quit after discharge (0.46; 0.34-0.63) and more common among those with longer stays (1.36; 1.14-1.62) and those experiencing cigarette cravings (moderate: 1.23; 1.14-1.33; severe: 1.25; 1.18-1.34). Nicotine replacement therapy ordered the day of admission was associated with less smoking before the counselor's visit (ARR, 0.83; 95% CI, 0.72-0.96) but not for the entire hospital stay. Conclusions: Nearly one-fifth of smokers admitted to a smoke-free hospital smoked during their hospital stay. Ordering nicotine replacement therapy routinely at admission and ongoing monitoring of patients' cigarette cravings might reduce smoking among admitted patients. C1 [Regan, Susan; Viana, Joseph C.; Reyen, Michele; Rigotti, Nancy A.] Massachusetts Gen Hosp, Div Gen Med, Dept Med, Boston, MA 02114 USA. [Regan, Susan; Viana, Joseph C.; Reyen, Michele; Rigotti, Nancy A.] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Dept Med, Boston, MA 02114 USA. [Regan, Susan; Rigotti, Nancy A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA. [Viana, Joseph C.; Rigotti, Nancy A.] Partners HealthCare, Mongan Inst Hlth Policy, Boston, MA USA. RP Regan, S (reprint author), Massachusetts Gen Hosp, Div Gen Med, Dept Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM sregan@partners.org OI Regan, Susan/0000-0003-0940-2017 FU Nabi Biopharmaceuticals; National Heart Lung and Blood Institute [RC1-HL099668-01, K24-HL08880-10] FX Dr Rigotti reported having received a research grant from Nabi Biopharmaceuticals, having been an unpaid consultant for Pfizer Inc and Alere Wellbeing Inc, and having received royalties for UpToDate Inc for smoking cessation activities.; This project was supported by grants RC1-HL099668-01 and K24-HL08880-10 from the National Heart Lung and Blood Institute. NR 23 TC 4 Z9 4 U1 0 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD NOV 26 PY 2012 VL 172 IS 21 BP 1670 EP 1674 DI 10.1001/2013.jamainternmed.300 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 042ZY UT WOS:000311513000014 PM 23128676 ER PT J AU Lin, NH Becerril, C Giguel, F Novitsky, V Moyo, S Makhema, J Essex, M Lockman, S Kuritzkes, DR Sagar, M AF Lin, Nina H. Becerril, Carlos Giguel, Francoise Novitsky, Vladimir Moyo, Sikhulile Makhema, Joseph Essex, Myron Lockman, Shahin Kuritzkes, Daniel R. Sagar, Manish TI Env sequence determinants in CXCR4-using human immunodeficiency virus type-1 subtype C SO VIROLOGY LA English DT Article DE HIV-1; Subtype C; CCR5; CXCR4; Phylogenetic; Envelope ID SYNCYTIUM-INDUCING PHENOTYPE; N-LINKED GLYCOSYLATION; HIV-1 SUBTYPE; V3 LOOP; CORECEPTOR USAGE; GENETIC SUBTYPES; SOUTH-AFRICA; ENVELOPE GLYCOPROTEIN; DISEASE PROGRESSION; DNA RECOMBINATION AB HIV-1 subtype C (HIV-1C) CXCR4-using virus is isolated infrequently and is poorly characterized. Understanding HIV-1C env characteristics has implications for the clinical use of antiretrovirals that target viral entry. A total of 209 env clones derived from 10 samples with mixed CCR5-(R5), CXCR4-using (X4) or dual-tropic HIV-1C were phenotyped for coreceptor usage. Intra-patient X4 and R5 variants generally formed distinct monophyletic phylogenetic clusters. X4 compared to R5 envs had significantly greater amino acid variability and insertions, higher net positive charge, fewer glycosylation sites and increased basic amino acid substitutions in the GPGQ crown. Basic amino acid substitution and/or insertion prior to the crown are highly sensitive characteristics for predicting X4 viruses. Chimeric env functional studies suggest that the V3 loop is necessary but often not sufficient to impart CXCR4 utilization. Our studies provide insights into the unique genotypic characteristics of X4 variants in HIV-1C. (C) 2012 Elsevier Inc. All rights reserved. C1 [Lin, Nina H.; Becerril, Carlos; Giguel, Francoise] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Lin, Nina H.; Lockman, Shahin; Kuritzkes, Daniel R.; Sagar, Manish] Harvard Univ, Sch Med, Boston, MA USA. [Giguel, Francoise; Lockman, Shahin; Kuritzkes, Daniel R.; Sagar, Manish] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Novitsky, Vladimir; Essex, Myron; Lockman, Shahin] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. [Novitsky, Vladimir; Moyo, Sikhulile; Makhema, Joseph; Essex, Myron; Lockman, Shahin] Botswana Harvard AIDS Inst, Gaborone, Botswana. RP Sagar, M (reprint author), Boston Univ, Dept Med, Div Infect Dis, 650 Albany St,Room 647, Boston, MA 02118 USA. EM msagar@bu.edu OI Sagar, Manish/0000-0001-9803-6594; Moyo, Sikhulile/0000-0003-3821-4592 FU Harvard Center for AIDS Research (CFAR) Scholar Award; Hearst Fund; Burroughs-Wellcome ASTMH Research Fellowship; NIH [RR016482, R37 AI055357, U01 AI068636, AI1077473] FX Dr. Lin was supported by the Harvard Center for AIDS Research (CFAR) Scholar Award, Hearst Fund and Burroughs-Wellcome ASTMH Research Fellowship. This work was supported by NIH Grants RR016482, R37 AI055357 and U01 AI068636 (an ACTG Virology Support contract) to D.R.K. and AI1077473 to M.S. NR 67 TC 12 Z9 12 U1 0 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD NOV 25 PY 2012 VL 433 IS 2 BP 296 EP 307 DI 10.1016/j.virol.2012.08.013 PG 12 WC Virology SC Virology GA 024FS UT WOS:000310095700003 PM 22954962 ER PT J AU Archary, D Rong, R Gordon, ML Boliar, S Madiga, M Gray, ES Dugast, AS Hermanus, T Goulder, PJR Coovadia, HM Werner, L Morris, L Alter, G Derdeyn, CA Ndung'u, T AF Archary, Derseree Rong, Rong Gordon, Michelle L. Boliar, Saikat Madiga, Maphuti Gray, Elin S. Dugast, Anne-Sophie Hermanus, Tandile Goulder, Philip J. R. Coovadia, Hoosen M. Werner, Lise Morris, Lynn Alter, Galit Derdeyn, Cynthia A. Ndung'u, Thumbi TI Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection SO VIROLOGY LA English DT Article DE HIV-1 subtype C; Neutralizing antibodies; Binding antibodies; Chronic infection ID IMMUNODEFICIENCY-VIRUS TYPE-1; FC-GAMMA-R; DISEASE PROGRESSION; MONOCLONAL-ANTIBODIES; VIRAL LOAD; ENV CLONES; ENVELOPE; RESPONSES; GLYCOSYLATION; VARIANTS AB Neutralizing (nAbs) and high affinity binding antibodies may be critical for an efficacious HIV-1 vaccine. We characterized virus-specific nAbs and binding antibody responses over 21 months in eight HIV-1 subtype C chronically infected individuals with heterogeneous rates of disease progression. Autologous nAb titers of study exit plasma against study entry viruses were significantly higher than contemporaneous responses at study entry (p=0.002) and exit (p=0.01). NAb breadth and potencies against subtype C viruses were significantly higher than for subtype A (p=0.03 and p=0.01) or B viruses (p=0.03; p=0.05) respectively. Gp41-IgG binding affinity was higher than gp120-IgG (p=0.0002). IgG-Fc gamma R1 affinity was significantly higher than Fc gamma RIIIa (p<0.005) at study entry and Fc gamma RIIb (p<0.05) or Fc gamma RIIIa (p<0.005) at study exit. Evolving IgG binding suggests alteration of immune function mediated by binding antibodies. Evolution of nAbs was a potential marker of HIV-1 disease progression. (C) 2012 Elsevier Inc. All rights reserved. C1 [Archary, Derseree; Gordon, Michelle L.; Coovadia, Hoosen M.; Ndung'u, Thumbi] Univ KwaZulu Natal, Doris Duke Med Res Inst, Nelson R Mandela Sch Med, HIV Pathogenesis Programme, ZA-4001 Durban, South Africa. [Archary, Derseree; Werner, Lise] Univ KwaZulu Natal, Ctr AIDS Programme Res S Africa, ZA-4001 Durban, South Africa. [Rong, Rong] Jiaotong Liverpool Univ XJTLU, Suzhou, Peoples R China. [Boliar, Saikat; Derdeyn, Cynthia A.] Emory Vaccine Ctr, Dept Pathol & Lab Med, Atlanta, GA USA. [Madiga, Maphuti; Hermanus, Tandile; Morris, Lynn] NICD, Johannesburg, South Africa. [Gray, Elin S.] Sir Charles Gairdner Hosp, Canc Council Clin Canc Res, Nedlands, WA, Australia. [Gray, Elin S.] Univ Western Australia, Nedlands, WA 6009, Australia. [Dugast, Anne-Sophie; Alter, Galit] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Boston, MA USA. [Goulder, Philip J. R.] Univ Oxford, Peter Medawar Bldg Pathogen Res, Dept Paediat, Oxford, England. RP Ndung'u, T (reprint author), Univ KwaZulu Natal, Doris Duke Med Res Inst, Nelson R Mandela Sch Med, HIV Pathogenesis Programme, Private Bag X7, ZA-4001 Durban, South Africa. EM ndungu@ukzn.ac.za RI Dugast, AnneSophie/L-9541-2015; OI , Lynn/0000-0003-3961-7828; Ndung'u, Thumbi/0000-0003-2962-3992; Gray, Elin/0000-0002-8613-3570 FU Howard Hughes Medical Institute; Hasso Plattner Foundation; South African Department of Science and Technology/National Research Foundation Research Chair Initiative; Columbia University-Southern African Fogarty AIDS International Training and Research Program; Fogarty International Center, NIH [D43TW00231]; NIH [R01 AI-58706] FX This work was supported by the Howard Hughes Medical Institute, the Hasso Plattner Foundation and the South African Department of Science and Technology/National Research Foundation Research Chair Initiative. D.A. was supported by the Columbia University-Southern African Fogarty AIDS International Training and Research Program funded by the Fogarty International Center, NIH (grant #D43TW00231) and NIH R01 AI-58706 to C.A.D. NR 70 TC 0 Z9 0 U1 1 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD NOV 25 PY 2012 VL 433 IS 2 BP 410 EP 420 DI 10.1016/j.virol.2012.08.033 PG 11 WC Virology SC Virology GA 024FS UT WOS:000310095700015 PM 22995189 ER PT J AU Hightower, GK Wong, JK Letendre, SL Umlauf, AA Ellis, RJ Ignacio, CC Heaton, RK Collier, AC Marra, CM Clifford, DB Gelman, BB McArthur, JC Morgello, S Simpson, DM McCutchan, JA Grant, I Little, SJ Richman, DD Pond, SLK Smith, DM AF Hightower, George K. Wong, Joseph K. Letendre, Scott L. Umlauf, Anya A. Ellis, Ronald J. Ignacio, Caroline C. Heaton, Robert K. Collier, Ann C. Marra, Christina M. Clifford, David B. Gelman, Benjamin B. McArthur, Justin C. Morgello, Susan Simpson, David M. McCutchan, J. A. Grant, Igor Little, Susan J. Richman, Douglas D. Pond, Sergei L. Kosakovsky Smith, Davey M. CA CHARTER Study Grp TI Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment SO VIROLOGY LA English DT Article DE HIV; AIDS; Genetic diversity; Neuropsychological impairment; Viral population dynamics ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIRETROVIRAL THERAPY; CEREBROSPINAL-FLUID; NEUROCOGNITIVE DISORDERS; POSITIVE SELECTION; PRIMARY INFECTION; RNA VIRUS; EVOLUTION; ESCAPE; DISEASE AB Standard methods used to estimate HIV-1 population diversity are often resource intensive (e.g., single genome amplification, clonal amplification and pyrosequencing) and not well suited for large study cohorts. Additional approaches are needed to address the relationships between intraindividual HIV-1 genetic diversity and 2 disease. With a small cohort of individuals, we validated three methods for measuring diversity: Shannon entropy and average pairwise distance (APD) using single genome sequences, and counts of mixed bases (i.e. ambiguous nucleotides) from population based sequences. In a large cohort, we then used the mixed base approach to determine associations between measure HIV-1 diversity and HIV associated disease. Normalized counts of mixed bases correlated with Shannon Entropy at both the nucleotide (rho=0.72, p=0.002) and amino acid level (rho=0.59, p =0.015), and APD (rho=0.75, p=0.001). Among participants who underwent neuropsychological and clinical assessments (n=187), increased HIV-1 population diversity was associated with both a diagnosis of AIDS and neuropsychological impairment. Published by Elsevier Inc. C1 [Hightower, George K.; Letendre, Scott L.; Umlauf, Anya A.; Ellis, Ronald J.; Ignacio, Caroline C.; Heaton, Robert K.; McCutchan, J. A.; Grant, Igor; Little, Susan J.; Richman, Douglas D.; Pond, Sergei L. Kosakovsky; Smith, Davey M.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Wong, Joseph K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Ellis, Ronald J.; Grant, Igor; Richman, Douglas D.; Smith, Davey M.] Vet Affairs San Diego Healthcare Syst San Diego, San Diego, CA USA. [Collier, Ann C.; Marra, Christina M.] Univ Washington, Seattle, WA 98195 USA. [Clifford, David B.] Washington Univ, St Louis, MO USA. [Gelman, Benjamin B.] Univ Texas Galveston, Med Branch, Galveston, TX 77555 USA. [McArthur, Justin C.] Johns Hopkins Univ, Baltimore, MD USA. [Morgello, Susan; Simpson, David M.] Mt Sinai Sch Med, New York, NY USA. [CHARTER Study Grp] Univ Calif San Diego, CNS HIV Antiretroviral Therapy Effects Res, San Diego, CA 92103 USA. RP Smith, DM (reprint author), Univ Calif San Diego, 9500 Gilman Dr 0679, La Jolla, CA 92093 USA. EM davey@ucsd.edu RI Pond, Sergei/G-9830-2012; Ellis, Ronald/K-3543-2015 OI Pond, Sergei/0000-0003-4817-4029; Ellis, Ronald/0000-0003-4931-752X FU Pendleton Foundation; National Institutes of Health [DA12065, DA034978, MH083552, AI077304, AI69432, MH62512, AI27670, AI38858, AI43638, AI43752, AI047745, NS51132]; UCSD Centers for AIDS Research Translational Virology Core [AI36214, AI29164, AI47745, AI64086, AI57167]; San Diego Veterans Affairs Healthcare System FX This work was supported by the Pendleton Foundation and National Institutes of Health Grants DA12065, DA034978, MH083552, AI077304, AI69432, MH62512, AI27670, AI38858, AI43638, AI43752, AI047745, NS51132, UCSD Centers for AIDS Research Translational Virology Core AI36214, AI29164, AI47745, AI64086, AI57167 and San Diego Veterans Affairs Healthcare System. NR 38 TC 4 Z9 4 U1 0 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD NOV 25 PY 2012 VL 433 IS 2 BP 498 EP 505 DI 10.1016/j.virol.2012.08.028 PG 8 WC Virology SC Virology GA 024FS UT WOS:000310095700024 PM 22999095 ER PT J AU Ahonkhai, AA Bassett, IV Ferris, TG Freedberg, KA AF Ahonkhai, Aima A. Bassett, Ingrid V. Ferris, Timothy G. Freedberg, Kenneth A. TI Improving HIV outcomes in resource-limited countries: the importance of quality indicators SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE HIV/AIDS; Resource-poor; Quality indicator; Quality improvement ID ANTIRETROVIRAL THERAPY PROGRAMS; SUB-SAHARAN AFRICA; LOW-INCOME COUNTRIES; OF-LIFE ASSESSMENT; SOUTH-AFRICA; FOLLOW-UP; PATIENT SATISFACTION; HEALTH-CARE; HIV-1-INFECTED PATIENTS; COLLABORATIVE ANALYSIS AB Background: Resource-limited countries increasingly depend on quality indicators to improve outcomes within HIV treatment programs, but indicators of program performance suitable for use at the local program level remain underdeveloped. Methods: Using the existing literature as a guide, we applied standard quality improvement (QI) concepts to the continuum of HIV care from HIV diagnosis, to enrollment and retention in care, and highlighted critical service delivery process steps to identify opportunities for performance indicator development. We then identified existing indicators to measure program performance, citing examples used by pivotal donor agencies, and assessed their feasibility for use in surveying local program performance. Clinical delivery steps without existing performance measures were identified as opportunities for measure development. Using National Quality Forum (NQF) criteria as a guide, we developed measurement concepts suitable for use at the local program level that address existing gaps in program performance assessment. Results: This analysis of the HIV continuum of care identified seven critical process steps providing numerous opportunities for performance measurement. Analysis of care delivery process steps and the application of NQF criteria identified 24 new measure concepts that are potentially useful for improving operational performance in HIV care at the local level. Conclusion: An evidence-based set of program-level quality indicators is critical for the improvement of HIV care in resource-limited settings. These performance indicators should be utilized as treatment programs continue to grow. C1 [Ahonkhai, Aima A.; Bassett, Ingrid V.; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA. [Ahonkhai, Aima A.; Bassett, Ingrid V.; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA. [Ferris, Timothy G.] Partners Healthcare, Boston, MA 02114 USA. [Freedberg, Kenneth A.] Harvard Univ, Ctr AIDS Res, Boston, MA 02115 USA. RP Ahonkhai, AA (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 50 Staniford St,9th Floor, Boston, MA 02114 USA. EM aahonkhai@partners.org FU National Institutes of Allergy and Infectious Disease [T32 AI 007433, K23 AI 068458, R01 AI058736]; National Institute of Mental Health [R01 MH090326] FX This work was supported in part by National Institutes of Allergy and Infectious Disease (T32 AI 007433, K23 AI 068458, R01 AI058736) and the National Institute of Mental Health (R01 MH090326). NR 102 TC 6 Z9 6 U1 3 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD NOV 24 PY 2012 VL 12 AR 427 DI 10.1186/1472-6963-12-427 PG 12 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 063XJ UT WOS:000313035100001 PM 23176556 ER PT J AU Didovyk, A Verdine, GL AF Didovyk, Andriy Verdine, Gregory L. TI Structural Origins of DNA Target Selection and Nucleobase Extrusion by a DNA Cytosine Methyltransferase SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID NUCLEIC-ACID STRUCTURES; HHAI METHYLTRANSFERASE; SOFTWARE; MECHANISM; VISUALIZATION; METHYLATION; SYSTEM; IDENTIFICATION; RECOGNITION; CATALYSIS AB Epigenetic methylation of cytosine residues in DNA is an essential element of genome maintenance and function in organisms ranging from bacteria to humans. DNA 5-cytosine methyltransferase enzymes (DCMTases) catalyze cytosine methylation via reaction intermediates in which the DNA is drastically remodeled, with the target cytosine residue extruded from the DNA helix and plunged into the active site pocket of the enzyme. We have determined a crystal structure of M.HaeIII DCMTase in complex with its DNA substrate at a previously unobserved state, prior to extrusion of the target cytosine and frameshifting of the DNA recognition sequence. The structure reveals that M.HaeIII selects the target cytosine and destabilizes its base-pairing through a precise, focused, and coordinated assault on the duplex DNA, which isolates the target cytosine from its nearest neighbors and thereby facilitates its extrusion from DNA. C1 [Verdine, Gregory L.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Didovyk, Andriy; Verdine, Gregory L.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA. [Verdine, Gregory L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA. [Verdine, Gregory L.] Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA. [Verdine, Gregory L.] Dana Farber Canc Inst, Chem Biol Initiat, Boston, MA 02115 USA. RP Verdine, GL (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, 12 Oxford St, Cambridge, MA 02138 USA. EM gregory_verdine@harvard.edu FU National Institutes of Health Grant [GM044853]; National Center for Research Resources at the National Institutes of Health [RR-15301]; National Institutes of Health from the NCI [Y1-CO-1020]; National Institutes of Health from the NIGMS [Y1-GM-1104]; United States Department of Energy (U.S. DOE) [DE-AC02-06CH11357]; U.S. DOE, Basic Energy Sciences, Office of Science [W-31-109-ENG-38] FX This work was supported, in whole or in part, by National Institutes of Health Grant GM044853 (to G. L. V.). This work is based upon research conducted at the Advanced Photon Source on the NE-CAT and GM/CA-CAT beamlines. NE-CAT is supported by award RR-15301 from the National Center for Research Resources at the National Institutes of Health. GM/CA-CAT was supported, in whole or in part, by National Institutes of Health Grants Y1-CO-1020 from the NCI and Y1-GM-1104 from the NIGMS. Use of the Advanced Photon Source was supported by the United States Department of Energy (U.S. DOE) under Contract DE-AC02-06CH11357 and by the U.S. DOE, Basic Energy Sciences, Office of Science, under Contract W-31-109-ENG-38. NR 31 TC 0 Z9 1 U1 0 U2 10 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 23 PY 2012 VL 287 IS 48 BP 40099 EP 40105 DI 10.1074/jbc.M112.413054 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 042CM UT WOS:000311448800001 PM 23012373 ER PT J AU Chintala, H Liu, HB Parmar, R Kamalska, M Kim, YJ Lovett, D Grant, MB Chaqour, B AF Chintala, Hembindu Liu, Haibo Parmar, Rahul Kamalska, Monika Kim, Yoon Ji Lovett, David Grant, Maria B. Chaqour, Brahim TI Connective Tissue Growth Factor Regulates Retinal Neovascularization through p53 Protein-dependent Transactivation of the Matrix Metalloproteinase (MMP)-2 Gene SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PROLIFERATIVE DIABETIC-RETINOPATHY; VASCULAR ENDOTHELIAL-CELLS; ANGIOGENESIS IN-VIVO; MATRIX-METALLOPROTEINASE-2 MMP-2; EXTRACELLULAR-MATRIX; FACTOR CYR61; ISCHEMIA; MICE; CCN; PREMATURITY AB Pathological angiogenesis in the retina is driven by dysregulation of hypoxia-driven stimuli that coordinate physiological vessel growth. How the various components of the neovascularization signaling network are integrated to yield pathological changes has not been defined. Connective tissue growth factor (CTGF/CCN2) is an inducible matricellular protein that plays a major role in fibroproliferative disorders. Here, we show that CTGF/CCN2 was dynamically expressed in the developing murine retinal vasculature and was abnormally increased and localized within neovascular tufts in the mouse eye with oxygen-induced retinopathy. Consistent with its propitious vascular localization, ectopic expression of the CTGF/CCN2 gene further accelerated neovascularization, whereas lentivirus-mediated loss-of-function or -expression of CTGF/CCN2 harnessed ischemia-induced neovessel outgrowth in oxygen-induced retinopathy mice. The neovascular effects of CTGF/CCN2 were mediated, at least in part, through increased expression and activity of matrix metalloproteinase (MMP)-2, which drives vascular remodeling through degradation of matrix and non matrix proteins, migration and invasion of endothelial cells, and formation of new vascular patterns. In cultured cells, CTGF/CCN2 activated the MMP-2 promoter through increased expression and tethering of the p53 transcription factor to a highly conserved p53-binding sequence within the MMP-2 promoter. Concordantly, the neovascular effects of CTGF/CCN2 were suppressed by p53 inhibition that culminated in reduced enrichment of the MMP-2 promoter with p53 and decreased MMP-2 gene expression. Our data identified new gene targets and downstream effectors of CTGF/CCN2 and provided the rational basis for targeting the p53 pathway to curtail the effects of CTGF/CCN2 on neovessel formation associated with ischemic retinopathy. C1 [Chintala, Hembindu; Liu, Haibo; Parmar, Rahul; Kamalska, Monika; Kim, Yoon Ji; Chaqour, Brahim] Suny Downstate Med Ctr, Dept Cell Biol, SUNY Eye Inst, Brooklyn, NY 11203 USA. [Chaqour, Brahim] Suny Downstate Med Ctr, Dept Ophthalmol, Brooklyn, NY 11203 USA. [Lovett, David] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Grant, Maria B.] Univ Florida, Dept Pharmacol, Gainesville, FL 32610 USA. [Grant, Maria B.] Univ Florida, Dept Therapeut, Gainesville, FL 32610 USA. RP Chaqour, B (reprint author), Suny Downstate Med Ctr, Dept Cell Biol, SUNY Eye Inst, 450 Clarkson Ave,Box 5, Brooklyn, NY 11203 USA. EM bchaqour@downstate.edu FU National Institutes of Health [EY022091-01, EY019387-01A1]; NEI [DK39776] FX This work was supported, in whole or in part, by National Institutes of Health Grants EY022091-01 and EY019387-01A1 (to B. C.) and DK39776 (to D. L.) from NEI. NR 69 TC 19 Z9 19 U1 0 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 23 PY 2012 VL 287 IS 48 BP 40570 EP 40585 DI 10.1074/jbc.M112.386565 PG 16 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 042CM UT WOS:000311448800047 PM 23048035 ER PT J AU Brautigam, H Steele, JW Westaway, D Fraser, PE St George-Hyslop, PH Gandy, S Hof, PR Dickstein, DL AF Brautigam, Hannah Steele, John W. Westaway, David Fraser, Paul E. St George-Hyslop, Peter H. Gandy, Sam Hof, Patrick R. Dickstein, Dara L. TI The isotropic fractionator provides evidence for differential loss of hippocampal neurons in two mouse models of Alzheimer's disease SO MOLECULAR NEURODEGENERATION LA English DT Article DE Alzheimer's disease; Mouse models; Amyloid beta (A beta); Isotropic fractionator; Neuronal loss ID AMYLOID-BETA OLIGOMERS; TRANSGENIC MICE; ACCUMULATION; BRAIN; TAU AB Background: The accumulation of amyloid beta (A beta) oligomers or fibrils is thought to be one of the main causes of synaptic and neuron loss, believed to underlie cognitive dysfunction in Alzheimer's disease (AD). Neuron loss has rarely been documented in amyloid precursor protein (APP) transgenic mouse models. We investigated whether two APP mouse models characterized by different folding states of amyloid showed different neuronal densities using an accurate method of cell counting. Findings: We examined total cell and neuronal populations in Swedish/Indiana APP mutant mice (TgCRND8) with severe A beta pathology that includes fibrils, plaques, and oligomers, and Dutch APP mutant mice with only A beta oligomer pathology. Using the isotropic fractionator, we found no differences from control mice in regional total cell populations in either TgCRND8 or Dutch mice. However, there were 31.8% fewer hippocampal neurons in TgCRND8 compared to controls, while no such changes were observed in Dutch mice. Conclusions: We show that the isotropic fractionator is a convenient method for estimating neuronal content in milligram quantities of brain tissue and represents a useful tool to assess cell loss efficiently in transgenic models with different types of neuropathology. Our data support the hypothesis that TgCRND8 mice with a spectrum of A beta plaque, fibril, and oligomer pathology exhibit neuronal loss whereas Dutch mice with only oligomers, showed no evidence for neuronal loss. This suggests that the combination of plaques, fibrils, and oligomers causes more damage to mouse hippocampal neurons than A beta oligomers alone. C1 [Brautigam, Hannah; Hof, Patrick R.; Dickstein, Dara L.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA. [Brautigam, Hannah; Steele, John W.; Gandy, Sam; Hof, Patrick R.; Dickstein, Dara L.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Gandy, Sam] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Brautigam, Hannah; Gandy, Sam; Hof, Patrick R.; Dickstein, Dara L.] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Steele, John W.; Gandy, Sam] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Steele, John W.] Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10065 USA. [Westaway, David] Univ Alberta, Ctr Prions & Prot Folding Dis, Edmonton, AB T6G 2M8, Canada. [Fraser, Paul E.; St George-Hyslop, Peter H.] Univ Toronto, Dept Med Biophys, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada. [Fraser, Paul E.; St George-Hyslop, Peter H.] Univ Toronto, Dept Med Neurol, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada. [St George-Hyslop, Peter H.] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England. [Dickstein, Dara L.] Leon & Norma Hess Ctr Sci & Med, Dept Neurosci, New York, NY 10029 USA. RP Dickstein, DL (reprint author), Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA. EM dara.dickstein@mssm.edu RI Dickstein, Dara/F-3036-2013 FU NIH [P50 AG05138, P01 AG10491, F31 AG039890]; Canadian Institutes of Health Research [MOP-115056]; Alberta Heritage Foundation for Medical Research; Wellcome Trust; Medical Research Council; Howard Hughes Medical Institute; Alzheimer Society of Ontario FX This work was supported by NIH grants P50 AG05138 (DLD, SG, PRH), P01 AG10491 (SG), and F31 AG039890 (HB). Support was also provided by the Canadian Institutes of Health Research (MOP-115056, PEF and PHH), Alberta Heritage Foundation for Medical Research (DW), and the Wellcome Trust, Medical Research Council, Howard Hughes Medical Institute, and Alzheimer Society of Ontario (PHH). We would like to thank the members of the Ehrlich, Gandy, and Hof laboratories for help and discussion, and Dr Suzana Herculano-Houzel (Federal University of Rio de Janeiro) for introducing us to the isotropic fractionator. We would like to acknowledge Dr Camilla Butti (Icahn School of Medicine at Mount Sinai) for her help with optimizing the isotropic fractionator protocol. NR 17 TC 8 Z9 8 U1 0 U2 8 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1750-1326 J9 MOL NEURODEGENER JI Mol. Neurodegener. PD NOV 22 PY 2012 VL 7 AR 58 DI 10.1186/1750-1326-7-58 PG 5 WC Neurosciences SC Neurosciences & Neurology GA 075LT UT WOS:000313888500001 PM 23173713 ER PT J AU Chen, K Nishi, H Travers, R Tsuboi, N Martinod, K Wagner, DD Stan, R Croce, K Mayadas, TN AF Chen, Kan Nishi, Hiroshi Travers, Richard Tsuboi, Naotake Martinod, Kimberly Wagner, Denisa D. Stan, Radu Croce, Kevin Mayadas, Tanya N. TI Endocytosis of soluble immune complexes leads to their clearance by Fc gamma RIIIB but induces neutrophil extracellular traps via Fc gamma RIIA in vivo SO BLOOD LA English DT Article ID GPI-ANCHORED PROTEINS; ACTIN POLYMERIZATION; COPY NUMBER; INDEPENDENT ENDOCYTOSIS; RECEPTOR; RECRUITMENT; MECHANISM; PHAGOCYTOSIS; ACTIVATION; PATHWAYS AB Soluble immune complexes (ICs) are abundant in autoimmune diseases, yet neutrophil responses to these soluble humoral factors remain uncharacterized. Moreover, the individual role of the uniquely human Fc gamma RIIA and glycophos-phatidylinositol (GPI)-linked Fc gamma RIIIB in IC-mediated inflammation is still debated. Here we exploited mice and cell lines expressing these human neutrophil Fc gamma Rs to demonstrate that Fc gamma RIIIB alone, in the absence of its known signaling partners Fc gamma RIIA and the integrin Mac-1, internalizes soluble ICs through a mechanism used by GPI-anchored receptors and fluid-phase endocytosis. Fc gamma RIIA also uses this pathway. As shown by intravital microscopy, Fc gamma RIIA but not Fc gamma RIIIB-mediated neutrophil interactions with extravascular soluble ICs results in the formation of neutrophil extracellular traps (NETs) in tissues. Unexpectedly, in wildtype mice, IC-induced NETosis does not rely on the NADPH oxidase, myeloperoxidase, or neutrophil elastase. In the context of soluble ICs present primarily within vessels, Fc gamma RIIIB-mediated neutrophil recruitment requires Mac-1 and is associated with the removal of intravascular IC deposits. Collectively, our studies assign a new role for Fc gamma RIIIB in the removal of soluble ICs within the vasculature that may serve to maintain homeostasis, whereas Fc gamma RIIA engagement of tissue soluble ICs generates NETs, a proinflammatory process linked to autoimmunity. (Blood. 2012;120(22):4421-4431) C1 [Chen, Kan; Nishi, Hiroshi; Tsuboi, Naotake; Mayadas, Tanya N.] Brigham & Womens Hosp, Dept Pathol, Ctr Excellence Vasc Biol, Boston, MA 02115 USA. [Travers, Richard; Croce, Kevin] Brigham & Womens Hosp, Dept Med, Cardiovasc Med Div, Boston, MA 02115 USA. [Martinod, Kimberly; Wagner, Denisa D.] Boston Childrens Hosp, Immune Dis Inst, Boston, MA USA. [Martinod, Kimberly; Wagner, Denisa D.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA. [Martinod, Kimberly] Harvard Univ, Sch Med, Div Med Sci, Grad Program Immunol, Boston, MA 02115 USA. [Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Stan, Radu] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pathol, Hanover, NH 03756 USA. RP Mayadas, TN (reprint author), Brigham & Womens Hosp, Dept Pathol, Ctr Excellence Vasc Biol, 77 Ave Louis Pasteur,NRB 752O, Boston, MA 02115 USA. EM tmayadas@rics.bwh.harvard.edu RI Stan, Radu/E-8876-2011 OI Stan, Radu/0000-0003-2969-1725 FU National Institutes of Health [HL065095, AR050800, HL102101]; Japan Society for the Promotion of Science FX This work was supported by the National Institutes of Health (HL065095 and AR050800, T.N.M.; HL102101, D.D.W.) and the Japan Society for the Promotion of Science (Postdoctoral Fellowship for Research Abroad; H.N.). NR 58 TC 50 Z9 50 U1 2 U2 24 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 22 PY 2012 VL 120 IS 22 BP 4421 EP 4431 DI 10.1182/blood-2011-12-401133 PG 11 WC Hematology SC Hematology GA 064YK UT WOS:000313111300025 PM 22955924 ER PT J AU Cheloufi, S Hochedlinger, K AF Cheloufi, Sihem Hochedlinger, Konrad TI REPRODUCTIVE BIOLOGY Stem cells bear eggs SO NATURE LA English DT Editorial Material C1 [Cheloufi, Sihem; Hochedlinger, Konrad] Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA. [Cheloufi, Sihem; Hochedlinger, Konrad] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Cheloufi, Sihem; Hochedlinger, Konrad] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP Cheloufi, S (reprint author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA. EM khochedlinger@helix.mgh.harvard.edu FU Howard Hughes Medical Institute NR 6 TC 2 Z9 2 U1 1 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD NOV 22 PY 2012 VL 491 IS 7425 BP 535 EP 536 PG 2 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 040RE UT WOS:000311339800037 PM 23172212 ER PT J AU Shah, DI Takahashi-Makise, N Cooney, JD Li, LT Schultz, IJ Pierce, EL Narla, A Seguin, A Hattangadi, SM Medlock, AE Langer, NB Dailey, TA Hurst, SN Faccenda, D Wiwczar, JM Heggers, SK Vogin, G Chen, W Chen, CY Campagna, DR Brugnara, C Zhou, Y Ebert, BL Danial, NN Fleming, MD Ward, DM Campanella, M Dailey, HA Kaplan, J Paw, BH AF Shah, Dhvanit I. Takahashi-Makise, Naoko Cooney, Jeffrey D. Li, Liangtao Schultz, Iman J. Pierce, Eric L. Narla, Anupama Seguin, Alexandra Hattangadi, Shilpa M. Medlock, Amy E. Langer, Nathaniel B. Dailey, Tamara A. Hurst, Slater N. Faccenda, Danilo Wiwczar, Jessica M. Heggers, Spencer K. Vogin, Guillaume Chen, Wen Chen, Caiyong Campagna, Dean R. Brugnara, Carlo Zhou, Yi Ebert, Benjamin L. Danial, Nika N. Fleming, Mark D. Ward, Diane M. Campanella, Michelangelo Dailey, Harry A. Kaplan, Jerry Paw, Barry H. TI Mitochondrial Atpif1 regulates haem synthesis in developing erythroblasts SO NATURE LA English DT Article ID IRON-METABOLISM; ZEBRAFISH; YEAST; FERROCHELATASE; INHIBITOR; TRANSPORT; DEFECTS; PROTEIN; CYTOSOL; ANEMIA AB Defects in the availability of haem substrates or the catalytic activity of the terminal enzyme in haem biosynthesis, ferrochelatase (Fech), impair haem synthesis and thus cause human congenital anaemias(1,2). The interdependent functions of regulators of mitochondrial homeostasis and enzymes responsible for haem synthesis are largely unknown. To investigate this we used zebrafish genetic screens and cloned mitochondrial ATPase inhibitory factor 1 (atpif1) from a zebrafish mutant with profound anaemia, pinotage (pnt (tq209)). Here we describe a direct mechanism establishing that Atpif1 regulates the catalytic efficiency of vertebrate Fech to synthesize haem. The loss of Atpif1 impairs haemoglobin synthesis in zebrafish, mouse and human haematopoietic models as a consequence of diminished Fech activity and elevated mitochondrial pH. To understand the relationship between mitochondrial pH, redox potential, [2Fe-2S] clusters and Fech activity, we used genetic complementation studies of Fech constructs with or without [2Fe-2S] clusters in pnt, as well as pharmacological agents modulating mitochondrial pH and redox potential. The presence of [2Fe-2S] cluster renders vertebrate Fech vulnerable to perturbations in Atpif1-regulated mitochondrial pH and redox potential. Therefore, Atpif1 deficiency reduces the efficiency of vertebrate Fech to synthesize haem, resulting in anaemia. The identification of mitochondrial Atpif1 as a regulator of haem synthesis advances our understanding of the mechanisms regulating mitochondrial haem homeostasis and red blood cell development. An ATPIF1 deficiency may contribute to important human diseases, such as congenital sideroblastic anaemias and mitochondriopathies. C1 [Shah, Dhvanit I.; Cooney, Jeffrey D.; Schultz, Iman J.; Pierce, Eric L.; Narla, Anupama; Langer, Nathaniel B.; Hurst, Slater N.; Heggers, Spencer K.; Vogin, Guillaume; Chen, Wen; Chen, Caiyong; Ebert, Benjamin L.; Paw, Barry H.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Hematol, Boston, MA 02115 USA. [Takahashi-Makise, Naoko; Li, Liangtao; Seguin, Alexandra; Ward, Diane M.; Kaplan, Jerry] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84312 USA. [Narla, Anupama; Hattangadi, Shilpa M.; Paw, Barry H.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Med,Div Hematol Oncol, Boston, MA 02115 USA. [Hattangadi, Shilpa M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA. [Hattangadi, Shilpa M.] MIT, Cambridge, MA 02142 USA. [Medlock, Amy E.; Dailey, Tamara A.; Dailey, Harry A.] Univ Georgia, Dept Microbiol, Biomed & Hlth Sci Inst, Athens, GA 30602 USA. [Medlock, Amy E.; Dailey, Tamara A.; Dailey, Harry A.] Univ Georgia, Dept Biochem, Biomed & Hlth Sci Inst, Athens, GA 30602 USA. [Medlock, Amy E.; Dailey, Tamara A.; Dailey, Harry A.] Univ Georgia, Dept Mol Biol, Biomed & Hlth Sci Inst, Athens, GA 30602 USA. [Faccenda, Danilo; Campanella, Michelangelo] Univ London Royal Vet Coll, London NW1 0TU, England. [Faccenda, Danilo; Campanella, Michelangelo] UCL, Consortium Mitochondrial Res, London NW1 0TU, England. [Wiwczar, Jessica M.; Danial, Nika N.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. [Campagna, Dean R.; Fleming, Mark D.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. [Brugnara, Carlo] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA. RP Paw, BH (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Hematol, Boston, MA 02115 USA. EM hdailey@uga.edu; jerry.kaplan@path.utah.edu; bpaw@rics.bwh.harvard.edu OI Medlock, Amy/0000-0001-9402-3593 FU Cooley's Anemia Foundation; March of Dimes Foundation; American Heart Association; Dutch National Science Fund; Fondation Soldati pour la Recherche en Cancerologie; Burroughs Welcome Fund; NIDDK; NHLBI FX We thank members of our laboratory (M. Cassim, A. Kaplan, G. Hildick-Smith and H. Anderson) and colleagues (S. L. Alper, K. Pepper and N. S. Trede) for critical review of the manuscript, T. C. Law for pnt adult blood characterization, H. Mulhern for help with the electron microscopy, and Christopher Lawrence and his team for the zebrafish husbandry. This research was supported in part by the Cooley's Anemia Foundation (D.I.S. and C.C.), the March of Dimes Foundation (B.H.P.), the American Heart Association (J.D.C. and A.E.M.), the Dutch National Science Fund (I.J.S.), the Fondation Soldati pour la Recherche en Cancerologie (G.V.), the Burroughs Welcome Fund (N.N.D.), the NIDDK (D.I.S., B.H.P., A.N., J.K., H.A.D. and S.M.H.) and the NHLBI (D.I.S. and B.H.P). NR 30 TC 32 Z9 37 U1 1 U2 19 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0028-0836 J9 NATURE JI Nature PD NOV 22 PY 2012 VL 491 IS 7425 BP 608 EP 612 DI 10.1038/nature11536 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 040RE UT WOS:000311339800055 PM 23135403 ER PT J AU Firth, P Ttendo, S AF Firth, Paul Ttendo, Stephen TI Intensive Care in Low-Income Countries - A Critical Need SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID AFRICA C1 [Firth, Paul] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Ttendo, Stephen] Mbarara Reg Referral Hosp, Dept Anaesthesia & Crit Care, Mbarara, Uganda. RP Firth, P (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. NR 5 TC 15 Z9 15 U1 0 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 22 PY 2012 VL 367 IS 21 BP 1974 EP 1976 DI 10.1056/NEJMp1204957 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 040RI UT WOS:000311340200003 PM 23171093 ER PT J AU Sheridan, RL Schaefer, PW Whalen, M Fagan, S Stoddard, FJ Schneider, JC McConkey, B Cancio, LC AF Sheridan, Robert L. Schaefer, Pamela W. Whalen, Michael Fagan, Shawn Stoddard, Frederick J., Jr. Schneider, Jeffrey C. McConkey, Brock Cancio, Leopoldo C. TI Case 36-2012: Recovery of a 16-Year-Old Girl from Trauma and Burns after a Car Accident SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; SEVERE HEAD-INJURY; QUALITY-OF-LIFE; BRAIN-INJURY; CHILDREN; IRAQ; MULTICENTER; SOLDIERS; MORPHINE; RETURN C1 [Sheridan, Robert L.; Fagan, Shawn] Massachusetts Gen Hosp, Burn Unit, Boston, MA 02114 USA. [Schaefer, Pamela W.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Whalen, Michael] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Sheridan, Robert L.; Fagan, Shawn] Shriners Hosp Children, Burn Unit, Sacramento, CA USA. [Stoddard, Frederick J., Jr.] Shriners Hosp Children, Dept Psychiat, Sacramento, CA USA. [Stoddard, Frederick J., Jr.] Shriners Hosp Children, Dept Prosthet, Sacramento, CA USA. [Schneider, Jeffrey C.] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Cambridge, MA USA. [Sheridan, Robert L.] VA Boston Healthcare Syst, Dept Surg, Boston, MA USA. [Sheridan, Robert L.; Fagan, Shawn] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA. [Schaefer, Pamela W.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA. [Whalen, Michael] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA. [Stoddard, Frederick J., Jr.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Schneider, Jeffrey C.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02115 USA. [Cancio, Leopoldo C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, San Antonio, TX 78229 USA. [Cancio, Leopoldo C.] USA, Inst Surg Res, San Antonio, TX USA. RP Sheridan, RL (reprint author), Massachusetts Gen Hosp, Burn Unit, Boston, MA 02114 USA. NR 34 TC 1 Z9 1 U1 1 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 22 PY 2012 VL 367 IS 21 BP 2027 EP 2037 DI 10.1056/NEJMcpc1200088 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 040RI UT WOS:000311340200012 PM 23171100 ER PT J AU Rosenbaum, L Lamas, D AF Rosenbaum, Lisa Lamas, Daniela TI Residents' Duty Hours - Toward an Empirical Narrative SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID INTERNS WORK HOURS; MORTALITY; REFORM; SLEEP C1 [Rosenbaum, Lisa] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Rosenbaum, Lisa] Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA. [Lamas, Daniela] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA 02114 USA. RP Rosenbaum, L (reprint author), Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. NR 13 TC 25 Z9 25 U1 1 U2 6 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 22 PY 2012 VL 367 IS 21 BP 2044 EP 2049 DI 10.1056/NEJMsr1210160 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 040RI UT WOS:000311340200016 PM 23171102 ER PT J AU Florez, JC AF Florez, Jose C. TI Clinical and Biomarker Changes in Alzheimer's Disease SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID DOWNS-SYNDROME; DEMENTIA C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Florez, JC (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM jcflorez@partners.org NR 4 TC 0 Z9 0 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 22 PY 2012 VL 367 IS 21 BP 2051 EP 2051 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 040RI UT WOS:000311340200019 PM 23171106 ER PT J AU Carrasquillo, R Tian, DQ Krishna, S Pollak, MR Greka, A Schlondorff, J AF Carrasquillo, Robert Tian, Dequan Krishna, Sneha Pollak, Martin R. Greka, Anna Schloendorff, Johannes TI SNF8, a member of the ESCRT-II complex, interacts with TRPC6 and enhances its channel activity SO BMC CELL BIOLOGY LA English DT Article DE Transient receptor potential; Calcium channel; Protein-protein interaction; Calcineurin-NFAT signaling ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; MULTIVESICULAR BODY BIOGENESIS; OPERATED CA2+ INFLUX; PLASMA-MEMBRANE; ENDOTHELIAL-CELLS; TYROSINE PHOSPHORYLATION; RECEPTOR ACTIVATION; LIPID RAFTS; PROTEIN; ENTRY AB Background: Transient receptor potential canonical (TRPC) channels are non-selective cation channels involved in receptor-mediated calcium signaling in diverse cells and tissues. The canonical transient receptor potential 6 (TRPC6) has been implicated in several pathological processes, including focal segmental glomerulosclerosis (FSGS), cardiac hypertrophy, and pulmonary hypertension. The two large cytoplasmic segments of the cation channel play a critical role in the proper regulation of channel activity, and are involved in several protein-protein interactions. Results: Here we report that SNF8, a component of the endosomal sorting complex for transport-II (ESCRT-II) complex, interacts with TRPC6. The interaction was initially observed in a yeast two-hybrid screen using the amino-terminal cytoplasmic domain of TRPC6 as bait, and confirmed by co-immunoprecipitation from eukaryotic cell extracts. The amino-terminal 107 amino acids are necessary and sufficient for the interaction. Overexpression of SNF8 enhances both wild-type and gain-of-function mutant TRPC6-mediated whole-cell currents in HEK293T cells. Furthermore, activation of NFAT-mediated transcription by gain-of-function mutants is enhanced by overexpression of SNF8, and partially inhibited by RNAi mediated knockdown of SNF8. Although the ESCRT-II complex functions in the endocytosis and lysosomal degradation of transmembrane proteins, SNF8 overexpression does not alter the amount of TRPC6 present on the cell surface. Conclusion: SNF8 is novel binding partner of TRPC6, binding to the amino-terminal cytoplasmic domain of the channel. Modulating SNF8 expression levels alters the TRPC6 channel current and can modulate activation of NFAT-mediated transcription downstream of gain-of-function mutant TRPC6. Taken together, these results identify SNF8 as a novel regulator of TRPC6. C1 [Tian, Dequan; Greka, Anna] Massachusetts Gen Hosp, Div Nephrol, Dept Med, Boston, MA 02114 USA. [Carrasquillo, Robert; Krishna, Sneha; Pollak, Martin R.; Schloendorff, Johannes] Beth Israel Deaconess Med Ctr, Div Nephrol, Boston, MA 02215 USA. [Carrasquillo, Robert; Tian, Dequan; Krishna, Sneha; Pollak, Martin R.; Greka, Anna; Schloendorff, Johannes] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Greka, A (reprint author), Massachusetts Gen Hosp, Div Nephrol, Dept Med, 149 13th St,Room 8-102, Boston, MA 02114 USA. EM greka.anna@mgh.harvard.edu; jschlond@bidmc.harvard.edu FU NIH [DK743082, DK080947]; ASN Young Investigator Award; NIH grant [DK59588, DK083511]; Graduate Prize Fellowship from the Harvard University Graduate School of Arts and Sciences; Office of Enrichment Programs at Harvard Medical School; Nephcure Young Investigator Award FX This work was supported by NIH grants DK743082 and DK080947 and an ASN Young Investigator Award (to J.S.), by NIH grant DK59588 (to M.R.P.), a Graduate Prize Fellowship from the Harvard University Graduate School of Arts and Sciences and a grant from the Office of Enrichment Programs at Harvard Medical School (to R.C.), and by a Nephcure Young Investigator Award, an ASN Young Investigator Award and NIH grant DK083511 (to A.G.). We are grateful to Dr. Cecilia Bucci for the HA-SNF8 expression construct and to Dr. Harald Stenmark for the kind gift of anti-SNF8 antibody. We would like to thank Arnolt Ramos for assistance with electrophysiology experiments. We appreciate the assistance of the Beth Israel Deaconess Confocal Imaging Core and the Dana Farber Cancer Center Flow Cytometry Core facilities. We thank the members of the Pollak lab for helpful discussions and suggestions. NR 71 TC 6 Z9 8 U1 1 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2121 J9 BMC CELL BIOL JI BMC Cell Biol. PD NOV 21 PY 2012 VL 13 AR 33 DI 10.1186/1471-2121-13-33 PG 12 WC Cell Biology SC Cell Biology GA 054BE UT WOS:000312318200001 PM 23171048 ER PT J AU Jimenez-Lozano, J Vacas-Jacques, P Anderson, RR Franco, W AF Jimenez-Lozano, Joel Vacas-Jacques, Paulino Anderson, R. Rox Franco, Walfre TI Selective and localized radiofrequency heating of skin and fat by controlling surface distributions of the applied voltage: analytical study SO PHYSICS IN MEDICINE AND BIOLOGY LA English DT Article ID THERMAL THERAPY; HYPERTHERMIA; CANCER; TISSUE; ABLATION; DEVICES AB At low frequencies (hundreds of kHz to a few MHz), local energy absorption is proportional to the conductivity of tissue and the intensity of the internal electric field. At 1 MHz, the electric conductivity ratio between skin and fat is approximately 10; hence, skin would heat more provided the intensity of the electric field is similar in both tissues. It follows that selective and localized heat deposition is only feasible by varying electric fields locally. In this study, we vary local intensities of the internal electric field in skin, fat and muscle by altering its direction through modifying surface distributions of the applied voltage. In addition, we assess the long-term effects of these variations on tissue thermal transport. To this end, analytical solutions of the electric and bioheat equations were obtained using a regular perturbation method. For voltage distributions given by second-and eight-degree functions, the power absorption in fat is much greater than in skin by the electrode center while the opposite is true by the electrode edge. For a sinusoidal function, the absorption in fat varies laterally from greater to lower than in skin, and then this trend repeats from the center to the edge of the electrode. Consequently, zones of thermal confinement selectively develop in the fat layer. Generalizing these functions by parametrization, it is shown that radiofrequency (RF) heating of layered tissues can be selective and precisely localized by controlling the spatial decay, extent and repetition of the surface distribution of the applied voltage. The clinical relevance of our study is to provide a simple, non-invasive method to spatially control the heat deposition in layered tissues. By knowing and controlling the internal electric field, different therapeutic strategies can be developed and implemented. C1 [Franco, Walfre] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA 02114 USA. RP Franco, W (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. EM wfranco@partners.org NR 20 TC 5 Z9 5 U1 0 U2 7 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 0031-9155 J9 PHYS MED BIOL JI Phys. Med. Biol. PD NOV 21 PY 2012 VL 57 IS 22 BP 7555 EP 7578 DI 10.1088/0031-9155/57/22/7555 PG 24 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA 033ZA UT WOS:000310838700024 PM 23104083 ER PT J AU Tsai, PI Wang, MY Kao, HH Cheng, YJ Walker, JA Chen, RH Chien, CT AF Tsai, Pei-I Wang, Manyu Kao, Hsiu-Hua Cheng, Ying-Ju Walker, James A. Chen, Ruey-Hwa Chien, Cheng-Ting TI Neurofibromin Mediates FAK Signaling in Confining Synapse Growth at Drosophila Neuromuscular Junctions SO JOURNAL OF NEUROSCIENCE LA English DT Article ID FOCAL ADHESION KINASE; NF1 TUMOR-SUPPRESSOR; ADENYLYL-CYCLASE; TYPE-1 NEUROFIBROMATOSIS; PROTEIN; PATHWAY; ACTIVATION; PLASTICITY; INTEGRIN; MUTANTS AB Neurofibromatosis type I (NF1), caused by the mutation in the NF1 gene, is characterized by multiple pathological symptoms. Importantly, similar to 50% of NF1 patients also suffer learning difficulty. Although downstream pathways are well studied, regulation of the NF1-encoded neurofibromin protein is less clear. Here, we focused on the pathophysiology of Drosophila NF1 mutants in synaptic growth at neuromuscular junctions. Our analysis suggests that the Drosophila neurofibromin protein NF1 is required to constrain synaptic growth and transmission. NF1 functions downstream of the Drosophila focal adhesion kinase (FAK) Fak56 and physically interacts with Fak56. The N-terminal region of NF1 mediates the interaction with Fak56 and is required for the signaling activity and presynaptic localization of NF1. In presynapses, NF1 acts via the cAMP pathway, but independent of its GAP activity, to restrain synaptic growth. Thus, presynaptic FAK signaling may be disrupted, causing abnormal synaptic growth and transmission in the NF1 genetic disorder. C1 [Tsai, Pei-I; Wang, Manyu; Kao, Hsiu-Hua; Cheng, Ying-Ju; Chien, Cheng-Ting] Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan. [Tsai, Pei-I; Wang, Manyu; Chen, Ruey-Hwa; Chien, Cheng-Ting] Natl Taiwan Univ, Inst Mol Med, Taipei 106, Taiwan. [Walker, James A.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA. [Walker, James A.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02129 USA. [Chen, Ruey-Hwa] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan. RP Chien, CT (reprint author), Acad Sinica, Inst Mol Biol, 128 Acad Rd,Sect 2, Taipei 115, Taiwan. EM ctchien@gate.sinica.edu.tw FU Academia Sinica; National Science Council FX This work was supported by grants from Academia Sinica and the National Science Council to C.-T.C. We thank N.H. Brown, R. Palmer, Y. Zhong, the Developmental Studies Hybridoma Bank, the Drosophila Genomics Resource Center, the Bloomington Drosophila Stock Center, and the Vienna Drosophila RNAi Center for fly stocks and antibodies. We are grateful to S.-P. Lee and S.-P. Tsai at the Institute of Molecular Biology Image Facility for assistance with confocal and electron microscopy. We also thank laboratory members in the laboratories of Drs. Chien and Chen for suggestions. NR 55 TC 7 Z9 7 U1 0 U2 11 PU SOC NEUROSCIENCE PI WASHINGTON PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA SN 0270-6474 J9 J NEUROSCI JI J. Neurosci. PD NOV 21 PY 2012 VL 32 IS 47 BP 16971 EP 16981 DI 10.1523/JNEUROSCI.1756-12.2012 PG 11 WC Neurosciences SC Neurosciences & Neurology GA 041SF UT WOS:000311420800040 PM 23175848 ER PT J AU Zafonte, RD Bagiella, E Ansel, BM Novack, TA Friedewald, WT Hesdorffer, DC Timmons, SD Jallo, J Eisenberg, H Hart, T Ricker, JH Diaz-Arrastia, R Merchant, RE Temkin, NR Melton, S Dikmen, SS AF Zafonte, Ross D. Bagiella, Emilia Ansel, Beth M. Novack, Thomas A. Friedewald, William T. Hesdorffer, Dale C. Timmons, Shelly D. Jallo, Jack Eisenberg, Howard Hart, Tessa Ricker, Joseph H. Diaz-Arrastia, Ramon Merchant, Randall E. Temkin, Nancy R. Melton, Sherry Dikmen, Sureyya S. TI Effect of Citicoline on Functional and Cognitive Status Among Patients With Traumatic Brain Injury Citicoline Brain Injury Treatment Trial (COBRIT) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MILD HEAD-INJURY; CDP-CHOLINE; MULTIPLE OUTCOMES; CLINICAL-TRIALS; FOLLOW-UP; HIPPOCAMPAL; SYMPTOMS; RECOVERY; TBI AB Context Traumatic brain injury (TBI) is a serious public health problem in the United States, yet no treatment is currently available to improve outcome after TBI. Approved for use in TBI in 59 countries, citicoline is an endogenous substance offering potential neuroprotective properties as well as facilitated neurorepair post injury. Objective To determine the ability of citicoline to positively affect functional and cognitive status in persons with complicated mild, moderate, and severe TBI. Design, Setting, and Patients The Citicoline Brain Injury Treatment Trial (COBRIT), a phase 3, double-blind randomized clinical trial conducted between July 20, 2007, and February 4, 2011, among 1213 patients at 8 US level 1 trauma centers to investigate effects of citicoline vs placebo in patients with TBI classified as complicated mild, moderate, or severe. Intervention Ninety-day regimen of daily enteral or oral citicoline (2000 mg) or placebo. Main Outcome Measures Functional and cognitive status, assessed at 90 days using the TBI-Clinical Trials Network Core Battery. A global statistical test was used to analyze the 9 scales of the core battery. Secondary outcomes were functional and cognitive improvement, assessed at 30, 90, and 180 days, and examination of the long-term maintenance of treatment effects. Results Rates of favorable improvement for the Glasgow Outcome Scale-Extended were 35.4% in the citicoline group and 35.6% in the placebo group. For all other scales the rate of improvement ranged from 37.3% to 86.5% in the citicoline group and from 42.7% to 84.0% in the placebo group. The citicoline and placebo groups did not differ significantly at the 90-day evaluation (global odds ratio [OR], 0.98 [95% CI, 0.83-1.15]); in addition, there was no significant treatment effect in the 2 severity subgroups (global OR, 1.14 [95% CI, 0.88-1.49] and 0.89 [95% CI, 0.72-1.49] for moderate/severe and complicated mild TBI, respectively). At the 180-day evaluation, the citicoline and placebo groups did not differ significantly with respect to the primary outcome (global OR, 0.87 [95% CI, 0.72-1.04]). Conclusion Among patients with traumatic brain injury, the use of citicoline compared with placebo for 90 days did not result in improvement in functional and cognitive status. C1 [Zafonte, Ross D.] Harvard Univ, Spaulding Rehabil Hosp Network, Sch Med, Dept Phys Med & Rehabil, Boston, MA 02114 USA. [Zafonte, Ross D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bagiella, Emilia] Mt Sinai Sch Med, Dept Hlth Evidence & Policy, New York, NY USA. [Ansel, Beth M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA. [Novack, Thomas A.; Melton, Sherry] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA. [Friedewald, William T.] Columbia Univ, Dept Biostat, New York, NY USA. [Hesdorffer, Dale C.] Columbia Univ, Dept Epidemiol, New York, NY USA. [Timmons, Shelly D.] Geisinger Med Ctr, Dept Neurosurg, Danville, PA 17822 USA. [Jallo, Jack] Thomas Jefferson Univ, Div Neurotrauma & Crit Care, Philadelphia, PA 19107 USA. [Eisenberg, Howard] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA. [Hart, Tessa] Moss Rehabil Res Inst, Philadelphia, PA USA. [Ricker, Joseph H.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Rockville, MD USA. [Merchant, Randall E.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA. [Temkin, Nancy R.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA. [Dikmen, Sureyya S.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. RP Zafonte, RD (reprint author), Harvard Univ, Spaulding Rehabil Hosp Network, Sch Med, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA. EM rzafonte@partners.org FU National Institute of Child Health and Human Development at Temple University [U01HD042738]; National Institute of Child Health and Human Development at University of Alabama at Birmingham [U01HD042687]; National Institute of Child Health and Human Development at University of Maryland [U01HD042736]; National Institute of Child Health and Human Development at University of Pittsburgh [U01HD042678]; National Institute of Child Health and Human Development at University of Tennessee Health Sciences Center [U01HD042686]; National Institute of Child Health and Human Development at University of Texas Southwestern [U01HD042652]; National Institute of Child Health and Human Development grants at University of Washington [U01HD042653]; National Institute of Child Health and Human Development grants at Virginia Commonwealth University [U01HD042689]; National Institute of Child Health and Human Development grants at Columbia University [Columbia University (U01HD042823] FX This study was supported by National Institute of Child Health and Human Development grants at the following institutions: Temple University (U01HD042738); University of Alabama at Birmingham (U01HD042687); University of Maryland (U01HD042736); University of Pittsburgh (U01HD042678); University of Tennessee Health Sciences Center (U01HD042686); University of Texas Southwestern (U01HD042652); University of Washington (U01HD042653); Virginia Commonwealth University (U01HD042689); and Columbia University (U01HD042823). Ferrer Grupo provided the citicoline and identical placebo used in the study. NR 40 TC 45 Z9 47 U1 4 U2 13 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD NOV 21 PY 2012 VL 308 IS 19 BP 1993 EP 2000 DI 10.1001/jama.2012.13256 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 040AQ UT WOS:000311291400023 PM 23168823 ER PT J AU Bouazoune, K Kingston, RE AF Bouazoune, Karim Kingston, Robert E. TI Chromatin remodeling by the CHD7 protein is impaired by mutations that cause human developmental disorders SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE SNF2H; idiopathic hypogonadotropic hypogonadism; chromodomains ID DNA-BINDING DOMAIN; CHARGE-SYNDROME; KALLMANN-SYNDROME; SWI-SNF; EXTRANUCLEOSOMAL DNA; HISTONE OCTAMER; MOUSE MODEL; NUCLEOSOME; GENE; DROSOPHILA AB Mutations in the CHD7 gene cause human developmental disorders including CHARGE syndrome. Genetic studies in model organisms have further established CHD7 as a central regulator of vertebrate development. Functional analysis of the CHD7 protein has been hampered by its large size. We used a dual-tag system to purify intact recombinant CHD7 protein and found that it is an ATP-dependent nucleosome remodeling factor. Biochemical analyses indicate that CHD7 has characteristics distinct from SWI/SNF- and ISWI-type remodelers. Further investigations show that CHD7 patient mutations have consequences that range from subtle to complete inactivation of remodeling activity, and that mutations leading to protein truncations upstream of amino acid 1899 of CHD7 are likely to cause a hypomorphic phenotype for remodeling. We propose that nucleosome remodeling is a key function for CHD7 during developmental processes and provide a molecular basis for predicting the impact of disease mutations on that function. C1 [Kingston, Robert E.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA. RP Kingston, RE (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. EM kingston@molbio.mgh.harvard.edu FU National Institutes of Health [5R37GM048405-20] FX We thank Joe Garlick for technical assistance; Dr. Daniel Grau for sharing reagents; and Dr. Karim-Jean Armache for sharing helpful expertise about protein purification. This work was supported by National Institutes of Health Grant 5R37GM048405-20. NR 64 TC 25 Z9 26 U1 1 U2 7 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 20 PY 2012 VL 109 IS 47 BP 19238 EP 19243 DI 10.1073/pnas.1213825109 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 049PZ UT WOS:000311997200049 PM 23134727 ER PT J AU Lockwood, WW Zejnullahu, K Bradner, JE Varmus, H AF Lockwood, William W. Zejnullahu, Kreshnik Bradner, James E. Varmus, Harold TI Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE drug development; chromatin ID BROMODOMAIN INHIBITION; C-MYC; TRANSCRIPTION; TUMORIGENESIS; CHROMATIN; LEUKEMIA; BRD4; EXPRESSION; FAMILY; AP-1 AB Bromodomain and extra terminal domain (BET) proteins function as epigenetic signaling factors that associate with acetylated histones and facilitate transcription of target genes. Inhibitors targeting the activity of BET proteins have shown potent antiproliferative effects in hematological cancers through the suppression of c-MYC and downstream target genes. However, as the epigenetic landscape of a cell varies drastically depending on lineage, transcriptional coactivators such as BETs would be expected to have different targets in cancers derived from different cells of origin, and this may influence the activity and mechanism of action of BET inhibitors. To test this hypothesis, we treated a panel of lung adenocarcinoma (LAC) cell lines with the BET inhibitor JQ1 and found that a subset is acutely susceptible to BET inhibition. In contrast to blood tumors, we showthat LAC cells are inhibited by JQ1 through a mechanism independent of cMYC down-regulation. Through gene expression profiling, we discovered that the oncogenic transcription factor FOSL1 and its targets are suppressed by JQ1 in a dose-dependant manner. Knockdown of BRD4 also decreased FOSL1 levels, and inhibition of FOSL1 phenocopied the effects of JQ1 treatment, suggesting that loss of this transcription factor may be partly responsible for the cytotoxic effects of BET inhibition in LAC cells, although ectopic expression of FOSL1 alone did not rescue the phenotype. Together, these findings suggest that BET inhibitors may be useful in solid tumors and that cell-lineage-specific differences in transcriptional targets of BETs may influence the activity of inhibitors of these proteins in different cancer types. C1 [Lockwood, William W.; Zejnullahu, Kreshnik; Varmus, Harold] NHGRI, Canc Biol & Genet Sect, Canc Genet Branch, NIH, Bethesda, MD 20892 USA. [Zejnullahu, Kreshnik] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA. [Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Bradner, James E.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA. RP Lockwood, WW (reprint author), NHGRI, Canc Biol & Genet Sect, Canc Genet Branch, NIH, Bethesda, MD 20892 USA. EM william.lockwood@nih.gov; harold.varmus@nih.gov FU National Institutes of Health Intramural Research Program; Canadian Institutes of Health Research Jean-Francois Saint Denis Fellowship in Cancer Research FX We thank Nancy Colburn and Matthew Young for providing the pFB-FRA1 construct. This work was funded by the National Institutes of Health Intramural Research Program. W. W. L. is supported by the Canadian Institutes of Health Research Jean-Francois Saint Denis Fellowship in Cancer Research. NR 24 TC 120 Z9 120 U1 4 U2 16 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 20 PY 2012 VL 109 IS 47 BP 19408 EP 19413 DI 10.1073/pnas.1216363109 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 049PZ UT WOS:000311997200078 PM 23129625 ER PT J AU Zanoni, BC Sunpath, H Feeney, ME AF Zanoni, Brian C. Sunpath, Henry Feeney, Margaret E. TI Pediatric Response to Second-Line Antiretroviral Therapy in South Africa SO PLOS ONE LA English DT Article ID HIV-INFECTED CHILDREN; PROTEASE INHIBITOR; HIV-1-INFECTED CHILDREN; VERTICAL TRANSMISSION; VIROLOGICAL FAILURE; VIRAL SUPPRESSION; NEVIRAPINE; LOPINAVIR; PHARMACOKINETICS; TUBERCULOSIS AB Background: With improved access to pediatric antiretroviral therapy (ART) in resource-limited settings, more children could experience first-line ART treatment failure. Methods: We performed a retrospective cohort analysis using electronic medical records from HIV-infected children who initiated ART at McCord Hospital's Sinikithemba Clinic in KwaZulu-Natal, South Africa, from August 2003 to December 2010. We analyzed all records from children who began second-line ART due to first-line treatment failure. We used logistic regression to compare viral outcomes in Protease Inhibitor (PI)-based versus Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-based second-line ART, controlling for time on first-line ART, sex, and whether HIV genotyping guided the regimen change. Results: Of the 880 children who initiated ART during this time period, 80 (9.1%) switched to second-line ART due to therapeutic failure of first-line ART after a median of 95 weeks (IQR 65-147 weeks). Eight (10%) of the failures received NNRTI-based second-line ART, all of whom failed a PI-based first-line regimen. Seventy (87.5%) received PI-based second-line ART, all of whom failed a NNRTI-based first-line regimen. Two children (2.5%) received non-standard dual therapy as second-line ART. Six months after switching ART regimens, the viral suppression rate was significantly higher in the PI group (82%) than in the NNRTI group (29%; p = 0.003). Forty-one children (51%) were tested for genotypic resistance prior to switching to second-line ART. There was no significant difference in six month viral suppression (p = 0.38) between children with and without genotype testing. Conclusion: NNRTI-based second-line ART carries a high risk of virologic failure compared to PI-based second-line ART. C1 [Zanoni, Brian C.; Feeney, Margaret E.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Charlestown, MA USA. [Zanoni, Brian C.] Harvard Univ, Sch Med, Boston, MA USA. [Zanoni, Brian C.; Sunpath, Henry; Feeney, Margaret E.] McCord Hosp, Sinikithemba Clin, Durban, South Africa. [Zanoni, Brian C.; Sunpath, Henry; Feeney, Margaret E.] McCord Hosp, Philani Program, Durban, South Africa. [Sunpath, Henry] Nelson Mandela Sch Med, Infect Dis Unit, Durban, South Africa. [Feeney, Margaret E.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA. RP Feeney, ME (reprint author), Ragon Inst Massachusetts Gen Hosp Massachusetts I, Charlestown, MA USA. EM margaret.feeney@ucsf.edu FU NIAID NIH HHS [P30 AI060354, T32 AI052074] NR 35 TC 9 Z9 9 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 20 PY 2012 VL 7 IS 11 AR e49591 DI 10.1371/journal.pone.0049591 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 043II UT WOS:000311535700039 PM 23185373 ER PT J AU Rathi, V Dzara, K Gross, CP Hrynaszkiewicz, I Joffe, S Krumholz, HM Strait, KM Ross, JS AF Rathi, Vinay Dzara, Kristina Gross, Cary P. Hrynaszkiewicz, Iain Joffe, Steven Krumholz, Harlan M. Strait, Kelly M. Ross, Joseph S. TI Sharing of clinical trial data among trialists: a cross sectional survey SO BRITISH MEDICAL JOURNAL LA English DT Article ID NATIONAL-SURVEY; OPEN SCIENCE; AUTHORS; ACCESS; TRANSPARENCY; GENETICS; JOURNALS; IMPROVE; AGENCY AB Objective To investigate clinical trialists' opinions and experiences of sharing of clinical trial data with investigators who are not directly collaborating with the research team. Design and setting Cross sectional, web based survey. Participants Clinical trialists who were corresponding authors of clinical trials published in 2010 or 2011 in one of six general medical journals with the highest impact factor in 2011. Main outcome measures Support for and prevalence of data sharing through data repositories and in response to individual requests, concerns with data sharing through repositories, and reasons for granting or denying requests. Results Of 683 potential respondents, 317 completed the survey (response rate 46%). In principle, 236 (74%) thought that sharing de-identified data through data repositories should be required, and 229 (72%) thought that investigators should be required to share de-identified data in response to individual requests. In practice, only 56 (18%) indicated that they were required by the trial funder to deposit the trial data in a repository; of these 32 (57%) had done so. In all, 149 respondents (47%) had received an individual request to share their clinical trial data; of these, 115 (77%) had granted and 56 (38%) had denied at least one request. Respondents' most common concerns about data sharing were related to appropriate data use, investigator or funder interests, and protection of research subjects. Conclusions We found strong support for sharing clinical trial data among corresponding authors of recently published trials in high impact general medical journals who responded to our survey, including a willingness to share data, although several practical concerns were identified. C1 [Dzara, Kristina; Gross, Cary P.; Ross, Joseph S.] Yale Univ, Sch Med, Gen Internal Med Sect, Dept Med, New Haven, CT 06520 USA. [Gross, Cary P.; Krumholz, Harlan M.; Ross, Joseph S.] Yale Univ, Sch Med, Dept Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT 06510 USA. [Hrynaszkiewicz, Iain] BioMed Cent, London, England. [Joffe, Steven] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Joffe, Steven] Boston Childrens Hosp, Dept Med, Boston, MA USA. [Krumholz, Harlan M.; Strait, Kelly M.; Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA. [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06510 USA. [Krumholz, Harlan M.] Yale Univ, Sch Epidemiol & Publ Hlth, New Haven, CT USA. RP Ross, JS (reprint author), Yale Univ, Sch Med, Gen Internal Med Sect, Dept Med, POB 208093, New Haven, CT 06520 USA. EM joseph.ross@yale.edu OI Hrynaszkiewicz, Iain/0000-0002-9673-5559; Joffe, Steven/0000-0002-0667-7384 FU Yale University School of Medicine Medical Student Research Fellowship; Centers of Medicare and Medicaid Services (CMS); National Heart Lung Blood Institute Cardiovascular Outcomes Center Award [1U01HL105270-02]; National Institute on Aging [K08 AG032886]; American Federation for Aging Research through the Paul B Beeson Career Development Award Program; Medtronic FX This study was not supported by any external grants or funds. VR received support from the Yale University School of Medicine Medical Student Research Fellowship. The five $100 Amazon gift certificates were paid for from JSR's institutional discretionary funds. HMK and JSR receive support from the Centers of Medicare and Medicaid Services (CMS) to develop and maintain hospital performance measures that are used for public reporting. HMK is supported by a National Heart Lung Blood Institute Cardiovascular Outcomes Center Award (1U01HL105270-02). JSR is supported by the National Institute on Aging (K08 AG032886) and by the American Federation for Aging Research through the Paul B Beeson Career Development Award Program.; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; CPG, HMK, and JSR receive research support from Medtronic to develop methods to promote data sharing; CPG and JSR are on a scientific advisory board for FAIR Health, a not-for-profit organisation with the mission to achieve fairness and transparency in healthcare reimbursement; HMK chairs a scientific advisory board for UnitedHealthcare, a health insurance company; SJ is a paid member of a data monitoring committee for Genzyme/Sanofi; no other relationships or activities that could appear to have influenced the submitted work. NR 45 TC 9 Z9 9 U1 0 U2 9 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1756-1833 J9 BRIT MED J JI Br. Med. J. PD NOV 20 PY 2012 VL 345 AR e7570 DI 10.1136/bmj.e7570 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 044GT UT WOS:000311608200005 ER PT J AU Qaseem, A Fihn, SD Williams, S Dallas, P Owens, DK Shekelle, P AF Qaseem, Amir Fihn, Stephan D. Williams, Sankey Dallas, Paul Owens, Douglas K. Shekelle, Paul CA Amer Coll Phys TI Diagnosis of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID CORONARY-ARTERY-DISEASE; BUNDLE-BRANCH-BLOCK; EMISSION COMPUTED-TOMOGRAPHY; INCREMENTAL PROGNOSTIC VALUE; HOSPITAL CARDIAC-ARREST; LEFT-VENTRICULAR MASS; SUPINE EXERCISE ELECTROCARDIOGRAPHY; MYOCARDIAL-PERFUSION SCINTIGRAPHY; ADENOSINE STRESS PERFUSION; MEDICALLY TREATED PATIENTS AB Description: The American College of Physicians (ACP) developed this guideline in collaboration with the American College of Cardiology Foundation (ACCF), American Heart Association (AHA), American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, and Society of Thoracic Surgeons to help clinicians diagnose known or suspected stable ischemic heart disease. Methods: Literature on this topic published before November 2011 was identified by using MEDLINE, Embase, Cochrane CENTRAL, PsychINFO, AMED, and SCOPUS. Searches were limited to human studies published in English. This guideline grades the evidence and recommendations according to a translation of the ACCF/AHA grading system into ACP's clinical practice guidelines grading system. Recommendations: This guideline includes 28 recommendations that address the following issues: the initial diagnosis of the patient who might have stable ischemic heart disease, cardiac stress testing to assess the risk for death or myocardial infarction in patients diagnosed with stable ischemic heart disease, and coronary angiography for risk assessment. Ann Intern Med. 2012; 157: 729-734. C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Univ Penn, Philadelphia, PA 19104 USA. Dept Vet Affairs, Seattle, WA USA. Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA. Stanford Univ, Stanford, CA 94305 USA. Virginia Tech, Caril Sch Med, Roanoke, VA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org FU ACP operating budget FX Financial support for the development of this guideline comes exclusively from the ACP operating budget. NR 127 TC 15 Z9 22 U1 0 U2 8 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 20 PY 2012 VL 157 IS 10 BP 729 EP + DI 10.7326/0003-4819-157-10-201211200-00010 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA 043VZ UT WOS:000311580000018 PM 23165664 ER PT J AU Qaseem, A Fihn, SD Dallas, P Williams, S Owens, DK Shekelle, P AF Qaseem, Amir Fihn, Stephan D. Dallas, Paul Williams, Sankey Owens, Douglas K. Shekelle, Paul CA Amer Coll Phys TI Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID CORONARY-ARTERY-DISEASE; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIAL; LEFT-VENTRICULAR DYSFUNCTION; LONG-TERM SURVIVAL; CONVERTING-ENZYME-INHIBITOR; PLACEBO-CONTROLLED TRIAL; VIRUS-INFECTED PATIENTS; OPTIMAL MEDICAL THERAPY; IN-HOSPITAL MORTALITY AB Description: The American College of Physicians (ACP) developed this guideline with the American College of Cardiology Foundation (ACCF), American Heart Association (AHA), American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, and Society of Thoracic Surgeons to present the available evidence on the management of stable known or suspected ischemic heart disease. Methods: Literature on this topic published before November 2011 was identified by using MEDLINE, Embase, Cochrane CENTRAL, PsychINFO, AMED, and SCOPUS. Searches were limited to human studies published in English. This guideline grades the evidence and recommendations according to a translation of the ACCF/AHA grading system into ACP's clinical practice guidelines grading system. Recommendations: The guideline includes 48 specific recommendations that address the following issues: patient education, management of proven risk factors (dyslipidemia, hypertension, diabetes, physical activity body weight, and smoking), risk factor reduction strategies of unproven benefit, medical therapy to prevent myocardial infarction and death and to relieve symptoms, alternative therapy, revascularization to improve survival and symptoms, and patient follow-up. Ann Intern Med. 2012;157:735-743. C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Univ Penn, Philadelphia, PA 19104 USA. Dept Vet Affairs, Seattle, WA USA. Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA. Stanford Univ, Stanford, CA 94305 USA. Virginia Tech Caril Sch Med, Roanoke, VA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org FU ACP operating budget FX Financial support for the development of this guideline comes exclusively from the ACP operating budget. NR 318 TC 31 Z9 33 U1 0 U2 10 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 20 PY 2012 VL 157 IS 10 BP 735 EP + DI 10.7326/0003-4819-157-10-201211200-00011 PG 31 WC Medicine, General & Internal SC General & Internal Medicine GA 043VZ UT WOS:000311580000019 PM 23165665 ER PT J AU Paltiel, AD Walensky, RP AF Paltiel, A. David Walensky, Rochelle P. TI Home HIV Testing: Good News but Not a Game Changer SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material C1 [Paltiel, A. David] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA. Yale Univ, Sch Management, New Haven, CT 06520 USA. Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA. Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA USA. RP Paltiel, AD (reprint author), Yale Univ, Sch Publ Hlth, 60 Coll St,Room 305, New Haven, CT 06520 USA. EM david.paltiel@yale.edu OI Walensky, Rochelle P./0000-0002-8795-379X FU NIAID NIH HHS [P30 AI060354, R37 AI42006, R37 AI042006]; NIDA NIH HHS [R01 DA015612]; NIMH NIH HHS [R01 MH065869, R01 MH65869] NR 10 TC 11 Z9 12 U1 0 U2 7 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 20 PY 2012 VL 157 IS 10 BP 744 EP + DI 10.7326/0003-4819-157-10-201211200-00545 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 043VZ UT WOS:000311580000020 PM 23044643 ER PT J AU Spitzer, TR AF Spitzer, Thomas R. TI Microtransplantation: A New Paradigm for the Separation of Graft Versus Host Disease and Graft Versus Tumor? SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material ID RECIPIENT LEUKOCYTE INFUSIONS; STEM-CELL TRANSPLANTATION; IFN-GAMMA; CHIMERISM; RESPONSES C1 Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Spitzer, TR (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 12 TC 3 Z9 4 U1 0 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2012 VL 30 IS 33 BP 4051 EP 4052 DI 10.1200/JCO.2012.45.2979 PG 2 WC Oncology SC Oncology GA 040DF UT WOS:000311300000008 PM 23045583 ER PT J AU Mroz, EA Rocco, JW AF Mroz, Edmund A. Rocco, James W. TI Gene Expression Analysis As a Tool in Early-Stage Oral Cancer Management SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material ID ELECTIVE NECK DISSECTION; CLINICALLY NEGATIVE NECK; SQUAMOUS-CELL CARCINOMAS; CAVITY CARCINOMA; HEAD; HETEROGENEITY; MORBIDITY; TONGUE; TRIAL C1 [Mroz, Edmund A.; Rocco, James W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rocco, James W.] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. RP Mroz, EA (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. FU NCI NIH HHS [R21 CA119591]; NIDCR NIH HHS [R01 DE022087] NR 25 TC 5 Z9 5 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2012 VL 30 IS 33 BP 4053 EP 4055 DI 10.1200/JCO.2012.44.8050 PG 3 WC Oncology SC Oncology GA 040DF UT WOS:000311300000009 PM 23045572 ER PT J AU Sekeres, MA Steensma, DP AF Sekeres, Mikkael A. Steensma, David P. TI Boulevard of Broken Dreams: Drug Approval for Older Adults With Acute Myeloid Leukemia SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Editorial Material ID DAUNORUBICIN; HYDROXYUREA; OUTCOMES C1 [Sekeres, Mikkael A.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. [Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Sekeres, MA (reprint author), Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA. OI Steensma, David/0000-0001-5130-9284 NR 15 TC 20 Z9 21 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2012 VL 30 IS 33 BP 4061 EP 4063 DI 10.1200/JCO.2012.44.2962 PG 3 WC Oncology SC Oncology GA 040DF UT WOS:000311300000012 PM 23008302 ER PT J AU Shulman, LN Cirrincione, CT Berry, DA Becker, HP Perez, EA O'Regan, R Martino, S Atkins, JN Mayer, E Schneider, CJ Kimmick, G Norton, L Muss, H Winer, EP Hudis, C AF Shulman, Lawrence N. Cirrincione, Constance T. Berry, Donald A. Becker, Heather P. Perez, Edith A. O'Regan, Ruth Martino, Silvana Atkins, James N. Mayer, Erica Schneider, Charles J. Kimmick, Gretchen Norton, Larry Muss, Hyman Winer, Eric P. Hudis, Clifford TI Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID PLUS CYCLOPHOSPHAMIDE; RANDOMIZED-TRIAL; HIGH-RISK; FLUOROURACIL; METHOTREXATE; DOCETAXEL; EPIRUBICIN; TAMOXIFEN; SURVIVAL; THERAPY AB Purpose The ideal duration of adjuvant chemotherapy for patients with lower risk primary breast cancer is not known. Cancer and Leukemia Group B trial 40101 was conducted using a phase III factorial design to define whether six cycles of a chemotherapy regimen are superior to four cycles. We also sought to determine whether paclitaxel (T) is as efficacious as doxorubicin/cyclophosphamide (AC), but with reduced toxicity. Patients and Methods Between 2002 and 2008, the study enrolled women with operable breast cancer and zero to three positive nodes. Patients were randomly assigned to either four or six cycles of either AC or T. Study stratifiers were estrogen receptor/progesterone receptor (ER/PgR), human epidermal growth factor receptor 2 (HER2), and menopausal status. After 2003, all treatment was administered in dose-dense fashion. The primary efficacy end point was relapse-free survival (RFS). Results A total of 3,171 patients were enrolled; 94% were node-negative and 6% had one to three positive nodes. At a median follow-up of 5.3 years, the 4-year RFS was 90.9% and 91.8% for six and four cycles, respectively. The adjusted hazard ratio (HR) of six to four cycles regarding RFS was 1.03 (95% CI, 0.84 to 1.28; P = .77). The 4-year OS was 95.3% and 96.3% for six and four cycles, respectively, with an HR of six to four cycles of 1.12 (95% CI, 0.84 to 1.49; P = .44). There was no interaction between treatment duration and chemotherapy regimen, ER/PgR, or HER2 status on RFS or OS. Conclusion For women with resected primary breast cancer and zero to three positive nodes, we found no evidence that extending chemotherapy regimens of AC or single-agent T from four to six cycles improves clinical outcome. C1 [Shulman, Lawrence N.; Mayer, Erica; Winer, Eric P.] Dana Farber Canc Inst, Boston, MA 02215 USA. [Cirrincione, Constance T.; Kimmick, Gretchen] Duke Univ Med Ctr, Durham, NC USA. [Berry, Donald A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Becker, Heather P.] Canc & Leukemia Grp B Cent Off, Chicago, IL USA. [Perez, Edith A.] Mayo Clin Florida, Jacksonville, FL USA. [O'Regan, Ruth] Emory Univ, Atlanta, GA 30322 USA. [Martino, Silvana] Angeles Clin & Res Inst, Los Angeles, CA USA. [Atkins, James N.] Community Clin Oncol Program, SE Canc Control Consortium, Goldsboro, NC USA. [Schneider, Charles J.] Christiana Care Hlth Syst, Wilmington, DE USA. [Norton, Larry; Hudis, Clifford] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Muss, Hyman] Univ N Carolina, Chapel Hill, NC USA. RP Shulman, LN (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM Lawrence_Shulman@dfci.harvard.edu OI Norton, Larry/0000-0003-3701-9250 FU National Cancer Institute [CA25224, CA21115, CA32102, CA32291, CA33601, CA45808, CA45418, CA47577, CA77651, CA47559]; Genentech FX Supported by Grants No. CA25224, CA21115, CA32102, CA32291, CA33601, CA45808, CA45418, CA47577, CA77651, and CA47559 from the National Cancer Institute.; Eric P. Winer, Genentech NR 17 TC 31 Z9 32 U1 1 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2012 VL 30 IS 33 BP 4071 EP 4076 DI 10.1200/JCO.2011.40.6405 PG 6 WC Oncology SC Oncology GA 040DF UT WOS:000311300000014 PM 22826271 ER PT J AU Womer, RB West, DC Krailo, MD Dickman, PS Pawel, BR Grier, HE Marcus, K Sailer, S Healey, JH Dormans, JP Weiss, AR AF Womer, Richard B. West, Daniel C. Krailo, Mark D. Dickman, Paul S. Pawel, Bruce R. Grier, Holcombe E. Marcus, Karen Sailer, Scott Healey, John H. Dormans, John P. Weiss, Aaron R. TI Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID COLONY-STIMULATING FACTOR; DOXORUBICIN DOSE INTENSITY; STANDARD CHEMOTHERAPY; HISTORICAL CONTROLS; MULTIMODAL THERAPY; PEDIATRIC-PATIENTS; INTERGROUP; CANCER; BONE; MANAGEMENT AB Purpose Chemotherapy with alternating vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide cycles and primary tumor treatment with surgery and/or radiation therapy constitute the usual approach to localized Ewing sarcoma in North America. We tested whether chemotherapy intensification through interval compression could improve outcome. Patients and Methods This was a prospective, randomized controlled trial for patients younger than 50 years old with newly diagnosed localized extradural Ewing sarcoma. Patients assigned to standard and intensified treatment were to begin chemotherapy cycles every 21 and 14 days, respectively, provided an absolute neutrophil count greater than 750 x 10(6)/L and a platelet count greater than 75 x 10(9)/L. Patients received vincristine (2 mg/m(2)), doxorubicin (75 mg/m(2)), and cyclophosphamide (1.2 g/m(2)) alternating with ifosfamide (9 g/m(2)) and etoposide (500 mg/m(2)) for 14 cycles, with filgrastim (5 mg/kg per day; maximum, 300 mg) between cycles. Primary tumor treatment (surgery, radiation, or both) was to begin at week 13 (after four cycles in the standard arm and six cycles in the intensified arm). The primary end point was event-free survival (EFS). The study is registered at ClinicalTrials.gov (identifier: NCT00006734). Results Five hundred eighty-seven patients were enrolled and randomly assigned, and 568 patients were eligible, with 284 patients in each regimen. For all cycles, the median cycle interval for standard treatment was 21 days (mean, 22.45 days); for intensified treatment, the median interval was 15 days (mean, 17.29 days). EFS at a median of 5 years was 65% in the standard arm and 73% in the intensified arm (P = .048). The toxicity of the regimens was similar. Conclusion For localized Ewing sarcoma, chemotherapy administered every 2 weeks is more effective than chemotherapy administered every 3 weeks, with no increase in toxicity. C1 [Womer, Richard B.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA. [Womer, Richard B.; Pawel, Bruce R.; Dormans, John P.] Univ Penn, Philadelphia, PA 19104 USA. [West, Daniel C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Krailo, Mark D.] Childrens Oncol Grp, Arcadia, CA USA. [Dickman, Paul S.] Phoenix Childrens Hosp, Phoenix, AZ USA. [Grier, Holcombe E.; Marcus, Karen] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sailer, Scott] Univ N Carolina, Chapel Hill, NC USA. [Healey, John H.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Weiss, Aaron R.] Univ Med & Dent New Jersey, Robert Wood Johnson Univ Hosp, New Brunswick, NJ USA. RP Womer, RB (reprint author), Childrens Hosp Philadelphia, Div Oncol, CTRB 10,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM rwomer@upenn.edu FU National Cancer Institute [U10-CA98543, U10-CA98413]; Daniel P. Sullivan Fund; Nick Curry Foundation at CureSearch for Children's Cancer FX Supported by National Cancer Institute Grants No. U10-CA98543 and U10-CA98413 to the Children's Oncology Group and by the Daniel P. Sullivan Fund (R. B. W. and J.H.H.). Partial support for statistical analyses came from the Nick Curry Foundation at CureSearch for Children's Cancer. NR 25 TC 118 Z9 124 U1 0 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 20 PY 2012 VL 30 IS 33 BP 4148 EP 4154 DI 10.1200/JCO.2011.41.5703 PG 7 WC Oncology SC Oncology GA 040DF UT WOS:000311300000025 PM 23091096 ER PT J AU Giugliano, RP Braunwald, E AF Giugliano, Robert P. Braunwald, Eugene TI The Year in Non-ST-Segment Elevation Acute Coronary Syndrome SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE acute coronary syndrome(s); myocardial infarction; unstable angina ID ACUTE MYOCARDIAL-INFARCTION; DUAL-ANTIPLATELET THERAPY; DRUG-ELUTING STENTS; INTERVENTION TRIAGE STRATEGY; CHRONIC KIDNEY-DISEASE; TRITON-TIMI 38; OPTIMIZING PLATELET INHIBITION; CARDIOVASCULAR DATA REGISTRY; ACUITY ACUTE CATHETERIZATION; AMERICAN-HEART-ASSOCIATION C1 [Giugliano, Robert P.; Braunwald, Eugene] Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Div Cardiovasc Med, Boston, MA 02115 USA. RP Braunwald, E (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Div Cardiovasc Med, 350 Longwood Ave, Boston, MA 02115 USA. EM ebraunwald@partners.org FU Eli Lilly Company; Astra Zeneca; Bayer; Bristol-Myers Squibb; Daiich Sankyo; GlaxoSmithKline; Genentech; Johnson Johnson; Merck; Roche Diagnostics; Sanofi Aventis FX From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Dr. Giugliano has relationships with Amgen, Daiichi-Sankyo, Merck, and Janssen. Dr. Braunwald is a consultant to Daiichi Sankyo, The Medicines Co., and Merck; has received lecture fees from Eli Lilly & Company; and has received grant support from Astra Zeneca, Bayer, Bristol-Myers Squibb, Daiich Sankyo, Eli Lilly & Company, GlaxoSmithKline, Genentech, Johnson & Johnson, Merck, Roche Diagnostics, and Sanofi Aventis. NR 99 TC 6 Z9 6 U1 0 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 20 PY 2012 VL 60 IS 21 BP 2127 EP 2139 DI 10.1016/j.jacc.2012.08.972 PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 037CC UT WOS:000311077600002 PM 23103037 ER PT J AU Chirinos, JA Kips, JG Jacobs, DR Brumback, L Duprez, DA Kronmal, R Bluemke, DA Townsend, RR Vermeersch, S Segers, P AF Chirinos, Julio A. Kips, Jan G. Jacobs, David R., Jr. Brumback, Lyndia Duprez, Daniel A. Kronmal, Richard Bluemke, David A. Townsend, Raymond R. Vermeersch, Sebastian Segers, Patrick TI Arterial Wave Reflections and Incident Cardiovascular Events and Heart Failure: MESA (Multiethnic Study of Atherosclerosis) SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE arterial hemodynamics; cardiovascular risk; heart failure; left ventricular afterload; wave reflections ID LEFT-VENTRICULAR MASS; INPUT IMPEDANCE; ALL-CAUSE; PRESSURE; RECLASSIFICATION; PREDICTION; STIFFNESS; VELOCITY; DISEASE; FORMS AB Objectives This study sought to assess the relationship between central pressure profiles and cardiovascular events (CVEs) in a large community-based sample. Background Experimental and physiologic data mechanistically implicate wave reflections in the pathogenesis of left ventricular failure and cardiovascular disease, but their association with these outcomes in the general population is unclear. Methods Aortic pressure waveforms were derived from a generalized transfer function applied to the radial pressure waveform recorded noninvasively from 5,960 participants in the Multiethnic Study of Atherosclerosis. The central pressure waveform was separated into forward and reflected waves using a physiologic flow waveform. Reflection magnitude (RM = [Reflected/Forward wave amplitude] x 100), augmentation index ([Second/First systolic peak] x 100) and pulse pressure amplification ([Radial/aortic pulse pressure] x 100) were assessed as predictors of CVEs and congestive heart failure (CHF) during a median follow-up of 7.61 years. Results After adjustment for established risk factors, aortic AIx independently predicted hard CVEs (hazard ratio [HR] per 10% increase: 1.08; 95% confidence interval [CI]: 1.01 to 1.14; p = 0.016), whereas PPA independently predicted all CVEs (HR per 10% increase: 0.82; 95% CI: 0.70 to 0.96; p = 0.012). RM was independently predictive of all CVEs (HR per 10% increase: 1.34; 95% CI: 1.08 to 1.67; p = 0.009) and hard CVEs (HR per 10% increase: 1.46; 95% CI: 1.12 to 1.90; p = 0.006) and was strongly predictive of new-onset CHF (HR per 10% increase: 2.69; 95% CI: 1.79 to 4.04; p < 0.0001), comparing favorably to other risk factors for CHF as per various measures of model performance, reclassification, and discrimination. In a fully adjusted model, compared to nonhypertensive subjects with low RM, the HRs (95% CI) for hypertensive subjects with low RM, nonhypertensive subjects with high RM, and hypertensive subjects with high RM were 1.81 (0.85 to 3.86), 2.16 (1.07 to 5.01), and 3.98 (1.96 to 8.05), respectively. Conclusions Arterial wave reflections represent a novel strong risk factor for CHF in the general population. (J Am Coll Cardiol 2012;60:2170-7) (C) 2012 by the American College of Cardiology Foundation C1 [Chirinos, Julio A.] Univ Penn, Sch Med, Dept Cardiol, Philadelphia, PA 19104 USA. [Chirinos, Julio A.; Townsend, Raymond R.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Kips, Jan G.; Vermeersch, Sebastian; Segers, Patrick] Univ Ghent, IBiTech, B-9000 Ghent, Belgium. [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA. [Jacobs, David R., Jr.] Univ Oslo, Dept Nutr, Oslo, Norway. [Brumback, Lyndia; Kronmal, Richard] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. [Duprez, Daniel A.] Univ Minnesota, Sch Med, Div Cardiol, Minneapolis, MN 55455 USA. [Bluemke, David A.] NIH, Ctr Clin, Bethesda, MD 20892 USA. RP Chirinos, JA (reprint author), Univ Penn, Sch Med, Dept Cardiol, Rm 8B111,Univ & Woodland Ave, Philadelphia, PA 19104 USA. EM julio.chirinos@uphs.upenn.edu OI Bluemke, David/0000-0002-8323-8086 FU National Heart, Lung, and Blood Institute [N01-HC-95159, N01-HC-95169]; American Heart Association grants [0885031N, R01-HL-098382]; Atcor Medical; Cardiodynamics; APC cardiovascular; Novartis; Genentech; Amarin; Merck; Pfizer; Boehringer Ingelheim; [RR-024156] FX This research was supported by contracts N01-HC-95159 through N01-HC-95169 from the National Heart, Lung, and Blood Institute and RR-024156 as well as American Heart Association grants 0885031N and R01-HL-098382. Dr. Chirinos has received minor support (equipment loans) from Atcor Medical, Cardiodynamics, and APC cardiovascular. Dr. Duprez has received research grants from Novartis, Genentech, and Amarin; and speakers' fees from Merck, Pfizer, Novartis, and Boehringer Ingelheim. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. NR 34 TC 135 Z9 135 U1 4 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD NOV 20 PY 2012 VL 60 IS 21 BP 2170 EP 2177 DI 10.1016/j.jacc.2012.07.054 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 037CC UT WOS:000311077600007 PM 23103044 ER PT J AU Abdelbaky, A Subramanian, S Brady, TJ Hoffman, U Farkouh, M Rudd, J Fayad, ZA Tawako, A AF Abdelbaky, Amr Subramanian, Sharath Brady, Thomas J. Hoffman, Udo Farkouh, Michael Rudd, James Fayad, Zahi A. Tawako, Ahmed TI Statins Reduce Aortic Valve Metabolic Activity: A Human Multi-Center FDG-PET/CT Study SO CIRCULATION LA English DT Meeting Abstract DE Aortic valve; Inflammation; Statins; Positron emission tomography C1 [Abdelbaky, Amr; Subramanian, Sharath; Brady, Thomas J.; Hoffman, Udo; Tawako, Ahmed] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA. [Farkouh, Michael] Mt Sinai, Cardiol, New York, NY USA. [Rudd, James] Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England. [Fayad, Zahi A.] Mt Sinai, Translat & Mol Imaging Inst, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 16114 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885006017 ER PT J AU Abdelbaky, A Corsini, E Subramanian, S Figueroa, AL Brady, TJ Hoffmann, U Tawakol, A AF Abdelbaky, Amr Corsini, Erin Subramanian, Sharath Figueroa, Amparo L. Brady, Thomas J. Hoffmann, Udo Tawakol, Ahmed TI Aortic Valve Inflammation precedes Calcification: A longitudinal FDG-PET/CT study SO CIRCULATION LA English DT Meeting Abstract DE Aortic valve; Calcification; Inflammation C1 [Abdelbaky, Amr; Corsini, Erin; Subramanian, Sharath; Figueroa, Amparo L.; Brady, Thomas J.; Hoffmann, Udo; Tawakol, Ahmed] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 12570 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885002302 ER PT J AU Acha, MR Nakamura, K Mills, R Lynch, S Hinson, T Ellinor, P Conklin, BR Wu, S Milan, DJ AF Acha, Moshe Rav Nakamura, Kenta Mills, Robert Lynch, Stacey Hinson, Travis Ellinor, Patrick Conklin, Bruce R. Wu, Sean Milan, David J. TI Human Induced Pluripotent Stem Cells Validate a Novel Iks Activator as a Potential Therapeutic for Long QT Syndrome SO CIRCULATION LA English DT Meeting Abstract DE Stem cell biology; Electrophysiology; Electropharmacology; Qt interval C1 [Acha, Moshe Rav; Nakamura, Kenta; Mills, Robert; Lynch, Stacey; Ellinor, Patrick; Wu, Sean; Milan, David J.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. [Hinson, Travis] Brigham & Womens Hosp, Cardiovasc Res Ctr, Boston, MA 02115 USA. [Conklin, Bruce R.] UCSF, Cardiovasc Res Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 16547 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885006204 ER PT J AU Aiyagari, R Wolfe, J Morell, E Ziniel, S Kulik, TJ Kheir, JN Taylor, L Pituch, K Blume, ED AF Aiyagari, Ranjit Wolfe, Joanne Morell, Emily Ziniel, Sonja Kulik, Thomas J. Kheir, John N. Taylor, Laura Pituch, Kenneth Blume, Elizabeth D. TI Parental Perspective on End-of-Life Care Discussions for Children with Advanced Heart Disease SO CIRCULATION LA English DT Meeting Abstract DE Palliative care; Behavioral aspects; Family; Congenital heart disease; End of life C1 [Aiyagari, Ranjit; Taylor, Laura; Pituch, Kenneth] Univ Michigan, Ann Arbor, MI 48109 USA. [Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA. [Morell, Emily; Ziniel, Sonja; Kulik, Thomas J.; Kheir, John N.; Blume, Elizabeth D.] Childrens Hosp Boston, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 15500 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885005220 ER PT J AU Arora, P Wu, C Khan, AM Bloch, D Davis-Dusenbery, B Ghorbani, A Spagnolli, E Martinez, A Ryan, A Tanish, LT Kim, S Miller, KK Hata, A Monte, FD Holmes, TM Buys, E Bloch, KD Wang, TJ Newton-Cheh, C AF Arora, Pankaj Wu, Connie Khan, Abigail M. Bloch, Donald Davis-Dusenbery, Brandi Ghorbani, Anahita Spagnolli, Ester Martinez, Andrew Ryan, Allicia Tanish, Laurel T. Kim, Samuel Miller, Karen K. Hata, Akiko Monte, Federica D. Holmes, Tara Minaker Buys, Emmanuel Bloch, Kenneth D. Wang, Thomas J. Newton-Cheh, Christopher TI Identification of a Mechanism vy Which Common Blood Pressure Genetic Variant in the Nppa Gene Regulates Anp Levels SO CIRCULATION LA English DT Meeting Abstract DE Natriuretic peptide; Microrna; Blood pressure; Genetics; Sodium C1 [Arora, Pankaj; Ghorbani, Anahita; Martinez, Andrew; Ryan, Allicia; Wang, Thomas J.; Newton-Cheh, Christopher] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Wu, Connie; Spagnolli, Ester; Tanish, Laurel T.; Buys, Emmanuel] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Khan, Abigail M.] Univ Penn, Philadelphia, PA 19104 USA. [Bloch, Donald] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Davis-Dusenbery, Brandi; Kim, Samuel] Harvard Univ, Sch Med, Boston, MA USA. [Miller, Karen K.] Massachusetts Gen Hosp, Neuroendocrine Div, Boston, MA 02114 USA. [Hata, Akiko] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Monte, Federica D.] Beth Israel Deaconess Med Cntr, Div Cardiol, Boston, MA USA. [Holmes, Tara Minaker] Massachusetts Gen Hosp, Clin Rsch Cntr, Boston, MA 02114 USA. [Bloch, Kenneth D.] Massachusetts Gen Hosp, Cardiovasc Rsch Cntr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 11740 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885001413 ER PT J AU Bengali, R Jiang, YD AF Bengali, Raheel Jiang, Yandong TI Are Chest Compressions Effective if Performed in an Adult in the Lateral Position? SO CIRCULATION LA English DT Meeting Abstract DE Wolff-Parkinson-White syndrome; Cardiac arrest; Cardiopulmonary resuscitation C1 [Bengali, Raheel; Jiang, Yandong] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14511 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004243 ER PT J AU Bhatia, RS Picard, MH Milford, CE Weiner, RB AF Bhatia, Rajan S. Picard, Michael H. Milford, Creagh E. Weiner, Rory B. TI An Educational Intervention Reduces the Rate of Inappropriate Echocardiograms Ordered on an Inpatient Medical Service SO CIRCULATION LA English DT Meeting Abstract DE Quality improvement; Echocardiography; Healthcare delivery systems; Health policy C1 [Bhatia, Rajan S.; Picard, Michael H.; Milford, Creagh E.; Weiner, Rory B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14850 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004391 ER PT J AU Bittencourt, MS Hulten, EA Abbara, S Ghoshhajra, B Murthy, VL Rybicki, FJ Steigner, M Truong, QA Brady, TJ Di Carli, M Hoffmann, U Blankstein, R AF Bittencourt, Marco S. Hulten, Edward A. Abbara, Suhny Ghoshhajra, Brian Murthy, Venkatesh L. Rybicki, Frank J. Steigner, Michael Truong, Quynh A. Brady, Thomas J. Di Carli, Marcelo Hoffmann, Udo Blankstein, Ron TI Renal Dysfunction Predicts the Presence and Extent of Coronary Artery Disease on Coronary CT Angiography SO CIRCULATION LA English DT Meeting Abstract DE Computed tomography; Renal function; Coronary artery disease; Prognosis C1 [Bittencourt, Marco S.; Hulten, Edward A.; Murthy, Venkatesh L.; Rybicki, Frank J.; Steigner, Michael; Di Carli, Marcelo; Blankstein, Ron] Brigham & Womens Hosp, Boston, MA 02115 USA. [Abbara, Suhny; Ghoshhajra, Brian; Truong, Quynh A.; Brady, Thomas J.; Hoffmann, Udo] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Murthy, Venkatesh/B-3448-2013; Bittencourt, Marcio/C-1444-2011 OI Murthy, Venkatesh/0000-0002-7901-1321; Bittencourt, Marcio/0000-0002-3711-1754 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 11565 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885001348 ER PT J AU Bonaca, MP Scirica, BM Braunwald, E Wiviott, SD Goto, S Nilsen, D Bonarjee, V Murphy, SA Morrow, DA AF Bonaca, Marc P. Scirica, Benjamin M. Braunwald, Eugene Wiviott, Stephen D. Goto, Shinya Nilsen, Dennis Bonarjee, Vernon Murphy, Sabina A. Morrow, David A. TI New Ischemic Stroke and Outcomes with Vorapaxar vs. Placebo: Results from TRA 2 degrees P-TIMI 50 Trial SO CIRCULATION LA English DT Meeting Abstract DE Stroke; Thrombin; Antiplatelet drugs C1 [Bonaca, Marc P.; Scirica, Benjamin M.; Braunwald, Eugene; Wiviott, Stephen D.; Murphy, Sabina A.; Morrow, David A.] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA. [Goto, Shinya] Tokai Univ, Sch Med, Tokai, Ibaraki, Japan. [Nilsen, Dennis; Bonarjee, Vernon] Stavanger Univ Hosp, Stavanger, Norway. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 19144 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008391 ER PT J AU Bonaca, MP Scirica, BM Braunwald, E White, HD Aylward, PE Grande, P Murphy, SA Morrow, DA AF Bonaca, Marc P. Scirica, Benjamin M. Braunwald, Eugene White, Harvey D. Aylward, Philip E. Grande, Peer Murphy, Sabina A. Morrow, David A. TI Efficacy of Vorapaxar is not Modified by Thienopyridine Therapy: Results from TRA 2 degrees P-TIMI 50 Trial SO CIRCULATION LA English DT Meeting Abstract DE Thrombin; Coronary heart disease; Antiplatelet drugs C1 [Bonaca, Marc P.; Scirica, Benjamin M.; Braunwald, Eugene; Morrow, David A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [White, Harvey D.] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand. [Aylward, Philip E.] Flinders Med Cntr, Adelaide Hlth Serv, Adelaide, SA, Australia. [Grande, Peer] Natl Univ Hosp, Copenhagen, Denmark. [Murphy, Sabina A.] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 18595 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008187 ER PT J AU Bui, AL Grau-Sepulveda, MV Hernandez, AF Peterson, ED Yancy, CW Bhatt, DL Fonarow, GC AF Bui, Anh L. Grau-Sepulveda, Maria V. Hernandez, Adrian F. Peterson, Eric D. Yancy, Clyde W. Bhatt, Deepak L. Fonarow, Gregg C. TI Admission Heart Rate and In-Hospital Outcomes in Patients Hospitalized for Heart Failure SO CIRCULATION LA English DT Meeting Abstract DE Heart failure; Heart rate/Heart rate variability; Atrial fibrillation C1 [Bui, Anh L.] Kaiser Permanente Med Cntr Los Angeles, Dept Cardiol, Los Angeles, CA USA. [Grau-Sepulveda, Maria V.; Hernandez, Adrian F.; Peterson, Eric D.] Duke Clin Rsch Inst, Durham, NC USA. [Yancy, Clyde W.] Northwestern Univ, Sch Med, Div Cardiol, Chicago, IL USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Dept Cardiol, VA Boston Healthcare Syst, Boston, MA 02115 USA. [Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Med Cntr, Ahmanson UCLA Cardiomyopathy Cntr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 9232 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885000059 ER PT J AU Cavender, MA Joynt, KE Resnic, FS Parzynski, CS Rumsfeld, JS Moscucci, M Masoudi, FA Curtis, JP Peterson, ED Gurm, HS AF Cavender, Matthew A. Joynt, Karen E. Resnic, Frederick S. Parzynski, Craig S. Rumsfeld, John S. Moscucci, Mauro Masoudi, Frederick A. Curtis, Jeptha P. Peterson, Eric D. Gurm, Hitinder S. TI State Mandated Public Reporting of Percutaneous Coronary Intervention Outcomes is Associated with Better Outcomes: A report from the NCDR (R) SO CIRCULATION LA English DT Meeting Abstract DE Percutaneous coronary intervention; Quality improvement; Health policy; Ischemic heart disease; STEMI C1 [Cavender, Matthew A.] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA. [Joynt, Karen E.; Resnic, Frederick S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Parzynski, Craig S.] Yale New Haven Med Ctr, Cntr Outcomes Rsch & Evaluat, New Haven, CT 06504 USA. [Rumsfeld, John S.] Denver VA Med Cntr, Denver, CO USA. [Moscucci, Mauro] Univ Miami Hlth Syst, Miami, FL USA. [Masoudi, Frederick A.] Univ Colorado, Aurora, CA USA. [Curtis, Jeptha P.] Yale New Haven Med Ctr, New Haven, CT 06504 USA. [Peterson, Eric D.] Duke Univ, Duke Clin Rsch Inst, Durham, NC USA. [Gurm, Hitinder S.] Univ Michigan, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 16534 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885006198 ER PT J AU Chatterjee, NA Upadhyay, GA Singal, G Parks, KA Singh, JP Dec, GW Lewis, GD AF Chatterjee, Neal A. Upadhyay, Gaurav A. Singal, Gaurav Parks, Kimberly A. Singh, Jagmeet P. Dec, G. W. Lewis, Gregory D. TI Mixed Pulmonary Hypertension Associated with Increased All-Cause Mortality in CRT SO CIRCULATION LA English DT Meeting Abstract DE Pulmonary hypertension; Resynchronization therapy; Heart failure C1 [Chatterjee, Neal A.; Singal, Gaurav; Parks, Kimberly A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Upadhyay, Gaurav A.; Singh, Jagmeet P.; Dec, G. W.; Lewis, Gregory D.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [Lewis, Gregory D.] Massachusetts Gen Hosp, Div Pulm & Crit Care, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 16956 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885006343 ER PT J AU Chatterjee, NA Upadhyay, GA Kandala, J Parks, KA Lewis, GD Singh, JP AF Chatterjee, Neal A. Upadhyay, Gaurav A. Kandala, Jagdesh Parks, Kimberly A. Lewis, Gregory D. Singh, Jagmeet P. TI RV Dilation and Geometric Remodeling Impact Mortality in Cardiac Resynchronization Therapy SO CIRCULATION LA English DT Meeting Abstract DE CRT; Resynchronization therapy; Heart failure C1 [Chatterjee, Neal A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Upadhyay, Gaurav A.; Kandala, Jagdesh; Parks, Kimberly A.; Lewis, Gregory D.; Singh, Jagmeet P.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [Lewis, Gregory D.] Massachusetts Gen Hosp, Div Pulm & Crit Care, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 16919 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885006327 ER PT J AU Choucair, WK Lip, GY Waldo, AL Bersohn, MM Martin, DT Akar, JG Wathen, M Neve, N Halperin, JL Ip, J AF Choucair, Wassim K. Lip, Gregory Y. Waldo, Albert L. Bersohn, Malcolm M. Martin, David T. Akar, Joseph G. Wathen, Mark Neve, Nathalie Halperin, Jonathan L. Ip, John TI Atrial Arrhythmias in ICD Versus CRT-D Subjects SO CIRCULATION LA English DT Meeting Abstract DE Atial arrhythmias; Device; CRT C1 [Choucair, Wassim K.] Cardiol Associates Corpus Christi, Corpus Christi, TX USA. [Lip, Gregory Y.] Univ Birmingham, Cntr Cardiovasc Sci, Birmingham, W Midlands, England. [Waldo, Albert L.] Harrington McLaughlin Heart & Vasc Inst Univ Hosp, Div Cardiovasc Med, Cleveland, OH USA. [Bersohn, Malcolm M.] UCLA Cardiol 111E, VA Greater Los Angeles Healthcare Syst, David Geffen Sch Med, Los Angeles, CA USA. [Martin, David T.] Lahey Clin Med Ctr, Dept Cardiovasc Med, Burlington, MA 01803 USA. [Akar, Joseph G.] Yale Univ, Sch Med, Div Cardiol, New Haven, CT USA. [Wathen, Mark] Tennessee Heart PLLC, Heart & Vasc Cntr, Cookeville, TN USA. [Neve, Nathalie] BIOTRONIK, Clin Studies, Lake Oswego, OR USA. [Halperin, Jonathan L.] Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA. [Ip, John] Thorac & Cardiovasc Healthcare Fdn, Lansing, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17907 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007332 ER PT J AU Coelho, O Shah, R Mitchell, R Moreno, H Kwong, R Jerosch-Herold, M AF Coelho-Filho, Otavio Shah, Ravi Mitchell, Richard Moreno, Hector Kwong, Raymond Jerosch-Herold, Michael TI MRI Based Non-Invasive Detection of Cardiomyocyte Hypertrophy and Cell Volume Changes SO CIRCULATION LA English DT Meeting Abstract DE Cardiac imaging C1 [Coelho-Filho, Otavio; Moreno, Hector] State Univ Campinas UNICAMP, Sao Paulo, Brazil. [Shah, Ravi] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mitchell, Richard] Brigham & Womens Hosp, Sao Paulo, MA USA. [Kwong, Raymond; Jerosch-Herold, Michael] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 19700 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885009177 ER PT J AU Daneshmand, A Habibollahi, P Heidari, P Mahmood, U Ayata, C AF Daneshmand, Ali Habibollahi, Peiman Heidari, Pedram Mahmood, Umar Ayata, Cenk TI Ketogenic Diet Reduces Glucose Uptake and Infarct Volume in Murine Stroke SO CIRCULATION LA English DT Meeting Abstract DE Stroke; Energy metabolism; Infarct size; Positron emission tomography C1 [Daneshmand, Ali; Habibollahi, Peiman; Heidari, Pedram; Mahmood, Umar; Ayata, Cenk] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 13129 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885003099 ER PT J AU Dhakal, BP Murphy, RM Chatterjee, NA Semigran, MJ Lewis, GD AF Dhakal, Bishnu P. Murphy, Ryan M. Chatterjee, Neal A. Semigran, Marc J. Lewis, Gregory D. TI Pulmonary Artery Pressure Response Pattern in Heart Failure with Preserved Ejection Fraction SO CIRCULATION LA English DT Meeting Abstract DE Exercise tests; Heart failure C1 [Dhakal, Bishnu P.; Murphy, Ryan M.; Chatterjee, Neal A.; Semigran, Marc J.; Lewis, Gregory D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 18563 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008172 ER PT J AU Diercks, D Mumma, BF Peacock, WF Hollander, JE Safdar, B Mahler, SA Miller, CD Nagurney, JT AF Diercks, Deborah Mumma, Bryn F. Peacock, W. Frank Hollander, Judd E. Safdar, Basmah Mahler, Simon A. Miller, Chadwick D. Nagurney, John T. TI Incremental Value of Objective Cardiac Testing in Addition to Physician Impression and Serial Contemporary Troponin Measurements in Women SO CIRCULATION LA English DT Meeting Abstract DE Cardiovascular imaging; Emergency care C1 [Diercks, Deborah; Mumma, Bryn F.] Univ Calif Davis, Dept Emergency Med, Sacramento, CA 95817 USA. [Peacock, W. Frank] Cleveland Clin, Dept Emergency Med, Cleveland, OH 44106 USA. [Hollander, Judd E.] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA. [Safdar, Basmah] Yale Univ, Dept Emergency Med, New Haven, CT USA. [Mahler, Simon A.; Miller, Chadwick D.] Wake Forest Univ Hlth Sci, Dept Emergency Med, Winston Salem, NC USA. [Nagurney, John T.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 18150 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008036 ER PT J AU Dudzinski, DM Gaggin, HK Belcher, A De Berardinis, B He, W Januzzi, JL AF Dudzinski, David M. Gaggin, Hanna K. Belcher, Arianna De Berardinis, Benedetta He, Wei Januzzi, James L. TI NT-proBNP %Guided" Outpatient Management of Systolic Heart Failure is Cost-Saving SO CIRCULATION LA English DT Meeting Abstract DE Natriuretic peptide; Heart failure; Biomarkers; Cost-effectiveness; Clinical trials C1 [Dudzinski, David M.; Gaggin, Hanna K.; Belcher, Arianna; He, Wei; Januzzi, James L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [De Berardinis, Benedetta] St Andrea Hosp, Emergency Dept, Rome, Italy. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 13263 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885003161 ER PT J AU Figueroa, AL Abdelbaky, A MacNabb, MH Lavender, ZR Lawler, MA Uthamalingam, S Truong, QA Brady, TJ Hoffmann, U Tawakol, A AF Figueroa, Amparo L. Abdelbaky, Amr MacNabb, Megan H. Lavender, Zachary R. Lawler, Meredith A. Uthamalingam, Shanmugam Truong, Quynh A. Brady, Thomas J. Hoffmann, Udo Tawakol, Ahmed TI FDG-PET-CT Measurement of Arterial Inflammation Provides Insight into Both Risk for and Timing of Future Cardiovascular Events SO CIRCULATION LA English DT Meeting Abstract DE Positron emission tomography; Inflammation; Cardiovascular disease; Arteriosclerosis; Computed tomography C1 [Figueroa, Amparo L.; Abdelbaky, Amr; MacNabb, Megan H.; Lavender, Zachary R.; Lawler, Meredith A.; Uthamalingam, Shanmugam; Truong, Quynh A.; Brady, Thomas J.; Hoffmann, Udo; Tawakol, Ahmed] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 16597 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885006225 ER PT J AU Figueroa, AL Abdelbaky, A MacNabb, MH Lavender, ZR Lawler, MA Uthamalingam, S Truong, QA Brady, TJ Hoffmann, U Tawakol, A AF Figueroa, Amparo L. Abdelbaky, Amr MacNabb, Megan H. Lavender, Zacharv R. Lawler, Meredith A. Uthamalingam, Shanmugam Truong, Quynh A. Brady, Thomas J. Hoffmann, Udo Tawakol, Ahmed TI Increased Arterial Inflammation by FDG-PET-CT is Associated with an Increased Risk of Cardiovascular Events among Obese Low-Intermediate Risk Individuals SO CIRCULATION LA English DT Meeting Abstract DE Positron emission tomography; Inflammation; Obesity; Cardiovascular disease; Computed tomography C1 [Figueroa, Amparo L.; Abdelbaky, Amr; MacNabb, Megan H.; Lavender, Zacharv R.; Lawler, Meredith A.; Uthamalingam, Shanmugam; Truong, Quynh A.; Brady, Thomas J.; Hoffmann, Udo; Tawakol, Ahmed] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 16509 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885006186 ER PT J AU Fletcher, RD Amdur, R Papademetriou, V Kheirbek, R Jones, RE AF Fletcher, Ross D. Amdur, Richard Papademetriou, Vasilios Kheirbek, Raya Jones, Ronald E. TI Controlling Hypertension in Blacks - A AVA 10 Year Multicenter Analysis SO CIRCULATION LA English DT Meeting Abstract DE Hypertension; Blood pressure C1 [Fletcher, Ross D.; Amdur, Richard; Papademetriou, Vasilios; Kheirbek, Raya; Jones, Ronald E.] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14756 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004346 ER PT J AU Friedman, DJ Upadhyay, GA Orencole, M Parks, KA Moore, SA Picard, MH Ruskin, JN Singh, JP Heist, EK AF Friedman, Daniel J. Upadhyay, Gaurav A. Orencole, Mary Parks, Kimberly A. Moore, Stephanie A. Picard, Michael H. Ruskin, Jeremy N. Singh, Jagmeet P. Heist, E. K. TI Progressive Ventricular Dilatation Despite Cardiac Resynchronization Therapy (CRT): Baseline Predictors and Associated Clinical Outcomes SO CIRCULATION LA English DT Meeting Abstract DE CRT; Heart failure; Ventricular arrhythmia; Risk factors C1 [Friedman, Daniel J.; Picard, Michael H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Upadhyay, Gaurav A.; Orencole, Mary; Ruskin, Jeremy N.; Singh, Jagmeet P.; Heist, E. K.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Parks, Kimberly A.; Moore, Stephanie A.] Massachusetts Gen Hosp, Heart Failure & Transplant Program, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14755 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004345 ER PT J AU Friedman, DJ Upadhyay, GA Singal, G Khalid, M Orencole, M Moore, SA Parks, KA Heist, EK Singh, JP AF Friedman, Daniel J. Upadhyay, Gaurav A. Singal, Gaurav Khalid, Mansoor Orencole, Mary Moore, Stephanie A. Parks, Kimberly A. Heist, E. K. Singh, Jagmeet P. TI Cardiac Resynchronization Therapy (CRT) in Dialysis Dependent Heart Failure Patients SO CIRCULATION LA English DT Meeting Abstract DE Heart failure; Renal function; Bi-ventricular pacing; Outcomes C1 [Friedman, Daniel J.; Singal, Gaurav] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Upadhyay, Gaurav A.; Khalid, Mansoor; Orencole, Mary; Heist, E. K.; Singh, Jagmeet P.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Moore, Stephanie A.; Parks, Kimberly A.] Massachusetts Gen Hosp, Heart Failure & Cardiac Transplantat Program, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 13594 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885003307 ER PT J AU Gaggin, HK Bystrom, C Clarke, N Belcher, A Januzzi, J AF Gaggin, Hanna K. Bystrom, Cory Clarke, Nigel Belcher, Arianna Januzzi, James TI A Novel and Validated Mass Spectrometry Assay for Characterizing in vitro Fragmentation of BNP and a Method to Inhibit Enzymatic Degradation of Intact BNP SO CIRCULATION LA English DT Meeting Abstract DE Biomarkers; Heart failure C1 [Gaggin, Hanna K.; Belcher, Arianna; Januzzi, James] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bystrom, Cory; Clarke, Nigel] Quest Diagnost Nichols Inst, San Juan Capistrano, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14919 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004422 ER PT J AU Goehler, A McMahon, P Lumish, HS Wu, C Munish, V Gilmore, M Chung, JH Siegel, EL Mark, D Troung, Q Gazelle, GS Hoffmann, U AF Goehler, Alexander McMahon, Pamela Lumish, Heidi S. Wu, Carol Munish, Vidit Gilmore, Michael Chung, Jonathan H. Siegel, Emily L. Mark, Daniel Quynh Troung Gazelle, G. Scott Hoffmann, Udo TI Health and Economic Outcomes after Detection of Incidental Pulmonary Nodules during Cardiac CT Angiography in Patients with suspected Coronary Artery Disease SO CIRCULATION LA English DT Meeting Abstract DE Cardiac imaging; Outcomes; Cost-effectiveness C1 [Goehler, Alexander; Lumish, Heidi S.; Siegel, Emily L.; Quynh Troung; Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Cardiac MR, PET CT Progam, Boston, MA 02114 USA. [Goehler, Alexander; Lumish, Heidi S.] Inst Technol Assessment, Boston, MA USA. [McMahon, Pamela; Munish, Vidit; Gilmore, Michael; Gazelle, G. Scott] Massachusetts Gen Hosp, Dept Radiol, Inst Technol Assessment, Boston, MA 02114 USA. [Wu, Carol] Massachusetts Gen Hosp, Dept Radiol, Div Thorac Imaging, Boston, MA 02114 USA. [Chung, Jonathan H.] Univ Washington, Dept Radiol, Denver, CO USA. [Mark, Daniel] Duke Hlth, Dept Cardiol, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17340 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007071 ER PT J AU Green, EM Hung, J Macgillivray, TE Stone, JR Macrae, CA AF Green, Eric M. Hung, Judy Macgillivray, Thomas E. Stone, James R. Macrae, Calum A. TI A 36-Year-Old Man with Stroke and Severe Hyperlipidemia: From Phenotype to Genotype SO CIRCULATION LA English DT Meeting Abstract DE Aorta; Acute coronary syndromes; Hyperlipidemia; Stroke C1 [Green, Eric M.; Macrae, Calum A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Hung, Judy; Macgillivray, Thomas E.; Stone, James R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 18972 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008326 ER PT J AU Hawkins, B Kaltenbach, L Shivapour, D Neely, M Rao, S Yeh, R AF Hawkins, Beau Kaltenbach, Lisa Shivapour, Daniel Neely, Megan Rao, Sunil Yeh, Robert TI Do Interventional Cardiology Training Programs Have Worse Outcomes Early in the Academic Year? An Assessment of the "July Effect" from the NCDR (R) SO CIRCULATION LA English DT Meeting Abstract DE Interventional cardiology; Percutaneous coronary intervention C1 [Hawkins, Beau; Shivapour, Daniel; Yeh, Robert] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kaltenbach, Lisa; Neely, Megan; Rao, Sunil] Duke Clin Rsch Inst, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 9264 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885000069 ER PT J AU Ho, JE Waters, DD DeMicco, DA Arsenault, BJ Boekholdt, SM Messig, M Kastelein, JJ Pedersen, TR AF Ho, Jennifer E. Waters, David D. DeMicco, David A. Arsenault, Benoit J. Boekholdt, S. Matthijs Messig, Michael Kastelein, John J. Pedersen, Terje R. TI Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy: Effect of Baseline Risk Factors for Diabetes SO CIRCULATION LA English DT Meeting Abstract DE Statins; Risk factors; Cardiovascular disease C1 [Ho, Jennifer E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Waters, David D.] San Francisco Gen Hosp, San Francisco, CA 94110 USA. [DeMicco, David A.; Messig, Michael] Pfizer Inc, New York, NY USA. [Arsenault, Benoit J.] Univ Laval, Quebec City, PQ, Canada. [Boekholdt, S. Matthijs; Kastelein, John J.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands. [Pedersen, Terje R.] Oslo Univ Hosp, Cntr Prevent Med, Oslo, Norway. RI Boekholdt, Matthijs/G-7562-2014 NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 15052 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885005052 ER PT J AU Hu, SN Tian, JW Dong, NN Sun, YL Han, X Cheng, W Jiang, YX Chang, L Ban, X Huang, O Jia, HB Xing, L Meng, LB Hou, JB Zhang, SS Yu, B Jang, IK AF Hu, Sining Tian, Jinwei Dong, Nana Sun, Yanli Han, Xue Cheng, Wen Jiang, Yongxing Chang, Liang Ban, Xiang Huang, Oi Jia, Haibo Xing, Lei Meng, Lingbo Hou, Jingbo Zhang, Shaosong Yu, Bo Jang, Ik-Kyung TI Bevacizumab for Plaque Stabilization: Evaluation of its Effect on Vasa Vasorum, Lipid Pool, and Atheroma Volume by Multimodality Imaging Techniques in an Atherosclerotic Rabbit Model SO CIRCULATION LA English DT Meeting Abstract DE Arteriosclerosis; Vasculogenesis; Interventional cardiology; Intravascular ultrasound/Doppler; Cardiovascular imaging C1 [Hu, Sining; Tian, Jinwei; Dong, Nana; Sun, Yanli; Xing, Lei; Meng, Lingbo; Hou, Jingbo; Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Harbin, Peoples R China. [Han, Xue; Cheng, Wen] Harbin Med Univ, Affiliated Hosp 3, Harbin, Peoples R China. [Jiang, Yongxing; Chang, Liang; Ban, Xiang; Huang, Oi] Harbin Med Univ, Harbin, Peoples R China. [Jia, Haibo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Zhang, Shaosong] St Jude Med, LightLab Imaging, Cardiol, Westford, MA USA. [Zhang, Shaosong] St Jude Med, LightLab Imaging, Cardiol, Boston, MA USA. [Jang, Ik-Kyung] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17934 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007349 ER PT J AU Huertas-Vazquez, A Nelson, CP Guo, XQ Reinier, K Uy-Evanado, A Teodorescu, C Ayala, J Jerger, K Chugh, H Braund, PS Hall, AS Ralmforth, AJ Jones, M Taylor, KD Pulit, S Newton-Cheh, C Gunson, K Jui, J Rotter, JI Albert, CM Samani, NJ Chugh, SS AF Huertas-Vazquez, Adriana Nelson, Christopher P. Guo, Xiuqing Reinier, Kyndaron Uy-Evanado, Audrey Teodorescu, Carmen Ayala, Jo Jerger, Katherine Chugh, Harpriya Braund, Peter S. Hall, Alistair S. Ralmforth, Anthony J. Jones, Michelle Taylor, Kent D. Pulit, Sara Newton-Cheh, Chistopher Gunson, Karen Jui, Jonathan Rotter, Jerome I. Albert, Christine M. Samani, Nilesh J. Chugh, Sumeet S. TI RAB3 GTPase Activating Protein Subunit 1 is a Novel Candidate Gene for Sudden Cardiac Death SO CIRCULATION LA English DT Meeting Abstract DE Sudden cardiac death; Genetics C1 [Huertas-Vazquez, Adriana; Reinier, Kyndaron; Uy-Evanado, Audrey; Teodorescu, Carmen; Ayala, Jo; Jerger, Katherine; Chugh, Harpriya; Chugh, Sumeet S.] Cedars Sinai Med Cntr, Inst Heart, Los Angeles, CA USA. [Nelson, Christopher P.; Braund, Peter S.; Samani, Nilesh J.] Univ Leicester, Leicester, Leics, England. [Guo, Xiuqing; Jones, Michelle; Taylor, Kent D.; Rotter, Jerome I.] Cedars Sinai Med Cntr, Los Angeles, CA USA. [Hall, Alistair S.] Univ Leeds, LIGHT Inst, Leeds, W Yorkshire, England. [Ralmforth, Anthony J.] Univ Leeds, Inst Cardiovasc Rsch, Leeds, W Yorkshire, England. [Pulit, Sara] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Newton-Cheh, Chistopher] Harvard Univ, Sch Med, Boston, MA USA. [Gunson, Karen; Jui, Jonathan] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Albert, Christine M.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 16094 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885006009 ER PT J AU Hulten, E Bittencourt, MS Ghosshajra, B Nasir, K Abbara, S Truong, QA Brady, TJ Hoffmann, U Blankstein, R AF Hulten, Edward Bittencourt, Marcio S. Ghosshajra, Brian Nasir, Khurram Abbara, Suhny Truong, Quynh A. Brady, Thomas J. Hoffmann, Udo Blankstein, Ron TI C-reactive Protein as a Predictor of Coronary Events and Coronary Artery Disease Prevalence, Extent, or Severity by Coronary CT Angiography SO CIRCULATION LA English DT Meeting Abstract DE CT angiography; Biomarkers; Prognosis; Coronary artery disease; Outcomes C1 [Hulten, Edward; Bittencourt, Marcio S.; Blankstein, Ron] Brigham & Womens Hosp, Boston, MA 02115 USA. [Ghosshajra, Brian; Truong, Quynh A.] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA. [Nasir, Khurram] Yale New Haven Med Ctr, New Haven, CT 06504 USA. [Abbara, Suhny; Brady, Thomas J.; Hoffmann, Udo] Massachusetts Gen Hosp, Boston, MA 02114 USA. RI Bittencourt, Marcio/C-1444-2011 OI Bittencourt, Marcio/0000-0002-3711-1754 NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 12239 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885002182 ER PT J AU Jansen, H Loley, C Lieb, W Pencina, MI Nelson, CP Kathiresan, S Reilly, MP Assimes, TL Boerwinkle, F Hall, AS Hengstenberg, C Laaksonen, R McPherson, R Thorsteinsdottir, U Peters, A Thompson, JR Koenig, IR Vasan, RS Erdmann, J Samani, N Schunkert, H AF Jansen, Henning Loley, Christina Lieb, Wolfpang Pencina, Michael I. Nelson, Christopher P. Kathiresan, Sekar Reilly, Muredach P. Assimes, Themistocles L. Boerwinkle, Fric Hall, Alistair S. Hengstenberg, Christian Laaksonen, Reiio McPherson, Ruth Thorsteinsdottir, Unnur Peters, Annette Thompson, John R. Koenig, Inke R. Vasan, Ramachandran S. Erdmann, Jeanette Samani, Nilesh Schunkert, Heribert TI Genetic Variants Primarily Associated eith Type 2 Diabetes Also Affect Coronary Artery Disease Risk SO CIRCULATION LA English DT Meeting Abstract DE Genome-wide association studies (GWAS) C1 [Jansen, Henning; Erdmann, Jeanette; Schunkert, Heribert] Univ Lubeck, Deutsch Zentrum Herz Kreislauf Zentrum DZHK, Med Klin 2, Lubeck, Germany. [Loley, Christina; Koenig, Inke R.] Univ Lubeck, Inst Med Biometrie & Stat, Lubeck, Germany. [Lieb, Wolfpang] Ernst Moritz Arndt Univ Greifswald, Inst Community Med, Greifswald, Germany. [Pencina, Michael I.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Nelson, Christopher P.; Samani, Nilesh] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England. [Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Rsch Cntr, Boston, MA 02114 USA. [Kathiresan, Sekar] Brigham & Womens Hosp, Div Cardiol, Boston, MA 02115 USA. [Reilly, Muredach P.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Assimes, Themistocles L.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA. [Boerwinkle, Fric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA. [Boerwinkle, Fric] Inst Mol Med, Houston, TX USA. [Hall, Alistair S.] Univ Leeds, Div Epidemiol, Leeds Inst Genet Hlth & Therapeut, Leeds, W Yorkshire, England. [Hengstenberg, Christian] Univ Regensburg, Klin & Poliklin Innere Med 2, D-93053 Regensburg, Germany. [Laaksonen, Reiio] Tampere Univ Hosp, Ctr Sci, Tampere, Finland. [McPherson, Ruth] Univ Ottawa, Inst Heart, John&Jennifer Ruddy Canadian Cardiovasc Genet Cnt, Ottawa, ON, Canada. [Thorsteinsdottir, Unnur] Univ Iceland, DeCODE Genet, Fac Med, Luebeck, Iceland. [Peters, Annette] Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany. [Thompson, John R.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England. [Vasan, Ramachandran S.] Boston Univ, Sch Publ Hlth, Sect Prevent Med & Epidemiol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17557 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007170 ER PT J AU Jansen, H Lieb, W Loley, C Kathiresan, S Reilly, MP Assimes, TL Boerwinkle, E Hall, AS Stark, K Hengstenberg, C Laaksonen, R McPherson, R Thorsteinsdottir, U Peters, A Thompson, JR Koenig, IR Erdmann, J Samani, NJ Schunkert, H AF Jansen, Henning Lieb, Wolfgang Loley, Christina Kathiresan, Sekar Reilly, Muredach P. Assimes, Themistocles L. Boerwinkle, Eric Hall, Alistair S. Stark, Klaus Hengstenberg, Christian Laaksonen, Reijo McPherson, Ruth Thorsteinsdottir, Unnur Peters, Annette Thompson, John R. Koenig, Inke R. Erdmann, Jeanette Samani, Nilesh J. Schunkert, Heribert TI Genetic Variants Primarily Associated with Rheumatoid Arthritis (RA) Do Not Effect Coronary Artery Disease Risk SO CIRCULATION LA English DT Meeting Abstract DE Genome-wide association studies (GWAS) C1 [Jansen, Henning; Erdmann, Jeanette; Schunkert, Heribert] Univ Lubeck, Med Klin 2, Deutsch Zentrum Herz Kreislauf Zentrum DZHK, Lubeck, Germany. [Lieb, Wolfgang] Ernst Moritz Arndt Univ Greifswald, Inst Community Med, Greifswald, Germany. [Loley, Christina; Koenig, Inke R.] Univ Lubeck, Inst Med Biometrie & Stat, Lubeck, Germany. [Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Rsch Cntr, Boston, MA 02114 USA. [Kathiresan, Sekar] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Reilly, Muredach P.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Assimes, Themistocles L.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA. [Boerwinkle, Eric] Univ Texas Hlth Sci Cntr, Human Genet Cntr, Houston, TX USA. [Boerwinkle, Eric] Univ Texas Hlth Sci Cntr, Inst Mol Med, Houston, TX USA. [Hall, Alistair S.] Univ Leeds, Div Epidemiol, Leeds Inst Genet Hlth & Therapeut, Leeds, W Yorkshire, England. [Stark, Klaus; Hengstenberg, Christian] Univ Regensburg, Klin & Poliklin Innere Med 2, D-93053 Regensburg, Germany. [Laaksonen, Reijo] Tampere Univ Hosp, Sci Cntr, Tampere, Finland. [McPherson, Ruth] Univ Ottawa, Inst Heart, John&Jennifer Ruddy Canadian Cardiovasc Genet Cnt, Ottawa, ON, Canada. [Thorsteinsdottir, Unnur] Univ Iceland, DeCODE Genet, Fac Med, Reykjavik, Iceland. [Peters, Annette] Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany. [Thompson, John R.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England. [Samani, Nilesh J.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17183 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007012 ER PT J AU Jesus, J Vantler, M Leppanen, O Berghausen, E Caglayan, E ten Freyhaus, H Zhao, J Blaschke, F Rosenkranz, S AF Jesus, Joana Vantler, Marius Leppanen, Olli Berghausen, Eva Caglayan, Evren ten Freyhaus, Hendrik Zhao, Jean Blaschke, Florian Rosenkranz, Stephan TI The Pi 3-kinase Isoform p110alpha is Essential for Neointima Formation Following Percutaneos Coronary Intervention (pci) by Mediating Vascular Smooth Muscle Cell Proliferation, Migration and Survival SO CIRCULATION LA English DT Meeting Abstract DE Restenosis; Growth factors; Cell signaling C1 [Jesus, Joana; Vantler, Marius; Berghausen, Eva; Caglayan, Evren; ten Freyhaus, Hendrik; Rosenkranz, Stephan] Clin Internal Med III Cologne, Cologne, Germany. [Leppanen, Olli] Uppsala Univ, Cty Council Gavleborg, Cntr R&D, Gavle, Sweden. [Zhao, Jean] Dana Farber Canc Inst, Boston, MA 02115 USA. [Blaschke, Florian] Charite Berlin Clin Internal Med, Berlin, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14682 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004316 ER PT J AU Kansal, P de Boer, RA Defilippi, CR Gaggin, H Muntendam, P Adourian, A van Veldhuisen, DJ Januzzi, JL Shah, SJ AF Kansal, Priya de Boer, Rudolph A. deFilippi, Christopher R. Gaggin, Hanna Muntendam, Pieter Adourian, Aram van Veldhuisen, Dirk J. Januzzi, James L. Shah, Sanjiv J. TI Use of Galectin-3 to Create a Simplified Heart Failure Rehospitalization Risk Model SO CIRCULATION LA English DT Meeting Abstract DE Heart failure; Outcomes; Biomarkers C1 [Kansal, Priya; Shah, Sanjiv J.] Northwestern Univ, Chicago, IL 60611 USA. [de Boer, Rudolph A.; van Veldhuisen, Dirk J.] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. [deFilippi, Christopher R.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Gaggin, Hanna; Januzzi, James L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Muntendam, Pieter; Adourian, Aram] BG Med Inc, Waltham, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17458 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007120 ER PT J AU Kato, K Yonetsu, T Kim, SJ Lee, H Abtahian, F Park, SJ Jang, Y Uemura, S Mizuno, K Jang, IK AF Kato, Koji Yonetsu, Taishi Kim, Soo-Joong Lee, Hang Abtahian, Farhad Park, Seung-Jung Jang, Yangsoo Uemura, Shiro Mizuno, Kyoichi Jang, Ik-Kyung TI Coronary Plaque Characteristics in Diabetic Patients: Diabetic Status and Insulin Therapy SO CIRCULATION LA English DT Meeting Abstract DE Coronary artery disease; Plaque C1 [Kato, Koji; Yonetsu, Taishi; Kim, Soo-Joong; Abtahian, Farhad; Jang, Ik-Kyung] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lee, Hang] Massachusetts Gen Hosp, Biostat Cntr, Boston, MA 02114 USA. [Park, Seung-Jung] Asan Med Cntr, Seoul, South Korea. [Jang, Yangsoo] Yonsei Univ, Seoul 120749, South Korea. [Uemura, Shiro] Nara Med Univ, Nara, Japan. [Mizuno, Kyoichi] Nippon Med Sch, Tokyo 113, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 11691 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885001391 ER PT J AU Kohli, P Laine, L Kaur, A Curtis, S Cannon, CP AF Kohli, Payal Laine, Loren Kaur, Amarjot Curtis, Sean Cannon, Christopher P. TI Atrial Fibrillation/Flutter Associated with Rheumatoid Arthritis vs. Osteoarthritis and the use of Etoricoxib vs. Diclofenac: Results from the MEDAL Program SO CIRCULATION LA English DT Meeting Abstract DE Atrial arrhythmias; Drugs C1 [Kohli, Payal] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA. [Laine, Loren] Yale Univ, New Haven, CT USA. [Kaur, Amarjot; Curtis, Sean] Merck Inc, Rsch, Whitehouse Stn, NJ USA. [Cannon, Christopher P.] Brigham & Womens Hosp, Div Cardiol, TIMI Study Grp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 19248 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008427 ER PT J AU Kohli, P Desai, NR Giugliano, RP O'Donoghue, ML Somaratne, R Hoffman, EB Huang, FN Wasserman, SM Scott, R Sabatine, MS AF Kohli, Payal Desai, Nihar R. Giugliano, Robert P. O'Donoghue, Michelle L. Somaratne, Ransi Hoffman, Elaine B. Huang, Fannie Wasserman, Scott M. Scott, Robert Sabatine, Marc S. TI Reduction in Lipoprotein (a) with the PCSK9 Inhibitor AMG145 in Hypercholesterolemic Patients on Background Statin: Results from the LAPLACE-TIMI 57 Trial SO CIRCULATION LA English DT Meeting Abstract DE Lipids C1 [Kohli, Payal] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA. [Desai, Nihar R.] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA. [Giugliano, Robert P.; O'Donoghue, Michelle L.; Sabatine, Marc S.] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiol, Boston, MA 02115 USA. [Somaratne, Ransi; Huang, Fannie; Wasserman, Scott M.; Scott, Robert] Amgen Inc, Rsch, Thousand Oaks, CA 91320 USA. [Hoffman, Elaine B.] TIMI Study Grp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17630 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007209 ER PT J AU Kostis, WJ Cabrara, J Hooper, WC Whelton, PK Espeland, MA Cosgrove, NM Sedjro, JE Cheng, JQ Deng, YZ De Staercke, C Pyle, M Maruthur, N Reyes, I Anderson, CA Liu, J Kostis, JB AF Kostis, William J. Cabrara, Javier Hooper, W. C. Whelton, Paul K. Espeland, Mark A. Cosgrove, Nora M. Sedjro, Jeanine E. Cheng, Jerry Q. Deng, Yingzi De Staercke, Christine Pyle, Meredith Maruthur, Nisa Reyes, Ingrid Anderson, Cheryl A. Liu, Jie Kostis, John B. TI Weight Sensitivity in Hypertension SO CIRCULATION LA English DT Meeting Abstract DE Clinical trials; Weight Loss; Sodium; Genetics C1 [Kostis, William J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Cabrara, Javier; Reyes, Ingrid; Liu, Jie] Rutgers State Univ, Dept Stat, Piscataway, NJ USA. [Hooper, W. C.; De Staercke, Christine; Pyle, Meredith] Cntrs Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. [Whelton, Paul K.] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Espeland, Mark A.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Cosgrove, Nora M.; Sedjro, Jeanine E.; Cheng, Jerry Q.; Deng, Yingzi; Kostis, John B.] UMDNJ Robert Wood Johnson Med Sch, Cardiovasc Inst, New Brunswick, NJ USA. [Cosgrove, Nora M.; Sedjro, Jeanine E.; Cheng, Jerry Q.; Deng, Yingzi; Kostis, John B.] UMDNJ Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ USA. [Maruthur, Nisa] Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD USA. [Anderson, Cheryl A.] Johns Hopkins Med Inst, Welch Cntr Prevent Epidemiol & Clin Rsch, Baltimore, MD 21205 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 16242 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885006071 ER PT J AU Kostis, WJ Cabrera, J Messerli, FH Cheng, JQ Cosgrove, NM Deng, YZ Pressel, SL Davis, BR Kostis, JB AF Kostis, William J. Cabrera, Javier Messerli, Franz H. Cheng, Jerry Q. Cosgrove, Nora M. Deng, Yingzi Pressel, Sara L. Davis, Barry R. Kostis, John B. TI The Systolic Hypertension in the Elderly Program: Competing Cardiovascular and Non-Cardiovascular Risk and Increased Longevity SO CIRCULATION LA English DT Meeting Abstract DE Hypertension; Clinical trials; Older population; Outcomes C1 [Kostis, William J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Cabrera, Javier] Rutgers State Univ, Dept Stat, Piscataway, NJ USA. [Messerli, Franz H.] Columbia Univ, Div Cardiol, New York, NY USA. [Cheng, Jerry Q.; Cosgrove, Nora M.; Deng, Yingzi; Kostis, John B.] UMDNJ Robert Wood Johnson Med Sch, Cardiovasc Inst, New Brunswick, NJ USA. [Cheng, Jerry Q.; Cosgrove, Nora M.; Deng, Yingzi; Kostis, John B.] UMDNJ Robert Wood Johnson Med Sch, Dept Med, New Brunswick, NJ USA. [Pressel, Sara L.; Davis, Barry R.] Univ Texas Sch Publ Hlth, Coordinating Cntr Clin Trials, Houston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 13664 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885003339 ER PT J AU Kumbhani, DJ Fonarow, GC Cannon, CP Hernandez, AF Peterson, ED Peacock, WF Laskey, WK Grau-Sepulveda, M Schwamm, LH Bhatt, DL AF Kumbhani, Dharam J. Fonarow, Gregg C. Cannon, Christopher P. Hernandez, Adrian F. Peterson, Eric D. Peacock, W. F. Laskey, Warren K. Grau-Sepulveda, Maria Schwamm, Lee H. Bhatt, Deepak L. TI A Comparison of Temporal Trends in In-hospital Adherence to Secondary Prevention Measures Among Patients Undergoing Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention or No Intervention: Insights From the GWTG-CAD SO CIRCULATION LA English DT Meeting Abstract DE Quality of medical care; Percutaneous coronary intervention; Cardiac surgery; Coronary artery disease; Quality improvement C1 [Kumbhani, Dharam J.; Cannon, Christopher P.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiovasc Med, Los Angeles, CA USA. [Hernandez, Adrian F.; Peterson, Eric D.] Duke Clin Rsch Inst, Div Cardiovasc Med, Durham, NC USA. [Peacock, W. F.] Cleveland Clin, Cleveland, OH 44106 USA. [Laskey, Warren K.] Univ New Mexico, Div Cardiovasc Med, Albuquerque, NM 87131 USA. [Grau-Sepulveda, Maria] Duke Univ, Div Cardiovasc Med, Durham, NC USA. [Schwamm, Lee H.] Massuchusetts Gen Hosp, Div Neurol, Boston, MA USA. [Bhatt, Deepak L.] VA Boston Healthcare Syst, Div Cardiovasc Med, West Roxbury, MA USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, West Roxbury, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17903 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007328 ER PT J AU Leuschner, F Courties, G Gorbatov, R Sena, B Novobrantseva, T Iwamoto, Y Pittet, M Swirski, F Koteliansky, V Weissleder, R Nahrendorf, M AF Leuschner, Florian Courties, Gabriel Gorbatov, Rostic Sena, Brena Novobrantseva, Tatiana Iwamoto, Yoshiko Pittet, Mikael Swirski, Filip Koteliansky, Victor Weissleder, Ralph Nahrendorf, Matthias TI Lipid Nanoparticle Encapsulated SiRNA Against CCR2 Ameliorates Autoimmune Myocarditis and Impacts Myeloid Progenitor Trafficking SO CIRCULATION LA English DT Meeting Abstract DE Inflammation; Myocarditis; Cardiac MRI C1 [Leuschner, Florian; Courties, Gabriel; Gorbatov, Rostic; Sena, Brena; Iwamoto, Yoshiko; Pittet, Mikael; Swirski, Filip; Weissleder, Ralph; Nahrendorf, Matthias] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cntr Syst Biol, Boston, MA 02114 USA. [Novobrantseva, Tatiana; Koteliansky, Victor] Alnylam Pharmaceut, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 11585 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885001358 ER PT J AU Lewis, GD Farell, L Domos, C Dhakal, B Shi, X Sinha, S Semigran, MJ Wang, TJ Sabatine, MS Clish, CB Gerszten, RE AF Lewis, Gregory D. Farell, Laurie Domos, Carly Dhakal, Bishnu Shi, Xu Sinha, Sumita Semigran, Marc J. Wang, Thomas J. Sabatine, Marc S. Clish, Clary B. Gerszten, Robert E. TI Metabolomic Signatures of Right Ventricular-Pulmonary Vascular Dysfunction SO CIRCULATION LA English DT Meeting Abstract DE Metabolomics; Pulmonary hypertension; Ventricular function; Exercise tests C1 [Lewis, Gregory D.; Farell, Laurie; Domos, Carly; Dhakal, Bishnu; Shi, Xu; Sinha, Sumita; Semigran, Marc J.; Wang, Thomas J.; Gerszten, Robert E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sabatine, Marc S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Clish, Clary B.] Broad Inst, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 18311 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008084 ER PT J AU Li, N Zhang, ST Hou, JB Yu, B Zhang, SS Jang, IK AF Li, Ning Zhang, Shaotao Hou, Jingbo Yu, Bo Zhang, Shaosong Jang, Ik-Kyung TI Assessment of Pulmonary Artery Morphology by Optical Coherence Tomography:comparison with Histology SO CIRCULATION LA English DT Meeting Abstract DE Pulmonary artery; Imaging agents; pulmonary artery; optical coherence tomography; histology; imaging C1 [Li, Ning; Zhang, Shaotao; Hou, Jingbo; Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Harbin, Peoples R China. [Zhang, Shaosong] St Jude Med, LightLab Imaging, Dept Cardiol, Westford, MA USA. [Jang, Ik-Kyung] Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 18007 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007376 ER PT J AU Liu, HX Hou, JB Hu, SN Fang, Y Jia, HB Feng, LX Zhang, LN Xie, ZL Zhang, SS Yu, B Jang, IK AF Liu, Haixia Hou, Jingbo Hu, Sining Fang, Yan Jia, Haibo Feng, Linxing Zhang, Linna Xie, Zulong Zhang, Shaosong Yu, Bo Jang, Ik-Kyung TI A Rabbit Model of Spontaneous Plaque Disruption and Thrombosis Induced by Lipopolysaccharide SO CIRCULATION LA English DT Meeting Abstract DE atherosclerosis; thrombosis; lipopolysaccharide; optical coherence tomography; rabbit C1 [Liu, Haixia; Hou, Jingbo; Hu, Sining; Fang, Yan; Jia, Haibo; Feng, Linxing; Zhang, Linna; Xie, Zulong; Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Harbin, Peoples R China. [Zhang, Shaosong] St Jude Med, LightLab Imaging, Westford, MA USA. [Jang, Ik-Kyung] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17924 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007345 ER PT J AU Lunze, FI Gauvreau, K Colan, SD Blume, ED Smith, RN Perez-Atayde, A Singh, TP AF Lunze, Fatima I. Gauvreau, Kimberlee Colan, Steven D. Blume, Elizabeth D. Smith, Rex Neal Perez-Atayde, Antonio Singh, Tajinder P. TI Tissue Doppler Imaging For Rejection Surveillance in Pediatric Heart Transplant Recipients SO CIRCULATION LA English DT Meeting Abstract DE Pediatric cardiology; Echocardiography; Tissue doppler; Transplantation C1 [Lunze, Fatima I.; Gauvreau, Kimberlee; Colan, Steven D.; Blume, Elizabeth D.; Perez-Atayde, Antonio; Singh, Tajinder P.] Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA. [Smith, Rex Neal] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 19355 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885009038 ER PT J AU Macri, V Mahida, S Zhang, M Sinner, MF Dolmatova, E Lunetta, KL Benjamin, EJ Ellinor, PT AF Macri, Vincenzo Mahida, Saagar Zhang, Michael Sinner, Moritz F. Dolmatova, Elena Lunetta, Kathryn L. Benjamin, Emeilia J. Ellinor, Patrick T. TI Novel loss of Function Mutations in HCN4 Identified in Early-Onset Atrial Fibrillation SO CIRCULATION LA English DT Meeting Abstract DE Atrial fibrillation; Genetics; Ion channels; Electrophysiology C1 [Macri, Vincenzo; Mahida, Saagar; Zhang, Michael; Sinner, Moritz F.; Dolmatova, Elena; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiovasc Rsch Cntr, Charlestown, MA USA. [Lunetta, Kathryn L.] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Benjamin, Emeilia J.] Boston Univ, Framingham Heart Study, Framingham, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17963 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007360 ER PT J AU Mahmood, SS Kasliwal, RR Trehan, N Wang, TJ AF Mahmood, Syed S. Kasliwal, Ravi R. Trehan, Naresh Wang, Thomas J. TI Acute Coronary Syndrome Presentation Among Young Patients in New Delhi and Boston SO CIRCULATION LA English DT Meeting Abstract DE Acute coronary syndromes; Myocardial infarction; STEMI; Lipids Smoking; International C1 [Mahmood, Syed S.; Wang, Thomas J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kasliwal, Ravi R.; Trehan, Naresh] Medanta Hosp, Gurgaon 122001, Haryana, India. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 13658 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885003336 ER PT J AU Majmudar, MD Keliher, E Yoo, J Truelove, J Sena, B Iwamoto, Y Di Carli, MF Weissleder, R Nahrendorf, M AF Majmudar, Maulik D. Keliher, Edmund Yoo, Jeongsoo Truelove, Jessica Sena, Brena Iwamoto, Yoshiko Di Carli, Marcelo F. Weissleder, Ralph Nahrendorf, Matthias TI PET/MR Imaging of Inflammation In Atherosclerotic Plaque with a Novel Dextran Nanoparticle SO CIRCULATION LA English DT Meeting Abstract C1 [Majmudar, Maulik D.; Keliher, Edmund; Yoo, Jeongsoo; Truelove, Jessica; Sena, Brena; Iwamoto, Yoshiko; Weissleder, Ralph; Nahrendorf, Matthias] Massachusetts Gen Hosp, Cntr Syst Biol, Boston, MA 02114 USA. [Di Carli, Marcelo F.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 10600 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885000316 ER PT J AU Majmudar, MD Heidt, T Keliher, E Truelove, J Sena, B Gorbatov, R Iwamoto, Y Di Carli, MF Weissleder, R Nahrendorf, M AF Majmudar, Maulik D. Heidt, Timo Keliher, Edmund Truelove, Jessica Sena, Brena Gorbatov, Rostic Iwamoto, Yoshiko Di Carli, Marcelo F. Weissleder, Ralph Nahrendorf, Matthias TI Dual Probe Hybrid Molecular PET/MR Imaging of Post-infarct Myocardial Inflammation and Healing SO CIRCULATION LA English DT Meeting Abstract DE Positron emission tomography; Magnetic resonance imaging; Myocardial infarction; Heart failure; Remodeling C1 [Majmudar, Maulik D.; Heidt, Timo; Keliher, Edmund; Truelove, Jessica; Sena, Brena; Gorbatov, Rostic; Iwamoto, Yoshiko; Weissleder, Ralph; Nahrendorf, Matthias] Massachusetts Gen Hosp, Cntr Syst Biol, Boston, MA 02114 USA. [Di Carli, Marcelo F.] Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 9453 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885000117 ER PT J AU Martyn, T Shakartzi, HR Mayeur, C Bloch, KD Malhotra, R AF Martyn, Trejeeve Shakartzi, Hannah R. Mayeur, Claire Bloch, Kenneth D. Malhotra, Rajeev TI Inhibiting Bone Morphogenetic Protein Signaling Reduces Diabetes-Associated Non-Alcoholic Fatty Liver Disease Independent of Plasma Lipid Levels SO CIRCULATION LA English DT Meeting Abstract DE Cell signaling; Lipids; Molecular biology; Metabolism; Type 2 Diabetes C1 [Martyn, Trejeeve; Shakartzi, Hannah R.; Mayeur, Claire; Bloch, Kenneth D.; Malhotra, Rajeev] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 18829 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008274 ER PT J AU Matteau, A Yeh, RW Orav, FJ Kereiakes, DI Massaro, J Wimmer, NJ Vasaiwala, S Mauri, M AF Matteau, Alexis Yeh, Robert W. Orav, F. J. Kereiakes, Dean I. Massaro, Joseph Wimmer, Neil J. Vasaiwala, Samip Mauri, Maura TI Variation in Aspirin Dose in Dual Antiplatelet Therapy After Percutaneous Coronary Intervention SO CIRCULATION LA English DT Meeting Abstract DE Antiplatelet drugs; Percutaneous coronary intervention; Coronary artery disease; Quality of medical care C1 [Matteau, Alexis; Wimmer, Neil J.; Vasaiwala, Samip; Mauri, Maura] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02115 USA. [Yeh, Robert W.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [Orav, F. J.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02115 USA. [Kereiakes, Dean I.] Christ Hosp, Heart & Vasc Cntr, Dept Med, Div Cardiovasc Med, Cincinnati, OH 45219 USA. [Kereiakes, Dean I.] Lindner Cntr Rsch & Educ, Cincinnati, OH USA. [Massaro, Joseph] Harvard Clin Rsch Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14793 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004366 ER PT J AU May, EAB Bonaca, MP Scirica, BM Morais, J Nieminen, M Murphy, SA Braunwald, E Morrow, DA AF May, Erin A. Bohula Bonaca, Marc P. Scirica, Benjamin M. Morais, Joao Nieminen, Markku Murphy, Sabina A. Braunwald, Eugene Morrow, David A. TI Rates of Arterial Revascularization in Patients Treated with Vorapaxar vs. Placebo in the TRA 2 degrees P-TIMI 50 Trial SO CIRCULATION LA English DT Meeting Abstract DE Antiplatelet drugs; Arteriosclerosis; Thrombin C1 [May, Erin A. Bohula; Bonaca, Marc P.; Scirica, Benjamin M.; Braunwald, Eugene; Morrow, David A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Morais, Joao] Santo Andre Hosp, Pousos, Portugal. [Nieminen, Markku] Univ Cent Hosp, Dept Cardiol, Helsinki, Finland. [Murphy, Sabina A.] TIMI Study Grp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 19221 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008417 ER PT J AU Minami, Y Sahara, M Nakajima, T Ikutomi, M Morita, T Yamashita, H Hirata, Y Nagai, R Sata, M AF Minami, Yoshiyasu Sahara, Makoto Nakajima, Toshiaki Ikutomi, Masayasu Morita, Toshihiro Yamashita, Hiroshi Hirata, Yasunobu Nagai, Ryozo Sata, Masataka TI Real Angiogenic Potential of Early or Late Outgrowth Endothelial Progenitor Cells is Rigorously Dependent on the Time of Emergence SO CIRCULATION LA English DT Meeting Abstract DE Angiogenesis; Endothelial progenitor cell; Regenerative medicine stem cells C1 [Minami, Yoshiyasu; Nakajima, Toshiaki; Ikutomi, Masayasu; Morita, Toshihiro; Yamashita, Hiroshi; Hirata, Yasunobu; Nagai, Ryozo] Univ Tokyo, Grad Sch Med, Tokyo, Japan. [Sahara, Makoto] Massachusetts Gen Hosp, Richard B Simches Rsch Cntr, Boston, MA 02114 USA. [Sata, Masataka] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Tokushima 770, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 9617 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885000168 ER PT J AU Naccarelli, G Bhatt, DL Camm, AJ Le Heuzey, JY Lombardi, F Tamargo, J Bozzi, S Marchese-Roland, C AF Naccarelli, Gerald Bhatt, Deepak L. Camm, A. J. Le Heuzey, Jean-Yves Lombardi, Federico Tamargo, Juan Bozzi, Sylvie Marchese-Roland, Catherine CA ARTEMIS Investigators TI Switching Patients with Atrial Fibrillation from Amiodarone to Dronedarone: Results of the ARTEMIS AF Studies SO CIRCULATION LA English DT Meeting Abstract DE Amiodarone; Atrial fibrillation; Arrhythmias, treatment of; Drugs; Clinical trials C1 [Naccarelli, Gerald] Penn State Univ, Bernard Trabin Chair Cardiol, Coll Med, Hershey, PA USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA USA. [Camm, A. J.] St Georges Univ London, Div Clin Sci, London, England. [Le Heuzey, Jean-Yves] Hop Europeen Georges Pompidou, Dept Cardiol & Rythmol, Paris, France. [Lombardi, Federico] Univ Milan, Milan, Italy. [Tamargo, Juan] Univ Complutense, E-28040 Madrid, Spain. [Bozzi, Sylvie; Marchese-Roland, Catherine] Sanofi, Global Strategy Unit Cardiothrombosis, Paris, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 15918 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885005365 ER PT J AU Natarajan, P Francis, S Dec, GW AF Natarajan, Pradeep Francis, Sanjeev Dec, George W. TI No Longer Idiopathic: A Case of Recurrent Pericarditis in a Military Recruit SO CIRCULATION LA English DT Meeting Abstract DE Pericarditis; Genetics; Inflammation C1 [Natarajan, Pradeep; Francis, Sanjeev; Dec, George W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 13604 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885003310 ER PT J AU Park, MY Upadhyay, GA Friedman, DJ Kandala, J Chatterjee, NA Orencole, M Singh, JP Picard, MH AF Park, Mi Young Upadhyay, Gaurav A. Friedman, Daniel J. Kandala, Jagdesh Chatterjee, Neal A. Orencole, Mary Singh, Jagmeet P. Picard, Michael H. TI Characteristics of Patients Requiring Long Atrio-Ventricular Delay Setting After Cardiac Resynchronization Therapy SO CIRCULATION LA English DT Meeting Abstract DE CRT; Cardiac imaging; Heart failure; Outcomes C1 [Park, Mi Young; Friedman, Daniel J.; Chatterjee, Neal A.; Singh, Jagmeet P.; Picard, Michael H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Upadhyay, Gaurav A.; Kandala, Jagdesh; Orencole, Mary] Massachusetts Gen Hosp, Heart Cntr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14393 PG 3 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004186 ER PT J AU Parvez, B Shah, A Muhammad, R Shoemaker, MB Graves, AJ Heckbert, SR Xu, H Ellinor, PT Benjamin, EJ Alonso, A Shintani, AK Roden, D Darbar, D AF Parvez, Babar Shah, Anushi Muhammad, Raafia Shoemaker, M. Benjamin Graves, Amy J. Heckbert, Susan R. Xu, Hua Ellinor, Patrick T. Benjamin, Emelia J. Alonso, Alvaro Shintani, Ayumi K. Roden, Dan Darbar, Dawood TI Replication of a Risk Prediction Model for Ambulatory Incident Atrial Fibrillation Using Electronic Medical Record SO CIRCULATION LA English DT Meeting Abstract DE Atrial fibrillation; Genomics; Epidemiology C1 [Parvez, Babar; Shah, Anushi; Muhammad, Raafia; Shoemaker, M. Benjamin; Graves, Amy J.; Xu, Hua; Shintani, Ayumi K.; Roden, Dan; Darbar, Dawood] Vanderbilt Univ, Nashville, TN 37235 USA. [Heckbert, Susan R.] Univ Washington, Seattle, WA 98195 USA. [Ellinor, Patrick T.] Massachusetts Gen Hosp, Heart Cntr, Boston, MA 02114 USA. [Benjamin, Emelia J.] Boston Univ, Boston, MA 02215 USA. [Alonso, Alvaro] Univ Minnesota, Minneapolis, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 18578 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008178 ER PT J AU Ptaszek, LM Heist, EK Caulfield, R Cordaro, K Ruskin, JN Mansour, M AF Ptaszek, Leon M. Heist, E. Kevin Caulfield, Ryan Cordaro, Kevin Ruskin, Jeremy N. Mansour, Moussa TI Use of an Infrared Probe Enhances Esophageal Temperature Monitoring during Left Atrial Radiofrequency Ablation SO CIRCULATION LA English DT Meeting Abstract DE Ablation, radiofrequency; Arrhythmias, treatment of; New technology; Patient safety; Research C1 [Ptaszek, Leon M.; Heist, E. Kevin; Caulfield, Ryan; Cordaro, Kevin; Ruskin, Jeremy N.; Mansour, Moussa] Massachusetts Gen Hosp, MGH Heart Cntr, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17516 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007150 ER PT J AU Roberts, LD AF Roberts, Lee D. TI Beta-Aminoisobutyric Acid Increases Browning of White Fat and is Inversely Correlated with Cardiometabolic Risk Factors in Humans SO CIRCULATION LA English DT Meeting Abstract DE Adipose; Metabolism; Metabolomics C1 [Roberts, Lee D.] Massachusetts Gen Hosp, Cardiovasc Rsch Cntr, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 15983 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885005388 ER PT J AU Salinardi, TC Batra, P Roberts, SB Urban, LE Robinson, LM Pittas, AG Lichtenstein, AH Deckersbach, T Saltzman, E Das, SK AF Salinardi, Taylor C. Batra, Payal Roberts, Susan B. Urban, Lorien E. Robinson, Lisa M. Pittas, Anastassios G. Lichtenstein, Alice H. Deckersbach, Thilo Saltzman, Edward Das, Sai Krupa TI A Lifestyle Intervention Reduces Body Weight and Improves Cardiornetabolic Risk Factors in Worksites. SO CIRCULATION LA English DT Meeting Abstract DE Weight Loss; Interventional studies; Obesity; Behavior change; Diet C1 [Salinardi, Taylor C.; Batra, Payal; Roberts, Susan B.; Saltzman, Edward; Das, Sai Krupa] Tufts Univ, Energy Metab Lab, Jean Mayer USDA Human Nutr Rsch Cntr Aging, Boston, MA 02111 USA. [Urban, Lorien E.] Tufts Univ, Energy Metab Lab, Boston, MA 02111 USA. [Robinson, Lisa M.] Boston Childrens Hosp, New Balance Fdn Obes Prevent Cntr, Boston, MA USA. [Pittas, Anastassios G.] Tufts Med Cntr, Div Endocrinol Diabet & Metab, Boston, MA USA. [Lichtenstein, Alice H.] Tufts Univ, Cardiovasc Nutr Lab, Jean Mayer USDA Human Nutr Rsch Cntr Aging, Boston, MA 02111 USA. [Deckersbach, Thilo] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 13112 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885003093 ER PT J AU Schlett, CL Torriani, MP Zanni, MV Fitch, KV Bredella, MA Tawakol, A Grinspoon, SK Hoffmann, U AF Schlett, Christopher L. Torriani, Martin P. Zanni, Markella V. Fitch, Kathleen V. Bredella, Miriam A. Tawakol, Ahmed Grinspoon, Steven K. Hoffmann, Udo TI CT Attenuation of Abdominal Adipose Tissue and its Correlation to (18)FDG-Activity in PET - A Potential Noninvasive Marker of Metabolic and Inflammatory Activity SO CIRCULATION LA English DT Meeting Abstract DE Computed tomography; Positron emission tomography; Inflammation; Adipose C1 [Schlett, Christopher L.; Torriani, Martin P.; Bredella, Miriam A.; Tawakol, Ahmed; Hoffmann, Udo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Zanni, Markella V.; Fitch, Kathleen V.; Grinspoon, Steven K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Nutr Metab, Boston, MA USA. [Zanni, Markella V.; Fitch, Kathleen V.; Grinspoon, Steven K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroendocrine Unit, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14920 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004423 ER PT J AU Schlett, CL Truong, QA Ahmed, W Blankstein, R Ferencik, M Uthamalingam, S Bamberg, F Koenig, W Januzzi, JL Hoffmann, U AF Schlett, Christopher L. Truong, Quynh A. Ahmed, Waleed Blankstein, Ron Ferencik, Maros Uthamalingam, Shanmugam Bamberg, Fabian Koenig, Wolfgang Januzzi, James L. Hoffmann, Udo TI Can Blood Biomarkers Predict Whose Heart is Healthy? - Discriminatory Capacity of High- sensitivity Troponin T and C- reactive Protein Between Patients With and Without Coronary Atherosclerosis, LV Hypertrophy/Dysfunction and Myocardial Perfusion Abnormalities as Assessed by Cardiac CT and SPECT Imaging SO CIRCULATION LA English DT Meeting Abstract DE 2020 Goals; Cardiovascular Imaging; Perfusion imaging; Biormarkers C1 [Schlett, Christopher L.; Truong, Quynh A.; Ahmed, Waleed; Ferencik, Maros; Uthamalingam, Shanmugam; Januzzi, James L.; Hoffmann, Udo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Blankstein, Ron] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Bamberg, Fabian] Univ Munich, Munich, Germany. [Koenig, Wolfgang] Univ Ulm, Dept Internal Med 2, Med Cntr, D-89069 Ulm, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 11655 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885001380 ER PT J AU Schopfer, DW Bhakhri, A Allsup, K Forman, DE Whooley, MA AF Schopfer, David W. Bhakhri, Amit Allsup, Kelly Forman, Daniel E. Whooley, Mary A. TI Barriers and Facilitators Associated with Utilization of Cardiac Rehabilitation Programs at VA Facilities SO CIRCULATION LA English DT Meeting Abstract DE Cardiac rehabilitation; Quality of medical care; Ischemic heart disease C1 [Schopfer, David W.; Bhakhri, Amit; Whooley, Mary A.] San Francisco VA Med Cntr, San Francisco, CA USA. [Allsup, Kelly] VA Boston Healthcare Syst, New England Geriatr Rsch Educ & Clin Cntr, Boston, MA USA. [Forman, Daniel E.] VA Boston Healthcare Syst, Div Cardiovasc Dis, Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17468 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007125 ER PT J AU Shah, R Heydari, B Coelho, O Francis, S Murthy, V Pencina, M Abbasi, S Feng, H Neilan, T Blankstein, R Steigner, M Jerosch-Herold, M Kwong, R AF Shah, Ravi Heydari, Bobak Coelho-Filho, Otavio Francis, Sanjeev Murthy, Venkatesh Pencina, Michael Abbasi, Siddique Feng, Henry Neilan, Tomas Blankstein, Ron Steigner, Michael Jerosch-Herold, Michael Kwong, Raymond TI Stress Perfusion Cardiac Magnetic Resonance Predicts Risk of Cardiac Events in Patients with Established Coronary Artery Disease SO CIRCULATION LA English DT Meeting Abstract DE Prognosis C1 [Shah, Ravi; Francis, Sanjeev; Neilan, Tomas] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Heydari, Bobak; Coelho-Filho, Otavio; Murthy, Venkatesh; Abbasi, Siddique; Feng, Henry; Blankstein, Ron; Steigner, Michael; Jerosch-Herold, Michael; Kwong, Raymond] Brigham & Womens Hosp, Boston, MA 02115 USA. [Pencina, Michael] Harvard Clin Rsch Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 19425 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885009067 ER PT J AU Shah, R Rao, A Garg, R Jerosch-Herold, M Kwong, R Perlstein, T Di Carli, M Adler, G AF Shah, Ravi Rao, Ajay Garg, Rajesh Jerosch-Herold, Michael Kwong, Raymond Perlstein, Todd Di Carli, Marcelo Adler, Gail TI Aldosterone and Diabetic Heart Disease: Relevance to Diffuse Myocardial Fibrosis and Coronary Microvascular Dysfunction SO CIRCULATION LA English DT Meeting Abstract DE Fibrosis; Type Diabetes C1 [Shah, Ravi] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Rao, Ajay; Garg, Rajesh; Jerosch-Herold, Michael; Kwong, Raymond; Perlstein, Todd; Adler, Gail] Brigham & Womens Hosp, Boston, MA 02115 USA. [Di Carli, Marcelo] Brigham & Womens Hosp, Dept Med, 5Noninvas Cardiovasc Imaging Program, Boston, MA 02115 USA. [Di Carli, Marcelo] Brigham & Womens Hosp, Dept Radiol, 5Noninvas Cardiovasc Imaging Program, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 19189 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008406 ER PT J AU Shen, L Shah, B Reyes, E Thomas, L Diem, P Leiter, L Charbonnel, B Mareev, V Horton, E Haffner, S Soska, V Holman, R Bethel, MA Schaper, F Sun, JL McMurray, J Califf, R Krum, H AF Shen, Lan Shah, Bimal Reyes, Eric Thomas, Laine Diem, Peter Leiter, Lawrence Charbonnel, Bernard Mareev, Viacheslav Horton, Edward Haffner, Steven Soska, Vladimir Holman, Rurv Bethel, M. Angelyn Schaper, Frank Sun, Jie-Lena McMurray, John Califf, Robert Krum, Henry TI Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study SO CIRCULATION LA English DT Meeting Abstract DE Beta-blocker; Statins; Diuretics; Type 2 Diabetes C1 [Shen, Lan; Shah, Bimal; Reyes, Eric; Thomas, Laine; Sun, Jie-Lena] Duke Univ Med Cntr, Duke Clin Rsch Inst, Durham, NC USA. [Diem, Peter] Univ Hosp Bern, CH-3010 Bern, Switzerland. [Leiter, Lawrence] Univ Toronto, Toronto, ON, Canada. [Charbonnel, Bernard] Univ Nantes, Nantes, France. [Mareev, Viacheslav] Cardiol Rsch Cntr, Moscow, Russia. [Horton, Edward] Harvard Univ, Sch Med, Joslin Diabet Cntr, Boston, MA USA. [Haffner, Steven] Baylor Coll Med, Houston, TX 77030 USA. [Soska, Vladimir] St Annes Univ Hosp, Brno, Czech Republic. [Holman, Rurv; Bethel, M. Angelyn] Univ Oxford, Diabet Trials Unit, Oxford, England. [Schaper, Frank] Tech Univ Dresden, Inst Clin Metab Rsch, D-01062 Dresden, Germany. [McMurray, John] Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Rsch Cntr, Glasgow, Lanark, Scotland. [Califf, Robert] Duke Univ Med Cntr, Duke Translat Med Inst, Durham, NC USA. [Krum, Henry] Monash Univ, Cntr Cardiovasc Rsch & Educ Therapeut, Melbourne, Vic 3004, Australia. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14642 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004304 ER PT J AU Singal, G Upadhyay, GA Friedman, D Chatterjee, NA Kandala, J Orencole, M Barrett, C Dec, GW Picard, MH Singh, JP AF Singal, Gaurav Upadhyay, Gaurav A. Friedman, Daniel Chatterjee, Neal A. Kandala, Jagdesh Orencole, Mary Barrett, Conor Dec, George W. Picard, Michael H. Singh, Jagmeet P. TI Renal Response in Patients with Chronic Kidney Disease (CKD) Predicts Outcome Following Cardiac Resynchronization Therapy (CRT) SO CIRCULATION LA English DT Meeting Abstract DE CRT; Heart failure; Renal function; Bi-ventricular pacing C1 [Singal, Gaurav; Upadhyay, Gaurav A.; Friedman, Daniel; Chatterjee, Neal A.; Kandala, Jagdesh; Orencole, Mary; Barrett, Conor; Dec, George W.; Picard, Michael H.; Singh, Jagmeet P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17791 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007282 ER PT J AU Singer, DE Chang, YC Fang, MC Reynolds, K Borowsky, LH Udaltsova, N Go, AS AF Singer, Daniel E. Chang, Yuchiao Fang, Margaret C. Reynolds, Kristi Borowsky, Leila H. Udaltsova, Natalia Go, Alan S. TI External Validation of a New Risk Score to Predict Stroke in Atrial Fibrillation SO CIRCULATION LA English DT Meeting Abstract DE Atrial fibrillation; Anticoagulation; Risk factors; Prevention C1 [Singer, Daniel E.; Chang, Yuchiao; Borowsky, Leila H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Fang, Margaret C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Reynolds, Kristi] Kaiser Permanente So Calif, Pasadena, CA 91101 USA. [Udaltsova, Natalia; Go, Alan S.] Kaiser Permanente No Calif, Div Rsch, Oakland, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 11999 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885002092 ER PT J AU Sinner, MF Krijthe, B Aspelund, T Stepas, K Pencina, M Moser, C Sootodehnia, N Fontes, J Janssens, C Kronmal, R Magnani, J Witteman, J Chamberlain, A Lubitz, S Schnabel, R Vasan, R Wang, T Agarwal, S McManus, D Ellinor, P Larson, M Burke, G Launer, L Hofman, A Levy, D Gottdiener, J Kaab, S Couper, D Harris, T Soliman, E Stricker, B Gudnason, V Heckbert, S Benjamin, E Alonso, A AF Sinner, Moritz F. Krijthe, Bouwe Aspelund, Thor Stepas, Katherine Pencina, Michael Moser, Carlee Sootodehnia, Nona Fontes, Joao Janssens, Cecile Kronmal, Richard Magnani, Jared Witteman, Jacqueline Chamberlain, Alanna Lubitz, Steven Schnabel, Renate Vasan, Ramachandran Wang, Thomas Agarwal, Sunil McManus, David Ellinor, Patrick Larson, Martin Burke, Gregory Launer, Leonore Hofman, Albert Levy, Daniel Gottdiener, John Kaeaeb, Stefan Couper, David Harris, Tamara Soliman, Elsayed Stricker, Bruno Gudnason, Vilmundur Heckbert, Susan Benjamin, Emelia Alonso, Alvaro TI B-Type-Natriuretic Peptide and C-Reactive Protein in the Prediction of Atrial Fibrillation Risk: The CHARGE-AF Consortium SO CIRCULATION LA English DT Meeting Abstract DE Atrial fibrillation; Risk factors; Biomarkers; Natriuretic peptide; Epidemiology C1 [Sinner, Moritz F.; Lubitz, Steven; Ellinor, Patrick] Massachusetts Gen Hosp, Cardiovasc Rsch Cntr, Charlestown, MA USA. [Krijthe, Bouwe; Janssens, Cecile; Witteman, Jacqueline; Hofman, Albert; Stricker, Bruno] Erasmus Med Cntr, Dept Epidemiolgy, Rotterdam, Netherlands. [Aspelund, Thor; Gudnason, Vilmundur] Iceland Heart Assoc, Rsch Inst, Kopavogur, Iceland. [Stepas, Katherine; Pencina, Michael; Moser, Carlee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Sootodehnia, Nona] Univ Washington, Div Cardiol, Seattle, WA 98195 USA. [Fontes, Joao; Magnani, Jared; Vasan, Ramachandran; Larson, Martin; Levy, Daniel; Benjamin, Emelia] Boston Univ, Framingham Heart study, Framingham, MA USA. [Kronmal, Richard] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Chamberlain, Alanna] Mayo Clini, Dept Hlth Sci Rsch, Rochester, MN USA. [Schnabel, Renate] Univ Heart Cntr, Dept Gen & Intervent Cardiol, Hamburg, Germany. [Wang, Thomas] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Agarwal, Sunil] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [McManus, David] Univ Massachusetts, Dept Med, Worcester, MA 01605 USA. [Burke, Gregory] Wake Forest Sch Med, Div Publ Hlth Sci, Winston Salem, NC USA. [Launer, Leonore; Harris, Tamara] NIA, Lab Epidemiol, Bethesda, MD 20892 USA. [Gottdiener, John] Univ Maryland, Med Ctr, Div Cardiol, Baltimore, MD 21201 USA. [Kaeaeb, Stefan] Univ Hosp Munich, Dept Med 1, Munich, Germany. [Couper, David] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA. [Soliman, Elsayed] Wake Forest Sch Med, Dept Epidemiol, Winston Salem, NC USA. [Heckbert, Susan] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Alonso, Alvaro] Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA. RI Gudnason, Vilmundur/K-6885-2015; Aspelund, Thor/C-5983-2008 OI Gudnason, Vilmundur/0000-0001-5696-0084; Aspelund, Thor/0000-0002-7998-5433 NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 12621 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885002323 ER PT J AU Steen, DL Cannon, CP Lele, S Rajapurkar, M Mukhopadhyay, B Scirica, BM Morrow, DA AF Steen, Dylan L. Cannon, Christopher P. Lele, Suhas Rajapurkar, Mohan Mukhopadhyay, Banibrata Scirica, Benjamin M. Morrow, David A. TI Prognostic Evaluation of Catalytic Iron in Patients with Acute Coronary Syndromes: Observations from OPUS-TIMI 16 SO CIRCULATION LA English DT Meeting Abstract DE Biomarkers; Acute coronary syndromes; Risk factors; Coronary heart disease; Coronary syndromes C1 [Steen, Dylan L.; Cannon, Christopher P.; Scirica, Benjamin M.; Morrow, David A.] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, Boston, MA 02115 USA. [Lele, Suhas] Bhailal Amin Gen Hosp, Div Cardiovasc, Baroda, Gujarat, India. [Rajapurkar, Mohan] Muljibhai Patel Urol Hosp, Dept Nephrol, Nadiad, India. [Mukhopadhyay, Banibrata] Muljibhai Patel Urol Hosp, Dept Biochem, Nadiad, India. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 18754 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008247 ER PT J AU Stefanescu, A Macklin, E Lin, E Dudzinski, D Yeh, DD Lui, G Bhatt, A AF Stefanescu, Ada Macklin, Eric Lin, Elaine Dudzinski, David Yeh, Doreen Defaria Lui, George Bhatt, Ami TI Predicting Outcome in Adult Congenital Heart Disease: Correlating the Seattle Heart Failure Model with peak VO2 from Cardiopulmonary Exercise Testing SO CIRCULATION LA English DT Meeting Abstract DE Adult congenital heart disease; Heart failure C1 [Stefanescu, Ada; Macklin, Eric; Dudzinski, David; Yeh, Doreen Defaria; Bhatt, Ami] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Lin, Elaine; Lui, George] Montefiore Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 19748 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885009190 ER PT J AU Steinberg, BA Kim, S Ansell, J Hylek, E Mahaffey, KW Singer, DE Ezekowitz, MD Fonarow, GC Go, AS Kowey, P Thomas, L Chang, P Piccini, JP Peterson, ED AF Steinberg, Benjamin A. Kim, Sunghee Ansell, Jack Hylek, Elaine Mahaffey, Kenneth W. Singer, Daniel E. Ezekowitz, Michael D. Fonarow, Gregg C. Go, Alan S. Kowey, Peter Thomas, Laine Chang, Paul Piccini, Jonathan P. Peterson, Eric D. TI High Use of Concomitant Antiplatelet Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Results from the ORBIT-AF Registry SO CIRCULATION LA English DT Meeting Abstract DE Atrial fibrillation; Antiplatelet drugs; Ischemic heart disease; Epidemiology; Valvular disease C1 [Steinberg, Benjamin A.] Duke Univ, Med Ctr, Durham, NC USA. [Kim, Sunghee; Mahaffey, Kenneth W.; Thomas, Laine; Piccini, Jonathan P.; Peterson, Eric D.] Duke Clin Rsch Inst, Durham, NC USA. [Ansell, Jack] NYU, Sch Med, Lenox Hill Hosp, New York, NY USA. [Hylek, Elaine] Boston Univ, Sch Med, Boston, MA 02118 USA. [Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA USA. [Singer, Daniel E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ezekowitz, Michael D.] Lankenau Inst Med Rsch, Wynnewood, PA USA. [Fonarow, Gregg C.] Ahmanson & Endash, Los Angeles, CA USA. [Fonarow, Gregg C.] Ronald Reagan UCLA Med Cntr, UCLA Cardiomyopathy Cntr, Los Angeles, CA USA. [Go, Alan S.] Kaiser Permanente, Rsch, Oakland, CA USA. [Kowey, Peter] MLH Heart Cntr, Wynnewood, PA USA. [Chang, Paul] Johnson & Johnson, Med Affairs, New Brunswick, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 13006 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885003052 ER PT J AU Tabtabai, S Upadhyay, G Park, MY Singh, J Mela, T Moore, S Orencole, M AF Tabtabai, Sara Upadhyay, Gaurav Park, Mi Young Singh, Jagmeet Mela, Theofanie Moore, Stephanie Orencole, Mary TI Females with Ischemic Cardiomyopathy Have Worse Outcomes with Cardiac Resynchronization Therapy (CRT) Compared to Males SO CIRCULATION LA English DT Meeting Abstract DE Heart failure; CRT; Outcomes; Ischemic heart disease C1 [Tabtabai, Sara; Upadhyay, Gaurav; Park, Mi Young; Singh, Jagmeet; Mela, Theofanie; Moore, Stephanie; Orencole, Mary] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 16980 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885006356 ER PT J AU Tan, TC Sawaya, H Sebaq, IA Cohen, V Martin, RP Picard, MH Passeri, JJ Kuter, I Scherrer-Crosbie, M AF Tan, Timothy C. Sawaya, Heloisa Sebaq, Igal A. Cohen, Victor Martin, Randolph P. Picard, Michael H. Passeri, Jonathan J. Kuter, Irene Scherrer-Crosbie, Marielle TI Time Trends of Echocardiography Measures of LV Function in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes and Trastuzumab SO CIRCULATION LA English DT Meeting Abstract DE Echocardiography; Strain rate; Heart failure C1 [Tan, Timothy C.; Sawaya, Heloisa; Picard, Michael H.; Passeri, Jonathan J.; Scherrer-Crosbie, Marielle] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Sebaq, Igal A.] Sir Mortimer B Davis Jewish Hosp, Dept Med, Echocardiog Lab, Montreal, PQ H3T 1E2, Canada. [Sebaq, Igal A.] Sir Mortimer B Davis Jewish Hosp, Dept Med, Div Cardiol, Montreal, PQ H3T 1E2, Canada. [Cohen, Victor] Hosp Univ Penn, Div Cardiol, Philadelphia, PA 19104 USA. [Martin, Randolph P.] Piedmont Heart Inst Phys, Atlanta, GA USA. [Kuter, Irene] Massachusetts Gen Hosp, Gillette Cntr Breast Canc, Boston, MA 02114 USA. [Kuter, Irene] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 19245 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008426 ER PT J AU Tan, TC Flynn, AW Rincon, LM Nunes, MP Mehrotra, P Agnihotri, AK Shahian, DM Picard, MH Afilalo, J AF Tan, Timothy C. Flynn, Aidan W. Rincon, Luis M. Nunes, Maria P. Mehrotra, Praveen Agnihotri, Arvind K. Shahian, David M. Picard, Michael H. Afilalo, Jonathan TI Functional Tricuspid Regurgitation is an Independent Predictor of Mortality and Morbidity in Patients with Aortic Stenosis Undergoing Valve Replacement SO CIRCULATION LA English DT Meeting Abstract DE Echocardiography; Tricuspid valve; Aortic valve stenosis; Aortic valve C1 [Tan, Timothy C.; Flynn, Aidan W.; Rincon, Luis M.; Nunes, Maria P.; Mehrotra, Praveen; Agnihotri, Arvind K.; Shahian, David M.; Picard, Michael H.; Afilalo, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 19057 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008355 ER PT J AU Thai, WE Wai, B Cheng, T Beaudoin, J Caulfield, R Cordaro, K Barrett, CD Danik, S Truong, QA AF Thai, Wai-ee Wai, Bryan Cheng, Teresa Beaudoin, Jonathan Caulfield, Ryan Cordaro, Kevin Barrett, Conor D. Danik, Stephan Truong, Quynh A. TI Myocardial Scar by Standard and Dual Energy Late Enhancement Computed Tomography: Comparison to Pathology in a Chronic Infarct Porcine Model SO CIRCULATION LA English DT Meeting Abstract DE Cardiac CT; Myocardial infarction; Infarct size; Electrophysiology C1 [Thai, Wai-ee; Wai, Bryan; Cheng, Teresa; Truong, Quynh A.] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA. [Beaudoin, Jonathan; Caulfield, Ryan; Cordaro, Kevin; Barrett, Conor D.; Danik, Stephan] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17629 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007208 ER PT J AU Tian, JW Hou, JB Xing, L Zhang, SS Yu, B Jang, K AF Tian, Jinwei Hou, Jingbo Xing, Lei Zhang, Shaosong Yu, Bo Jang, Kyung TI Association Between Lp-PLA2 & rtf-inf-end;Activity and Fibrous Cap Thickness and Plaque Volume in Patients with ACS: An Optical Coherence Tomography and Intravascular Ultrasound Study SO CIRCULATION LA English DT Meeting Abstract DE Arteriosclerosis; Lipoproteins; Cardiovascular imaging; Acute coronary syndromes; Intravascular ultrasound/Doppler C1 [Tian, Jinwei; Hou, Jingbo; Xing, Lei; Yu, Bo] Harbin Med Univ, Affiliated Hosp 2, Dept Cardiol, Haerbin, Peoples R China. [Zhang, Shaosong] St Jude Med, LightLab Imaging, Westford, MA USA. [Jang, Kyung] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17883 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007323 ER PT J AU Truong, QA Hayden, D Woodard, PK Kirby, R Chou, ET Wiviott, SD Fleg, JL Schoenfeld, DA Udelson, JE Hoffmann, U AF Truong, Quynh A. Hayden, Douglas Woodard, Pamela K. Kirby, Ruth Chou, Eric T. Wiviott, Stephen D. Fleg, Jerome L. Schoenfeld, David A. Udelson, James E. Hoffmann, Udo TI Women Benefit Most from Early CCTA Compared to Standard ED Evaluation for Acute Chest Pain: The ROMICAT II Trial SO CIRCULATION LA English DT Meeting Abstract DE Cardiac CT; Emergency care; Comparative effectiveness; Clinical trials; Cardiovascular imaging C1 [Truong, Quynh A.; Hoffmann, Udo] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Div Cardiol, Boston, MA 02114 USA. [Truong, Quynh A.; Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Hayden, Douglas; Schoenfeld, David A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Woodard, Pamela K.] Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, St Louis, MO 63110 USA. [Kirby, Ruth; Fleg, Jerome L.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA. [Chou, Eric T.] Kaiser Permanente Fontana Med Cntr, Fontana, CA USA. [Wiviott, Stephen D.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA. [Udelson, James E.] Tufts Med Cntr, Cardiol & CardioVasc Cntr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 12596 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885002314 ER PT J AU Upadhyay, GA Kandala, J Singal, G Friedman, DJ Chatterjee, NA Singh, JP Fifer, MA Mela, T AF Upadhyay, Gaurav A. Kandala, Jagdesh Singal, Gaurav Friedman, Daniel J. Chatterjee, Neal A. Singh, Jagmeet P. Fifer, Michael A. Mela, Theofanie TI End-Stage Hypertrophic Cardiomyopathy Treated with Cardiac Resynchronization Therapy (CRT) SO CIRCULATION LA English DT Meeting Abstract DE Hypertrophic cardiomyopathy; Resynchroniation therapy; Pacemakers; Outcomes; CRT C1 [Upadhyay, Gaurav A.; Kandala, Jagdesh; Chatterjee, Neal A.; Singh, Jagmeet P.; Mela, Theofanie] Massachusetts Gen Hosp, Div Cardiol, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Singal, Gaurav; Friedman, Daniel J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Fifer, Michael A.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 17353 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885007081 ER PT J AU Upadhyay, GA Kandala, J Chatterjee, NA Friedman, DJ Parks, KA Park, MY Lewis, GD Mela, T Hung, JW Singh, JP AF Upadhyay, Gaurav A. Kandala, Jagdesh Chatterjee, Neal A. Friedman, Daniel J. Parks, Kimberly A. Park, Mi Young Lewis, Gregory D. Mela, Theofanie Hung, Judy W. Singh, Jagmeet P. TI Tricuspid Regurgitation Predicts Mortality after Cardiac Resynchronization Therapy (CRT) SO CIRCULATION LA English DT Meeting Abstract DE Tricuspid valve; CRT; Heart failure; Outcomes; Device C1 [Upadhyay, Gaurav A.; Kandala, Jagdesh; Mela, Theofanie; Singh, Jagmeet P.] Massachusetts Gen Hosp, Div Cardiol, Cardiac Arrhythmia Serv, Boston, MA 02114 USA. [Chatterjee, Neal A.; Friedman, Daniel J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Parks, Kimberly A.; Lewis, Gregory D.] Massachusetts Gen Hosp, Div Cardiol, Heart Failure Serv, Boston, MA 02114 USA. [Park, Mi Young; Hung, Judy W.] Massachusetts Gen Hosp, Div Cardiol, Echocardiog Lab, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 12543 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885002291 ER PT J AU Vandenwijngaert, S Swinnen, M Pokreisz, P Gillijns, H Caluwe, E Bartunek, J Bloch, KD Janssens, SP AF Vandenwijngaert, Sara Swinnen, Melissa Pokreisz, Peter Gillijns, Hilde Caluwe, Ellen Bartunek, Jozef Bloch, Kenneth D. Janssens, Stefan P. TI Cardiac Soluble Guanylate Cyclase Protects Against Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice SO CIRCULATION LA English DT Meeting Abstract DE Ventricular remodeling; Cardioprotection; Nitric oxide; Transgenic models C1 [Vandenwijngaert, Sara; Swinnen, Melissa; Pokreisz, Peter; Gillijns, Hilde; Caluwe, Ellen; Janssens, Stefan P.] Katholieke Univ Leuven, Dept Cardiovasc Sci, Louvain, Belgium. [Bartunek, Jozef] Onze Lieve Vrouw Hosp, Cardiovasc Cntr, Aalst, Belgium. [Bloch, Kenneth D.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Bloch, Kenneth D.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 18928 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008309 ER PT J AU Welch, MP Prutkin, JM Greenspon, AJ Sohail, MR Vikram, HR Baddour, LM Danik, SB Peacock, JE del Rio, A Miro, JM Waidelich, L Naber, C Carrillo, RG Hellinger, WC Tseng, CH Uslan, DZ AF Welch, Mariko P. Prutkin, Jordan M. Greenspon, Arnold J. Sohail, Muhammed R. Vikram, Holenarasipur R. Baddour, Larry M. Danik, Stephan B. Peacock, James E. del Rio, Ana Miro, Jose M. Waidelich, Lioba Naber, Christoph Carrillo, Roger G. Hellinger, Walter C. Tseng, Chi-Hong Uslan, Daniel Z. CA MEDIC Investigators TI Variability in Clinical Features of Early versus Late Cardiovascular Implantable Electronic Device Pocket Infections SO CIRCULATION LA English DT Meeting Abstract DE Pacemaker, artificial; Endocarditis; Electrophysiology C1 [Welch, Mariko P.; Prutkin, Jordan M.] Univ Washington, Seattle, WA 98195 USA. [Greenspon, Arnold J.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Sohail, Muhammed R.; Baddour, Larry M.] Mayo Clin, Coll Med, Rochester, MN USA. [Vikram, Holenarasipur R.] Mayo Clin, Phoenix, AZ USA. [Danik, Stephan B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Peacock, James E.] Wake Forest Univ, Winston Salem, NC 27109 USA. [del Rio, Ana; Miro, Jose M.] Univ Barcelona, IDIBAPS, Barcelona, Spain. [Waidelich, Lioba; Naber, Christoph] Elisabeth Hosp, Essen, Germany. [Carrillo, Roger G.] Univ Miami, Miami, FL USA. [Hellinger, Walter C.] Mayo Clin, Jacksonville, FL 32224 USA. [Tseng, Chi-Hong; Uslan, Daniel Z.] Univ Calif Los Angeles, Los Angeles, CA USA. RI Carrillo, Roger/C-2231-2015; Sohail, Muhammad/K-1803-2016 OI Carrillo, Roger/0000-0002-0443-8689; Sohail, Muhammad/0000-0001-6355-0526 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 13539 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885003279 ER PT J AU Weyman, AE Geiser, EA Subhiyah, R AF Weyman, Arthur E. Geiser, Edward A. Subhiyah, Raja CA Natl Board Echocardiography Natl Board Med Examiners TI ASCeXAM at Sixteen SO CIRCULATION LA English DT Meeting Abstract DE Echocardiography; Health education; Quality assessment C1 [Weyman, Arthur E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Geiser, Edward A.] Natl Board Echocardiog, Raleigh, NC USA. [Subhiyah, Raja] Natl Board Med Examiners, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14261 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004127 ER PT J AU Wimmer, NJ Mauri, L Matheny, ME Pomerantsev, E Ho, KK Robbins, S Matteau, A Vasaiwala, S Resnic, FS Yeh, RW AF Wimmer, Neil J. Mauri, Laura Matheny, Michael E. Pomerantsev, Eugene Ho, Kalon K. Robbins, Susan Matteau, Alexis Vasaiwala, Samip Resnic, Frederic S. Yeh, Robert W. TI Risk-Treatment Paradox in the Selection of Transradial Access for Percutaneous Coronary Intervention: An Opportunity for Quality Improvement SO CIRCULATION LA English DT Meeting Abstract DE Quality improvement; Percutaneous coronary intervention; Vascular C1 [Wimmer, Neil J.; Mauri, Laura; Robbins, Susan; Matteau, Alexis; Vasaiwala, Samip; Resnic, Frederic S.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA. [Matheny, Michael E.] Vanderbilt Univ, Med Cntr, Div Gen Internal Med, Nashville, TN 37235 USA. [Pomerantsev, Eugene; Yeh, Robert W.] Massachusetts Gen Hosp, Div Cardiovasc Med, Boston, MA 02114 USA. [Ho, Kalon K.] Beth Israel Deaconness Med Cntr, Div Cardiol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14773 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004355 ER PT J AU Wimmer, NJ Yeh, RW Cutlip, DE Mauri, L AF Wimmer, Neil J. Yeh, Robert W. Cutlip, Donald E. Mauri, Laura TI A Pre-procedural Risk Model and Risk Score for Adverse Events after Carotid Artery Stenting in High-Surgical Risk Patients from the Stenting and Angioplasty with Protection in Patients at High-Risk for Endarterctomy Worldwide Study SO CIRCULATION LA English DT Meeting Abstract DE Carotid arteries; Stroke; Stent; Risk factors C1 [Wimmer, Neil J.; Mauri, Laura] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA. [Yeh, Robert W.] Massachusetts Gen Hosp, Div Cardiovasc Med, Boston, MA 02114 USA. [Cutlip, Donald E.] Beth Israel Deaconness Med Cntr, Div Cardiol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 11335 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885001267 ER PT J AU Xian, Y Holloway, RG Smith, EE Schwamm, LH Reeves, MJ Cox, M Olson, DM Hernandez, AF Lytle, B Fonarow, GC Peterson, ED AF Xian, Ying Holloway, Robert G. Smith, Eric E. Schwamm, Lee H. Reeves, Mathew J. Cox, Margueritte Olson, DaiWai M. Hernandez, Adrian F. Lytle, Barbara Fonarow, Gregg C. Peterson, Eric D. TI Race/Ethnic Differences in Mortality Among Patients Hospitalized with Intracerebral Hemorrhage SO CIRCULATION LA English DT Meeting Abstract DE Stroke C1 [Xian, Ying; Cox, Margueritte; Olson, DaiWai M.; Hernandez, Adrian F.; Lytle, Barbara; Peterson, Eric D.] Duke Univ, Duke Clin Rsch Inst, Durham, NC USA. [Holloway, Robert G.] Univ Rochester, Dept Neurol, Med Cntr, Rochester, NY USA. [Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada. [Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Reeves, Mathew J.] Michigan State Univ, Dept Epidemiol, Durham, MI USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA. RI Smith, Eric/C-5443-2012 OI Smith, Eric/0000-0003-3956-1668 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 18919 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008304 ER PT J AU Xu, YX Ashline, D Liu, L Ravid, K Layne, M Reinhold, V Kathiresan, S AF Xu, Yu-Xin Ashline, David Liu, Li Ravid, Katya Layne, Matthew Reinhold, Vernon Kathiresan, Sekar TI Glycosylation-Dependent Lipoprotein Binding of Low-Density Lipoprotein Receptor-Like Domain of Perlecan and Implications for Atherosclerosis SO CIRCULATION LA English DT Meeting Abstract DE Arteriosclerosis; Plaque; Molecular biology C1 [Xu, Yu-Xin; Kathiresan, Sekar] Massachusetts Gen Hosp, Cntr Human Genet Rsch, Boston, MA 02114 USA. [Ashline, David; Reinhold, Vernon] Univ New Hampshire, Dept Chem, Glyc Cntr, Durham, NH 03824 USA. [Liu, Li] Boston Univ, Goldman Sch Dent Med, Boston, MA 02215 USA. [Ravid, Katya] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Layne, Matthew] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 14476 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885004232 ER PT J AU Zhang, ZG Edwards, F Kolm, P Grau-Sepulveda, M O'Brien, S Shahian, D Ponirakis, A Klein, LW Grover, FL Garratt, K Mckay, C Weintraub, WS AF Zhang, Zugui Edwards, Fred Kolm, Paul Grau-Sepulveda, Maria O'Brien, Sean Shahian, David Ponirakis, Angelo Klein, Lloyd W. Grover, Frederick L. Garratt, Kirk Mckay, Charles Weintraub, William S. TI Cost-effectiveness of Revascularization Strategies: A Preliminary Study from ASCERT SO CIRCULATION LA English DT Meeting Abstract DE Coronary artery disease; Percutaneous coronary intervention; Cost-effectiveness; Cardiovascular disease; Comparative effectiveness C1 [Zhang, Zugui; Kolm, Paul] Christiana Care Hlth Syst, Cntr Outcomes Rsch, Newark, DE USA. [Edwards, Fred] Univ Florida Shands Jacksonville, Div Cardiothorac Surg, Jacksonville, FL USA. [Grau-Sepulveda, Maria; O'Brien, Sean] Duke Clin Rsch Inst, Durham, NC USA. [Shahian, David] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Shahian, David] Massachusetts Gen Hosp, Cntr Qual & Safety, Boston, MA 02114 USA. [Ponirakis, Angelo] Amer Coll Cardiol, Cntr Outcomes Rsch, Washington, DC USA. [Klein, Lloyd W.] Rush Univ, Med Cntr, Melrose Pk, IL USA. [Grover, Frederick L.] Univ Colorado, Sch Med, Denver Dept Vet Affairs Med Cntr, Aurora, CO USA. [Garratt, Kirk] Lenox Hill Heart & Vasc Inst New York, New York, NY USA. [Mckay, Charles] Harbor UCLA Med Cntr, Torrance, CA USA. [Weintraub, William S.] Christian Care Hlth Syst, Cntr Outcomes Rsch, Newark, DE USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 18630 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008200 ER PT J AU Zhou, GL Beloiartsev, A Yu, BL Baron, DM Zhou, WH Niedra, R Lu, NF Zapol, WM Seed, B Bloch, KD AF Zhou, Guo Ling Beloiartsev, Arkadi Yu, Binglan Baron, David M. Zhou, Weihua Niedra, Rasma Lu, Naifang Zapol, Warren M. Seed, Brian Bloch, Kenneth D. TI Products of Murine Cytochrome P450 Cyp2j Locus Regulate Pulmonary Vascular Response to Alveolar Hypoxia SO CIRCULATION LA English DT Meeting Abstract DE Pulmonary circulation; Hypoxia; Vasoconstriction; Genetic techniques; Gene mutations C1 [Zhou, Guo Ling; Zhou, Weihua; Niedra, Rasma; Lu, Naifang; Seed, Brian] Massachusetts Gen Hosp, Cntr Computat Integrat Biol, Boston, MA 02114 USA. [Beloiartsev, Arkadi; Yu, Binglan; Baron, David M.; Zapol, Warren M.; Bloch, Kenneth D.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Dept Anesthesia & Crit Care, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 20 PY 2012 VL 126 IS 21 SU S MA 19164 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA V31LL UT WOS:000208885008396 ER PT J AU Oxlade, O Murray, M AF Oxlade, Olivia Murray, Megan TI Tuberculosis and Poverty: Why Are the Poor at Greater Risk in India? SO PLOS ONE LA English DT Article ID SOCIAL DETERMINANTS; PULMONARY TUBERCULOSIS; MULTILEVEL ANALYSIS; PREVALENCE; TRENDS; COSTS; EPIDEMIOLOGY; EXPENDITURE; BURDEN; WEALTH AB Background: Although poverty is widely recognized as an important risk factor for tuberculosis (TB) disease, the specific proximal risk factors that mediate this association are less clear. The objective of our study was to investigate the mechanisms by which poverty increases the risk of TB. Methods: Using individual level data from 198,754 people from the 2006 Demographic Health Survey (DHS) for India, we assessed self-reported TB status, TB determinants and household socioeconomic status. We used these data to calculate the population attributable fractions (PAF) for each key TB risk factor based on the prevalence of determinants and estimates of the effect of these risk factors derived from published sources. We conducted a mediation analysis using principal components analysis (PCA) and regression to demonstrate how the association between poverty and TB prevalence is mediated. Results: The prevalence of self-reported TB in the 2006 DHS for India was 545 per 100,000 and ranged from 201 in the highest quintile to 1100 in the lowest quintile. Among those in the poorest population, the PAFs for low body mass index (BMI) and indoor air pollution were 34.2% and 28.5% respectively. Conclusion: TB control strategies should be targeted to the poorest populations that are most at risk, and should address the most important determinants of disease-specifically low BMI and indoor air pollution. C1 [Oxlade, Olivia; Murray, Megan] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Murray, Megan] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA. [Murray, Megan] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA. RP Murray, M (reprint author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. EM mmurray@hsph.harvard.edu FU Canadian Institute of Health Research [FRN 106987] FX The Canadian Institute of Health Research [FRN 106987 to OO] ( http://www.cihr-irsc.gc.ca). No additional funding to MM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 41 Z9 42 U1 2 U2 25 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 19 PY 2012 VL 7 IS 11 AR e47533 DI 10.1371/journal.pone.0047533 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 040PB UT WOS:000311333800003 PM 23185241 ER PT J AU Zhang, ZY Yang, ZH Zhu, B Hu, J Liew, CW Zhang, YY Leopold, JA Handy, DE Loscalzo, J Stanton, RC AF Zhang, Zhaoyun Yang, Zhihong Zhu, Bo Hu, Ji Liew, Chong Wee Zhang, Yingyi Leopold, Jane A. Handy, Diane E. Loscalzo, Joseph Stanton, Robert C. TI Increasing Glucose 6-Phosphate Dehydrogenase Activity Restores Redox Balance in Vascular Endothelial Cells Exposed to High Glucose SO PLOS ONE LA English DT Article ID INHIBITS SUPEROXIDE FORMATION; OXIDATIVE STRESS; DIABETIC COMPLICATIONS; CELLULAR REDOX; OXIDANT STRESS; NITRIC-OXIDE; BLOOD-CELLS; NADPH; EXPRESSION; GLUTATHIONE AB Previous studies have shown that high glucose increases reactive oxygen species (ROS) in endothelial cells that contributes to vascular dysfunction and atherosclerosis. Accumulation of ROS is due to dysregulated redox balance between ROS-producing systems and antioxidant systems. Previous research from our laboratory has shown that high glucose decreases the principal cellular reductant, NADPH by impairing the activity of glucose 6-phosphate dehydrogenase (G6PD). We and others also have shown that the high glucose-induced decrease in G6PD activity is mediated, at least in part, by cAMP-dependent protein kinase A (PKA). As both the major antioxidant enzymes and NADPH oxidase, a major source of ROS, use NADPH as substrate, we explored whether G6PD activity was a critical mediator of redox balance. We found that overexpression of G6PD by pAD-G6PD infection restored redox balance. Moreover inhibition of PKA decreased ROS accumulation and increased redox enzymes, while not altering the protein expression level of redox enzymes. Interestingly, high glucose stimulated an increase in NADPH oxidase (NOX) and colocalization of G6PD with NOX, which was inhibited by the PKA inhibitor. Lastly, inhibition of PKA ameliorated high glucose mediated increase in cell death and inhibition of cell growth. These studies illustrate that increasing G6PD activity restores redox balance in endothelial cells exposed to high glucose, which is a potentially important therapeutic target to protect ECs from the deleterious effects of high glucose. C1 [Zhang, Zhaoyun; Yang, Zhihong; Liew, Chong Wee; Stanton, Robert C.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA. [Zhang, Zhaoyun] Huashan Hosp, Div Endocrinol & Metab, Shanghai, Peoples R China. [Zhang, Yingyi; Leopold, Jane A.; Handy, Diane E.; Loscalzo, Joseph] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Zhu, Bo] Nanfang Hosp, Div Endocrinol & Metab, Guangzhou, Guangdong, Peoples R China. [Hu, Ji] Soochow Univ, Affiliated Hosp 2, Div Endocrinol & Metab, Suzhou, Peoples R China. RP Stanton, RC (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA. EM robert.stanton@joslin.harvard.edu FU National Institutes of Health (NIH)/The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01-DK54380]; NIH/National Heart, Lung, and Blood Institute (NHLBI) [R37-HL61795, R01-HL58796, P01-HL81587, K02 HL081110, U54-HL70819]; National Natural Science Foundation of China (NSFC) [30900502]; SCSTM [11PJ1402000]; SMHB [XYQ2011002] FX This work was supported by National Institutes of Health (NIH)/The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant #R01-DK54380 to RCS; NIH/National Heart, Lung, and Blood Institute (NHLBI) grants # R37-HL61795, R01-HL58796 and P01-HL81587 to JL; and K02 HL081110 and U54-HL70819 to JAL, The National Natural Science Foundation of China (NSFC) grant # 30900502, SCSTM grant # 11PJ1402000 and SMHB grant XYQ2011002 to ZZ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 50 TC 18 Z9 20 U1 0 U2 15 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 19 PY 2012 VL 7 IS 11 AR e49128 DI 10.1371/journal.pone.0049128 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 040PB UT WOS:000311333800019 PM 23185302 ER PT J AU Abayasekara, N Narla, A Hurst, S Sun, H Virgilio, M Payne, E Ebert, BL Look, AT Berliner, N Khanna-Gupta, A AF Abayasekara, Nirmalee Narla, Anupama Hurst, Slater Sun, Hong Virgilio, Maria Payne, Elspeth Ebert, Benjamin L. Look, A. Thomas Berliner, Nancy Khanna-Gupta, Arati TI L-Leucine Improves the Anemia of DBA and the 5q-Syndrome Via Activation of the mTOR Pathway in a p53-Independent Manner SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Narla, Anupama] Harvard Med Coll, Dept Med, Div Hematol, Brigham & Womens Hosp, Boston, MA USA. [Payne, Elspeth; Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. [Khanna-Gupta, Arati] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1257 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902309 ER PT J AU Abdel-Wahab, O Gao, J Adli, M Chung, YR Koche, R Shih, AH Pandey, S La-Fave, LM Ndiaye-Lobry, D Shin, YS Bhatt, PK Patel, JP Zhao, XY Park, CY Jaffe, JD Bernstein, BE Aifantis, I Levine, RL AF Abdel-Wahab, Omar Gao, Jie Adli, Mazhar Chung, Young Rock Koche, Richard Shih, Alan H. Pandey, Suveg La-Fave, Lindsay M. Ndiaye-Lobry, Delphine Shin, Yu Sup Bhatt, Parva K. Patel, Jay P. Zhao, Xinyang Park, Christopher Y. Jaffe, Jacob D. Bernstein, Bradley E. Aifantis, Iannis Levine, Ross L. TI Conditional Deletion of Asxl1 Results in Myelodysplasia SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Chung, Young Rock; Shih, Alan H.; Pandey, Suveg; La-Fave, Lindsay M.; Shin, Yu Sup; Bhatt, Parva K.; Patel, Jay P.; Park, Christopher Y.; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [Abdel-Wahab, Omar; Chung, Young Rock; Shih, Alan H.; Pandey, Suveg; La-Fave, Lindsay M.; Bhatt, Parva K.; Patel, Jay P.; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10021 USA. [Gao, Jie; Ndiaye-Lobry, Delphine; Aifantis, Iannis] NYU, Sch Med, New York, NY USA. [Adli, Mazhar; Koche, Richard] Massachusetts Gen Hosp, Dept Pathol, Broad Inst Harvard & MIT, Howard Hughes Med Inst, Boston, MA 02114 USA. [Adli, Mazhar; Koche, Richard; Bernstein, Bradley E.] Harvard Univ, Sch Med, Boston, MA USA. [Zhao, Xinyang] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA. [Jaffe, Jacob D.] Broad Inst Harvard & MIT, Cambridge, MA USA. [Bernstein, Bradley E.] Massachusetts Gen Hosp, Dept Pathol, Broad Inst Harvard & MIT, Oward Hughes Med Inst, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 6 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 308 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902152 ER PT J AU Abdel-Wahab, O Gao, J Adli, M Chung, YR Koche, R Shih, AH Pandey, S La-Fave, LM Ndiaye-Lobry, D Shin, YS Bhatt, PK Patel, JP Zhao, XY Park, CY Jaffe, JD Bernstein, BE Aifantis, I Levine, RL AF Abdel-Wahab, Omar Gao, Jie Adli, Mazhar Chung, Young Rock Koche, Richard Shih, Alan H. Pandey, Suveg La-Fave, Lindsay M. Ndiaye-Lobry, Delphine Shin, Yu Sup Bhatt, Parva K. Patel, Jay P. Zhao, Xinyang Park, Christopher Y. Jaffe, Jacob D. Bernstein, Bradley E. Aifantis, Iannis Levine, Ross L. TI Conditional Deletion of Asxl1 Results in Myelodysplasia SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Abdel-Wahab, Omar; Chung, Young Rock; Shih, Alan H.; Pandey, Suveg; La-Fave, Lindsay M.; Bhatt, Parva K.; Patel, Jay P.; Park, Christopher Y.; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [Abdel-Wahab, Omar; Chung, Young Rock; Shih, Alan H.; Pandey, Suveg; La-Fave, Lindsay M.; Bhatt, Parva K.; Patel, Jay P.; Levine, Ross L.] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10021 USA. [Gao, Jie; Ndiaye-Lobry, Delphine; Aifantis, Iannis] NYU, Sch Med, New York, NY USA. [Adli, Mazhar; Koche, Richard; Bernstein, Bradley E.] Broad Inst Harvard & MIT, Howard Hughes Med Inst, Dept Pathol, Massachusetts Gen Hosp, Boston, MA USA. [Adli, Mazhar; Koche, Richard; Bernstein, Bradley E.] Harvard Univ, Sch Med, Boston, MA USA. [Shin, Yu Sup] Mem Sloan Kettering Canc Ctr, Pathol & Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [Zhao, Xinyang] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA. [Jaffe, Jacob D.] Broad Inst Harvard & MIT, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 6 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 308 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838901328 ER PT J AU Abramson, JS Barnes, JA Feng, Y Takvorian, T Neuberg, DS Hochberg, EP Sohani, AR AF Abramson, Jeremy S. Barnes, Jeffrey A. Feng, Yang Takvorian, Tak Neuberg, Donna S. Hochberg, Ephraim P. Sohani, Aliyah R. TI Double Hit Lymphomas: Evaluation of Prognostic Factors and Impact of Therapy SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Abramson, Jeremy S.; Barnes, Jeffrey A.; Takvorian, Tak; Hochberg, Ephraim P.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. [Feng, Yang; Neuberg, Donna S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sohani, Aliyah R.] Massachusetts Gen Hosp, Dept Pathol, Ctr Canc, Boston, MA 02114 USA. NR 0 TC 3 Z9 3 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1619 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601038 ER PT J AU Acuna-Villaorduna, A McMillin, DW Mitsiades, CS AF Acuna-Villaorduna, Ana McMillin, Douglas W. Mitsiades, Constantine S. TI Accessory Cells From Diverse Tissue Microenvironments Alter Tumor Cell Responses to Multitargeted Kinase Inhibitors: Therapeutic Implications From a Large-Scale Systematic Evaluation SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Acuna-Villaorduna, Ana; McMillin, Douglas W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2469 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049602212 ER PT J AU Advani, RH Li, HL Hoppe, RT Bartlett, NL Bennett, JM Neuberg, DS Cassileth, PA Kahl, BS Horning, SJ AF Advani, Ranjana H. Li, Hailun Hoppe, Richard T. Bartlett, Nancy L. Bennett, John M. Neuberg, Donna S. Cassileth, Peter A. Kahl, Brad S. Horning, Sandra J. TI Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Advani, Ranjana H.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Li, Hailun] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Hoppe, Richard T.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Bartlett, Nancy L.] Washington Univ, Sch Med, St Louis, MO USA. [Bennett, John M.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. [Cassileth, Peter A.] Univ Miami, Miami, FL USA. [Kahl, Brad S.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 4779 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049604223 ER PT J AU Alachkar, H Maharry, K Santhanam, R Neviani, P Volinia, S Kohlschmidt, J Metzeler, KH Dorrance, AM Schwind, S Becker, H Mendler, JH Eisfeld, AK Whitman, S Mrozek, K Garzon, R Perrotti, D Caligiuri, MA Stone, RM Marcucci, G Bloomfield, CD AF Alachkar, Houda Maharry, Kati Santhanam, Ramasamy Neviani, Paolo Volinia, Stefano Kohlschmidt, Jessica Metzeler, Klaus H. Dorrance, Adrienne M. Schwind, Sebastian Becker, Heiko Mendler, Jason H. Eisfeld, Aim-Kathrin Whitman, Susan Mrozek, Krzysztof Garzon, Ramiro Perrotti, Danilo Caligiuri, Michael A. Stone, Richard M. Marcucci, Guido Bloomfield, Clara D. TI SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML) SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Alachkar, Houda; Maharry, Kati; Santhanam, Ramasamy; Neviani, Paolo; Volinia, Stefano; Kohlschmidt, Jessica; Metzeler, Klaus H.; Dorrance, Adrienne M.; Schwind, Sebastian; Becker, Heiko; Mendler, Jason H.; Eisfeld, Aim-Kathrin; Whitman, Susan; Mrozek, Krzysztof; Garzon, Ramiro; Perrotti, Danilo; Caligiuri, Michael A.; Marcucci, Guido; Bloomfield, Clara D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Stone, Richard M.] HMS, Boston, MA USA. RI Volinia, Stefano/A-3029-2010; Mrozek, Krzysztof/A-3142-2008; Garzon, Ramiro/E-3104-2011 OI Volinia, Stefano/0000-0003-0910-3893; NR 0 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 773 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838900186 ER PT J AU Alter, BP Giri, N Calvo, KR Maric, I Arthur, DC Hickstein, DD Hastings, CA Lee, MA Hsu, A Holland, SM AF Alter, Blanche P. Giri, Neelam Calvo, Katherine R. Maric, Irina Arthur, Diane C. Hickstein, Dennis D. Hastings, Caroline A. Lee, Michelle A. Hsu, Amy Holland, Steven M. TI Clinically Silent Carriers in Families with Myelodysplastic Syndrome Due to GATA2 Mutations SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Alter, Blanche P.; Giri, Neelam] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, Rockville, MD USA. [Calvo, Katherine R.] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA. [Maric, Irina] NIH, Hematol Sect, Dept Lab, CCR, Bethesda, MD 20892 USA. [Arthur, Diane C.] NCI, Pathol Lab, NIH, CCR, Bethesda, MD 20892 USA. [Hickstein, Dennis D.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA. [Hastings, Caroline A.] Childrens Hosp & Res Ctr Oakland, Oakland, CA USA. [Lee, Michelle A.] Dana Farber Canc Inst, Brookline, MA USA. [Hsu, Amy] NIH, Lab Clin Infect Dis, Bethesda, MD 20892 USA. [Holland, Steven M.] NIAID, Lab Clin Infect Dis, Bethesda, MD 20892 USA. RI Calvo, Katherine/A-8109-2009 NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1264 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902302 ER PT J AU Amodio, N Di Martino, MT Foresta, U Rossi, M Leotta, M Leone, E Lionetti, M Gulla, A D'Aquila, P Bellizzi, D Passarino, G Fabiani, F Fulciniti, M Ferrarini, M Morabito, F Neri, A Munshi, NC Anderson, KC Tagliaferri, P Tassone, P AF Amodio, Nicola Di Martino, Maria Teresa Foresta, Umberto Rossi, Marco Leotta, Marzia Leone, Emanuela Lionetti, Marta Gulla, Annamaria D'Aquila, Patrizia Bellizzi, Dina Passarino, Giuseppe Fabiani, Fernanda Fulciniti, Mariateresa Ferrarini, Manlio Morabito, Fortunato Neri, Antonino Munshi, Nikhil C. Anderson, Kenneth C. Tagliaferri, Pierosandro Tassone, Pierfrancesco TI MiR-29b Exerts Anti-Multiple Myeloma Activity by Targeting Key Oncogenic Pathways and Modulating DNA Methylation Profile. SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Amodio, Nicola; Di Martino, Maria Teresa; Foresta, Umberto; Rossi, Marco; Leotta, Marzia; Leone, Emanuela; Gulla, Annamaria; Tagliaferri, Pierosandro; Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, Catanzaro, Italy. [Di Martino, Maria Teresa; Foresta, Umberto; Rossi, Marco; Leotta, Marzia; Gulla, Annamaria; Tagliaferri, Pierosandro; Tassone, Pierfrancesco] T Campanella Canc Ctr, Catanzaro, Italy. [Lionetti, Marta; Neri, Antonino] Fdn Ca Granda IRCCS Osped Maggiore Policlin, Hematol BMT Unit, Milan, Italy. [Lionetti, Marta; Neri, Antonino] Univ Milan, Milan, Italy. [D'Aquila, Patrizia; Bellizzi, Dina; Passarino, Giuseppe] Univ Calabria, Dept Cell Biol, I-87036 Cosenza, Italy. [Fabiani, Fernanda] Magna Graecia Univ Catanzaro, Catanzaro, Italy. [Fulciniti, Mariateresa; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Fulciniti, Mariateresa; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Ferrarini, Manlio] IST, Natl Inst Canc Res, Med Oncol Dept C, Genoa, Italy. [Morabito, Fortunato] Hosp Cosenza, Dept Oncohematol, Cosenza, Italy. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2941 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049600133 ER PT J AU Bae, J Prabhala, RH Song, WH Tai, YT Anderson, KC Munshi, NC AF Bae, Jooeun Prabhala, Rao H. Song, Weihua Tai, Yu-Tzu Anderson, Kenneth C. Munshi, Nikhil C. TI Induction of T Cell Immunity Using a Multipeptide Cocktail Containing XBP1, CD138 and CS1 Peptides in Smoldering Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Tai, Yu-Tzu; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 5039 PG 1 WC Hematology SC Hematology GA 077SZ UT WOS:000314049605245 ER PT J AU Ban-Hoefen, M Vanderplas, A Kelly, JL Crosby-Thompson, A Abel, GA Czuczman, MS Gordon, LI Kaminski, MS Millenson, M Nademanee, A Rodriguez, MA Zelenetz, AD Niland, J LaCasce, A Friedberg, JW AF Ban-Hoefen, Makiko Vanderplas, Ann Kelly, Jennifer L. Crosby-Thompson, Allison Abel, Gregory A. Czuczman, Myron S. Gordon, Leo I. Kaminski, Mark S. Millenson, Michael Nademanee, Auayporn Rodriguez, Maria A. Zelenetz, Andrew D. Niland, Joyce LaCasce, Ann Friedberg, Jonathan W. TI Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database. SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Ban-Hoefen, Makiko; Kelly, Jennifer L.; Friedberg, Jonathan W.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. [Crosby-Thompson, Allison; Abel, Gregory A.; LaCasce, Ann] Dana Farber Canc Inst, Boston, MA 02115 USA. [Czuczman, Myron S.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Gordon, Leo I.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. [Kaminski, Mark S.] Univ Michigan, Ann Arbor, MI 48109 USA. [Millenson, Michael] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Rodriguez, Maria A.] UT MD Anderson Canc Ctr, Houston, TX USA. [Zelenetz, Andrew D.] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY 10021 USA. [Niland, Joyce] City Hope Natl Med Ctr, Data Coordinating Ctr, Duarte, CA 91010 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2669 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838903124 ER PT J AU Baron, DM Beloiartsev, A Nakagawa, A Stowell, CP Bloch, KD Zapol, WM AF Baron, David M. Beloiartsev, Arkadi Nakagawa, Akito Stowell, Christopher P. Bloch, Kenneth D. Zapol, Warren M. TI Prevention of Pulmonary Hypertension and Suppression of Pulmonary Inflammation and Platelet Activation by Breathing Nitric Oxide in Lambs Subjected to Hemorrhagic Shock and Autologous Stored Blood Transfusion SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Stowell, Christopher P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Bloch, Kenneth D.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Anesthesia Ctr Crit Care Res, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 841 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838901023 ER PT J AU Bauer, DE Kamran, SC Xu, J Lin, C Shao, Z Fujiwara, Y Voit, RA Porteus, MH Stamatoyannopoulos, JA Orkin, SH AF Bauer, Daniel E. Kamran, Sophia C. Xu, Jian Lin, Carrie Shao, Zhen Fujiwara, Yuko Voit, Richard A. Porteus, Matthew H. Stamatoyannopoulos, John A. Orkin, Stuart H. TI HbF-Associated Genetic Variation Marks an Erythroid Regulatory Element Essential for BCL11A Transcription and Subsequent Stage-Specific Globin Expression SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Bauer, Daniel E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Hematol Oncol,Boston Childrens Hosp, Boston, MA 02115 USA. [Kamran, Sophia C.] Harvard Univ, Sch Med, Boston, MA USA. [Voit, Richard A.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA. [Porteus, Matthew H.] Stanford Univ, Palo Alto, CA 94304 USA. [Stamatoyannopoulos, John A.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Orkin, Stuart H.] Childrens Hosp, Dana Farber Canc Inst, Howard Hughes Med Inst, Dept Pediat Oncol,Harvard Stem Cell Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 828 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838901036 ER PT J AU Bejar, R Stevenson, KE Stojanov, P Zaneveld, JE Bar-Natan, M Caughey, B Wang, H Garcia-Manero, G Kantarjian, HM Cutler, C Ritz, J Cibulskis, K Getz, G Steensma, DP Stone, RM Chen, R Neuberg, DS Ebert, BL AF Bejar, Rafael Stevenson, Kristen E. Stojanov, Petar Zaneveld, J. Eric Bar-Natan, Michal Caughey, Bennett Wang, Hui Garcia-Manero, Guillermo Kantarjian, Hagop M. Cutler, Corey Ritz, Jerome Cibulskis, Kristian Getz, Gad Steensma, David P. Stone, Richard M. Chen, Rui Neuberg, Donna S. Ebert, Benjamin L. TI Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Bejar, Rafael] UCSD, La Jolla, CA USA. [Stevenson, Kristen E.; Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Stojanov, Petar; Cibulskis, Kristian] Broad Inst, Cambridge, MA USA. [Caughey, Bennett] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA. [Wang, Hui] Funct Genome Initiat Core, Human Genome Sequencing Ctr, Houston, TX USA. [Garcia-Manero, Guillermo; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Getz, Gad] Harvard Univ, Broad Inst, Canc Program, Cambridge, MA 02138 USA. [Getz, Gad] MIT, Cambridge, MA 02139 USA. [Chen, Rui] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA. [Ebert, Benjamin L.] Brigham & Womens Hosp, Harvard Med Coll, Div Hematol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 311 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902149 ER PT J AU Bejar, R Stevenson, KE Stojanov, P Zaneveld, JE Bar-Natan, M Caughey, B Wang, H Garcia-Manero, G Kantarjian, HM Cutler, C Ritz, J Cibulskis, K Getz, G Steensma, DP Stone, RM Chen, R Neuberg, DS Ebert, BL AF Bejar, Rafael Stevenson, Kristen E. Stojanov, Petar Zaneveld, J. Eric Bar-Natan, Michal Caughey, Bennett Wang, Hui Garcia-Manero, Guillermo Kantarjian, Hagop M. Cutler, Corey Ritz, Jerome Cibulskis, Kristian Getz, Gad Steensma, David P. Stone, Richard M. Chen, Rui Neuberg, Donna S. Ebert, Benjamin L. TI Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Bejar, Rafael] UCSD, La Jolla, CA USA. [Stevenson, Kristen E.; Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Wang, Hui] Funct Genome Initiat Core, Human Genome Sequencing Ctr, Houston, TX USA. [Garcia-Manero, Guillermo; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Bar-Natan, Michal; Ritz, Jerome; Stone, Richard M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Getz, Gad] Harvard Univ, Broad Inst, Canc Program, Cambridge, MA 02138 USA. [Getz, Gad] MIT, Cambridge, MA 02139 USA. [Chen, Rui] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA. [Ebert, Benjamin L.] Brigham & Womens Hosp, Div Hematol, Harvard Med Coll, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 311 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838901325 ER PT J AU Benson, DM Cohen, AD Munshi, NC Jagannath, S Spitzer, G Hofmeister, CC Zerbib, R Andre, P Efebera, YA Oxier, S Caligiuri, MA AF Benson, Don M., Jr. Cohen, Adam D. Munshi, Nikhil C. Jagannath, Sundar Spitzer, Gary Hofmeister, Craig C. Zerbib, Robert Andre, Pascale Efebera, Yvonne A. Oxier, Shawna Caligiuri, Michael A. TI A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Benson, Don M., Jr.; Oxier, Shawna] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Cohen, Adam D.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Jagannath, Sundar] Mt Sinai Sch Med, Multiple Myeloma Program, New York, NY USA. [Spitzer, Gary] St Francis Hosp, Greenville, SC USA. [Andre, Pascale] Innate Pharma, Res & Dev, Marseille, France. [Caligiuri, Michael A.] Ohio State Univ, Integrated Biomed Sci Grad Program, Columbus, OH 43210 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 4058 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049603042 ER PT J AU Bhatt, AS Freeman, SS Herrera, AF Pedamallu, CS Gevers, D Duke, F Jung, J Walker, BJ Young, S Earl, A Kostic, A Ojesina, AI Soriano, G Antin, JH Soiffer, RJ Baden, LR Hornick, JL Marty, FM Meyerson, M AF Bhatt, Ami S. Freeman, Samuel S. Herrera, Alex F. Pedamallu, Chandra Sekhar Gevers, Dirk Duke, Fujiko Jung, Joonil Walker, Bruce J. Young, Sarah Earl, Ashlee Kostic, Aleksandar Ojesina, Akinyemi I. Soriano, Gabriela Antin, Joseph H. Soiffer, Robert J. Baden, Lindsey R. Hornick, Jason L. Marty, Francisco M. Meyerson, Matthew TI Next-Generation Sequencing for the Identification of Transplantation-Associated Pathogens SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Bhatt, Ami S.; Freeman, Samuel S.; Gevers, Dirk; Duke, Fujiko; Jung, Joonil; Walker, Bruce J.; Young, Sarah; Earl, Ashlee] Broad Inst, Cambridge, MA USA. [Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Soriano, Gabriela] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Soiffer, Robert J.] Dana Farber Canc Inst, Div Hematol Malignancies, Dept Med Oncol, Boston, MA 02115 USA. [Baden, Lindsey R.; Marty, Francisco M.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Hornick, Jason L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 4 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838900037 ER PT J AU Blum, W Sanford, B Klisovic, RB DeAngelo, DJ Uy, G Powell, BL Stock, W Baer, MR Kolitz, JE Wetzler, M Hoke, E Bloomfield, CD Geyer, S Marcucci, G Stone, RM Larson, RA AF Blum, William Sanford, Ben Klisovic, Rebecca B. DeAngelo, Daniel J. Uy, Geoffrey Powell, Bayard L. Stock, Wendy Baer, Maria R. Kolitz, Jonathan E. Wetzler, Meir Hoke, Eva Bloomfield, Clara D. Geyer, Susan Marcucci, Guido Stone, Richard M. Larson, Richard A. TI Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance) SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Blum, William; Klisovic, Rebecca B.; Bloomfield, Clara D.] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA. [Sanford, Ben; Hoke, Eva] Duke Univ, Med Ctr, Alliance Clin Trials Oncol Stat, Durham, NC USA. [Sanford, Ben; Hoke, Eva] Duke Univ, Med Ctr, Ctr Data, Durham, NC USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Uy, Geoffrey] Washington Univ, St Louis, MO USA. [Powell, Bayard L.] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA. [Stock, Wendy] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Baer, Maria R.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA. [Kolitz, Jonathan E.] Hofstra N Shore LIJ Sch Med, Dept Med, Hempstead, NY USA. [Wetzler, Meir] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Bloomfield, Clara D.; Marcucci, Guido] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Geyer, Susan] Ohio State Univ, James Canc Ctr, Columbus, OH 43210 USA. [Stone, Richard M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Stone, Richard M.] HMS, Boston, MA USA. [Larson, Richard A.] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA. RI Blum, William/E-2769-2011; Geyer, Susan/E-3112-2011; Klisovic, Rebecca/E-3401-2011 NR 0 TC 0 Z9 0 U1 1 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 44 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838900120 ER PT J AU Bommarito, D Martin, A Nastke, MD Ritz, J Bellucci, R AF Bommarito, Davide Martin, Allison Nastke, Maria-Dorothea Ritz, Jerome Bellucci, Roberto TI Enhancement of Tumor Cell Susceptibility to NK Cell Activity Through Inhibition of the PI3K Signaling Pathway. SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Ritz, Jerome; Bellucci, Roberto] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2152 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838905284 ER PT J AU Boulad, F Davies, SM Williams, DA Margolis, DA Klein, EG Lehmann, LE Duncan, C Guinan, EC Mehta, PA AF Boulad, Farid Davies, Stella M. Williams, David A. Margolis, David A. Klein, Elizabeth G. Lehmann, Leslie E. Duncan, Christine Guinan, Eva C. Mehta, Parinda A. TI Chemotherapy-Only Preparative Regimen for T-Cell Depleted Hematopoietic Stem Cell Transplantation of Patients with Fanconi Anemia From Alternative Donors SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Boulad, Farid] Mem Sloan Kettering Canc Ctr, Allogene Bone Marrow Transplant Serv Pediat, New York, NY 10021 USA. [Davies, Stella M.] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Cincinnati, OH USA. [Williams, David A.] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA. [Margolis, David A.] Med Coll Wisconsin, BMT Program, Milwaukee, WI 53226 USA. [Klein, Elizabeth G.] Mem Sloan Kettering Canc Ctr, Bone Marrow Transplantat Serv Pediat, New York, NY 10021 USA. [Duncan, Christine; Guinan, Eva C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mehta, Parinda A.] Cincinnati Childrens Hosp Med Ctr, Dept Hematol Oncol, Cincinnati, OH USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3471 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049604056 ER PT J AU Bradner, JE AF Bradner, James E. TI Targeting Bromodomains in Myeloma SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Bradner, James E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 6 PG 1 WC Hematology SC Hematology GA 074UG UT WOS:000313838900028 ER PT J AU Brunner, AM Campigotto, F Drapkin, BJ Sadrzadeh, H Neuberg, DS Fathi, AT AF Brunner, Andrew M. Campigotto, Federico Drapkin, Benjamin J. Sadrzadeh, Hossein Neuberg, Donna S. Fathi, Amir T. TI Trends in All-Cause Mortality Among Older Patients with CML: A SEER Database Analysis SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Brunner, Andrew M.; Drapkin, Benjamin J.; Sadrzadeh, Hossein; Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Campigotto, Federico] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3772 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601293 ER PT J AU Brunner, AM Spitzer, TR Chen, YBA Coughlin, E McAfee, SL Ballen, KK Attar, EC Caron, M Preffer, FI Yeap, BY Dey, BR AF Brunner, Andrew M. Spitzer, Thomas R. Chen, Yi-Bin A. Coughlin, Erin McAfee, Steven L. Ballen, Karen K. Attar, Eyal C. Caron, Martin Preffer, Frederic I. Yeap, Beow Y. Dey, Bimalangshu R. TI Urate Oxidase (Rasburicase) to Inhibit Graft Versus Host Disease (GVHD) After Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation (HCT). SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Spitzer, Thomas R.; Chen, Yi-Bin A.; McAfee, Steven L.; Ballen, Karen K.; Attar, Eyal C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med Leukemia & Bone Marrow Transplant, Boston, MA USA. [Caron, Martin] Massachusetts Gen Hosp, Canc Ctr Bone Marrow Transplant, Boston, MA 02114 USA. [Yeap, Beow Y.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3063 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601200 ER PT J AU Brunner, AM Feng, Y Drapkin, BJ Sadrzadeh, H Ballen, KK Attar, EC Amrein, PC McAfee, SL Neuberg, DS Fathi, AT AF Brunner, Andrew M. Feng, Yang Drapkin, Benjamin J. Sadrzadeh, Hossein Ballen, Karen K. Attar, Eyal C. Amrein, Philip C. McAfee, Steven L. Neuberg, Donna S. Fathi, Amir T. TI Association of Baseline Body Mass Index (BMI) with Overall Survival Among Patients Over Age 60 with Acute Myeloid Leukemia (AML) SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Brunner, Andrew M.; Drapkin, Benjamin J.; Sadrzadeh, Hossein; Ballen, Karen K.; Attar, Eyal C.; Amrein, Philip C.; Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Feng, Yang; Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [McAfee, Steven L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1484 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838905149 ER PT J AU Cagnetta, A Cea, M Acharya, C Calimeri, T Tai, YT Hideshima, T Chauhan, D Patrone, F Gobbi, M Munshi, NC Anderson, KC AF Cagnetta, Antonia Cea, Michele Acharya, Chirag Calimeri, Teresa Tai, Yu-Tzu Hideshima, Teru Chauhan, Dharminder Patrone, Franco Gobbi, Marco Munshi, Nikhil C. Anderson, Kenneth C. TI Intracellular NAD(+) Depletion Enhances Bortezomib-Induced Myeloma Cytotoxicity SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Cagnetta, Antonia; Cea, Michele; Acharya, Chirag; Calimeri, Teresa; Tai, Yu-Tzu; Chauhan, Dharminder; Munshi, Nikhil C.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Cagnetta, Antonia; Cea, Michele; Acharya, Chirag; Calimeri, Teresa; Tai, Yu-Tzu; Chauhan, Dharminder; Munshi, Nikhil C.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Hideshima, Teru] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. [Patrone, Franco; Gobbi, Marco] IRCCS Azienda Osped Univ S Martino IST, Dept Hematol & Oncol, Genoa, Italy. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 330 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902130 ER PT J AU Cagnetta, A Cea, M Acharya, C Calimeri, T Tai, YT Hideshima, T Chauhan, D Patrone, F Gobbi, M Munshi, NC Anderson, KC AF Cagnetta, Antonia Cea, Michele Acharya, Chirag Calimeri, Teresa Tai, Yu-Tzu Hideshima, Teru Chauhan, Dharminder Patrone, Franco Gobbi, Marco Munshi, Nikhil C. Anderson, Kenneth C. TI Intracellular NAD(+) Depletion Enhances Bortezomib-Induced Myeloma Cytotoxicity SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Cagnetta, Antonia; Cea, Michele; Acharya, Chirag; Calimeri, Teresa; Tai, Yu-Tzu; Chauhan, Dharminder; Munshi, Nikhil C.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Cagnetta, Antonia; Cea, Michele; Acharya, Chirag; Calimeri, Teresa; Tai, Yu-Tzu; Chauhan, Dharminder; Munshi, Nikhil C.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Hideshima, Teru] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. [Patrone, Franco; Gobbi, Marco] IRCCS Azienda Osped Univ S Martino IST, Dept Hematol & Oncol, Genoa, Italy. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 330 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838901306 ER PT J AU Calimeri, T Fulciniti, M Lin, JH Samur, MK Calkins, AS Vahia, AV Pal, J Cea, M Cagnetta, A Cottini, F Adamia, S Azab, A Minvielle, S Avet-Loiseau, H Li, C Lazaro, JB Anderson, KC Tassone, P Shammas, MA Munshi, NC AF Calimeri, Teresa Fulciniti, Mariateresa Lin, Jianhong Samur, Mehmet Kemal Calkins, Anne S. Vahia, Ankit V. Pal, Jagannath Cea, Michele Cagnetta, Antonia Cottini, Francesca Adamia, Sophia Azab, AbdelKareem Minvielle, Stephane Avet-Loiseau, Herve Li, Cheng Lazaro, Jean-Bernard Anderson, Kenneth C. Tassone, Pierfrancesco Shammas, Masood A. Munshi, Nikhil C. TI Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Calimeri, Teresa; Fulciniti, Mariateresa; Lin, Jianhong; Vahia, Ankit V.; Pal, Jagannath; Cea, Michele; Cagnetta, Antonia; Cottini, Francesca; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Calimeri, Teresa; Fulciniti, Mariateresa; Lin, Jianhong; Vahia, Ankit V.; Pal, Jagannath; Cea, Michele; Cagnetta, Antonia; Cottini, Francesca; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Adamia, Sophia] HMS, Boston, MA USA. [Minvielle, Stephane; Avet-Loiseau, Herve] CHU Nantes, F-44035 Nantes 01, France. [Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, Catanzaro, Italy. [Shammas, Masood A.; Munshi, Nikhil C.] Boston VA Hlth Care Syst, Boston, MA USA. RI Minvielle, Stephane/K-8251-2015 NR 0 TC 1 Z9 1 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2932 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049600123 ER PT J AU Cao, Y Xu, L Liu, X Zhou, YS Yang, G Patterson, CJ Treon, SP Hunter, Z AF Cao, Yang Xu, Lian Liu, Xia Zhou, Yangsheng Yang, Guang Patterson, Christopher J. Treon, Steven Peter Hunter, Zachary TI Whole Genome Sequencing Identifies Recurring Somatic Mutations in the C-Terminal Domain of CXCR4, Including a Gain of Function Mutation in Waldenstrom's Macroglobinemia SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Cao, Yang; Xu, Lian; Liu, Xia; Zhou, Yangsheng] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA. [Yang, Guang] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Patterson, Christopher J.] Dana Farber Canc Inst, Waldenstroms Macroglubulinemia Ctr, Boston, MA 02115 USA. RI Hunter, Zachary/H-3018-2013 OI Hunter, Zachary/0000-0002-1689-1691 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2715 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049604010 ER PT J AU Cassaday, RD Guthrie, KA Budde, LE Thompson, L Till, BG Press, OW Chauncey, T Pagel, JM Petersdorf, SH Bensinger, WI Holmberg, L Shustov, AR Green, DJ Libby, EN Maloney, DG Gopal, AK AF Cassaday, Ryan D. Guthrie, Katherine A. Budde, Lihua E. Thompson, Leslie Till, Brian G. Press, Oliver W. Chauncey, Thomas Pagel, John M. Petersdorf, Stephen H. Bensinger, William I. Holmberg, Leona Shustov, Andrei R. Green, Damian J. Libby, Edward N., III Maloney, David G. Gopal, Ajay K. TI Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation. SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Cassaday, Ryan D.; Budde, Lihua E.; Thompson, Leslie; Till, Brian G.; Press, Oliver W.; Pagel, John M.; Petersdorf, Stephen H.; Bensinger, William I.; Holmberg, Leona; Shustov, Andrei R.; Green, Damian J.; Libby, Edward N., III; Maloney, David G.; Gopal, Ajay K.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Chauncey, Thomas] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3082 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601181 ER PT J AU Cea, M Cagnetta, A Munshi, A Tai, YT Hideshima, T Chauhan, D Patrone, F Gobbi, M Munshi, NC Anderson, KC AF Cea, Michele Cagnetta, Antonia Munshi, Aditya Tai, Yu-Tzu Hideshima, Teru Chauhan, Dharminder Patrone, Franco Gobbi, Marco Munshi, Nikhil C. Anderson, Kenneth C. TI Compromised Nuclear Sirtuins Activity Sensitizes BRCA-Proficient multiple Myeloma Cells to DNA Damage Agents SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Cea, Michele; Cagnetta, Antonia; Munshi, Aditya; Tai, Yu-Tzu; Hideshima, Teru; Chauhan, Dharminder; Munshi, Nikhil C.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Cea, Michele; Cagnetta, Antonia; Munshi, Aditya; Tai, Yu-Tzu; Hideshima, Teru; Chauhan, Dharminder; Munshi, Nikhil C.; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Upper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Patrone, Franco; Gobbi, Marco] IRCCS Azienda Osped Univ S Martino IST, Dept Hematol & Oncol, Genoa, Italy. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 723 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838900236 ER PT J AU Chapuy, B Monti, S Takeyama, K Rodig, SJ Hao, YS Yeda, KT Inguilizian, H Mermel, C Currie, T Dogan, A Kutok, J Beroukhim, R Neuberg, DS Habermann, TM Getz, G Kung, AL Golub, TR Shipp, MA AF Chapuy, Bjoern Monti, Stefano Takeyama, Kunihiko Rodig, Scott J. Hao, Yansheng Yeda, Kelly T. Inguilizian, Haig Mermel, Craig Currie, Treeve Dogan, Ahmet Kutok, Jeffery Beroukhim, Rameen Neuberg, Donna S. Habermann, Thomas M. Getz, Gad Kung, Andrew L. Golub, Todd R. Shipp, Margaret A. TI A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Monti, Stefano; Mermel, Craig; Beroukhim, Rameen; Getz, Gad; Golub, Todd R.] Harvard Univ, Broad Inst, Canc Program, Cambridge, MA 02138 USA. [Monti, Stefano; Mermel, Craig; Beroukhim, Rameen; Getz, Gad; Golub, Todd R.] MIT, Cambridge, MA 02139 USA. [Rodig, Scott J.; Currie, Treeve; Kutok, Jeffery] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA. [Inguilizian, Haig] Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA 02115 USA. [Inguilizian, Haig] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Inguilizian, Haig] Childrens Hosp Boston, Boston, MA USA. [Dogan, Ahmet] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Habermann, Thomas M.] Mayo Clin, Div Hematol, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1534 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838906244 ER PT J AU Chen, LY Deshpande, AJ Banka, D Kathrin, B Dias, S Buske, C Olhava, EJ Daigle, SR Richon, VM Pollock, RM Armstrong, SA AF Chen, Liying Deshpande, Aniruddha J. Banka, Deepti Kathrin, Bernt Dias, Stuart Buske, Christian Olhava, Edward J. Daigle, Scott R. Richon, Victoria M. Pollock, Roy M. Armstrong, Scott A. TI Abrogation of MLL-AF10 and CALM-AF10 Mediated Transformation Through Genetic Inactivation or Pharmacological Inhibition of the H3K79 Methyltransferase DOT1L SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Chen, Liying] Harvard Univ, Cambridge, MA 02138 USA. [Deshpande, Aniruddha J.; Banka, Deepti; Dias, Stuart; Armstrong, Scott A.] Childrens Hosp Boston, Boston, MA USA. [Kathrin, Bernt] Univ Colorado, BMT, Aurora, CO USA. [Buske, Christian] Univ Hosp Ulm, Inst Expt Canc Res, Ulm, Germany. [Olhava, Edward J.; Daigle, Scott R.; Richon, Victoria M.; Pollock, Roy M.] Epizyme Inc, Cambridge, MA USA. [Armstrong, Scott A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2384 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601077 ER PT J AU Cirstea, D Hideshima, T Santo, L Eda, H Scullen, TA Nemani, N Mahindra, A Yee, A Hu, YG Mimura, N Minami, J Ohguchi, H Suzuki, R Cottini, F Guichard, SM Anderson, KC Raje, N AF Cirstea, Diana Hideshima, Teru Santo, Loredana Eda, Homare Scullen, Tyler A. Nemani, Neeharika Mahindra, Anuj Yee, Andrew Hu, Yiguo Mimura, Naoya Minami, Jiro Ohguchi, Hiroto Suzuki, Rikio Cottini, Francesca Guichard, Sylvie M. Anderson, Kenneth C. Raje, Noopur TI Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Cirstea, Diana; Hideshima, Teru; Hu, Yiguo; Mimura, Naoya; Minami, Jiro; Ohguchi, Hiroto; Suzuki, Rikio; Cottini, Francesca; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Cirstea, Diana; Hideshima, Teru; Hu, Yiguo; Mimura, Naoya; Minami, Jiro; Ohguchi, Hiroto; Suzuki, Rikio; Cottini, Francesca; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Santo, Loredana; Eda, Homare; Scullen, Tyler A.; Nemani, Neeharika; Mahindra, Anuj; Yee, Andrew; Raje, Noopur] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA. [Guichard, Sylvie M.] AstraZeneca, Alderley Pk, Macclesfield, Cheshire, England. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 4023 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049603077 ER PT J AU Cluzeau, T Robert, G Karsenti, JM Luciano, F Puissant, A Legrand, F Mannone, L Rennmille, A Preudhomme, C Fenaux, P Cassuto, JP Raynaud, S Mounier, N Auberger, P AF Cluzeau, Thomas Robert, Guillaume Karsenti, Jean-Michel Luciano, Frederic Puissant, Alexandre Legrand, Faezeh Mannone, Lionel Rennmille, Aline Preudhomme, Claude Fenaux, Pierre Cassuto, Jill-Patrice Raynaud, Sophie Mounier, Nicolas Auberger, Patrick TI BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Cluzeau, Thomas] CHU Archet, Serv Hematol, Nice, France. [Robert, Guillaume] IINSERM, U1065, Team 2, Equipe Labellisee LNCC, Nice, France. [Karsenti, Jean-Michel; Legrand, Faezeh; Mannone, Lionel; Cassuto, Jill-Patrice; Mounier, Nicolas] Hop Archet, Serv Hematol Clin, Nice, France. [Luciano, Frederic; Auberger, Patrick] INSERM, U1065, Team 2, Equipe Labellisee LNCC, Nice, France. [Puissant, Alexandre] Dana Farber Canc Inst, Boston, MA USA. [Rennmille, Aline] CHRU Lille, Ctr Biol Pathol, Hematol Lab, Lille, France. [Preudhomme, Claude] Univ Lille, CHRU Lille, Lille, France. [Fenaux, Pierre] Univ Paris 13, Hosp Avicenne, APHP, Dept Hematol, Bobigny, France. [Raynaud, Sophie] Univ Nice, CHU Archet, Hematol Lab, Nice, France. RI AUBERGER, Patrick/G-1491-2013 OI AUBERGER, Patrick/0000-0002-2481-8275 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 701 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838900256 ER PT J AU Cooney, JD Hildick-Smith, GJ Garone, C Thon, JN Akman, OH Chen, CY Shah, DI Branco, DS Miyata, N Freedman, ML Calvo, SE Mootha, VK Koehler, CM Italian, JE Donati, MA DiMauro, S Paw, BH AF Cooney, Jeffrey D. Hildick-Smith, Gordon J. Garone, Caterina Thon, Jonathan N. Akman, Orhan H. Chen, Caiyong Shah, Dhvanit I. Branco, Diana Santos Miyata, Non Freedman, Matthew L. Calvo, Sarah E. Mootha, Vamsi K. Koehler, Carla M. Italian, Joseph E., Jr. Donati, M. Alice DiMauro, Salvatore Paw, Barry H. TI Megaloblastic Anemia and Mitochondriopathy Caused by a Homozygous Mutation in Sideroflexin-4. SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Cooney, Jeffrey D.; Hildick-Smith, Gordon J.; Chen, Caiyong; Shah, Dhvanit I.; Branco, Diana Santos; Italian, Joseph E., Jr.; Paw, Barry H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol,Dept Med, Boston, MA 02115 USA. [Garone, Caterina; Akman, Orhan H.; DiMauro, Salvatore] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA. [Miyata, Non; Koehler, Carla M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Chem & Biochem, Los Angeles, CA 90095 USA. [Freedman, Matthew L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Broad Inst Harvard & MIT, Boston, MA 02115 USA. [Calvo, Sarah E.; Mootha, Vamsi K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Syst Biol,Broad Inst Harvard & MIT, Boston, MA USA. [Donati, M. Alice] Univ Florence, Anna Meyer Childrens Hosp, Dept Pediat Neurol & Metab, Florence, Italy. [Donati, M. Alice] Univ Florence, Anna Meyer Childrens Hosp, Dept Neuromuscular Disorders, Florence, Italy. NR 0 TC 0 Z9 0 U1 0 U2 6 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 79 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838900086 ER PT J AU Cortes, JE Kim, DW Pinilla-Ibarz, J le Coutre, P Paquette, R Chuah, C Nicolini, FE Apperley, J Khoury, HJ Talpaz, M DiPersio, JF DeAngelo, DJ Abruzzese, E Rea, D Baccarani, M Muller, MC Gambacorti-Passerini, C Wong, S Lustgarten, S Rivera, VM Clarkson, T Turner, CD Haluska, FG Guilhot, F Deininger, MW Hochhaus, A Hughes, T Goldman, JM Shah, N Kantarjian, HM AF Cortes, Jorge E. Kim, Dong-Wook Pinilla-Ibarz, Javier le Coutre, Philipp Paquette, Ron Chuah, Charles Nicolini, Franck E. Apperley, Jane Khoury, H. Jean Talpaz, Moshe DiPersio, John F. DeAngelo, Daniel J. Abruzzese, Elisabetta Rea, Delphine Baccarani, Michele Muller, Martin C. Gambacorti-Passerini, Carlo Wong, Stephane Lustgarten, Stephanie Rivera, Victor M. Clarkson, Tim Turner, Christopher D. Haluska, Frank G. Guilhot, Francois Deininger, Michael W. Hochhaus, Andreas Hughes, Timothy Goldman, John M. Shah, Neil Kantarjian, Hagop M. CA PACE Study Grp TI A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Cortes, Jorge E.; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Kim, Dong-Wook] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea. [Pinilla-Ibarz, Javier] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [le Coutre, Philipp] Charite, D-13353 Berlin, Germany. [Paquette, Ron] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA. [Chuah, Charles] Singapore Gen Hosp, Duke NUS Grad Med Sch, Singapore, Singapore. [Nicolini, Franck E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France. [Apperley, Jane] Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Hammersmith Hosp, London, England. [Khoury, H. Jean] Emory Winship Canc Inst, Atlanta, GA USA. [Talpaz, Moshe] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [DiPersio, John F.] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA. [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Abruzzese, Elisabetta] Osped S Eugenio, Rome, Italy. [Rea, Delphine] Hop St Louis, Dept Hematol, Paris, France. [Baccarani, Michele] Univ Bologna, Dept Hematol & Med Oncol, Bologna, Italy. [Muller, Martin C.] Univ Med Mannheim, Med Klin 3, Mannheim, Germany. [Gambacorti-Passerini, Carlo] Univ Milano Bicocca, Dept Hematol, Monza, Italy. [Gambacorti-Passerini, Carlo] S Gerardo Hosp, Monza, Italy. [Wong, Stephane] MolecularMD Corp, Portland, OR USA. [Lustgarten, Stephanie; Rivera, Victor M.; Clarkson, Tim; Turner, Christopher D.; Haluska, Frank G.; PACE Study Grp] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA. [Guilhot, Francois] CHU Poitiers, INSERM, CIC 0802, Poitiers, France. [Deininger, Michael W.] Univ Utah, Div Hematol & Hematol Malignancies, Huntsman Canc Inst, Salt Lake City, UT USA. [Hochhaus, Andreas] Univ Klinikum Jena, Jena, Germany. [Hughes, Timothy] Inst Med & Vet Sci, Adelaide, SA 5000, Australia. [Goldman, John M.] Univ London Imperial Coll Sci Technol & Med, Dept Hematol, London, England. [Shah, Neil] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. NR 0 TC 5 Z9 5 U1 0 U2 12 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 163 PG 3 WC Hematology SC Hematology GA 074UG UT WOS:000313838900294 ER PT J AU Cortes, M Natsuhara, K Goessling, W North, TE AF Cortes, Mauricio Natsuhara, Kelsey Goessling, Wolfram North, Trista E. TI Vitamin D3 Modulates Definitive Hematopoiesis by Two Distinct Mechanisms in the Developing Zebrafish Embryo SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Cortes, Mauricio; North, Trista E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA. [Natsuhara, Kelsey] Harvard Univ, Cambridge, MA 02138 USA. [Goessling, Wolfram] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Genet, Boston, MA 02115 USA. [Goessling, Wolfram] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gastroenterol, Boston, MA 02115 USA. [Goessling, Wolfram] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 763 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838900196 ER PT J AU Costa, LJ Lill, M Yeh, RF Stuart, RK Lim, S Waller, EK Shore, TB Craig, M Freytes, CO Shea, TC Rodriguez, TE Flinn, IW Comeau, T Pulsipher, MA Bence-Bruckler, I Laneuville, P Bierman, P Chen, AI Yu, LH Patil, S Sun, YP Armstrong, E Smith, A Elekes, A Kato, K Vaughan, W AF Costa, Luciano J. Lill, Michael Yeh, Rosa F. Stuart, Robert K. Lim, Stephen Waller, Edmund K. Shore, Tsiporah B. Craig, Michael Freytes, Cesar O. Shea, Thomas C. Rodriguez, Tulio E. Flinn, Ian W. Comeau, Terrance Pulsipher, Michael A. Bence-Bruckler, Isabelle Laneuville, Pierre Bierman, Philip Chen, Andy I. Yu, Louie H. Patil, Shiva Sun, Yiping Armstrong, Elizabeth Smith, Angela Elekes, Agnes Kato, Kazunobu Vaughan, William TI Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Costa, Luciano J.; Stuart, Robert K.] Med Univ S Carolina, Div Hematol Oncol, Charleston, SC 29425 USA. [Lill, Michael; Lim, Stephen] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Yeh, Rosa F.; Yu, Louie H.] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98104 USA. [Waller, Edmund K.] Emory Univ, Div BMT, Winship Canc Inst Hematol & Med Oncol, Atlanta, GA 30322 USA. [Shore, Tsiporah B.] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA. [Craig, Michael] W Virginia Univ, Hlth Sci Ctr, Morgantown, WV 26506 USA. [Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Shea, Thomas C.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Rodriguez, Tulio E.] Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA. [Flinn, Ian W.] Sarah Cannon Res Inst, Nashville, TN USA. [Comeau, Terrance] New Brunswick Stem Cell Transplant Program, St John, NB, Canada. [Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA. [Bence-Bruckler, Isabelle] Univ Ottawa, Ottawa, ON, Canada. [Laneuville, Pierre] McGill Univ, Ctr Hlth, Div Haematol, Montreal, PQ, Canada. [Bierman, Philip] Univ Nebraska Med Ctr, Div Hematol Oncol, Omaha, NE USA. [Chen, Andy I.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Patil, Shiva; Sun, Yiping; Armstrong, Elizabeth; Smith, Angela; Elekes, Agnes; Kato, Kazunobu] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA. [Vaughan, William] Univ Alabaman Birmingham, Bone Marrow Transplantat Program, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 813 PG 3 WC Hematology SC Hematology GA 074UG UT WOS:000313838901051 ER PT J AU Cottini, F Hideshima, T Sattler, M Caligaris-Cappio, F Anderson, KC Tonon, G AF Cottini, Francesca Hideshima, Teru Sattler, Martin Caligaris-Cappio, Federico Anderson, Kenneth C. Tonon, Giovanni TI The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Cottini, Francesca; Hideshima, Teru; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. [Caligaris-Cappio, Federico] Univ Vita Salute San Raffaele, Div Mol Oncol, Milan, Italy. [Caligaris-Cappio, Federico] Univ Vita Salute San Raffaele, Dept Oncohematol, Milan, Italy. [Tonon, Giovanni] Ist Sci San Raffaele, Div Mol Oncol, I-20132 Milan, Italy. NR 0 TC 0 Z9 0 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 725 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838900234 ER PT J AU Cutler, C Logan, BR Nakamura, R Johnston, L Choi, SW Porter, DL Hogan, WJ Pasquini, MC MacMillan, ML Wingard, JR Waller, EK Grupp, SA McCarthy, PL Wu, J Hu, ZH Carter, SL Horowitz, MM Antin, JH AF Cutler, Corey Logan, Brent R. Nakamura, Ryotaro Johnston, Laura Choi, Sung W. Porter, David L. Hogan, William J. Pasquini, Marcelo C. MacMillan, Margaret L. Wingard, John R. Waller, Edmund K. Grupp, Stephan A. McCarthy, Philip L. Wu, Juan Hu, Zhenhuan Carter, Shelly L. Horowitz, Mary M. Antin, Joseph H. TI Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402 SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Logan, Brent R.; Pasquini, Marcelo C.; Horowitz, Mary M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Nakamura, Ryotaro] City Hope Natl Med Ctr, Dept Hematol HCT, Duarte, CA 91010 USA. [Johnston, Laura] Stanford Univ, Med BMT, Stanford, CA 94305 USA. [Choi, Sung W.] Univ Michigan, Pediat Blood & Marrow Transplant Program, Ann Arbor, MI 48109 USA. [Porter, David L.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Hogan, William J.] Mayo Clin, Div Hematol, Rochester, MN USA. [MacMillan, Margaret L.] Univ Minnesota, Blood & Marrow Transplant Program, Minneapolis, MN USA. [Wingard, John R.] Univ Florida, Shands Canc Ctr, Gainesville, FL USA. [Waller, Edmund K.] Emory Univ, Div BMT, Winship Canc Inst Hematol & Med Oncol, Atlanta, GA 30322 USA. [Grupp, Stephan A.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA. [McCarthy, Philip L.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Wu, Juan; Carter, Shelly L.] EMMES Corp, Rockville, MD USA. [Hu, Zhenhuan] Med Coll Wisconsin CIBMTR, Milwaukee, WI USA. NR 0 TC 10 Z9 10 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 739 PG 3 WC Hematology SC Hematology GA 074UG UT WOS:000313838900220 ER PT J AU Dao, KHT Rotelli, MD Yates, JE Brown, B Rantala, J Rathbun, K Tyner, JW Druker, BJ Bagby, GC AF Dao, Kim-Hien T. Rotelli, Michael D. Yates, Jane E. Brown, Brieanna Rantala, Juha Rathbun, Keaney Tyner, Jeffrey W. Druker, Brian J. Bagby, Grover C., Jr. TI Regulation of FANCL by Glycogen Synthase Kinase-3beta Links the Fanconi anemia pathway to Self Renewal and Survival Signals SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Yates, Jane E.; Rathbun, Keaney] NW VA Canc Res Ctr, Portland, OR USA. [Rantala, Juha] Oregon Hlth & Sci Univ, Dept Biomed, Portland, OR 97201 USA. [Tyner, Jeffrey W.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell & Dev Biol, Portland, OR 97201 USA. [Bagby, Grover C., Jr.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1263 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902303 ER PT J AU Davids, MS Roberts, AW Anderson, MA Pagel, JM Kahl, BS Gerecitano, JF Darden, DE Nolan, CE Gressick, LA Yang, JN Chyla, BJ Busman, TA Graham, AM Cerri, E Enschede, SH Humerickhouse, RA Seymour, JF AF Davids, Matthew S. Roberts, Andrew W. Anderson, Mary Ann Pagel, John M. Kahl, Brad S. Gerecitano, John F. Darden, David E. Nolan, Cathy E. Gressick, Lori A. Yang, Jianning Chyla, Brenda J. Busman, Todd A. Graham, Alison M. Cerri, Elisa Enschede, Sari H. Humerickhouse, Rod A. Seymour, John F. TI The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Davids, Matthew S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Roberts, Andrew W.] Royal Melbourne Hosp, Dept Clin Haematol & Med Oncol, Parkville, Vic 3050, Australia. [Pagel, John M.] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA. [Kahl, Brad S.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Gerecitano, John F.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Darden, David E.; Nolan, Cathy E.; Gressick, Lori A.; Yang, Jianning; Chyla, Brenda J.; Busman, Todd A.; Graham, Alison M.; Cerri, Elisa; Enschede, Sari H.; Humerickhouse, Rod A.] Abbott Labs, Abbott Pk, IL 60064 USA. [Seymour, John F.] Peter MacCallum Canc Inst, Melbourne, Australia. RI Jones, Jeffrey/E-9827-2013 NR 0 TC 5 Z9 5 U1 0 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 304 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902156 ER PT J AU Davids, MS Roberts, AW Anderson, MA Pagel, JM Kahl, BS Gerecitano, JF Darden, DE Nolan, CE Gressick, LA Yang, JN Chyla, BJ Busman, TA Graham, AM Cerri, E Enschede, SH Humerickhouse, RA Seymour, JF AF Davids, Matthew S. Roberts, Andrew W. Anderson, Mary Ann Pagel, John M. Kahl, Brad S. Gerecitano, John F. Darden, David E. Nolan, Cathy E. Gressick, Lori A. Yang, Jianning Chyla, Brenda J. Busman, Todd A. Graham, Alison M. Cerri, Elisa Enschede, Sari H. Humerickhouse, Rod A. Seymour, John F. TI The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Davids, Matthew S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Roberts, Andrew W.] Royal Melbourne Hosp, Dept Clin Haematol & Med Oncol, Parkville, Vic 3050, Australia. [Pagel, John M.] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA. [Kahl, Brad S.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Gerecitano, John F.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Darden, David E.; Nolan, Cathy E.; Gressick, Lori A.; Yang, Jianning; Chyla, Brenda J.; Busman, Todd A.; Graham, Alison M.; Cerri, Elisa; Enschede, Sari H.; Humerickhouse, Rod A.] Abbott Labs, Abbott Pk, IL 60064 USA. [Seymour, John F.] Peter MacCallum Canc Ctr, Melbourne, Australia. RI Jones, Jeffrey/E-9827-2013 NR 0 TC 0 Z9 0 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 304 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838901332 ER PT J AU DeAngelo, D Stock, W Petersdorf, S Wang, SL Volkert, A Vandendries, E Advani, A AF DeAngelo, Daniel Stock, Wendy Petersdorf, Stephen Wang, Shaw-Ling Volkert, Angela Vandendries, Erik Advani, Anjali TI Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [DeAngelo, Daniel] Dana Farber Canc Inst, Boston, MA 02115 USA. [Stock, Wendy] Univ Chicago, Chicago, IL 60637 USA. [Petersdorf, Stephen] Univ Washington, Seattle, WA 98195 USA. [Wang, Shaw-Ling] Pfizer Inc, La Jolla, CA USA. [Volkert, Angela; Vandendries, Erik] Pfizer Inc, Cambridge, MA USA. [Advani, Anjali] Cleveland Clin, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2612 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049602270 ER PT J AU DeAngelo, D Stock, W Petersdorf, S Wang, SL Volkert, A Vandendries, E Advani, A AF DeAngelo, Daniel Stock, Wendy Petersdorf, Stephen Wang, Shaw-Ling Volkert, Angela Vandendries, Erik Advani, Anjali TI Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia. SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [DeAngelo, Daniel] Dana Farber Canc Inst, Boston, MA 02115 USA. [Stock, Wendy] Univ Chicago, Chicago, IL 60637 USA. [Petersdorf, Stephen] Univ Washington, Seattle, WA 98195 USA. [Wang, Shaw-Ling] Pfizer Inc, La Jolla, CA USA. [Volkert, Angela; Vandendries, Erik] Pfizer Inc, Cambridge, MA USA. [Advani, Anjali] Cleveland Clin, Cleveland, OH 44106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2612 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838903181 ER PT J AU DeAngelo, DJ Chen, L Guerin, A Styles, A Aberki, C Giguere-Duval, P Wu, EQ AF DeAngelo, Daniel J. Chen, Lei Guerin, Annie Styles, Amy Aberki, Clemence Giguere-Duval, Philippe Wu, Eric Qiong TI Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis. SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [DeAngelo, Daniel J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Chen, Lei] Novartis Pharmaceut, E Hanover, NJ USA. [Guerin, Annie; Styles, Amy; Aberki, Clemence; Giguere-Duval, Philippe; Wu, Eric Qiong] Anal Grp Inc, Consulting, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2792 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049603305 ER PT J AU Deshpande, AJ Chen, LY Fazio, M Sinha, AU Bernt, KM Banka, D Dias, S Olhava, EJ Daigle, SR Richon, VM Pollock, RM Armstrong, SA AF Deshpande, Aniruddha J. Chen, Liying Fazio, Maurizio Sinha, Amit U. Bernt, Kathrin M. Banka, Deepti Dias, Stuart Olhava, Edward J. Daigle, Scott R. Richon, Victoria M. Pollock, Roy M. Armstrong, Scott A. TI MLL-AF6 Mediated Transformation Is Dependent On the H3K79 Methyltransferase Dot1l SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Deshpande, Aniruddha J.; Fazio, Maurizio; Sinha, Amit U.; Bernt, Kathrin M.; Banka, Deepti; Dias, Stuart; Armstrong, Scott A.] Childrens Hosp, Boston, MA 02115 USA. [Chen, Liying] Harvard Univ, Cambridge, MA 02138 USA. [Sinha, Amit U.; Bernt, Kathrin M.; Armstrong, Scott A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Olhava, Edward J.; Daigle, Scott R.; Richon, Victoria M.; Pollock, Roy M.] Epizyme Inc, Cambridge, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3502 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049604025 ER PT J AU Deshpande, AJ Chen, LY Bernt, KM Dias, S Banka, D Sinha, AU Chen, D Punt, N Bradner, JE Armstrong, SA AF Deshpande, Aniruddha J. Chen, Liying Bernt, Kathrin M. Dias, Stuart Banka, Deepti Sinha, Amit U. Chen, David Punt, Natalie Bradner, James E. Armstrong, Scott A. TI The Interaction Between DOT1L and AF10 Is Required for H3K79 Dimethylation and MLL-AF9 Leukemia SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Chen, Liying] Harvard Univ, Cambridge, MA 02138 USA. [Bernt, Kathrin M.; Punt, Natalie] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Chen, David] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Bradner, James E.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 401 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902259 ER PT J AU Deveau, A Forrester, AM Grabher, C Coombs, AJ Chute, I Leger, D Lewis, S Look, AT Berman, JN AF Deveau, Adam Forrester, A. Michael Grabher, Clemens Coombs, Andrew J. Chute, Ian Leger, Daniel Lewis, Stephen Look, A. Thomas Berman, Jason N. TI Epigenetic Therapy Inhibits NUP98-HOXA9-Mediated Myeloid Disease-Decitabine and Valproic Acid Work Synergistically to Rescue Normal Hematopoiesis in Transgenic Zebrafish SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Grabher, Clemens] Karlsruhe Inst Technol, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany. [Chute, Ian; Leger, Daniel; Lewis, Stephen] Atlantic Canc Res Inst, Moncton, NB, Canada. [Look, A. Thomas] Dana Farber Canc Inst, Boston, MA 02115 USA. [Berman, Jason N.] Dalhousie Univ, IWK Hlth Ctr, Halifax, NS, Canada. NR 0 TC 1 Z9 1 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2391 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601070 ER PT J AU Devine, SM Owzar, K Blum, W DeAngelo, D Stone, RM Hsu, JW Champlin, RE Chen, YBA Vij, R Slack, JL Soiffer, RJ Larson, RA Shea, TC Hars, V Bennett, E Spangle, S Giralt, SA Carter, SL Horowitz, MM Linker, C Alyea, EP AF Devine, Steven M. Owzar, Kouros Blum, William DeAngelo, Daniel Stone, Richard M. Hsu, Jack W. Champlin, Richard E. Chen, Yi-Bin A. Vij, Ravi Slack, James L. Soiffer, Robert J. Larson, Richard A. Shea, Thomas C. Hars, Vera Bennett, Elizabeth Spangle, Sada Giralt, Sergio A. Carter, Shelly L. Horowitz, Mary M. Linker, Charles Alyea, Edwin P., III TI A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502 SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Devine, Steven M.] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA. [Owzar, Kouros] Duke Univ, Med Ctr, Alliance Biostat & Data Ctr, Durham, NC USA. [Blum, William] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA. [Stone, Richard M.] HMS, Boston, MA USA. [Hsu, Jack W.] Univ Florida, Gainesville, FL USA. [Champlin, Richard E.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA. [Chen, Yi-Bin A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Vij, Ravi] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA. [Slack, James L.] Mayo Clin Arizona, Phoenix, AZ USA. [Soiffer, Robert J.] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02115 USA. [Larson, Richard A.] Univ Chicago, Hematol Oncol & Comprehens Canc Ctr, Chicago, IL 60637 USA. [Shea, Thomas C.] Univ N Carolina, Chapel Hill, NC USA. [Hars, Vera; Bennett, Elizabeth; Spangle, Sada] Duke Univ, Med Ctr, Alliance Stat & Data Ctr, Durham, NC USA. [Giralt, Sergio A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Carter, Shelly L.] EMMES Corp, Rockville, MD USA. [Horowitz, Mary M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Linker, Charles] Univ Calif San Francisco, San Francisco, CA 94143 USA. RI Blum, William/E-2769-2011 NR 0 TC 10 Z9 10 U1 0 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 230 PG 3 WC Hematology SC Hematology GA 074UG UT WOS:000313838901094 ER PT J AU Dhimolea, E Jakubikova, J Groen, RWJ Delmore, JE Jacobs, HM McMilllin, DW Acuna-Villaorduna, A Hayes, CA Lawasut, P Mitsiades, CS AF Dhimolea, Eugen Jakubikova, Jana Groen, Richard W. J. Delmore, Jake E. Jacobs, Hannah M. McMilllin, Douglas W. Acuna-Villaorduna, Ana Hayes, Catriona A. Lawasut, Panisinee Mitsiades, Constantine S. TI Tumor Cell-Dependent Differences in Stroma-Induced Changes to Bortezomib Sensitivity SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Groen, Richard W. J.; Delmore, Jake E.; McMilllin, Douglas W.; Acuna-Villaorduna, Ana; Lawasut, Panisinee] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2468 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049602213 ER PT J AU DiNardo, CD Levine, RL Propert, KJ Loren, AW Paietta, E Sun, ZX Straley, K Yen, K Patel, JP Agresta, S Abdel-Wahab, O Perl, AE Fernandez, HF Margolis, D Tallman, MS Luger, SM Carroll, M AF DiNardo, Courtney D. Levine, Ross L. Propert, Kathleen J. Loren, Alison W. Paietta, Elisabeth Sun, Zhouxin Straley, Kimberly Yen, Katharine Patel, Jay P. Agresta, Samuel Abdel-Wahab, Omar Perl, Alexander E. Fernandez, Hugo F. Margolis, David Tallman, Martin S. Luger, Selina M. Carroll, Martin TI Serum 2-Hydroxyglutarate Levels Predict Isocitrate Dehydrogenase Mutations and Clinical Outcome in Acute Myeloid Leukemia SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [DiNardo, Courtney D.; Perl, Alexander E.; Luger, Selina M.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Levine, Ross L.; Patel, Jay P.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA. [Levine, Ross L.] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10021 USA. [Paietta, Elisabeth] Montefiore Med Ctr, Bronx, NY 10467 USA. [Sun, Zhouxin] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA USA. [Straley, Kimberly; Yen, Katharine; Agresta, Samuel] Agios Pharmaceut, Cambridge, MA USA. [Fernandez, Hugo F.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [Carroll, Martin] Univ Penn, Div Hematol & Oncol, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2481 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049602200 ER PT J AU Emadi, A Jun, SA Tsukamoto, T Fathi, AT Minden, MD Dang, CV AF Emadi, Ashkan Jun, Sung Ah Tsukamoto, Takashi Fathi, Amir T. Minden, Mark D. Chi Van Dang TI Glutaminase Inhibition Selectively Slows the Growth of Primary Acute Myeloid Leukemia (AML) Cells with Isocitrate Dehydrogenase (IDH) Mutations SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Emadi, Ashkan] Univ Maryland, Dept Med, Greenebaum Canc Ctr, Div Hematol Oncol, Baltimore, MD 21201 USA. [Jun, Sung Ah] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada. [Tsukamoto, Takashi] Johns Hopkins Univ, Brain Sci Inst, Baltimore, MD USA. [Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Minden, Mark D.] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada. [Chi Van Dang] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2624 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049602258 ER PT J AU Emadi, A Jun, SA Tsukamoto, T Fathi, AT Minden, MD Dang, CV AF Emadi, Ashkan Jun, Sung Ah Tsukamoto, Takashi Fathi, Amir T. Minden, Mark D. Dang, Chi Van TI Glutaminase Inhibition Selectively Slows the Growth of Primary Acute Myeloid Leukemia (AML) Cells with Isocitrate Dehydrogenase (IDH) Mutations. SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Emadi, Ashkan] Univ Maryland, Dept Med, Div Hematol Oncol, Greenebaum Canc Ctr, Baltimore, MD 21201 USA. [Jun, Sung Ah] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada. [Tsukamoto, Takashi] Johns Hopkins Univ, Brain Sci Inst, Baltimore, MD USA. [Fathi, Amir T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Minden, Mark D.] Univ Toronto, Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada. [Dang, Chi Van] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2624 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838903169 ER PT J AU Ettinger, RA Epstein, MS Puranik, K Hughes, RJ Liberman, JA James, E Howard, TE Cole, SS Matthews, DC Pratt, KP AF Ettinger, Ruth A. Epstein, Melinda S. Puranik, Komal Hughes, Richard J. Liberman, Joseph A. James, Eddie Howard, Tom E. Cole, Shelley S. Matthews, Dana C. Pratt, Kathleen P. TI Sequence-Modified Factor VIII Variants Having Reduced Immunogenicity SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Ettinger, Ruth A.; Puranik, Komal; Liberman, Joseph A.; Pratt, Kathleen P.] Puget Sound Blood Ctr Res Inst, Seattle, WA USA. [Epstein, Melinda S.; Hughes, Richard J.] Greater Los Angeles Vet Adm, Los Angeles, CA USA. [James, Eddie] Benaroya Res Inst, Seattle, WA USA. [Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Pathol & Lab Med, Los Angeles, CA USA. [Cole, Shelley S.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA. [Matthews, Dana C.] Seattle Childrens Hosp, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 39 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838900125 ER PT J AU Evens, AM Feldman, T Kroll, A Muffly, LS Winer, E Flowers, C Lansigan, F Nabhan, C Nastoupil, L Kim, A Li, XN Waksmundzki, K Lam, D Draper, JT Meilleur, A Nath, R Cygan, P Castillo, JJ Goy, A Woda, B Smith, SM Rosen, ST Abramson, JS AF Evens, Andrew M. Feldman, Tatyana Kroll, Aimee Muffly, Lori S. Winer, Eric Flowers, Christopher Lansigan, Frederick Nabhan, Chadi Nastoupil, Loretta Kim, Austin Li, Xiuning Waksmundzki, Kathryn Lam, David Draper, Jacqueline Tessa Meilleur, Ashley Nath, Rajneesh Cygan, Peter Castillo, Jorge J. Goy, Andre Woda, Bruce Smith, Sonali M. Rosen, Steven T. Abramson, Jeremy S. TI Survival of Newly Diagnosed T-Cell Lymphoma (TCL) in the Modern Era: Investigation of Prognostic Factors with Critical Examination of Therapy in a Multicenter US Cohort SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Evens, Andrew M.] Univ Massachusetts, Sch Med, Div Hematol Oncol, Worcester, MA USA. [Feldman, Tatyana; Goy, Andre] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Muffly, Lori S.] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA. [Winer, Eric] Rhode Isl Hosp, Div Hematol Oncol, Providence, RI USA. [Flowers, Christopher] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA. [Lansigan, Frederick; Lam, David] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Nabhan, Chadi] Advocate Lutheran Gen Hosp, Div Hematol & Oncol, Park Ridge, IL USA. [Nastoupil, Loretta] Emory Univ, Div BMT, Winship Canc Inst Hematol & Med Oncol, Atlanta, GA 30322 USA. [Meilleur, Ashley; Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. [Nath, Rajneesh] UMass Mem Med Ctr, Dept Med, Div Hematol Oncol, Worcester, MA USA. [Cygan, Peter] Lutheran Gen Hosp, Park Ridge, IL 60068 USA. [Castillo, Jorge J.] Miriam Hosp, Providence, RI 02906 USA. [Rosen, Steven T.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2728 PG 3 WC Hematology SC Hematology GA 077SZ UT WOS:000314049603369 ER PT J AU Foudi, A Hock, H AF Foudi, Adlen Hock, Hanno TI The Balance of Gfi-1 and Gfi-1b Maintains the Undifferentiated, Multipotent State of Hematopoietic Stem Cells and Regulates Lineage-Commitment SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Foudi, Adlen] Harvard Stem Cell Inst, Boston, MA USA. [Hock, Hanno] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Hock, Hanno] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1210 PG 1 WC Hematology SC Hematology GA 074UG UT WOS:000313838902356 ER PT J AU Frelinger, AL Jakubowski, JA Brooks, JK Zayas, SL Berny-Lang, MA Barnard, MR Heeney, MM Michelson, AD AF Frelinger, Andrew L., III Jakubowski, Joseph A. Brooks, Julie K. Zayas, Sabrina L. Berny-Lang, Michelle A. Barnard, Marc R. Heeney, Matthew M. Michelson, Alan D. TI Platelet Activation and Inhibition in Sickle Cell Disease (PAINS) Study SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Frelinger, Andrew L., III; Brooks, Julie K.; Zayas, Sabrina L.; Barnard, Marc R.] Boston Childrens Hosp, Dana Farber Canc Inst, Ctr Platelet Res Studies, Boston, MA USA. [Jakubowski, Joseph A.] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA. [Berny-Lang, Michelle A.; Heeney, Matthew M.; Michelson, Alan D.] Harvard Univ, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 5147 PG 1 WC Hematology SC Hematology GA 077SZ UT WOS:000314049605441 ER PT J AU Frelinger, AL Bhatt, DL Lee, RD Mulford, DJ Wu, JT Nudurupati, S Nigam, A Lampa, M Brooks, JK Barnard, MR Michelson, AD AF Frelinger, Andrew L., III Bhatt, Deepak L. Lee, Ronald D. Mulford, Darcy J. Wu, Jingtao Nudurupati, Sai Nigam, Anu Lampa, Michael Brooks, Julie K. Barnard, Marc R. Michelson, Alan D. TI Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Non-Compliance, Diet, Smoking, Co-Medications (including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Frelinger, Andrew L., III; Nigam, Anu; Lampa, Michael; Brooks, Julie K.; Barnard, Marc R.] Boston Childrens Hosp, Dana Farber Canc Inst, Ctr Platelet Res Studies, Boston, MA USA. [Bhatt, Deepak L.; Michelson, Alan D.] Harvard Univ, Sch Med, Boston, MA USA. [Lee, Ronald D.; Mulford, Darcy J.; Wu, Jingtao; Nudurupati, Sai] Takeda Global Res & Dev Ctr, Deerfield, IL USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 4356 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049605166 ER PT J AU Frost, P Gera, J Lichtenstein, AK AF Frost, Patrick Gera, Joseph Lichtenstein, Alan K. TI The Internal Ribosome Entry Site-Medaited Expression of VEGF Rescues HS Sultan Tumor Cells From Mammalian Target of Rapamycin (mTOR)-Inhibitors Induced Apoptosis in Vivo SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Frost, Patrick] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Gera, Joseph] UCLA W LA VA Med Ctr, Los Angeles, CA USA. [Lichtenstein, Alan K.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1659 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049600379 ER PT J AU Fulciniti, M Li, YX Wang, XJ Samur, MK Yan, ZY Amin, SB Li, C Anderson, KC Munshi, NC AF Fulciniti, Mariateresa Li, Yingxiang Wang, Xujun Samur, Mehmet K. Yan, Zhenyu Amin, Samir B. Li, Cheng Anderson, Kenneth C. Munshi, Nikhil C. TI Integrating Gene and Mir Expression Profiles and Regulatory Network Structures to Define Aberrent Feed Forward Loops with Functional and Clinical Implications in Myeloma SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Li, Yingxiang; Wang, Xujun] Tongji Univ, Sch Life Sci & Technol, Dept Bioinformat, Shanghai 200092, Peoples R China. [Samur, Mehmet K.] Akdeniz Univ, Dept Biostat & Med Informat, TR-07058 Antalya, Turkey. [Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston VA Healthcare Syst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2386 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601075 ER PT J AU Furman, M Abramson, JS Beltran, BE Bibas, M Bower, M Collins, J Connors, JM Cwynarski, K Nguyen, ML Ribera, JM Tanaka, PY Vose, JM Castillo, JJ AF Furman, Michael Abramson, Jeremy S. Beltran, Brady E. Bibas, Michele Bower, Mark Collins, Jaime Connors, Joseph M. Cwynarski, Kate Minh-Li Nguyen Ribera, Josep-Maria Tanaka, Paula Y. Vose, Julie M. Castillo, Jorge J. TI Prognostic Factors in Patients with HIV-Associated Hodgkin Lymphoma: An Analysis of 199 Cases SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Furman, Michael; Castillo, Jorge J.] Miriam Hosp, Providence, RI 02906 USA. [Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Canc, Ctr Lymphoma, Boston, MA USA. [Beltran, Brady E.] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru. [Bibas, Michele] Natl Inst Infect Dis, Rome, Italy. [Bower, Mark] Chelsea & Westminster Hosp, London, England. [Collins, Jaime] Hosp Guillermo Almenara, Lima, Peru. [Connors, Joseph M.] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada. [Cwynarski, Kate] Royal Free Hosp, London NW3 2QG, England. [Minh-Li Nguyen] Emory Med Sch, Atlanta, GA USA. [Ribera, Josep-Maria] ICO Hosp Germans Trias & Pujol, Jose Carreras Leukemia Res Inst, Badalona, Spain. [Ribera, Josep-Maria] PETHEMA Grp, Badalona, Spain. [Ribera, Josep-Maria] GELTAMO Grp, Badalona, Spain. [Ribera, Josep-Maria] GELCAB Grp, Badalona, Spain. [Ribera, Josep-Maria] GESIDA Grp, Badalona, Spain. [Tanaka, Paula Y.] Inst Infectol Emilio Ribas, Sao Paulo, Brazil. [Vose, Julie M.] Nebraska Med Ctr, Omaha, NE USA. RI Bibas, Michele/E-7130-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1528 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838906238 ER PT J AU Garfall, AL Kim, HT Cutler, C Ho, VT Koreth, J Armand, P Chen, YBA McAfee, SL Dey, BR Liney, D Alyea, E Soiffer, RJ Spitzer, TR Antin, JH Ballen, KK AF Garfall, Alfred L. Kim, Haesook T. Cutler, Corey Ho, Vincent T. Koreth, John Armand, Philippe Chen, Yi-Bin A. McAfee, Steven L. Dey, Bimalangshu R. Liney, Deborah Alyea, Edwin Soiffer, Robert J. Spitzer, Thomas R. Antin, Joseph H. Ballen, Karen K. TI Allele Matching At HLA-C or DRB1 Is Associated with Improved Survival After Reduced Intensity Double Umbilical Cord Blood Transplantation SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Garfall, Alfred L.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Koreth, John; Liney, Deborah; Alyea, Edwin; Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [McAfee, Steven L.; Dey, Bimalangshu R.; Spitzer, Thomas R.; Ballen, Karen K.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2010 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049603285 ER PT J AU Garrett, WS AF Garrett, Wendy S. TI Gut Microbiota and Intestinal Inflammation SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Garrett, Wendy S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 49 PG 1 WC Hematology SC Hematology GA 074UG UT WOS:000313838900036 ER PT J AU Gazourian, L Coronata, AMF Rogers, AJ Weinhouse, GL Soiffer, RJ Antin, JH Ritz, J Ho, VT Baron, RM Washko, GR AF Gazourian, Lee Coronata, Anna Maria F. Rogers, Angela J. Weinhouse, Gerald L. Soiffer, Robert J. Antin, Joseph H. Ritz, Jerome Ho, Vincent T. Baron, Rebecca M. Washko, George R. TI Airway Dilation in Bronchiolitis Obliterans After Allogeneic Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Gazourian, Lee; Coronata, Anna Maria F.; Weinhouse, Gerald L.; Baron, Rebecca M.; Washko, George R.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Rogers, Angela J.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA. [Soiffer, Robert J.; Antin, Joseph H.] Dana Farber Canc Inst, Div Hematol Malignancies, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3058 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601205 ER PT J AU Ghobrial, IM Siegel, D Vij, R Wolf, JL Berdeja, JG Matous, JV Lipman, P Patel, C Le, T Rommel, C Berk, G AF Ghobrial, Irene M. Siegel, David Vij, Ravi Wolf, Jeffrey L. Berdeja, Jesus G. Matous, Jeffrey V. Lipman, Peter Patel, Chirag Le, Trinh Rommel, Christian Berk, Gregory TI MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Ghobrial, Irene M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Siegel, David] Hackensack Univ Med Ctr, Hackensack, NJ USA. [Vij, Ravi] Washington Univ Sch Med, Div Oncol, Dept Med, St Louis, MO USA. [Wolf, Jeffrey L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Berdeja, Jesus G.] Sarah Cannon Res Inst, Nashville, TN USA. [Matous, Jeffrey V.] Colorado Blood Canc Inst, Denver, CO USA. [Lipman, Peter; Patel, Chirag; Berk, Gregory] Millennium Pharmaceut Inc, Cambridge, MA USA. [Le, Trinh; Rommel, Christian] Intellikine LLC, La Jolla, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 4038 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049603062 ER PT J AU Goswami, RS Xuan, YL Waldron, L Sukhai, MA Reis, PP Sun, T Datti, A Xu, W Kuruvilla, J Good, D Lai, R Lam, W Church, A LeBrun, D Sehn, LH Farinha, P Jurisica, I Bailey, D Gascoyne, RD Crump, M Kamel-Reid, S AF Goswami, Rashmi S. Xuan, Yali Waldron, Levi Sukhai, Mahadeo A. Reis, Patricia P. Sun, Thomas Datti, Alessandro Xu, Wei Kuruvilla, John Good, David Lai, Raymond Lam, Wilson Church, Alanna LeBrun, David Sehn, Laurie H. Farinha, Pedro Jurisica, Igor Bailey, Denis Gascoyne, Randy D. Crump, Michael Kamel-Reid, Suzanne TI A 7-Gene Microrna Signature Characteristic of Mantle Cell Lymphoma Reveals Focal Adhesion and Integrin Signalling, Proteasome-Mediated Degradation, and the PI3K Signalling Cascade As Important to MCL Pathogenesis SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Waldron, Levi] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Sukhai, Mahadeo A.] Princess Margaret Hosp, Ontario Canc Inst, Univ Hlth Network, Toronto, ON M4X 1K9, Canada. [Reis, Patricia P.] Sao Paulo State Univ UNESP, Dept Surg & Orthoped, Botucatu, SP, Brazil. [Sun, Thomas; Datti, Alessandro] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada. [Xu, Wei] Princess Margaret Hosp, Dept Biostat, Toronto, ON M4X 1K9, Canada. [Kuruvilla, John] Princess Margaret Hosp, Dept Med Oncol & Hematol, Univ Hlth Network, Toronto, ON M4X 1K9, Canada. [Good, David; Lam, Wilson; Church, Alanna] Queens Univ, Kingston Gen Hosp, Dept Pathol & Mol Med, Kingston, ON, Canada. [Lai, Raymond] Univ Alberta, Dept Lab Med & Pathol, Cross Canc Inst, Edmonton, AB, Canada. [LeBrun, David] Queens Univ, Div Canc Biol & Genet, Kingston, ON, Canada. [Sehn, Laurie H.] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada. [Farinha, Pedro] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada. [Jurisica, Igor] Ontario Canc Inst, Div Signalling Biol, Toronto, ON M4X 1K9, Canada. [Jurisica, Igor] Campbell Family Inst Canc Res, Toronto, ON, Canada. [Bailey, Denis] Toronto Gen Hosp, Dept Pathol, Univ Hlth Network, Toronto, ON, Canada. [Gascoyne, Randy D.] BC Canc Agcy Ctr Lymphoid Canc, Dept Pathol, Vancouver, BC, Canada. [Kamel-Reid, Suzanne] Univ Toronto, Toronto, ON, Canada. RI Reis, Patricia/F-4701-2012 OI Reis, Patricia/0000-0003-3775-3797 NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1586 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838906296 ER PT J AU Grabowski, EF Kushak, RI Ingelfinger, JR AF Grabowski, Eric F. Kushak, Rafail I. Ingelfinger, Julie R. TI Shiga Toxin Upregulates Tissue Factor Gene Expression in and Functional Tissue Factor On Endothelium in the Presence of Complement Activation SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Grabowski, Eric F.; Kushak, Rafail I.; Ingelfinger, Julie R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1075 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601381 ER PT J AU Griffin, JD Guerin, A Chen, L Macalalad, AR Luo, JY Wu, EQ AF Griffin, James D. Guerin, Annie Chen, Lei Macalalad, Alexander R. Luo, Jiayuan Wu, Eric Qiong TI Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy. SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Griffin, James D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Guerin, Annie; Macalalad, Alexander R.; Luo, Jiayuan; Wu, Eric Qiong] Anal Grp Inc, Consulting, Boston, MA USA. [Chen, Lei] Novartis Pharmaceut, E Hanover, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2796 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049603301 ER PT J AU Gritsman, K Clayton, L Gilliland, DG Roberts, TM Zhao, J AF Gritsman, Kira Clayton, Linda Gilliland, D. Gary Roberts, Thomas M. Zhao, Jean TI The p110alpha and p110delta Isoforms of PI3 Kinase Are Dispensable for Hematopoietic Stem Cell Self-Renewal but Have Redundant Roles in B Cell Differentiation. SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Gritsman, Kira] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Clayton, Linda] Whitehead Inst, Jamaica Plain, MA USA. [Gilliland, D. Gary] Merck & Co Inc, N Wales, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2322 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601138 ER PT J AU Grompe, M Postlethwait, J D'Andrea, AD Olson, SB Zhang, QS Bagby, GC AF Grompe, Markus Postlethwait, John D'Andrea, Alan D. Olson, Susan B. Zhang, Qingshuo Bagby, Grover C., Jr. TI Fanconi Anemia: Emerging Therapeutic Opportunities SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Grompe, Markus; Zhang, Qingshuo] Oregon Hlth & Sci Univ, Oregon Stem Cell Ctr, Portland, OR 97201 USA. [Postlethwait, John] Univ Oregon, Eugene, OR 97403 USA. [D'Andrea, Alan D.] Dana Farber Canc Inst, Dept Rad Onc, Boston, MA 02115 USA. [Olson, Susan B.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA. [Bagby, Grover C., Jr.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 7 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1 PG 1 WC Hematology SC Hematology GA 074UG UT WOS:000313838900033 ER PT J AU Gutierrez, A Kentsis, A Pan, L Baleydier, F Marineau, J Grebliunaite, R Kozakewich, E Reed, C Pflumio, F Poglio, S Uzan, B Clemons, PA VerPlank, L An, WF Burbank, J Norton, S Tolliday, NJ Steen, H Bradner, JE Look, AT Aster, JC AF Gutierrez, Alejandro Kentsis, Alex Pan, Li Baleydier, Frederic Marineau, Jason Grebliunaite, Ruta Kozakewich, Elena Reed, Casie Pflumio, Francoise Poglio, Sandrine Uzan, Benjamin Clemons, Paul A. VerPlank, Lynn An, W. Frank Burbank, Jason Norton, Stephanie Tolliday, Nicola J. Steen, Hanno Bradner, James E. Look, A. Thomas Aster, Jon C. TI Phenothiazines Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia by Activating the Phosphatase Activity of the PP2A Tumor Suppressor SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Gutierrez, Alejandro; Kentsis, Alex] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA. [Pan, Li; Aster, Jon C.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Baleydier, Frederic] Hosp Civils Lyon, Lyon, France. [Pflumio, Francoise; Poglio, Sandrine; Uzan, Benjamin] CEA, Normal & Leukem Hematopoiet Stem Cell Lab, Fontenay Aux Roses, France. [Pflumio, Francoise; Poglio, Sandrine; Uzan, Benjamin] INSERM, U967, Fontenay Aux Roses, France. [Clemons, Paul A.; VerPlank, Lynn; An, W. Frank; Burbank, Jason; Norton, Stephanie; Tolliday, Nicola J.] Broad Inst, Cambridge, MA USA. [Steen, Hanno] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. RI Pflumio, Francoise/E-2074-2017 NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3558 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838906099 ER PT J AU Habermann, TM Hong, F Morrison, VA Dakhil, SR Weick, JK Frankel, SR Gascoyne, RD Fisher, RI Cheson, BD Weller, EA Kahl, BS Peterson, BA Hochster, HS Horning, SJ AF Habermann, Thomas M. Hong, Fangxin Morrison, Vicki A. Dakhil, Shaker R. Weick, James K. Frankel, Stanley R. Gascoyne, Randy D. Fisher, Richard I. Cheson, Bruce D. Weller, Edie A. Kahl, Brad S. Peterson, Bruce A. Hochster, Howard S. Horning, Sandra J. TI Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Habermann, Thomas M.] Mayo Clin, Div Hematol, Rochester, MN USA. [Hong, Fangxin] Dana Farber Canc Inst, Boston, MA USA. [Morrison, Vicki A.] Univ Minnesota, VA Med Ctr, Minneapolis, MN USA. [Dakhil, Shaker R.] Univ Kansas, Sch Med, Wichita, KS 67214 USA. [Weick, James K.] VA Med Ctr, Riviera Beach, FL USA. [Frankel, Stanley R.] Hoffmann La Roche Inc, Nutley, NJ 07110 USA. [Gascoyne, Randy D.] BC Canc Agcy, Ctr Lymphoid Canc, Dept Pathol, Vancouver, BC, Canada. [Fisher, Richard I.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. [Cheson, Bruce D.] Georgetown Univ Hosp, Washington, DC 20007 USA. [Weller, Edie A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Kahl, Brad S.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. [Hochster, Howard S.] Yale Univ, Sch Med, New Haven, CT USA. [Horning, Sandra J.] Genentech Inc Current, San Francisco, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3705 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049600213 ER PT J AU Hanna, M Tesar, B Stevenson, KE Vartanov, AR Fernandes, SM Macconaill, L Landau, DA Wu, CJ Neuberg, DS Freedman, AS Brown, JR AF Hanna, Megan Tesar, Bethany Stevenson, Kristen E. Vartanov, Alexander R. Fernandes, Stacey M. Macconaill, Laura Landau, Dan-Avi Wu, Catherine J. Neuberg, Donna S. Freedman, Arnold S. Brown, Jennifer R. TI Somatic and Germline Copy Neutral Loss of Heterozygosity Are Common in Chronic Lymphocytic Leukemia SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Hanna, Megan; Macconaill, Laura] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA. [Tesar, Bethany; Vartanov, Alexander R.; Fernandes, Stacey M.; Landau, Dan-Avi; Freedman, Arnold S.; Brown, Jennifer R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Stevenson, Kristen E.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 4567 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049605515 ER PT J AU Heffner, LT Jagannath, S Zimmerman, TM Lee, KP Rosenblatt, J Lonial, S Lutz, RJ Czeloth, N Osterroth, F Ruehle, M Beelitz, MA Wartenberg-Demand, A Haeder, T Anderson, KC Munshi, NC AF Heffner, Leonard T. Jagannath, Sundar Zimmerman, Todd M. Lee, Kelvin P. Rosenblatt, Jacalyn Lonial, Sagar Lutz, Robert J. Czeloth, Niklas Osterroth, Frank Ruehle, Markus Beelitz, Michelle A. Wartenberg-Demand, Andrea Haeder, Thomas Anderson, Kenneth C. Munshi, Nikhil C. TI BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Heffner, Leonard T.; Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Jagannath, Sundar] Mt Sinai Sch Med, Multiple Myeloma Program, New York, NY USA. [Zimmerman, Todd M.] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Lee, Kelvin P.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Rosenblatt, Jacalyn] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Lutz, Robert J.] ImmunoGen Inc, Translat Res & Dev, Waltham, MA USA. [Czeloth, Niklas] Biotest AG, Pharmacol Biotherapeut, Dreieich, Germany. [Osterroth, Frank] Biotest AG, GBU Biotherapeut, Dreieich, Germany. [Ruehle, Markus] Biotest AG, Corp Drug Safety, Dreieich, Germany. [Beelitz, Michelle A.] Biotest Pharmaceut Corp, Clin Res, Boca Raton, FL USA. [Wartenberg-Demand, Andrea; Haeder, Thomas] Biotest AG, Corp Clin Res, Dreieich, Germany. [Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 2 Z9 2 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 4042 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049603058 ER PT J AU Heidel, FH Bullinger, L Wang, Z Arreba-Tutusaus, P Hirt, C Niederwieser, D Dohner, K Fischer, T Armstrong, SA AF Heidel, Florian H. Bullinger, Lars Wang, Zhu Arreba-Tutusaus, Patricia Hirt, Carsten Niederwieser, Dietger Dohner, Konstanze Fischer, Thomas Armstrong, Scott A. TI Inactivation of the Cell Fate Determinate Llgl1 (Lethal Giant Larvae Homolog 1) Leads to Enhanced HSC Fitness and Predicts a Poor Prognosis in AML SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Heidel, Florian H.; Fischer, Thomas] Univ Magdeburg, Univ Hosp, Dept Hematol Oncol, D-39106 Magdeburg, Germany. [Bullinger, Lars] Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany. [Wang, Zhu; Armstrong, Scott A.] Childrens Hosp, Boston, MA 02115 USA. [Arreba-Tutusaus, Patricia] Univ Magdeburg, Med Ctr, D-39106 Magdeburg, Germany. [Hirt, Carsten] Ernst Moritz Arndt Univ Greifswald, Klinikum Ernst Moritz Arndt, Klin & Poliklin Innere Med C, Greifswald, Germany. [Niederwieser, Dietger] Univ Leipzig, Dept Hematol & Oncol, D-04109 Leipzig, Germany. [Dohner, Konstanze] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany. [Armstrong, Scott A.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2293 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049600087 ER PT J AU Herrera, AF Crosby-Thompson, A Friedberg, JW Abel, GA Czuczman, MS Gordon, LI Kaminski, MS Millenson, M Nademanee, A Niland, J Rodriguez, MA Zelenetz, AD LaCasce, AS AF Herrera, Alex F. Crosby-Thompson, Allison Friedberg, Jonathan W. Abel, Gregory A. Czuczman, Myron S. Gordon, Leo I. Kaminski, Mark S. Millenson, Michael Nademanee, Auayporn Niland, Joyce Rodriguez, Maria A. Zelenetz, Andrew D. LaCasce, Ann S. TI Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Herrera, Alex F.; Crosby-Thompson, Allison; Abel, Gregory A.; LaCasce, Ann S.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Friedberg, Jonathan W.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA. [Czuczman, Myron S.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Gordon, Leo I.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA. [Kaminski, Mark S.] Univ Michigan, Ann Arbor, MI 48109 USA. [Millenson, Michael] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Nademanee, Auayporn] City Hope Natl Med Ctr, Hematol & Stem Cell Transplantat, Duarte, CA USA. [Niland, Joyce] City Hope Natl Med Ctr, Data Coordinating Ctr, Duarte, CA 91010 USA. [Rodriguez, Maria A.] UT MD Anderson Canc Ctr, Houston, TX USA. [Zelenetz, Andrew D.] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1610 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601047 ER PT J AU Hitzler, JK He, WS Doyle, JJ Bitan, M Cairo, MS Camitta, B Chan, KW Diaz, MA Fraser, C Gross, T Horan, JT Kasow, KA Kennedy-Nasser, A Kitko, C Kurtzberg, J Lehmann, LE Mitchell, D O'Brien, T Pulsipher, MA Smith, FO Yu, LC Zhang, MJ Eapen, M Carpenter, PA AF Hitzler, Johann K. He, Wensheng Doyle, John J. Bitan, Menachem Cairo, Mitchell S. Camitta, Bruce Chan, Ka Wah Angel Diaz, Miguel Fraser, Christopher Gross, Thomas Horan, John T. Kasow, Kimberly A. Kennedy-Nasser, Alana Kitko, Carrie Kurtzberg, Joanne Lehmann, Leslie E. Mitchell, David O'Brien, Tracey Pulsipher, Michael A. Smith, Franklin O. Yu, Lolie C. Zhang, Mei-Jie Eapen, Mary Carpenter, Paul A. TI Outcome of Transplantation for Acute Leukemia in Down Syndrome SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Hitzler, Johann K.] Hosp Sick Children, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada. [He, Wensheng] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Doyle, John J.] Univ Toronto, Hosp Sick Children, Dept Hem Onc BMT, Toronto, ON M5G 1X8, Canada. [Bitan, Menachem] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel. [Cairo, Mitchell S.] Columbia Univ, Med Ctr, Div Pediat Hematol & Blood & Marrow Transplantat, New York, NY USA. [Camitta, Bruce] Med Coll Wisconsin, Wauwatosa, WI USA. [Chan, Ka Wah] Texas Transplant Inst, San Antonio, TX USA. [Angel Diaz, Miguel] Nino Jesus Childrens Hosp, Madrid, Spain. [Fraser, Christopher] Royal Childrens Hosp, Brisbane, Qld, Australia. [Gross, Thomas] Ohio State Univ, Nationwide Childrens Hosp, Columbus, OH 43210 USA. [Horan, John T.] Chidlrens Healthcare Atlanta, Dept Pediat, Atlanta, GA USA. [Kasow, Kimberly A.] Univ N Carolina Hosp, Chapel Hill, NC USA. [Kennedy-Nasser, Alana] Methodist Hosp, Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA. [Kitko, Carrie] Univ Michigan, Blood & Marrow Transplant Program, Ann Arbor, MI 48109 USA. [Kurtzberg, Joanne] Duke Univ, Med Ctr, Durham, NC USA. [Lehmann, Leslie E.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mitchell, David] Montreal Childrens Hosp, Montreal, PQ, Canada. [O'Brien, Tracey] Sydney Childrens Hosp, Ctr Childrens Canc & Blood Disorders, Randwick, NSW, Australia. [Pulsipher, Michael A.] Univ Utah, Salt Lake City, UT USA. [Smith, Franklin O.] Univ Cincinnati, Coll Med, Div Hematol Oncol, Cincinnati, OH USA. [Yu, Lolie C.] Childrens Hosp, New Orleans, LA USA. [Carpenter, Paul A.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1991 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902379 ER PT J AU Hochhaus, A Kim, DW Pinilla-Ibarz, J le Coutre, P Paquette, R Chuah, C Nicolini, FE Apperley, J Khoury, HJ Talpaz, M DiPersio, JF DeAngelo, D Abruzzese, E Rea, D Baccarani, M Muller, MC Gambacorti-Passerini, C Wong, S Lustgarten, S Rivera, VM Clackson, T Turner, CD Haluska, FG Guilhot, F Deininger, MW Hughes, TP Goldman, JM Shah, N Kantarjian, HM Cortes, JE AF Hochhaus, Andreas Kim, Dong-Wook Pinilla-Ibarz, Javier le Coutre, Philipp Paquette, Ronald Chuah, Charles Nicolini, Franck E. Apperley, Jane Khoury, H. Jean Talpaz, Moshe DiPersio, John F. DeAngelo, Daniel Abruzzese, Elisabetta Rea, Delphine Baccarani, Michele Muller, Martin C. Gambacorti-Passerini, Carlo Wong, Stephane Lustgarten, Stephanie Rivera, Victor M. Clackson, Tim Turner, Christopher D. Haluska, Frank G. Guilhot, Francois Deininger, Michael W. Hughes, Timothy P. Goldman, John M. Shah, Neil Kantarjian, Hagop M. Cortes, Jorge E. CA PACE Study Grp TI Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph plus ) Leukemia: Results From the PACE Trial SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Hochhaus, Andreas] Univ Klinikum Jena, Dept Hematol & Oncol, Jena, Germany. [Kim, Dong-Wook] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Div Hematol, Seoul, South Korea. [Pinilla-Ibarz, Javier] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [le Coutre, Philipp] Univ Med Berlin, Charite, Med Klin MS, Berlin, Germany. [Paquette, Ronald] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA. [Chuah, Charles] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Singapore Gen Hosp, Dept Hematol, Singapore, Singapore. [Nicolini, Franck E.] Ctr Hosp Lyon Sud, Pierre Benite, France. [Apperley, Jane] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, London, England. [Khoury, H. Jean] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Talpaz, Moshe] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [DiPersio, John F.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. [DeAngelo, Daniel] Dana Farber Canc Inst, Boston, MA 02115 USA. [Abruzzese, Elisabetta] Univ Roma Tor Vergata, Osped S Eugenio, Rome, Italy. [Rea, Delphine] Hop St Louis, Serv Malad Sang, Paris, France. [Rea, Delphine] Hop St Louis, EA3518, Paris, France. [Baccarani, Michele] Univ Bologna, Bologna, Italy. [Muller, Martin C.] Univ Med Mannheim, Med Klin 3, Mannheim, Germany. [Gambacorti-Passerini, Carlo] Univ Milano Bicocca, Monza, Italy. [Wong, Stephane] MolecularMD Corp, Portland, OR USA. [Lustgarten, Stephanie; Rivera, Victor M.; Clackson, Tim; Turner, Christopher D.; Haluska, Frank G.; PACE Study Grp] ARIAD Pharmaceut Inc, Cambridge, MA USA. [Guilhot, Francois] CHU Poitiers, Poitiers, France. [Deininger, Michael W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Hughes, Timothy P.] Royal Adelaide Hosp, Dept Haematol, SA Pathol, Adelaide, SA 5000, Australia. [Goldman, John M.] Univ London Imperial Coll Sci Technol & Med, Dept Hematol, London, England. [Shah, Neil] Univ Calif San Francisco, San Francisco Sch Med, San Francisco, CA 94143 USA. [Kantarjian, Hagop M.; Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3763 PG 3 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601302 ER PT J AU Hope, C Hebron, E Kim, J Jensen, J Flanagan, C Bhatia, N Leith, C Maroulakou, I Mitsiades, CS Miyamoto, S Callander, N Hematti, P Asimakopoulos, F AF Hope, Chelsea Hebron, Ellen Kim, Jaehyup Jensen, Jeff Flanagan, Claire Bhatia, Neehar Leith, Catherine Maroulakou, Ioanna Mitsiades, Constantine S. Miyamoto, Shigeki Callander, Natalie Hematti, Peiman Asimakopoulos, Fotis TI Molecular Pathways That Determine the Activation State of Macrophages within the Myeloma Niche SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Maroulakou, Ioanna] Democritus Univ Thrace, Alexandroupolis, Greece. [Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Hematti, Peiman; Asimakopoulos, Fotis] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 443 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902217 ER PT J AU Howard, TE Drigalenko, E Johnson, MP Cole, SS Kim, B Viel, KR Sauna, ZE Curran, JE Blangero, J Almasy, LA Goring, HH AF Howard, Tom E. Drigalenko, Eugene Johnson, Matthew P. Cole, Shelley S. Kim, Benjamin Viel, Kevin R. Sauna, Zuben E. Curran, Joanne E. Blangero, John Almasy, Laura A. Goering, Harald H. TI Common SNPs within or near Three Immune Response Genes Implicated in the Risk of FVIII Immunogenicity in Hemophilia A Do Not Influence Steady-State Levels of Their Encoded mRNAs SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Howard, Tom E.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol & Lab Med, Los Angeles, CA USA. [Drigalenko, Eugene; Johnson, Matthew P.; Cole, Shelley S.; Curran, Joanne E.; Blangero, John; Almasy, Laura A.; Goering, Harald H.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA. [Kim, Benjamin] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA USA. [Viel, Kevin R.] Histonis Inc, Atlanta, GA USA. [Sauna, Zuben E.] US FDA, Ctr Biol Evaluat & Res, Div Hematol, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3366 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049602318 ER PT J AU Hsu, JM Huang, HT Lee, CT Yu, SQ Gerber, S Zon, LI Speck, NA AF Hsu, Jingmei Huang, Hsuan-Ting Lee, Chung-Tsai Yu, Shuqian Gerber, Scott Zon, Leonard I. Speck, Nancy A. TI CHD7 Negatively Regulates Hematopoietic Stem Cell Potency SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Hsu, Jingmei] Hosp Univ Penn, Dept Hematol Oncol, Philadelphia, PA 19104 USA. [Huang, Hsuan-Ting] Harvard Univ, Sch Med, Dana Farber Canc Inst, HHMI,Harvard Stem Cell Inst, Boston, MA 02115 USA. [Lee, Chung-Tsai] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA. [Lee, Chung-Tsai] Univ Penn, Abramson Family Canc Ctr Res Inst, Philadelphia, PA 19104 USA. [Yu, Shuqian; Speck, Nancy A.] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA. [Gerber, Scott] Dartmouth Hitchcock Med Sch, Dept Genet, Lebanon, NH USA. [Zon, Leonard I.] Childrens Hosp, Howard Hughes Med Inst, Stem Cell Program, Boston, MA 02115 USA. [Zon, Leonard I.] Childrens Hosp, Howard Hughes Med Inst, Div Hematol Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 850 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838901014 ER PT J AU Hurtz, C Ramezani-Rad, P Geng, HM Kharabi, B Carroll, WL Willman, CL Armstrong, SA Melnick, A Muschen, M AF Hurtz, Christian Ramezani-Rad, Parham Geng, Huimin Kharabi, Behzad Carroll, William L. Willman, Cheryl L. Armstrong, Scott A. Melnick, Ari Muschen, Markus TI Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Hurtz, Christian; Ramezani-Rad, Parham; Muschen, Markus] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Kharabi, Behzad] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Carroll, William L.] NYU, Inst Canc, New York, NY USA. [Willman, Cheryl L.] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA. [Armstrong, Scott A.] Childrens Hosp, Boston, MA 02115 USA. [Armstrong, Scott A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Melnick, Ari] Weill Cornell Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 776 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838900183 ER PT J AU Inamoto, Y Chai, XY Kurland, B Weisdorf, DJ Martin, PJ Jacobsohn, D Pidala, J Palmer, J Arai, S Cutler, C Jagasia, M Flowers, MED Arora, M Pavletic, SZ Vogelsang, GB Lee, SJ Carpenter, PA AF Inamoto, Yoshihiro Chai, Xiaoyu Kurland, Brenda Weisdorf, Daniel J. Martin, Paul J. Jacobsohn, David Pidala, Joseph Palmer, Jeanne Arai, Sally Cutler, Corey Jagasia, Madan Flowers, Mary E. D. Arora, Mukta Pavletic, Steven Z. Vogelsang, Georgia B. Lee, Stephanie J. Carpenter, Paul A. TI Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Weisdorf, Daniel J.; Arora, Mukta] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Martin, Paul J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA. [Jacobsohn, David] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Pidala, Joseph] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA. [Palmer, Jeanne] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Arai, Sally] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Cutler, Corey] Dana Farber Canc Inst, Boston, MA 02115 USA. [Jagasia, Madan] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. [Pavletic, Steven Z.] NCI, Bethesda, MD 20892 USA. [Vogelsang, Georgia B.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 464 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838901372 ER PT J AU Jacobsen, ED Advani, RH Oki, Y Sharman, J Horwitz, SM Forero-Torres, A O'Connor, OA Shustov, AR Siddiqi, T Grove, LE Bartlett, NL AF Jacobsen, Eric D. Advani, Ranjana H. Oki, Yasuhiro Sharman, Jeff Horwitz, Steven M. Forero-Torres, Andres O'Connor, Owen A. Shustov, Andrei R. Siddiqi, Tanya Grove, Laurie E. Bartlett, Nancy L. TI A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Jacobsen, Eric D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Advani, Ranjana H.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Oki, Yasuhiro] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Sharman, Jeff] Willamette Valley Canc Inst, Eugene, OR USA. [Sharman, Jeff] Res Ctr US Oncol Res, Eugene, OR USA. [Horwitz, Steven M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA. [Forero-Torres, Andres] Univ Alabama Birmingham, Birmingham, AL USA. [O'Connor, Owen A.] Columbia Univ, Dept Med, Med Ctr, Ctr Lymphoid Malignancies, New York, NY USA. [Shustov, Andrei R.] Univ Washington, Med Ctr, Seattle, WA 98195 USA. [Siddiqi, Tanya] City Hope Natl Med Ctr, Hematol HCT, Duarte, CA 91010 USA. [Grove, Laurie E.] Seattle Genet Inc, Bothell, WA USA. [Bartlett, Nancy L.] Washington Univ, Sch Med, St Louis, MO USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 2746 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049603351 ER PT J AU Jacobson, CA Geary, J Kim, HT McDonough, S Reynolds, CG Herrera, MI Koreth, J Cutler, C Ho, VT Alyea, EP Armand, P Soiffer, RJ Antin, JH Ritz, J AF Jacobson, Caron A. Geary, Joshua Kim, Haesook T. McDonough, Sean Reynolds, Carol G. Herrera, Maria I. Koreth, John Cutler, Corey Ho, Vincent T. Alyea, Edwin P., III Armand, Philippe Soiffer, Robert J. Antin, Joseph H. Ritz, Jerome TI Differential Plasma Cytokine Levels in Patients with and without Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Soiffer, Robert J.] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02115 USA. [Ritz, Jerome] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Neoplasia, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 4476 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049605330 ER PT J AU Jagannath, S Hofmeister, CC Siegel, DS Vij, R Lonial, S Anderson, KC Chen, M Zaki, M Richardson, PG AF Jagannath, Sundar Hofmeister, Craig C. Siegel, David S. Vij, Ravi Lonial, Sagar Anderson, Kenneth C. Chen, Min Zaki, Mohamed Richardson, Paul G. TI Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Jagannath, Sundar] Mt Sinai Med Ctr, New York, NY 10029 USA. [Hofmeister, Craig C.] Ohio State Univ, Columbus, OH 43210 USA. [Siegel, David S.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Vij, Ravi] Washington Univ, Sch Med, St Louis, MO USA. [Lonial, Sagar] Emory Univ, Winship Canc Inst Hematol & Med Oncol, Div BMT, Atlanta, GA 30322 USA. [Anderson, Kenneth C.] Emory Univ, Sch Med, Atlanta, GA USA. [Chen, Min; Zaki, Mohamed] Celgene Corp, Summit, NJ USA. [Richardson, Paul G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 450 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902210 ER PT J AU Jagannath, S Hofmeister, CC Siegel, DS Vij, R Lonial, S Anderson, KC Chen, M Zaki, M Richardson, PG AF Jagannath, Sundar Hofmeister, Craig C. Siegel, David S. Vij, Ravi Lonial, Sagar Anderson, Kenneth C. Chen, Min Zaki, Mohamed Richardson, Paul G. TI Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Jagannath, Sundar] Mt Sinai Med Ctr, New York, NY 10029 USA. [Hofmeister, Craig C.] Ohio State Univ, Columbus, OH 43210 USA. [Siegel, David S.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA. [Vij, Ravi] Washington Univ, Sch Med, St Louis, MO USA. [Lonial, Sagar] Emory Univ, Div BMT, Winship Canc Inst Hematol & Med Oncol, Atlanta, GA 30322 USA. [Anderson, Kenneth C.] Emory Univ, Sch Med, Atlanta, GA USA. [Chen, Min; Zaki, Mohamed] Celgene Corp, Summit, NJ USA. [Richardson, Paul G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 450 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902010 ER PT J AU Kahl, BS Li, HL Smith, MR Gascoyne, RD Yang, DT Paietta, E Advani, RH Horning, SJ AF Kahl, Brad S. Li, Hailun Smith, Mitchell R. Gascoyne, Randy D. Yang, David T. Paietta, Elisabeth Advani, Ranjana H. Horning, Sandra J. TI Mature Results From ECOG Study E1405-A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Kahl, Brad S.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Li, Hailun] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Smith, Mitchell R.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA. [Gascoyne, Randy D.] BC Canc Agcy, Dept Pathol, Ctr Lymphoid Canc, Vancouver, BC, Canada. [Paietta, Elisabeth] Montefiore Med Ctr, Bronx, NY 10467 USA. [Advani, Ranjana H.] Stanford Univ, Div Oncol, Sch Med, Stanford, CA 94305 USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 153 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838900306 ER PT J AU Kahn, AR Hartwell, KA Miller, PG Ebert, BL Golub, TR Moore, MASA AF Kahn, Alissa R. Hartwell, Kimberly A. Miller, Peter G. Ebert, Benjamin L. Golub, Todd R. Moore, Malcolm A. S. As TI Identification of Small Molecules Selectively Targeting Leukemic Stem Cells within Their Stromal Niche SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Hartwell, Kimberly A.; Golub, Todd R.] Harvard Univ, Canc Program, Broad Inst, Cambridge, MA 02138 USA. [Hartwell, Kimberly A.; Golub, Todd R.] MIT, Cambridge, MA 02139 USA. [Ebert, Benjamin L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. [Moore, Malcolm A. S. As] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 413 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902247 ER PT J AU Kantarjian, HM Kim, DW Pinilla-Ibarz, J le Coutre, P Paquette, R Chuah, C Nicolini, FE Apperley, J Khoury, HJ Talpaz, M DiPersio, JF DeAngelo, D Abruzzese, E Rea, D Baccarani, M Muller, MC Gambacorti-Passerini, C Wong, S Lustgarten, S Rivera, VM Clackson, T Turner, CD Haluska, FG Guilhot, F Deininger, MW Hochhaus, A Hughes, TP Goldman, J Shah, N Cortes, JE AF Kantarjian, Hagop M. Kim, Dong-Wook Pinilla-Ibarz, Javier le Coutre, Philipp Paquette, Ronald Chuah, Charles Nicolini, Franck E. Apperley, Jane Khoury, H. Jean Talpaz, Moshe DiPersio, John F. DeAngelo, Daniel Abruzzese, Elisabetta Rea, Delphine Baccarani, Michele Muller, Martin C. Gambacorti-Passerini, Carlo Wong, Stephane Lustgarten, Stephanie Rivera, Victor M. Clackson, Tim Turner, Christopher D. Haluska, Frank G. Guilhot, Francois Deininger, Michael W. Hochhaus, Andreas Hughes, Timothy P. Goldman, John Shah, Neil Cortes, Jorge E. CA PACE Study Grp TI Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Kantarjian, Hagop M.; Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Kim, Dong-Wook] Catholic Univ Korea, Div Hematol, Seoul St Marys Hosp, Coll Med, Seoul, South Korea. [Pinilla-Ibarz, Javier] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [le Coutre, Philipp] Charite, D-13353 Berlin, Germany. [Paquette, Ronald] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA. [Chuah, Charles] Singapore Gen Hosp, Dept Hematol, Canc & Stem Cell Biol Program, Duke NUS Grad Med Sch, Singapore, Singapore. [Nicolini, Franck E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France. [Apperley, Jane] Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Hammersmith Hosp, London, England. [Khoury, H. Jean] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Talpaz, Moshe] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [DiPersio, John F.] Washington Univ, St Louis, MO USA. [DeAngelo, Daniel] Dana Farber Canc Inst, Boston, MA 02115 USA. [Abruzzese, Elisabetta] Univ Roma Tor Vergata, Osped S Eugenio, Rome, Italy. [Rea, Delphine] Hop St Louis, Serv Malad Sang, Paris, France. [Rea, Delphine] Hop St Louis, EA3518, Paris, France. [Baccarani, Michele] Univ Bologna, Bologna, Italy. [Muller, Martin C.] Univ Med Mannheim, Med Klin 3, Mannheim, Germany. [Gambacorti-Passerini, Carlo] Univ Milano Bicocca, Unita Ric Clin Ematol, Azienda Osped San Gerardo, Monza, Italy. [Wong, Stephane] MolecularMD Corp, Portland, OR USA. [Lustgarten, Stephanie; Rivera, Victor M.; Clackson, Tim; Turner, Christopher D.; Haluska, Frank G.; PACE Study Grp] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA. [Guilhot, Francois] CHU Poitiers, Poitiers, France. [Deininger, Michael W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Hochhaus, Andreas] Univ Klinikum Jena, Dept Hematol & Oncol, Jena, Germany. [Hughes, Timothy P.] Royal Adelaide Hosp, Dept Haematol, SA Pathol, Adelaide, SA 5000, Australia. [Goldman, John] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, London, England. [Shah, Neil] Univ Calif San Francisco, San Francisco Sch Med, San Francisco, CA 94143 USA. NR 0 TC 1 Z9 1 U1 0 U2 4 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 915 PG 3 WC Hematology SC Hematology GA 074UG UT WOS:000313838902046 ER PT J AU Kantarjian, HM Kim, DW Pinilla-Ibarz, J le Coutre, P Paquette, R Chuah, C Nicolini, FE Apperley, J Khoury, HJ Talpaz, M DiPersio, JF DeAngelo, D Abruzzese, E Rea, D Baccarani, M Muller, MC Gambacorti-Passerini, C Wong, S Lustgarten, S Rivera, VM Clackson, T Turner, CD Haluska, FG Guilhot, F Deininger, MW Hochhaus, A Hughes, TP Goldman, J Shah, N Cortes, JE AF Kantarjian, Hagop M. Kim, Dong-Wook Pinilla-Ibarz, Javier le Coutre, Philipp Paquette, Ronald Chuah, Charles Nicolini, Franck E. Apperley, Jane Khoury, H. Jean Talpaz, Moshe DiPersio, John F. DeAngelo, Daniel Abruzzese, Elisabetta Rea, Delphine Baccarani, Michele Muller, Martin C. Gambacorti-Passerini, Carlo Wong, Stephane Lustgarten, Stephanie Rivera, Victor M. Clackson, Tim Turner, Christopher D. Haluska, Frank G. Guilhot, Francois Deininger, Michael W. Hochhaus, Andreas Hughes, Timothy P. Goldman, John Shah, Neil Cortes, Jorge E. CA PACE Study Grp TI Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Kantarjian, Hagop M.; Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Kim, Dong-Wook] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Div Hematol, Seoul, South Korea. [Pinilla-Ibarz, Javier] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [le Coutre, Philipp] Charite, D-13353 Berlin, Germany. [Paquette, Ronald] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA. [Chuah, Charles] Singapore Gen Hosp, Dept Hematol, Canc & Stem Cell Biol Program, Duke NUS Grad Med Sch, Singapore, Singapore. [Nicolini, Franck E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France. [Apperley, Jane] Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Hammersmith Hosp, London, England. [Khoury, H. Jean] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Talpaz, Moshe] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [DiPersio, John F.] Washington Univ, St Louis, MO USA. [DeAngelo, Daniel] Dana Farber Canc Inst, Boston, MA 02115 USA. [Abruzzese, Elisabetta] Univ Roma Tor Vergata, Osped S Eugenio, Rome, Italy. [Rea, Delphine] Hop St Louis, Serv Malad Sang, Paris, France. [Rea, Delphine] Hop St Louis, EA3518, Paris, France. [Baccarani, Michele] Univ Bologna, Bologna, Italy. [Muller, Martin C.] Univ Med Mannheim, Med Klin 3, Mannheim, Germany. [Gambacorti-Passerini, Carlo] Univ Milano Bicocca, Azienda Osped San Gerardo, Unita Ric Clin Ematol, Monza, Italy. [Wong, Stephane] MolecularMD Corp, Portland, OR USA. [Lustgarten, Stephanie; Rivera, Victor M.; Clackson, Tim; Turner, Christopher D.; Haluska, Frank G.; PACE Study Grp] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA. [Guilhot, Francois] CHU Poitiers, Poitiers, France. [Deininger, Michael W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Hochhaus, Andreas] Univ Klinikum Jena, Dept Hematol & Oncol, Jena, Germany. [Hughes, Timothy P.] Royal Adelaide Hosp, SA Pathol, Dept Haematol, Adelaide, SA 5000, Australia. [Goldman, John] Univ London Imperial Coll Sci Technol & Med, Ctr Haematol, London, England. [Shah, Neil] Univ Calif San Francisco, San Francisco Sch Med, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 915 PG 3 WC Hematology SC Hematology GA 074UG UT WOS:000313838901222 ER PT J AU Kaufman, JL Shah, JJ Laubach, JP Mitchell, AR Sharp, C Lewis, C Harvey, RD Gleason, C Casbourne, D Nooka, AK Heffner, LT Richardson, PG Orlowski, RZ Lonial, S AF Kaufman, Jonathan L. Shah, Jatin J. Laubach, Jacob P. Mitchell, Alaina R. Sharp, Cathy Lewis, Colleen Harvey, R. Donald Gleason, Charise Casbourne, Daniela Nooka, Ajay K. Heffner, Leonard T. Richardson, Paul G. Orlowski, Robert Z. Lonial, Sagar TI Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Kaufman, Jonathan L.; Mitchell, Alaina R.; Sharp, Cathy; Lewis, Colleen; Harvey, R. Donald; Gleason, Charise; Casbourne, Daniela; Nooka, Ajay K.; Heffner, Leonard T.; Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Shah, Jatin J.; Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA. [Laubach, Jacob P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Laubach, Jacob P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 1 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 336 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902124 ER PT J AU Kaufman, JL Shah, JJ Laubach, JP Mitchell, AR Sharp, C Lewis, C Harvey, RD Gleason, C Casbourne, D Nooka, AK Heffner, LT Richardson, PG Orlowski, RZ Lonial, S AF Kaufman, Jonathan L. Shah, Jatin J. Laubach, Jacob P. Mitchell, Alaina R. Sharp, Cathy Lewis, Colleen Harvey, R. Donald Gleason, Charise Casbourne, Daniela Nooka, Ajay K. Heffner, Leonard T. Richardson, Paul G. Orlowski, Robert Z. Lonial, Sagar TI Lenalidomide, Bortezomib, and Dexamethasone (RVD) in Combination with Vorinostat As Front-Line Therapy for Patients with Multiple Myeloma (MM): Results of a Phase 1 Study SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Kaufman, Jonathan L.; Mitchell, Alaina R.; Sharp, Cathy; Lewis, Colleen; Harvey, R. Donald; Gleason, Charise; Casbourne, Daniela; Nooka, Ajay K.; Heffner, Leonard T.; Lonial, Sagar] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Shah, Jatin J.; Orlowski, Robert Z.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA. [Laubach, Jacob P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA. [Laubach, Jacob P.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA. [Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 336 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838901300 ER PT J AU Kim, DW Cortes, JE Pinilla-Ibarz, J le Coutre, P Paquette, R Chuah, C Nicolini, FE Apperley, J Khoury, HJ Talpaz, M DiPersio, JF DeAngelo, D Abruzzese, E Rea, D Baccarani, M Muller, MC Gambacorti-Passerini, C Wong, S Lustgarten, S Rivera, VM Clackson, T Turner, CD Haluska, FG Guilhot, F Deininger, MW Hochhaus, A Hughes, TP Goldman, JM Shah, N Kantarjian, HM AF Kim, Dong-Wook Cortes, Jorge E. Pinilla-Ibarz, Javier le Coutre, Philipp Paquette, Ronald Chuah, Charles Nicolini, Franck E. Apperley, Jane Khoury, H. Jean Talpaz, Moshe DiPersio, John F. DeAngelo, Daniel Abruzzese, Elisabetta Rea, Delphine Baccarani, Michele Muller, Martin C. Gambacorti-Passerini, Carlo Wong, Stephane Lustgarten, Stephanie Rivera, Victor M. Clackson, Tim Turner, Christopher D. Haluska, Frank G. Guilhot, Francois Deininger, Michael W. Hochhaus, Andreas Hughes, Timothy P. Goldman, John M. Shah, Neil Kantarjian, Hagop M. CA PACE Study Grp TI Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Kim, Dong-Wook] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Div Hematol, Seoul, South Korea. [Cortes, Jorge E.; Kantarjian, Hagop M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA. [Pinilla-Ibarz, Javier] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA. [le Coutre, Philipp] Charite, D-13353 Berlin, Germany. [Paquette, Ronald] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA. [Chuah, Charles] Singapore Gen Hosp, Duke NUS Grad Med Sch, Dept Hematol, Canc & Stem Cell Biol Program, Singapore, Singapore. [Nicolini, Franck E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France. [Apperley, Jane] Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Hammersmith Hosp, London, England. [Khoury, H. Jean] Emory Winship Canc Inst, Atlanta, GA USA. [Talpaz, Moshe] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA. [DiPersio, John F.] Washington Univ, St Louis, MO USA. [DeAngelo, Daniel] Dana Farber Canc Inst, Boston, MA 02115 USA. [Abruzzese, Elisabetta] Univ Roma Tor Vergata, Osped S Eugenio, Rome, Italy. [Rea, Delphine] Hop St Louis, Serv Malad Sang, Paris, France. [Rea, Delphine] Hop St Louis, EA3518, Paris, France. [Baccarani, Michele] Univ Bologna, Bologna, Italy. [Muller, Martin C.] Univ Med Mannheim, Med Klin 3, Mannheim, Germany. [Gambacorti-Passerini, Carlo] Univ Milano Bicocca, Azienda Osped San Gerardo, Unita Ric Clin Ematol, Monza, Italy. [Wong, Stephane] MolecularMD Corp, Portland, OR USA. [Lustgarten, Stephanie; Rivera, Victor M.; Clackson, Tim; Turner, Christopher D.; Haluska, Frank G.; PACE Study Grp] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA. [Guilhot, Francois] CHU Poitiers, Poitiers, France. [Deininger, Michael W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Hochhaus, Andreas] Univ Klinikum Jena, Dept Hematol & Oncol, Jena, Germany. [Hughes, Timothy P.] Royal Adelaide Hosp, Dept Haematol, SA Pathol, Adelaide, SA 5000, Australia. [Goldman, John M.] Univ London Imperial Coll Sci Technol & Med, Dept Hematol, London, England. [Shah, Neil] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. NR 0 TC 2 Z9 2 U1 0 U2 5 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 3749 PG 3 WC Hematology SC Hematology GA 077SZ UT WOS:000314049601316 ER PT J AU Kim, HT Frederick, DG Andler, E Armand, P Kao, G Cutler, C Koreth, J Alyea, E Antin, JH Soiffer, RJ Ritz, J Ho, VT AF Kim, Haesook T. Frederick, David G. Andler, Emily Armand, Philippe Kao, Grace Cutler, Corey Koreth, John Alyea, Edwin Antin, Joseph H. Soiffer, Robert J. Ritz, Jerome Ho, Vincent T. TI Impact of White Blood Cell Count Recovery On Clinical Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Koreth, John] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Alyea, Edwin; Soiffer, Robert J.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA. [Ritz, Jerome] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 4136 PG 2 WC Hematology SC Hematology GA 077SZ UT WOS:000314049604192 ER PT J AU Krause, DS Fulzele, K Catic, A Hurley, M Lezeau, S Attar, EC Wu, JY Lin, HYF Divieti-Pajevic, P Hasserjian, R Schipani, E Van Etten, RA Scadden, DT AF Krause, Daniela S. Fulzele, Keertik Catic, Andre Hurley, Michael Lezeau, Sanon Attar, Eyal C. Wu, Joy Y. Lin, Herbert Yih-Fuu Divieti-Pajevic, Paola Hasserjian, Robert Schipani, Ernestina Van Etten, Richard A. Scadden, David T. TI Differential Regulation of Myeloid Leukemias by the Bone Marrow Microenvironment SO BLOOD LA English DT Meeting Abstract CT 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) CY DEC 08-11, 2012 CL Atlanta, GA SP Amer Soc Hematol (ASH) C1 [Krause, Daniela S.; Catic, Andre; Hurley, Michael; Lezeau, Sanon] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA. [Fulzele, Keertik; Wu, Joy Y.; Divieti-Pajevic, Paola; Schipani, Ernestina] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Attar, Eyal C.] Massachusetts Gen Hosp, Bone Marrow Transplant Unit, Boston, MA 02114 USA. [Lin, Herbert Yih-Fuu] Massachusetts Gen Hosp, Div Nephrol, Program Membrane Biol, Ctr Syst Biol, Boston, MA 02114 USA. [Hasserjian, Robert] Massachusetts Gen Hosp, Dept Pathol WRN 244, Boston, MA 02114 USA. [Van Etten, Richard A.] Tufts Med Ctr, Boston, MA USA. [Scadden, David T.] Harvard Stem Cell Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 J9 BLOOD JI Blood PD NOV 16 PY 2012 VL 120 IS 21 MA 1245 PG 2 WC Hematology SC Hematology GA 074UG UT WOS:000313838902321 ER EF